Torsade	B_Disease
de	I_Disease
pointes	I_Disease
ventricular	B_Disease
tachycardia	I_Disease
during	O
low	O
dose	O
intermittent	O
dobutamine	B_Chemical
treatment	O
in	O
a	O
patient	O
with	O
dilated	B_Disease
cardiomyopathy	I_Disease
and	O
congestive	B_Disease
heart	I_Disease
failure	I_Disease
.	O

The	O
authors	O
describe	O
the	O
case	O
of	O
a	O
56-year-old	O
woman	O
with	O
chronic	O
,	O
severe	O
heart	B_Disease
failure	I_Disease
secondary	O
to	O
dilated	B_Disease
cardiomyopathy	I_Disease
and	O
absence	O
of	O
significant	O
ventricular	B_Disease
arrhythmias	I_Disease
who	O
developed	O
QT	B_Disease
prolongation	I_Disease
and	O
torsade	B_Disease
de	I_Disease
pointes	I_Disease
ventricular	B_Disease
tachycardia	I_Disease
during	O
one	O
cycle	O
of	O
intermittent	O
low	O
dose	O
(	O
2.5	O
mcg/kg	O
per	O
min	O
)	O
dobutamine	B_Chemical
.	O

This	O
report	O
of	O
torsade	B_Disease
de	I_Disease
pointes	I_Disease
ventricular	B_Disease
tachycardia	I_Disease
during	O
intermittent	O
dobutamine	B_Chemical
supports	O
the	O
hypothesis	O
that	O
unpredictable	O
fatal	O
arrhythmias	B_Disease
may	O
occur	O
even	O
with	O
low	O
doses	O
and	O
in	O
patients	O
with	O
no	O
history	O
of	O
significant	O
rhythm	O
disturbances	O
.	O

The	O
mechanisms	O
of	O
proarrhythmic	O
effects	O
of	O
Dubutamine	B_Chemical
are	O
discussed	O
.	O

Positive	O
skin	O
tests	O
in	O
late	O
reactions	O
to	O
radiographic	O
contrast	O
media	O
.	O

In	O
the	O
last	O
few	O
years	O
delayed	O
reactions	O
several	O
hours	O
after	O
the	O
injection	O
of	O
radiographic	O
and	O
contrast	B_Chemical
materials	I_Chemical
(	O
PRC	B_Chemical
)	O
have	O
been	O
described	O
with	O
increasing	O
frequency	O
.	O

The	O
authors	O
report	O
two	O
observations	O
on	O
patients	O
with	O
delayed	O
reactions	O
in	O
whom	O
intradermoreactions	O
(	O
IDR	O
)	O
and	O
patch	O
tests	O
to	O
a	O
series	O
of	O
ionic	O
and	O
non	O
ionic	O
PRC	B_Chemical
were	O
studied	O
.	O

After	O
angiography	O
by	O
the	O
venous	O
route	O
in	O
patient	O
n	O
degree	O
1	O
a	O
biphasic	O
reaction	O
with	O
an	O
immediate	O
reaction	O
(	O
dyspnea	B_Disease
,	O
loss	B_Disease
of	I_Disease
consciousness	I_Disease
)	O
and	O
delayed	O
macro-papular	B_Disease
rash	I_Disease
appeared	O
,	O
whilst	O
patient	O
n	O
degree	O
2	O
developed	O
a	O
generalised	O
sensation	O
of	O
heat	O
,	O
persistent	O
pain	B_Disease
at	O
the	O
site	O
of	O
injection	O
immediately	O
and	O
a	O
generalised	O
macro-papular	O
reaction	O
after	O
24	O
hours	O
.	O

The	O
skin	O
tests	O
revealed	O
positive	O
delayed	O
reactions	O
of	O
24	O
hours	O
and	O
48	O
hours	O
by	O
IDR	O
and	O
patch	O
tests	O
to	O
only	O
some	O
PRC	B_Chemical
with	O
common	O
chains	O
in	O
their	O
structures	O
.	O

The	O
positive	O
skin	O
tests	O
are	O
in	O
favour	O
of	O
immunological	O
reactions	O
and	O
may	O
help	O
in	O
diagnosis	O
of	O
allergy	B_Disease
in	O
the	O
patients	O
.	O

Risk	O
of	O
transient	O
hyperammonemic	B_Disease
encephalopathy	B_Disease
in	O
cancer	B_Disease
patients	O
who	O
received	O
continuous	O
infusion	O
of	O
5-fluorouracil	B_Chemical
with	O
the	O
complication	O
of	O
dehydration	B_Disease
and	O
infection	B_Disease
.	O

From	O
1986	O
to	O
1998	O
,	O
29	O
cancer	B_Disease
patients	O
who	O
had	O
32	O
episodes	O
of	O
transient	O
hyperammonemic	B_Disease
encephalopathy	B_Disease
related	O
to	O
continuous	O
infusion	O
of	O
5-fluorouracil	B_Chemical
(	O
5-FU	B_Chemical
)	O
were	O
identified	O
.	O

None	O
of	O
the	O
patients	O
had	O
decompensated	O
liver	B_Disease
disease	I_Disease
.	O

Onset	O
of	O
hyperammonemic	B_Disease
encephalopathy	B_Disease
varied	O
from	O
0.5	O
to	O
5	O
days	O
(	O
mean	O
:	O
2.6	O
+	O
/-	O

1.3	O
days	O
)	O
after	O
the	O
initiation	O
of	O
chemotherapy	O
.	O

Plasma	O
ammonium	B_Chemical
level	O
ranged	O
from	O
248	O
to	O
2387	O
microg%	O
(	O
mean	O
:	O
626	O
+	O
/-	O
431	O
microg%	O
)	O
.	O

Among	O
the	O
32	O
episodes	O
,	O
26	O
(	O
81	O
%	O
)	O
had	O
various	O
degrees	O
of	O
azotemia	B_Disease
,	O
18	O
(	O
56	O
%	O
)	O
occurred	O
during	O
bacterial	B_Disease
infections	I_Disease
and	O
14	O
(	O
44	O
%	O
)	O
without	O
infection	B_Disease
occurred	O
during	O
periods	O
of	O
dehydration	B_Disease
.	O

Higher	O
plasma	O
ammonium	B_Chemical
levels	O
and	O
more	O
rapid	O
onset	O
of	O
hyperammonemia	B_Disease
were	O
seen	O
in	O
18	O
patients	O
with	O
bacterial	B_Disease
infections	I_Disease
(	O
p=0.003	O
and	O
0.0006	O
,	O
respectively	O
)	O
and	O
in	O
nine	O
patients	O
receiving	O
high	O
daily	O
doses	O
(	O
2600	O
or	O
1800	O
mg/m2	O
)	O
of	O
5-FU	B_Chemical
(	O
p=0.0001	O
and	O
<	O
0.0001	O
,	O
respectively	O
)	O
.	O

In	O
25	O
out	O
of	O
32	O
episodes	O
(	O
78	O
%	O
)	O
,	O
plasma	O
ammonium	B_Chemical
levels	O
and	O
mental	O
status	O
returned	O
to	O
normal	O
within	O
2	O
days	O
after	O
adequate	O
management	O
.	O

In	O
conclusion	O
,	O
hyperammonemic	B_Disease
encephalopathy	B_Disease
can	O
occur	O
in	O
patients	O
receiving	O
continuous	O
infusion	O
of	O
5-FU	B_Chemical
.	O

Azotemia	B_Disease
,	O
body	O
fluid	O
insufficiency	O
and	O
bacterial	B_Disease
infections	I_Disease
were	O
frequently	O
found	O
in	O
these	O
patients	O
.	O

It	O
is	O
therefore	O
important	O
to	O
recognize	O
this	O
condition	O
in	O
patients	O
receiving	O
continuous	O
infusion	O
of	O
5-FU	B_Chemical
.	O

The	O
effects	O
of	O
quinine	B_Chemical
and	O
4-aminopyridine	B_Chemical
on	O
conditioned	O
place	O
preference	O
and	O
changes	O
in	O
motor	O
activity	O
induced	O
by	O
morphine	B_Chemical
in	O
rats.1	O
.	O

The	O
effects	O
of	O
two	O
unselective	O
potassium	B_Chemical
(	O
K(+)-	O
)	O
channel	O
blockers	O
,	O
quinine	B_Chemical
(	O
12.5	O
,	O
25	O
and	O
50	O
mg/kg	O
)	O
and	O
4-aminopyridine	B_Chemical
(	O
1	O
and	O
2	O
mg/kg	O
)	O
,	O
on	O
conditioned	O
place	O
preference	O
and	O
biphasic	O
changes	O
in	O
motor	O
activity	O
induced	O
by	O
morphine	B_Chemical
(	O
10	O
mg/kg	O
)	O
were	O
tested	O
in	O
Wistar	O
rats	O
.	O

Quinine	B_Chemical
is	O
known	O
to	O
block	O
voltage-	O
,	O
calcium-	O
and	O
ATP-sensitive	O
K(+)-channels	O
while	O
4-aminopyridine	B_Chemical
is	O
known	O
to	O
block	O
voltage-sensitive	O
K(+)-channels	O
.	O

2	O
.	O
In	O
the	O
counterbalanced	O
method	O
,	O
quinine	B_Chemical
attenuated	O
morphine-induced	O
place	O
preference	O
,	O
whereas	O
4-aminopyridine	B_Chemical
was	O
ineffective	O
.	O

In	O
the	O
motor	O
activity	O
test	O
measured	O
with	O
an	O
Animex-activity	O
meter	O
neither	O
of	O
the	O
K(+)-channel	O
blockers	O
affected	O
morphine-induced	O
hypoactivity	B_Disease
,	O
but	O
both	O
K(+)-channel	O
blockers	O
prevented	O
morphine-induced	O
secondary	O
hyperactivity	B_Disease
.	O

3	O
.	O

These	O
results	O
suggest	O
the	O
involvement	O
of	O
quinine-sensitive	O
but	O
not	O
4-aminopyridine-sensitive	O
K(+)-channels	O
in	O
morphine	B_Chemical
reward	O
.	O

It	O
is	O
also	O
suggested	O
that	O
the	O
blockade	O
of	O
K(+)-channels	O
sensitive	O
to	O
these	O
blockers	O
is	O
not	O
sufficient	O
to	O
prevent	O
morphine-induced	O
hypoactivity	B_Disease
whereas	O
morphine-induced	O
hyperactivity	B_Disease
seems	O
to	O
be	O
connected	O
to	O
both	O
quinine-	O
and	O
4-aminopyridine-sensitive	O
K(+)-channels	O
.	O

Nociceptin/orphanin	O
FQ	O
and	O
nocistatin	B_Chemical
on	O
learning	B_Disease
and	I_Disease
memory	B_Disease
impairment	I_Disease
induced	O
by	O
scopolamine	B_Chemical
in	O
mice.1	O
.	O

Nociceptin	B_Chemical
,	O
also	O
known	O
as	O
orphanin	B_Chemical
FQ	I_Chemical
,	O
is	O
an	O
endogenous	O
ligand	O
for	O
the	O
orphan	O
opioid	O
receptor-like	O
receptor	O
1	O
(	O
ORL1	O
)	O
and	O
involves	O
in	O
various	O
functions	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
nocistatin	B_Chemical
is	O
recently	O
isolated	O
from	O
the	O
same	O
precursor	O
as	O
nociceptin	B_Chemical
and	O
blocks	O
nociceptin-induced	O
allodynia	B_Disease
and	O
hyperalgesia	B_Disease
.	O

2	O
.	O
Although	O
ORL1	O
receptors	O
which	O
display	O
a	O
high	O
degree	O
of	O
sequence	O
homology	O
with	O
classical	O
opioid	O
receptors	O
are	O
abundant	O
in	O
the	O
hippocampus	O
,	O
little	O
is	O
known	O
regarding	O
their	O
role	O
in	O
learning	O
and	O
memory	O
.	O

3	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
whether	O
nociceptin/orphanin	O
FQ	O
and	O
nocistatin	B_Chemical
could	O
modulate	O
impairment	B_Disease
of	I_Disease
learning	I_Disease
and	I_Disease
memory	I_Disease
induced	O
by	O
scopolamine	B_Chemical
,	O
a	O
muscarinic	O
cholinergic	O
receptor	O
antagonist	O
,	O
using	O
spontaneous	O
alternation	O
of	O
Y-maze	O
and	O
step-down	O
type	O
passive	O
avoidance	O
tasks	O
in	O
mice	O
.	O

4	O
.	O
While	O
nocistatin	B_Chemical
(	O
0.5	O
-	O
5.0	O
nmol	O
mouse-1	O
,	O
i.c.v	O
.	O
)	O
administered	O
30	O
min	O
before	O
spontaneous	O
alternation	O
performance	O
or	O
the	O
training	O
session	O
of	O
the	O
passive	O
avoidance	O
task	O
,	O
had	O
no	O
effect	O
on	O
spontaneous	O
alternation	O
or	O
passive	O
avoidance	O
behaviours	O
,	O
a	O
lower	O
per	O
cent	O
alternation	O
and	O
shorter	O
median	O
step-down	O
latency	O
in	O
the	O
retention	O
test	O
were	O
obtained	O
in	O
nociceptin	B_Chemical
(	O
1.5	O
and/or	O
5.0	O
nmol	O
mouse-1	O
,	O
i.c.v.)-treated	O
normal	O
mice	O
.	O

5	O
.	O

Administration	O
of	O
nocistatin	B_Chemical
(	O
1.5	O
and/or	O
5.0	O
nmol	O
mouse-1	O
,	O
i.c.v	O
.	O
)	O
30	O
min	O
before	O
spontaneous	O
alternation	O
performance	O
or	O
the	O
training	O
session	O
of	O
the	O
passive	O
avoidance	O
task	O
,	O
attenuated	O
the	O
scopolamine-induced	O
impairment	O
of	O
spontaneous	O
alternation	O
and	O
passive	O
avoidance	O
behaviours	O
.	O

6	O
.	O

These	O
results	O
indicated	O
that	O
nocistatin	B_Chemical
,	O
a	O
new	O
biologically	O
active	O
peptide	O
,	O
ameliorates	O
impairments	O
of	O
spontaneous	O
alternation	O
and	O
passive	O
avoidance	O
induced	O
by	O
scopolamine	B_Chemical
,	O
and	O
suggested	O
that	O
these	O
peptides	O
play	O
opposite	O
roles	O
in	O
learning	O
and	O
memory	O
.	O

Meloxicam-induced	O
liver	B_Disease
toxicity	I_Disease
.	O

We	O
report	O
the	O
case	O
of	O
a	O
female	O
patient	O
with	O
rheumatoid	B_Disease
arthritis	I_Disease
who	O
developed	O
acute	O
cytolytic	O
hepatitis	B_Disease
due	O
to	O
meloxicam	B_Chemical
.	O

Recently	O
introduced	O
in	O
Belgium	O
,	O
meloxicam	B_Chemical
is	O
the	O
first	O
nonsteroidal	O
antiinflammatory	O
drug	O
with	O
selective	O
action	O
on	O
the	O
inducible	O
form	O
of	O
cyclooxygenase	O
2	O
.	O

The	O
acute	O
cytolytic	O
hepatitis	B_Disease
occurred	O
rapidly	O
after	O
meloxicam	B_Chemical
administration	O
and	O
was	O
associated	O
with	O
the	O
development	O
of	O
antinuclear	O
antibodies	O
suggesting	O
a	O
hypersensitivity	B_Disease
mechanism	O
.	O

This	O
first	O
case	O
of	O
meloxicam	B_Chemical
related	O
liver	B_Disease
toxicity	I_Disease
demonstrates	O
the	O
potential	O
of	O
this	O
drug	O
to	O
induce	O
hepatic	B_Disease
damage	I_Disease
.	O

Induction	O
of	O
apoptosis	O
by	O
remoxipride	B_Chemical
metabolites	O
in	O
HL60	O
and	O
CD34+/CD19-	O
human	O
bone	O
marrow	O
progenitor	O
cells	O
:	O
potential	O
relevance	O
to	O
remoxipride-induced	O
aplastic	B_Disease
anemia	I_Disease
.	O

The	O
antipsychotic	O
agent	O
,	O
remoxipride	B_Chemical
[	O
(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz	B_Chemical
amide	I_Chemical
]	O
has	O
been	O
associated	O
with	O
acquired	O
aplastic	B_Disease
anemia	I_Disease
.	O

We	O
have	O
examined	O
the	O
ability	O
of	O
remoxipride	B_Chemical
,	O
three	O
pyrrolidine	B_Chemical
ring	O
metabolites	O
and	O
five	O
aromatic	O
ring	O
metabolites	O
of	O
the	O
parent	O
compound	O
to	O
induce	O
apoptosis	O
in	O
HL60	O
cells	O
and	O
human	O
bone	O
marrow	O
progenitor	O
(	O
HBMP	O
)	O
cells	O
.	O

Cells	O
were	O
treated	O
for	O
0	O
-	O
24	O
h	O
with	O
each	O
compound	O
(	O
0	O
-	O
200	O
microM	O
)	O
.	O

Apoptosis	O
was	O
assessed	O
by	O
fluorescence	O
microscopy	O
in	O
Hoechst	O
33342-	O
and	O
propidium	B_Chemical
iodide	I_Chemical
stained	O
cell	O
samples	O
.	O

Results	O
were	O
confirmed	O
by	O
determination	O
of	O
internucleosomal	O
DNA	O
fragmentation	O
using	O
gel	O
electrophoresis	O
for	O
HL60	O
cell	O
samples	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
assay	O
in	O
HBMP	O
cells	O
.	O

The	O
catechol	B_Chemical
and	O
hydroquinone	B_Chemical
metabolites	O
,	O
NCQ436	B_Chemical
and	O
NCQ344	B_Chemical
,	O
induced	O
apoptosis	O
in	O
HL60	O
and	O
HBMP	O
cells	O
in	O
a	O
time-	O
and	O
concentration	O
dependent	O
manner	O
,	O
while	O
the	O
phenols	B_Chemical
,	O
NCR181	O
,	O
FLA873	O
,	O
and	O
FLA797	B_Chemical
,	O
and	O
the	O
derivatives	O
formed	O
by	O
oxidation	O
of	O
the	O
pyrrolidine	B_Chemical
ring	O
,	O
FLA838	O
,	O
NCM001	O
,	O
and	O
NCL118	O
,	O
had	O
no	O
effect	O
.	O

No	O
necrosis	B_Disease
was	O
observed	O
in	O
cells	O
treated	O
with	O
NCQ436	B_Chemical
but	O
NCQ344	B_Chemical
had	O
a	O
biphasic	O
effect	O
in	O
both	O
cell	O
types	O
,	O
inducing	O
apoptosis	O
at	O
lower	O
concentrations	O
and	O
necrosis	B_Disease
at	O
higher	O
concentrations	O
.	O

These	O
data	O
show	O
that	O
the	O
catechol	B_Chemical
and	O
hydroquinone	B_Chemical
metabolites	O
of	O
remoxipride	B_Chemical
have	O
direct	O
toxic	O
effects	O
in	O
HL60	O
and	O
HBMP	O
cells	O
,	O
leading	O
to	O
apoptosis	O
,	O
while	O
the	O
phenol	B_Chemical
metabolites	O
were	O
inactive	O
.	O

Similarly	O
,	O
benzene-derived	O
catechol	B_Chemical
and	O
hydroquinone	B_Chemical
,	O
but	O
not	O
phenol	B_Chemical
,	O
induce	O
apoptosis	O
in	O
HBMP	O
cells	O
[	O
Moran	O
et	O
al.	O
,	O
Mol	O
.	O

Pharmacol	O
.	O
,	O
50	O
(	O
1996	O
)	O
610	O
-	O
615	O
]	O
.	O

We	O
propose	O
that	O
remoxipride	B_Chemical
and	O
benzene	B_Chemical
may	O
induce	O
aplastic	B_Disease
anemia	I_Disease
via	O
production	O
of	O
similar	O
reactive	O
metabolites	O
and	O
that	O
the	O
ability	O
of	O
NCQ436	B_Chemical
and	O
NCQ344	B_Chemical
to	O
induce	O
apoptosis	O
in	O
HBMP	O
cells	O
may	O
contribute	O
to	O
the	O
mechanism	O
underlying	O
acquired	O
aplastic	B_Disease
anemia	I_Disease
that	O
has	O
been	O
associated	O
with	O
remoxipride	B_Chemical
.	O

Synthesis	O
and	O
preliminary	O
pharmacological	O
investigations	O
of	O
1-(1,2-dihydro-2-acenaphthylenyl)piperazine	O
derivatives	O
as	O
potential	O
atypical	O
antipsychotic	O
agents	O
in	O
mice	O
.	O

In	O
research	O
towards	O
the	O
development	O
of	O
new	O
atypical	O
antipsychotic	O
agents	O
,	O
one	O
strategy	O
is	O
that	O
the	O
dopaminergic	O
system	O
can	O
be	O
modulated	O
through	O
manipulation	O
of	O
the	O
serotonergic	O
system	O
.	O

The	O
synthesis	O
and	O
preliminary	O
pharmacological	O
evaluation	O
of	O
a	O
series	O
of	O
potential	O
atypical	O
antipsychotic	O
agents	O
based	O
on	O
the	O
structure	O
of	O
1-(1,2-dihydro-2-acenaphthylenyl)piperazine	B_Chemical
(	O
7	O
)	O
is	O
described	O
.	O

Compound	O
7e	O
,	O
5-{2-[4-(1,2-dihydro-2-acenaphthylenyl)piperazinyl]ethyl}-2,3-dihy	B_Chemical
dro-1H-	I_Chemical
indol-2-one	I_Chemical
,	O
from	O
this	O
series	O
showed	O
significant	O
affinities	O
at	O
the	O
5-HT1A	O
and	O
5-HT2A	O
receptors	O
and	O
moderate	O
affinity	O
at	O
the	O
D2	O
receptor	O
.	O

7e	O
exhibits	O
a	O
high	O
reversal	O
of	O
catalepsy	B_Disease
induced	O
by	O
haloperidol	B_Chemical
indicating	O
its	O
atypical	O
antipsychotic	O
nature	O
.	O

Sub-chronic	O
inhibition	O
of	O
nitric-oxide	B_Chemical
synthesis	O
modifies	O
haloperidol-induced	O
catalepsy	B_Disease
and	O
the	O
number	O
of	O
NADPH-diaphorase	O
neurons	O
in	O
mice	O
.	O

RATIONALE	O
:	O
NG-nitro-L-arginine	B_Chemical
(	O
L-NOARG	B_Chemical
)	O
,	O
an	O
inhibitor	O
of	O
nitric-oxide	B_Chemical
synthase	O
(	O
NOS	O
)	O
,	O
induces	O
catalepsy	B_Disease
in	O
mice	O
.	O

This	O
effect	O
undergoes	O
rapid	O
tolerance	O
,	O
showing	O
a	O
significant	O
decrease	O
after	O
2	O
days	O
of	O
sub-chronic	O
L-NOARG	B_Chemical
treatment	O
.	O

Nitric	B_Chemical
oxide	I_Chemical
(	O
NO	B_Chemical
)	O
has	O
been	O
shown	O
to	O
influence	O
dopaminergic	O
neurotransmission	O
in	O
the	O
striatum	O
.	O

Neuroleptic	O
drugs	O
such	O
as	O
haloperidol	B_Chemical
,	O
which	O
block	O
dopamine	B_Chemical
receptors	O
,	O
also	O
cause	O
catalepsy	B_Disease
in	O
rodents	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
effects	O
of	O
subchronic	O
L-NOARG	B_Chemical
treatment	O
in	O
haloperidol-induced	O
catalepsy	B_Disease
and	O
the	O
number	O
of	O
NOS	O
neurons	O
in	O
areas	O
related	O
to	O
motor	O
control	O
.	O

METHODS	O
:	O
Male	O
albino	O
Swiss	O
mice	O
were	O
treated	O
sub-chronically	O
(	O
twice	O
a	O
day	O
for	O
4	O
days	O
)	O
with	O
L-NOARG	B_Chemical
(	O
40	O
mg/kg	O
i.p	O
.	O
)	O
or	O
haloperidol	B_Chemical
(	O
1	O
mg/kg	O
i.p	O
.	O
)	O
.	O

Catalepsy	B_Disease
was	O
evaluated	O
at	O
the	O
beginning	O
and	O
the	O
end	O
of	O
the	O
treatments	O
.	O

Reduced	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate-diaphorase	O
(	O
NADPH-d	O
)	O
histochemistry	O
was	O
also	O
employed	O
to	O
visualize	O
NOS	O
as	O
an	O
index	O
of	O
enzyme	O
expression	O
in	O
mice	O
brain	O
regions	O
related	O
to	O
motor	O
control	O
.	O

RESULTS	O
:	O
L-NOARG	B_Chemical
sub-chronic	O
administration	O
produced	O
tolerance	O
of	O
L-NOARG	B_Chemical
and	O
of	O
haloperidol-induced	O
catalepsy	B_Disease
.	O

It	O
also	O
induced	O
an	O
increase	O
in	O
the	O
number	O
of	O
NADPH-d-positive	O
cells	O
in	O
the	O
dorsal	O
part	O
of	O
the	O
caudate	O
and	O
accumbens	O
nuclei	O
compared	O
with	O
haloperidol	B_Chemical
and	O
in	O
the	O
pedunculopontine	O
tegmental	O
nucleus	O
compared	O
with	O
saline	O
.	O

In	O
contrast	O
,	O
there	O
was	O
a	O
decrease	O
in	O
NADPH-d	O
neuron	O
number	O
in	O
the	O
substantia	O
nigra	O
,	O
pars	O
compacta	O
in	O
both	O
haloperidol-treated	O
and	O
L-NOARG-treated	O
animals	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
give	O
further	O
support	O
to	O
the	O
hypothesis	O
that	O
NO	B_Chemical
plays	O
a	O
role	O
in	O
motor	O
behavior	O
control	O
and	O
suggest	O
that	O
it	O
may	O
take	O
part	O
in	O
the	O
synaptic	O
changes	O
produced	O
by	O
antipsychotic	O
treatment	O
.	O

Prolonged	O
left	B_Disease
ventricular	I_Disease
dysfunction	I_Disease
occurs	O
in	O
patients	O
with	O
coronary	B_Disease
artery	I_Disease
disease	I_Disease
after	O
both	O
dobutamine	B_Chemical
and	O
exercise	O
induced	O
myocardial	B_Disease
ischaemia	I_Disease
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
pharmacological	O
stress	O
leads	O
to	O
prolonged	O
but	O
reversible	O
left	B_Disease
ventricular	I_Disease
dysfunction	I_Disease
in	O
patients	O
with	O
coronary	B_Disease
artery	I_Disease
disease	I_Disease
,	O
similar	O
to	O
that	O
seen	O
after	O
exercise	O
.	O

DESIGN	O
:	O
A	O
randomised	O
crossover	O
study	O
of	O
recovery	O
time	O
of	O
systolic	O
and	O
diastolic	O
left	O
ventricular	O
function	O
after	O
exercise	O
and	O
dobutamine	B_Chemical
induced	O
ischaemia	B_Disease
.	O

SUBJECTS	O
:	O
10	O
patients	O
with	O
stable	B_Disease
angina	I_Disease
,	O
angiographically	O
proven	O
coronary	B_Disease
artery	I_Disease
disease	I_Disease
,	O
and	O
normal	O
left	O
ventricular	O
function	O
.	O

INTERVENTIONS	O
:	O
Treadmill	O
exercise	O
and	O
dobutamine	B_Chemical
stress	O
were	O
performed	O
on	O
different	O
days	O
.	O

Quantitative	O
assessment	O
of	O
systolic	O
and	O
diastolic	O
left	O
ventricular	O
function	O
was	O
performed	O
using	O
transthoracic	O
echocardiography	O
at	O
baseline	O
and	O
at	O
regular	O
intervals	O
after	O
each	O
test	O
.	O

RESULTS	O
:	O
Both	O
forms	O
of	O
stress	O
led	O
to	O
prolonged	O
but	O
reversible	O
systolic	O
and	O
diastolic	O
dysfunction	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
maximum	O
double	O
product	O
(	O
p	O
=	O
0.53	O
)	O
or	O
ST	O
depression	B_Disease
(	O
p	O
=	O
0.63	O
)	O
with	O
either	O
form	O
of	O
stress	O
.	O

After	O
exercise	O
,	O
ejection	O
fraction	O
was	O
reduced	O
at	O
15	O
and	O
30	O
minutes	O
compared	O
with	O
baseline	O
(	O
mean	O
(	O
SEM	O
)	O
,	O
-5.6	O
(1.5)%	O
,	O
p	O
<	O
0.05	O
;	O
and	O
-6.1	O
(2.2)%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
at	O
30	O
and	O
45	O
minutes	O
after	O
dobutamine	B_Chemical
(	O
-10.8	O
(1.8)%	O
and	O
-5	O
.	O
5	O
(1.8)%	O
,	O
both	O
p	O
<	O
0.01	O
)	O
.	O

Regional	O
analysis	O
showed	O
a	O
reduction	O
in	O
the	O
worst	O
affected	O
segment	O
15	O
and	O
30	O
minutes	O
after	O
exercise	O
(	O
-27.9	O
(7.2)%	O
and	O
-28.6	O
(5.7)%	O
,	O
both	O
p	O
<	O
0.01	O
)	O
,	O
and	O
at	O
30	O
minutes	O
after	O
dobutamine	B_Chemical
(	O
-32	O
(5.3)%	O
,	O
p	O
<	O
0.01	O
)	O
.	O

The	O
isovolumic	O
relaxation	O
period	O
was	O
prolonged	O
45	O
minutes	O
after	O
each	O
form	O
of	O
stress	O
(	O
p	O
<	O
0.05	O
)	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
coronary	B_Disease
artery	I_Disease
disease	I_Disease
,	O
dobutamine	B_Chemical
induced	O
ischaemia	B_Disease
results	O
in	O
prolonged	O
reversible	O
left	B_Disease
ventricular	I_Disease
dysfunction	I_Disease
,	O
presumed	O
to	O
be	O
myocardial	B_Disease
stunning	I_Disease
,	O
similar	O
to	O
that	O
seen	O
after	O
exercise	O
.	O

Dobutamine	B_Chemical
induced	O
ischaemia	B_Disease
could	O
therefore	O
be	O
used	O
to	O
study	O
the	O
pathophysiology	O
of	O
this	O
phenomenon	O
further	O
in	O
patients	O
with	O
coronary	B_Disease
artery	I_Disease
disease	I_Disease
.	O

Anorexigens	O
and	O
pulmonary	B_Disease
hypertension	I_Disease
in	O
the	O
United	O
States	O
:	O
results	O
from	O
the	O
surveillance	O
of	O
North	O
American	O
pulmonary	B_Disease
hypertension	I_Disease
.	O

BACKGROUND	O
:	O
The	O
use	O
of	O
appetite	O
suppressants	O
in	O
Europe	O
has	O
been	O
associated	O
with	O
the	O
development	O
of	O
primary	B_Disease
pulmonary	I_Disease
hypertension	I_Disease
(	O
PPH	B_Disease
)	O
.	O

Recently	O
,	O
fenfluramine	B_Chemical
appetite	O
suppressants	O
became	O
widely	O
used	O
in	O
the	O
United	O
States	O
but	O
were	O
withdrawn	O
in	O
September	O
1997	O
because	O
of	O
concerns	O
over	O
adverse	O
effects	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
conducted	O
a	O
prospective	O
surveillance	O
study	O
on	O
patients	O
diagnosed	O
with	O
pulmonary	B_Disease
hypertension	I_Disease
at	O
12	O
large	O
referral	O
centers	O
in	O
North	O
America	O
.	O

Data	O
collected	O
on	O
patients	O
seen	O
from	O
September	O
1	O
,	O
1996	O
,	O
to	O
December	O
31	O
,	O
1997	O
,	O
included	O
the	O
cause	O
of	O
the	O
pulmonary	B_Disease
hypertension	I_Disease
and	O
its	O
severity	O
.	O

Patients	O
with	O
no	O
identifiable	O
cause	O
of	O
pulmonary	B_Disease
hypertension	I_Disease
were	O
classed	O
as	O
PPH	B_Disease
.	O

A	O
history	O
of	O
drug	O
exposure	O
also	O
was	O
taken	O
with	O
special	O
attention	O
on	O
the	O
use	O
of	O
antidepressants	O
,	O
anorexigens	O
,	O
and	O
amphetamines	B_Chemical
.	O

RESULTS	O
:	O
Five	O
hundred	O
seventy-nine	O
patients	O
were	O
studied	O
,	O
205	O
with	O
PPH	B_Disease
and	O
374	O
with	O
pulmonary	B_Disease
hypertension	I_Disease
from	O
other	O
causes	O
(	O
secondary	O
pulmonary	B_Disease
hypertension	I_Disease
[	O
SPH	O
]	O
)	O
.	O

The	O
use	O
of	O
anorexigens	O
was	O
common	O
in	O
both	O
groups	O
.	O

However	O
,	O
of	O
the	O
medications	O
surveyed	O
,	O
only	O
the	O
fenfluramines	B_Chemical
had	O
a	O
significant	O
preferential	O
association	O
with	O
PPH	B_Disease
as	O
compared	O
with	O
SPH	O
(	O
adjusted	O
odds	O
ratio	O
for	O
use	O
>	O
6	O
months	O
,	O
7.5	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.7	O
to	O
32.4	O
)	O
.	O

The	O
association	O
was	O
stronger	O
with	O
longer	O
duration	O
of	O
use	O
when	O
compared	O
to	O
shorter	O
duration	O
of	O
use	O
and	O
was	O
more	O
pronounced	O
in	O
recent	O
users	O
than	O
in	O
remote	O
users	O
.	O

An	O
unexpectedly	O
high	O
(	O
11.4	O
%	O
)	O
number	O
of	O
patients	O
with	O
SPH	O
had	O
used	O
anorexigens	O
.	O

CONCLUSION	O
:	O
The	O
magnitude	O
of	O
the	O
association	O
with	O
PPH	B_Disease
,	O
the	O
increase	O
of	O
association	O
with	O
increasing	O
duration	O
of	O
use	O
,	O
and	O
the	O
specificity	O
for	O
fenfluramines	B_Chemical
are	O
consistent	O
with	O
previous	O
studies	O
indicating	O
that	O
fenfluramines	B_Chemical
are	O
causally	O
related	O
to	O
PPH	B_Disease
.	O

The	O
high	O
prevalence	O
of	O
anorexigen	O
use	O
in	O
patients	O
with	O
SPH	O
also	O
raises	O
the	O
possibility	O
that	O
these	O
drugs	O
precipitate	O
pulmonary	B_Disease
hypertension	I_Disease
in	O
patients	O
with	O
underlying	O
conditions	O
associated	O
with	O
SPH	O
.	O

Clinical	O
aspects	O
of	O
heparin-induced	O
thrombocytopenia	B_Disease
and	O
thrombosis	B_Disease
and	O
other	O
side	O
effects	O
of	O
heparin	B_Chemical
therapy	O
.	O

Heparin	B_Chemical
,	O
first	O
used	O
to	O
prevent	O
the	O
clotting	O
of	O
blood	O
in	O
vitro	O
,	O
has	O
been	O
clinically	O
used	O
to	O
treat	O
thrombosis	B_Disease
for	O
more	O
than	O
50	O
years	O
.	O

Although	O
several	O
new	O
anticoagulant	O
drugs	O
are	O
in	O
development	O
,	O
heparin	B_Chemical
remains	O
the	O
anticoagulant	O
of	O
choice	O
to	O
treat	O
acute	O
thrombotic	B_Disease
episodes	O
.	O

The	O
clinical	O
effects	O
of	O
heparin	B_Chemical
are	O
meritorious	O
,	O
but	O
side	O
effects	O
do	O
exist	O
.	O

Bleeding	B_Disease
is	O
the	O
primary	O
untoward	O
effect	O
of	O
heparin	B_Chemical
.	O

Major	O
bleeding	B_Disease
is	O
of	O
primary	O
concern	O
in	O
patients	O
receiving	O
heparin	B_Chemical
therapy	O
.	O

However	O
,	O
additional	O
important	O
untoward	O
effects	O
of	O
heparin	B_Chemical
therapy	O
include	O
heparin-induced	O
thrombocytopenia	B_Disease
,	O
heparin-associated	O
osteoporosis	B_Disease
,	O
eosinophilia	B_Disease
,	O
skin	B_Disease
reactions	I_Disease
,	O
allergic	B_Disease
reactions	I_Disease
other	O
than	O
thrombocytopenia	B_Disease
,	O
alopecia	B_Disease
,	O
transaminasemia	O
,	O
hyperkalemia	B_Disease
,	O
hypoaldosteronism	B_Disease
,	O
and	O
priapism	B_Disease
.	O

These	O
side	O
effects	O
are	O
relatively	O
rare	O
in	O
a	O
given	O
individual	O
,	O
but	O
given	O
the	O
extremely	O
widespread	O
use	O
of	O
heparin	B_Chemical
,	O
some	O
are	O
quite	O
common	O
,	O
particularly	O
HITT	B_Disease
and	O
osteoporosis	B_Disease
.	O

Although	O
reasonable	O
incidences	O
of	O
many	O
of	O
these	O
side	O
effects	O
can	O
be	O
"	O
softly	O
"	O
deduced	O
from	O
current	O
reports	O
dealing	O
with	O
unfractionated	O
heparin	B_Chemical
,	O
at	O
present	O
the	O
incidences	O
of	O
these	O
side	O
effects	O
with	O
newer	O
low	O
molecular	O
weight	O
heparins	B_Chemical
appear	O
to	O
be	O
much	O
less	O
common	O
.	O

However	O
,	O
only	O
longer	O
experience	O
will	O
more	O
clearly	O
define	O
the	O
incidence	O
of	O
each	O
side	O
effect	O
with	O
low	O
molecular	O
weight	O
preparations	O
.	O

A	O
case	O
of	O
bilateral	O
optic	B_Disease
neuropathy	I_Disease
in	O
a	O
patient	O
on	O
tacrolimus	B_Chemical
(	O
FK506	B_Chemical
)	O
therapy	O
after	O
liver	O
transplantation	O
.	O

PURPOSE	O
:	O
To	O
report	O
a	O
case	O
of	O
bilateral	O
optic	B_Disease
neuropathy	I_Disease
in	O
a	O
patient	O
receiving	O
tacrolimus	B_Chemical
(	O
FK	B_Chemical
506	I_Chemical
,	O
Prograf	O
;	O
Fujisawa	O
USA	O
,	O
Inc	O
,	O
Deerfield	O
,	O
Illinois	O
)	O
for	O
immunosuppression	O
after	O
orthotropic	O
liver	O
transplantation	O
.	O

METHOD	O
:	O
Case	O
report	O
.	O

In	O
a	O
58-year-old	O
man	O
receiving	O
tacrolimus	B_Chemical
after	O
orthotropic	O
liver	O
transplantation	O
,	O
serial	O
neuro-ophthalmologic	O
examinations	O
and	O
laboratory	O
studies	O
were	O
performed	O
.	O

RESULTS	O
:	O
The	O
patient	O
had	O
episodic	O
deterioration	O
of	O
vision	O
in	O
both	O
eyes	O
,	O
with	O
clinical	O
features	O
resembling	O
ischemic	B_Disease
optic	I_Disease
neuropathies	I_Disease
.	O

Deterioration	B_Disease
of	I_Disease
vision	I_Disease
occurred	O
despite	O
discontinuation	O
of	O
the	O
tacrolimus	B_Chemical
.	O

CONCLUSION	O
:	O
Tacrolimus	B_Chemical
and	O
other	O
immunosuppressive	O
agents	O
may	O
be	O
associated	O
with	O
optic	B_Disease
nerve	I_Disease
toxicity	I_Disease
.	O

Hypercalcemia	B_Disease
,	O
arrhythmia	B_Disease
,	O
and	O
mood	O
stabilizers	O
.	O

Recent	O
findings	O
in	O
a	O
bipolar	B_Disease
patient	O
receiving	O
maintenance	O
lithium	B_Chemical
therapy	O
who	O
developed	O
hypercalcemia	B_Disease
and	O
severe	O
bradyarrhythmia	B_Disease
prompted	O
the	O
authors	O
to	O
conduct	O
a	O
retrospective	O
study	O
of	O
bipolar	B_Disease
patients	O
with	O
lithium-associated	O
hypercalcemia	B_Disease
.	O

A	O
printout	O
of	O
all	O
cases	O
of	O
hypercalcemia	B_Disease
that	O
presented	O
during	O
a	O
1-year	O
period	O
was	O
generated	O
.	O

After	O
eliminating	O
spurious	O
hypercalcemias	B_Disease
or	O
those	O
associated	O
with	O
intravenous	O
fluids	O
,	O
the	O
authors	O
identified	O
18	O
non-lithium-treated	O
patients	O
with	O
hypercalcemias	B_Disease
related	O
to	O
malignancies	B_Disease
and	O
other	O
medical	O
conditions	O
(	O
group	O
A	O
)	O
and	O
12	O
patients	O
with	O
lithium-associated	O
hypercalcemia	B_Disease
(	O
group	O
B	O
)	O
.	O

Patients	O
in	O
group	O
B	O
were	O
not	O
comparable	O
to	O
those	O
in	O
group	O
A	O
,	O
as	O
the	O
latter	O
were	O
medically	O
compromised	O
and	O
were	O
receiving	O
multiple	O
pharmacotherapies	O
.	O

Thus	O
,	O
two	O
control	O
groups	O
were	O
generated	O
:	O
group	O
C1	O
,	O
which	O
included	O
age-	O
and	O
sex-comparable	O
lithium-treated	O
bipolar	B_Disease
normocalcemic	O
patients	O
,	O
and	O
group	O
C2	O
,	O
which	O
included	O
bipolar	B_Disease
normocalcemic	O
patients	O
treated	O
with	O
anticonvulsant	O
mood	O
stabilizers	O
.	O

The	O
electrocardiographic	O
(	O
ECG	O
)	O
findings	O
for	O
patients	O
in	O
group	O
B	O
were	O
compared	O
with	O
those	O
of	O
patients	O
in	O
groups	O
C1	O
and	O
C2	O
.	O

It	O
was	O
found	O
that	O
these	O
groups	O
did	O
not	O
differ	O
in	O
their	O
overall	O
frequency	O
of	O
ECG	O
abnormalities	O
;	O
however	O
,	O
there	O
were	O
significant	O
differences	O
in	O
the	O
frequency	O
of	O
conduction	O
defects	O
.	O

Patients	O
with	O
hypercalcemia	B_Disease
resulting	O
from	O
medical	O
diseases	O
and	O
bipolar	B_Disease
patients	O
with	O
lithium-associated	O
hypercalcemia	B_Disease
had	O
significantly	O
higher	O
frequencies	O
of	O
conduction	O
defects	O
.	O

Patients	O
in	O
group	O
A	O
had	O
significant	O
mortality	O
at	O
2-year	O
follow-up	O
(	O
28	O
%	O
)	O
,	O
in	O
contrast	O
to	O
zero	O
mortality	O
in	O
the	O
other	O
three	O
groups	O
.	O

The	O
clinical	O
implications	O
of	O
these	O
findings	O
are	O
discussed	O
.	O

Attenuation	O
of	O
nephrotoxicity	B_Disease
by	O
a	O
novel	O
lipid	O
nanosphere	O
(	O
NS-718	O
)	O
incorporating	O
amphotericin	O
B.NS-718	O
,	O
a	O
lipid	O
nanosphere	O
incorporating	O
amphotericin	B_Chemical
B	I_Chemical
,	O
is	O
effective	O
against	O
pathogenic	O
fungi	O
and	O
has	O
low	O
toxicity	B_Disease
.	O

We	O
compared	O
the	O
toxicity	B_Disease
of	O
NS-718	O
with	O
that	O
of	O
Fungizone	B_Chemical
(	O
amphotericin	B_Chemical
B-sodium	I_Chemical
deoxycholate	I_Chemical
;	O
D-AmB	B_Chemical
)	O
in	O
vitro	O
using	O
renal	O
cell	O
cultures	O
and	O
in	O
vivo	O
by	O
biochemical	O
analysis	O
,	O
histopathological	O
study	O
of	O
the	O
kidney	O
and	O
pharmacokinetic	O
study	O
of	O
amphotericin	B_Chemical
B	I_Chemical
following	O
intravenous	O
infusion	O
of	O
the	O
formulation	O
in	O
rats	O
.	O

Incubation	O
with	O
NS-718	O
resulted	O
in	O
significantly	O
less	O
damage	O
of	O
cultured	O
human	O
renal	O
proximal	O
tubular	O
epithelial	O
cells	O
compared	O
with	O
D-AmB.	O
Serum	O
blood	O
urea	B_Chemical
and	O
creatinine	B_Chemical
concentrations	O
increased	O
significantly	O
in	O
rats	O
given	O
an	O
iv	O
infusion	O
of	O
D-AmB	B_Chemical
3	O
mg/kg	O
but	O
not	O
in	O
those	O
given	O
the	O
same	O
dose	O
of	O
NS-718	O
.	O

Histopathological	O
examination	O
of	O
the	O
kidney	O
showed	O
tubular	B_Disease
necrosis	I_Disease
in	O
D-AmB-treated	O
rats	O
but	O
no	O
change	O
in	O
NS-718-treated	O
rats	O
.	O

Amphotericin	B_Chemical
B	I_Chemical
concentrations	O
in	O
the	O
kidney	O
in	O
NS-718-treated	O
rats	O
were	O
higher	O
than	O
those	O
in	O
D-AmB-treated	O
rats	O
.	O

Our	O
in	O
vitro	O
and	O
in	O
vivo	O
results	O
suggest	O
that	O
incorporation	O
of	O
amphotericin	B_Chemical
B	I_Chemical
into	O
lipid	O
nanospheres	O
of	O
NS-718	O
attenuates	O
the	O
nephrotoxicity	B_Disease
of	O
amphotericin	O
B.	O

Patterns	O
of	O
sulfadiazine	B_Chemical
acute	B_Disease
nephrotoxicity	I_Disease
.	O

Sulfadiazine	B_Chemical
acute	B_Disease
nephrotoxicity	I_Disease
is	O
reviving	O
specially	O
because	O
of	O
its	O
use	O
in	O
toxoplasmosis	B_Disease
in	O
HIV-positive	O
patients	O
.	O

We	O
report	O
4	O
cases	O
,	O
one	O
of	O
them	O
in	O
a	O
previously	O
healthy	O
person	O
.	O

Under	O
treatment	O
with	O
sulfadiazine	B_Chemical
they	O
developed	O
oliguria	B_Disease
,	O
abdominal	B_Disease
pain	I_Disease
,	O
renal	B_Disease
failure	I_Disease
and	O
showed	O
multiple	O
radiolucent	O
renal	B_Disease
calculi	I_Disease
in	O
echography	O
.	O

All	O
patients	O
recovered	O
their	O
previous	O
normal	O
renal	O
function	O
after	O
adequate	O
hydration	O
and	O
alcalinization	O
.	O

A	O
nephrostomy	O
tube	O
had	O
to	O
be	O
placed	O
in	O
one	O
of	O
the	O
patients	O
for	O
ureteral	B_Disease
lithiasis	I_Disease
in	O
a	O
single	O
functional	O
kidney	O
.	O

None	O
of	O
them	O
needed	O
dialysis	O
or	O
a	O
renal	O
biopsy	O
because	O
of	O
a	O
typical	O
benign	O
course	O
.	O

Treatment	O
with	O
sulfadiazine	B_Chemical
requires	O
exquisite	O
control	O
of	O
renal	O
function	O
,	O
an	O
increase	O
in	O
water	O
ingestion	O
and	O
possibly	O
the	O
alcalinization	O
of	O
the	O
urine	O
.	O

We	O
communicate	O
a	O
case	O
in	O
a	O
previously	O
healthy	O
person	O
,	O
a	O
fact	O
not	O
found	O
in	O
the	O
recent	O
literature	O
.	O

Probably	O
many	O
more	O
cases	O
are	O
not	O
detected	O
.	O

We	O
think	O
that	O
a	O
prospective	O
study	O
would	O
be	O
useful	O
.	O

Downbeat	B_Disease
nystagmus	I_Disease
associated	O
with	O
intravenous	O
patient-controlled	O
administration	O
of	O
morphine	B_Chemical
.	O

IMPLICATIONS	O
:	O
This	O
case	O
documents	O
a	O
patient	O
who	O
developed	O
dizziness	B_Disease
with	O
downbeating	B_Disease
nystagmus	I_Disease
while	O
receiving	O
a	O
relatively	O
large	O
dose	O
of	O
IV	O
patient-controlled	O
analgesia	O
morphine	B_Chemical
.	O

Although	O
there	O
have	O
been	O
case	O
reports	O
of	O
epidural	O
morphine	B_Chemical
with	O
these	O
symptoms	O
and	O
signs	O
,	O
this	O
has	O
not	O
been	O
previously	O
documented	O
with	O
IV	O
or	O
patient-controlled	O
analgesia	O
morphine	B_Chemical
.	O

Hemodynamic	O
and	O
antiadrenergic	O
effects	O
of	O
dronedarone	B_Chemical
and	O
amiodarone	B_Chemical
in	O
animals	O
with	O
a	O
healed	O
myocardial	B_Disease
infarction	I_Disease
.	O

The	O
hemodynamic	O
and	O
antiadrenergic	O
effects	O
of	O
dronedarone	B_Chemical
,	O
a	O
noniodinated	O
compound	O
structurally	O
related	O
to	O
amiodarone	B_Chemical
,	O
were	O
compared	O
with	O
those	O
of	O
amiodarone	B_Chemical
after	O
prolonged	O
oral	O
administration	O
,	O
both	O
at	O
rest	O
and	O
during	O
sympathetic	O
stimulation	O
in	O
conscious	O
dogs	O
with	O
a	O
healed	O
myocardial	B_Disease
infarction	I_Disease
.	O

All	O
dogs	O
(	O
n	O
=	O
6	O
)	O
randomly	O
received	O
orally	O
dronedarone	B_Chemical
(	O
10	O
and	O
30	O
mg/kg	O
)	O
,	O
amiodarone	B_Chemical
(	O
10	O
and	O
30	O
mg/kg	O
)	O
,	O
and	O
placebo	O
twice	O
daily	O
for	O
7	O
days	O
,	O
with	O
a	O
3-week	O
washout	O
between	O
consecutive	O
treatments	O
.	O

Heart	O
rate	O
(	O
HR	O
)	O
,	O
mean	O
arterial	O
pressure	O
(	O
MBP	O
)	O
,	O
positive	O
rate	O
of	O
increase	O
of	O
left	O
ventricular	O
pressure	O
(	O
+	O
LVdP/dt	O
)	O
,	O
echocardiographically	O
assessed	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
,	O
and	O
fractional	O
shortening	O
(	O
FS	O
)	O
,	O
as	O
well	O
as	O
chronotropic	O
response	O
to	O
isoproterenol	B_Chemical
and	O
exercise-induced	O
sympathetic	O
stimulation	O
were	O
evaluated	O
under	O
baseline	O
and	O
posttreatment	O
conditions	O
.	O

Resting	O
values	O
of	O
LVEF	O
,	O
FS	O
,	O
+	O
LVdP/dt	O
,	O
and	O
MBP	O
remained	O
unchanged	O
whatever	O
the	O
drug	O
and	O
the	O
dosing	O
regimen	O
,	O
whereas	O
resting	O
HR	O
was	O
significantly	O
and	O
dose-dependently	O
lowered	O
after	O
dronedarone	B_Chemical
and	O
to	O
a	O
lesser	O
extent	O
after	O
amiodarone	B_Chemical
.	O

Both	O
dronedarone	B_Chemical
and	O
amiodarone	B_Chemical
significantly	O
reduced	O
the	O
exercise-induced	O
tachycardia	B_Disease
and	O
,	O
at	O
the	O
highest	O
dose	O
,	O
decreased	O
the	O
isoproterenol-induced	O
tachycardia	B_Disease
.	O

Thus	O
,	O
dronedarone	B_Chemical
and	O
amiodarone	B_Chemical
displayed	O
a	O
similar	O
level	O
of	O
antiadrenergic	O
effect	O
and	O
did	O
not	O
impair	O
the	O
resting	O
left	O
ventricular	O
function	O
.	O

Consequently	O
,	O
dronedarone	B_Chemical
might	O
be	O
particularly	O
suitable	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
various	O
clinical	O
arrhythmias	B_Disease
,	O
without	O
compromising	O
the	O
left	O
ventricular	O
function	O
.	O

Phase	O
2	O
trial	O
of	O
liposomal	O
doxorubicin	B_Chemical
(	O
40	O
mg/m(2	O
)	O
)	O
in	O
platinum/paclitaxel-refractory	O
ovarian	B_Disease
and	I_Disease
fallopian	B_Disease
tube	I_Disease
cancers	I_Disease
and	O
primary	O
carcinoma	B_Disease
of	I_Disease
the	I_Disease
peritoneum	I_Disease
.	O

BACKGROUND	O
:	O
Several	O
studies	O
have	O
demonstrated	O
liposomal	O
doxorubicin	B_Chemical
(	O
Doxil	B_Chemical
)	O
to	O
be	O
an	O
active	O
antineoplastic	O
agent	O
in	O
platinum-resistant	O
ovarian	B_Disease
cancer	I_Disease
,	O
with	O
dose	O
limiting	O
toxicity	B_Disease
of	O
the	O
standard	O
dosing	O
regimen	O
(	O
50	O
mg/m(2	O
)	O
q	O
4	O
weeks	O
)	O
being	O
severe	O
erythrodysesthesia	B_Disease
(	O
"	O
hand-foot	B_Disease
syndrome	I_Disease
"	O
)	O
and	O
stomatitis	B_Disease
.	O

We	O
wished	O
to	O
develop	O
a	O
more	O
tolerable	O
liposomal	O
doxorubicin	B_Chemical
treatment	O
regimen	O
and	O
document	O
its	O
level	O
of	O
activity	O
in	O
a	O
well-defined	O
patient	O
population	O
with	O
platinum/paclitaxel-refractory	O
disease	O
.	O

METHODS	O
AND	O
MATERIALS	O
:	O
Patients	O
with	O
ovarian	B_Disease
or	I_Disease
fallopian	B_Disease
tube	I_Disease
cancers	I_Disease
or	O
primary	O
peritoneal	B_Disease
carcinoma	I_Disease
with	O
platinum/paclitaxel-refractory	O
disease	O
(	O
stable	O
or	O
progressive	O
disease	O
following	O
treatment	O
with	O
these	O
agents	O
or	O
previous	O
objective	O
response	O
<3	O
months	O
in	O
duration	O
)	O
were	O
treated	O
with	O
liposomal	O
doxorubicin	B_Chemical
at	O
a	O
dose	O
of	O
40	O
mg/m(2	O
)	O
q	O
4	O
weeks	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
49	O
patients	O
(	O
median	O
age	O
:	O
60	O
;	O
range	O
41	O
-	O
81	O
)	O
entered	O
this	O
phase	O
2	O
trial	O
.	O

The	O
median	O
number	O
of	O
prior	O
regimens	O
was	O
2	O
(	O
range	O
:	O
1	O
-	O
6	O
)	O
.	O

Six	O
(	O
12	O
%	O
)	O
and	O
4	O
(	O
8	O
%	O
)	O
patients	O
experienced	O
grade	O
2	O
hand-foot	B_Disease
syndrome	I_Disease
and	O
stomatitis	B_Disease
,	O
respectively	O
(	O
no	O
episodes	O
of	O
grade	O
3	O
)	O
.	O

One	O
patient	O
developed	O
grade	O
3	O
diarrhea	B_Disease
requiring	O
hospitalization	O
for	O
hydration	O
.	O

Six	O
(	O
12	O
%	O
)	O
individuals	O
required	O
dose	O
reductions	O
.	O

The	O
median	O
number	O
of	O
courses	O
of	O
liposomal	O
doxorubicin	B_Chemical
administered	O
on	O
this	O
protocol	O
was	O
2	O
(	O
range	O
:	O
1	O
-	O
12	O
)	O
.	O

Four	O
of	O
44	O
patients	O
(	O
9	O
%	O
)	O
evaluable	O
for	O
response	O
exhibited	O
objective	O
and	O
subjective	O
evidence	O
of	O
an	O
antineoplastic	O
effect	O
of	O
therapy	O
.	O

CONCLUSION	O
:	O
This	O
modified	O
liposomal	O
doxorubicin	B_Chemical
regimen	O
results	O
in	O
less	O
toxicity	B_Disease
(	O
stomatitis	B_Disease
,	O
hand-foot	B_Disease
syndrome	I_Disease
)	O
than	O
the	O
standard	O
FDA-approved	O
dose	O
schedule	O
.	O

Definite	O
,	O
although	O
limited	O
,	O
antineoplastic	O
activity	O
is	O
observed	O
in	O
patients	O
with	O
well-defined	O
platinum-	O
and	O
paclitaxel-refractory	O
ovarian	B_Disease
cancer	I_Disease
.	O

Efficacy	O
of	O
olanzapine	B_Chemical
in	O
acute	O
bipolar	B_Disease
mania	I_Disease
:	O
a	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O

The	O
Olanzipine	B_Chemical
HGGW	O
Study	O
Group	O
.	O

BACKGROUND	O
:	O
We	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
olanzapine	B_Chemical
vs	O
placebo	O
for	O
the	O
treatment	O
of	O
acute	O
bipolar	B_Disease
mania	I_Disease
.	O

METHODS	O
:	O
Four-week	O
,	O
randomized	O
,	O
double-blind	O
,	O
parallel	O
study	O
.	O

A	O
total	O
of	O
115	O
patients	O
with	O
a	O
DSM-IV	O
diagnosis	O
of	O
bipolar	B_Disease
disorder	I_Disease
,	O
manic	B_Disease
or	O
mixed	O
,	O
were	O
randomized	O
to	O
olanzapine	B_Chemical
,	O
5	O
to	O
20	O
mg/d	O
(	O
n	O
=	O
55	O
)	O
,	O
or	O
placebo	O
(	O
n	O
=	O
60	O
)	O
.	O

The	O
primary	O
efficacy	O
measure	O
was	O
the	O
Young-Mania	O
Rating	O
Scale	O
(	O
Y-MRS	O
)	O
total	O
score	O
.	O

Response	O
and	O
euthymia	O
were	O
defined	O
,	O
a	O
priori	O
,	O
as	O
at	O
least	O
a	O
50	O
%	O
improvement	O
from	O
baseline	O
to	O
end	O
point	O
and	O
as	O
a	O
score	O
of	O
no	O
less	O
than	O
12	O
at	O
end	O
point	O
in	O
the	O
Y-MRS	O
total	O
score	O
,	O
respectively	O
.	O

Safety	O
was	O
assessed	O
using	O
adverse	O
events	O
,	O
Extrapyramidal	B_Disease
Symptom	I_Disease
(	O
EPS	B_Disease
)	O
rating	O
scales	O
,	O
laboratory	O
values	O
,	O
electrocardiograms	O
,	O
vital	O
signs	O
,	O
and	O
weight	O
change	O
.	O

RESULTS	O
:	O
Olanzapine-treated	O
patients	O
demonstrated	O
a	O
statistically	O
significant	O
greater	O
mean	O
(	O
+	O
/-	O
SD	O
)	O
improvement	O
in	O
Y-MRS	O
total	O
score	O
than	O
placebo-treated	O
patients	O
(	O
-14.8	O
+	O
/-	O
12.5	O
and	O
-8.1	O
+	O
/-	O
12.7	O
,	O
respectively	O
;	O
P<.001	O
)	O
,	O
which	O
was	O
evident	O
at	O
the	O
first	O
postbaseline	O
observation	O
1	O
week	O
after	O
randomization	O
and	O
was	O
maintained	O
throughout	O
the	O
study	O
(	O
last	O
observation	O
carried	O
forward	O
)	O
.	O

Olanzapine-treated	O
patients	O
demonstrated	O
a	O
higher	O
rate	O
of	O
response	O
(	O
65	O
%	O
vs	O
43	O
%	O
,	O
respectively	O
;	O
P	O
=	O
.02	O
)	O
and	O
euthymia	O
(	O
61	O
%	O
vs	O
36	O
%	O
,	O
respectively	O
;	O
P	O
=	O
.	O
01	O
)	O
than	O
placebo-treated	O
patients	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
EPSs	B_Disease
between	O
groups	O
.	O

However	O
,	O
olanzapine-treated	O
patients	O
had	O
a	O
statistically	O
significant	O
greater	O
mean	O
(	O
+	O
/-	O
SD	O
)	O
weight	B_Disease
gain	I_Disease
than	O
placebo-treated	O
patients	O
(	O
2.1	O
+	O
/-	O
2.8	O
vs	O
0.45	O
+	O
/-	O
2.3	O
kg	O
,	O
respectively	O
)	O
and	O
also	O
experienced	O
more	O
treatment-emergent	O
somnolence	B_Disease
(	O
21	O
patients	O
[	O
38.2	O
%	O
]	O
vs	O
5	O
[	O
8.3	O
%	O
]	O
,	O
respectively	O
)	O
.	O

CONCLUSION	O
:	O
Olanzapine	B_Chemical
demonstrated	O
greater	O
efficacy	O
than	O
placebo	O
in	O
the	O
treatment	O
of	O
acute	O
bipolar	B_Disease
mania	I_Disease
and	O
was	O
generally	O
well	O
tolerated	O
.	O

The	O
effect	O
of	O
pupil	B_Disease
dilation	I_Disease
with	O
tropicamide	B_Chemical
on	O
vision	O
and	O
driving	O
simulator	O
performance	O
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
effect	O
of	O
pupil	B_Disease
dilation	I_Disease
on	O
vision	O
and	O
driving	O
ability	O
.	O

METHODS	O
:	O
A	O
series	O
of	O
tests	O
on	O
various	O
parameters	O
of	O
visual	O
function	O
and	O
driving	O
simulator	O
performance	O
were	O
performed	O
on	O
12	O
healthy	O
drivers	O
,	O
before	O
and	O
after	O
pupil	B_Disease
dilation	I_Disease
using	O
guttae	O
tropicamide	B_Chemical
1	O
%	O
.	O

A	O
driving	O
simulator	O
(	O
Transport	O
Research	O
Laboratory	O
)	O
was	O
used	O
to	O
measure	O
reaction	O
time	O
(	O
RT	O
)	O
,	O
speed	O
maintenance	O
and	O
steering	O
accuracy	O
.	O

Tests	O
of	O
basic	O
visual	O
function	O
included	O
high-	O
and	O
low-contrast	O
visual	O
acuity	O
(	O
HCVA	O
and	O
LCVA	O
)	O
,	O
Pelli-Robson	O
contrast	O
threshold	O
(	O
CT	O
)	O
and	O
Goldmann	O
perimetry	O
(	O
FIELDS	O
)	O
.	O

Useful	O
Field	O
of	O
View	O
(	O
UFOV	O
--	O
a	O
test	O
of	O
visual	O
attention	O
)	O
was	O
also	O
undertaken	O
.	O

The	O
mean	O
differences	O
in	O
the	O
pre-	O
and	O
post-dilatation	O
measurements	O
were	O
tested	O
for	O
statistical	O
significance	O
at	O
the	O
95	O
%	O
level	O
using	O
one-tail	O
paired	O
t-tests	O
.	O

RESULTS	O
:	O
Pupillary	B_Disease
dilation	I_Disease
resulted	O
in	O
a	O
statistically	O
significant	O
deterioration	O
in	O
CT	O
and	O
HCVA	O
only	O
.	O

Five	O
of	O
12	O
drivers	O
also	O
exhibited	O
deterioration	O
in	O
LCVA	O
,	O
CT	O
and	O
RT	O
.	O

Little	O
evidence	O
emerged	O
for	O
deterioration	O
in	O
FIELDS	O
and	O
UFOV	O
.	O

Also	O
,	O
7	O
of	O
12	O
drivers	O
appeared	O
to	O
adjust	O
their	O
driving	O
behaviour	O
by	O
reducing	O
their	O
speed	O
on	O
the	O
driving	O
simulator	O
,	O
leading	O
to	O
improved	O
steering	O
accuracy	O
.	O

CONCLUSIONS	O
:	O
Pupillary	B_Disease
dilation	I_Disease
may	O
lead	O
to	O
a	O
decrease	O
in	O
vision	O
and	O
daylight	O
driving	O
performance	O
in	O
young	O
people	O
.	O

A	O
larger	O
study	O
,	O
including	O
a	O
broader	O
spectrum	O
of	O
subjects	O
,	O
is	O
warranted	O
before	O
guidelines	O
can	O
be	O
recommended	O
.	O

A	O
case	O
of	O
isotretinoin	B_Disease
embryopathy	I_Disease
with	O
bilateral	O
anotia	B_Disease
and	O
Taussig-Bing	B_Disease
malformation	I_Disease
.	O

We	O
report	O
a	O
newborn	O
infant	O
with	O
multiple	O
congenital	O
anomalies	O
(	O
anotia	B_Disease
and	O
Taussig-Bing	B_Disease
malformation	I_Disease
)	O
due	O
to	O
exposure	O
to	O
isotretinoin	B_Chemical
within	O
the	O
first	O
trimester	O
.	O

In	O
this	O
paper	O
we	O
aim	O
to	O
draw	O
to	O
the	O
fact	O
that	O
caution	O
is	O
needed	O
when	O
prescribing	O
vitamin	O
A-containing	O
drugs	O
to	O
women	O
of	O
childbearing	O
years	O
.	O

Effect	O
of	O
methoxamine	B_Chemical
on	O
maximum	O
urethral	O
pressure	O
in	O
women	O
with	O
genuine	O
stress	B_Disease
incontinence	I_Disease
:	O
a	O
placebo-controlled	O
,	O
double-blind	O
crossover	O
study	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
potential	O
role	O
for	O
a	O
selective	O
alpha1-adrenoceptor	O
agonist	O
in	O
the	O
treatment	O
of	O
urinary	B_Disease
stress	I_Disease
incontinence	I_Disease
.	O

A	O
randomised	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
crossover	O
study	O
design	O
was	O
employed	O
.	O

Half	O
log	O
incremental	O
doses	O
of	O
intravenous	O
methoxamine	B_Chemical
or	O
placebo	O
(	O
saline	O
)	O
were	O
administered	O
to	O
a	O
group	O
of	O
women	O
with	O
genuine	O
stress	B_Disease
incontinence	I_Disease
while	O
measuring	O
maximum	O
urethral	O
pressure	O
(	O
MUP	O
)	O
,	O
blood	O
pressure	O
,	O
heart	O
rate	O
,	O
and	O
symptomatic	O
side	O
effects	O
.	O

Methoxamine	B_Chemical
evoked	O
non-significant	O
increases	O
in	O
MUP	O
and	O
diastolic	O
blood	O
pressure	O
but	O
caused	O
a	B_Disease
significant	I_Disease
rise	I_Disease
in	I_Disease
systolic	I_Disease
blood	I_Disease
pressure	I_Disease
and	O
significant	O
fall	O
in	O
heart	O
rate	O
at	O
maximum	O
dosage	O
.	O

Systemic	O
side	O
effects	O
including	O
piloerection	O
,	O
headache	B_Disease
,	O
and	O
cold	O
extremities	O
were	O
experienced	O
in	O
all	O
subjects	O
.	O

The	O
results	O
indicate	O
that	O
the	O
clinical	O
usefulness	O
of	O
direct	O
,	O
peripherally	O
acting	O
sub-type-selective	O
alpha1-adrenoceptor	O
agonists	O
in	O
the	O
medical	O
treatment	O
of	O
stress	B_Disease
incontinence	I_Disease
may	O
be	O
limited	O
by	O
associated	O
piloerection	O
and	O
cardiovascular	O
side	O
effects	O
.	O

Hyperglycemic	B_Disease
effect	O
of	O
amino	B_Chemical
compounds	O
structurally	O
related	O
to	O
caproate	B_Chemical
in	O
rats	O
.	O

The	O
chronic	O
feeding	O
of	O
small	O
amounts	O
(	O
0.3	O
-	O
3	O
%	O
of	O
diet	O
weight	O
)	O
of	O
certain	O
amino	B_Chemical
derivatives	O
of	O
caproate	B_Chemical
resulted	O
in	O
hyperglycemia	B_Disease
,	O
an	O
elevated	O
glucose	B_Chemical
tolerance	O
curve	O
and	O
,	O
occasionally	O
,	O
glucosuria	B_Disease
.	O

Effective	O
compounds	O
included	O
norleucine	B_Chemical
,	O
norvaline	B_Chemical
,	O
glutamate	B_Chemical
,	O
epsilon-aminocaproate	B_Chemical
,	O
methionine	B_Chemical
,	O
and	O
leucine	B_Chemical
.	O

Toleration	O
of	O
high	O
doses	O
of	O
angiotensin-converting	B_Chemical
enzyme	I_Chemical
inhibitors	I_Chemical
in	O
patients	O
with	O
chronic	O
heart	B_Disease
failure	I_Disease
:	O
results	O
from	O
the	O
ATLAS	O
trial	O
.	O

The	O
Assessment	O
of	O
Treatment	O
with	O
Lisinopril	B_Chemical
and	O
Survival	O
.	O

BACKGROUND	O
:	O
Treatment	O
with	O
angiotensin-converting	B_Chemical
enzyme	I_Chemical
(	I_Chemical
ACE	I_Chemical
)	I_Chemical
inhibitors	I_Chemical
reduces	O
mortality	O
and	O
morbidity	O
in	O
patients	O
with	O
chronic	O
heart	B_Disease
failure	I_Disease
(	O
CHF	B_Disease
)	O
,	O
but	O
most	O
affected	O
patients	O
are	O
not	O
receiving	O
these	O
agents	O
or	O
are	O
being	O
treated	O
with	O
doses	O
lower	O
than	O
those	O
found	O
to	O
be	O
efficacious	O
in	O
trials	O
,	O
primarily	O
because	O
of	O
concerns	O
about	O
the	O
safety	O
and	O
tolerability	O
of	O
these	O
agents	O
,	O
especially	O
at	O
the	O
recommended	O
doses	O
.	O

The	O
present	O
study	O
examines	O
the	O
safety	O
and	O
tolerability	O
of	O
high-	O
compared	O
with	O
low-dose	O
lisinopril	B_Chemical
in	O
CHF	B_Disease
.	O

METHODS	O
:	O
The	O
Assessment	O
of	O
Lisinopril	B_Chemical
and	O
Survival	O
study	O
was	O
a	O
multicenter	O
,	O
randomized	O
,	O
double-blind	O
trial	O
in	O
which	O
patients	O
with	O
or	O
without	O
previous	O
ACE	B_Chemical
inhibitor	I_Chemical
treatment	O
were	O
stabilized	O
receiving	O
medium-dose	O
lisinopril	B_Chemical
(	O
12.5	O
or	O
15.0	O
mg	O
once	O
daily	O
[	O
OD	O
]	O
)	O
for	O
2	O
to	O
4	O
weeks	O
and	O
then	O
randomized	O
to	O
high-	O
(	O
35.0	O
or	O
32.5	O
mg	O
OD	O
)	O
or	O
low-dose	O
(	O
5.0	O
or	O
2.5	O
mg	O
OD	O
)	O
groups	O
.	O

Patients	O
with	O
New	O
York	O
Heart	O
Association	O
classes	O
II	O
to	O
IV	O
CHF	B_Disease
and	O
left	O
ventricular	O
ejection	O
fractions	O
of	O
no	O
greater	O
than	O
0.30	O
(	O
n	O
=	O
3164	O
)	O
were	O
randomized	O
and	O
followed	O
up	O
for	O
a	O
median	O
of	O
46	O
months	O
.	O

We	O
examined	O
the	O
occurrence	O
of	O
adverse	O
events	O
and	O
the	O
need	O
for	O
discontinuation	O
and	O
dose	O
reduction	O
during	O
treatment	O
,	O
with	O
a	O
focus	O
on	O
hypotension	B_Disease
and	O
renal	B_Disease
dysfunction	I_Disease
.	O

RESULTS	O
:	O
Of	O
405	O
patients	O
not	O
previously	O
receiving	O
an	O
ACE	B_Chemical
inhibitor	I_Chemical
,	O
doses	O
in	O
only	O
4.2	O
%	O
could	O
not	O
be	O
titrated	O
to	O
the	O
medium	O
doses	O
required	O
for	O
randomization	O
because	O
of	O
symptoms	O
possibly	O
related	O
to	O
hypotension	B_Disease
(	O
2.0	O
%	O
)	O
or	O
because	O
of	O
renal	B_Disease
dysfunction	I_Disease
or	O
hyperkalemia	B_Disease
(	O
2.3	O
%	O
)	O
.	O

Doses	O
in	O
more	O
than	O
90	O
%	O
of	O
randomized	O
patients	O
in	O
the	O
high-	O
and	O
low-dose	O
groups	O
were	O
titrated	O
to	O
their	O
assigned	O
target	O
,	O
and	O
the	O
mean	O
doses	O
of	O
blinded	O
medication	O
in	O
both	O
groups	O
remained	O
similar	O
throughout	O
the	O
study	O
.	O

Withdrawals	O
occurred	O
in	O
27.1	O
%	O
of	O
the	O
high-	O
and	O
30.7	O
%	O
of	O
the	O
low-dose	O
groups	O
.	O

Subgroups	O
presumed	O
to	O
be	O
at	O
higher	O
risk	O
for	O
ACE	B_Chemical
inhibitor	I_Chemical
intolerance	O
(	O
blood	O
pressure	O
,	O
<	O
120	O
mm	O
Hg	O
;	O
creatinine	B_Chemical
,	O
>	O
or	O
=	O
132.6	O
micromol/L	O
[	O
>	O
or	O
=	O
1.5	O
mg/dL	O
]	O
;	O
age	O
,	O
>	O
or	O
=	O
70	O
years	O
;	O
and	O
patients	O
with	O
diabetes	B_Disease
)	O
generally	O
tolerated	O
the	O
high-dose	O
strategy	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
demonstrate	O
that	O
ACE	B_Chemical
inhibitor	I_Chemical
therapy	O
in	O
most	O
patients	O
with	O
CHF	B_Disease
can	O
be	O
successfully	O
titrated	O
to	O
and	O
maintained	O
at	O
high	O
doses	O
,	O
and	O
that	O
more	O
aggressive	O
use	O
of	O
these	O
agents	O
is	O
warranted	O
.	O

Cocaine	B_Chemical
,	O
ethanol	B_Chemical
,	O
and	O
cocaethylene	B_Chemical
cardiotoxity	B_Disease
in	O
an	O
animal	O
model	O
of	O
cocaine	B_Disease
and	I_Disease
ethanol	B_Disease
abuse	I_Disease
.	O

OBJECTIVES	O
:	O
Simultaneous	O
abuse	B_Disease
of	I_Disease
cocaine	I_Disease
and	I_Disease
ethanol	I_Disease
affects	O
12	O
million	O
Americans	O
annually	O
.	O

In	O
combination	O
,	O
these	O
substances	O
are	O
substantially	O
more	O
toxic	O
than	O
either	O
drug	O
alone	O
.	O

Their	O
combined	O
cardiac	B_Disease
toxicity	I_Disease
may	O
be	O
due	O
to	O
independent	O
effects	O
of	O
each	O
drug	O
;	O
however	O
,	O
they	O
may	O
also	O
be	O
due	O
to	O
cocaethylene	B_Chemical
(	O
CE	B_Chemical
)	O
,	O
a	O
cocaine	B_Chemical
metabolite	O
formed	O
only	O
in	O
the	O
presence	O
of	O
ethanol	B_Chemical
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
delineate	O
the	O
role	O
of	O
CE	B_Chemical
in	O
the	O
combined	O
cardiotoxicity	B_Disease
of	O
cocaine	B_Chemical
and	O
ethanol	B_Chemical
in	O
a	O
model	O
simulating	O
their	O
abuse	O
.	O

METHODS	O
:	O
Twenty-three	O
dogs	O
were	O
randomized	O
to	O
receive	O
either	O
1	O
)	O
three	O
intravenous	O
(	O
IV	O
)	O
boluses	O
of	O
cocaine	B_Chemical
7.5	O
mg/kg	O
with	O
ethanol	B_Chemical
(	O
1	O
g/kg	O
)	O
as	O
an	O
IV	O
infusion	O
(	O
C+E	O
,	O
n	O
=	O
8)	O
,	O
2	O
)	O
three	O
cocaine	B_Chemical
boluses	O
only	O
(	O
C	O
,	O
n	O
=	O
6	O
)	O
,	O
3	O
)	O
ethanol	B_Chemical
infusion	O
only	O
(	O
E	O
,	O
n	O
=	O
5	O
)	O
,	O
or	O
4	O
)	O
placebo	O
boluses	O
and	O
infusion	O
(	O
n	O
=	O
4	O
)	O
.	O

Hemodynamic	O
measurements	O
,	O
electrocardiograms	O
,	O
and	O
serum	O
drug	O
concentrations	O
were	O
obtained	O
at	O
baseline	O
,	O
and	O
then	O
at	O
fixed	O
time	O
intervals	O
after	O
each	O
drug	O
was	O
administered	O
.	O

RESULTS	O
:	O
Two	O
of	O
eight	O
dogs	O
in	O
the	O
C+E	O
group	O
experienced	O
cardiovascular	B_Disease
collapse	I_Disease
.	O

The	O
most	O
dramatic	O
hemodynamic	O
changes	O
occurred	O
after	O
each	O
cocaine	B_Chemical
bolus	O
in	O
the	O
C+E	O
and	O
C	O
only	O
groups	O
;	O
however	O
,	O
persistent	O
hemodynamic	O
changes	O
occurred	O
in	O
the	O
C+E	O
group	O
.	O

Peak	O
CE	B_Chemical
levels	O
were	O
associated	O
with	O
a	O
45	O
%	O
(	O
SD	O
+	O
/-	O
22	O
%	O
,	O
95	O
%	O
CI	O
=	O
22	O
%	O
to	O
69	O
%	O
)	O
decrease	B_Disease
in	I_Disease
cardiac	I_Disease
output	I_Disease
(	O
p	O
<	O
0.05	O
)	O
,	O
a	O
56	O
%	O
(	O
SD	O
+	O
/-	O
23	O
%	O
,	O
95	O
%	O
CI	O
=	O
32	O
%	O
to	O
80	O
%	O
)	O
decrease	O
in	O
dP/dt(max	O
)	O
(	O
p	O
<	O
.006	O
)	O
,	O
and	O
a	O
23	O
%	O
(	O
SD	O
+	O
/-	O
15	O
%	O
,	O
95	O
%	O
CI	O
=	O
7	O
%	O
to	O
49	O
%	O
)	O
decrease	O
in	O
SVO(2	O
)	O
(	O
p	O
<	O
0.025	O
)	O
.	O

Ventricular	B_Disease
arrhythmias	I_Disease
were	O
primarily	O
observed	O
in	O
the	O
C+E	O
group	O
,	O
in	O
which	O
four	O
of	O
eight	O
dogs	O
experienced	O
ventricular	B_Disease
tachycardia	I_Disease
.	O

CONCLUSIONS	O
:	O
Cocaine	B_Chemical
and	O
ethanol	B_Chemical
in	O
combination	O
were	O
more	O
toxic	O
than	O
either	O
substance	O
alone	O
.	O

Co-administration	O
resulted	O
in	O
prolonged	O
cardiac	B_Disease
toxicity	I_Disease
and	O
was	O
dysrhythmogenic	O
.	O

Peak	O
serum	O
cocaethylene	B_Chemical
concentrations	O
were	O
associated	O
with	O
prolonged	O
myocardial	B_Disease
depression	I_Disease
.	O

Worsening	O
of	O
Parkinsonism	B_Disease
after	O
the	O
use	O
of	O
veralipride	B_Chemical
for	O
treatment	O
of	O
menopause	O
:	O
case	O
report	O
.	O

We	O
describe	O
a	O
female	O
patient	O
with	O
stable	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
who	O
has	O
shown	O
a	O
marked	O
worsening	O
of	O
her	O
motor	O
functions	O
following	O
therapy	O
of	O
menopause	O
related	O
symptoms	O
with	O
veralipride	B_Chemical
,	O
as	O
well	O
as	O
the	O
improvement	O
of	O
her	O
symptoms	O
back	O
to	O
baseline	O
after	O
discontinuation	O
of	O
the	O
drug	O
.	O

We	O
emphasize	O
the	O
anti-dopaminergic	O
effect	O
of	O
veralipride	B_Chemical
.	O

Viracept	B_Chemical
and	O
irregular	B_Disease
heartbeat	I_Disease
warning	O
.	O

A	O
group	O
of	O
doctors	O
in	O
Boston	O
warn	O
that	O
the	O
protease	O
inhibitor	O
Viracept	B_Chemical
may	O
cause	O
an	O
irregular	B_Disease
heart	I_Disease
beat	I_Disease
,	O
known	O
as	O
bradycardia	B_Disease
,	O
in	O
people	O
with	O
HIV	O
.	O

Bradycardia	B_Disease
occurred	O
in	O
a	O
45-year-old	O
male	O
patient	O
who	O
was	O
Viracept	B_Chemical
in	O
combination	O
with	O
other	O
anti-HIV	O
drugs	O
.	O

The	O
symptoms	O
ceased	O
after	O
switching	O
to	O
another	O
drug	O
combination	O
.	O

Frequency	O
of	O
appearance	O
of	O
myeloperoxidase-antineutrophil	O
cytoplasmic	O
antibody	O
(	O
MPO-ANCA	O
)	O
in	O
Graves	B_Disease
'	I_Disease
disease	I_Disease
patients	O
treated	O
with	O
propylthiouracil	B_Chemical
and	O
the	O
relationship	O
between	O
MPO-ANCA	O
and	O
clinical	O
manifestations	O
.	O

OBJECTIVE	O
:	O
Myeloperoxidase	O
antineutrophil	O
cytoplasmic	O
antibody	O
(MPO-ANCA)-positive	O
vasculitis	B_Disease
has	O
been	O
reported	O
in	O
patients	O
with	O
Graves	B_Disease
'	I_Disease
disease	I_Disease
who	O
were	O
treated	O
with	O
propylthiouracil	B_Chemical
(	O
PTU	B_Chemical
)	O
.	O

The	O
appearance	O
of	O
MPO-ANCA	O
in	O
these	O
cases	O
was	O
suspected	O
of	O
being	O
related	O
to	O
PTU	B_Chemical
because	O
the	O
titres	O
of	O
MPO-ANCA	O
decreased	O
when	O
PTU	B_Chemical
was	O
stopped	O
.	O

Nevertheless	O
,	O
there	O
have	O
been	O
no	O
studies	O
on	O
the	O
temporal	O
relationship	O
between	O
the	O
appearance	O
of	O
MPO-ANCA	O
and	O
vasculitis	B_Disease
during	O
PTU	B_Chemical
therapy	O
,	O
or	O
on	O
the	O
incidence	O
of	O
MPO-ANCA	O
in	O
untreated	O
Graves	B_Disease
'	I_Disease
disease	I_Disease
patients	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
address	O
these	O
parameters	O
in	O
patients	O
with	O
Graves	B_Disease
'	I_Disease
disease	I_Disease
.	O

PATIENTS	O
:	O
We	O
investigated	O
102	O
untreated	O
patients	O
with	O
hyperthyroidism	B_Disease
due	O
to	O
Graves	B_Disease
'	I_Disease
disease	I_Disease
for	O
the	O
presence	O
of	O
MPO-ANCA	O
,	O
and	O
for	O
the	O
development	O
vasculitis	B_Disease
after	O
starting	O
PTU	B_Chemical
therapy	O
.	O

Twenty-nine	O
of	O
them	O
were	O
later	O
excluded	O
because	O
of	O
adverse	O
effects	O
of	O
PTU	B_Chemical
or	O
because	O
the	O
observation	O
period	O
was	O
less	O
than	O
3	O
months	O
.	O

The	O
remaining	O
73	O
patients	O
(	O
55	O
women	O
and	O
18	O
men	O
)	O
,	O
all	O
of	O
whom	O
were	O
examined	O
for	O
more	O
than	O
3	O
months	O
,	O
were	O
adopted	O
as	O
the	O
subjects	O
of	O
the	O
investigation	O
.	O

The	O
median	O
observation	O
period	O
was	O
23.6	O
months	O
(	O
range	O
:	O
3	O
-	O
37	O
months	O
)	O
.	O

MEASUREMENTS	O
:	O
MPO-ANCA	O
was	O
measured	O
at	O
intervals	O
of	O
2	O
-	O
6	O
months	O
.	O

RESULTS	O
:	O
Before	O
treatment	O
,	O
the	O
MPO-ANCA	O
titres	O
of	O
all	O
102	O
untreated	O
Graves	B_Disease
'	I_Disease
disease	I_Disease
patients	O
were	O
within	O
the	O
reference	O
range	O
(	O
below	O
10	O
U/ml	O
)	O
.	O

Three	O
(	O
4.1	O
%	O
)	O
of	O
the	O
73	O
patients	O
were	O
positive	O
for	O
MPO-ANCA	O
at	O
13	O
,	O
16	O
and	O
17	O
months	O
,	O
respectively	O
,	O
after	O
the	O
start	O
of	O
PTU	B_Chemical
therapy	O
.	O

In	O
two	O
of	O
them	O
,	O
the	O
MPO-ANCA	O
titres	O
transiently	O
increased	O
to	O
12.8	O
and	O
15.0	O
U/ml	O
,	O
respectively	O
,	O
despite	O
continued	O
PTU	B_Chemical
therapy	O
,	O
but	O
no	O
vasculitic	B_Disease
disorders	I_Disease
developed	O
.	O

In	O
the	O
third	O
patient	O
,	O
the	O
MPO-ANCA	O
titre	O
increased	O
to	O
204	O
U/ml	O
and	O
she	O
developed	O
a	O
higher	O
fever	B_Disease
,	O
oral	B_Disease
ulcers	I_Disease
and	O
polyarthralgia	B_Disease
,	O
but	O
the	O
symptoms	O
resolved	O
2	O
weeks	O
after	O
stopping	O
PTU	B_Chemical
therapy	O
,	O
and	O
the	O
MPO-ANCA	O
titre	O
decreased	O
to	O
20.7	O
U/ml	O
by	O
4	O
months	O
after	O
discontinuing	O
PTU	B_Chemical
.	O

CONCLUSIONS	O
:	O
PTU	B_Chemical
therapy	O
may	O
be	O
related	O
to	O
the	O
appearance	O
of	O
MPO-ANCA	O
,	O
but	O
MPO-ANCA	O
does	O
not	O
appear	O
to	O
be	O
closely	O
related	O
to	O
vasculitis	B_Disease
.	O

Prevalence	O
of	O
heart	B_Disease
disease	I_Disease
in	O
asymptomatic	O
chronic	O
cocaine	B_Chemical
users	O
.	O

To	O
determine	O
the	O
prevalence	O
of	O
heart	B_Disease
disease	I_Disease
in	O
outpatient	O
young	O
asymptomatic	O
chronic	O
cocaine	B_Chemical
users	O
,	O
35	O
cocaine	B_Chemical
users	O
and	O
32	O
age-matched	O
controls	O
underwent	O
resting	O
and	O
exercise	O
electrocardiography	O
(	O
ECG	O
)	O
and	O
Doppler	O
echocardiography	O
.	O

Findings	O
consistent	O
with	O
coronary	B_Disease
artery	I_Disease
disease	I_Disease
were	O
detected	O
in	O
12	O
(	O
34	O
%	O
)	O
patients	O
and	O
3	O
(	O
9	O
%	O
)	O
controls	O
(	O
p	O
=	O
0.01	O
)	O
.	O

Decreased	O
left	O
ventricular	O
systolic	O
function	O
was	O
demonstrated	O
in	O
5	O
(	O
14	O
%	O
)	O
patients	O
,	O
but	O
in	O
none	O
of	O
the	O
controls	O
(	O
p	O
=	O
0.055	O
)	O
.	O

Finally	O
,	O
resting	O
and	O
peak	O
exercise	O
abnormal	B_Disease
left	I_Disease
ventricular	I_Disease
filling	I_Disease
was	O
detected	O
in	O
38	O
and	O
35	O
%	O
of	O
patients	O
as	O
compared	O
to	O
19	O
and	O
9	O
%	O
of	O
controls	O
,	O
respectively	O
(	O
p	O
=	O
0.11	O
and	O
0.02	O
,	O
respectively	O
)	O
.	O

We	O
conclude	O
that	O
coronary	B_Disease
artery	I_Disease
or	I_Disease
myocardial	B_Disease
disease	I_Disease
is	O
common	O
(	O
38	O
%	O
)	O
in	O
young	O
asymptomatic	O
chronic	O
cocaine	B_Chemical
users	O
.	O

Therefore	O
,	O
screening	O
ECG	O
and	O
echocardiography	O
may	O
be	O
warranted	O
in	O
these	O
patients	O
.	O

Cardioprotective	O
effects	O
of	O
Picrorrhiza	O
kurroa	O
against	O
isoproterenol-induced	O
myocardial	O
stress	O
in	O
rats	O
.	O

The	O
cardioprotective	O
effect	O
of	O
the	O
ethanol	B_Chemical
extract	O
of	O
Picrorrhiza	O
kurroa	O
rhizomes	O
and	O
roots	O
(	O
PK	O
)	O
on	O
isoproterenol-induced	O
myocardial	B_Disease
infarction	I_Disease
in	O
rats	O
with	O
respect	O
to	O
lipid	O
metabolism	O
in	O
serum	O
and	O
heart	O
tissue	O
has	O
been	O
investigated	O
.	O

Oral	O
pre-treatment	O
with	O
PK	O
(	O
80	O
mg	O
kg(-1	O
)	O
day(-1	O
)	O
for	O
15	O
days	O
)	O
significantly	O
prevented	O
the	O
isoproterenol-induced	O
myocardial	B_Disease
infarction	I_Disease
and	O
maintained	O
the	O
rats	O
at	O
near	O
normal	O
status	O
.	O

Phase	O
2	O
early	O
afterdepolarization	O
as	O
a	O
trigger	O
of	O
polymorphic	O
ventricular	B_Disease
tachycardia	I_Disease
in	O
acquired	O
long-QT	B_Disease
syndrome	I_Disease
:	O
direct	O
evidence	O
from	O
intracellular	O
recordings	O
in	O
the	O
intact	O
left	O
ventricular	O
wall	O
.	O

BACKGROUND	O
:	O
This	O
study	O
examined	O
the	O
role	O
of	O
phase	O
2	O
early	O
afterdepolarization	O
(	O
EAD	O
)	O
in	O
producing	O
a	O
trigger	O
to	O
initiate	O
torsade	B_Disease
de	I_Disease
pointes	I_Disease
(	O
TdP	B_Disease
)	O
with	O
QT	B_Disease
prolongation	I_Disease
induced	O
by	O
dl-sotalol	O
and	O
azimilide	B_Chemical
.	O

The	O
contribution	O
of	O
transmural	O
dispersion	O
of	O
repolarization	O
(	O
TDR	O
)	O
to	O
transmural	O
propagation	O
of	O
EAD	O
and	O
the	O
maintenance	O
of	O
TdP	B_Disease
was	O
also	O
evaluated	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Transmembrane	O
action	O
potentials	O
from	O
epicardium	O
,	O
midmyocardium	O
,	O
and	O
endocardium	O
were	O
recorded	O
simultaneously	O
,	O
together	O
with	O
a	O
transmural	O
ECG	O
,	O
in	O
arterially	O
perfused	O
canine	O
and	O
rabbit	O
left	O
ventricular	O
preparations	O
.	O

dl-Sotalol	O
preferentially	O
prolonged	O
action	O
potential	O
duration	O
(	O
APD	O
)	O
in	O
M	O
cells	O
dose-dependently	O
(	O
1	O
to	O
100	O
micromol/L	O
)	O
,	O
leading	O
to	O
QT	B_Disease
prolongation	I_Disease
and	O
an	O
increase	O
in	O
TDR	O
.	O

Azimilide	B_Chemical
,	O
however	O
,	O
significantly	O
prolonged	O
APD	O
and	O
QT	O
interval	O
at	O
concentrations	O
from	O
0.1	O
to	O
10	O
micromol/L	O
but	O
shortened	O
them	O
at	O
30	O
micromol/L.	O
Unlike	O
dl-sotalol	O
,	O
azimilide	B_Chemical
(	O
>	O
3	O
micromol/L	O
)	O
increased	O
epicardial	O
APD	O
markedly	O
,	O
causing	O
a	O
diminished	O
TDR	O
.	O

Although	O
both	O
dl-sotalol	O
and	O
azimilide	B_Chemical
rarely	O
induced	O
EADs	O
in	O
canine	O
left	O
ventricles	O
,	O
they	O
produced	O
frequent	O
EADs	O
in	O
rabbits	O
,	O
in	O
which	O
more	O
pronounced	O
QT	B_Disease
prolongation	I_Disease
was	O
seen	O
.	O

An	O
increase	O
in	O
TDR	O
by	O
dl-sotalol	O
facilitated	O
transmural	O
propagation	O
of	O
EADs	O
that	O
initiated	O
multiple	O
episodes	O
of	O
spontaneous	O
TdP	B_Disease
in	O
3	O
of	O
6	O
rabbit	O
left	O
ventricles	O
.	O

Of	O
note	O
,	O
although	O
azimilide	B_Chemical
(	O
3	O
to	O
10	O
micromol/L	O
)	O
increased	O
APD	O
more	O
than	O
dl-sotalol	O
,	O
its	O
EADs	O
often	O
failed	O
to	O
propagate	O
transmurally	O
,	O
probably	O
because	O
of	O
a	O
diminished	O
TDR	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
provides	O
the	O
first	O
direct	O
evidence	O
from	O
intracellular	O
action	O
potential	O
recordings	O
that	O
phase	O
2	O
EAD	O
can	O
be	O
generated	O
from	O
intact	O
ventricular	O
wall	O
and	O
produce	O
a	O
trigger	O
to	O
initiate	O
the	O
onset	O
of	O
TdP	B_Disease
under	O
QT	B_Disease
prolongation	I_Disease
.	O

A	O
pilot	O
study	O
to	O
assess	O
the	O
safety	O
of	O
dobutamine	B_Chemical
stress	O
echocardiography	O
in	O
the	O
emergency	O
department	O
evaluation	O
of	O
cocaine-associated	O
chest	B_Disease
pain	I_Disease
.	O

STUDY	O
OBJECTIVE	O
:	O
Chest	B_Disease
pain	I_Disease
in	O
the	O
setting	O
of	O
cocaine	B_Chemical
use	O
poses	O
a	O
diagnostic	O
dilemma	O
.	O

Dobutamine	B_Chemical
stress	O
echocardiography	O
(	O
DSE	O
)	O
is	O
a	O
widely	O
available	O
and	O
sensitive	O
test	O
for	O
evaluating	O
cardiac	O
ischemia	B_Disease
.	O

Because	O
of	O
the	O
theoretical	O
concern	O
regarding	O
administration	O
of	O
dobutamine	B_Chemical
in	O
the	O
setting	O
of	O
cocaine	B_Chemical
use	O
,	O
we	O
conducted	O
a	O
pilot	O
study	O
to	O
assess	O
the	O
safety	O
of	O
DSE	O
in	O
emergency	O
department	O
patients	O
with	O
cocaine-associated	O
chest	B_Disease
pain	I_Disease
.	O

METHODS	O
:	O
A	O
prospective	O
case	O
series	O
was	O
conducted	O
in	O
the	O
intensive	O
diagnostic	O
and	O
treatment	O
unit	O
in	O
the	O
ED	O
of	O
an	O
urban	O
tertiary-care	O
teaching	O
hospital	O
.	O

Patients	O
were	O
eligible	O
for	O
DSE	O
if	O
they	O
had	O
used	O
cocaine	B_Chemical
within	O
24	O
hours	O
preceding	O
the	O
onset	O
of	O
chest	B_Disease
pain	I_Disease
and	O
had	O
a	O
normal	O
ECG	O
and	O
tropinin	O
I	O
level	O
.	O

Patients	O
exhibiting	O
signs	O
of	O
continuing	O
cocaine	B_Chemical
toxicity	B_Disease
were	O
excluded	O
from	O
the	O
study	O
.	O

All	O
patients	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
serial	O
testing	O
after	O
the	O
DSE	O
testing	O
in	O
the	O
intensive	O
diagnostic	O
and	O
treatment	O
unit	O
.	O

RESULTS	O
:	O
Twenty-four	O
patients	O
were	O
enrolled	O
.	O

Two	O
patients	O
had	O
inadequate	O
resting	O
images	O
,	O
one	O
DSE	O
was	O
terminated	O
because	O
of	O
inferior	O
hypokinesis	B_Disease
,	O
another	O
DSE	O
was	O
terminated	O
because	O
of	O
a	O
rate-related	O
atrial	O
conduction	O
deficit	O
,	O
and	O
1	O
patient	O
did	O
not	O
reach	O
the	O
target	O
heart	O
rate	O
.	O

Thus	O
,	O
19	O
patients	O
completed	O
a	O
DSE	O
and	O
reached	O
their	O
target	O
heart	O
rates	O
.	O

None	O
of	O
the	O
patients	O
experienced	O
signs	O
of	O
exaggerated	O
adrenergic	O
response	O
,	O
which	O
was	O
defined	O
as	O
a	O
systolic	O
blood	O
pressure	O
of	O
greater	O
than	O
200	O
mm	O
Hg	O
or	O
the	O
occurrence	O
of	O
tachydysrhythmias	B_Disease
(	O
excluding	O
sinus	B_Disease
tachycardia	I_Disease
)	O
.	O

Further	O
suggesting	O
lack	O
of	O
exaggerated	O
adrenergic	O
response	O
,	O
13	O
(	O
65	O
%	O
)	O
of	O
20	O
patients	O
required	O
supplemental	O
atropine	B_Chemical
to	O
reach	O
their	O
target	O
heart	O
rates	O
.	O

CONCLUSION	O
:	O
No	O
exaggerated	O
adrenergic	O
response	O
was	O
detected	O
when	O
dobutamine	B_Chemical
was	O
administered	O
to	O
patients	O
with	O
cocaine-related	O
chest	B_Disease
pain	I_Disease
.	O

Prenatal	O
cocaine	B_Chemical
exposure	O
and	O
cranial	O
sonographic	O
findings	O
in	O
preterm	B_Disease
infants	I_Disease
.	O

PURPOSE	O
:	O
Prenatal	O
cocaine	B_Chemical
exposure	O
has	O
been	O
linked	O
with	O
subependymal	O
hemorrhage	B_Disease
and	O
the	O
formation	O
of	O
cysts	B_Disease
that	O
are	O
detectable	O
on	O
cranial	O
sonography	O
in	O
neonates	O
born	O
at	O
term	O
.	O

We	O
sought	O
to	O
determine	O
if	O
prenatal	O
cocaine	B_Chemical
exposure	O
increases	O
the	O
incidence	O
of	O
subependymal	B_Disease
cysts	B_Disease
in	O
preterm	B_Disease
infants	I_Disease
.	O

METHODS	O
:	O
We	O
retrospectively	O
reviewed	O
the	O
medical	O
records	O
and	O
cranial	O
sonograms	O
obtained	O
during	O
a	O
1-year	O
period	O
on	O
122	O
premature	B_Disease
(	I_Disease
<	I_Disease
36	I_Disease
weeks	I_Disease
of	I_Disease
gestation	I_Disease
)	I_Disease
infants	I_Disease
.	O

Infants	O
were	O
categorized	O
into	O
1	O
of	O
2	O
groups	O
:	O
those	O
exposed	O
to	O
cocaine	B_Chemical
and	O
those	O
not	O
exposed	O
to	O
cocaine	B_Chemical
.	O

Infants	O
were	O
assigned	O
to	O
the	O
cocaine-exposed	O
group	O
if	O
there	O
was	O
a	O
maternal	O
history	O
of	O
cocaine	B_Disease
abuse	I_Disease
during	O
pregnancy	O
or	O
if	O
maternal	O
or	O
neonatal	O
urine	O
toxicology	O
results	O
were	O
positive	O
at	O
the	O
time	O
of	O
delivery	O
.	O

RESULTS	O
:	O
Five	O
of	O
the	O
122	O
infants	O
were	O
excluded	O
from	O
the	O
study	O
because	O
of	O
insufficient	O
medical	O
and	O
drug	O
histories	O
.	O

The	O
incidence	O
of	O
subependymal	B_Disease
cysts	B_Disease
in	O
the	O
117	O
remaining	O
infants	O
was	O
14	O
%	O
(	O
16	O
of	O
117	O
)	O
.	O

The	O
incidence	O
of	O
subependymal	B_Disease
cysts	B_Disease
in	O
infants	O
exposed	O
to	O
cocaine	B_Chemical
prenatally	O
was	O
44	O
%	O
(	O
8	O
of	O
18	O
)	O
compared	O
with	O
8	O
%	O
(	O
8	O
of	O
99	O
)	O
in	O
the	O
unexposed	O
group	O
(	O
p	O
<	O
0.01	O
)	O
.	O

CONCLUSIONS	O
:	O
We	O
found	O
an	O
increased	O
incidence	O
of	O
subependymal	B_Disease
cyst	B_Disease
formation	O
in	O
preterm	B_Disease
infants	I_Disease
who	O
were	O
exposed	O
to	O
cocaine	B_Chemical
prenatally	O
.	O

This	O
result	O
is	O
consistent	O
with	O
results	O
of	O
similar	O
studies	O
in	O
term	O
infants	O
.	O

Thalidomide	B_Chemical
neuropathy	B_Disease
in	O
patients	O
treated	O
for	O
metastatic	O
prostate	B_Disease
cancer	I_Disease
.	O

We	O
prospectively	O
evaluated	O
thalidomide-induced	O
neuropathy	B_Disease
using	O
electrodiagnostic	O
studies	O
.	O

Sixty-seven	O
men	O
with	O
metastatic	O
androgen-independent	O
prostate	B_Disease
cancer	I_Disease
in	O
an	O
open-label	O
trial	O
of	O
oral	O
thalidomide	B_Chemical
underwent	O
neurologic	O
examinations	O
and	O
nerve	O
conduction	O
studies	O
(	O
NCS	O
)	O
prior	O
to	O
and	O
at	O
3-month	O
intervals	O
during	O
treatment	O
.	O

NCS	O
included	O
recording	O
of	O
sensory	O
nerve	O
action	O
potentials	O
(	O
SNAPs	O
)	O
from	O
median	O
,	O
radial	O
,	O
ulnar	O
,	O
and	O
sural	O
nerves	O
.	O

SNAP	O
amplitudes	O
for	O
each	O
nerve	O
were	O
expressed	O
as	O
the	O
percentage	O
of	O
its	O
baseline	O
,	O
and	O
the	O
mean	O
of	O
the	O
four	O
was	O
termed	O
the	O
SNAP	O
index	O
.	O

A	O
40	O
%	O
decline	O
in	O
the	O
SNAP	O
index	O
was	O
considered	O
clinically	O
significant	O
.	O

Thalidomide	B_Chemical
was	O
discontinued	O
in	O
55	O
patients	O
for	O
lack	O
of	O
therapeutic	O
response	O
.	O

Of	O
67	O
patients	O
initially	O
enrolled	O
,	O
24	O
remained	O
on	O
thalidomide	B_Chemical
for	O
3	O
months	O
,	O
8	O
remained	O
at	O
6	O
months	O
,	O
and	O
3	O
remained	O
at	O
9	O
months	O
.	O

Six	O
patients	O
developed	O
neuropathy	B_Disease
.	O

Clinical	O
symptoms	O
and	O
a	O
decline	O
in	O
the	O
SNAP	O
index	O
occurred	O
concurrently	O
.	O

Older	O
age	O
and	O
cumulative	O
dose	O
were	O
possible	O
contributing	O
factors	O
.	O

Neuropathy	B_Disease
may	O
thus	O
be	O
a	O
common	O
complication	O
of	O
thalidomide	B_Chemical
in	O
older	O
patients	O
.	O

The	O
SNAP	O
index	O
can	O
be	O
used	O
to	O
monitor	O
peripheral	B_Disease
neuropathy	I_Disease
,	O
but	O
not	O
for	O
early	O
detection	O
.	O

Overexpression	O
of	O
copper/zinc-superoxide	O
dismutase	O
protects	O
from	O
kanamycin-induced	O
hearing	B_Disease
loss	I_Disease
.	O

The	O
participation	O
of	O
reactive	O
oxygen	B_Chemical
species	O
in	O
aminoglycoside-induced	O
ototoxicity	B_Disease
has	O
been	O
deduced	O
from	O
observations	O
that	O
aminoglycoside-iron	O
complexes	O
catalyze	O
the	O
formation	O
of	O
superoxide	B_Chemical
radicals	O
in	O
vitro	O
and	O
that	O
antioxidants	O
attenuate	O
ototoxicity	B_Disease
in	O
vivo	O
.	O

We	O
therefore	O
hypothesized	O
that	O
overexpression	O
of	O
Cu/Zn-superoxide	O
dismutase	O
(	O
h-SOD1	O
)	O
should	O
protect	O
transgenic	O
mice	O
from	O
ototoxicity	B_Disease
.	O

Immunocytochemistry	O
confirmed	O
expression	O
of	O
h-SOD1	O
in	O
inner	O
ear	O
tissues	O
of	O
transgenic	O
C57BL/6-TgN[SOD1]3Cje	O
mice	O
.	O

Transgenic	O
and	O
nontransgenic	O
littermates	O
received	O
kanamycin	B_Chemical
(	O
400	O
mg/kg	O
body	O
weight/day	O
)	O
for	O
10	O
days	O
beginning	O
on	O
day	O
10	O
after	O
birth	O
.	O

Auditory	O
thresholds	O
were	O
tested	O
by	O
evoked	O
auditory	O
brain	O
stem	O
responses	O
at	O
1	O
month	O
after	O
birth	O
.	O

In	O
nontransgenic	O
animals	O
,	O
the	O
threshold	O
in	O
the	O
kanamycin-treated	O
group	O
was	O
45	O
-	O
50	O
dB	O
higher	O
than	O
in	O
saline-injected	O
controls	O
.	O

In	O
the	O
transgenic	O
group	O
,	O
kanamycin	B_Chemical
increased	O
the	O
threshold	O
by	O
only	O
15	O
dB	O
over	O
the	O
respective	O
controls	O
.	O

The	O
effects	O
were	O
similar	O
at	O
12	O
and	O
24	O
kHz	O
.	O

The	O
protection	O
by	O
overexpression	O
of	O
superoxide	B_Chemical
dismutase	O
supports	O
the	O
hypothesis	O
that	O
oxidant	O
stress	O
plays	O
a	O
significant	O
role	O
in	O
aminoglycoside-induced	O
ototoxicity	B_Disease
.	O

The	O
results	O
also	O
suggest	O
transgenic	O
animals	O
as	O
suitable	O
models	O
to	O
investigate	O
the	O
underlying	O
mechanisms	O
and	O
possible	O
strategies	O
for	O
prevention	O
.	O

Fatty	B_Disease
liver	I_Disease
induced	O
by	O
tetracycline	B_Chemical
in	O
the	O
rat	O
.	O

Dose-response	O
relationships	O
and	O
effect	O
of	O
sex	O
.	O

Dose-response	O
relationships	O
,	O
biochemical	O
mechanisms	O
,	O
and	O
sex	O
differences	O
in	O
the	O
experimental	O
fatty	B_Disease
liver	I_Disease
induced	O
by	O
tetracycline	B_Chemical
were	O
studied	O
in	O
the	O
intact	O
rat	O
and	O
with	O
the	O
isolated	O
perfused	O
rat	O
liver	O
in	O
vitro	O
.	O

In	O
the	O
intact	O
male	O
and	O
female	O
rat	O
,	O
no	O
direct	O
relationship	O
was	O
observed	O
between	O
dose	O
of	O
tetracycline	B_Chemical
and	O
hepatic	O
accumulation	O
of	O
triglyceride	B_Chemical
.	O

With	O
provision	O
of	O
adequate	O
oleic	B_Chemical
acid	I_Chemical
as	O
a	O
substrate	O
for	O
the	O
isolated	O
perfused	O
liver	O
,	O
a	O
direct	O
relationship	O
was	O
observed	O
between	O
dose	O
of	O
tetracycline	B_Chemical
and	O
both	O
accumulation	O
of	O
triglyceride	B_Chemical
in	O
the	O
liver	O
and	O
depression	B_Disease
of	O
output	O
of	O
triglyceride	B_Chemical
by	O
livers	O
from	O
male	O
and	O
female	O
rats	O
.	O

Marked	O
differences	O
were	O
observed	O
between	O
female	O
and	O
male	O
rats	O
with	O
regard	O
to	O
base	O
line	O
(	O
control	O
)	O
hepatic	O
concentration	O
of	O
triglyceride	B_Chemical
and	O
output	O
of	O
triglyceride	B_Chemical
.	O

Accumulation	O
of	O
hepatic	O
triglyceride	B_Chemical
,	O
as	O
a	O
per	O
cent	O
of	O
control	O
values	O
,	O
in	O
response	O
to	O
graded	O
doses	O
of	O
tetracycline	B_Chemical
,	O
did	O
not	O
differ	O
significantly	O
between	O
male	O
,	O
female	O
and	O
pregnant	O
rat	O
livers	O
.	O

However	O
,	O
livers	O
from	O
female	O
,	O
and	O
especially	O
pregnant	O
female	O
rats	O
,	O
were	O
strikingly	O
resistant	O
to	O
the	O
effects	O
of	O
tetracycline	B_Chemical
on	O
depression	B_Disease
of	O
output	O
of	O
triglyceride	B_Chemical
under	O
these	O
experimental	O
conditions	O
.	O

These	O
differences	O
between	O
the	O
sexes	O
could	O
not	O
be	O
related	O
to	O
altered	O
disposition	O
of	O
tetracycline	B_Chemical
or	O
altered	O
uptake	O
of	O
oleic	B_Chemical
acid	I_Chemical
.	O

Depressed	O
hepatic	O
secretion	O
of	O
triglyceride	B_Chemical
accounted	O
only	O
for	O
30	O
to	O
50	O
%	O
of	O
accumulated	O
hepatic	O
triglyceride	B_Chemical
,	O
indicating	O
that	O
additional	O
mechanisms	O
must	O
be	O
involved	O
in	O
the	O
production	O
of	O
the	O
triglyceride-rich	O
fatty	B_Disease
liver	I_Disease
in	O
response	O
to	O
tetracycline	B_Chemical
.	O

Prednisone	B_Chemical
induces	O
anxiety	B_Disease
and	O
glial	O
cerebral	O
changes	O
in	O
rats	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
whether	O
prednisone	B_Chemical
(	O
PDN	B_Chemical
)	O
produces	O
anxiety	B_Disease
and/or	O
cerebral	O
glial	O
changes	O
in	O
rats	O
.	O

METHODS	O
:	O
Male	O
Wistar	O
rats	O
were	O
studied	O
and	O
3	O
groups	O
were	O
formed	O
(	O
8	O
rats	O
per	O
group	O
)	O
.	O

The	O
moderate-dose	O
group	O
received	O
5	O
mg/kg/day	O
PDN	B_Chemical
released	O
from	O
a	O
subcutaneous	O
implant	O
.	O

In	O
the	O
high-dose	O
group	O
,	O
implants	O
containing	O
PDN	B_Chemical
equivalent	O
to	O
60	O
mg/kg/day	O
were	O
applied	O
.	O

In	O
the	O
control	O
group	O
implants	O
contained	O
no	O
PDN	B_Chemical
.	O

Anxiety	B_Disease
was	O
assessed	O
using	O
an	O
open	O
field	O
and	O
elevated	O
plus-maze	O
devices	O
.	O

The	O
number	O
of	O
cells	O
and	O
cytoplasmic	O
transformation	O
of	O
astrocytes	O
and	O
microglia	O
cells	O
were	O
assessed	O
by	O
immunohistochemical	O
analyses	O
.	O

RESULTS	O
:	O
Anxiety	B_Disease
was	O
documented	O
in	O
both	O
groups	O
of	O
PDN	B_Chemical
treated	O
rats	O
compared	O
with	O
controls	O
.	O

The	O
magnitude	O
of	O
transformation	O
of	O
the	O
microglia	O
assessed	O
by	O
the	O
number	O
of	O
intersections	O
was	O
significantly	O
higher	O
in	O
the	O
PDN	B_Chemical
groups	O
than	O
in	O
controls	O
in	O
the	O
prefrontal	O
cortex	O
(	O
moderate-dose	O
,	O
24.1	O
;	O
high-dose	O
,	O
23.6	O
;	O
controls	O
18.7	O
;	O
p	O
<	O
0.01	O
)	O
and	O
striatum	O
(	O
moderate-dose	O
25.6	O
;	O
high-dose	O
26.3	O
;	O
controls	O
18.9	O
;	O
p	O
<	O
0.01	O
)	O
,	O
but	O
not	O
in	O
hippocampus	O
.	O

The	O
number	O
of	O
stained	O
microglia	O
cells	O
was	O
significantly	O
higher	O
in	O
the	O
PDN	B_Chemical
treated	O
groups	O
in	O
the	O
prefrontal	O
cortex	O
than	O
in	O
controls	O
(	O
moderate-dose	O
,	O
29.1	O
;	O
high-dose	O
,	O
28.4	O
;	O
control	O
,	O
17.7	O
cells	O
per	O
field	O
;	O
p	O
<	O
0.01	O
)	O
.	O

Stained	O
microglia	O
cells	O
were	O
significantly	O
more	O
numerous	O
striatum	O
and	O
hippocampus	O
in	O
the	O
high-dose	O
group	O
compared	O
to	O
controls	O
.	O

CONCLUSION	O
:	O
Subacute	O
exposure	O
to	O
PDN	B_Chemical
induced	O
anxiety	B_Disease
and	O
reactivity	O
of	O
microglia	O
.	O

The	O
relevance	O
of	O
these	O
features	O
for	O
patients	O
using	O
PDN	B_Chemical
remains	O
to	O
be	O
elucidated	O
.	O

Phase	O
II	O
study	O
of	O
carboplatin	B_Chemical
and	O
liposomal	O
doxorubicin	B_Chemical
in	O
patients	O
with	O
recurrent	O
squamous	B_Disease
cell	I_Disease
carcinoma	B_Disease
of	I_Disease
the	I_Disease
cervix	I_Disease
.	O

BACKGROUND	O
:	O
The	O
activity	O
of	O
the	O
combination	O
of	O
carboplatin	B_Chemical
and	O
liposomal	O
doxorubicin	B_Chemical
was	O
tested	O
in	O
a	O
Phase	O
II	O
study	O
of	O
patients	O
with	O
recurrent	O
cervical	B_Disease
carcinoma	I_Disease
.	O

METHODS	O
:	O
The	O
combination	O
of	O
carboplatin	B_Chemical
(	O
area	O
under	O
the	O
concentration	O
curve	O
[	O
AUC	O
]	O
,	O
5	O
)	O
and	O
liposomal	O
doxorubicin	B_Chemical
(	O
Doxil	B_Chemical
;	O
starting	O
dose	O
,	O
40	O
mg/m(2	O
)	O
)	O
was	O
administered	O
intravenously	O
every	O
28	O
days	O
to	O
37	O
patients	O
with	O
recurrent	O
squamous	B_Disease
cell	I_Disease
cervical	B_Disease
carcinoma	I_Disease
to	O
determine	O
antitumor	O
activity	O
and	O
toxicity	B_Disease
profile	O
.	O

RESULTS	O
:	O
Twenty-nine	O
patients	O
were	O
assessable	O
for	O
response	O
,	O
and	O
35	O
patients	O
were	O
assessable	O
for	O
toxicity	B_Disease
.	O

The	O
overall	O
response	O
rate	O
was	O
38	O
%	O
,	O
the	O
median	O
time	O
to	O
response	O
was	O
10	O
weeks	O
,	O
the	O
median	O
duration	O
of	O
response	O
was	O
26	O
weeks	O
,	O
and	O
the	O
median	O
survival	O
was	O
37	O
weeks	O
.	O

The	O
main	O
toxic	O
effect	O
was	O
myelosuppression	B_Disease
,	O
with	O
Grade	O
3	O
and	O
4	O
neutropenia	B_Disease
in	O
16	O
patients	O
,	O
anemia	B_Disease
in	O
12	O
patients	O
,	O
thrombocytopenia	B_Disease
in	O
11	O
patients	O
,	O
and	O
neutropenic	B_Disease
fever	B_Disease
in	O
3	O
patients	O
.	O

Four	O
patients	O
had	O
five	O
infusion-related	O
reactions	O
during	O
the	O
infusion	O
of	O
liposomal	O
doxorubicin	B_Chemical
,	O
leading	O
to	O
treatment	O
discontinuation	O
in	O
three	O
patients	O
.	O

Grade	O
>	O
or	O
=	O
2	O
nonhematologic	O
toxicity	B_Disease
included	O
nausea	B_Disease
in	O
17	O
patients	O
,	O
emesis	B_Disease
in	O
14	O
patients	O
,	O
fatigue	B_Disease
in	O
9	O
patients	O
,	O
mucositis	B_Disease
and/or	O
stomatitis	B_Disease
in	O
8	O
patients	O
,	O
constipation	B_Disease
in	O
6	O
patients	O
,	O
weight	B_Disease
loss	I_Disease
in	O
5	O
patients	O
,	O
hand-foot	B_Disease
syndrome	I_Disease
in	O
2	O
patients	O
,	O
and	O
skin	B_Disease
reactions	I_Disease
in	O
3	O
patients	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
carboplatin	B_Chemical
and	O
liposomal	O
doxorubicin	B_Chemical
has	O
modest	O
activity	O
in	O
patients	O
with	O
recurrent	O
cervical	B_Disease
carcinoma	I_Disease
.	O

Antimicrobial-induced	O
mania	B_Disease
(	O
antibiomania	B_Disease
):	O
a	O
review	O
of	O
spontaneous	O
reports	O
.	O

The	O
authors	O
reviewed	O
reported	O
cases	O
of	O
antibiotic-induced	O
manic	B_Disease
episodes	O
by	O
means	O
of	O
a	O
MEDLINE	O
and	O
PsychLit	O
search	O
for	O
reports	O
of	O
antibiotic-induced	O
mania	B_Disease
.	O

Unpublished	O
reports	O
were	O
requested	O
from	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
and	O
the	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
.	O

Twenty-one	O
reports	O
of	O
antimicrobial-induced	O
mania	B_Disease
were	O
found	O
in	O
the	O
literature	O
.	O

There	O
were	O
6	O
cases	O
implicating	O
clarithromycin	B_Chemical
,	O
13	O
implicating	O
isoniazid	B_Chemical
,	O
and	O
1	O
case	O
each	O
implicating	O
erythromycin	B_Chemical
and	O
amoxicillin	B_Chemical
.	O

The	O
WHO	O
reported	O
82	O
cases	O
.	O

Of	O
these	O
,	O
clarithromycin	B_Chemical
was	O
implicated	O
in	O
23	O
(	O
27.6	O
%	O
)	O
cases	O
,	O
ciprofloxacin	B_Chemical
in	O
12	O
(	O
14.4	O
%	O
)	O
cases	O
,	O
and	O
ofloxacin	B_Chemical
in	O
10	O
(	O
12	O
%	O
)	O
cases	O
.	O

Cotrimoxazole	B_Chemical
,	O
metronidazole	B_Chemical
,	O
and	O
erythromycin	B_Chemical
were	O
involved	O
in	O
15	O
reported	O
manic	B_Disease
episodes	O
.	O

Cases	O
reported	O
by	O
the	O
FDA	O
showed	O
clarithromycin	B_Chemical
and	O
ciprofloxacin	B_Chemical
to	O
be	O
the	O
most	O
frequently	O
associated	O
with	O
the	O
development	O
of	O
mania	B_Disease
.	O

Statistical	O
analysis	O
of	O
the	O
data	O
would	O
not	O
have	O
demonstrated	O
a	O
significant	O
statistical	O
correlative	O
risk	O
and	O
was	O
therefore	O
not	O
undertaken	O
.	O

Patients	O
have	O
an	O
increased	O
risk	O
of	O
developing	O
mania	B_Disease
while	O
being	O
treated	O
with	O
antimicrobials	O
.	O

Although	O
this	O
is	O
not	O
a	O
statistically	O
significant	O
risk	O
,	O
physicians	O
must	O
be	O
aware	O
of	O
the	O
effect	O
and	O
reversibility	O
.	O

Further	O
research	O
clearly	O
is	O
required	O
to	O
determine	O
the	O
incidence	O
of	O
antimicrobial-induced	O
mania	B_Disease
,	O
the	O
relative	O
risk	O
factors	O
of	O
developing	O
an	O
antimicrobial-induced	O
manic	B_Disease
episode	O
among	O
various	O
demographic	O
populations	O
,	O
and	O
the	O
incidence	O
of	O
patients	O
who	O
continue	O
to	O
have	O
persistent	O
affective	O
disorders	O
once	O
the	O
initial	O
episode	O
,	O
which	O
occurs	O
while	O
the	O
patient	O
is	O
taking	O
antibiotics	O
,	O
subsides	O
.	O

The	O
authors	O
elected	O
to	O
name	O
this	O
syndrome	O
"	O
antibiomania	B_Disease
.	O
"	O

Levodopa-induced	O
ocular	B_Disease
dyskinesias	I_Disease
in	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
.	O

Levodopa-induced	O
ocular	B_Disease
dyskinesias	I_Disease
are	O
very	O
uncommon	O
.	O

Usually	O
they	O
occur	O
simultaneously	O
with	O
limb	O
peak-dose	O
choreatic	B_Disease
dyskinesias	I_Disease
.	O

We	O
report	O
on	O
a	O
patient	O
with	O
leftward	O
and	O
upward	O
deviations	O
of	O
gaze	O
during	O
the	O
peak	O
effect	O
of	O
levodopa	B_Chemical
,	O
and	O
hypothesize	O
that	O
a	O
severe	O
dopaminergic	O
denervation	O
in	O
the	O
caudate	O
nucleus	O
is	O
needed	O
for	O
the	O
appearance	O
of	O
these	O
levodopa-induce	O
ocular	B_Disease
dyskinesias	I_Disease
.	O

A	O
comparison	O
of	O
glyceryl	B_Chemical
trinitrate	I_Chemical
with	O
diclofenac	B_Chemical
for	O
the	O
treatment	O
of	O
primary	O
dysmenorrhea	B_Disease
:	O
an	O
open	O
,	O
randomized	O
,	O
cross-over	O
trial	O
.	O

Primary	O
dysmenorrhea	B_Disease
is	O
a	O
syndrome	O
characterized	O
by	O
painful	O
uterine	O
contractility	O
caused	O
by	O
a	O
hypersecretion	O
of	O
endometrial	O
prostaglandins	B_Chemical
;	O
non-steroidal	O
anti-inflammatory	O
drugs	O
are	O
the	O
first	O
choice	O
for	O
its	O
treatment	O
.	O

However	O
,	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
have	O
demonstrated	O
that	O
myometrial	O
cells	O
are	O
also	O
targets	O
of	O
the	O
relaxant	O
effects	O
of	O
nitric	B_Chemical
oxide	I_Chemical
(	O
NO	B_Chemical
)	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
efficacy	O
of	O
glyceryl	B_Chemical
trinitrate	I_Chemical
(	O
GTN	B_Chemical
)	O
,	O
an	O
NO	B_Chemical
donor	O
,	O
in	O
the	O
resolution	O
of	O
primary	O
dysmenorrhea	B_Disease
in	O
comparison	O
with	O
diclofenac	B_Chemical
(	O
DCF	B_Chemical
)	O
.	O

A	O
total	O
of	O
24	O
patients	O
with	O
the	O
diagnosis	O
of	O
severe	O
primary	O
dysmenorrhea	B_Disease
were	O
studied	O
during	O
two	O
consecutive	O
menstrual	O
cycles	O
.	O

In	O
an	O
open	O
,	O
cross-over	O
,	O
controlled	O
design	O
,	O
patients	O
were	O
randomized	O
to	O
receive	O
either	O
DCF	B_Chemical
per	O
os	O
or	O
GTN	B_Chemical
patches	O
the	O
first	O
days	O
of	O
menses	O
,	O
when	O
menstrual	O
cramps	O
became	O
unendurable	O
.	O

In	O
the	O
subsequent	O
cycle	O
the	O
other	O
treatment	O
was	O
used	O
.	O

Patients	O
received	O
up	O
to	O
3	O
doses/day	O
of	O
50	O
mg	O
DCF	B_Chemical
or	O
2.5	O
mg/24	O
h	O
transdermal	O
GTN	B_Chemical
for	O
the	O
first	O
3	O
days	O
of	O
the	O
cycle	O
,	O
according	O
to	O
their	O
needs	O
.	O

The	O
participants	O
recorded	O
menstrual	O
symptoms	O
and	O
possible	O
side-effects	O
at	O
different	O
times	O
(	O
0	O
,	O
30	O
,	O
60	O
,	O
120	O
minutes	O
)	O
after	O
the	O
first	O
dose	O
of	O
medication	O
on	O
the	O
first	O
day	O
of	O
the	O
cycle	O
,	O
with	O
both	O
drugs	O
.	O

The	O
difference	O
in	O
pain	B_Disease
intensity	O
score	O
(	O
DPI	O
)	O
was	O
the	O
main	O
outcome	O
variable	O
.	O

Both	O
treatments	O
significantly	O
reduced	O
DPI	O
by	O
the	O
30th	O
minute	O
(	O
GTN	B_Chemical
,	O
-12.8	O
+	O
/-	O
17.9	O
;	O
DCF	B_Chemical
,	O
-18.9	O
+	O
/-	O
16.6	O
)	O
.	O

However	O
,	O
DCF	B_Chemical
continued	O
to	O
be	O
effective	O
in	O
reducing	O
pelvic	B_Disease
pain	I_Disease
for	O
two	O
hours	O
,	O
whereas	O
GTN	B_Chemical
scores	O
remained	O
more	O
or	O
less	O
stable	O
after	O
30	O
min	O
and	O
significantly	O
higher	O
than	O
those	O
for	O
DFC	O
(	O
after	O
one	O
hour	O
:	O
GTN	B_Chemical
,	O
-12.8	O
+	O
/-	O
17.9	O
;	O
DFC	O
,	O
-18.9	O
+	O
/-	O
16.6	O
and	O
after	O
two	O
hours	O
:	O
GTN	B_Chemical
,	O
-23.7	O
+	O
/-	O
20.5	O
;	O
DFC	O
,	O
-59.7	O
+	O
/-	O
17.9	O
,	O
p	O
=	O
0.0001	O
)	O
.	O

Low	B_Disease
back	I_Disease
pain	I_Disease
was	O
also	O
relieved	O
by	O
both	O
drugs	O
.	O

Headache	B_Disease
was	O
significantly	O
increased	O
by	O
GTN	B_Chemical
but	O
not	O
by	O
DCF	B_Chemical
.	O

Eight	O
patients	O
stopped	O
using	O
GTN	B_Chemical
because	O
headache	B_Disease
--	O
attributed	O
to	O
its	O
use	O
--	O
became	O
intolerable	O
.	O

These	O
findings	O
indicate	O
that	O
GTN	B_Chemical
has	O
a	O
reduced	O
efficacy	O
and	O
tolerability	O
by	O
comparison	O
with	O
DCF	B_Chemical
in	O
the	O
treatment	O
of	O
primary	O
dysmenorrhea	B_Disease
.	O

Temocapril	B_Chemical
,	O
a	O
long-acting	O
non-SH	O
group	O
angiotensin	B_Chemical
converting	O
enzyme	O
inhibitor	O
,	O
modulates	O
glomerular	B_Disease
injury	I_Disease
in	O
chronic	O
puromycin	B_Chemical
aminonucleoside	I_Chemical
nephrosis	B_Disease
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
whether	O
chronic	O
administration	O
of	O
temocapril	B_Chemical
,	O
a	O
long-acting	O
non-SH	O
group	O
angiotensin	B_Chemical
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
,	O
reduced	O
proteinuria	B_Disease
,	O
inhibited	O
glomerular	O
hypertrophy	B_Disease
and	O
prevented	O
glomerulosclerosis	B_Disease
in	O
chronic	O
puromycin	B_Chemical
aminonucleoside	I_Chemical
(	O
PAN	B_Chemical
)	O
-	O
induced	O
nephrotic	B_Disease
rats	O
.	O

Nephrosis	B_Disease
was	O
induced	O
by	O
injection	O
of	O
PAN	B_Chemical
(	O
15mg/100	O
g	O
body	O
weight	O
)	O
in	O
male	O
Sprague-Dawley	O
(	O
SD	O
)	O
rats	O
.	O

Four	O
groups	O
were	O
used	O
,	O
i	O
)	O
the	O
PAN	B_Chemical
group	O
(	O
14	O
)	O
,	O
ii	O
)	O
PAN/temocapril	O
(	O
13	O
)	O
,	O
iii	O
)	O
temocapril	B_Chemical
(	O
14	O
)	O
and	O
iv	O
)	O
untreated	O
controls	O
(	O
15	O
)	O
.	O

Temocapril	B_Chemical
(	O
8	O
mg/kg/day	O
)	O
was	O
administered	O
to	O
the	O
rats	O
which	O
were	O
killed	O
at	O
weeks	O
4	O
,	O
14	O
or	O
20	O
.	O

At	O
each	O
time	O
point	O
,	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
,	O
urinary	O
protein	O
excretion	O
and	O
renal	O
histopathological	O
findings	O
were	O
evaluated	O
,	O
and	O
morphometric	O
image	O
analysis	O
was	O
done	O
.	O

Systolic	O
BP	O
in	O
the	O
PAN	B_Chemical
group	O
was	O
significantly	O
high	O
at	O
4	O
,	O
14	O
and	O
20	O
weeks	O
,	O
but	O
was	O
normal	O
in	O
the	O
PAN/temocapril	O
group	O
.	O

Urinary	O
protein	O
excretion	O
in	O
the	O
PAN	B_Chemical
group	O
increased	O
significantly	O
,	O
peaking	O
at	O
8	O
days	O
,	O
then	O
decreased	O
at	O
4	O
weeks	O
,	O
but	O
rose	O
again	O
significantly	O
at	O
14	O
and	O
20	O
weeks	O
.	O

Temocapril	B_Chemical
did	O
not	O
attenuate	O
proteinuria	B_Disease
at	O
8	O
days	O
,	O
but	O
it	O
did	O
markedly	O
lower	O
it	O
from	O
weeks	O
4	O
to	O
20	O
.	O

The	O
glomerulosclerosis	B_Disease
index	O
(	O
GSI	O
)	O
was	O
6.21	O
%	O
at	O
4	O
weeks	O
and	O
respectively	O
25.35	O
%	O
and	O
30.49	O
%	O
at	O
14	O
and	O
20	O
weeks	O
in	O
the	O
PAN	B_Chemical
group	O
.	O

There	O
was	O
a	O
significant	O
correlation	O
between	O
urinary	O
protein	O
excretion	O
and	O
GSI	O
(	O
r	O
=	O
0.808	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

The	O
ratio	O
of	O
glomerular	O
tuft	O
area	O
to	O
the	O
area	O
of	O
Bowman	O
's	O
capsules	O
(	O
GT/BC	O
)	O
in	O
the	O
PAN	B_Chemical
group	O
was	O
significantly	O
increased	O
,	O
but	O
it	O
was	O
significantly	O
lower	O
in	O
the	O
PAN/temocapril	O
group	O
.	O

It	O
appears	O
that	O
temocapril	B_Chemical
was	O
effective	O
in	O
retarding	O
renal	O
progression	O
and	O
protected	O
renal	O
function	O
in	O
PAN	B_Chemical
neprotic	B_Disease
rats	O
.	O

Pulmonary	B_Disease
hypertension	I_Disease
after	O
ibuprofen	B_Chemical
prophylaxis	O
in	O
very	O
preterm	O
infants	O
.	O

We	O
report	O
three	O
cases	O
of	O
severe	O
hypoxaemia	B_Disease
after	O
ibuprofen	B_Chemical
administration	O
during	O
a	O
randomised	O
controlled	O
trial	O
of	O
prophylactic	O
treatment	O
of	O
patent	B_Disease
ductus	I_Disease
arteriosus	I_Disease
with	O
ibuprofen	B_Chemical
in	O
premature	O
infants	O
born	O
at	O
less	O
than	O
28	O
weeks	O
of	O
gestation	O
.	O

Echocardiography	O
showed	O
severely	O
decreased	O
pulmonary	O
blood	O
flow	O
.	O

Hypoxaemia	B_Disease
resolved	O
quickly	O
on	O
inhaled	O
nitric	B_Chemical
oxide	I_Chemical
therapy	O
.	O

We	O
suggest	O
that	O
investigators	O
involved	O
in	O
similar	O
trials	O
pay	O
close	O
attention	O
to	O
pulmonary	O
pressure	O
if	O
hypoxaemia	B_Disease
occurs	O
after	O
prophylactic	O
administration	O
of	O
ibuprofen	B_Chemical
.	O

Hyponatremia	B_Disease
and	O
syndrome	B_Disease
of	I_Disease
inappropriate	I_Disease
anti-diuretic	I_Disease
hormone	I_Disease
reported	O
with	O
the	O
use	O
of	O
Vincristine	B_Chemical
:	O
an	O
over-representation	O
of	O
Asians?PURPOSE	O
:	O
This	O
retrospective	O
study	O
used	O
a	O
pharmaceutical	O
company	O
's	O
global	O
safety	O
database	O
to	O
determine	O
the	O
reporting	O
rate	O
of	O
hyponatremia	B_Disease
and/or	O
syndrome	B_Disease
of	I_Disease
inappropriate	I_Disease
secretion	I_Disease
of	I_Disease
anti-diuretic	I_Disease
hormone	I_Disease
(	O
SIADH	B_Disease
)	O
among	O
vincristine-treated	O
patients	O
and	O
to	O
explore	O
the	O
possibility	O
of	O
at-risk	O
population	O
subgroups	O
.	O

METHOD	O
:	O
We	O
searched	O
the	O
Eli	O
Lilly	O
and	O
Company	O
's	O
computerized	O
adverse	O
event	O
database	O
for	O
all	O
reported	O
cases	O
of	O
hyponatremia	B_Disease
and/or	O
SIADH	B_Disease
as	O
of	O
1	O
November	O
1999	O
that	O
had	O
been	O
reported	O
during	O
the	O
use	O
of	O
vincristine	B_Chemical
.	O

RESULTS	O
:	O
A	O
total	O
of	O
76	O
cases	O
of	O
hyponatremia	B_Disease
and/or	O
SIADH	B_Disease
associated	O
with	O
vincristine	B_Chemical
use	O
were	O
identified	O
.	O

The	O
overall	O
reporting	O
rate	O
was	O
estimated	O
to	O
be	O
1.3/100,000	O
treated	O
patients	O
.	O

The	O
average	O
age	O
of	O
patients	O
was	O
35.6	O
+	O
/-	O
28.3	O
years	O
,	O
and	O
62	O
%	O
were	O
males	O
.	O

Approximately	O
75	O
%	O
of	O
the	O
patients	O
were	O
receiving	O
treatment	O
for	O
leukemia	B_Disease
or	O
lymphoma	B_Disease
.	O

Among	O
the	O
39	O
reports	O
that	O
included	O
information	O
on	O
race	O
,	O
the	O
racial	O
distribution	O
was	O
:	O
1	O
Black	O
,	O
3	O
Caucasian	O
,	O
and	O
35	O
Asian	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
Asian	O
patients	O
may	O
be	O
at	O
increased	O
risk	O
of	O
hyponatremia	B_Disease
and/or	O
SIADH	B_Disease
associated	O
with	O
vincristine	B_Chemical
use	O
.	O

Although	O
the	O
overall	O
reported	O
rate	O
of	O
SIADH	B_Disease
associated	O
with	O
vincristine	B_Chemical
is	O
very	O
low	O
,	O
physicians	O
caring	O
for	O
Asian	O
oncology	O
patients	O
should	O
be	O
aware	O
of	O
this	O
potential	O
serious	O
but	O
reversible	O
adverse	O
event	O
.	O

Delayed	O
toxicity	B_Disease
of	O
cyclophosphamide	B_Chemical
on	O
the	O
bladder	O
of	O
DBA/2	O
and	O
C57BL/6	O
female	O
mouse	O
.	O

The	O
present	O
study	O
describes	O
the	O
delayed	O
development	O
of	O
a	O
severe	O
bladder	O
pathology	O
in	O
a	O
susceptible	O
strain	O
of	O
mice	O
(	O
DBA/2	O
)	O
but	O
not	O
in	O
a	O
resistant	O
strain	O
(	O
C57BL/6	O
)	O
when	O
both	O
were	O
treated	O
with	O
a	O
single	O
300	O
mg/kg	O
dose	O
of	O
cyclophosphamide	B_Chemical
(	O
CY	B_Chemical
)	O
.	O

Inbred	O
DBA/2	O
and	O
C57BL/6	O
female	O
mice	O
were	O
injected	O
with	O
CY	B_Chemical
,	O
and	O
the	O
effect	O
of	O
the	O
drug	O
on	O
the	O
bladder	O
was	O
assessed	O
during	O
100	O
days	O
by	O
light	O
microscopy	O
using	O
different	O
staining	O
procedures	O
,	O
and	O
after	O
30	O
days	O
by	O
conventional	O
electron	O
microscopy	O
.	O

Early	O
CY	B_Chemical
toxicity	B_Disease
caused	O
a	O
typical	O
haemorrhagic	B_Disease
cystitis	B_Disease
in	O
both	O
strains	O
that	O
was	O
completely	O
repaired	O
in	O
about	O
7	O
-	O
10	O
days	O
.	O

After	O
30	O
days	O
of	O
CY	B_Chemical
injection	O
ulcerous	O
and	O
non-ulcerous	O
forms	O
of	O
chronic	O
cystitis	B_Disease
appeared	O
in	O
86	O
%	O
of	O
DBA/2	O
mice	O
but	O
only	O
in	O
4	O
%	O
of	O
C57BL/6	O
mice	O
.	O

Delayed	O
cystitis	B_Disease
was	O
characterized	O
by	O
infiltration	O
and	O
transepithelial	O
passage	O
into	O
the	O
lumen	O
of	O
inflammatory	O
cells	O
and	O
by	O
frequent	O
exfoliation	O
of	O
the	O
urothelium	O
.	O

Mast	O
cells	O
appeared	O
in	O
the	O
connective	O
and	O
muscular	O
layers	O
of	O
the	O
bladder	O
at	O
a	O
much	O
higher	O
number	O
in	O
DBA/2	O
mice	O
than	O
in	O
C57BL/6	O
mice	O
or	O
untreated	O
controls	O
.	O

Electron	O
microscopy	O
disclosed	O
the	O
absence	O
of	O
the	O
typical	O
discoidal	O
vesicles	O
normally	O
present	O
in	O
the	O
cytoplasm	O
of	O
surface	O
cells	O
.	O

Instead	O
,	O
numerous	O
abnormal	O
vesicles	O
containing	O
one	O
or	O
several	O
dark	O
granules	O
were	O
observed	O
in	O
the	O
cytoplasm	O
of	O
cells	O
from	O
all	O
the	O
epithelial	O
layers	O
.	O

Delayed	O
cystitis	B_Disease
still	O
persisted	O
in	O
DBA/2	O
mice	O
100	O
days	O
after	O
treatment	O
.	O

These	O
results	O
indicate	O
that	O
delayed	O
toxicity	B_Disease
of	O
CY	B_Chemical
in	O
female	O
DBA/2	O
mice	O
causes	O
a	O
bladder	O
pathology	O
that	O
is	O
not	O
observed	O
in	O
C57BL/6	O
mice	O
.	O

This	O
pathology	O
resembles	O
interstitial	B_Disease
cystitis	I_Disease
in	O
humans	O
and	O
could	O
perhaps	O
be	O
used	O
as	O
an	O
animal	O
model	O
for	O
studies	O
on	O
the	O
disease	O
.	O

High-dose	O
5-fluorouracil	B_Chemical
/	O
folinic	B_Chemical
acid	I_Chemical
in	O
combination	O
with	O
three-weekly	O
mitomycin	B_Chemical
C	I_Chemical
in	O
the	O
treatment	O
of	O
advanced	O
gastric	B_Disease
cancer	I_Disease
.	O

A	O
phase	O
II	O
study	O
.	O

BACKGROUND	O
:	O
The	O
24-hour	O
continuous	O
infusion	O
of	O
5-fluorouracil	B_Chemical
(	O
5-FU	B_Chemical
)	O
and	O
folinic	B_Chemical
acid	I_Chemical
(	O
FA	B_Chemical
)	O
as	O
part	O
of	O
several	O
new	O
multidrug	O
chemotherapy	O
regimens	O
in	O
advanced	O
gastric	B_Disease
cancer	I_Disease
(	O
AGC	B_Disease
)	O
has	O
shown	O
to	O
be	O
effective	O
,	O
with	O
low	O
toxicity	B_Disease
.	O

In	O
a	O
previous	O
phase	O
II	O
study	O
with	O
3-weekly	O
bolus	O
5-FU	B_Chemical
,	O
FA	B_Chemical
and	O
mitomycin	B_Chemical
C	I_Chemical
(	O
MMC	B_Chemical
)	O
we	O
found	O
a	O
low	O
toxicity	B_Disease
rate	O
and	O
response	O
rates	O
comparable	O
to	O
those	O
of	O
regimens	O
such	O
as	O
ELF	O
,	O
FAM	O
or	O
FAMTX	O
,	O
and	O
a	O
promising	O
median	O
overall	O
survival	O
.	O

In	O
order	O
to	O
improve	O
this	O
MMC-dependent	O
schedule	O
we	O
initiated	O
a	O
phase	O
II	O
study	O
with	O
high-dose	O
5-FU/FA	O
and	O
3-weekly	O
bolus	O
MMC	B_Chemical
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
From	O
February	O
,	O
1998	O
to	O
September	O
,	O
2000	O
we	O
recruited	O
33	O
patients	O
with	O
AGC	B_Disease
to	O
receive	O
weekly	O
24-hour	O
5-FU	B_Chemical
2,600	O
mg/m(2	O
)	O
preceded	O
by	O
2-hour	O
FA	B_Chemical
500	O
mg/m(2	O
)	O
for	O
6	O
weeks	O
,	O
followed	O
by	O
a	O
2-week	O
rest	O
period	O
.	O

Bolus	O
MMC	B_Chemical
10	O
mg/m(2	O
)	O
was	O
added	O
in	O
3-weekly	O
intervals	O
.	O

Treatment	O
given	O
on	O
an	O
outpatient	O
basis	O
,	O
using	O
portable	O
pump	O
systems	O
,	O
was	O
repeated	O
on	O
day	O
57	O
.	O

Patients	O
'	O
characteristics	O
were	O
:	O
male/female	O
ratio	O
20/13	O
;	O
median	O
age	O
57	O
(	O
27	O
-	O
75	O
)	O
years	O
;	O
median	O
WHO	O
status	O
1	O
(	O
0	O
-	O
2	O
)	O
.	O

18	O
patients	O
had	O
a	O
primary	O
AGC	B_Disease
,	O
and	O
15	O
showed	O
a	O
relapsed	O
AGC	B_Disease
.	O

Median	O
follow-up	O
was	O
11.8	O
months	O
(	O
range	O
of	O
those	O
surviving	O
:	O
2.7	O
-	O
11.8	O
months	O
)	O
.	O

RESULTS	O
:	O
32	O
patients	O
were	O
evaluable	O
for	O
response	O
-	O
complete	O
remission	O
9.1	O
%	O
(	O
n	O
=	O
3	O
)	O
,	O
partial	O
remission	O
45.5	O
%	O
(	O
n	O
=	O
15	O
)	O
,	O
no	O
change	O
27.3	O
%	O
(	O
n	O
=	O
9	O
)	O
,	O
progressive	O
disease	O
15.1	O
%	O
(	O
n	O
=	O
5	O
)	O
.	O

Median	O
overall	O
survival	O
time	O
was	O
10.2	O
months	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
):	O
8.7	O
-	O
11.6	O
]	O
,	O
and	O
median	O
progression-free	O
survival	O
time	O
was	O
7.6	O
months	O
(	O
95	O
%	O
CI	O
:	O
4.4	O
-	O
10.9	O
)	O
.	O

The	O
worst	O
toxicities	B_Disease
(	O
%	O
)	O
observed	O
were	O
(	O
CTC-NCI	O
1/2/3	O
):	O
leukopenia	B_Disease
45.5/18.2/6.1	O
,	O
thrombocytopenia	B_Disease
33.3/9.1/6.1	O
,	O
vomitus	B_Disease
24.2/9.1/0	O
,	O
diarrhea	B_Disease
36.4/6.1/3.0	O
,	O
stomatitis	B_Disease
18.2/9.1/0	O
,	O
hand-foot	B_Disease
syndrome	I_Disease
12.1/0/0	O
.	O

Two	O
patients	O
developed	O
hemolytic-uremic	B_Disease
syndrome	I_Disease
(	O
HUS	B_Disease
)	O
.	O

CONCLUSIONS	O
:	O
High-dose	O
5-FU/FA/MMC	O
is	O
an	O
effective	O
and	O
well-tolerated	O
outpatient	O
regimen	O
for	O
AGC	B_Disease
(	O
objective	O
response	O
rate	O
54.6	O
%	O
)	O
.	O

It	O
may	O
serve	O
as	O
an	O
alternative	O
to	O
cisplatin-containing	O
regimens	O
;	O
however	O
,	O
it	O
has	O
to	O
be	O
considered	O
that	O
possibly	O
HUS	B_Disease
may	O
occur	O
.	O

Persistent	O
sterile	O
leukocyturia	B_Disease
is	O
associated	O
with	O
impaired	B_Disease
renal	I_Disease
function	I_Disease
in	O
human	B_Disease
immunodeficiency	I_Disease
virus	I_Disease
type	I_Disease
1-infected	I_Disease
children	O
treated	O
with	O
indinavir	B_Chemical
.	O

BACKGROUND	O
:	O
Prolonged	O
administration	O
of	O
indinavir	B_Chemical
is	O
associated	O
with	O
the	O
occurrence	O
of	O
a	O
variety	O
of	O
renal	O
complications	O
in	O
adults	O
.	O

These	O
well-documented	O
side	O
effects	O
have	O
restricted	O
the	O
use	O
of	O
this	O
potent	O
protease	O
inhibitor	O
in	O
children	O
.	O

DESIGN	O
:	O
A	O
prospective	O
study	O
to	O
monitor	O
indinavir-related	O
nephrotoxicity	B_Disease
in	O
a	O
cohort	O
of	O
30	O
human	B_Disease
immunodeficiency	I_Disease
virus	I_Disease
type	I_Disease
1-infected	I_Disease
children	O
treated	O
with	O
indinavir	B_Chemical
.	O

METHODS	O
:	O
Urinary	O
pH	O
,	O
albumin	O
,	O
creatinine	B_Chemical
,	O
the	O
presence	O
of	O
erythrocytes	O
,	O
leukocytes	O
,	O
bacteria	O
and	O
crystals	O
,	O
and	O
culture	O
were	O
analyzed	O
every	O
3	O
months	O
for	O
96	O
weeks	O
.	O

Serum	O
creatinine	B_Chemical
levels	O
were	O
routinely	O
determined	O
at	O
the	O
same	O
time	O
points	O
.	O

Steady-state	O
pharmacokinetics	O
of	O
indinavir	B_Chemical
were	O
done	O
at	O
week	O
4	O
after	O
the	O
initiation	O
of	O
indinavir	B_Chemical
.	O

RESULTS	O
:	O
The	O
cumulative	O
incidence	O
of	O
persistent	O
sterile	O
leukocyturia	B_Disease
(	O
>	O
or	O
=	O
75	O
cells/	O
micro	O
L	O
in	O
at	O
least	O
2	O
consecutive	O
visits	O
)	O
after	O
96	O
weeks	O
was	O
53	O
%	O
.	O

Persistent	O
sterile	O
leukocyturia	B_Disease
was	O
frequently	O
associated	O
with	O
a	O
mild	O
increase	O
in	O
the	O
urine	O
albumin/creatinine	O
ratio	O
and	O
by	O
microscopic	O
hematuria	B_Disease
.	O

The	O
cumulative	O
incidence	O
of	O
serum	O
creatinine	B_Chemical
levels	O
>	O
50	O
%	O
above	O
normal	O
was	O
33	O
%	O
after	O
96	O
weeks	O
.	O

Children	O
with	O
persistent	O
sterile	O
leukocyturia	B_Disease
more	O
frequently	O
had	O
serum	O
creatinine	B_Chemical
levels	O
of	O
50	O
%	O
above	O
normal	O
than	O
those	O
children	O
without	O
persistent	O
sterile	O
leukocyturia	B_Disease
.	O

In	O
children	O
younger	O
than	O
5.6	O
years	O
,	O
persistent	O
sterile	O
leukocyturia	B_Disease
was	O
significantly	O
more	O
frequent	O
than	O
in	O
older	O
children	O
.	O

A	O
higher	O
cumulative	O
incidence	O
of	O
persistent	O
leukocyturia	B_Disease
was	O
found	O
in	O
children	O
with	O
an	O
area	O
under	O
the	O
curve	O
>	O
19	O
mg/L	O
x	O
h	O
or	O
a	O
peak	O
serum	O
level	O
of	O
indinavir	B_Chemical
>	O
12	O
mg/L.	O
In	O
4	O
children	O
,	O
indinavir	B_Chemical
was	O
discontinued	O
because	O
of	O
nephrotoxicity	B_Disease
.	O

Subsequently	O
,	O
the	O
serum	O
creatinine	B_Chemical
levels	O
decreased	O
,	O
the	O
urine	O
albumin/creatinine	O
ratios	O
returned	O
to	O
zero	O
,	O
and	O
the	O
leukocyturia	B_Disease
disappeared	O
within	O
3	O
months	O
.	O

CONCLUSIONS	O
:	O
Children	O
treated	O
with	O
indinavir	B_Chemical
have	O
a	O
high	O
cumulative	O
incidence	O
of	O
persistent	O
sterile	O
leukocyturia	B_Disease
.	O

Children	O
with	O
persistent	O
sterile	O
leukocyturia	B_Disease
more	O
frequently	O
had	O
an	O
increase	O
in	O
serum	O
creatinine	B_Chemical
levels	O
of	O
>	O
50	O
%	O
above	O
normal	O
.	O

Younger	O
children	O
have	O
an	O
additional	O
risk	O
for	O
renal	O
complications	O
.	O

The	O
impairment	B_Disease
of	I_Disease
the	I_Disease
renal	I_Disease
function	I_Disease
in	O
these	O
children	O
occurred	O
in	O
the	O
absence	O
of	O
clinical	O
symptoms	O
of	O
nephrolithiasis	B_Disease
.	O

Indinavir-associated	O
nephrotoxicity	B_Disease
must	O
be	O
monitored	O
closely	O
,	O
especially	O
in	O
children	O
with	O
risk	O
factors	O
such	O
as	O
persistent	O
sterile	O
leukocyturia	B_Disease
,	O
age	O
<	O
5.6	O
years	O
,	O
an	O
area	O
under	O
the	O
curve	O
of	O
indinavir	B_Chemical
>	O
19	O
mg/L	O
x	O
h	O
,	O
and	O
a	O
C(max	O
)	O
>	O
12	O
mg/L.	O

Utility	O
of	O
troponin	O
I	O
in	O
patients	O
with	O
cocaine-associated	O
chest	B_Disease
pain	I_Disease
.	O

Baseline	O
electrocardiogram	O
abnormalities	O
and	O
market	O
elevations	O
not	O
associated	O
with	O
myocardial	B_Disease
necrosis	I_Disease
make	O
accurate	O
diagnosis	O
of	O
myocardial	B_Disease
infarction	I_Disease
(	O
MI	B_Disease
)	O
difficult	O
in	O
patients	O
with	O
cocaine-associated	O
chest	B_Disease
pain	I_Disease
.	O

Troponin	O
sampling	O
may	O
offer	O
greater	O
diagnostic	O
utility	O
in	O
these	O
patients	O
.	O

OBJECTIVE	O
:	O
To	O
assess	O
outcomes	O
based	O
on	O
troponin	O
positivity	O
in	O
patients	O
with	O
cocaine	B_Chemical
chest	B_Disease
pain	I_Disease
admitted	O
for	O
exclusion	O
of	O
MI	B_Disease
.	O

METHODS	O
:	O
Outcomes	O
were	O
examined	O
in	O
patients	O
admitted	O
for	O
possible	O
MI	B_Disease
after	O
cocaine	B_Chemical
use	O
.	O

All	O
patients	O
underwent	O
a	O
rapid	O
rule-in	O
protocol	O
that	O
included	O
serial	O
sampling	O
of	O
creatine	B_Chemical
kinase	O
(	O
CK	O
)	O
,	O
CK-MB	O
,	O
and	O
cardiac	O
troponin	O
I	O
(	O
cTnI	O
)	O
over	O
eight	O
hours	O
.	O

Outcomes	O
included	O
CK-MB	O
MI	B_Disease
(	O
CK-MB	O
>	O
or=	O
8	O
ng/mL	O
with	O
a	O
relative	O
index	O
[	O
(	O
CK-MB	O
x	O
100)/total	O
CK	O
]	O
>	O
or=	O
4	O
,	O
cardiac	B_Disease
death	I_Disease
,	O
and	O
significant	O
coronary	B_Disease
disease	I_Disease
(	O
>	O
or=50	O
%	O
)	O
.	O

RESULTS	O
:	O
Of	O
the	O
246	O
admitted	O
patients	O
,	O
34	O
(	O
14	O
%	O
)	O
met	O
CK-MB	O
criteria	O
for	O
MI	B_Disease
and	O
38	O
(	O
16	O
%	O
)	O
had	O
cTnI	O
elevations	O
.	O

Angiography	O
was	O
performed	O
in	O
29	O
of	O
38	O
patients	O
who	O
were	O
cTnI-positive	O
,	O
with	O
significant	O
disease	O
present	O
in	O
25	O
(	O
86	O
%	O
)	O
.	O

Three	O
of	O
the	O
four	O
patients	O
without	O
significant	O
disease	O
who	O
had	O
cTnI	O
elevations	O
met	O
CK-MB	O
criteria	O
for	O
MI	B_Disease
,	O
and	O
the	O
other	O
had	O
a	O
peak	O
CK-MB	O
level	O
of	O
13	O
ng/mL.	O
Sensitivities	O
,	O
specificities	O
,	O
and	O
positive	O
and	O
negative	O
likelihood	O
ratios	O
for	O
predicting	O
cardiac	B_Disease
death	I_Disease
or	O
significant	O
disease	O
were	O
high	O
for	O
both	O
CK-MB	O
MI	B_Disease
and	O
cTnI	O
and	O
were	O
not	O
significantly	O
different	O
.	O

CONCLUSIONS	O
:	O
Most	O
patients	O
with	O
cTnI	O
elevations	O
meet	O
CK-MB	O
criteria	O
for	O
MI	B_Disease
,	O
as	O
well	O
as	O
have	O
a	O
high	O
incidence	O
of	O
underlying	O
significant	O
disease	O
.	O

Troponin	O
appears	O
to	O
have	O
an	O
equivalent	O
diagnostic	O
accuracy	O
compared	O
with	O
CK-MB	O
for	O
diagnosing	O
necrosis	B_Disease
in	O
patients	O
with	O
cocaine-associated	O
chest	B_Disease
pain	I_Disease
and	O
suspected	O
MI	B_Disease
.	O

Acute	O
interstitial	B_Disease
nephritis	I_Disease
due	O
to	O
nicergoline	B_Chemical
(Sermion).We	O
report	O
a	O
case	O
of	O
acute	O
interstitial	B_Disease
nephritis	I_Disease
(	O
AIN	B_Disease
)	O
due	O
to	O
nicergoline	B_Chemical
(	O
Sermion	B_Chemical
)	O
.	O

A	O
50-year-old	O
patient	O
admitted	O
to	O
our	O
hospital	O
for	O
fever	B_Disease
and	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
.	O

Before	O
admission	O
,	O
he	O
had	O
been	O
taking	O
nicergoline	B_Chemical
and	O
bendazac	B_Chemical
lysine	I_Chemical
due	O
to	O
retinal	B_Disease
vein	I_Disease
occlusion	I_Disease
at	O
ophthalmologic	O
department	O
.	O

Thereafter	O
,	O
he	O
experienced	O
intermittent	O
fever	B_Disease
and	O
skin	B_Disease
rash	I_Disease
.	O

On	O
admission	O
,	O
clinical	O
symptoms	O
(	O
i.e.	O
arthralgia	B_Disease
and	O
fever	B_Disease
)	O
and	O
laboratory	O
findings	O
(	O
i.e.	O
eosinophilia	B_Disease
and	O
renal	B_Disease
failure	I_Disease
)	O
suggested	O
AIN	B_Disease
,	O
and	O
which	O
was	O
confirmed	O
by	O
pathologic	O
findings	O
on	O
renal	O
biopsy	O
.	O

A	O
lymphocyte	O
transformation	O
test	O
demonstrated	O
a	O
positive	O
result	O
against	O
nicergoline	B_Chemical
.	O

Treatment	O
was	O
consisted	O
of	O
withdrawal	O
of	O
nicergoline	B_Chemical
and	O
intravenous	O
methylprednisolone	B_Chemical
,	O
and	O
his	O
renal	O
function	O
was	O
completely	O
recovered	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
nicergoline-associated	O
AIN	B_Disease
.	O

Neuroleptic	B_Disease
malignant	I_Disease
syndrome	I_Disease
complicated	O
by	O
massive	O
intestinal	O
bleeding	B_Disease
in	O
a	O
patient	O
with	O
chronic	B_Disease
renal	I_Disease
failure	I_Disease
.	O

A	O
patient	O
with	O
chronic	B_Disease
renal	I_Disease
failure	I_Disease
(	O
CRF	B_Disease
)	O
developed	O
neuroleptic	B_Disease
malignant	I_Disease
syndrome	I_Disease
(	O
NMS	B_Disease
)	O
after	O
administration	O
of	O
risperidone	B_Chemical
and	O
levomepromazine	B_Chemical
.	O

In	O
addition	O
to	O
the	O
typical	O
symptoms	O
of	O
NMS	B_Disease
,	O
massive	O
intestinal	O
bleeding	B_Disease
was	O
observed	O
during	O
the	O
episode	O
.	O

This	O
report	O
suggests	O
that	O
NMS	B_Disease
in	O
a	O
patient	O
with	O
CRF	B_Disease
may	O
be	O
complicated	O
by	O
intestinal	O
bleeding	B_Disease
and	O
needs	O
special	O
caution	O
for	O
this	O
complication	O
.	O

Blood	O
brain	O
barrier	O
in	O
right-	O
and	O
left-pawed	O
female	O
rats	O
assessed	O
by	O
a	O
new	O
staining	O
method	O
.	O

The	O
asymmetrical	O
breakdown	O
of	O
the	O
blood-brain	O
barrier	O
(	O
BBB	O
)	O
was	O
studied	O
in	O
female	O
rats	O
.	O

Paw	O
preference	O
was	O
assessed	O
by	O
a	O
food	O
reaching	O
test	O
.	O

Adrenaline-induced	O
hypertension	B_Disease
was	O
used	O
to	O
destroy	O
the	O
BBB	O
,	O
which	O
was	O
evaluated	O
using	O
triphenyltetrazolium	B_Chemical
(	O
TTC	B_Chemical
)	O
staining	O
of	O
the	O
brain	O
slices	O
just	O
after	O
giving	O
adrenaline	B_Chemical
for	O
30	O
s.	O
In	O
normal	O
rats	O
,	O
the	O
whole	O
brain	O
sections	O
exhibited	O
complete	O
staining	O
with	O
TTC	B_Chemical
.	O

After	O
adrenaline	B_Chemical
infusion	O
for	O
30	O
s	O
,	O
there	O
were	O
large	O
unstained	O
areas	O
in	O
the	O
left	O
brain	O
in	O
right-pawed	O
animals	O
,	O
and	O
vice	O
versa	O
in	O
left-pawed	O
animals	O
.	O

Similar	O
results	O
were	O
obtained	O
in	O
seizure-induced	O
breakdown	O
of	O
BBB	O
.	O

These	O
results	O
were	O
explained	O
by	O
an	O
asymmetric	O
cerebral	O
blood	O
flow	O
depending	O
upon	O
the	O
paw	O
preference	O
in	O
rats	O
.	O

It	O
was	O
suggested	O
that	O
this	O
new	O
method	O
and	O
the	O
results	O
are	O
consistent	O
with	O
contralateral	O
motor	O
control	O
that	O
may	O
be	O
important	O
in	O
determining	O
the	O
dominant	O
cerebral	O
hemisphere	O
in	O
animals	O
.	O

Carvedilol	B_Chemical
protects	O
against	O
doxorubicin-induced	O
mitochondrial	O
cardiomyopathy	B_Disease
.	O

Several	O
cytopathic	O
mechanisms	O
have	O
been	O
suggested	O
to	O
mediate	O
the	O
dose-limiting	O
cumulative	O
and	O
irreversible	O
cardiomyopathy	B_Disease
caused	O
by	O
doxorubicin	B_Chemical
.	O

Recent	O
evidence	O
indicates	O
that	O
oxidative	O
stress	O
and	O
mitochondrial	B_Disease
dysfunction	I_Disease
are	O
key	O
factors	O
in	O
the	O
pathogenic	O
process	O
.	O

The	O
objective	O
of	O
this	O
investigation	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
carvedilol	B_Chemical
,	O
a	O
nonselective	O
beta-adrenergic	O
receptor	O
antagonist	O
with	O
potent	O
antioxidant	O
properties	O
,	O
protects	O
against	O
the	O
cardiac	O
and	O
hepatic	O
mitochondrial	O
bioenergetic	O
dysfunction	O
associated	O
with	O
subchronic	O
doxorubicin	B_Chemical
toxicity	B_Disease
.	O

Heart	O
and	O
liver	O
mitochondria	O
were	O
isolated	O
from	O
rats	O
treated	O
for	O
7	O
weeks	O
with	O
doxorubicin	B_Chemical
(	O
2	O
mg/kg	O
sc/week	O
)	O
,	O
carvedilol	B_Chemical
(	O
1	O
mg/kg	O
ip/week	O
)	O
,	O
or	O
the	O
combination	O
of	O
the	O
two	O
drugs	O
.	O

Heart	O
mitochondria	O
isolated	O
from	O
doxorubicin-treated	O
rats	O
exhibited	O
depressed	O
rates	O
for	O
state	O
3	O
respiration	O
(	O
336	O
+	O
/-	O
26	O
versus	O
425	O
+	O
/-	O
53	O
natom	O
O/min/mg	O
protein	O
)	O
and	O
a	O
lower	O
respiratory	O
control	O
ratio	O
(	O
RCR	O
)	O
(	O
4.3	O
+	O
/-	O
0.6	O
versus	O
5.8	O
+	O
/-	O
0.4	O
)	O
compared	O
with	O
cardiac	O
mitochondria	O
isolated	O
from	O
saline-treated	O
rats	O
.	O

Mitochondrial	O
calcium-loading	O
capacity	O
and	O
the	O
activity	O
of	O
NADH-dehydrogenase	O
were	O
also	O
suppressed	O
in	O
cardiac	O
mitochondria	O
from	O
doxorubicin-treated	O
rats	O
.	O

Doxorubicin	B_Chemical
treatment	O
also	O
caused	O
a	O
decrease	O
in	O
RCR	O
for	O
liver	O
mitochondria	O
(	O
3.9	O
+	O
/-	O
0.9	O
versus	O
5.6	O
+	O
/-	O
0.7	O
for	O
control	O
rats	O
)	O
and	O
inhibition	O
of	O
hepatic	O
cytochrome	O
oxidase	O
activity	O
.	O

Coadministration	O
of	O
carvedilol	B_Chemical
decreased	O
the	O
extent	O
of	O
cellular	O
vacuolization	O
in	O
cardiac	O
myocytes	O
and	O
prevented	O
the	O
inhibitory	O
effect	O
of	O
doxorubicin	B_Chemical
on	O
mitochondrial	O
respiration	O
in	O
both	O
heart	O
and	O
liver	O
.	O

Carvedilol	B_Chemical
also	O
prevented	O
the	O
decrease	O
in	O
mitochondrial	O
Ca(2	O
+	O
)	O
loading	O
capacity	O
and	O
the	O
inhibition	O
of	O
the	O
respiratory	O
complexes	O
of	O
heart	O
mitochondria	O
caused	O
by	O
doxorubicin	B_Chemical
.	O

Carvedilol	B_Chemical
by	O
itself	O
did	O
not	O
affect	O
any	O
of	O
the	O
parameters	O
measured	O
for	O
heart	O
or	O
liver	O
mitochondria	O
.	O

It	O
is	O
concluded	O
that	O
this	O
protection	O
by	O
carvedilol	B_Chemical
against	O
both	O
the	O
structural	O
and	O
functional	O
cardiac	O
tissue	O
damage	O
may	O
afford	O
significant	O
clinical	O
advantage	O
in	O
minimizing	O
the	O
dose-limiting	O
mitochondrial	B_Disease
dysfunction	I_Disease
and	O
cardiomyopathy	B_Disease
that	O
accompanies	O
long-term	O
doxorubicin	B_Chemical
therapy	O
in	O
cancer	B_Disease
patients	O
.	O

Cocaine-induced	O
hyperactivity	B_Disease
is	O
more	O
influenced	O
by	O
adenosine	B_Chemical
receptor	O
agonists	O
than	O
amphetamine-induced	O
hyperactivity	B_Disease
.	O

The	O
influence	O
of	O
adenosine	B_Chemical
receptor	O
agonists	O
and	O
antagonists	O
on	O
cocaine-and	O
amphetamine-induced	O
hyperactivity	B_Disease
was	O
examined	O
in	O
mice	O
.	O

All	O
adenosine	B_Chemical
receptor	O
agonists	O
significantly	O
decreased	B_Disease
the	I_Disease
locomotor	I_Disease
activity	I_Disease
in	O
mice	O
,	O
and	O
the	O
effects	O
were	O
dose-dependent	O
.	O

It	O
seems	O
that	O
adenosine	B_Chemical
A1	O
and	O
A2	O
receptors	O
might	O
be	O
involved	O
in	O
this	O
reaction	O
.	O

Moreover	O
,	O
all	O
adenosine	B_Chemical
receptor	O
agonists	O
:	O
2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine	B_Chemical
(	O
CGS	B_Chemical
21680	I_Chemical
)	O
,	O
A2A	O
receptor	O
agonist	O
,	O
N6-cyclopentyladenosine	B_Chemical
(	O
CPA	B_Chemical
)	O
,	O
A1	O
receptor	O
agonist	O
,	O
and	O
5'-N-ethylcarboxamidoadenosine	B_Chemical
(	O
NECA	B_Chemical
)	O
,	O
A2/A1	O
receptor	O
agonist	O
significantly	O
and	O
dose-dependently	O
decreased	O
cocaine-induced	O
locomotor	O
activity	O
.	O

CPA	B_Chemical
reduced	O
cocaine	B_Chemical
action	O
at	O
the	O
doses	O
which	O
,	O
given	O
alone	O
,	O
did	O
not	O
influence	O
motility	O
,	O
while	O
CGS	B_Chemical
21680	I_Chemical
and	O
NECA	B_Chemical
decreased	O
the	O
action	O
of	O
cocaine	B_Chemical
at	O
the	O
doses	O
which	O
,	O
given	O
alone	O
,	O
decreased	O
locomotor	O
activity	O
in	O
animals	O
.	O

These	O
results	O
suggest	O
the	O
involvement	O
of	O
both	O
adenosine	B_Chemical
receptors	O
in	O
the	O
action	O
of	O
cocaine	B_Chemical
although	O
agonists	O
of	O
A1	O
receptors	O
seem	O
to	O
have	O
stronger	O
influence	O
on	O
it	O
.	O

The	O
selective	O
blockade	O
of	O
A2	O
adenosine	B_Chemical
receptor	O
by	O
DMPX	B_Chemical
(	O
3,7-dimethyl-1-propargylxanthine	B_Chemical
)	O
significantly	O
enhanced	O
cocaine-induced	O
locomotor	O
activity	O
of	O
animals	O
.	O

Caffeine	B_Chemical
had	O
similar	O
action	O
but	O
the	O
effect	O
was	O
not	O
significant	O
.	O

CPT	B_Chemical
(8-cyclopentyltheophylline)--A1	O
receptor	O
antagonist	O
,	O
did	O
not	O
show	O
any	O
influence	O
in	O
this	O
test	O
.	O

Similarly	O
,	O
all	O
adenosine	B_Chemical
receptor	O
agonists	O
decreased	O
amphetamine-induced	O
hyperactivity	B_Disease
,	O
but	O
at	O
the	O
higher	O
doses	O
than	O
those	O
which	O
were	O
active	O
in	O
cocaine-induced	O
hyperactivity	B_Disease
.	O

The	O
selective	O
blockade	O
of	O
A2	O
adenosine	B_Chemical
receptors	O
(	O
DMPX	B_Chemical
)	O
and	O
non-selective	O
blockade	O
of	O
adenosine	B_Chemical
receptors	O
(	O
caffeine	B_Chemical
)	O
significantly	O
increased	O
the	O
action	O
of	O
amphetamine	B_Chemical
in	O
the	O
locomotor	O
activity	O
test	O
.	O

Our	O
results	O
have	O
shown	O
that	O
all	O
adenosine	B_Chemical
receptor	O
agonists	O
(	O
A1	O
and	O
A2	O
)	O
reduce	O
cocaine-	O
and	O
amphetamine-induced	O
locomotor	O
activity	O
and	O
indicate	O
that	O
cocaine-induced	O
hyperactivity	B_Disease
is	O
more	O
influenced	O
by	O
adenosine	B_Chemical
receptor	O
agonists	O
(	O
particularly	O
A1	O
receptors	O
)	O
than	O
amphetamine-induced	O
hyperactivity	B_Disease
.	O

Amiodarone	B_Chemical
and	O
the	O
risk	O
of	O
bradyarrhythmia	B_Disease
requiring	O
permanent	O
pacemaker	O
in	O
elderly	O
patients	O
with	O
atrial	B_Disease
fibrillation	I_Disease
and	O
prior	O
myocardial	B_Disease
infarction	I_Disease
.	O

OBJECTIVES	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
use	O
of	O
amiodarone	B_Chemical
in	O
patients	O
with	O
atrial	B_Disease
fibrillation	I_Disease
(	O
AF	B_Disease
)	O
increases	O
the	O
risk	O
of	O
bradyarrhythmia	B_Disease
requiring	O
a	O
permanent	O
pacemaker	O
.	O

BACKGROUND	O
:	O
Reports	O
of	O
severe	O
bradyarrhythmia	B_Disease
during	O
amiodarone	B_Chemical
therapy	O
are	O
infrequent	O
and	O
limited	O
to	O
studies	O
assessing	O
the	O
therapy	O
's	O
use	O
in	O
the	O
management	O
of	O
patients	O
with	O
ventricular	B_Disease
arrhythmias	I_Disease
.	O

METHODS	O
:	O
A	O
study	O
cohort	O
of	O
8,770	O
patients	O
age	O
>	O
or	O
=	O
65	O
years	O
with	O
a	O
new	O
diagnosis	O
of	O
AF	B_Disease
was	O
identified	O
from	O
a	O
provincewide	O
database	O
of	O
Quebec	O
residents	O
with	O
a	O
myocardial	B_Disease
infarction	I_Disease
(	O
MI	B_Disease
)	O
between	O
1991	O
and	O
1999	O
.	O

Using	O
a	O
nested	O
case-control	O
design	O
,	O
477	O
cases	O
of	O
bradyarrhythmia	B_Disease
requiring	O
a	O
permanent	O
pacemaker	O
were	O
matched	O
(	O
1:4	O
)	O
to	O
1,908	O
controls	O
.	O

Multivariable	O
logistic	O
regression	O
was	O
used	O
to	O
estimate	O
the	O
odds	O
ratio	O
(	O
OR	O
)	O
of	O
pacemaker	O
insertion	O
associated	O
with	O
amiodarone	B_Chemical
use	O
,	O
controlling	O
for	O
baseline	O
risk	O
factors	O
and	O
exposure	O
to	O
sotalol	B_Chemical
,	O
Class	O
I	O
antiarrhythmic	O
agents	O
,	O
beta-blockers	O
,	O
calcium	B_Chemical
channel	O
blockers	O
,	O
and	O
digoxin	B_Chemical
.	O

RESULTS	O
:	O
amiodarone	B_Chemical
use	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
pacemaker	O
insertion	O
(	O
OR	O
:	O
2.14	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
1.30	O
to	O
3.54	O
)	O
.	O

This	O
effect	O
was	O
modified	O
by	O
gender	O
,	O
with	O
a	O
greater	O
risk	O
in	O
women	O
versus	O
men	O
(	O
OR	O
:	O
3.86	O
,	O
95	O
%	O
CI	O
:	O
1.70	O
to	O
8.75	O
vs.	O
OR	O
:	O
1.52	O
,	O
95	O
%	O
CI	O
:	O
0.80	O
to	O
2.89	O
)	O
.	O

Digoxin	B_Chemical
was	O
the	O
only	O
other	O
medication	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
pacemaker	O
insertion	O
(	O
OR	O
:	O
1.78	O
,	O
95	O
%	O
CI	O
:	O
1.37	O
to	O
2.31	O
)	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
suggests	O
that	O
the	O
use	O
of	O
amiodarone	B_Chemical
in	O
elderly	O
patients	O
with	O
AF	B_Disease
and	O
a	O
previous	O
MI	B_Disease
increases	O
the	O
risk	O
of	O
bradyarrhythmia	B_Disease
requiring	O
a	O
permanent	O
pacemaker	O
.	O

The	O
finding	O
of	O
an	O
augmented	O
risk	O
of	O
pacemaker	O
insertion	O
in	O
elderly	O
women	O
receiving	O
amiodarone	B_Chemical
requires	O
further	O
investigation	O
.	O

Indomethacin-induced	O
morphologic	O
changes	O
in	O
the	O
rat	O
urinary	O
bladder	O
epithelium	O
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
morphologic	O
changes	O
in	O
rat	O
urothelium	O
induced	O
by	O
indomethacin	B_Chemical
.	O

Nonsteroidal	O
anti-inflammatory	O
drug-induced	O
cystitis	B_Disease
is	O
a	O
poorly	O
recognized	O
and	O
under-reported	O
condition	O
.	O

In	O
addition	O
to	O
tiaprofenic	B_Chemical
acid	I_Chemical
,	O
indomethacin	B_Chemical
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
this	O
condition	O
.	O

METHODS	O
:	O
Three	O
groups	O
were	O
established	O
:	O
a	O
control	O
group	O
(	O
n	O
=	O
10	O
)	O
,	O
a	O
high-dose	O
group	O
(	O
n	O
=	O
10	O
)	O
,	O
treated	O
with	O
one	O
intraperitoneal	O
injection	O
of	O
indomethacin	B_Chemical
20	O
mg/kg	O
,	O
and	O
a	O
therapeutic	O
dose	O
group	O
(	O
n	O
=	O
10	O
)	O
in	O
which	O
oral	O
indomethacin	B_Chemical
was	O
administered	O
3.25	O
mg/kg	O
body	O
weight	O
daily	O
for	O
3	O
weeks	O
.	O

The	O
animals	O
were	O
then	O
killed	O
and	O
the	O
bladders	O
removed	O
for	O
light	O
and	O
electron	O
microscopic	O
studies	O
.	O

RESULTS	O
:	O
The	O
light	O
microscopic	O
findings	O
showed	O
some	O
focal	O
epithelial	O
degeneration	O
that	O
was	O
more	O
prominent	O
in	O
the	O
high-dose	O
group	O
.	O

When	O
compared	O
with	O
the	O
control	O
group	O
,	O
both	O
indomethacin	B_Chemical
groups	O
revealed	O
statistically	O
increased	O
numbers	O
of	O
mast	O
cells	O
in	O
the	O
mucosa	O
(	O
P	O
<	O
0.0001	O
)	O
and	O
penetration	O
of	O
lanthanum	B_Chemical
nitrate	I_Chemical
through	O
intercellular	O
areas	O
of	O
the	O
epithelium	O
.	O

Furthermore	O
,	O
the	O
difference	O
in	O
mast	O
cell	O
counts	O
between	O
the	O
high	O
and	O
therapeutic	O
dose	O
groups	O
was	O
also	O
statistically	O
significant	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

CONCLUSIONS	O
:	O
Indomethacin	B_Chemical
resulted	O
in	O
histopathologic	O
findings	O
typical	O
of	O
interstitial	B_Disease
cystitis	I_Disease
,	O
such	O
as	O
leaky	O
bladder	O
epithelium	O
and	O
mucosal	O
mastocytosis	B_Disease
.	O

The	O
true	O
incidence	O
of	O
nonsteroidal	O
anti-inflammatory	O
drug-induced	O
cystitis	B_Disease
in	O
humans	O
must	O
be	O
clarified	O
by	O
prospective	O
clinical	O
trials	O
.	O

An	O
open-label	O
phase	O
II	O
study	O
of	O
low-dose	O
thalidomide	B_Chemical
in	O
androgen-independent	O
prostate	B_Disease
cancer	I_Disease
.	O

The	O
antiangiogenic	O
effects	O
of	O
thalidomide	B_Chemical
have	O
been	O
assessed	O
in	O
clinical	O
trials	O
in	O
patients	O
with	O
various	O
solid	O
and	O
haematological	B_Disease
malignancies	I_Disease
.	O

Thalidomide	B_Chemical
blocks	O
the	O
activity	O
of	O
angiogenic	O
agents	O
including	O
bFGF	O
,	O
VEGF	O
and	O
IL-6	O
.	O

We	O
undertook	O
an	O
open-label	O
study	O
using	O
thalidomide	B_Chemical
100	O
mg	O
once	O
daily	O
for	O
up	O
to	O
6	O
months	O
in	O
20	O
men	O
with	O
androgen-independent	O
prostate	B_Disease
cancer	I_Disease
.	O

The	O
mean	O
time	O
of	O
study	O
was	O
109	O
days	O
(	O
median	O
107	O
,	O
range	O
4	O
-	O
184	O
days	O
)	O
.	O

Patients	O
underwent	O
regular	O
measurement	O
of	O
prostate-specific	O
antigen	O
(	O
PSA	O
)	O
,	O
urea	B_Chemical
and	O
electrolytes	O
,	O
serum	O
bFGF	O
and	O
VEGF	O
.	O

Three	O
men	O
(	O
15	O
%	O
)	O
showed	O
a	O
decline	O
in	O
serum	O
PSA	O
of	O
at	O
least	O
50	O
%	O
,	O
sustained	O
throughout	O
treatment	O
.	O

Of	O
16	O
men	O
treated	O
for	O
at	O
least	O
2	O
months	O
,	O
six	O
(	O
37.5	O
%	O
)	O
showed	O
a	O
fall	O
in	O
absolute	O
PSA	O
by	O
a	O
median	O
of	O
48	O
%	O
.	O

Increasing	O
levels	O
of	O
serum	O
bFGF	O
and	O
VEGF	O
were	O
associated	O
with	O
progressive	O
disease	O
;	O
five	O
of	O
six	O
men	O
who	O
demonstrated	O
a	O
fall	O
in	O
PSA	O
also	O
showed	O
a	O
decline	O
in	O
bFGF	O
and	O
VEGF	O
levels	O
,	O
and	O
three	O
of	O
four	O
men	O
with	O
a	O
rising	O
PSA	O
showed	O
an	O
increase	O
in	O
both	O
growth	O
factors	O
.	O

Adverse	O
effects	O
included	O
constipation	B_Disease
,	O
morning	O
drowsiness	B_Disease
,	O
dizziness	B_Disease
and	O
rash	B_Disease
,	O
and	O
resulted	O
in	O
withdrawal	O
from	O
the	O
study	O
by	O
three	O
men	O
.	O

Evidence	O
of	O
peripheral	B_Disease
sensory	I_Disease
neuropathy	I_Disease
was	O
found	O
in	O
nine	O
of	O
13	O
men	O
before	O
treatment	O
.	O

In	O
the	O
seven	O
men	O
who	O
completed	O
six	O
months	O
on	O
thalidomide	B_Chemical
,	O
subclinical	O
evidence	O
of	O
peripheral	B_Disease
neuropathy	I_Disease
was	O
found	O
in	O
four	O
before	O
treatment	O
,	O
but	O
in	O
all	O
seven	O
at	O
repeat	O
testing	O
.	O

The	O
findings	O
indicate	O
that	O
thalidomide	B_Chemical
may	O
be	O
an	O
option	O
for	O
patients	O
who	O
have	O
failed	O
other	O
forms	O
of	O
therapy	O
,	O
provided	O
close	O
follow-up	O
is	O
maintained	O
for	O
development	O
of	O
peripheral	B_Disease
neuropathy	I_Disease
.	O

Central	B_Disease
nervous	I_Disease
system	I_Disease
toxicity	I_Disease
following	O
the	O
administration	O
of	O
levobupivacaine	B_Chemical
for	O
lumbar	O
plexus	O
block	O
:	O
A	O
report	O
of	O
two	O
cases	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
Central	B_Disease
nervous	I_Disease
system	I_Disease
and	I_Disease
cardiac	B_Disease
toxicity	I_Disease
following	O
the	O
administration	O
of	O
local	O
anesthetics	O
is	O
a	O
recognized	O
complication	O
of	O
regional	O
anesthesia	O
.	O

Levobupivacaine	B_Chemical
,	O
the	O
pure	O
S(-	O
)	O
enantiomer	O
of	O
bupivacaine	B_Chemical
,	O
was	O
developed	O
to	O
improve	O
the	O
cardiac	O
safety	O
profile	O
of	O
bupivacaine	B_Chemical
.	O

We	O
describe	O
2	O
cases	O
of	O
grand	B_Disease
mal	I_Disease
seizures	I_Disease
following	O
accidental	O
intravascular	O
injection	O
of	O
levobupivacaine	B_Chemical
.	O

CASE	O
REPORT	O
:	O
Two	O
patients	O
presenting	O
for	O
elective	O
orthopedic	O
surgery	O
of	O
the	O
lower	O
limb	O
underwent	O
blockade	O
of	O
the	O
lumbar	O
plexus	O
via	O
the	O
posterior	O
approach	O
.	O

Immediately	O
after	O
the	O
administration	O
of	O
levobupivacaine	B_Chemical
0.5	O
%	O
with	O
epinephrine	B_Chemical
2.5	O
microgram/mL	O
,	O
the	O
patients	O
developed	O
grand	B_Disease
mal	I_Disease
seizures	I_Disease
,	O
despite	O
negative	O
aspiration	O
for	O
blood	O
and	O
no	O
clinical	O
signs	O
of	O
intravenous	O
epinephrine	B_Chemical
administration	O
.	O

The	O
seizures	B_Disease
were	O
successfully	O
treated	O
with	O
sodium	B_Chemical
thiopental	I_Chemical
in	O
addition	O
to	O
succinylcholine	B_Chemical
in	O
1	O
patient	O
.	O

Neither	O
patient	O
developed	O
signs	O
of	O
cardiovascular	B_Disease
toxicity	I_Disease
.	O

Both	O
patients	O
were	O
treated	O
preoperatively	O
with	O
beta-adrenergic	O
antagonist	O
medications	O
,	O
which	O
may	O
have	O
masked	O
the	O
cardiovascular	O
signs	O
of	O
the	O
unintentional	O
intravascular	O
administration	O
of	O
levobupivacaine	B_Chemical
with	O
epinephrine	B_Chemical
.	O

CONCLUSIONS	O
:	O
Although	O
levobupivacaine	B_Chemical
may	O
have	O
a	O
safer	O
cardiac	B_Disease
toxicity	I_Disease
profile	O
than	O
racemic	O
bupivacaine	B_Chemical
,	O
if	O
adequate	O
amounts	O
of	O
levobupivacaine	B_Chemical
reach	O
the	O
circulation	O
,	O
it	O
will	O
result	O
in	O
convulsions	B_Disease
.	O

Plasma	O
concentrations	O
sufficient	O
to	O
result	O
in	O
central	B_Disease
nervous	I_Disease
system	I_Disease
toxicity	I_Disease
did	O
not	O
produce	O
manifestations	O
of	O
cardiac	B_Disease
toxicity	I_Disease
in	O
these	O
2	O
patients	O
.	O

Amiodarone-induced	O
torsade	B_Disease
de	I_Disease
pointes	I_Disease
during	O
bladder	O
irrigation	O
:	O
an	O
unusual	O
presentation	O
--	O
a	O
case	O
report	O
.	O

The	O
authors	O
present	O
a	O
case	O
of	O
early	O
(	O
within	O
4	O
days	O
)	O
development	O
of	O
torsade	B_Disease
de	I_Disease
pointes	I_Disease
(	O
TdP	B_Disease
)	O
associated	O
with	O
oral	O
amiodarone	B_Chemical
therapy	O
.	O

Consistent	O
with	O
other	O
reports	O
this	O
case	O
of	O
TdP	B_Disease
occurred	O
in	O
the	O
context	O
of	O
multiple	O
exacerbating	O
factors	O
including	O
hypokalemia	B_Disease
and	O
digoxin	B_Chemical
excess	O
.	O

Transient	O
prolongation	O
of	O
the	O
QT	O
during	O
bladder	O
irrigation	O
prompted	O
the	O
episode	O
of	O
TdP.	O
It	O
is	O
well	O
known	O
that	O
bradycardia	B_Disease
exacerbates	O
acquired	O
TdP.	O
The	O
authors	O
speculate	O
that	O
the	O
increased	O
vagal	O
tone	O
during	O
bladder	O
irrigation	O
,	O
a	O
vagal	O
maneuver	O
,	O
in	O
the	O
context	O
of	O
amiodarone	B_Chemical
therapy	O
resulted	O
in	O
amiodarone-induced	O
proarrhythmia	B_Disease
.	O

In	O
the	O
absence	O
of	O
amiodarone	B_Chemical
therapy	O
,	O
a	O
second	O
bladder	O
irrigation	O
did	O
not	O
induce	O
TdP	B_Disease
despite	O
hypokalemia	B_Disease
and	O
hypomagnesemia	B_Disease
.	O

Anaesthetic	O
complications	O
associated	O
with	O
myotonia	B_Disease
congenita	I_Disease
:	O
case	O
study	O
and	O
comparison	O
with	O
other	O
myotonic	B_Disease
disorders	I_Disease
.	O

Myotonia	B_Disease
congenita	I_Disease
(	O
MC	B_Disease
)	O
is	O
caused	O
by	O
a	O
defect	O
in	O
the	O
skeletal	O
muscle	O
chloride	B_Chemical
channel	O
function	O
,	O
which	O
may	O
cause	O
sustained	B_Disease
membrane	I_Disease
depolarisation	I_Disease
.	O

We	O
describe	O
a	O
previously	O
healthy	O
32-year-old	O
woman	O
who	O
developed	O
a	O
life-threatening	O
muscle	B_Disease
spasm	I_Disease
and	O
secondary	O
ventilation	O
difficulties	O
following	O
a	O
preoperative	O
injection	O
of	O
suxamethonium	B_Chemical
.	O

The	O
muscle	B_Disease
spasms	I_Disease
disappeared	O
spontaneously	O
and	O
the	O
surgery	O
proceeded	O
without	O
further	O
problems	O
.	O

When	O
subsequently	O
questioned	O
,	O
she	O
reported	O
minor	O
symptoms	O
suggesting	O
a	O
myotonic	B_Disease
condition	I_Disease
.	O

Myotonia	B_Disease
was	O
found	O
on	O
clinical	O
examination	O
and	O
EMG	O
.	O

The	O
diagnosis	O
MC	B_Disease
was	O
confirmed	O
genetically	O
.	O

Neither	O
the	O
patient	O
nor	O
the	O
anaesthetist	O
were	O
aware	O
of	O
the	O
diagnosis	O
before	O
this	O
potentially	O
lethal	O
complication	O
occurred	O
.	O

We	O
give	O
a	O
brief	O
overview	O
of	O
ion	B_Disease
channel	I_Disease
disorders	I_Disease
including	O
malignant	B_Disease
hyperthermia	I_Disease
and	O
their	O
anaesthetic	O
considerations	O
.	O

Respiratory	O
pattern	O
in	O
a	O
rat	O
model	O
of	O
epilepsy	O
.	O

PURPOSE	O
:	O
Apnea	B_Disease
is	O
known	O
to	O
occur	O
during	O
seizures	B_Disease
,	O
but	O
systematic	O
studies	O
of	O
ictal	O
respiratory	O
changes	O
in	O
adults	O
are	O
few	O
.	O

Data	O
regarding	O
respiratory	O
pattern	O
defects	O
during	O
interictal	O
periods	O
also	O
are	O
scarce	O
.	O

Here	O
we	O
sought	O
to	O
generate	O
information	O
with	O
regard	O
to	O
the	O
interictal	O
period	O
in	O
animals	O
with	O
pilocarpine-induced	O
epilepsy	B_Disease
.	O

METHODS	O
:	O
Twelve	O
rats	O
(	O
six	O
chronically	O
epileptic	B_Disease
animals	O
and	O
six	O
controls	O
)	O
were	O
anesthetized	O
,	O
given	O
tracheotomies	O
,	O
and	O
subjected	O
to	O
hyperventilation	B_Disease
or	O
hypoventilation	O
conditions	O
.	O

Breathing	O
movements	O
caused	O
changes	O
in	O
thoracic	O
volume	O
and	O
forced	O
air	O
to	O
flow	O
tidally	O
through	O
a	O
pneumotachograph	O
.	O

This	O
flow	O
was	O
measured	O
by	O
using	O
a	O
differential	O
pressure	O
transducer	O
,	O
passed	O
through	O
a	O
polygraph	O
,	O
and	O
from	O
this	O
to	O
a	O
computer	O
with	O
custom	O
software	O
that	O
derived	O
ventilation	O
(	O
VE	O
)	O
,	O
tidal	O
volume	O
(	O
VT	O
)	O
,	O
inspiratory	O
time	O
(	O
TI	O
)	O
,	O
expiratory	O
time	O
(	O
TE	O
)	O
,	O
breathing	O
frequency	O
(	O
f	O
)	O
,	O
and	O
mean	O
inspiratory	O
flow	O
(	O
VT/TI	O
)	O
on	O
a	O
breath-by-breath	O
basis	O
.	O

RESULTS	O
:	O
The	O
hyperventilation	B_Disease
maneuver	O
caused	O
a	O
decrease	O
in	O
spontaneous	O
ventilation	O
in	O
pilocarpine-treated	O
and	O
control	O
rats	O
.	O

Although	O
VE	O
had	O
a	O
similar	O
decrease	O
in	O
both	O
groups	O
,	O
in	O
the	O
epileptic	B_Disease
group	O
,	O
the	O
decrease	O
in	O
VE	O
was	O
due	O
to	O
a	O
significant	O
(	O
p	O
<	O
0.05	O
)	O
increase	O
in	O
TE	O
peak	O
in	O
relation	O
to	O
that	O
of	O
the	O
control	O
animals	O
.	O

The	O
hypoventilation	O
maneuver	O
led	O
to	O
an	O
increase	O
in	O
the	O
arterial	O
Paco2	O
,	O
followed	O
by	O
an	O
increase	O
in	O
VE	O
.	O

In	O
the	O
epileptic	B_Disease
group	O
,	O
the	O
increase	O
in	O
VE	O
was	O
mediated	O
by	O
a	O
significant	O
(	O
p	O
<	O
0.05	O
)	O
decrease	O
in	O
TE	O
peak	O
compared	O
with	O
the	O
control	O
group	O
.	O

Systemic	O
application	O
of	O
KCN	O
,	O
to	O
evaluate	O
the	O
effects	O
of	O
peripheral	O
chemoreception	O
activation	O
on	O
ventilation	O
,	O
led	O
to	O
a	O
similar	O
increase	O
in	O
VE	O
for	O
both	O
groups	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
indicate	O
that	O
pilocarpine-treated	O
animals	O
have	O
an	O
altered	O
ability	O
to	O
react	O
to	O
(	O
or	O
compensate	O
for	O
)	O
blood	O
gas	O
changes	O
with	O
changes	O
in	O
ventilation	O
and	O
suggest	O
that	O
it	O
is	O
centrally	O
determined	O
.	O

We	O
speculate	O
on	O
the	O
possible	O
relation	O
of	O
the	O
current	O
findings	O
on	O
treating	O
different	O
epilepsy-associated	O
conditions	O
.	O

Fatal	O
myeloencephalopathy	B_Disease
due	O
to	O
intrathecal	O
vincristine	B_Chemical
administration	O
.	O

Vincristine	B_Chemical
was	O
accidentally	O
given	O
intrathecally	O
to	O
a	O
child	O
with	O
leukaemia	B_Disease
,	O
producing	O
sensory	B_Disease
and	I_Disease
motor	I_Disease
dysfunction	I_Disease
followed	O
by	O
encephalopathy	B_Disease
and	O
death	O
.	O

Separate	O
times	O
for	O
administering	O
vincristine	B_Chemical
and	O
intrathecal	O
therapy	O
is	O
recommended	O
.	O

Progesterone	B_Chemical
potentiation	O
of	O
bupivacaine	B_Chemical
arrhythmogenicity	O
in	O
pentobarbital-anesthetized	O
rats	O
and	O
beating	O
rat	O
heart	O
cell	O
cultures	O
.	O

The	O
effects	O
of	O
progesterone	B_Chemical
treatment	O
on	O
bupivacaine	B_Chemical
arrhythmogenicity	O
in	O
beating	O
rat	O
heart	O
myocyte	O
cultures	O
and	O
on	O
anesthetized	O
rats	O
were	O
determined	O
.	O

After	O
determining	O
the	O
bupivacaine	B_Chemical
AD50	O
(	O
the	O
concentration	O
of	O
bupivacaine	B_Chemical
that	O
caused	O
50	O
%	O
of	O
all	O
beating	O
rat	O
heart	O
myocyte	O
cultures	O
to	O
become	O
arrhythmic	B_Disease
)	O
,	O
we	O
determined	O
the	O
effect	O
of	O
1-hour	O
progesterone	B_Chemical
HCl	B_Chemical
exposure	O
on	O
myocyte	O
contractile	O
rhythm	O
.	O

Each	O
concentration	O
of	O
progesterone	B_Chemical
(	O
6.25	O
,	O
12.5	O
,	O
25	O
,	O
and	O
50	O
micrograms/ml	O
)	O
caused	O
a	O
significant	O
and	O
concentration-dependent	O
reduction	O
in	O
the	O
AD50	O
for	O
bupivacaine	B_Chemical
.	O

Estradiol	B_Chemical
treatment	O
also	O
increased	O
the	O
arrhythmogenicity	O
of	O
bupivacaine	B_Chemical
in	O
myocyte	O
cultures	O
,	O
but	O
was	O
only	O
one	O
fourth	O
as	O
potent	O
as	O
progesterone	B_Chemical
.	O

Neither	O
progesterone	B_Chemical
nor	O
estradiol	B_Chemical
effects	O
on	O
bupivacaine	B_Chemical
arrhythmogenicity	O
were	O
potentiated	O
by	O
epinephrine	B_Chemical
.	O

Chronic	O
progesterone	B_Chemical
pretreatment	O
(	O
5	O
mg/kg/day	O
for	O
21	O
days	O
)	O
caused	O
a	O
significant	O
increase	O
in	O
bupivacaine	B_Chemical
arrhythmogenicity	O
in	O
intact	O
pentobarbital-anesthetized	O
rats	O
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
time	O
to	O
onset	O
of	O
arrhythmia	B_Disease
as	O
compared	O
with	O
control	O
nonprogesterone-treated	O
rats	O
(	O
6.2	O
+	O
/-	O
1.3	O
vs.	O
30.8	O
+	O
/-	O
2.5	O
min	O
,	O
mean	O
+	O
/-	O
SE	O
)	O
.	O

The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
progesterone	B_Chemical
can	O
potentiate	O
bupivacaine	B_Chemical
arrhythmogenicity	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Potentiation	O
of	O
bupivacaine	B_Chemical
arrhythmia	B_Disease
in	O
myocyte	O
cultures	O
suggests	O
that	O
this	O
effect	O
is	O
at	O
least	O
partly	O
mediated	O
at	O
the	O
myocyte	O
level	O
.	O

Increased	O
serum	O
soluble	O
Fas	O
in	O
patients	O
with	O
acute	B_Disease
liver	I_Disease
failure	I_Disease
due	O
to	O
paracetamol	B_Chemical
overdose	B_Disease
.	O

BACKGROUND/AIMS	O
:	O
Experimental	O
studies	O
have	O
suggested	O
that	O
apoptosis	O
via	O
the	O
Fas/Fas	O
Ligand	O
signaling	O
system	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
acute	B_Disease
liver	I_Disease
failure	I_Disease
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
soluble	O
form	O
of	O
Fas	O
in	O
patients	O
with	O
acute	B_Disease
liver	I_Disease
failure	I_Disease
.	O

METHODOLOGY	O
:	O
Serum	O
levels	O
of	O
sFas	O
(	O
soluble	O
Fas	O
)	O
were	O
measured	O
by	O
ELISA	O
in	O
24	O
patients	O
with	O
acute	B_Disease
liver	I_Disease
failure	I_Disease
and	O
10	O
normal	O
control	O
subjects	O
.	O

Serum	O
levels	O
of	O
tumor	B_Disease
necrosis	B_Disease
factor-alpha	O
and	O
interferon-gamma	O
were	O
also	O
determined	O
by	O
ELISA	O
.	O

RESULTS	O
:	O
Serum	O
sFas	O
was	O
significantly	O
increased	O
in	O
patients	O
with	O
acute	B_Disease
liver	I_Disease
failure	I_Disease
(	O
median	O
,	O
26.8	O
U/mL	O
;	O
range	O
,	O
6.9	O
-	O
52.7	O
U/mL	O
)	O
compared	O
to	O
the	O
normal	O
controls	O
(	O
median	O
,	O
8.6	O
U/mL	O
;	O
range	O
,	O
6.5	O
-	O
12.0	O
U/mL	O
,	O
P	O
<	O
0.0001	O
)	O
.	O

Levels	O
were	O
significantly	O
greater	O
in	O
patients	O
with	O
acute	B_Disease
liver	I_Disease
failure	I_Disease
due	O
to	O
paracetamol	B_Chemical
overdose	B_Disease
(	O
median	O
,	O
28.7	O
U/mL	O
;	O
range	O
,	O
12.8	O
-	O
52.7	O
U/mL	O
,	O
n	O
=	O
17	O
)	O
than	O
those	O
due	O
to	O
non-A	O
to	O
E	O
hepatitis	B_Disease
(	O
median	O
,	O
12.5	O
U/mL	O
;	O
range	O
,	O
6.9	O
-	O
46.0	O
U/mL	O
,	O
n	O
=	O
7	O
,	O
P	O
<	O
0.01	O
)	O
.	O

There	O
was	O
no	O
relationship	O
of	O
sFas	O
to	O
eventual	O
outcome	O
in	O
the	O
patients	O
.	O

A	O
significant	O
correlation	O
was	O
observed	O
between	O
serum	O
sFas	O
levels	O
and	O
aspartate	B_Chemical
aminotransferase	O
(	O
r	O
=	O
0.613	O
,	O
P	O
<	O
0.01	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
increased	O
concentration	O
of	O
sFas	O
in	O
serum	O
of	O
patients	O
with	O
acute	B_Disease
liver	I_Disease
failure	I_Disease
may	O
reflect	O
activation	O
of	O
Fas-mediated	O
apoptosis	O
in	O
the	O
liver	O
and	O
this	O
together	O
with	O
increased	O
tumor	B_Disease
necrosis	B_Disease
factor-alpha	O
may	O
be	O
an	O
important	O
factor	O
in	O
liver	O
cell	O
loss	O
.	O

Bilateral	O
subthalamic	O
nucleus	O
stimulation	O
for	O
Parkinson	O
's	O
disease	O
.	O

High	O
frequency	O
stimulation	O
of	O
the	O
subthalamic	O
nucleus	O
(	O
STN	O
)	O
is	O
known	O
to	O
ameliorate	O
the	O
signs	O
and	O
symptoms	O
of	O
advanced	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
.	O

AIM	O
:	O
We	O
studied	O
the	O
effect	O
of	O
high	O
frequency	O
STN	O
stimulation	O
in	O
23	O
patients	O
.	O

METHOD	O
:	O
Twenty-three	O
patients	O
suffering	O
from	O
severe	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
(	O
Stages	O
III-V	O
on	O
Hoehn	O
and	O
Yahr	O
scale	O
)	O
and	O
,	O
particularly	O
bradykinesia	B_Disease
,	O
rigidity	B_Disease
,	O
and	O
levodopa-induced	O
dyskinesias	B_Disease
underwent	O
bilateral	O
implantation	O
of	O
electrodes	O
in	O
the	O
STN	O
.	O

Preoperative	O
and	O
postoperative	O
assessments	O
of	O
these	O
patients	O
at	O
1	O
,	O
3	O
,	O
6	O
and	O
12	O
months	O
follow-up	O
,	O
in	O
"	O
on	O
"	O
and	O
"	O
off	O
"	O
drug	O
conditions	O
,	O
was	O
carried	O
out	O
using	O
Unified	O
Parkinson	B_Disease
's	I_Disease
Disease	I_Disease
Rating	O
Scale	O
,	O
Hoehn	O
and	O
Yahr	O
staging	O
,	O
England	O
activities	O
of	O
daily	O
living	O
score	O
and	O
video	O
recordings	O
.	O

RESULTS	O
:	O
After	O
one	O
year	O
of	O
electrical	O
stimulation	O
of	O
the	O
STN	O
,	O
the	O
patients	O
'	O
scores	O
for	O
activities	O
of	O
daily	O
living	O
and	O
motor	O
examination	O
scores	O
(	O
Unified	O
Parkinson	B_Disease
's	I_Disease
Disease	I_Disease
Rating	O
Scale	O
parts	O
II	O
and	O
III	O
)	O
off	O
medication	O
improved	O
by	O
62	O
%	O
and	O
61	O
%	O
respectively	O
(	O
p<0.0005	O
)	O
.	O

The	O
subscores	O
for	O
the	O
akinesia	B_Disease
,	O
rigidity	B_Disease
,	O
tremor	B_Disease
and	O
gait	O
also	O
improved	O
.	O

(	O
p<0.0005	O
)	O
.	O

The	O
average	O
levodopa	B_Chemical
dose	O
decreased	O
from	O
813	O
mg	O
to	O
359	O
mg	O
.	O

The	O
cognitive	O
functions	O
remained	O
unchanged	O
.	O

Two	O
patients	O
developed	O
device-related	O
complications	O
and	O
two	O
patients	O
experienced	O
abnormal	O
weight	O
gain	O
.	O

CONCLUSION	O
:	O
Bilateral	O
subthalamic	O
nucleus	O
stimulation	O
is	O
an	O
effective	O
treatment	O
for	O
advanced	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
.	O

It	O
reduces	O
the	O
severity	O
of	O
"	O
off	O
"	O
phase	O
symptoms	O
,	O
improves	O
the	O
axial	O
symptoms	O
and	O
reduces	O
levodopa	B_Chemical
requirements	O
.	O

The	O
reduction	O
in	O
the	O
levodopa	B_Chemical
dose	O
is	O
useful	O
in	O
controlling	O
drug-induced	B_Disease
dyskinesias	I_Disease
.	O

Acute	B_Disease
renal	I_Disease
failure	I_Disease
occurring	O
during	O
intravenous	O
desferrioxamine	B_Chemical
therapy	O
:	O
recovery	O
after	O
haemodialysis	O
.	O

A	O
patient	O
with	O
transfusion-dependent	O
thalassemia	B_Disease
was	O
undergoing	O
home	O
intravenous	O
desferrioxamine	B_Chemical
(	O
DFX	B_Chemical
)	O
treatment	O
by	O
means	O
of	O
a	O
totally	O
implanted	O
system	O
because	O
of	O
his	O
poor	O
compliance	O
with	O
the	O
nightly	O
subcutaneous	O
therapy	O
.	O

Due	O
to	O
an	O
accidental	O
malfunctioning	O
of	O
the	O
infusion	O
pump	O
,	O
the	O
patient	O
was	O
inadvertently	O
administered	O
a	O
toxic	O
dosage	O
of	O
the	O
drug	O
which	O
caused	O
renal	B_Disease
insufficiency	I_Disease
.	O

Given	O
the	O
progressive	O
deterioration	O
of	O
the	O
symptoms	O
and	O
of	O
the	O
laboratory	O
values	O
,	O
despite	O
adequate	O
medical	O
treatment	O
,	O
a	O
decision	O
was	O
made	O
to	O
introduce	O
haemodialytical	O
therapy	O
in	O
order	O
to	O
remove	O
the	O
drug	O
and	O
therapy	O
reduce	O
the	O
nephrotoxicity	B_Disease
.	O

From	O
the	O
results	O
obtained	O
,	O
haemodialysis	O
can	O
therefore	O
be	O
suggested	O
as	O
a	O
useful	O
therapy	O
in	O
rare	O
cases	O
of	O
progressive	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
caused	O
by	O
desferrioxamine	B_Chemical
.	O

Ocular	O
motility	O
changes	O
after	O
subtenon	O
carboplatin	B_Chemical
chemotherapy	O
for	O
retinoblastoma	B_Disease
.	O

BACKGROUND	O
:	O
Focal	O
subtenon	O
carboplatin	B_Chemical
injections	O
have	O
recently	O
been	O
used	O
as	O
a	O
presumably	O
toxicity-free	O
adjunct	O
to	O
systemic	O
chemotherapy	O
for	O
intraocular	O
retinoblastoma	B_Disease
.	O

OBJECTIVE	O
:	O
To	O
report	O
our	O
clinical	O
experience	O
with	O
abnormal	B_Disease
ocular	I_Disease
motility	I_Disease
in	O
patients	O
treated	O
with	O
subtenon	O
carboplatin	B_Chemical
chemotherapy	O
.	O

METHODS	O
:	O
We	O
noted	O
abnormal	B_Disease
ocular	I_Disease
motility	I_Disease
in	O
10	O
consecutive	O
patients	O
with	O
retinoblastoma	B_Disease
who	O
had	O
received	O
subtenon	O
carboplatin	B_Chemical
.	O

During	O
ocular	O
manipulation	O
under	O
general	O
anesthesia	O
,	O
we	O
assessed	O
their	O
eyes	O
by	O
forced	O
duction	O
testing	O
,	O
comparing	O
ocular	O
motility	O
after	O
tumor	B_Disease
control	O
with	O
ocular	O
motility	O
at	O
diagnosis	O
.	O

Eyes	O
subsequently	O
enucleated	O
because	O
of	O
treatment	O
failure	O
(	O
n	O
=	O
4	O
)	O
were	O
examined	O
histologically	O
.	O

RESULTS	O
:	O
Limitation	O
of	O
ocular	O
motility	O
was	O
detected	O
in	O
all	O
12	O
eyes	O
of	O
10	O
patients	O
treated	O
for	O
intraocular	O
retinoblastoma	B_Disease
with	O
1	O
to	O
6	O
injections	O
of	O
subtenon	O
carboplatin	B_Chemical
as	O
part	O
of	O
multimodality	O
therapy	O
.	O

Histopathological	O
examination	O
revealed	O
many	O
lipophages	O
in	O
the	O
periorbital	O
fat	O
surrounding	O
the	O
optic	O
nerve	O
in	O
1	O
eye	O
,	O
indicative	O
of	O
phagocytosis	O
of	O
previously	O
existing	O
fat	O
cells	O
and	O
suggesting	O
prior	O
fat	O
necrosis	B_Disease
.	O

The	O
enucleations	O
were	O
technically	O
difficult	O
and	O
hazardous	O
for	O
globe	O
rupture	B_Disease
because	O
of	O
extensive	O
orbital	O
soft	O
tissue	O
adhesions	O
.	O

CONCLUSIONS	O
:	O
Subtenon	O
carboplatin	B_Chemical
chemotherapy	O
is	O
associated	O
with	O
significant	O
fibrosis	B_Disease
of	O
orbital	O
soft	O
tissues	O
,	O
leading	O
to	O
mechanical	O
restriction	O
of	O
eye	O
movements	O
and	O
making	O
subsequent	O
enucleation	O
difficult	O
.	O

Subtenon	O
carboplatin	B_Chemical
is	O
not	O
free	O
of	O
toxicity	B_Disease
,	O
and	O
its	O
use	O
is	O
best	O
restricted	O
to	O
specific	O
indications	O
.	O

Ethambutol	B_Chemical
and	O
optic	B_Disease
neuropathy	I_Disease
.	O

PURPOSE	O
:	O
To	O
demonstrate	O
the	O
association	O
between	O
ethambutol	B_Chemical
and	O
optic	B_Disease
neuropathy	I_Disease
.	O

METHOD	O
:	O
Thirteen	O
patients	O
who	O
developed	O
optic	B_Disease
neuropathy	I_Disease
after	O
being	O
treated	O
with	O
ethambutol	B_Chemical
for	O
tuberculosis	B_Disease
of	I_Disease
the	I_Disease
lung	I_Disease
or	I_Disease
lymph	I_Disease
node	I_Disease
at	O
Siriraj	O
Hospital	O
between	O
1997	O
and	O
2001	O
were	O
retrospectively	O
reviewed	O
.	O

The	O
clinical	O
characteristics	O
and	O
initial	O
and	O
final	O
visual	O
acuity	O
were	O
analyzed	O
to	O
determine	O
visual	O
outcome	O
.	O

RESULTS	O
:	O
All	O
patients	O
had	O
optic	B_Disease
neuropathy	I_Disease
between	O
1	O
to	O
6	O
months	O
(	O
mean	O
=	O
2.9	O
months	O
)	O
after	O
starting	O
ethambutol	B_Chemical
therapy	O
at	O
a	O
dosage	O
ranging	O
from	O
13	O
to	O
20	O
mg/kg/day	O
(	O
mean	O
=	O
17	O
mg/kg/day	O
)	O
.	O

Seven	O
(	O
54	O
%	O
)	O
of	O
the	O
13	O
patients	O
experienced	O
visual	O
recovery	O
after	O
stopping	O
the	O
drug	O
.	O

Of	O
6	O
patients	O
with	O
irreversible	O
visual	B_Disease
impairment	I_Disease
,	O
4	O
patients	O
had	O
diabetes	B_Disease
mellitus	I_Disease
,	O
glaucoma	B_Disease
and	O
a	O
history	O
of	O
heavy	O
smoking	O
.	O

CONCLUSION	O
:	O
Early	O
recognition	O
of	O
optic	B_Disease
neuropathy	I_Disease
should	O
be	O
considered	O
in	O
patients	O
with	O
ethambutol	B_Chemical
therapy	O
.	O

A	O
low	O
dose	O
and	O
prompt	O
discontinuation	O
of	O
the	O
drug	O
is	O
recommended	O
particularly	O
in	O
individuals	O
with	O
diabetes	B_Disease
mellitus	I_Disease
,	O
glaucoma	B_Disease
or	O
who	O
are	O
heavy	O
smokers	O
.	O

Treatment	O
of	O
compensatory	O
gustatory	B_Disease
hyperhidrosis	I_Disease
with	O
topical	O
glycopyrrolate	B_Chemical
.	O

Gustatory	B_Disease
hyperhidrosis	I_Disease
is	O
facial	O
sweating	B_Disease
usually	O
associated	O
with	O
the	O
eating	O
of	O
hot	O
spicy	O
food	O
or	O
even	O
smelling	O
this	O
food	O
.	O

Current	O
options	O
of	O
treatment	O
include	O
oral	O
anticholinergic	O
drugs	O
,	O
the	O
topical	O
application	O
of	O
anticholinergics	O
or	O
aluminum	B_Chemical
chloride	I_Chemical
,	O
and	O
the	O
injection	O
of	O
botulinum	O
toxin	O
.	O

Thirteen	O
patients	O
have	O
been	O
treated	O
to	O
date	O
with	O
1.5	O
%	O
or	O
2	O
%	O
topical	O
glycopyrrolate	B_Chemical
.	O

All	O
patients	O
had	O
gustatory	B_Disease
hyperhidrosis	I_Disease
,	O
which	O
interfered	O
with	O
their	O
social	O
activities	O
,	O
after	O
transthroacic	O
endoscopic	O
sympathectomy	O
,	O
and	O
which	O
was	O
associated	O
with	O
compensatory	O
focal	O
hyperhidrosis	B_Disease
.	O

After	O
applying	O
topical	O
glycopyrrolate	B_Chemical
,	O
the	O
subjective	O
effect	O
was	O
excellent	O
(	O
no	O
sweating	B_Disease
after	O
eating	O
hot	O
spicy	O
food	O
)	O
in	O
10	O
patients	O
(	O
77	O
%	O
)	O
,	O
and	O
fair	O
(	O
clearly	O
reduced	O
sweating	B_Disease
)	O
in	O
3	O
patients	O
(	O
23	O
%	O
)	O
.	O

All	O
had	O
reported	O
incidents	O
of	O
being	O
very	O
embarrassed	O
whilst	O
eating	O
hot	O
spicy	O
foods	O
.	O

Adverse	O
effects	O
included	O
a	O
mildly	O
dry	B_Disease
mouth	I_Disease
and	O
a	O
sore	B_Disease
throat	I_Disease
in	O
2	O
patients	O
(	O
2	O
%	O
glycopyrrolate	B_Chemical
)	O
,	O
a	O
light	O
headache	B_Disease
in	O
1	O
patient	O
(	O
1.5	O
%	O
glycopyrrolate	B_Chemical
)	O
.	O

The	O
topical	O
application	O
of	O
a	O
glycopyrrolate	B_Chemical
pad	O
appeared	O
to	O
be	O
safe	O
,	O
efficacious	O
,	O
well	O
tolerated	O
,	O
and	O
a	O
convenient	O
method	O
of	O
treatment	O
for	O
moderate	O
to	O
severe	O
symptoms	O
of	O
gustatory	B_Disease
hyperhidrosis	I_Disease
in	O
post	O
transthoracic	O
endoscopic	O
sympathectomy	O
or	O
sympathicotomy	O
patients	O
,	O
with	O
few	O
side	O
effects	O
.	O

Neuroleptic-associated	O
hyperprolactinemia	B_Disease
.	O
Can	O
it	O
be	O
treated	O
with	O
bromocriptine?Six	O
stable	O
psychiatric	O
outpatients	O
with	O
hyperprolactinemia	B_Disease
and	O
amenorrhea/oligomenorrhea	O
associated	O
with	O
their	O
neuroleptic	B_Chemical
medications	I_Chemical
were	O
treated	O
with	O
bromocriptine	B_Chemical
.	O

Daily	O
dosages	O
of	O
5	O
-	O
10	O
mg	O
corrected	O
the	O
hyperprolactinemia	B_Disease
and	O
restored	O
menstruation	O
in	O
four	O
of	O
the	O
six	O
patients	O
.	O

One	O
woman	O
,	O
however	O
,	O
developed	O
worsened	O
psychiatric	B_Disease
symptoms	I_Disease
while	O
taking	O
bromocriptine	B_Chemical
,	O
and	O
it	O
was	O
discontinued	O
.	O

Thus	O
,	O
three	O
of	O
six	O
patients	O
had	O
their	O
menstrual	O
irregularity	O
successfully	O
corrected	O
with	O
bromocriptine	B_Chemical
.	O

This	O
suggests	O
that	O
bromocriptine	B_Chemical
should	O
be	O
further	O
evaluated	O
as	O
potential	O
therapy	O
for	O
neuroleptic-associated	O
hyperprolactinemia	B_Disease
and	O
amenorrhea/galactorrhea	O
.	O

Ethacrynic	O
acid-induced	O
convulsions	B_Disease
and	O
brain	O
neurotransmitters	O
in	O
mice	O
.	O

Intracerebroventricular	O
injection	O
of	O
ethacrynic	B_Chemical
acid	I_Chemical
(	O
50	O
%	O
convulsive	B_Disease
dose	O
;	O
50	O
micrograms/mouse	O
)	O
accelerated	O
the	O
synthesis/turnover	O
of	O
5-hydroxytryptamine	B_Chemical
(	O
5-HT	B_Chemical
)	O
but	O
suppressed	O
the	O
synthesis	O
of	O
gamma-aminobutyric	B_Chemical
acid	I_Chemical
and	O
acetylcholine	B_Chemical
in	O
mouse	O
brain	O
.	O

These	O
effects	O
were	O
completely	O
antagonized	O
by	O
pretreatment	O
with	O
a	O
glutamate/N-methyl-D-aspartate	O
antagonist	O
,	O
aminophosphonovaleric	B_Chemical
acid	I_Chemical
.	O

In	O
ethacrynic	O
acid-induced	O
convulsions	B_Disease
,	O
these	O
neurotransmitter	O
systems	O
may	O
be	O
differentially	O
modulated	O
,	O
probably	O
through	O
activation	O
of	O
glutaminergic	O
neurons	O
in	O
the	O
brain	O
.	O

Pharmacology	O
of	O
gamma-aminobutyric	O
acidA	O
receptor	O
complex	O
after	O
the	O
in	O
vivo	O
administration	O
of	O
the	O
anxioselective	O
and	O
anticonvulsant	O
beta-carboline	B_Chemical
derivative	O
abecarnil	B_Chemical
.	O

In	O
rodents	O
,	O
the	O
effect	O
of	O
the	O
beta-carboline	B_Chemical
derivative	O
isopropyl-6-	B_Chemical
benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylate	I_Chemical
(	O
abecarrnil	B_Chemical
)	O
,	O
a	O
new	O
ligand	O
for	O
benzodiazepine	B_Chemical
receptors	O
possessing	O
anxiolytic	O
and	O
anticonvulsant	O
properties	O
,	O
was	O
evaluated	O
on	O
the	O
function	O
of	O
central	O
gamma-aminobutyric	B_Chemical
acid	I_Chemical
(GABA)A	O
receptor	O
complex	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Added	O
in	O
vitro	O
to	O
rat	O
cortical	O
membrane	O
preparation	O
,	O
abecarnil	B_Chemical
increased	O
[3H]GABA	O
binding	O
,	O
enhanced	O
muscimol-stimulated	O
36Cl-	O
uptake	O
and	O
reduced	O
the	O
binding	O
of	O
t-[35S]butylbicyclophosphorothionate	B_Chemical
(	O
[35S]TBPS	B_Chemical
)	O
.	O

These	O
effects	O
were	O
similar	O
to	O
those	O
induced	O
by	O
diazepam	B_Chemical
,	O
whereas	O
the	O
partial	O
agonist	O
Ro	B_Chemical
16	I_Chemical
-	I_Chemical
6028	I_Chemical
(	O
tert-butyl-(S)-8-bromo-11,12,13,13a-tetrahydro-9-oxo-9H-	B_Chemical
imidazo[1,5-a]-pyrrolo-[2,1-c][1,4]benzodiazepine-1-carboxylate	I_Chemical
)	O
showed	O
very	O
weak	O
efficacy	O
in	O
these	O
biochemical	O
tests	O
.	O

After	O
i.p	O
.	O

injection	O
to	O
rats	O
,	O
abecarnil	B_Chemical
and	O
diazepam	B_Chemical
decreased	O
in	O
a	O
time-dependent	O
and	O
dose-related	O
(	O
0.25	O
-	O
20	O
mg/kg	O
i.p	O
.	O
)	O
manner	O
[35S]TBPS	B_Chemical
binding	O
measured	O
ex	O
vivo	O
in	O
the	O
cerebral	O
cortex	O
.	O

Moreover	O
,	O
both	O
drugs	O
at	O
the	O
dose	O
of	O
0.5	O
mg/kg	O
antagonized	O
completely	O
the	O
convulsant	O
activity	O
and	O
the	O
increase	O
of	O
[35S]TBPS	B_Chemical
binding	O
induced	O
by	O
isoniazide	B_Chemical
(	O
350	O
mg/kg	O
s.c	O
.	O
)	O
as	O
well	O
as	O
the	O
increase	O
of	O
[35S]TBPS	B_Chemical
binding	O
induced	O
by	O
foot-shock	O
stress	O
.	O

To	O
better	O
correlate	O
the	O
biochemical	O
and	O
the	O
pharmacological	O
effects	O
,	O
we	O
studied	O
the	O
action	O
of	O
abecarnil	B_Chemical
on	O
[35S]TBPS	B_Chemical
binding	O
,	O
exploratory	O
motility	O
and	O
on	O
isoniazid-induced	O
biochemical	O
and	O
pharmacological	O
effects	O
in	O
mice	O
.	O

In	O
these	O
animals	O
,	O
abecarnil	B_Chemical
produced	O
a	O
paralleled	O
dose-dependent	O
(	O
0.05	O
-	O
1	O
mg/kg	O
i.p	O
.	O
)	O
reduction	O
of	O
both	O
motor	O
behavior	O
and	O
cortical	O
[35S]TBPS	O
binding	O
.	O

Moreover	O
,	O
0.05	O
mg/kg	O
of	O
this	O
beta-carboline	B_Chemical
reduced	O
markedly	O
the	O
increase	O
of	O
[35S]TBPS	B_Chemical
binding	O
and	O
the	O
convulsions	B_Disease
induced	O
by	O
isoniazid	B_Chemical
(	O
200	O
mg/kg	O
s.c.).(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Recurrent	O
myocardial	B_Disease
infarction	I_Disease
in	O
a	O
postpartum	O
patient	O
receiving	O
bromocriptine	B_Chemical
.	O

Myocardial	B_Disease
infarction	I_Disease
in	O
puerperium	O
is	O
infrequently	O
reported	O
.	O

Spasm	B_Disease
,	O
coronary	O
dissection	O
,	O
or	O
atheromatous	O
etiology	O
has	O
been	O
described	O
.	O

Bromocriptine	B_Chemical
has	O
been	O
implicated	O
in	O
several	O
previous	O
case	O
reports	O
of	O
myocardial	B_Disease
infarction	I_Disease
in	O
the	O
puerperium	O
.	O

Our	O
case	O
(	O
including	O
an	O
inadvertent	O
rechallenge	O
)	O
suggests	O
such	O
a	O
relationship	O
.	O

Although	O
generally	O
regarded	O
as	O
"	O
safe	O
,	O
"	O
possible	O
serious	O
cardiac	O
effects	O
of	O
bromocriptine	B_Chemical
should	O
be	O
acknowledged	O
.	O

Asterixis	B_Disease
induced	O
by	O
carbamazepine	B_Chemical
therapy	O
.	O

There	O
are	O
very	O
few	O
reports	O
about	O
asterixis	B_Disease
as	O
a	O
side	O
effect	O
of	O
treatment	O
with	O
psychopharmacologic	O
agents	O
.	O

In	O
this	O
report	O
we	O
present	O
four	O
patients	O
treated	O
with	O
a	O
combination	O
of	O
different	O
psychotropic	O
drugs	O
,	O
in	O
whom	O
asterixis	B_Disease
was	O
triggered	O
either	O
by	O
adding	O
carbamazepine	B_Chemical
(	O
CBZ	B_Chemical
)	O
to	O
a	O
treatment	O
regimen	O
,	O
or	O
by	O
increasing	O
its	O
dosage	O
.	O

Neither	O
dosage	O
nor	O
serum	O
levels	O
of	O
CBZ	B_Chemical
were	O
in	O
a	O
higher	O
range	O
.	O

We	O
consider	O
asterixis	B_Disease
to	O
be	O
an	O
easily	O
overlooked	O
sign	O
of	O
neurotoxicity	B_Disease
,	O
which	O
may	O
occur	O
even	O
at	O
low	O
or	O
moderate	O
dosage	O
levels	O
,	O
if	O
certain	O
drugs	O
as	O
lithium	B_Chemical
or	O
clozapine	B_Chemical
are	O
used	O
in	O
combination	O
with	O
CBZ	B_Chemical
.	O

Pharmacodynamics	O
of	O
the	O
hypotensive	B_Disease
effect	O
of	O
levodopa	B_Chemical
in	O
parkinsonian	B_Disease
patients	O
.	O

Blood	O
pressure	O
effects	O
of	O
i.v	O
.	O

levodopa	B_Chemical
were	O
examined	O
in	O
parkinsonian	B_Disease
patients	O
with	O
stable	O
and	O
fluctuating	O
responses	O
to	O
levodopa	B_Chemical
.	O

The	O
magnitude	O
of	O
the	O
hypotensive	B_Disease
effect	O
of	O
levodopa	B_Chemical
was	O
concentration	O
dependent	O
and	O
was	O
fit	O
to	O
an	O
Emax	O
model	O
in	O
fluctuating	O
responders	O
.	O

Stable	O
responders	O
demonstrated	O
a	O
small	O
hypotensive	B_Disease
response	O
.	O

Baseline	O
blood	O
pressures	O
were	O
higher	O
in	O
fluctuating	O
patients	O
;	O
a	O
higher	O
baseline	O
blood	O
pressure	O
correlated	O
with	O
greater	O
hypotensive	B_Disease
effects	O
.	O

Antiparkinsonian	O
effects	O
of	O
levodopa	B_Chemical
temporally	O
correlated	O
with	O
blood	O
pressure	O
changes	O
.	O

Phenylalanine	B_Chemical
,	O
a	O
large	O
neutral	O
amino	B_Chemical
acid	I_Chemical
(	O
LNAA	O
)	O
competing	O
with	O
levodopa	B_Chemical
for	O
transport	O
across	O
the	O
blood-brain	O
barrier	O
,	O
reduced	O
the	O
hypotensive	B_Disease
and	O
antiparkinsonian	O
effects	O
of	O
levodopa	B_Chemical
.	O

We	O
conclude	O
that	O
levodopa	B_Chemical
has	O
a	O
central	O
hypotensive	B_Disease
action	O
that	O
parallels	O
the	O
motor	O
effects	O
in	O
fluctuating	O
patients	O
.	O

The	O
hypotensive	B_Disease
effect	O
appears	O
to	O
be	O
related	O
to	O
the	O
higher	O
baseline	O
blood	O
pressure	O
we	O
observed	O
in	O
fluctuating	O
patients	O
relative	O
to	O
stable	O
patients	O
.	O

Syndrome	B_Disease
of	I_Disease
inappropriate	I_Disease
secretion	I_Disease
of	I_Disease
antidiuretic	I_Disease
hormone	I_Disease
after	O
infusional	O
vincristine	B_Chemical
.	O

A	O
77-year-old	O
woman	O
with	O
refractory	O
multiple	B_Disease
myeloma	I_Disease
was	O
treated	O
with	O
a	O
4-day	O
continuous	O
intravenous	O
infusion	O
of	O
vincristine	B_Chemical
and	O
doxorubicin	B_Chemical
and	O
4	O
days	O
of	O
oral	O
dexamethasone	B_Chemical
.	O

Nine	O
days	O
after	O
her	O
second	O
cycle	O
she	O
presented	O
with	O
lethargy	B_Disease
and	O
weakness	B_Disease
associated	O
with	O
hyponatremia	B_Disease
.	O

Evaluation	O
revealed	O
the	O
syndrome	B_Disease
of	I_Disease
inappropriate	I_Disease
secretion	I_Disease
of	I_Disease
antidiuretic	I_Disease
hormone	I_Disease
,	O
which	O
was	O
attributed	O
to	O
the	O
vincristine	B_Chemical
infusion	O
.	O

After	O
normal	O
serum	O
sodium	B_Chemical
levels	O
returned	O
,	O
further	O
doxorubicin	B_Chemical
and	O
dexamethasone	B_Chemical
chemotherapy	O
without	O
vincristine	B_Chemical
did	O
not	O
produce	O
this	O
complication	O
.	O

Heart	O
failure	O
:	O
to	O
digitalise	O
or	O
not	O
?	O
The	O
view	O
against	O
.	O

Despite	O
extensive	O
clinical	O
experience	O
the	O
role	O
of	O
digoxin	B_Chemical
is	O
still	O
not	O
well	O
defined	O
.	O

In	O
patients	O
with	O
atrial	B_Disease
fibrillation	I_Disease
digoxin	B_Chemical
is	O
beneficial	O
for	O
ventricular	O
rate	O
control	O
.	O

For	O
patients	O
in	O
sinus	O
rhythm	O
and	O
heart	B_Disease
failure	I_Disease
the	O
situation	O
is	O
less	O
clear	O
.	O

Digoxin	B_Chemical
has	O
a	O
narrow	O
therapeutic	O
:	O
toxic	O
ratio	O
and	O
concentrations	O
are	O
affected	O
by	O
a	O
number	O
of	O
drugs	O
.	O

Also	O
,	O
digoxin	B_Chemical
has	O
undesirable	O
effects	O
such	O
as	O
increasing	O
peripheral	O
resistance	O
and	O
myocardial	O
demands	O
,	O
and	O
causing	O
arrhythmias	B_Disease
.	O

There	O
is	O
a	O
paucity	O
of	O
data	O
from	O
well-designed	O
trials	O
.	O

The	O
trials	O
that	O
are	O
available	O
are	O
generally	O
small	O
with	O
limitations	O
in	O
design	O
and	O
these	O
show	O
variation	O
in	O
patient	O
benefit	O
.	O

More	O
convincing	O
evidence	O
is	O
required	O
showing	O
that	O
digoxin	B_Chemical
improves	O
symptoms	O
or	O
exercise	O
capacity	O
.	O

Furthermore	O
,	O
no	O
trial	O
has	O
had	O
sufficient	O
power	O
to	O
evaluate	O
mortality	O
.	O

Pooled	O
analysis	O
of	O
the	O
effects	O
of	O
other	O
inotropic	O
drugs	O
shows	O
an	O
excess	O
mortality	O
and	O
there	O
is	O
a	O
possibility	O
that	O
digoxin	B_Chemical
may	O
increase	O
mortality	O
after	O
myocardial	B_Disease
infarction	I_Disease
(	O
MI	B_Disease
)	O
.	O

Angiotensin-converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitors	O
should	O
be	O
used	O
first	O
as	O
they	O
are	O
safer	O
,	O
do	O
not	O
require	O
blood	O
level	O
monitoring	O
,	O
modify	O
progression	O
of	O
disease	O
,	O
relieve	O
symptoms	O
,	O
improve	O
exercise	O
tolerance	O
and	O
reduce	O
mortality	O
.	O

Caution	O
should	O
be	O
exercised	O
in	O
using	O
digoxin	B_Chemical
until	O
large	O
mortality	O
trials	O
are	O
completed	O
showing	O
either	O
benefit	O
or	O
harm	O
.	O

Until	O
then	O
digoxin	B_Chemical
should	O
be	O
considered	O
a	O
third-line	O
therapy	O
.	O

Isradipine	B_Chemical
treatment	O
for	O
hypertension	B_Disease
in	O
general	O
practice	O
in	O
Hong	O
Kong	O
.	O

A	O
6-week	O
open	O
study	O
of	O
the	O
introduction	O
of	O
isradipine	B_Chemical
treatment	O
was	O
conducted	O
in	O
general	O
practice	O
in	O
Hong	O
Kong	O
.	O

303	O
Chinese	O
patients	O
with	O
mild	O
to	O
moderate	O
hypertension	B_Disease
entered	O
the	O
study	O
.	O

Side	O
effects	O
were	O
reported	O
in	O
21	O
%	O
of	O
patients	O
and	O
caused	O
withdrawal	O
from	O
the	O
study	O
in	O
3	O
patients	O
.	O

The	O
main	O
side-effects	O
were	O
headache	B_Disease
,	O
dizziness	B_Disease
,	O
palpitation	B_Disease
and	O
flushing	B_Disease
and	O
these	O
were	O
not	O
more	O
frequent	O
than	O
reported	O
in	O
other	O
studies	O
with	O
isradipine	B_Chemical
or	O
with	O
placebo	O
.	O

Supine	O
blood	O
pressure	O
was	O
reduced	O
(	O
P	O
less	O
than	O
0.01	O
)	O
from	O
170	O
+	O
/-	O
20/102	O
+	O
/-	O
6	O
mmHg	O
to	O
153	O
+	O
/-	O
19/92	O
+	O
/-	O
8	O
,	O
147	O
+	O
/-	O
18/88	O
+	O
/-	O
7	O
and	O
144	O
+	O
/-	O
14/87	O
+	O
/-	O
6	O
mmHg	O
at	O
2	O
,	O
4	O
and	O
6	O
weeks	O
respectively	O
in	O
evaluable	O
patients	O
.	O

Similar	O
reductions	O
occurred	O
in	O
standing	O
blood	O
pressure	O
and	O
there	O
was	O
no	O
evidence	O
of	O
postural	B_Disease
hypotension	I_Disease
.	O

Normalization	O
and	O
responder	O
rates	O
at	O
6	O
weeks	O
were	O
86	O
%	O
and	O
69	O
%	O
respectively	O
.	O

Dosage	O
was	O
increased	O
from	O
2.5	O
mg	O
b.d	O
.	O
to	O
5	O
mg	O
b.d	O
.	O

at	O
4	O
weeks	O
in	O
patients	O
with	O
diastolic	O
blood	O
pressure	O
greater	O
than	O
90	O
mmHg	O
and	O
their	O
further	O
response	O
was	O
greater	O
than	O
those	O
remaining	O
on	O
2.5	O
mg	O
b.d	O
.	O

Pharmacological	O
characteristics	O
and	O
side	O
effects	O
of	O
a	O
new	O
galenic	O
formulation	O
of	O
propofol	O
without	O
soyabean	O
oil	O
.	O

We	O
compared	O
the	O
pharmacokinetics	O
,	O
pharmacodynamics	O
and	O
safety	O
profile	O
of	O
a	O
new	O
galenic	O
formulation	O
of	O
propofol	B_Chemical
(	O
AM149	O
1	O
%	O
)	O
,	O
which	O
does	O
not	O
contain	O
soyabean	O
oil	O
,	O
with	O
a	O
standard	O
formulation	O
of	O
propofol	B_Chemical
(	O
Disoprivan	B_Chemical
1	O
%	O
)	O
.	O

In	O
a	O
randomised	O
,	O
double-blind	O
,	O
cross-over	O
study	O
,	O
30	O
healthy	O
volunteers	O
received	O
a	O
single	O
intravenous	O
bolus	O
injection	O
of	O
2.5	O
mg.kg-1	O
propofol	B_Chemical
.	O

Plasma	O
propofol	B_Chemical
levels	O
were	O
measured	O
for	O
48	O
h	O
following	O
drug	O
administration	O
and	O
evaluated	O
according	O
to	O
a	O
three-compartment	O
model	O
.	O

The	O
pharmacodynamic	O
parameters	O
assessed	O
included	O
induction	O
and	O
emergence	O
times	O
,	O
respiratory	O
and	O
cardiovascular	O
effects	O
,	O
and	O
pain	B_Disease
on	O
injection	O
.	O

Patients	O
were	O
monitored	O
for	O
side	O
effects	O
over	O
48	O
h.	O
Owing	O
to	O
a	O
high	O
incidence	O
of	O
thrombophlebitis	B_Disease
,	O
the	O
study	O
was	O
terminated	O
prematurely	O
and	O
only	O
the	O
data	O
of	O
the	O
two	O
parallel	O
treatment	O
groups	O
(	O
15	O
patients	O
in	O
each	O
group	O
)	O
were	O
analysed	O
.	O

Plasma	O
concentrations	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
formulations	O
.	O

Anaesthesia	O
induction	O
and	O
emergence	O
times	O
,	O
respiratory	O
and	O
cardiovascular	O
variables	O
showed	O
no	O
significant	O
differences	O
between	O
the	O
two	O
treatment	O
groups	O
.	O

Pain	B_Disease
on	O
injection	O
(	O
80	O
vs.	O
20	O
%	O
,	O
p	O
<	O
0.01	O
)	O
and	O
thrombophlebitis	B_Disease
(	O
93.3	O
vs.	O
6.6	O
%	O
,	O
p	O
<	O
0.001	O
)	O
occurred	O
more	O
frequently	O
with	O
AM149	O
than	O
with	O
Disoprivan	B_Chemical
.	O
Although	O
both	O
formulations	O
had	O
similar	O
pharmacokinetic	O
and	O
pharmacodynamic	O
profiles	O
the	O
new	O
formulation	O
is	O
not	O
suitable	O
for	O
clinical	O
use	O
due	O
to	O
the	O
high	O
incidence	O
of	O
thrombophlebitis	B_Disease
produced	O
.	O

Pure	B_Disease
red	I_Disease
cell	I_Disease
aplasia	I_Disease
,	O
toxic	B_Disease
dermatitis	I_Disease
and	O
lymphadenopathy	B_Disease
in	O
a	O
patient	O
taking	O
diphenylhydantoin	B_Chemical
.	O

A	O
patient	O
taking	O
diphenylhydantoin	B_Chemical
for	O
3	O
weeks	O
developed	O
a	O
generalized	O
skin	B_Disease
rash	I_Disease
,	O
lymphadenopathy	B_Disease
and	O
pure	B_Disease
red	I_Disease
cell	I_Disease
aplasia	I_Disease
.	O

After	O
withdrawal	O
of	O
the	O
pharmacon	O
all	O
symptoms	O
disappeared	O
spontaneously	O
.	O

Skin	B_Disease
rash	I_Disease
is	O
a	O
well-known	O
complication	O
of	O
diphenylhydantoin	B_Chemical
treatment	O
as	O
is	O
benign	O
and	O
malignant	O
lymphadenopathy	B_Disease
.	O

Pure	B_Disease
red	I_Disease
cell	I_Disease
aplasia	I_Disease
associated	O
with	O
diphenylhydantoin	B_Chemical
medication	O
has	O
been	O
reported	O
in	O
3	O
patients	O
.	O

The	O
exact	O
mechanism	O
by	O
which	O
diphenylhydantoin	B_Chemical
exerts	O
its	O
toxic	O
effects	O
is	O
not	O
known	O
.	O

In	O
this	O
patient	O
the	O
time	O
relation	O
between	O
the	O
ingestion	O
of	O
diphenylhydantoin	B_Chemical
and	O
the	O
occurrence	O
of	O
the	O
skin	B_Disease
rash	I_Disease
,	O
lymphadenopathy	B_Disease
and	O
pure	B_Disease
red	I_Disease
cell	I_Disease
aplasia	I_Disease
is	O
very	O
suggestive	O
of	O
a	O
direct	O
connection	O
.	O

Vinorelbine-related	O
cardiac	O
events	O
:	O
a	O
meta-analysis	O
of	O
randomized	O
clinical	O
trials	O
.	O

Several	O
cases	O
of	O
cardiac	O
adverse	O
reactions	O
related	O
to	O
vinorelbine	B_Chemical
(	O
VNR	B_Chemical
)	O
have	O
been	O
reported	O
in	O
the	O
literature	O
.	O

In	O
order	O
to	O
quantify	O
the	O
incidence	O
of	O
these	O
cardiac	O
events	O
,	O
we	O
performed	O
a	O
meta-analysis	O
of	O
clinical	O
trials	O
comparing	O
VNR	B_Chemical
with	O
other	O
chemotherapeutic	O
agents	O
in	O
the	O
treatment	O
of	O
various	O
malignancies	B_Disease
.	O

Randomized	O
clinical	O
trials	O
comparing	O
VNR	B_Chemical
with	O
other	O
drugs	O
in	O
the	O
treatment	O
of	O
cancer	B_Disease
were	O
searched	O
in	O
Medline	O
,	O
Embase	O
,	O
Evidence-based	O
Medicine	O
Reviews	O
databases	O
and	O
the	O
Cochrane	O
library	O
from	O
1987	O
to	O
2002	O
.	O

Outcomes	O
of	O
interest	O
were	O
severe	O
cardiac	O
events	O
,	O
toxic	O
deaths	O
and	O
cardiac	O
event-related	O
deaths	O
reported	O
in	O
each	O
publication	O
.	O

We	O
found	O
19	O
trials	O
,	O
involving	O
2441	O
patients	O
treated	O
by	O
VNR	B_Chemical
and	O
2050	O
control	O
patients	O
.	O

The	O
incidence	O
of	O
cardiac	O
events	O
with	O
VNR	B_Chemical
was	O
1.19	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
(	O
0.75	O
;	O
1.67	O
)	O
]	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
risk	O
of	O
cardiac	O
events	O
between	O
VNR	B_Chemical
and	O
other	O
drugs	O
[	O
odds	O
ratio	O
:	O
0.92	O
,	O
95	O
%	O
CI	O
(	O
0.54	O
;	O
1.55	O
)	O
]	O
.	O

The	O
risk	O
of	O
VNR	B_Chemical
cardiac	O
events	O
was	O
similar	O
to	O
vindesine	B_Chemical
(	O
VDS	B_Chemical
)	O
and	O
other	O
cardiotoxic	B_Disease
drugs	O
[	O
fluorouracil	B_Chemical
,	O
anthracyclines	B_Chemical
,	O
gemcitabine	B_Chemical
(	O
GEM	B_Chemical
)	O
em	O
leader	O
]	O
.	O

Even	O
if	O
it	O
did	O
not	O
reach	O
statistical	O
significance	O
because	O
of	O
a	O
few	O
number	O
of	O
cases	O
,	O
the	O
risk	O
was	O
lower	O
in	O
trials	O
excluding	O
patients	O
with	O
cardiac	O
history	O
,	O
and	O
seemed	O
to	O
be	O
higher	O
in	O
trials	O
including	O
patients	O
with	O
pre-existing	O
cardiac	B_Disease
diseases	I_Disease
.	O

Vinorelbine-related	O
cardiac	O
events	O
concern	O
about	O
1	O
%	O
of	O
treated	O
patients	O
in	O
clinical	O
trials	O
.	O

However	O
,	O
the	O
risk	O
associated	O
with	O
VNR	B_Chemical
seems	O
to	O
be	O
similar	O
to	O
that	O
of	O
other	O
chemotherapeutic	O
agents	O
in	O
the	O
same	O
indications	O
.	O

MRI	O
findings	O
of	O
hypoxic	O
cortical	O
laminar	O
necrosis	B_Disease
in	O
a	O
child	O
with	O
hemolytic	B_Disease
anemia	I_Disease
crisis	O
.	O

We	O
present	O
magnetic	O
resonance	O
imaging	O
findings	O
of	O
a	O
5-year-old	O
girl	O
who	O
had	O
a	O
rapidly	O
installing	O
hemolytic	B_Disease
anemia	I_Disease
crisis	O
induced	O
by	O
trimethoprim-sulfomethoxazole	B_Chemical
,	O
resulting	O
in	O
cerebral	B_Disease
anoxia	I_Disease
leading	O
to	O
permanent	O
damage	O
.	O

Magnetic	O
Resonance	O
imaging	O
revealed	O
cortical	O
laminar	O
necrosis	B_Disease
in	O
arterial	O
border	O
zones	O
in	O
both	O
cerebral	O
hemispheres	O
,	O
ischemic	O
changes	O
in	O
subcortical	O
white	O
matter	O
of	O
left	O
cerebral	O
hemisphere	O
,	O
and	O
in	O
the	O
left	O
putamen	O
.	O

Although	O
cortical	O
laminar	O
necrosis	B_Disease
is	O
a	O
classic	O
entity	O
in	O
adulthood	O
related	O
to	O
conditions	O
of	O
energy	O
depletions	O
,	O
there	O
are	O
few	O
reports	O
available	O
in	O
children	O
.	O

A	O
wide	O
review	O
of	O
the	O
literature	O
is	O
also	O
presented	O
.	O

The	O
natural	O
history	O
of	O
Vigabatrin	B_Chemical
associated	O
visual	B_Disease
field	I_Disease
defects	I_Disease
in	O
patients	O
electing	O
to	O
continue	O
their	O
medication	O
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
natural	O
history	O
of	O
visual	B_Disease
field	I_Disease
defects	I_Disease
in	O
a	O
group	O
of	O
patients	O
known	O
to	O
have	O
Vigabatrin-associated	O
changes	O
who	O
elected	O
to	O
continue	O
the	O
medication	O
because	O
of	O
good	O
seizure	B_Disease
control	O
.	O

METHODS	O
:	O
All	O
patients	O
taking	O
Vigabatrin	B_Chemical
alone	O
or	O
in	O
combination	O
with	O
other	O
antiepileptic	O
drugs	O
for	O
at	O
least	O
5	O
years	O
(	O
range	O
5	O
-	O
12	O
years	O
)	O
were	O
entered	O
into	O
a	O
visual	O
surveillance	O
programme	O
.	O

Patients	O
were	O
followed	O
up	O
at	O
6-monthly	O
intervals	O
for	O
not	O
less	O
than	O
18	O
months	O
(	O
range	O
18	O
-	O
43	O
months	O
)	O
.	O

In	O
all	O
,	O
16	O
patients	O
with	O
unequivocal	O
defects	O
continued	O
the	O
medication	O
.	O

Following	O
already	O
published	O
methodology	O
(	O
Eye	O
2002	O
;	O
16;567	O
-	O
571	O
)	O
monocular	O
mean	O
radial	O
degrees	O
(	O
MRDs	O
)	O
to	O
the	O
I/4e	O
isopter	O
on	O
Goldmann	O
perimetry	O
was	O
calculated	O
for	O
the	O
right	O
eye	O
at	O
the	O
time	O
of	O
discovery	O
of	O
a	O
visual	B_Disease
field	I_Disease
defect	I_Disease
and	O
again	O
after	O
not	O
less	O
than	O
18	O
months	O
follow-up	O
.	O

RESULTS	O
:	O
Mean	O
right	O
eye	O
MRD	O
at	O
presentation	O
was	O
36.98	O
degrees	O
(	O
range	O
22.25	O
-	O
51.0	O
)	O
,	O
compared	O
to	O
38.40	O
degrees	O
(	O
range	O
22.5	O
-	O
49.75	O
)	O
after	O
follow-up	O
;	O
P=0.338	O
unpaired	O
t-test	O
.	O

Only	O
one	O
patient	O
demonstrated	O
a	O
deterioration	B_Disease
in	I_Disease
visual	I_Disease
field	I_Disease
during	O
the	O
study	O
period	O
and	O
discontinued	O
treatment	O
.	O

CONCLUSION	O
:	O
Established	O
visual	B_Disease
field	I_Disease
defects	I_Disease
presumed	O
to	O
be	O
due	O
to	O
Vigabatrin	B_Chemical
therapy	O
did	O
not	O
usually	O
progress	O
in	O
spite	O
of	O
continuing	O
use	O
of	O
the	O
medication	O
.	O

These	O
data	O
give	O
support	O
to	O
the	O
hypothesis	O
that	O
the	O
pathogenesis	O
of	O
Vigabatrin-associated	O
visual	B_Disease
field	I_Disease
defects	I_Disease
may	O
be	O
an	O
idiosyncratic	O
adverse	O
drug	O
reaction	O
rather	O
than	O
dose-dependent	O
toxicity	B_Disease
.	O

Induction	O
of	O
rosaceiform	O
dermatitis	B_Disease
during	O
treatment	O
of	O
facial	B_Disease
inflammatory	I_Disease
dermatoses	I_Disease
with	O
tacrolimus	B_Chemical
ointment	O
.	O

BACKGROUND	O
:	O
Tacrolimus	B_Chemical
ointment	O
is	O
increasingly	O
used	O
for	O
anti-inflammatory	O
treatment	O
of	O
sensitive	O
areas	O
such	O
as	O
the	O
face	O
,	O
and	O
recent	O
observations	O
indicate	O
that	O
the	O
treatment	O
is	O
effective	O
in	O
steroid-aggravated	O
rosacea	B_Disease
and	O
perioral	B_Disease
dermatitis	I_Disease
.	O

We	O
report	O
on	O
rosaceiform	O
dermatitis	B_Disease
as	O
a	O
complication	O
of	O
treatment	O
with	O
tacrolimus	B_Chemical
ointment	O
.	O

OBSERVATIONS	O
:	O
Six	O
adult	O
patients	O
with	O
inflammatory	B_Disease
facial	I_Disease
dermatoses	I_Disease
were	O
treated	O
with	O
tacrolimus	B_Chemical
ointment	O
because	O
of	O
the	O
ineffectiveness	O
of	O
standard	O
treatments	O
.	O

Within	O
2	O
to	O
3	O
weeks	O
of	O
initially	O
effective	O
and	O
well-tolerated	O
treatment	O
,	O
3	O
patients	O
with	O
a	O
history	O
of	O
rosacea	B_Disease
and	O
1	O
with	O
a	O
history	O
of	O
acne	B_Disease
experienced	O
sudden	O
worsening	O
with	O
pustular	O
rosaceiform	O
lesions	O
.	O

Biopsy	O
revealed	O
an	O
abundance	O
of	O
Demodex	O
mites	O
in	O
2	O
of	O
these	O
patients	O
.	O

In	O
1	O
patient	O
with	O
eyelid	O
eczema	B_Disease
,	O
rosaceiform	O
periocular	B_Disease
dermatitis	I_Disease
gradually	O
appeared	O
after	O
3	O
weeks	O
of	O
treatment	O
.	O

In	O
1	O
patient	O
with	O
atopic	B_Disease
dermatitis	I_Disease
,	O
telangiectatic	O
and	O
papular	B_Disease
rosacea	I_Disease
insidiously	O
appeared	O
after	O
5	O
months	O
of	O
treatment	O
.	O

CONCLUSIONS	O
:	O
Our	O
observations	O
suggest	O
that	O
the	O
spectrum	O
of	O
rosaceiform	O
dermatitis	B_Disease
as	O
a	O
complication	O
of	O
treatment	O
with	O
tacrolimus	B_Chemical
ointment	O
is	O
heterogeneous	O
.	O

A	O
variety	O
of	O
factors	O
,	O
such	O
as	O
vasoactive	O
properties	O
of	O
tacrolimus	B_Chemical
,	O
proliferation	O
of	O
Demodex	O
due	O
to	O
local	O
immunosuppression	O
,	O
and	O
the	O
occlusive	O
properties	O
of	O
the	O
ointment	O
,	O
may	O
be	O
involved	O
in	O
the	O
observed	O
phenomena	O
.	O

Future	O
studies	O
are	O
needed	O
to	O
identify	O
individual	O
risk	O
factors	O
.	O

Intravascular	O
hemolysis	B_Disease
and	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
following	O
intermittent	O
rifampin	B_Chemical
therapy	O
.	O

Renal	B_Disease
failure	I_Disease
is	O
a	O
rare	O
complication	O
associated	O
with	O
the	O
use	O
of	O
rifampin	B_Chemical
.	O

Intravascular	O
hemolysis	B_Disease
leading	O
to	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
following	O
rifampin	B_Chemical
therapy	O
is	O
extremely	O
rare	O
.	O

Two	O
patients	O
with	O
leprosy	B_Disease
who	O
developed	O
hemolysis	B_Disease
and	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
following	O
rifampin	B_Chemical
are	O
reported	O
.	O

Structural	O
abnormalities	O
in	O
the	O
brains	O
of	O
human	O
subjects	O
who	O
use	O
methamphetamine	O
.	O

We	O
visualize	O
,	O
for	O
the	O
first	O
time	O
,	O
the	O
profile	O
of	O
structural	B_Disease
deficits	I_Disease
in	I_Disease
the	I_Disease
human	I_Disease
brain	I_Disease
associated	O
with	O
chronic	O
methamphetamine	B_Chemical
(	O
MA	B_Chemical
)	O
abuse	O
.	O

Studies	O
of	O
human	O
subjects	O
who	O
have	O
used	O
MA	B_Chemical
chronically	O
have	O
revealed	O
deficits	O
in	O
dopaminergic	O
and	O
serotonergic	O
systems	O
and	O
cerebral	O
metabolic	B_Disease
abnormalities	I_Disease
.	O

Using	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
and	O
new	O
computational	O
brain-mapping	O
techniques	O
,	O
we	O
determined	O
the	O
pattern	O
of	O
structural	O
brain	O
alterations	O
associated	O
with	O
chronic	O
MA	B_Chemical
abuse	O
in	O
human	O
subjects	O
and	O
related	O
these	O
deficits	O
to	O
cognitive	B_Disease
impairment	I_Disease
.	O

We	O
used	O
high-resolution	O
MRI	O
and	O
surface-based	O
computational	O
image	O
analyses	O
to	O
map	O
regional	O
abnormalities	B_Disease
in	I_Disease
the	I_Disease
cortex	I_Disease
,	I_Disease
hippocampus	I_Disease
,	I_Disease
white	I_Disease
matter	I_Disease
,	I_Disease
and	I_Disease
ventricles	I_Disease
in	O
22	O
human	O
subjects	O
who	O
used	O
MA	B_Chemical
and	O
21	O
age-matched	O
,	O
healthy	O
controls	O
.	O

Cortical	O
maps	O
revealed	O
severe	O
gray-matter	O
deficits	O
in	O
the	O
cingulate	O
,	O
limbic	O
,	O
and	O
paralimbic	O
cortices	O
of	O
MA	B_Chemical
abusers	O
(	O
averaging	O
11.3	O
%	O
below	O
control	O
;	O
p	O
<	O
0.05	O
)	O
.	O

On	O
average	O
,	O
MA	B_Chemical
abusers	O
had	O
7.8	O
%	O
smaller	O
hippocampal	O
volumes	O
than	O
control	O
subjects	O
(	O
p	O
<	O
0.01	O
;	O
left	O
,	O
p	O
=	O
0.01	O
;	O
right	O
,	O
p	O
<	O
0.05	O
)	O
and	O
significant	O
white-matter	O
hypertrophy	B_Disease
(	O
7.0	O
%	O
;	O
p	O
<	O
0.01	O
)	O
.	O

Hippocampal	O
deficits	O
were	O
mapped	O
and	O
correlated	O
with	O
memory	O
performance	O
on	O
a	O
word-recall	O
test	O
(	O
p	O
<	O
0.05	O
)	O
.	O

MRI-based	O
maps	O
suggest	O
that	O
chronic	O
methamphetamine	B_Chemical
abuse	O
causes	O
a	O
selective	O
pattern	O
of	O
cerebral	O
deterioration	O
that	O
contributes	O
to	O
impaired	B_Disease
memory	I_Disease
performance	I_Disease
.	O

MA	B_Chemical
may	O
selectively	O
damage	O
the	O
medial	O
temporal	O
lobe	O
and	O
,	O
consistent	O
with	O
metabolic	O
studies	O
,	O
the	O
cingulate-limbic	O
cortex	O
,	O
inducing	O
neuroadaptation	O
,	O
neuropil	O
reduction	O
,	O
or	O
cell	O
death	O
.	O

Prominent	O
white-matter	O
hypertrophy	B_Disease
may	O
result	O
from	O
altered	O
myelination	O
and	O
adaptive	O
glial	O
changes	O
,	O
including	O
gliosis	B_Disease
secondary	O
to	O
neuronal	B_Disease
damage	I_Disease
.	O

These	O
brain	O
substrates	O
may	O
help	O
account	O
for	O
the	O
symptoms	O
of	O
MA	B_Chemical
abuse	O
,	O
providing	O
therapeutic	O
targets	O
for	O
drug-induced	O
brain	B_Disease
injury	I_Disease
.	O

Disruption	O
of	O
hepatic	O
lipid	O
homeostasis	O
in	O
mice	O
after	O
amiodarone	O
treatment	O
is	O
associated	O
with	O
peroxisome	O
proliferator-activated	O
receptor-alpha	O
target	O
gene	O
activation	O
.	O

Amiodarone	B_Chemical
,	O
an	O
efficacious	O
and	O
widely	O
used	O
antiarrhythmic	O
agent	O
,	O
has	O
been	O
reported	O
to	O
cause	O
hepatotoxicity	B_Disease
in	O
some	O
patients	O
.	O

To	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
this	O
unwanted	O
effect	O
,	O
mice	O
were	O
administered	O
various	O
doses	O
of	O
amiodarone	B_Chemical
and	O
examined	O
for	O
changes	O
in	O
hepatic	O
histology	O
and	O
gene	O
regulation	O
.	O

Amiodarone	B_Chemical
induced	O
hepatomegaly	B_Disease
,	O
hepatocyte	O
microvesicular	O
lipid	O
accumulation	O
,	O
and	O
a	O
significant	O
decrease	O
in	O
serum	O
triglycerides	B_Chemical
and	O
glucose	B_Chemical
.	O

Northern	O
blot	O
analysis	O
of	O
hepatic	O
RNA	O
revealed	O
a	O
dose-dependent	O
increase	O
in	O
the	O
expression	O
of	O
a	O
number	O
of	O
genes	O
critical	O
for	O
fatty	B_Chemical
acid	I_Chemical
oxidation	O
,	O
lipoprotein	O
assembly	O
,	O
and	O
lipid	O
transport	O
.	O

Many	O
of	O
these	O
genes	O
are	O
regulated	O
by	O
the	O
peroxisome	O
proliferator-activated	O
receptor-alpha	O
(	O
PPARalpha	O
)	O
,	O
a	O
ligand-activated	O
nuclear	O
hormone	O
receptor	O
transcription	O
factor	O
.	O

The	O
absence	O
of	O
induction	O
of	O
these	O
genes	O
as	O
well	O
as	O
hepatomegaly	B_Disease
in	O
PPARalpha	O
knockout	O
[	O
PPARalpha-/-	O
]	O
mice	O
indicated	O
that	O
the	O
effects	O
of	O
amiodarone	B_Chemical
were	O
dependent	O
upon	O
the	O
presence	O
of	O
a	O
functional	O
PPARalpha	O
gene	O
.	O

Compared	O
to	O
wild-type	O
mice	O
,	O
treatment	O
of	O
PPARalpha-/-	O
mice	O
with	O
amiodarone	B_Chemical
resulted	O
in	O
an	O
increased	O
rate	O
and	O
extent	O
of	O
total	O
body	O
weight	B_Disease
loss	I_Disease
.	O

The	O
inability	O
of	O
amiodarone	B_Chemical
to	O
directly	O
activate	O
either	O
human	O
or	O
mouse	O
PPARalpha	O
transiently	O
expressed	O
in	O
human	O
HepG2	O
hepatoma	B_Disease
cells	O
indicates	O
that	O
the	O
effects	O
of	O
amiodarone	B_Chemical
on	O
the	O
function	O
of	O
this	O
receptor	O
were	O
indirect	O
.	O

Based	O
upon	O
these	O
results	O
,	O
we	O
conclude	O
that	O
amiodarone	B_Chemical
disrupts	O
hepatic	O
lipid	O
homeostasis	O
and	O
that	O
the	O
increased	O
expression	O
of	O
PPARalpha	O
target	O
genes	O
is	O
secondary	O
to	O
this	O
toxic	O
effect	O
.	O

These	O
results	O
provide	O
important	O
new	O
mechanistic	O
information	O
regarding	O
the	O
hepatotoxic	B_Disease
effects	O
of	O
amiodarone	B_Chemical
and	O
indicate	O
that	O
PPARalpha	O
protects	O
against	O
amiodarone-induced	O
hepatotoxicity	B_Disease
.	O

Safety	O
and	O
compliance	O
with	O
once-daily	O
niacin	O
extended-release/lovastatin	O
as	O
initial	O
therapy	O
in	O
the	O
Impact	O
of	O
Medical	O
Subspecialty	O
on	O
Patient	O
Compliance	O
to	O
Treatment	O
(	O
IMPACT	O
)	O
study	O
.	O

Niacin	B_Chemical
extended-release/lovastatin	I_Chemical
is	O
a	O
new	O
combination	O
product	O
approved	O
for	O
treatment	O
of	O
primary	O
hypercholesterolemia	B_Disease
and	O
mixed	O
dyslipidemia	B_Disease
.	O

This	O
open-labeled	O
,	O
multicenter	O
study	O
evaluated	O
the	O
safety	O
of	O
bedtime	O
niacin	B_Chemical
extended-release/lovastatin	I_Chemical
when	O
dosed	O
as	O
initial	O
therapy	O
and	O
patient	O
compliance	O
to	O
treatment	O
in	O
various	O
clinical	O
practice	O
settings	O
.	O

A	O
total	O
of	O
4,499	O
patients	O
with	O
dyslipidemia	B_Disease
requiring	O
drug	O
intervention	O
was	O
enrolled	O
at	O
1,081	O
sites	O
.	O

Patients	O
were	O
treated	O
with	O
1	O
tablet	O
(	O
500	O
mg	O
of	O
niacin	B_Chemical
extended-release/20	O
mg	O
of	O
lovastatin	B_Chemical
)	O
once	O
nightly	O
for	O
4	O
weeks	O
and	O
then	O
2	O
tablets	O
for	O
8	O
weeks	O
.	O

Patients	O
also	O
received	O
dietary	O
counseling	O
,	O
educational	O
materials	O
,	O
and	O
reminders	O
to	O
call	O
a	O
toll-free	O
number	O
that	O
provided	O
further	O
education	O
about	O
dyslipidemia	B_Disease
and	O
niacin	B_Chemical
extended-release/lovastatin	I_Chemical
.	O

Primary	O
end	O
points	O
were	O
study	O
compliance	O
,	O
increases	O
in	O
liver	O
transaminases	O
to	O
>	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
,	O
and	O
clinical	O
myopathy	B_Disease
.	O

Final	O
study	O
status	O
was	O
available	O
for	O
4,217	O
patients	O
(	O
94	O
%	O
)	O
.	O

Compliance	O
to	O
niacin	B_Chemical
extended-release/lovastatin	I_Chemical
was	O
77	O
%	O
,	O
with	O
3,245	O
patients	O
completing	O
the	O
study	O
.	O

Patients	O
in	O
the	O
southeast	O
and	O
those	O
enrolled	O
by	O
endocrinologists	O
had	O
the	O
lowest	O
compliance	O
and	O
highest	O
adverse	O
event	O
rates	O
.	O

Flushing	B_Disease
was	O
the	O
most	O
common	O
adverse	O
event	O
,	O
reported	O
by	O
18	O
%	O
of	O
patients	O
and	O
leading	O
to	O
discontinuation	O
by	O
6	O
%	O
.	O

Incidence	O
of	O
increased	O
aspartate	B_Chemical
aminotransferase	O
and/or	O
alanine	B_Chemical
aminotransferase	O
>	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
was	O
<	O
0.3	O
%	O
.	O

An	O
increase	O
of	O
creatine	B_Chemical
phosphokinase	O
to	O
>	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
occurred	O
in	O
0.24	O
%	O
of	O
patients	O
,	O
and	O
no	O
cases	O
of	O
drug-induced	O
myopathy	B_Disease
were	O
observed	O
.	O

Niacin	B_Chemical
extended-release/lovastatin	I_Chemical
1,000/40	O
mg	O
,	O
dosed	O
as	O
initial	O
therapy	O
,	O
was	O
associated	O
with	O
good	O
compliance	O
and	O
safety	O
and	O
had	O
very	O
low	O
incidences	O
of	O
increased	O
liver	O
and	O
muscle	O
enzymes	O
.	O

Protective	O
effect	O
of	O
Terminalia	B_Chemical
chebula	I_Chemical
against	O
experimental	O
myocardial	B_Disease
injury	I_Disease
induced	O
by	O
isoproterenol	B_Chemical
.	O

Cardioprotective	O
effect	O
of	O
ethanolic	B_Chemical
extract	I_Chemical
of	I_Chemical
Terminalia	I_Chemical
chebula	I_Chemical
fruits	I_Chemical
(	O
500	O
mg/kg	O
body	O
wt	O
)	O
was	O
examined	O
in	O
isoproterenol	B_Chemical
(	O
200	O
mg/kg	O
body	O
wt	O
)	O
induced	O
myocardial	B_Disease
damage	I_Disease
in	O
rats	O
.	O

In	O
isoproterenol	B_Chemical
administered	O
rats	O
,	O
the	O
level	O
of	O
lipid	O
peroxides	B_Chemical
increased	O
significantly	O
in	O
the	O
serum	O
and	O
heart	O
.	O

A	O
significant	O
decrease	O
was	O
observed	O
in	O
the	O
activity	O
of	O
the	O
myocardial	O
marker	O
enzymes	O
with	O
a	O
concomitant	O
increase	O
in	O
their	O
activity	O
in	O
serum	O
.	O

Histopathological	O
examination	O
was	O
carried	O
out	O
to	O
confirm	O
the	O
myocardial	O
necrosis	B_Disease
.	O

T.	B_Chemical
chebula	I_Chemical
extract	I_Chemical
pretreatment	O
was	O
found	O
to	O
ameliorate	O
the	O
effect	O
of	O
isoproterenol	B_Chemical
on	O
lipid	O
peroxide	B_Chemical
formation	O
and	O
retained	O
the	O
activities	O
of	O
the	O
diagnostic	O
marker	O
enzymes	O
.	O

A	O
case	O
of	O
postoperative	O
anxiety	B_Disease
due	O
to	O
low	O
dose	O
droperidol	B_Chemical
used	O
with	O
patient-controlled	O
analgesia	O
.	O

A	O
multiparous	O
woman	O
in	O
good	O
psychological	O
health	O
underwent	O
urgent	O
caesarean	O
section	O
in	O
labour	O
.	O

Postoperatively	O
,	O
she	O
was	O
given	O
a	O
patient-controlled	O
analgesia	O
device	O
delivering	O
boluses	O
of	O
diamorphine	B_Chemical
0.5	O
mg	O
and	O
droperidol	B_Chemical
0.025	O
mg	O
.	O

Whilst	O
using	O
the	O
device	O
she	O
gradually	O
became	O
anxious	O
,	O
the	O
feeling	O
worsening	O
after	O
each	O
bolus	O
.	O

The	O
diagnosis	O
of	O
droperidol-induced	O
psychological	B_Disease
disturbance	I_Disease
was	O
not	O
made	O
straight	O
away	O
although	O
on	O
subsequent	O
close	O
questioning	O
the	O
patient	O
gave	O
a	O
very	O
clear	O
history	O
.	O

After	O
she	O
had	O
received	O
a	O
total	O
of	O
only	O
0.9	O
mg	O
droperidol	B_Chemical
,	O
a	O
syringe	O
containing	O
diamorphine	B_Chemical
only	O
was	O
substituted	O
and	O
her	O
unease	O
resolved	O
completely	O
.	O

We	O
feel	O
that	O
,	O
although	O
the	O
dramatic	O
extrapyramidal	O
side	O
effects	O
of	O
dopaminergic	O
antiemetics	O
are	O
well	O
known	O
,	O
more	O
subtle	O
manifestations	O
may	O
easily	O
be	O
overlooked	O
.	O

Accurate	O
patient	O
history	O
contributes	O
to	O
differentiating	O
diabetes	O
insipidus	O
:	O
a	O
case	O
study	O
.	O

This	O
case	O
study	O
highlights	O
the	O
important	O
contribution	O
of	O
nursing	O
in	O
obtaining	O
an	O
accurate	O
health	O
history	O
.	O

The	O
case	O
discussed	O
herein	O
initially	O
appeared	O
to	O
be	O
neurogenic	B_Disease
diabetes	I_Disease
insipidus	I_Disease
(	O
DI	B_Disease
)	O
secondary	O
to	O
a	O
traumatic	B_Disease
brain	I_Disease
injury	I_Disease
.	O

The	O
nursing	O
staff	O
,	O
by	O
reviewing	O
the	O
patient	O
's	O
health	O
history	O
with	O
his	O
family	O
,	O
discovered	O
a	O
history	O
of	O
polydipsia	B_Disease
and	O
long-standing	O
lithium	B_Chemical
use	O
.	O

Lithium	B_Chemical
is	O
implicated	O
in	O
drug-induced	O
nephrogenic	B_Disease
DI	I_Disease
,	O
and	O
because	O
the	O
patient	O
had	O
not	O
received	O
lithium	B_Chemical
since	O
being	O
admitted	O
to	O
the	O
hospital	O
,	O
his	O
treatment	O
changed	O
to	O
focus	O
on	O
nephrogenic	B_Disease
DI	I_Disease
.	O

By	O
combining	O
information	O
from	O
the	O
patient	O
history	O
,	O
the	O
physical	O
examination	O
,	O
and	O
radiologic	O
and	O
laboratory	O
studies	O
,	O
the	O
critical	O
care	O
team	O
demonstrated	O
that	O
the	O
patient	O
had	O
been	O
self-treating	O
his	O
lithium-induced	O
nephrogenic	B_Disease
DI	I_Disease
and	O
developed	O
neurogenic	B_Disease
DI	I_Disease
secondary	O
to	O
brain	B_Disease
trauma	I_Disease
.	O

Thus	O
successful	O
treatment	O
required	O
that	O
nephrogenic	O
and	O
neurogenic	B_Disease
DI	I_Disease
be	O
treated	O
concomitantly	O
.	O

Factors	O
contributing	O
to	O
ribavirin-induced	O
anemia	B_Disease
.	O

BACKGROUND	O
AND	O
AIM	O
:	O
Interferon	B_Chemical
and	O
ribavirin	B_Chemical
combination	O
therapy	O
for	O
chronic	B_Disease
hepatitis	I_Disease
C	I_Disease
produces	O
hemolytic	B_Disease
anemia	I_Disease
.	O

This	O
study	O
was	O
conducted	O
to	O
identify	O
the	O
factors	O
contributing	O
to	O
ribavirin-induced	O
anemia	B_Disease
.	O

METHODS	O
:	O
Eighty-eight	O
patients	O
with	O
chronic	B_Disease
hepatitis	I_Disease
C	I_Disease
who	O
received	O
interferon-alpha-2b	B_Chemical
at	O
a	O
dose	O
of	O
6	O
MU	O
administered	O
intramuscularly	O
for	O
24	O
weeks	O
in	O
combination	O
with	O
ribavirin	B_Chemical
administered	O
orally	O
at	O
a	O
dose	O
of	O
600	O
mg	O
or	O
800	O
mg	O
participated	O
in	O
the	O
study	O
.	O

A	O
hemoglobin	O
concentration	O
of	O
<	O
10	O
g/dL	O
was	O
defined	O
as	O
ribavirin-induced	O
anemia	B_Disease
.	O

RESULTS	O
:	O
Ribavirin-induced	O
anemia	B_Disease
occurred	O
in	O
18	O
(	O
20.5	O
%	O
)	O
patients	O
during	O
treatment	O
.	O

A	O
2	O
g/dL	O
decrease	O
in	O
hemoglobin	O
concentrations	O
in	O
patients	O
with	O
anemia	B_Disease
was	O
observed	O
at	O
week	O
2	O
after	O
the	O
start	O
of	O
treatment	O
.	O

The	O
hemoglobin	O
concentration	O
in	O
patients	O
with	O
>	O
or	O
=	O
2	O
g/dL	O
decrease	O
at	O
week	O
2	O
was	O
observed	O
to	O
be	O
significantly	O
lower	O
even	O
after	O
week	O
2	O
than	O
in	O
patients	O
with	O
<	O
2	O
g/dL	O
decrease	O
(	O
P	O
<	O
0.01	O
)	O
.	O

A	O
significant	O
relationship	O
was	O
observed	O
between	O
the	O
rate	O
of	O
reduction	O
of	O
hemoglobin	O
concentrations	O
at	O
week	O
2	O
and	O
the	O
severity	O
of	O
anemia	B_Disease
(	O
P	O
<	O
0.01	O
)	O
.	O

Such	O
factors	O
as	O
sex	O
(	O
female	O
)	O
,	O
age	O
(	O
>	O
or	O
=	O
60	O
years	O
old	O
)	O
,	O
and	O
the	O
ribavirin	B_Chemical
dose	O
by	O
body	O
weight	O
(	O
12	O
mg/kg	O
or	O
more	O
)	O
were	O
significant	O
by	O
univariate	O
analysis	O
.	O

CONCLUSIONS	O
:	O
Careful	O
administration	O
is	O
necessary	O
in	O
patients	O
>	O
or	O
=	O
60	O
years	O
old	O
,	O
in	O
female	O
patients	O
,	O
and	O
in	O
patients	O
receiving	O
a	O
ribavirin	B_Chemical
dose	O
of	O
12	O
mg/kg	O
or	O
more	O
.	O

Patients	O
who	O
experience	O
a	O
fall	O
in	O
hemoglobin	O
concentrations	O
of	O
2	O
g/dL	O
or	O
more	O
at	O
week	O
2	O
after	O
the	O
start	O
of	O
treatment	O
should	O
be	O
monitored	O
with	O
particular	O
care	O
.	O

Zidovudine-induced	O
hepatitis	B_Disease
.	O

A	O
case	O
of	O
acute	O
hepatitis	B_Disease
induced	O
by	O
zidovudine	B_Chemical
in	O
a	O
38-year-old	O
patient	O
with	O
AIDS	B_Disease
is	O
presented	O
.	O

The	O
mechanism	O
whereby	O
the	O
hepatitis	B_Disease
was	O
induced	O
is	O
not	O
known	O
.	O

However	O
,	O
the	O
patient	O
tolerated	O
well	O
an	O
alternative	O
reverse	O
transcriptase	O
inhibitor	O
,	O
2'3	B_Chemical
'	I_Chemical
dideoxyinosine	I_Chemical
.	O

Physicians	O
caring	O
for	O
patients	O
with	O
AIDS	B_Disease
should	O
be	O
aware	O
of	O
this	O
hitherto	O
rarely	O
reported	O
complication	O
.	O

Oxidative	O
damage	O
precedes	O
nitrative	O
damage	O
in	O
adriamycin-induced	O
cardiac	O
mitochondrial	B_Disease
injury	I_Disease
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
elevated	O
reactive	O
oxygen	B_Chemical
(ROS)/nitrogen	O
species	O
(	O
RNS	O
)	O
reported	O
to	O
be	O
present	O
in	O
adriamycin	B_Chemical
(ADR)-induced	O
cardiotoxicity	B_Disease
actually	O
resulted	O
in	O
cardiomyocyte	O
oxidative/nitrative	O
damage	O
,	O
and	O
to	O
quantitatively	O
determine	O
the	O
time	O
course	O
and	O
subcellular	O
localization	O
of	O
these	O
postulated	O
damage	O
products	O
using	O
an	O
in	O
vivo	O
approach	O
.	O

B6C3	O
mice	O
were	O
treated	O
with	O
a	O
single	O
dose	O
of	O
20	O
mg/kg	O
ADR	B_Chemical
.	O

Ultrastructural	O
damage	O
and	O
levels	O
of	O
4-hydroxy-2-nonenal	B_Chemical
(4HNE)-protein	O
adducts	O
and	O
3-nitrotyrosine	B_Chemical
(	O
3NT	B_Chemical
)	O
were	O
analyzed	O
.	O

Quantitative	O
ultrastructural	O
damage	O
using	O
computerized	O
image	O
techniques	O
showed	O
cardiomyocyte	O
injury	O
as	O
early	O
as	O
3	O
hours	O
,	O
with	O
mitochondria	O
being	O
the	O
most	O
extensively	O
and	O
progressively	O
injured	O
subcellular	O
organelle	O
.	O

Analysis	O
of	O
4HNE	B_Chemical
protein	O
adducts	O
by	O
immunogold	O
electron	O
microscopy	O
showed	O
appearance	O
of	O
4HNE	B_Chemical
protein	O
adducts	O
in	O
mitochondria	O
as	O
early	O
as	O
3	O
hours	O
,	O
with	O
a	O
peak	O
at	O
6	O
hours	O
and	O
subsequent	O
decline	O
at	O
24	O
hours	O
.	O

3NT	B_Chemical
levels	O
were	O
significantly	O
increased	O
in	O
all	O
subcellular	O
compartments	O
at	O
6	O
hours	O
and	O
subsequently	O
declined	O
at	O
24	O
hours	O
.	O

Our	O
data	O
showed	O
ADR	B_Chemical
induced	O
4HNE-protein	O
adducts	O
in	O
mitochondria	O
at	O
the	O
same	O
time	O
point	O
as	O
when	O
mitochondrial	B_Disease
injury	I_Disease
initially	O
appeared	O
.	O

These	O
results	O
document	O
for	O
the	O
first	O
time	O
in	O
vivo	O
that	O
mitochondrial	B_Disease
oxidative	I_Disease
damage	I_Disease
precedes	O
nitrative	O
damage	O
.	O

The	O
progressive	O
nature	O
of	O
mitochondrial	B_Disease
injury	I_Disease
suggests	O
that	O
mitochondria	O
,	O
not	O
other	O
subcellular	O
organelles	O
,	O
are	O
the	O
major	O
site	O
of	O
intracellular	O
injury	O
.	O

Sotalol-induced	O
coronary	B_Disease
spasm	I_Disease
in	O
a	O
patient	O
with	O
dilated	B_Disease
cardiomyopathy	I_Disease
associated	O
with	O
sustained	O
ventricular	B_Disease
tachycardia	I_Disease
.	O

A	O
54-year-old	O
man	O
with	O
severe	O
left	O
ventricular	B_Disease
dysfunction	I_Disease
due	O
to	O
dilated	B_Disease
cardiomyopathy	I_Disease
was	O
referred	O
to	O
our	O
hospital	O
for	O
symptomatic	O
incessant	O
sustained	O
ventricular	B_Disease
tachycardia	I_Disease
(	O
VT	B_Disease
)	O
.	O

After	O
the	O
administration	O
of	O
nifekalant	B_Chemical
hydrochloride	I_Chemical
,	O
sustained	O
VT	B_Disease
was	O
terminated	O
.	O

An	O
alternate	O
class	O
III	O
agent	O
,	O
sotalol	B_Chemical
,	O
was	O
also	O
effective	O
for	O
the	O
prevention	O
of	O
VT	B_Disease
.	O

However	O
,	O
one	O
month	O
after	O
switching	O
over	O
nifekalant	B_Chemical
to	O
sotalol	B_Chemical
,	O
a	O
short	O
duration	O
of	O
ST	O
elevation	O
was	O
documented	O
in	O
ECG	O
monitoring	O
at	O
almost	O
the	O
same	O
time	O
for	O
three	O
consecutive	O
days	O
.	O

ST	O
elevation	O
with	O
chest	O
discomfort	O
disappeared	O
since	O
he	O
began	O
taking	O
long-acting	O
diltiazem	B_Chemical
.	O

Coronary	B_Disease
vasospasm	I_Disease
may	O
be	O
induced	O
by	O
the	O
non-selective	O
beta-blocking	O
properties	O
of	O
sotalol	B_Chemical
.	O

Effects	O
of	O
the	O
antidepressant	O
trazodone	B_Chemical
,	O
a	O
5-HT	B_Chemical
2A/2C	O
receptor	O
antagonist	O
,	O
on	O
dopamine-dependent	O
behaviors	O
in	O
rats	O
.	O

RATIONALE	O
:	O
5-Hydroxytryptamine	B_Chemical
,	O
via	O
stimulation	O
of	O
5-HT	B_Chemical
2C	O
receptors	O
,	O
exerts	O
a	O
tonic	O
inhibitory	O
influence	O
on	O
dopaminergic	O
neurotransmission	O
,	O
whereas	O
activation	O
of	O
5-HT	B_Chemical
2A	O
receptors	O
enhances	O
stimulated	O
DAergic	O
neurotransmission	O
.	O

The	O
antidepressant	O
trazodone	B_Chemical
is	O
a	O
5-HT	B_Chemical
2A/2C	O
receptor	O
antagonist	O
.	O

OBJECTIVES	O
:	O
To	O
evaluate	O
the	O
effect	O
of	O
trazodone	B_Chemical
treatment	O
on	O
behaviors	O
dependent	O
on	O
the	O
functional	O
status	O
of	O
the	O
nigrostriatal	O
DAergic	O
system	O
.	O

METHODS	O
:	O
The	O
effect	O
of	O
pretreatment	O
with	O
trazodone	B_Chemical
on	O
dexamphetamine-	O
and	O
apomorphine-induced	O
oral	B_Disease
stereotypies	I_Disease
,	O
on	O
catalepsy	B_Disease
induced	O
by	O
haloperidol	B_Chemical
and	O
apomorphine	B_Chemical
(	O
0.05	O
mg/kg	O
,	O
i.p	O
.	O
)	O
,	O
on	O
ergometrine-induced	O
wet	O
dog	O
shake	O
(	O
WDS	O
)	O
behavior	O
and	O
fluoxetine-induced	O
penile	O
erections	O
was	O
studied	O
in	O
rats	O
.	O

We	O
also	O
investigated	O
whether	O
trazodone	B_Chemical
induces	O
catalepsy	B_Disease
in	O
rats	O
.	O

RESULTS	O
:	O
Trazodone	B_Chemical
at	O
2.5	O
-	O
20	O
mg/kg	O
i.p	O
.	O
did	O
not	O
induce	O
catalepsy	B_Disease
,	O
and	O
did	O
not	O
antagonize	O
apomorphine	B_Chemical
(	O
1.5	O
and	O
3	O
mg/kg	O
)	O
stereotypy	O
and	O
apomorphine	B_Chemical
(	O
0.05	O
mg/kg)-induced	O
catalepsy	B_Disease
.	O

However	O
,	O
pretreatment	O
with	O
5	O
,	O
10	O
and	O
20	O
mg/kg	O
i.p	O
.	O

trazodone	B_Chemical
enhanced	O
dexamphetamine	B_Chemical
stereotypy	O
,	O
and	O
antagonized	O
haloperidol	B_Chemical
catalepsy	B_Disease
,	O
ergometrine-induced	O
WDS	O
behavior	O
and	O
fluoxetine-induced	O
penile	O
erections	O
.	O

Trazodone	B_Chemical
at	O
30	O
,	O
40	O
and	O
50	O
mg/kg	O
i.p	O
.	O
induced	O
catalepsy	B_Disease
and	O
antagonized	O
apomorphine	B_Chemical
and	O
dexamphetamine	B_Chemical
stereotypies	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
trazodone	B_Chemical
at	O
2.5	O
-	O
20	O
mg/kg	O
does	O
not	O
block	O
pre-	O
and	O
postsynaptic	O
striatal	O
D2	O
DA	O
receptors	O
,	O
while	O
at	O
30	O
,	O
40	O
and	O
50	O
mg/kg	O
it	O
blocks	O
postsynaptic	O
striatal	O
D2	O
DA	O
receptors	O
.	O

Furthermore	O
,	O
at	O
5	O
,	O
10	O
and	O
20	O
mg/kg	O
,	O
trazodone	B_Chemical
blocks	O
5-HT	B_Chemical
2A	O
and	O
5-HT	B_Chemical
2C	O
receptors	O
.	O

We	O
suggest	O
that	O
trazodone	B_Chemical
(	O
5	O
,	O
10	O
and	O
20	O
mg/kg	O
)	O
,	O
by	O
blocking	O
the	O
5-HT	B_Chemical
2C	O
receptors	O
,	O
releases	O
the	O
nigrostriatal	O
DAergic	O
neurons	O
from	O
tonic	O
inhibition	O
caused	O
by	O
5-HT	B_Chemical
,	O
and	O
thereby	O
potentiates	O
dexamphetamine	B_Chemical
stereotypy	O
and	O
antagonizes	O
haloperidol	B_Chemical
catalepsy	B_Disease
.	O

Swallowing	B_Disease
abnormalities	I_Disease
and	O
dyskinesia	B_Disease
in	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
.	O

Gastrointestinal	B_Disease
abnormalities	I_Disease
in	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
(	O
PD	B_Disease
)	O
have	O
been	O
known	O
for	O
almost	O
two	O
centuries	O
,	O
but	O
many	O
aspects	O
concerning	O
their	O
pathophysiology	O
have	O
not	O
been	O
completely	O
clarified	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
oropharyngeal	O
dynamics	O
in	O
PD	B_Disease
patients	O
with	O
and	O
without	O
levodopa-induced	O
dyskinesia	B_Disease
.	O

Fifteen	O
dyskinetic	B_Disease
,	O
12	O
nondyskinetic	O
patients	O
,	O
and	O
a	O
control	O
group	O
were	O
included	O
.	O

Patients	O
were	O
asked	O
about	O
dysphagia	B_Disease
and	O
evaluated	O
with	O
the	O
Unified	O
Parkinson	B_Disease
's	I_Disease
Disease	I_Disease
Rating	O
Scale	O
Parts	O
II	O
and	O
III	O
and	O
the	O
Hoehn	O
and	O
Yahr	O
scale	O
.	O

Deglutition	O
was	O
assessed	O
using	O
modified	O
barium	B_Chemical
swallow	O
with	O
videofluoroscopy	O
.	O

Nondyskinetic	O
patients	O
,	O
but	O
not	O
the	O
dyskinetic	B_Disease
ones	O
,	O
showed	O
less	O
oropharyngeal	O
swallowing	O
efficiency	O
(	O
OPSE	O
)	O
for	O
liquid	O
food	O
than	O
controls	O
(	O
Dunnett	O
,	O
P	O
=	O
0.02	O
)	O
.	O

Dyskinetic	B_Disease
patients	O
tended	O
to	O
have	O
a	O
greater	O
OPSE	O
than	O
nondyskinetic	O
(	O
Dunnett	O
,	O
P	O
=	O
0.06	O
)	O
.	O

Patients	O
who	O
were	O
using	O
a	O
higher	O
dose	O
of	O
levodopa	B_Chemical
had	O
a	O
greater	O
OPSE	O
and	O
a	O
trend	O
toward	O
a	O
smaller	O
oral	O
transit	O
time	O
(	O
Pearson	O
's	O
correlation	O
,	O
P	O
=	O
0.01	O
and	O
0.08	O
,	O
respectively	O
)	O
.	O

Neither	O
the	O
report	O
of	O
dysphagia	B_Disease
nor	O
any	O
of	O
the	O
PD	B_Disease
severity	O
parameters	O
correlated	O
to	O
the	O
videofluoroscopic	O
variables	O
.	O

In	O
the	O
current	O
study	O
,	O
dyskinetic	B_Disease
patients	O
performed	O
better	O
in	O
swallowing	O
function	O
,	O
which	O
could	O
be	O
explained	O
on	O
the	O
basis	O
of	O
a	O
greater	O
levodopa	B_Chemical
dose	O
.	O

Our	O
results	O
suggest	O
a	O
role	O
for	O
levodopa	B_Chemical
in	O
the	O
oral	O
phase	O
of	O
deglutition	O
and	O
confirm	O
that	O
dysphagia	B_Disease
is	O
not	O
a	O
good	O
predictor	O
of	O
deglutition	O
alterations	O
in	O
PD	B_Disease
.	O

Inhibition	O
of	O
nuclear	O
factor-kappaB	O
activation	O
attenuates	O
tubulointerstitial	B_Disease
nephritis	I_Disease
induced	O
by	O
gentamicin	B_Chemical
.	O

BACKGROUND	O
:	O
Animals	O
treated	O
with	O
gentamicin	B_Chemical
can	O
show	O
residual	O
areas	O
of	O
interstitial	O
fibrosis	B_Disease
in	O
the	O
renal	O
cortex	O
.	O

This	O
study	O
investigated	O
the	O
expression	O
of	O
nuclear	O
factor-kappaB	O
(	O
NF-kappaB	O
)	O
,	O
mitogen-activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
and	O
macrophages	O
in	O
the	O
renal	O
cortex	O
and	O
structural	O
and	O
functional	O
renal	O
changes	O
of	O
rats	O
treated	O
with	O
gentamicin	B_Chemical
or	O
gentamicin	B_Chemical
+	O
pyrrolidine	B_Chemical
dithiocarbamate	I_Chemical
(	O
PDTC	B_Chemical
)	O
,	O
an	O
NF-kappaB	O
inhibitor	O
.	O

METHODS	O
:	O
38	O
female	O
Wistar	O
rats	O
were	O
injected	O
with	O
gentamicin	B_Chemical
,	O
40	O
mg/kg	O
,	O
twice	O
a	O
day	O
for	O
9	O
days	O
,	O
38	O
with	O
gentamicin	B_Chemical
+	O
PDTC	B_Chemical
,	O
and	O
28	O
with	O
0.15	O
M	O
NaCl	B_Chemical
solution	O
.	O

The	O
animals	O
were	O
killed	O
5	O
and	O
30	O
days	O
after	O
these	O
injections	O
and	O
the	O
kidneys	O
were	O
removed	O
for	O
histological	O
and	O
immunohistochemical	O
studies	O
.	O

The	O
results	O
of	O
the	O
immunohistochemical	O
studies	O
were	O
scored	O
according	O
to	O
the	O
extent	O
of	O
staining	O
.	O

The	O
fractional	O
interstitial	O
area	O
was	O
determined	O
by	O
morphometry	O
.	O

RESULTS	O
:	O
Gentamicin-treated	O
rats	O
presented	O
a	O
transitory	O
increase	O
in	O
plasma	O
creatinine	B_Chemical
levels	O
.	O

Increased	O
ED-1	O
,	O
MAP	O
kinases	O
and	O
NF-kappaB	O
staining	O
were	O
also	O
observed	O
in	O
the	O
renal	O
cortex	O
from	O
all	O
gentamicin-treated	O
rats	O
compared	O
to	O
control	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
animals	O
killed	O
on	O
day	O
30	O
also	O
presented	O
fibrosis	B_Disease
in	O
the	O
renal	O
cortex	O
despite	O
the	O
recovery	O
of	O
renal	O
function	O
.	O

Treatment	O
with	O
PDTC	B_Chemical
reduced	O
the	O
functional	O
and	O
structural	O
changes	O
induced	O
by	O
gentamicin	B_Chemical
.	O

CONCLUSIONS	O
:	O
These	O
data	O
show	O
that	O
inhibition	O
of	O
NF-kappaB	O
activation	O
attenuates	O
tubulointerstitial	B_Disease
nephritis	I_Disease
induced	O
by	O
gentamicin	B_Chemical
.	O

Glucose	B_Chemical
metabolism	O
in	O
patients	O
with	O
schizophrenia	B_Disease
treated	O
with	O
atypical	O
antipsychotic	O
agents	O
:	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B_Chemical
tolerance	O
test	O
and	O
minimal	O
model	O
analysis	O
.	O

BACKGROUND	O
:	O
While	O
the	O
incidence	O
of	O
new-onset	O
diabetes	B_Disease
mellitus	I_Disease
may	O
be	O
increasing	O
in	O
patients	O
with	O
schizophrenia	B_Disease
treated	O
with	O
certain	O
atypical	O
antipsychotic	O
agents	O
,	O
it	O
remains	O
unclear	O
whether	O
atypical	O
agents	O
are	O
directly	O
affecting	O
glucose	B_Chemical
metabolism	O
or	O
simply	O
increasing	O
known	O
risk	O
factors	O
for	O
diabetes	B_Disease
.	O

OBJECTIVE	O
:	O
To	O
study	O
the	O
2	O
drugs	O
most	O
clearly	O
implicated	O
(	O
clozapine	B_Chemical
and	O
olanzapine	B_Chemical
)	O
and	O
risperidone	B_Chemical
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B_Chemical
tolerance	O
test	O
.	O

DESIGN	O
:	O
A	O
cross-sectional	O
design	O
in	O
stable	O
,	O
treated	O
patients	O
with	O
schizophrenia	B_Disease
evaluated	O
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B_Chemical
tolerance	O
test	O
and	O
the	O
Bergman	O
minimal	O
model	O
analysis	O
.	O

SETTING	O
:	O
Subjects	O
were	O
recruited	O
from	O
an	O
urban	O
community	O
mental	O
health	O
clinic	O
and	O
were	O
studied	O
at	O
a	O
general	O
clinical	O
research	O
center	O
.	O

Patients	O
Fifty	O
subjects	O
signed	O
informed	O
consent	O
and	O
41	O
underwent	O
the	O
frequently	O
sampled	O
intravenous	O
glucose	B_Chemical
tolerance	O
test	O
.	O

Thirty-six	O
nonobese	O
subjects	O
with	O
schizophrenia	B_Disease
or	O
schizoaffective	B_Disease
disorder	I_Disease
,	O
matched	O
by	O
body	O
mass	O
index	O
and	O
treated	O
with	O
either	O
clozapine	B_Chemical
,	O
olanzapine	B_Chemical
,	O
or	O
risperidone	B_Chemical
,	O
were	O
included	O
in	O
the	O
analysis	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Fasting	O
plasma	O
glucose	B_Chemical
and	O
fasting	O
serum	O
insulin	O
levels	O
,	O
insulin	B_Disease
sensitivity	I_Disease
index	O
,	O
homeostasis	O
model	O
assessment	O
of	O
insulin	B_Disease
resistance	I_Disease
,	O
and	O
glucose	B_Chemical
effectiveness	O
.	O

RESULTS	O
:	O
The	O
mean	O
+	O
/-	O
SD	O
duration	O
of	O
treatment	O
with	O
the	O
identified	O
atypical	O
antipsychotic	O
agent	O
was	O
68.3	O
+	O
/-	O
28.9	O
months	O
(	O
clozapine	B_Chemical
)	O
,	O
29.5	O
+	O
/-	O
17.5	O
months	O
(	O
olanzapine	B_Chemical
)	O
,	O
and	O
40.9	O
+	O
/-	O
33.7	O
(	O
risperidone	B_Chemical
)	O
.	O

Fasting	O
serum	O
insulin	O
concentrations	O
differed	O
among	O
groups	O
(	O
F(33	O
)	O
=	O
3.35	O
;	O
P	O
=	O
.047	O
)	O
(	O
clozapine	B_Chemical
>	O
olanzapine	B_Chemical
>	O
risperidone	B_Chemical
)	O
with	O
significant	O
differences	O
between	O
clozapine	B_Chemical
and	O
risperidone	B_Chemical
(	O
t(33	O
)	O
=	O
2.32	O
;	O
P	O
=	O
.03	O
)	O
and	O
olanzapine	B_Chemical
and	O
risperidone	B_Chemical
(	O
t(33	O
)	O
=	O
2.15	O
;	O
P	O
=	O
.04	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
insulin	B_Disease
sensitivity	I_Disease
index	O
among	O
groups	O
(	O
F(33	O
)	O
=	O
10.66	O
;	O
P<.001	O
)	O
(	O
clozapine	B_Chemical
<	O
olanzapine	B_Chemical
<	O
risperidone	B_Chemical
)	O
,	O
with	O
subjects	O
who	O
received	O
clozapine	B_Chemical
and	O
olanzapine	B_Chemical
exhibiting	O
significant	O
insulin	B_Disease
resistance	I_Disease
compared	O
with	O
subjects	O
who	O
were	O
treated	O
with	O
risperidone	B_Chemical
(	O
clozapine	B_Chemical
vs	O
risperidone	B_Chemical
,	O
t(33	O
)	O
=	O
-4.29	O
;	O
P<.001	O
;	O
olanzapine	B_Chemical
vs	O
risperidone	B_Chemical
,	O
t(33	O
)	O
=	O
-3.62	O
;	O
P	O
=	O
.001	O
[	O
P<.001	O
]	O
)	O
.	O

The	O
homeostasis	O
model	O
assessment	O
of	O
insulin	B_Disease
resistance	I_Disease
also	O
differed	O
significantly	O
among	O
groups	O
(	O
F(33	O
)	O
=	O
4.92	O
;	O
P	O
=	O
.01	O
)	O
(	O
clozapine	B_Chemical
>	O
olanzapine	B_Chemical
>	O
risperidone	B_Chemical
)	O
(	O
clozapine	B_Chemical
vs	O
risperidone	B_Chemical
,	O
t(33	O
)	O
=	O
2.94	O
;	O
P	O
=	O
.006	O
;	O
olanzapine	B_Chemical
vs	O
risperidone	B_Chemical
,	O
t(33	O
)	O
=	O
2.42	O
;	O
P	O
=	O
.02	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
among	O
groups	O
in	O
glucose	B_Chemical
effectiveness	O
(	O
F(30	O
)	O
=	O
4.18	O
;	O
P	O
=	O
.02	O
)	O
(	O
clozapine	B_Chemical
<	O
olanzapine	B_Chemical
<	O
risperidone	B_Chemical
)	O
with	O
significant	O
differences	O
between	O
clozapine	B_Chemical
and	O
risperidone	B_Chemical
(	O
t(30	O
)	O
=	O
-2.59	O
;	O
P	O
=	O
.02	O
)	O
and	O
olanzapine	B_Chemical
and	O
risperidone	B_Chemical
(	O
t(30	O
)	O
=	O
-2.34	O
,	O
P	O
=	O
.03	O
)	O
.	O

CONCLUSIONS	O
:	O
Both	O
nonobese	O
clozapine-	O
and	O
olanzapine-treated	O
groups	O
displayed	O
significant	O
insulin	B_Disease
resistance	I_Disease
and	O
impairment	O
of	O
glucose	B_Chemical
effectiveness	O
compared	O
with	O
risperidone-treated	O
subjects	O
.	O

Patients	O
taking	O
clozapine	B_Chemical
and	O
olanzapine	B_Chemical
must	O
be	O
examined	O
for	O
insulin	B_Disease
resistance	I_Disease
and	O
its	O
consequences	O
.	O

Thoracic	B_Disease
hematomyelia	I_Disease
secondary	O
to	O
coumadin	B_Chemical
anticoagulant	O
therapy	O
:	O
a	O
case	O
report	O
.	O

A	O
case	O
of	O
thoracic	O
hematomyelia	O
secondary	O
to	O
anticoagulant	O
therapy	O
is	O
presented	O
.	O

Clinical	O
features	O
,	O
similar	O
to	O
2	O
other	O
previously	O
reported	O
cases	O
,	O
are	O
discussed	O
.	O

A	O
high	O
index	O
of	O
suspicion	O
may	O
lead	O
to	O
a	O
quick	O
diagnostic	O
procedure	O
and	O
successful	O
decompressive	O
surgery	O
.	O

Mania	B_Disease
associated	O
with	O
fluoxetine	B_Chemical
treatment	O
in	O
adolescents	O
.	O

Fluoxetine	B_Chemical
,	O
a	O
selective	O
serotonin	B_Chemical
reuptake	O
inhibitor	O
,	O
is	O
gaining	O
increased	O
acceptance	O
in	O
the	O
treatment	O
of	O
adolescent	O
depression	B_Disease
.	O

Generally	O
safe	O
and	O
well	O
tolerated	O
by	O
adults	O
,	O
fluoxetine	B_Chemical
has	O
been	O
reported	O
to	O
induce	O
mania	B_Disease
.	O

The	O
cases	O
of	O
five	O
depressed	B_Disease
adolescents	O
,	O
14	O
-	O
16	O
years	O
of	O
age	O
,	O
who	O
developed	O
mania	B_Disease
during	O
pharmacotherapy	O
with	O
fluoxetine	B_Chemical
,	O
are	O
reported	O
here	O
.	O

Apparent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
mania	B_Disease
or	O
hypomania	B_Disease
during	O
fluoxetine	B_Chemical
pharmacotherapy	O
in	O
this	O
population	O
were	O
the	O
combination	O
of	O
attention-deficit	B_Disease
hyperactivity	I_Disease
disorder	I_Disease
and	O
affective	O
instability	O
;	O
major	O
depression	B_Disease
with	O
psychotic	B_Disease
features	O
;	O
a	O
family	O
history	O
of	O
affective	B_Disease
disorder	I_Disease
,	O
especially	O
bipolar	B_Disease
disorder	I_Disease
;	O
and	O
a	O
diagnosis	O
of	O
bipolar	B_Disease
disorder	I_Disease
.	O

Further	O
study	O
is	O
needed	O
to	O
determine	O
the	O
optimal	O
dosage	O
and	O
to	O
identify	O
risk	O
factors	O
that	O
increase	O
individual	O
vulnerability	O
to	O
fluoxetine	B_Chemical
induced	O
mania	B_Disease
in	O
adolescents	O
.	O

Acute	B_Disease
renal	I_Disease
insufficiency	I_Disease
after	O
high-dose	O
melphalan	B_Chemical
in	O
patients	O
with	O
primary	B_Disease
systemic	I_Disease
amyloidosis	I_Disease
during	O
stem	O
cell	O
transplantation	O
.	O

BACKGROUND	O
:	O
Patients	O
with	O
primary	B_Disease
systemic	I_Disease
amyloidosis	I_Disease
(	O
AL	B_Disease
)	O
have	O
a	O
poor	O
prognosis	O
.	O

Median	O
survival	O
time	O
from	O
standard	O
treatments	O
is	O
only	O
17	O
months	O
.	O

High-dose	O
intravenous	O
melphalan	B_Chemical
followed	O
by	O
peripheral	O
blood	O
stem	O
cell	O
transplant	O
(	O
PBSCT	O
)	O
appears	O
to	O
be	O
the	O
most	O
promising	O
therapy	O
,	O
but	O
treatment	O
mortality	O
can	O
be	O
high	O
.	O

The	O
authors	O
have	O
noted	O
the	O
development	O
of	O
acute	B_Disease
renal	I_Disease
insufficiency	I_Disease
immediately	O
after	O
melphalan	B_Chemical
conditioning	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
further	O
examine	O
its	O
risk	O
factors	O
and	O
impact	O
on	O
posttransplant	O
mortality	O
.	O

METHODS	O
:	O
Consecutive	O
AL	B_Disease
patients	O
who	O
underwent	O
PBSCT	O
were	O
studied	O
retrospectively	O
.	O

Acute	B_Disease
renal	I_Disease
insufficiency	I_Disease
(	O
ARI	B_Disease
)	O
after	O
high-dose	O
melphalan	B_Chemical
was	O
defined	O
by	O
a	O
minimum	O
increase	O
of	O
0.5	O
mg/dL	O
(	O
44	O
micromol/L	O
)	O
in	O
the	O
serum	O
creatinine	B_Chemical
level	O
that	O
is	O
greater	O
than	O
50	O
%	O
of	O
baseline	O
immediately	O
after	O
conditioning	O
.	O

Urine	O
sediment	O
score	O
was	O
the	O
sum	O
of	O
the	O
individual	O
types	O
of	O
sediment	O
identified	O
on	O
urine	O
microscopy	O
.	O

RESULTS	O
:	O
Of	O
the	O
80	O
patients	O
studied	O
,	O
ARI	B_Disease
developed	O
in	O
18.8	O
%	O
of	O
the	O
patients	O
after	O
high-dose	O
melphalan	B_Chemical
.	O

Univariate	O
analysis	O
identified	O
age	O
,	O
hypoalbuminemia	B_Disease
,	O
heavy	O
proteinuria	B_Disease
,	O
diuretic	O
use	O
,	O
and	O
urine	O
sediment	O
score	O
(	O
>	O
3	O
)	O
as	O
risk	O
factors	O
.	O

Age	O
and	O
urine	O
sediment	O
score	O
remained	O
independently	O
significant	O
risk	O
factors	O
in	O
the	O
multivariate	O
analysis	O
.	O

Patients	O
who	O
had	O
ARI	B_Disease
after	O
high-dose	O
melphalan	B_Chemical
underwent	O
dialysis	O
more	O
often	O
(	O
P	O
=	O
0.007	O
)	O
,	O
and	O
had	O
a	O
worse	O
1-year	O
survival	O
(	O
P	O
=	O
0.03	O
)	O
.	O

CONCLUSION	O
:	O
The	O
timing	O
of	O
renal	B_Disease
injury	I_Disease
strongly	O
suggests	O
melphalan	B_Chemical
as	O
the	O
causative	O
agent	O
.	O

Ongoing	O
tubular	B_Disease
injury	I_Disease
may	O
be	O
a	O
prerequisite	O
for	O
renal	B_Disease
injury	I_Disease
by	O
melphalan	B_Chemical
as	O
evidenced	O
by	O
the	O
active	O
urinary	O
sediment	O
.	O

Development	O
of	O
ARI	B_Disease
adversely	O
affected	O
the	O
outcome	O
after	O
PBSCT	O
.	O

Effective	O
preventive	O
measures	O
may	O
help	O
decrease	O
the	O
treatment	O
mortality	O
of	O
PBSCT	O
in	O
AL	B_Disease
patients	O
.	O

Focal	O
cerebral	B_Disease
ischemia	I_Disease
in	O
rats	O
:	O
effect	O
of	O
phenylephrine-induced	O
hypertension	B_Disease
during	O
reperfusion	O
.	O

After	O
180	O
min	O
of	O
temporary	O
middle	B_Disease
cerebral	I_Disease
artery	I_Disease
occlusion	I_Disease
in	O
spontaneously	O
hypertensive	B_Disease
rats	O
,	O
the	O
effect	O
of	O
phenylephrine-induced	O
hypertension	B_Disease
on	O
ischemic	B_Disease
brain	I_Disease
injury	I_Disease
and	O
blood-brain	O
barrier	O
permeability	O
was	O
determined	O
.	O

Blood	O
pressure	O
was	O
manipulated	O
by	O
one	O
of	O
the	O
following	O
schedules	O
during	O
120	O
min	O
of	O
reperfusion	O
:	O
Control	O
,	O
normotensive	O
reperfusion	O
;	O
90/hypertension	O
(	O
90/HTN	O
)	O
,	O
blood	O
pressure	O
was	O
increased	O
by	O
35	O
mm	O
Hg	O
during	O
the	O
initial	O
90	O
min	O
of	O
reperfusion	O
only	O
;	O
15/hypertension	O
(	O
15/HTN	O
)	O
,	O
normotensive	O
reperfusion	O
for	O
30	O
min	O
followed	O
by	O
15	O
min	O
of	O
hypertension	B_Disease
and	O
75	O
min	O
of	O
normotension	O
.	O

Part	O
A	O
,	O
for	O
eight	O
rats	O
in	O
each	O
group	O
brain	B_Disease
injury	I_Disease
was	O
evaluated	O
by	O
staining	O
tissue	O
using	O
2,3,5-triphenyltetrazolium	B_Chemical
chloride	I_Chemical
and	O
edema	B_Disease
was	O
evaluated	O
by	O
microgravimetry	O
.	O

Part	O
B	O
,	O
for	O
eight	O
different	O
rats	O
in	O
each	O
group	O
blood-brain	O
barrier	O
permeability	O
was	O
evaluated	O
by	O
measuring	O
the	O
amount	O
and	O
extent	O
of	O
extravasation	O
of	O
Evans	O
Blue	O
dye	O
.	O

Brain	B_Disease
injury	I_Disease
(	O
percentage	O
of	O
the	O
ischemic	B_Disease
hemisphere	I_Disease
)	O
was	O
less	O
in	O
the	O
15/HTN	O
group	O
(	O
16	O
+	O
/-	O
6	O
,	O
mean	O
+	O
/-	O
SD	O
)	O
versus	O
the	O
90/HTN	O
group	O
(	O
30	O
+	O
/-	O
6	O
)	O
,	O
which	O
was	O
in	O
turn	O
less	O
than	O
the	O
control	O
group	O
(	O
42	O
+	O
/-	O
5	O
)	O
.	O

Specific	O
gravity	O
was	O
greater	O
in	O
the	O
15/HTN	O
group	O
(	O
1.043	O
+	O
/-	O
0.002	O
)	O
versus	O
the	O
90/HTN	O
(	O
1.036	O
+	O
/-	O
0.003	O
)	O
and	O
control	O
(	O
1.037	O
+	O
/-	O
0.003	O
)	O
groups	O
.	O

Evans	B_Chemical
Blue	I_Chemical
(	O
mug	O
g-1	O
of	O
brain	O
tissue	O
)	O
was	O
greater	O
in	O
the	O
90/HTN	O
group	O
(	O
24.4	O
+	O
/-	O
6.0	O
)	O
versus	O
the	O
control	O
group	O
(	O
12.3	O
+	O
/-	O
4.1	O
)	O
,	O
which	O
was	O
in	O
turn	O
greater	O
than	O
the	O
15/HTN	O
group	O
(	O
7.3	O
+	O
/-	O
3.2	O
)	O
.	O

This	O
study	O
supports	O
a	O
hypothesis	O
that	O
during	O
reperfusion	O
,	O
a	O
short	O
interval	O
of	O
hypertension	B_Disease
decreases	O
brain	B_Disease
injury	I_Disease
and	O
edema	B_Disease
;	O
and	O
that	O
sustained	O
hypertension	B_Disease
increases	O
the	O
risk	O
of	O
vasogenic	B_Disease
edema	I_Disease
.	O

People	O
aged	O
over	O
75	O
in	O
atrial	B_Disease
fibrillation	I_Disease
on	O
warfarin	B_Chemical
:	O
the	O
rate	O
of	O
major	O
hemorrhage	B_Disease
and	O
stroke	B_Disease
in	O
more	O
than	O
500	O
patient-years	O
of	O
follow-up	O
.	O

OBJECTIVES	O
:	O
To	O
determine	O
the	O
incidence	O
of	O
major	O
hemorrhage	B_Disease
and	O
stroke	B_Disease
in	O
people	O
aged	O
76	O
and	O
older	O
with	O
atrial	B_Disease
fibrillation	I_Disease
on	O
adjusted-dose	O
warfarin	B_Chemical
who	O
had	O
been	O
recently	O
been	O
admitted	O
to	O
hospital	O
.	O

DESIGN	O
:	O
A	O
retrospective	O
observational	O
cohort	O
study	O
.	O

SETTING	O
:	O
A	O
major	O
healthcare	O
network	O
involving	O
four	O
tertiary	O
hospitals	O
.	O

PARTICIPANTS	O
:	O
Two	O
hundred	O
thirty-five	O
patients	O
aged	O
76	O
and	O
older	O
admitted	O
to	O
a	O
major	O
healthcare	O
network	O
between	O
July	O
1	O
,	O
2001	O
,	O
and	O
June	O
30	O
,	O
2002	O
,	O
with	O
atrial	B_Disease
fibrillation	I_Disease
on	O
warfarin	B_Chemical
were	O
enrolled	O
.	O

MEASUREMENTS	O
:	O
Information	O
regarding	O
major	O
bleeding	B_Disease
episodes	O
,	O
strokes	B_Disease
,	O
and	O
warfarin	B_Chemical
use	O
was	O
obtained	O
from	O
patients	O
,	O
relatives	O
,	O
primary	O
physicians	O
,	O
and	O
medical	O
records	O
.	O

RESULTS	O
:	O
Two	O
hundred	O
twenty-eight	O
patients	O
(	O
42	O
%	O
men	O
)	O
with	O
a	O
mean	O
age	O
of	O
81.1	O
(	O
range	O
76	O
-	O
94	O
)	O
were	O
included	O
in	O
the	O
analysis	O
.	O

Total	O
follow-up	O
on	O
warfarin	B_Chemical
was	O
530	O
years	O
(	O
mean	O
28	O
months	O
)	O
.	O

There	O
were	O
53	O
major	O
hemorrhages	B_Disease
,	O
for	O
an	O
annual	O
rate	O
of	O
10.0	O
%	O
,	O
including	O
24	O
(	O
45.3	O
%	O
)	O
life-threatening	O
and	O
five	O
(	O
9.4	O
%	O
)	O
fatal	O
bleeds	O
.	O

The	O
annual	O
stroke	B_Disease
rate	O
after	O
initiation	O
of	O
warfarin	B_Chemical
was	O
2.6	O
%	O
.	O

CONCLUSION	O
:	O
The	O
rate	O
of	O
major	O
hemorrhage	B_Disease
was	O
high	O
in	O
this	O
old	O
,	O
frail	O
group	O
,	O
but	O
excluding	O
fatalities	O
,	O
resulted	O
in	O
no	O
long-term	O
sequelae	O
,	O
and	O
the	O
stroke	B_Disease
rate	O
on	O
warfarin	B_Chemical
was	O
low	O
,	O
demonstrating	O
how	O
effective	O
warfarin	B_Chemical
treatment	O
is	O
.	O

Safety	O
of	O
celecoxib	B_Chemical
in	O
patients	O
with	O
adverse	O
skin	B_Disease
reactions	I_Disease
to	O
acetaminophen	B_Chemical
(	O
paracetamol	B_Chemical
)	O
and	O
nimesulide	B_Chemical
associated	O
or	O
not	O
with	O
common	O
non-steroidal	O
anti-inflammatory	O
drugs	O
.	O

BACKGROUND	O
:	O
Acetaminophen	B_Chemical
(	O
paracetamol	B_Chemical
--	O
P	B_Chemical
)	O
and	O
Nimesulide	B_Chemical
(	O
N	B_Chemical
)	O
are	O
widely	O
used	O
analgesic-antipyretic/anti-inflammatory	O
drugs	O
.	O

The	O
rate	O
of	O
adverse	O
hypersensitivity	B_Disease
reactions	O
to	O
these	O
agents	O
is	O
generally	O
low	O
.	O

On	O
the	O
contrary	O
non-steroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
are	O
commonly	O
involved	O
in	O
such	O
reactions	O
.	O

Celecoxib	B_Chemical
(	O
CE	B_Chemical
)	O
is	O
a	O
novel	O
drug	O
,	O
with	O
high	O
selectivity	O
and	O
affinity	O
for	O
COX-2	O
enzyme	O
.	O

OBJECTIVE	O
:	O
We	O
evaluated	O
the	O
tolerability	O
of	O
CE	B_Chemical
in	O
a	O
group	O
of	O
patients	O
with	O
documented	O
history	O
of	O
adverse	O
cutaneous	B_Disease
reactions	I_Disease
to	O
P	B_Chemical
and	O
N	B_Chemical
associated	O
or	O
not	O
to	O
classic	O
NSAIDs	O
.	O

METHODS	O
:	O
We	O
studied	O
9	O
patients	O
with	O
hypersensitivity	B_Disease
to	O
P	B_Chemical
and	O
N	B_Chemical
with	O
or	O
without	O
associated	O
reactions	O
to	O
classic	O
NSAIDs	O
.	O

The	O
diagnosis	O
of	O
P	B_Chemical
and	O
N-induced	O
skin	B_Disease
reactions	I_Disease
was	O
based	O
in	O
vivo	O
challenge	O
.	O

The	O
placebo	O
was	O
blindly	O
administered	O
at	O
the	O
beginning	O
of	O
each	O
challenge	O
.	O

After	O
three	O
days	O
,	O
a	O
cumulative	O
dosage	O
of	O
200	O
mg	O
of	O
CE	B_Chemical
in	O
refracted	O
doses	O
were	O
given	O
.	O

After	O
2	O
-	O
3	O
days	O
,	O
a	O
single	O
dose	O
of	O
200	O
mg	O
was	O
administered	O
.	O

All	O
patients	O
were	O
observed	O
for	O
6	O
hours	O
after	O
each	O
challenge	O
,	O
and	O
controlled	O
again	O
after	O
24	O
hours	O
to	O
exclude	O
delayed	O
reactions	O
.	O

The	O
challenge	O
was	O
considered	O
positive	O
if	O
one	O
or	O
more	O
of	O
the	O
following	O
appeared	O
:	O
erythema	B_Disease
,	O
rush	O
or	O
urticaria-angioedema	O
.	O

RESULTS	O
:	O
No	O
reaction	O
was	O
observed	O
with	O
placebo	O
and	O
eight	O
patients	O
(	O
88.8	O
%	O
)	O
tolerated	O
CE	B_Chemical
.	O

Only	O
one	O
patient	O
developed	O
a	O
moderate	O
angioedema	B_Disease
of	O
the	O
lips	O
.	O

CONCLUSION	O
:	O
Only	O
one	O
hypersensitivity	B_Disease
reaction	O
to	O
CE	B_Chemical
was	O
documented	O
among	O
9	O
P	B_Chemical
and	O
N-highly	O
NSAIDs	O
intolerant	O
patients	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
CE	B_Chemical
is	O
a	O
reasonably	O
safe	O
alternative	O
to	O
be	O
used	O
in	O
subjects	O
who	O
do	O
not	O
tolerate	O
P	B_Chemical
and	O
N.	O

Case-control	O
study	O
of	O
regular	O
analgesic	O
and	O
nonsteroidal	O
anti-inflammatory	O
use	O
and	O
end-stage	O
renal	O
disease	O
.	O

BACKGROUND	O
:	O
Studies	O
on	O
the	O
association	O
between	O
the	O
long-term	O
use	O
of	O
aspirin	B_Chemical
and	O
other	O
analgesic	O
and	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
and	O
end-stage	B_Disease
renal	I_Disease
disease	I_Disease
(	O
ESRD	B_Disease
)	O
have	O
given	O
conflicting	O
results	O
.	O

In	O
order	O
to	O
examine	O
this	O
association	O
,	O
a	O
case-control	O
study	O
with	O
incident	O
cases	O
of	O
ESRD	B_Disease
was	O
carried	O
out	O
.	O

METHODS	O
:	O
The	O
cases	O
were	O
all	O
patients	O
entering	O
the	O
local	O
dialysis	O
program	O
because	O
of	O
ESRD	B_Disease
in	O
the	O
study	O
area	O
between	O
June	O
1	O
,	O
1995	O
and	O
November	O
30	O
,	O
1997	O
.	O
They	O
were	O
classified	O
according	O
to	O
the	O
underlying	O
disease	O
,	O
which	O
had	O
presumably	O
led	O
them	O
to	O
ESRD	B_Disease
.	O

Controls	O
were	O
patients	O
admitted	O
to	O
the	O
same	O
hospitals	O
from	O
where	O
the	O
cases	O
arose	O
,	O
also	O
matched	O
by	O
age	O
and	O
sex	O
.	O

Odds	O
ratios	O
were	O
calculated	O
using	O
a	O
conditional	O
logistic	O
model	O
,	O
including	O
potential	O
confounding	O
factors	O
,	O
both	O
for	O
the	O
whole	O
study	O
population	O
and	O
for	O
the	O
various	O
underlying	O
diseases	O
.	O

RESULTS	O
:	O
Five	O
hundred	O
and	O
eighty-three	O
cases	O
and	O
1190	O
controls	O
were	O
included	O
in	O
the	O
analysis	O
.	O

Long-term	O
use	O
of	O
any	O
analgesic	O
was	O
associated	O
with	O
an	O
overall	O
odds	O
ratio	O
of	O
1.22	O
(	O
95	O
%	O
CI	O
,	O
0.89	O
-	O
1.66	O
)	O
.	O

For	O
specific	O
groups	O
of	O
drugs	O
,	O
the	O
risks	O
were	O
1.56	O
(	O
1.05	O
-	O
2.30	O
)	O
for	O
aspirin	B_Chemical
,	O
1.03	O
(	O
0.60	O
-	O
1.76	O
)	O
for	O
pyrazolones	B_Chemical
,	O
0.80	O
(	O
0.39	O
-	O
1.63	O
)	O
for	O
paracetamol	B_Chemical
,	O
and	O
0.94	O
(	O
0.57	O
-	O
1.56	O
)	O
for	O
nonaspirin	O
NSAIDs	O
.	O

The	O
risk	O
of	O
ESRD	B_Disease
associated	O
with	O
aspirin	B_Chemical
was	O
related	O
to	O
the	O
cumulated	O
dose	O
and	O
duration	O
of	O
use	O
,	O
and	O
it	O
was	O
particularly	O
high	O
among	O
the	O
subset	O
of	O
patients	O
with	O
vascular	O
nephropathy	B_Disease
as	O
underlying	O
disease	O
[	O
2.35	O
(	O
1.17	O
-	O
4.72	O
)	O
]	O
.	O

CONCLUSION	O
:	O
Our	O
data	O
indicate	O
that	O
long-term	O
use	O
of	O
nonaspirin	O
analgesic	O
drugs	O
and	O
NSAIDs	O
is	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
ESRD	B_Disease
.	O

However	O
,	O
the	O
chronic	O
use	O
of	O
aspirin	B_Chemical
may	O
increase	O
the	O
risk	O
of	O
ESRD	B_Disease
.	O

Two	O
cases	O
of	O
amisulpride	B_Chemical
overdose	B_Disease
:	O
a	O
cause	O
for	O
prolonged	B_Disease
QT	I_Disease
syndrome	I_Disease
.	O

Two	O
cases	O
of	O
deliberate	O
self-poisoning	O
with	O
5	O
g	O
and	O
3.6	O
g	O
of	O
amisulpride	B_Chemical
,	O
respectively	O
,	O
are	O
reported	O
.	O

In	O
both	O
cases	O
,	O
QT	B_Disease
prolongation	I_Disease
and	O
hypocalcaemia	B_Disease
were	O
noted	O
.	O

The	O
QT	B_Disease
prolongation	I_Disease
appeared	O
to	O
respond	O
to	O
administration	O
of	O
i.v	O
.	O
calcium	B_Chemical
gluconate	I_Chemical
.	O

Growth-associated	O
protein	O
43	O
expression	O
in	O
hippocampal	O
molecular	O
layer	O
of	O
chronic	O
epileptic	B_Disease
rats	O
treated	O
with	O
cycloheximide	B_Chemical
.	O

PURPOSE	O
:	O
GAP43	O
has	O
been	O
thought	O
to	O
be	O
linked	O
with	O
mossy	O
fiber	O
sprouting	O
(	O
MFS	O
)	O
in	O
various	O
experimental	O
models	O
of	O
epilepsy	B_Disease
.	O

To	O
investigate	O
how	O
GAP43	O
expression	O
(	O
GAP43-ir	O
)	O
correlates	O
with	O
MFS	O
,	O
we	O
assessed	O
the	O
intensity	O
(	O
densitometry	O
)	O
and	O
extension	O
(	O
width	O
)	O
of	O
GAP43-ir	O
in	O
the	O
inner	O
molecular	O
layer	O
of	O
the	O
dentate	O
gyrus	O
(	O
IML	O
)	O
of	O
rats	O
subject	O
to	O
status	B_Disease
epilepticus	I_Disease
induced	O
by	O
pilocarpine	B_Chemical
(	O
Pilo	B_Chemical
)	O
,	O
previously	O
injected	O
or	O
not	O
with	O
cycloheximide	B_Chemical
(	O
CHX	B_Chemical
)	O
,	O
which	O
has	O
been	O
shown	O
to	O
inhibit	O
MFS	O
.	O

METHODS	O
:	O
CHX	B_Chemical
was	O
injected	O
before	O
the	O
Pilo	B_Chemical
injection	O
in	O
adult	O
Wistar	O
rats	O
.	O

The	O
Pilo	B_Chemical
group	O
was	O
injected	O
with	O
the	O
same	O
drugs	O
,	O
except	O
for	O
CHX	B_Chemical
.	O

Animals	O
were	O
killed	O
between	O
30	O
and	O
60	O
days	O
later	O
,	O
and	O
brain	O
sections	O
were	O
processed	O
for	O
GAP43	O
immunohistochemistry	O
.	O

RESULTS	O
:	O
Densitometry	O
showed	O
no	O
significant	O
difference	O
regarding	O
GAP43-ir	O
in	O
the	O
IML	O
between	O
Pilo	B_Chemical
,	O
CHX+Pilo	O
,	O
and	O
control	O
groups	O
.	O

However	O
,	O
the	O
results	O
of	O
the	O
width	O
of	O
the	O
GAP43-ir	O
band	O
in	O
the	O
IML	O
showed	O
that	O
CHX+Pilo	O
and	O
control	O
animals	O
had	O
a	O
significantly	O
larger	O
band	O
(	O
p	O
=	O
0.03	O
)	O
as	O
compared	O
with	O
that	O
in	O
the	O
Pilo	B_Chemical
group	O
.	O

CONCLUSIONS	O
:	O
Our	O
current	O
finding	O
that	O
animals	O
in	O
the	O
CHX+Pilo	O
group	O
have	O
a	O
GAP43-ir	O
band	O
in	O
the	O
IML	O
,	O
similar	O
to	O
that	O
of	O
controls	O
,	O
reinforces	O
prior	O
data	O
on	O
the	O
blockade	O
of	O
MFS	O
in	O
these	O
animals	O
.	O

The	O
change	O
in	O
GAP43-ir	O
present	O
in	O
Pilo-treated	O
animals	O
was	O
a	O
thinning	O
of	O
the	O
band	O
to	O
a	O
very	O
narrow	O
layer	O
just	O
above	O
the	O
granule	O
cell	O
layer	O
that	O
is	O
likely	O
to	O
be	O
associated	O
with	O
the	O
loss	O
of	O
hilar	O
cell	O
projections	O
that	O
express	O
GAP-43	O
.	O

Nicotine	B_Chemical
antagonizes	O
caffeine-	O
but	O
not	O
pentylenetetrazole-induced	O
anxiogenic	O
effect	O
in	O
mice	O
.	O

RATIONALE	O
:	O
Nicotine	B_Chemical
and	O
caffeine	B_Chemical
are	O
widely	O
consumed	O
licit	O
psychoactive	O
drugs	O
worldwide	O
.	O

Epidemiological	O
studies	O
showed	O
that	O
they	O
were	O
generally	O
used	O
concurrently	O
.	O

Although	O
some	O
studies	O
in	O
experimental	O
animals	O
indicate	O
clear	O
pharmacological	O
interactions	O
between	O
them	O
,	O
no	O
studies	O
have	O
shown	O
a	O
specific	O
interaction	O
on	O
anxiety	B_Disease
responses	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
study	O
investigates	O
the	O
effects	O
of	O
nicotine	B_Chemical
on	O
anxiety	B_Disease
induced	O
by	O
caffeine	B_Chemical
and	O
another	O
anxiogenic	O
drug	O
,	O
pentylenetetrazole	B_Chemical
,	O
in	O
mice	O
.	O

The	O
elevated	O
plus-maze	O
(	O
EPM	O
)	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
effects	O
of	O
drugs	O
on	O
anxiety	B_Disease
.	O

METHODS	O
:	O
Adult	O
male	O
Swiss	O
Webster	O
mice	O
(	O
25	O
-	O
32	O
g	O
)	O
were	O
given	O
nicotine	B_Chemical
(	O
0.05	O
-	O
0.25	O
mg/kg	O
s.c	O
.	O
)	O
or	O
saline	O
10	O
min	O
before	O
caffeine	B_Chemical
(	O
70	O
mg/kg	O
i.p	O
.	O
)	O
or	O
pentylenetetrazole	B_Chemical
(	O
15	O
and	O
30	O
mg/kg	O
i.p	O
.	O
)	O
injections	O
.	O

After	O
15	O
min	O
,	O
mice	O
were	O
evaluated	O
for	O
their	O
open-	O
and	O
closed-arm	O
time	O
and	O
entries	O
on	O
the	O
EPM	O
for	O
a	O
10-min	O
session	O
.	O

Locomotor	O
activity	O
was	O
recorded	O
for	O
individual	O
groups	O
by	O
using	O
the	O
same	O
treatment	O
protocol	O
with	O
the	O
EPM	O
test	O
.	O

RESULTS	O
:	O
Nicotine	B_Chemical
(	O
0.05	O
-	O
0.25	O
mg/kg	O
)	O
itself	O
did	O
not	O
produce	O
any	O
significant	O
effect	O
in	O
the	O
EPM	O
test	O
,	O
whereas	O
caffeine	B_Chemical
(	O
70	O
mg/kg	O
)	O
and	O
pentylenetetrazole	B_Chemical
(	O
30	O
mg/kg	O
)	O
produced	O
an	O
anxiogenic	O
effect	O
,	O
apparent	O
with	O
decreases	O
in	O
open-arm	O
time	O
and	O
entry	O
.	O

Nicotine	B_Chemical
(	O
0.25	O
mg/kg	O
)	O
pretreatment	O
blocked	O
the	O
caffeine-	O
but	O
not	O
pentylenetetrazole-induced	O
anxiety	B_Disease
.	O

Administration	O
of	O
each	O
drug	O
and	O
their	O
combinations	O
did	O
not	O
produce	O
any	O
effect	O
on	O
locomotor	O
activity	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
antagonistic	O
effect	O
of	O
nicotine	B_Chemical
on	O
caffeine-induced	O
anxiety	B_Disease
is	O
specific	O
to	O
caffeine	B_Chemical
,	O
instead	O
of	O
a	O
non-specific	O
anxiolytic	O
effect	O
.	O

Thus	O
,	O
it	O
may	O
extend	O
the	O
current	O
findings	O
on	O
the	O
interaction	O
between	O
nicotine	B_Chemical
and	O
caffeine	B_Chemical
.	O

Long	O
term	O
hormone	O
therapy	O
for	O
perimenopausal	O
and	O
postmenopausal	O
women	O
.	O

BACKGROUND	O
:	O
Hormone	O
therapy	O
(	O
HT	O
)	O
is	O
widely	O
used	O
for	O
controlling	O
menopausal	B_Disease
symptoms	I_Disease
.	O

It	O
has	O
also	O
been	O
used	O
for	O
the	O
management	O
and	O
prevention	O
of	O
cardiovascular	B_Disease
disease	I_Disease
,	O
osteoporosis	B_Disease
and	O
dementia	B_Disease
in	O
older	O
women	O
but	O
the	O
evidence	O
supporting	O
its	O
use	O
for	O
these	O
indications	O
is	O
largely	O
observational	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
effect	O
of	O
long-term	O
HT	O
on	O
mortality	O
,	O
heart	B_Disease
disease	I_Disease
,	O
venous	B_Disease
thromboembolism	I_Disease
,	O
stroke	B_Disease
,	O
transient	B_Disease
ischaemic	I_Disease
attacks	I_Disease
,	O
breast	B_Disease
cancer	I_Disease
,	O
colorectal	B_Disease
cancer	I_Disease
,	O
ovarian	B_Disease
cancer	I_Disease
,	O
endometrial	B_Disease
cancer	I_Disease
,	O
gallbladder	B_Disease
disease	I_Disease
,	O
cognitive	O
function	O
,	O
dementia	B_Disease
,	O
fractures	B_Disease
and	O
quality	O
of	O
life	O
.	O

SEARCH	O
STRATEGY	O
:	O
We	O
searched	O
the	O
following	O
databases	O
up	O
to	O
November	O
2004	O
:	O
the	O
Cochrane	O
Menstrual	O
Disorders	O
and	O
Subfertility	O
Group	O
Trials	O
Register	O
,	O
Cochrane	O
Central	O
Register	O
of	O
Controlled	O
Trials	O
(	O
CENTRAL	O
)	O
,	O
MEDLINE	O
,	O
EMBASE	O
,	O
Biological	O
Abstracts	O
.	O

Relevant	O
non-indexed	O
journals	O
and	O
conference	O
abstracts	O
were	O
also	O
searched	O
.	O

SELECTION	O
CRITERIA	O
:	O
Randomised	O
double-blind	O
trials	O
of	O
HT	O
(	O
oestrogens	B_Chemical
with	O
or	O
without	O
progestogens	B_Chemical
)	O
versus	O
placebo	O
,	O
taken	O
for	O
at	O
least	O
one	O
year	O
by	O
perimenopausal	O
or	O
postmenopausal	O
women	O
.	O

DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O
Fifteen	O
RCTs	O
were	O
included	O
.	O

Trials	O
were	O
assessed	O
for	O
quality	O
and	O
two	O
review	O
authors	O
extracted	O
data	O
independently	O
.	O

They	O
calculated	O
risk	O
ratios	O
for	O
dichotomous	O
outcomes	O
and	O
weighted	O
mean	O
differences	O
for	O
continuous	O
outcomes	O
.	O

Clinical	O
heterogeneity	O
precluded	O
meta-analysis	O
for	O
most	O
outcomes	O
.	O

MAIN	O
RESULTS	O
:	O
All	O
the	O
statistically	O
significant	O
results	O
were	O
derived	O
from	O
the	O
two	O
biggest	O
trials	O
.	O

In	O
relatively	O
healthy	O
women	O
,	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	B_Disease
thromboembolism	I_Disease
or	O
coronary	O
event	O
(	O
after	O
one	O
year	O
's	O
use	O
)	O
,	O
stroke	B_Disease
(	O
after	O
3	O
years	O
)	O
,	O
breast	B_Disease
cancer	I_Disease
(	O
after	O
5	O
years	O
)	O
and	O
gallbladder	B_Disease
disease	I_Disease
.	O

Long-term	O
oestrogen-only	O
HT	O
also	O
significantly	O
increased	O
the	O
risk	O
of	O
stroke	B_Disease
and	O
gallbladder	B_Disease
disease	I_Disease
.	O

Overall	O
,	O
the	O
only	O
statistically	O
significant	O
benefits	O
of	O
HT	O
were	O
a	O
decreased	O
incidence	O
of	O
fractures	B_Disease
and	O
colon	B_Disease
cancer	I_Disease
with	O
long-term	O
use	O
.	O

Among	O
relatively	O
healthy	O
women	O
over	O
65	O
years	O
taking	O
continuous	O
combined	O
HT	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
increase	O
in	O
the	O
incidence	O
of	O
dementia	B_Disease
.	O

Among	O
women	O
with	O
cardiovascular	B_Disease
disease	I_Disease
,	O
long-term	O
use	O
of	O
combined	O
continuous	O
HT	O
significantly	O
increased	O
the	O
risk	O
of	O
venous	B_Disease
thromboembolism	I_Disease
.	O

No	O
trials	O
focussed	O
specifically	O
on	O
younger	O
women	O
.	O

However	O
,	O
one	O
trial	O
analysed	O
subgroups	O
of	O
2839	O
relatively	O
healthy	O
50	O
to	O
59	O
year-old	O
women	O
taking	O
combined	O
continuous	O
HT	O
and	O
1637	O
taking	O
oestrogen-only	O
HT	O
,	O
versus	O
similar-sized	O
placebo	O
groups	O
.	O

The	O
only	O
significantly	O
increased	O
risk	O
reported	O
was	O
for	O
venous	B_Disease
thromboembolism	I_Disease
in	O
women	O
taking	O
combined	O
continuous	O
HT	O
;	O
their	O
absolute	O
risk	O
remained	O
very	O
low	O
.	O
AUTHORS	O
'	O
CONCLUSIONS	O
:	O
HT	O
is	O
not	O
indicated	O
for	O
the	O
routine	O
management	O
of	O
chronic	B_Disease
disease	I_Disease
.	O

We	O
need	O
more	O
evidence	O
on	O
the	O
safety	O
of	O
HT	O
for	O
menopausal	O
symptom	O
control	O
,	O
though	O
short-term	O
use	O
appears	O
to	O
be	O
relatively	O
safe	O
for	O
healthy	O
younger	O
women	O
.	O

Drug-induced	O
liver	O
injury	O
:	O
an	O
analysis	O
of	O
461	O
incidences	O
submitted	O
to	O
the	O
Spanish	O
registry	O
over	O
a	O
10-year	O
period	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
Progress	O
in	O
the	O
understanding	O
of	O
susceptibility	O
factors	O
to	O
drug-induced	B_Disease
liver	I_Disease
injury	I_Disease
(	O
DILI	B_Disease
)	O
and	O
outcome	O
predictability	O
are	O
hampered	O
by	O
the	O
lack	O
of	O
systematic	O
programs	O
to	O
detect	O
bona	O
fide	O
cases	O
.	O

METHODS	O
:	O
A	O
cooperative	O
network	O
was	O
created	O
in	O
1994	O
in	O
Spain	O
to	O
identify	O
all	O
suspicions	O
of	O
DILI	B_Disease
following	O
a	O
prospective	O
structured	O
report	O
form	O
.	O

The	O
liver	B_Disease
damage	I_Disease
was	O
characterized	O
according	O
to	O
hepatocellular	O
,	O
cholestatic	B_Disease
,	O
and	O
mixed	O
laboratory	O
criteria	O
and	O
to	O
histologic	O
criteria	O
when	O
available	O
.	O

Further	O
evaluation	O
of	O
causality	O
assessment	O
was	O
centrally	O
performed	O
.	O

RESULTS	O
:	O
Since	O
April	O
1994	O
to	O
August	O
2004	O
,	O
461	O
out	O
of	O
570	O
submitted	O
cases	O
,	O
involving	O
505	O
drugs	O
,	O
were	O
deemed	O
to	O
be	O
related	O
to	O
DILI	B_Disease
.	O

The	O
antiinfective	O
group	O
of	O
drugs	O
was	O
the	O
more	O
frequently	O
incriminated	O
,	O
amoxicillin-clavulanate	B_Chemical
accounting	O
for	O
the	O
12.8	O
%	O
of	O
the	O
whole	O
series	O
.	O

The	O
hepatocellular	O
pattern	O
of	O
damage	O
was	O
the	O
most	O
common	O
(	O
58	O
%	O
)	O
,	O
was	O
inversely	O
correlated	O
with	O
age	O
(	O
P	O
<	O
.0001	O
)	O
,	O
and	O
had	O
the	O
worst	O
outcome	O
(	O
Cox	O
regression	O
,	O
P	O
<	O
.034	O
)	O
.	O

Indeed	O
,	O
the	O
incidence	O
of	O
liver	O
transplantation	O
and	O
death	O
in	O
this	O
group	O
was	O
11.7	O
%	O
if	O
patients	O
had	O
jaundice	B_Disease
at	O
presentation	O
,	O
whereas	O
the	O
corresponding	O
figure	O
was	O
3.8	O
%	O
in	O
nonjaundiced	O
patients	O
(	O
P	O
<	O
.04	O
)	O
.	O

Factors	O
associated	O
with	O
the	O
development	O
of	O
fulminant	B_Disease
hepatic	I_Disease
failure	I_Disease
were	O
female	O
sex	O
(	O
OR	O
=	O
25	O
;	O
95	O
%	O
CI	O
:	O
4.1	O
-	O
151	O
;	O
P	O
<	O
.0001	O
)	O
,	O
hepatocellular	O
damage	O
(	O
OR	O
=	O
7.9	O
;	O
95	O
%	O
CI	O
:	O
1.6	O
-	O
37	O
;	O
P	O
<	O
.009	O
)	O
,	O
and	O
higher	O
baseline	O
plasma	O
bilirubin	B_Chemical
value	O
(	O
OR	O
=	O
1.15	O
;	O
95	O
%	O
CI	O
:	O
1.09	O
-	O
1.22	O
;	O
P	O
<	O
.0001	O
)	O
.	O

CONCLUSIONS	O
:	O
Patients	O
with	O
drug-induced	O
hepatocellular	O
jaundice	B_Disease
have	O
11.7	O
%	O
chance	O
of	O
progressing	O
to	O
death	O
or	O
transplantation	O
.	O

Amoxicillin-clavulanate	B_Chemical
stands	O
out	O
as	O
the	O
most	O
common	O
drug	O
related	O
to	O
DILI	B_Disease
.	O

Morphological	O
evaluation	O
of	O
the	O
effect	O
of	O
d-ribose	B_Chemical
on	O
adriamycin-evoked	O
cardiotoxicity	B_Disease
in	O
rats	O
.	O

The	O
influence	O
of	O
d-ribose	B_Chemical
on	O
adriamycin-induced	O
myocardiopathy	B_Disease
in	O
rats	O
was	O
studied	O
.	O

Adriamycin	B_Chemical
in	O
the	O
cumulative	O
dose	O
of	O
25	O
mg/kg	O
evoked	O
fully	O
developed	O
cardiac	B_Disease
toxicity	I_Disease
.	O

D-ribose	B_Chemical
in	O
the	O
multiple	O
doses	O
of	O
200	O
mg/kg	O
did	O
not	O
influence	O
ADR	B_Chemical
cardiotoxicity	B_Disease
.	O

In	O
vivo	O
evidences	O
suggesting	O
the	O
role	O
of	O
oxidative	O
stress	O
in	O
pathogenesis	O
of	O
vancomycin-induced	O
nephrotoxicity	B_Disease
:	O
protection	O
by	O
erdosteine	B_Chemical
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
examine	O
vancomycin	B_Chemical
(VCM)-induced	O
oxidative	O
stress	O
that	O
promotes	O
production	O
of	O
reactive	O
oxygen	B_Chemical
species	O
(	O
ROS	O
)	O
and	O
to	O
investigate	O
the	O
role	O
of	O
erdosteine	B_Chemical
,	O
an	O
expectorant	O
agent	O
,	O
which	O
has	O
also	O
antioxidant	O
properties	O
,	O
on	O
kidney	O
tissue	O
against	O
the	O
possible	O
VCM-induced	O
renal	B_Disease
impairment	I_Disease
in	O
rats	O
.	O

Rats	O
were	O
divided	O
into	O
three	O
groups	O
:	O
sham	O
,	O
VCM	B_Chemical
and	O
VCM	B_Chemical
plus	O
erdosteine	B_Chemical
.	O

VCM	B_Chemical
was	O
administrated	O
intraperitoneally	O
(	O
i.p	O
.	O
)	O
with	O
200mgkg(-1	O
)	O
twice	O
daily	O
for	O
7	O
days	O
.	O

Erdosteine	B_Chemical
was	O
administered	O
orally	O
.	O

VCM	B_Chemical
administration	O
to	O
control	O
rats	O
significantly	O
increased	O
renal	O
malondialdehyde	B_Chemical
(	O
MDA	B_Chemical
)	O
and	O
urinary	O
N-acetyl-beta-d-glucosaminidase	O
(	O
NAG	O
,	O
a	O
marker	O
of	O
renal	B_Disease
tubular	I_Disease
injury	I_Disease
)	O
excretion	O
but	O
decreased	O
superoxide	B_Chemical
dismutase	O
(	O
SOD	O
)	O
and	O
catalase	O
(	O
CAT	O
)	O
activities	O
.	O

Erdosteine	B_Chemical
administration	O
with	O
VCM	B_Chemical
injections	O
caused	O
significantly	O
decreased	O
renal	O
MDA	B_Chemical
and	O
urinary	O
NAG	O
excretion	O
,	O
and	O
increased	O
SOD	O
activity	O
,	O
but	O
not	O
CAT	O
activity	O
in	O
renal	O
tissue	O
when	O
compared	O
with	O
VCM	B_Chemical
alone	O
.	O

Erdosteine	B_Chemical
showed	O
histopathological	O
protection	O
against	O
VCM-induced	O
nephrotoxicity	B_Disease
.	O

There	O
were	O
a	O
significant	O
dilatation	O
of	O
tubular	O
lumens	O
,	O
extensive	O
epithelial	O
cell	O
vacuolization	O
,	O
atrophy	B_Disease
,	O
desquamation	B_Disease
,	O
and	O
necrosis	B_Disease
in	O
VCM-treated	O
rats	O
more	O
than	O
those	O
of	O
the	O
control	O
and	O
the	O
erdosteine	B_Chemical
groups	O
.	O

Erdosteine	B_Chemical
caused	O
a	O
marked	O
reduction	O
in	O
the	O
extent	O
of	O
tubular	O
damage	O
.	O

It	O
is	O
concluded	O
that	O
oxidative	O
tubular	O
damage	O
plays	O
an	O
important	O
role	O
in	O
the	O
VCM-induced	O
nephrotoxicity	B_Disease
and	O
the	O
modulation	O
of	O
oxidative	O
stress	O
with	O
erdosteine	B_Chemical
reduces	O
the	O
VCM-induced	O
kidney	B_Disease
damage	I_Disease
both	O
at	O
the	O
biochemical	O
and	O
histological	O
levels	O
.	O

Gemfibrozil-lovastatin	O
therapy	O
for	O
primary	O
hyperlipoproteinemias	B_Disease
.	O

The	O
specific	O
aim	O
of	O
this	O
retrospective	O
,	O
observational	O
study	O
was	O
to	O
assess	O
safety	O
and	O
efficacy	O
of	O
long-term	O
(	O
21	O
months/patient	O
)	O
,	O
open-label	O
,	O
gemfibrozil-lovastatin	O
treatment	O
in	O
80	O
patients	O
with	O
primary	O
mixed	O
hyperlipidemia	B_Disease
(	O
68	O
%	O
of	O
whom	O
had	O
atherosclerotic	B_Disease
vascular	I_Disease
disease	I_Disease
)	O
.	O

Because	O
ideal	O
lipid	O
targets	O
were	O
not	O
reached	O
(	O
low-density	O
lipoprotein	O
(	O
LDL	O
)	O
cholesterol	B_Chemical
less	O
than	O
130	O
mg/dl	O
,	O
high-density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	B_Chemical
greater	O
than	O
35	O
mg/dl	O
,	O
or	O
total	O
cholesterol/HDL	O
cholesterol	B_Chemical
less	O
than	O
4.5	O
mg/dl	O
)	O
with	O
diet	O
plus	O
a	O
single	O
drug	O
,	O
gemfibrozil	B_Chemical
(	O
1.2	O
g/day)-lovastatin	O
(	O
primarily	O
20	O
or	O
40	O
mg	O
)	O
treatment	O
was	O
given	O
.	O

Follow-up	O
visits	O
were	O
scheduled	O
with	O
2-drug	O
therapy	O
every	O
6	O
to	O
8	O
weeks	O
,	O
an	O
average	O
of	O
10.3	O
visits	O
per	O
patient	O
,	O
with	O
741	O
batteries	O
of	O
6	O
liver	O
function	O
tests	O
and	O
714	O
creatine	B_Chemical
phosphokinase	O
levels	O
measured	O
.	O

Only	O
1	O
of	O
the	O
4,446	O
liver	O
function	O
tests	O
(	O
0.02	O
%	O
)	O
,	O
a	O
gamma	O
glutamyl	O
transferase	O
,	O
was	O
greater	O
than	O
or	O
equal	O
to	O
3	O
times	O
the	O
upper	O
normal	O
limit	O
.	O

Of	O
the	O
714	O
creatine	B_Chemical
phosphokinase	O
levels	O
,	O
9	O
%	O
were	O
high	O
;	O
only	O
1	O
(	O
0.1	O
%	O
)	O
was	O
greater	O
than	O
or	O
equal	O
to	O
3	O
times	O
the	O
upper	O
normal	O
limit	O
.	O

With	O
2-drug	O
therapy	O
,	O
mean	O
total	O
cholesterol	B_Chemical
decreased	O
22	O
%	O
from	O
255	O
to	O
200	O
mg/dl	O
,	O
triglyceride	B_Chemical
levels	O
decreased	O
35	O
%	O
from	O
236	O
to	O
154	O
mg/dl	O
,	O
LDL	O
cholesterol	B_Chemical
decreased	O
26	O
%	O
from	O
176	O
to	O
131	O
mg/dl	O
,	O
and	O
the	O
total	O
cholesterol/HDL	O
cholesterol	B_Chemical
ratio	O
decreased	O
24	O
%	O
from	O
7.1	O
to	O
5.4	O
,	O
all	O
p	O
less	O
than	O
or	O
equal	O
to	O
0.0001	O
.	O

Myositis	B_Disease
,	O
attributable	O
to	O
the	O
drug	O
combination	O
and	O
symptomatic	O
enough	O
to	O
discontinue	O
it	O
,	O
occurred	O
in	O
3	O
%	O
of	O
patients	O
,	O
and	O
in	O
1	O
%	O
with	O
concurrent	O
high	O
creatine	B_Chemical
phosphokinase	O
(	O
769	O
U/liter	O
)	O
;	O
no	O
patients	O
had	O
rhabdomyolysis	B_Disease
or	O
myoglobinuria.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Does	O
domperidone	B_Chemical
potentiate	O
mirtazapine-associated	O
restless	O
legs	O
syndrome?There	O
is	O
now	O
evidence	O
to	O
suggest	O
a	O
central	O
role	O
for	O
the	O
dopaminergic	O
system	O
in	O
restless	B_Disease
legs	I_Disease
syndrome	I_Disease
(	O
RLS	B_Disease
)	O
.	O

For	O
example	O
,	O
the	O
symptoms	O
of	O
RLS	B_Disease
can	O
be	O
dramatically	O
improved	O
by	O
levodopa	B_Chemical
and	O
dopamine	B_Chemical
agonists	O
,	O
whereas	O
central	O
dopamine	B_Chemical
D2	O
receptor	O
antagonists	O
can	O
induce	O
or	O
aggravate	O
RLS	B_Disease
symptoms	O
.	O

To	O
our	O
knowledge	O
,	O
there	O
is	O
no	O
previous	O
report	O
regarding	O
whether	O
domperidone	B_Chemical
,	O
a	O
peripheral	O
dopamine	B_Chemical
D2	O
receptor	O
antagonist	O
,	O
can	O
also	O
induce	O
or	O
aggravate	O
symptoms	O
of	O
RLS	B_Disease
.	O

Mirtazapine	B_Chemical
,	O
the	O
first	O
noradrenergic	O
and	O
specific	O
serotonergic	O
antidepressant	O
(	O
NaSSA	O
)	O
,	O
has	O
been	O
associated	O
with	O
RLS	B_Disease
in	O
several	O
recent	O
publications	O
.	O

The	O
authors	O
report	O
here	O
a	O
depressed	O
patient	O
comorbid	O
with	O
postprandial	B_Disease
dyspepsia	I_Disease
who	O
developed	O
RLS	B_Disease
after	O
mirtazapine	B_Chemical
had	O
been	O
added	O
to	O
his	O
domperidone	B_Chemical
therapy	O
.	O

Our	O
patient	O
started	O
to	O
have	O
symptoms	O
of	O
RLS	B_Disease
only	O
after	O
he	O
had	O
been	O
treated	O
with	O
mirtazapine	B_Chemical
,	O
and	O
his	O
RLS	B_Disease
symptoms	O
resolved	O
completely	O
upon	O
discontinuation	O
of	O
his	O
mirtazapine	B_Chemical
.	O

Such	O
a	O
temporal	O
relationship	O
between	O
the	O
use	O
of	O
mirtazapine	B_Chemical
and	O
the	O
symptoms	O
of	O
RLS	B_Disease
in	O
our	O
patient	O
did	O
not	O
support	O
a	O
potentiating	O
effect	O
of	O
domperione	B_Chemical
on	O
mirtazapine-associated	O
RLS	B_Disease
.	O

However	O
,	O
physicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
that	O
mirtazapine	B_Chemical
can	O
be	O
associated	O
with	O
RLS	B_Disease
in	O
some	O
individuals	O
,	O
especially	O
those	O
receiving	O
concomitant	O
dopamine	B_Chemical
D2	O
receptor	O
antagonists	O
.	O

Antiandrogenic	O
therapy	O
can	O
cause	O
coronary	O
arterial	O
disease	O
.	O

AIM	O
:	O
To	O
study	O
the	O
change	O
of	O
lipid	O
metabolism	O
by	O
antiandrogen	O
therapy	O
in	O
patients	O
with	O
prostate	B_Disease
cancer	I_Disease
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
studied	O
with	O
a	O
2.5	O
years	O
follow-up	O
the	O
changes	O
in	O
plasma	O
cholesterols	B_Chemical
(	O
C	B_Chemical
)	O
,	O
triglycerides	B_Chemical
(	O
TG	B_Chemical
)	O
,	O
lipoproteins	O
(	O
LP	O
)	O
,	O
and	O
apolipoproteins	O
(	O
Apo	O
)	O
B-100	O
,	O
A-I	O
,	O
and	O
A-II	O
pro	O
fi	O
les	O
in	O
24	O
patients	O
of	O
mean	O
age	O
60	O
years	O
with	O
low	O
risk	O
prostate	B_Disease
cancer	I_Disease
(	O
stage	O
:	O
T1cN0M0	O
,	O
Gleason	O
score	O
:	O
2	O
-	O
5	O
)	O
during	O
treatment	O
with	O
cyproterone	B_Chemical
acetate	I_Chemical
(	O
CPA	B_Chemical
)	O
without	O
surgical	O
management	O
or	O
radiation	O
therapy	O
.	O

RESULTS	O
:	O
Significant	O
decreases	O
of	O
HDL-C	O
,	O
Apo	O
A-I	O
and	O
Apo	O
A-II	O
and	O
an	O
increase	O
of	O
triglyceride	B_Chemical
levels	O
in	O
VLDL	O
were	O
induced	O
by	O
CPA	B_Chemical
.	O

After	O
a	O
period	O
of	O
2.5	O
years	O
on	O
CPA	B_Chemical
treatment	O
,	O
four	O
patients	O
out	O
of	O
twenty-four	O
were	O
found	O
to	O
be	O
affected	O
by	O
coronary	B_Disease
heart	I_Disease
disease	I_Disease
.	O

CONCLUSIONS	O
:	O
Ischaemic	O
coronary	B_Disease
arteriosclerosis	I_Disease
with	O
an	O
incidence	O
rate	O
of	O
16.6	O
%	O
as	O
caused	O
by	O
prolonged	O
CPA	B_Chemical
therapy	O
is	O
mediated	O
through	O
changes	O
in	O
HDL	O
cholesterol	B_Chemical
,	O
Apo	O
A-I	O
and	O
Apo	O
A-II	O
pro	O
fi	O
les	O
,	O
other	O
than	O
the	O
well-known	O
hyperglyceridemic	B_Disease
effect	I_Disease
caused	O
by	O
estrogen	B_Chemical
.	O

5-Fluorouracil	B_Chemical
cardiotoxicity	B_Disease
induced	O
by	O
alpha-fluoro-beta-alanine	B_Chemical
.	O

Cardiotoxicity	B_Disease
is	O
a	O
rare	O
complication	O
occurring	O
during	O
5-fluorouracil	B_Chemical
(	O
5-FU	B_Chemical
)	O
treatment	O
for	O
malignancies	B_Disease
.	O

We	O
herein	O
report	O
the	O
case	O
of	O
a	O
70-year-old	O
man	O
with	O
5-FU-induced	O
cardiotoxicity	B_Disease
,	O
in	O
whom	O
a	O
high	O
serum	O
level	O
of	O
alpha-fluoro-beta-alanine	B_Chemical
(	O
FBAL	B_Chemical
)	O
was	O
observed	O
.	O

The	O
patient	O
,	O
who	O
had	O
unresectable	O
colon	B_Disease
cancer	I_Disease
metastases	O
to	O
the	O
liver	O
and	O
lung	O
,	O
was	O
referred	O
to	O
us	O
for	O
chemotherapy	O
from	O
an	O
affiliated	O
hospital	O
;	O
he	O
had	O
no	O
cardiac	O
history	O
.	O

After	O
admission	O
,	O
the	O
patient	O
received	O
a	O
continuous	O
intravenous	O
infusion	O
of	O
5-FU	B_Chemical
(	O
1000	O
mg/day	O
)	O
,	O
during	O
which	O
precordial	B_Disease
pain	I_Disease
with	O
right	B_Disease
bundle	I_Disease
branch	I_Disease
block	I_Disease
occurred	O
concomitantly	O
with	O
a	O
high	O
serum	O
FBAL	B_Chemical
concentration	O
of	O
1955	O
ng/ml	O
.	O

Both	O
the	O
precordial	B_Disease
pain	I_Disease
and	O
the	O
electrocardiographic	O
changes	O
disappeared	O
spontaneously	O
after	O
the	O
discontinuation	O
of	O
5-FU	B_Chemical
.	O

As	O
the	O
precordial	B_Disease
pain	I_Disease
in	O
this	O
patient	O
was	O
considered	O
to	O
have	O
been	O
due	O
to	O
5-FU-induced	O
cardiotoxicity	B_Disease
,	O
the	O
administration	O
of	O
5-FU	B_Chemical
was	O
abandoned	O
.	O

Instead	O
,	O
oral	O
administration	O
of	O
S-1	O
(	O
a	O
derivative	O
of	O
5-FU	B_Chemical
)	O
,	O
at	O
200	O
mg/day	O
twice	O
a	O
week	O
,	O
was	O
instituted	O
,	O
because	O
S-1	O
has	O
a	O
strong	O
inhibitory	O
effect	O
on	O
dihydropyrimidine	B_Chemical
dehydrogenase	O
,	O
which	O
catalyzes	O
the	O
degradative	O
of	O
5-FU	B_Chemical
into	O
FBAL	B_Chemical
.	O

The	O
serum	O
FBAL	B_Chemical
concentration	O
subsequently	O
decreased	O
to	O
352	O
ng/ml	O
,	O
the	O
same	O
as	O
the	O
value	O
measured	O
on	O
the	O
first	O
day	O
of	O
S-1	O
administration	O
.	O

Thereafter	O
,	O
no	O
cardiac	B_Disease
symptoms	I_Disease
were	O
observed	O
.	O

The	O
patient	O
achieved	O
a	O
partial	O
response	O
6	O
months	O
after	O
the	O
initiation	O
of	O
the	O
S-1	O
treatment	O
.	O

The	O
experience	O
of	O
this	O
case	O
,	O
together	O
with	O
a	O
review	O
of	O
the	O
literature	O
,	O
suggests	O
that	O
FBAL	B_Chemical
is	O
related	O
to	O
5-FU-induced	O
cardiotoxicity	B_Disease
.	O

S-1	O
may	O
be	O
administered	O
safely	O
to	O
patients	O
with	O
5-FU-induced	O
cardiotoxicity	B_Disease
.	O

Hepatocellular	B_Disease
carcinoma	I_Disease
in	O
Fanconi	B_Disease
's	I_Disease
anemia	I_Disease
treated	O
with	O
androgen	B_Chemical
and	O
corticosteroid	B_Chemical
.	O

The	O
case	O
of	O
an	O
11-year-old	O
boy	O
is	O
reported	O
who	O
was	O
known	O
to	O
have	O
Fanconi	B_Disease
's	I_Disease
anemia	I_Disease
for	O
3	O
years	O
and	O
was	O
treated	O
with	O
androgens	B_Chemical
,	O
corticosteroids	B_Chemical
and	O
transfusions	O
.	O

Two	O
weeks	O
before	O
his	O
death	O
he	O
was	O
readmitted	O
because	O
of	O
aplastic	O
crisis	O
with	O
septicemia	B_Disease
and	O
marked	O
abnormalities	O
in	O
liver	O
function	O
and	O
died	O
of	O
hemorrhagic	B_Disease
bronchopneumonia	I_Disease
.	O

At	O
autopsy	O
peliosis	B_Disease
and	O
multiple	O
hepatic	B_Disease
tumors	I_Disease
were	O
found	O
which	O
histologically	O
proved	O
to	O
be	O
well-differentiated	O
hepatocellular	B_Disease
carcinoma	I_Disease
.	O

This	O
case	O
contributes	O
to	O
the	O
previous	O
observations	O
that	O
non-metastasizing	O
hepatic	B_Disease
neoplasms	I_Disease
and	O
peliosis	B_Disease
can	O
develop	O
in	O
patients	O
with	O
androgen-	O
and	O
corticosteroid-treated	O
Fanconi	B_Disease
's	I_Disease
anemia	I_Disease
.	O

The	O
influence	O
of	O
the	O
time	O
interval	O
between	O
monoHER	B_Chemical
and	O
doxorubicin	B_Chemical
administration	O
on	O
the	O
protection	O
against	O
doxorubicin-induced	O
cardiotoxicity	B_Disease
in	O
mice	O
.	O

PURPOSE	O
:	O
Despite	O
its	O
well-known	O
cardiotoxicity	B_Disease
,	O
the	O
anthracyclin	O
doxorubicin	B_Chemical
(	O
DOX	B_Chemical
)	O
continues	O
to	O
be	O
an	O
effective	O
and	O
widely	O
used	O
chemotherapeutic	O
agent	O
.	O

DOX-induced	O
cardiac	B_Disease
damage	I_Disease
presumably	O
results	O
from	O
the	O
formation	O
of	O
free	O
radicals	O
by	O
DOX	B_Chemical
.	O

Reactive	O
oxygen	B_Chemical
species	O
particularly	O
affect	O
the	O
cardiac	O
myocytes	O
because	O
these	O
cells	O
seem	O
to	O
have	O
a	O
relatively	O
poor	O
antioxidant	O
defense	O
system	O
.	O

The	O
semisynthetic	O
flavonoid	B_Chemical
monohydroxyethylrutoside	B_Chemical
(	O
monoHER	B_Chemical
)	O
showed	O
cardioprotection	O
against	O
DOX-induced	O
cardiotoxicity	B_Disease
through	O
its	O
radical	O
scavenging	O
and	O
iron	B_Chemical
chelating	O
properties	O
.	O

Because	O
of	O
the	O
relatively	O
short	O
final	O
half-life	O
of	O
monoHER	B_Chemical
(	O
about	O
30	O
min	O
)	O
,	O
it	O
is	O
expected	O
that	O
the	O
time	O
interval	O
between	O
monoHER	B_Chemical
and	O
DOX	B_Chemical
might	O
be	O
of	O
influence	O
on	O
the	O
cardioprotective	O
effect	O
of	O
monoHER	B_Chemical
.	O

Therefore	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
this	O
possible	O
effect	O
.	O

METHODS	O
:	O
Six	O
groups	O
of	O
6	O
BALB/c	O
mice	O
were	O
treated	O
with	O
saline	O
,	O
DOX	B_Chemical
alone	O
or	O
DOX	B_Chemical
(	O
4	O
mg/kg	O
i.v	O
.	O
)	O
preceded	O
by	O
monoHER	B_Chemical
(	O
500	O
mg/kg	O
i.p	O
.	O
)	O
with	O
an	O
interval	O
of	O
10	O
,	O
30	O
,	O
60	O
or	O
120	O
min	O
.	O

After	O
a	O
6-week	O
treatment	O
period	O
and	O
additional	O
observation	O
for	O
2	O
weeks	O
,	O
the	O
mice	O
were	O
sacrificed	O
.	O

Their	O
cardiac	O
tissues	O
were	O
processed	O
for	O
light	O
microscopy	O
,	O
after	O
which	O
cardiomyocyte	B_Disease
damage	I_Disease
was	O
evaluated	O
according	O
to	O
Billingham	O
(	O
in	O
Cancer	B_Disease
Treat	O
Rep	O
62(6):865	O
-	O
872	O
,	O
1978	O
)	O
.	O

Microscopic	O
evaluation	O
revealed	O
that	O
treatment	O
with	O
DOX	B_Chemical
alone	O
induced	O
significant	O
cardiac	B_Disease
damage	I_Disease
in	O
comparison	O
to	O
the	O
saline	O
control	O
group	O
(	O
P<0.001	O
)	O
.	O

RESULTS	O
:	O
The	O
number	O
of	O
damaged	O
cardiomyocytes	O
was	O
9.6-fold	O
(	O
95	O
%	O
CI	O
4.4	O
-	O
21.0	O
)	O
higher	O
in	O
mice	O
treated	O
with	O
DOX	B_Chemical
alone	O
than	O
that	O
in	O
animals	O
of	O
the	O
control	O
group	O
.	O

The	O
ratio	O
of	O
aberrant	O
cardiomyocytes	O
in	O
mice	O
treated	O
with	O
DOX	B_Chemical
preceded	O
by	O
monoHER	B_Chemical
and	O
those	O
in	O
mice	O
treated	O
with	O
saline	O
ranged	O
from	O
1.6	O
to	O
2.8	O
(	O
mean	O
2.2	O
,	O
95	O
%	O
CI	O
1.2	O
-	O
4.1	O
,	O
P=0.019	O
)	O
.	O

The	O
mean	O
protective	O
effect	O
by	O
adding	O
monoHER	B_Chemical
before	O
DOX	B_Chemical
led	O
to	O
a	O
significant	O
4.4-fold	O
reduction	O
(	O
P<0.001	O
,	O
95	O
%	O
CI	O
2.3	O
-	O
8.2	O
)	O
of	O
abnormal	O
cardiomyocytes	O
.	O

This	O
protective	O
effect	O
did	O
not	O
depend	O
on	O
the	O
time	O
interval	O
between	O
monoHER	B_Chemical
and	O
DOX	B_Chemical
administration	O
(	O
P=0.345	O
)	O
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	O
that	O
in	O
an	O
outpatient	O
clinical	O
setting	O
monoHER	B_Chemical
may	O
be	O
administered	O
shortly	O
before	O
DOX	B_Chemical
.	O

Clinical	O
evaluation	O
of	O
adverse	O
effects	O
during	O
bepridil	B_Chemical
administration	O
for	O
atrial	B_Disease
fibrillation	I_Disease
and	I_Disease
flutter	I_Disease
.	O

BACKGROUND	O
:	O
Bepridil	B_Chemical
hydrochloride	I_Chemical
(	O
Bpd	B_Chemical
)	O
has	O
attracted	O
attention	O
as	O
an	O
effective	O
drug	O
for	O
atrial	B_Disease
fibrillation	I_Disease
(	O
AF	B_Disease
)	O
and	O
atrial	B_Disease
flutter	I_Disease
(	O
AFL	B_Disease
)	O
.	O

However	O
,	O
serious	O
adverse	O
effects	O
,	O
including	O
torsade	B_Disease
de	I_Disease
pointes	I_Disease
(	O
Tdp	B_Disease
)	O
,	O
have	O
been	O
reported	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Adverse	O
effects	O
of	O
Bpd	B_Chemical
requiring	O
discontinuation	O
of	O
treatment	O
were	O
evaluated	O
.	O

Bpd	B_Chemical
was	O
administered	O
to	O
459	O
patients	O
(	O
361	O
males	O
,	O
63+/-12	O
years	O
old	O
)	O
comprising	O
378	O
AF	B_Disease
and	O
81	O
AFL	B_Disease
cases	O
.	O

Mean	O
left	O
ventricular	O
ejection	O
fraction	O
and	O
atrial	O
dimension	O
(	O
LAD	O
)	O
were	O
66+/-11	O
%	O
and	O
40+/-6	O
mm	O
,	O
respectively	O
.	O

Adverse	O
effects	O
were	O
observed	O
in	O
19	O
patients	O
(	O
4	O
%	O
)	O
during	O
an	O
average	O
follow-up	O
of	O
20	O
months	O
.	O

There	O
was	O
marked	O
QT	B_Disease
prolongation	I_Disease
greater	O
than	O
0.55	O
s	O
in	O
13	O
patients	O
,	O
bradycardia	B_Disease
less	O
than	O
40	O
beats/min	O
in	O
6	O
patients	O
,	O
dizziness	B_Disease
and	O
general	O
fatigue	B_Disease
in	O
1	O
patient	O
each	O
.	O

In	O
4	O
of	O
13	O
patients	O
with	O
QT	B_Disease
prolongation	I_Disease
,	O
Tdp	B_Disease
occurred	O
.	O

The	O
major	O
triggering	O
factors	O
of	O
Tdp	B_Disease
were	O
hypokalemia	B_Disease
and	O
sudden	O
decrease	O
in	O
heart	O
rate	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
clinical	O
backgrounds	O
of	O
the	O
patients	O
with	O
and	O
without	O
Tdp	B_Disease
other	O
than	O
LAD	O
and	O
age	O
,	O
which	O
were	O
larger	O
and	O
older	O
in	O
the	O
patients	O
with	O
Tdp	B_Disease
.	O

CONCLUSION	O
:	O
Careful	O
observation	O
of	O
serum	O
potassium	B_Chemical
concentration	O
and	O
the	O
ECG	O
should	O
always	O
be	O
done	O
during	O
Bpd	B_Chemical
administration	O
,	O
particularly	O
in	O
elderly	O
patients	O
.	O

Enhanced	O
isoproterenol-induced	O
cardiac	B_Disease
hypertrophy	I_Disease
in	O
transgenic	O
rats	O
with	O
low	O
brain	O
angiotensinogen	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
permanent	O
deficiency	O
in	O
the	O
brain	O
renin-angiotensin	O
system	O
(	O
RAS	O
)	O
may	O
increase	O
the	O
sensitivity	O
of	O
the	O
baroreflex	O
control	O
of	O
heart	O
rate	O
.	O

In	O
this	O
study	O
we	O
aimed	O
at	O
studying	O
the	O
involvement	O
of	O
the	O
brain	O
RAS	O
in	O
the	O
cardiac	O
reactivity	O
to	O
the	O
beta-adrenoceptor	O
(	O
beta-AR	O
)	O
agonist	O
isoproterenol	B_Chemical
(	O
Iso	B_Chemical
)	O
.	O

Transgenic	O
rats	O
with	O
low	O
brain	O
angiotensinogen	O
(	O
TGR	O
)	O
were	O
used	O
.	O

In	O
isolated	O
hearts	O
,	O
Iso	B_Chemical
induced	O
a	O
significantly	O
greater	O
increase	O
in	O
left	O
ventricular	O
(	O
LV	O
)	O
pressure	O
and	O
maximal	O
contraction	O
(	O
+	O
dP/dt(max	O
)	O
)	O
in	O
the	O
TGR	O
than	O
in	O
the	O
Sprague-Dawley	O
(	O
SD	O
)	O
rats	O
.	O

LV	B_Disease
hypertrophy	I_Disease
induced	O
by	O
Iso	B_Chemical
treatment	O
was	O
significantly	O
higher	O
in	O
TGR	O
than	O
in	O
SD	O
rats	O
(	O
in	O
g	O
LV	O
wt/100	O
g	O
body	O
wt	O
,	O
0.28	O
+	O
/-	O
0.004	O
vs.	O
0.24	O
+	O
/-	O
0.004	O
,	O
respectively	O
)	O
.	O

The	O
greater	O
LV	B_Disease
hypertrophy	I_Disease
in	O
TGR	O
rats	O
was	O
associated	O
with	O
more	O
pronounced	O
downregulation	O
of	O
beta-AR	O
and	O
upregulation	O
of	O
LV	O
beta-AR	O
kinase-1	O
mRNA	O
levels	O
compared	O
with	O
those	O
in	O
SD	O
rats	O
.	O

The	O
decrease	O
in	O
the	O
heart	O
rate	O
(	O
HR	O
)	O
induced	O
by	O
the	O
beta-AR	O
antagonist	O
metoprolol	B_Chemical
in	O
conscious	O
rats	O
was	O
significantly	O
attenuated	O
in	O
TGR	O
compared	O
with	O
SD	O
rats	O
(	O
-9.9	O
+	O
/-	O
1.7	O
%	O
vs.	O
-18.1	O
+	O
/-	O
1.5	O
%	O
)	O
,	O
whereas	O
the	O
effect	O
of	O
parasympathetic	O
blockade	O
by	O
atropine	B_Chemical
on	O
HR	O
was	O
similar	O
in	O
both	O
strains	O
.	O

These	O
results	O
indicate	O
that	O
TGR	O
are	O
more	O
sensitive	O
to	O
beta-AR	O
agonist-induced	O
cardiac	B_Disease
inotropic	I_Disease
response	O
and	O
hypertrophy	B_Disease
,	O
possibly	O
due	O
to	O
chronically	O
low	O
sympathetic	O
outflow	O
directed	O
to	O
the	O
heart	O
.	O

Drug-induced	O
long	B_Disease
QT	I_Disease
syndrome	I_Disease
in	O
injection	O
drug	O
users	O
receiving	O
methadone	B_Chemical
:	O
high	O
frequency	O
in	O
hospitalized	O
patients	O
and	O
risk	O
factors	O
.	O

BACKGROUND	O
:	O
Drug-induced	O
long	B_Disease
QT	I_Disease
syndrome	I_Disease
is	O
a	O
serious	O
adverse	O
drug	O
reaction	O
.	O

Methadone	B_Chemical
prolongs	O
the	O
QT	O
interval	O
in	O
vitro	O
in	O
a	O
dose-dependent	O
manner	O
.	O

In	O
the	O
inpatient	O
setting	O
,	O
the	O
frequency	O
of	O
QT	B_Disease
interval	I_Disease
prolongation	I_Disease
with	O
methadone	B_Chemical
treatment	O
,	O
its	O
dose	O
dependence	O
,	O
and	O
the	O
importance	O
of	O
cofactors	O
such	O
as	O
drug-drug	O
interactions	O
remain	O
unknown	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
systematic	O
,	O
retrospective	O
study	O
comparing	O
active	O
or	O
former	O
intravenous	O
drug	O
users	O
receiving	O
methadone	B_Chemical
and	O
those	O
not	O
receiving	O
methadone	B_Chemical
among	O
all	O
patients	O
hospitalized	O
over	O
a	O
5-year	O
period	O
in	O
a	O
tertiary	O
care	O
hospital	O
.	O

A	O
total	O
of	O
167	O
patients	O
receiving	O
methadone	B_Chemical
fulfilled	O
the	O
inclusion	O
criteria	O
and	O
were	O
compared	O
with	O
a	O
control	O
group	O
of	O
80	O
injection	O
drug	O
users	O
not	O
receiving	O
methadone	B_Chemical
.	O

In	O
addition	O
to	O
methadone	B_Chemical
dose	O
,	O
15	O
demographic	O
,	O
biological	O
,	O
and	O
pharmacological	O
variables	O
were	O
considered	O
as	O
potential	O
risk	O
factors	O
for	O
QT	B_Disease
prolongation	I_Disease
.	O

RESULTS	O
:	O
Among	O
167	O
methadone	B_Chemical
maintenance	O
patients	O
,	O
the	O
prevalence	O
of	O
QTc	O
prolongation	O
to	O
0.50	O
second((1/2	O
)	O
)	O
or	O
longer	O
was	O
16.2	O
%	O
compared	O
with	O
0	O
%	O
in	O
80	O
control	O
subjects	O
.	O

Six	O
patients	O
(	O
3.6	O
%	O
)	O
in	O
the	O
methadone	B_Chemical
group	O
presented	O
torsades	B_Disease
de	I_Disease
pointes	I_Disease
.	O

QTc	O
length	O
was	O
weakly	O
but	O
significantly	O
associated	O
with	O
methadone	B_Chemical
daily	O
dose	O
(	O
Spearman	O
rank	O
correlation	O
coefficient	O
,	O
0.20	O
;	O
P<.01	O
)	O
.	O

Multivariate	O
regression	O
analysis	O
allowed	O
attribution	O
of	O
31.8	O
%	O
of	O
QTc	O
variability	O
to	O
methadone	B_Chemical
dose	O
,	O
cytochrome	O
P-450	O
3A4	O
drug-drug	O
interactions	O
,	O
hypokalemia	B_Disease
,	O
and	O
altered	O
liver	O
function	O
.	O

CONCLUSIONS	O
:	O
QT	B_Disease
interval	I_Disease
prolongation	I_Disease
in	O
methadone	B_Chemical
maintenance	O
patients	O
hospitalized	O
in	O
a	O
tertiary	O
care	O
center	O
is	O
a	O
frequent	O
finding	O
.	O

Methadone	B_Chemical
dose	O
,	O
presence	O
of	O
cytochrome	O
P-450	O
3A4	O
inhibitors	O
,	O
potassium	B_Chemical
level	O
,	O
and	O
liver	O
function	O
contribute	O
to	O
QT	B_Disease
prolongation	I_Disease
.	O

Long	B_Disease
QT	I_Disease
syndrome	I_Disease
can	O
occur	O
with	O
low	O
doses	O
of	O
methadone	B_Chemical
.	O

Mechanisms	O
of	O
hypertension	B_Disease
induced	O
by	O
nitric	B_Chemical
oxide	I_Chemical
(	O
NO	B_Chemical
)	O
deficiency	O
:	O
focus	O
on	O
venous	O
function	O
.	O

Loss	O
of	O
endothelial	O
cell-derived	O
nitric	B_Chemical
oxide	I_Chemical
(	O
NO	B_Chemical
)	O
in	O
hypertension	B_Disease
is	O
a	O
hallmark	O
of	O
arterial	B_Disease
dysfunction	I_Disease
.	O

Experimental	O
hypertension	B_Disease
created	O
by	O
the	O
removal	O
of	O
NO	B_Chemical
,	O
however	O
,	O
involves	O
mechanisms	O
in	O
addition	O
to	O
decreased	O
arterial	O
vasodilator	O
activity	O
.	O

These	O
include	O
augmented	O
endothelin-1	O
(	O
ET-1	O
)	O
release	O
,	O
increased	O
sympathetic	O
nervous	O
system	O
activity	O
,	O
and	O
elevated	O
tissue	O
oxidative	O
stress	O
.	O

We	O
hypothesized	O
that	O
increased	O
venous	O
smooth	O
muscle	O
(	O
venomotor	O
)	O
tone	O
plays	O
a	O
role	O
in	O
Nomega-nitro-L-arginine	B_Chemical
(	O
LNNA	B_Chemical
)	O
hypertension	B_Disease
through	O
these	O
mechanisms	O
.	O

Rats	O
were	O
treated	O
with	O
the	O
NO	B_Chemical
synthase	O
inhibitor	O
LNNA	B_Chemical
(	O
0.5	O
g/L	O
in	O
drinking	O
water	O
)	O
for	O
2	O
weeks	O
.	O

Mean	O
arterial	O
pressure	O
of	O
conscious	O
rats	O
was	O
119	O
+	O
/-	O
2	O
mm	O
Hg	O
in	O
control	O
and	O
194	O
+	O
/-	O
5	O
mm	O
Hg	O
in	O
LNNA	B_Chemical
rats	O
(	O
P<0.05	O
)	O
.	O

Carotid	O
arteries	O
and	O
vena	O
cava	O
were	O
removed	O
for	O
measurement	O
of	O
isometric	O
contraction	O
.	O

Maximal	O
contraction	O
to	O
norepinephrine	B_Chemical
was	O
modestly	O
reduced	O
in	O
arteries	O
from	O
LNNA	B_Chemical
compared	O
with	O
control	O
rats	O
whereas	O
the	O
maximum	O
contraction	O
to	O
ET-1	O
was	O
significantly	O
reduced	O
(	O
54	O
%	O
control	O
)	O
.	O

Maximum	O
contraction	O
of	O
vena	O
cava	O
to	O
norepinephrine	B_Chemical
(	O
37	O
%	O
control	O
)	O
also	O
was	O
reduced	O
but	O
no	O
change	O
in	O
response	O
to	O
ET-1	O
was	O
observed	O
.	O

Mean	O
circulatory	O
filling	O
pressure	O
,	O
an	O
in	O
vivo	O
measure	O
of	O
venomotor	O
tone	O
,	O
was	O
not	O
elevated	O
in	O
LNNA	B_Chemical
hypertension	B_Disease
at	O
1	O
or	O
2	O
weeks	O
after	O
LNNA	B_Chemical
.	O

The	O
superoxide	B_Chemical
scavenger	O
tempol	B_Chemical
(	O
30	O
,	O
100	O
,	O
and	O
300	O
micromol	O
kg(-1	O
)	O
,	O
IV	O
)	O
did	O
not	O
change	O
arterial	O
pressure	O
in	O
control	O
rats	O
but	O
caused	O
a	O
dose-dependent	O
decrease	O
in	O
LNNA	B_Chemical
rats	O
(	O
-18	O
+	O
/-	O
8	O
,	O
-26	O
+	O
/-	O
15	O
,	O
and	O
-54	O
+	O
/-	O
11	O
mm	O
Hg	O
)	O
.	O

Similarly	O
,	O
ganglionic	O
blockade	O
with	O
hexamethonium	B_Chemical
caused	O
a	O
significantly	O
greater	O
fall	O
in	O
LNNA	B_Chemical
hypertensive	B_Disease
rats	O
(	O
76	O
+	O
/-	O
9	O
mm	O
Hg	O
)	O
compared	O
with	O
control	O
rats	O
(	O
35	O
+	O
/-	O
10	O
mm	O
Hg	O
)	O
.	O

Carotid	O
arteries	O
,	O
vena	O
cava	O
,	O
and	O
sympathetic	O
ganglia	O
from	O
LNNA	B_Chemical
rats	O
had	O
higher	O
basal	O
levels	O
of	O
superoxide	B_Chemical
compared	O
with	O
those	O
from	O
control	O
rats	O
.	O

These	O
data	O
suggest	O
that	O
while	O
NO	B_Chemical
deficiency	O
increases	O
oxidative	O
stress	O
and	O
sympathetic	O
activity	O
in	O
both	O
arterial	O
and	O
venous	O
vessels	O
,	O
the	O
impact	O
on	O
veins	O
does	O
not	O
make	O
a	O
major	O
contribution	O
to	O
this	O
form	O
of	O
hypertension	B_Disease
.	O

Association	O
of	O
DRD2	O
polymorphisms	O
and	O
chlorpromazine-induced	O
extrapyramidal	B_Disease
syndrome	I_Disease
in	O
Chinese	O
schizophrenic	B_Disease
patients	O
.	O

AIM	O
:	O
Extrapyramidal	B_Disease
syndrome	I_Disease
(	O
EPS	B_Disease
)	O
is	O
most	O
commonly	O
affected	O
by	O
typical	O
antipsychotic	O
drugs	O
that	O
have	O
a	O
high	O
affinity	O
with	O
the	O
D2	O
receptor	O
.	O

Recently	O
,	O
many	O
research	O
groups	O
have	O
reported	O
on	O
the	O
positive	O
relationship	O
between	O
the	O
genetic	O
variations	O
in	O
the	O
DRD2	O
gene	O
and	O
the	O
therapeutic	O
response	O
in	O
schizophrenia	B_Disease
patients	O
as	O
a	O
result	O
of	O
the	O
role	O
of	O
variations	O
in	O
the	O
receptor	O
in	O
modulating	O
receptor	O
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluate	O
the	O
role	O
DRD2	O
plays	O
in	O
chlorpromazine-induced	O
EPS	B_Disease
in	O
schizophrenic	B_Disease
patients	O
.	O

METHODS	O
:	O
We	O
identified	O
seven	O
SNP(single	O
nucleotide	O
polymorphism	O
)	O
(	O
-141Cins	O
>	O
del	O
,	O
TaqIB	O
,	O
TaqID	O
,	O
Ser311Cys	O
,	O
rs6275	O
,	O
rs6277	O
and	O
TaqIA	O
)	O
in	O
the	O
DRD2	O
gene	O
in	O
146	O
schizophrenic	B_Disease
inpatients	O
(	O
59	O
with	O
EPS	B_Disease
and	O
87	O
without	O
EPS	B_Disease
according	O
to	O
the	O
Simpson-Angus	O
Scale	O
)	O
treated	O
with	O
chlorpromazine	B_Chemical
after	O
8	O
weeks	O
.	O

The	O
alleles	O
of	O
all	O
loci	O
were	O
determined	O
by	O
PCR	O
(	O
polymerase	O
chain	O
reaction	O
)	O
.	O

RESULTS	O
:	O
Polymorphisms	O
TaqID	O
,	O
Ser311Cys	O
and	O
rs6277	O
were	O
not	O
polymorphic	O
in	O
the	O
population	O
recruited	O
in	O
the	O
present	O
study	O
.	O

No	O
statistical	O
significance	O
was	O
found	O
in	O
the	O
allele	O
distribution	O
of	O
-141Cins	O
>	O
del	O
,	O
TaqIB	O
,	O
rs6275	O
and	O
TaqIA	O
or	O
in	O
the	O
estimated	O
haplotypes	O
(	O
constituted	O
by	O
TaqIB	O
,	O
rs6275	O
and	O
TaqIA	O
)	O
in	O
linkage	O
disequilibrium	O
between	O
the	O
two	O
groups	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
did	O
not	O
lend	O
strong	O
support	O
to	O
the	O
view	O
that	O
the	O
genetic	O
variation	O
of	O
the	O
DRD2	O
gene	O
plays	O
a	O
major	O
role	O
in	O
the	O
individually	O
variable	O
adverse	O
effect	O
induced	O
by	O
chlorpromazine	B_Chemical
,	O
at	O
least	O
in	O
Chinese	O
patients	O
with	O
schizophrenia	B_Disease
.	O

Our	O
results	O
confirmed	O
a	O
previous	O
study	O
on	O
the	O
relationship	O
between	O
DRD2	O
and	O
EPS	B_Disease
in	O
Caucasians	O
.	O

Physical	O
training	O
decreases	O
susceptibility	O
to	O
subsequent	O
pilocarpine-induced	O
seizures	B_Disease
in	O
the	O
rat	O
.	O

Regular	O
motor	O
activity	O
has	O
many	O
benefits	O
for	O
mental	O
and	O
physical	O
condition	O
but	O
its	O
implications	O
for	O
epilepsy	B_Disease
are	O
still	O
controversial	O
.	O

In	O
order	O
to	O
elucidate	O
this	O
problem	O
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
long-term	O
physical	O
activity	O
on	O
susceptibility	O
to	O
subsequent	O
seizures	B_Disease
.	O

Male	O
Wistar	O
rats	O
were	O
subjected	O
to	O
repeated	O
training	O
sessions	O
in	O
a	O
treadmill	O
and	O
swimming	O
pool	O
.	O

Thereafter	O
,	O
seizures	B_Disease
were	O
induced	O
by	O
pilocarpine	B_Chemical
injections	O
in	O
trained	O
and	O
non-trained	O
control	O
groups	O
.	O

During	O
the	O
acute	O
period	O
of	O
status	B_Disease
epilepticus	I_Disease
,	O
we	O
measured	O
:	O
(	O
1	O
)	O
the	O
latency	O
of	O
the	O
first	O
motor	O
sign	O
,	O
(	O
2	O
)	O
the	O
intensity	O
of	O
seizures	B_Disease
,	O
(	O
3	O
)	O
the	O
time	O
when	O
it	O
occurred	O
within	O
the	O
6-h	O
observation	O
period	O
,	O
and	O
(	O
4	O
)	O
the	O
time	O
when	O
the	O
acute	O
period	O
ended	O
.	O

All	O
these	O
behavioral	O
parameters	O
showed	O
statistically	O
significant	O
changes	O
suggesting	O
that	O
regular	O
physical	O
exercises	O
decrease	O
susceptibility	O
to	O
subsequently	O
induced	O
seizures	B_Disease
and	O
ameliorate	O
the	O
course	O
of	O
experimentally	O
induced	O
status	B_Disease
epilepticus	I_Disease
.	O

Tonic	O
dopaminergic	O
stimulation	O
impairs	O
associative	O
learning	O
in	O
healthy	O
subjects	O
.	O

Endogenous	O
dopamine	B_Chemical
plays	O
a	O
central	O
role	O
in	O
salience	O
coding	O
during	O
associative	O
learning	O
.	O

Administration	O
of	O
the	O
dopamine	B_Chemical
precursor	O
levodopa	B_Chemical
enhances	O
learning	O
in	O
healthy	O
subjects	O
and	O
stroke	B_Disease
patients	O
.	O

Because	O
levodopa	B_Chemical
increases	O
both	O
phasic	O
and	O
tonic	O
dopaminergic	O
neurotransmission	O
,	O
the	O
critical	O
mechanism	O
mediating	O
the	O
enhancement	O
of	O
learning	O
is	O
unresolved	O
.	O

We	O
here	O
probed	O
how	O
selective	O
tonic	O
dopaminergic	O
stimulation	O
affects	O
associative	O
learning	O
.	O

Forty	O
healthy	O
subjects	O
were	O
trained	O
in	O
a	O
novel	O
vocabulary	O
of	O
45	O
concrete	O
nouns	O
over	O
the	O
course	O
of	O
5	O
consecutive	O
training	O
days	O
in	O
a	O
prospective	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
design	O
.	O

Subjects	O
received	O
the	O
tonically	O
stimulating	O
dopamine-receptor	O
agonist	O
pergolide	B_Chemical
(	O
0.1	O
mg	O
)	O
vs	O
placebo	O
120	O
min	O
before	O
training	O
on	O
each	O
training	O
day	O
.	O

The	O
dopamine	B_Chemical
agonist	O
significantly	O
impaired	B_Disease
novel	I_Disease
word	I_Disease
learning	I_Disease
compared	O
to	O
placebo	O
.	O

This	O
learning	O
decrement	O
persisted	O
up	O
to	O
the	O
last	O
follow-up	O
4	O
weeks	O
post-training	O
.	O

Subjects	O
treated	O
with	O
pergolide	B_Chemical
also	O
showed	O
restricted	O
emotional	O
responses	O
compared	O
to	O
the	O
PLACEBO	O
group	O
.	O

The	O
extent	O
of	O
'	O
flattened	O
'	O
affect	O
with	O
pergolide	B_Chemical
was	O
related	O
to	O
the	O
degree	O
of	O
learning	O
inhibition	O
.	O

These	O
findings	O
suggest	O
that	O
tonic	O
occupation	O
of	O
dopamine	B_Chemical
receptors	O
impairs	O
learning	O
by	O
competition	O
with	O
phasic	O
dopamine	B_Chemical
signals	O
.	O

Thus	O
,	O
phasic	O
signaling	O
seems	O
to	O
be	O
the	O
critical	O
mechanism	O
by	O
which	O
dopamine	B_Chemical
enhances	O
associative	O
learning	O
in	O
healthy	O
subjects	O
and	O
stroke	B_Disease
patients	O
.	O

Minocycline-induced	O
vasculitis	B_Disease
fulfilling	O
the	O
criteria	O
of	O
polyarteritis	B_Disease
nodosa	I_Disease
.	O

A	O
47-year-old	O
man	O
who	O
had	O
been	O
taking	O
minocycline	B_Chemical
for	O
palmoplantar	B_Disease
pustulosis	I_Disease
developed	O
fever	B_Disease
,	O
myalgias	B_Disease
,	O
polyneuropathy	B_Disease
,	O
and	O
testicular	B_Disease
pain	I_Disease
,	O
with	O
elevated	O
C-reactive	O
protein	O
(	O
CRP	O
)	O
.	O

Neither	O
myeloperoxidase-	O
nor	O
proteinase-3-antineutrophil	O
cytoplasmic	O
antibody	O
was	O
positive	O
.	O

These	O
manifestations	O
met	O
the	O
American	O
College	O
of	O
Rheumatology	O
1990	O
criteria	O
for	O
the	O
classification	O
of	O
polyarteritis	B_Disease
nodosa	I_Disease
.	O

Stopping	O
minocycline	B_Chemical
led	O
to	O
amelioration	O
of	O
symptoms	O
and	O
normalization	O
of	O
CRP	O
level	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
second	O
case	O
of	O
minocycline-induced	O
vasculitis	B_Disease
satisfying	O
the	O
criteria	O
.	O

Differential	O
diagnosis	O
for	O
drug-induced	O
disease	O
is	O
invaluable	O
even	O
for	O
patients	O
with	O
classical	O
polyarteritis	B_Disease
nodosa	I_Disease
.	O

Intramuscular	O
hepatitis	B_Disease
B	I_Disease
immune	O
globulin	O
combined	O
with	O
lamivudine	B_Chemical
in	O
prevention	O
of	O
hepatitis	B_Disease
B	I_Disease
recurrence	O
after	O
liver	O
transplantation	O
.	O

BACKGROUND	O
:	O
Combined	O
hepatitis	B_Disease
B	I_Disease
immune	O
globulin	O
(	O
HBIg	O
)	O
and	O
lamivudine	B_Chemical
in	O
prophylaxis	O
of	O
the	O
recurrence	O
of	O
hepatitis	B_Disease
B	I_Disease
after	O
liver	O
transplantation	O
has	O
significantly	O
improved	O
the	O
survival	O
of	O
HBsAg	B_Chemical
positive	O
patients	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
outcomes	O
of	O
liver	O
transplantation	O
for	O
patients	O
with	O
hepatitis	B_Disease
B	I_Disease
virus	O
(	O
HBV	O
)	O
.	O

METHODS	O
:	O
A	O
retrospective	O
chart	O
analysis	O
and	O
a	O
review	O
of	O
the	O
organ	O
transplant	O
database	O
identified	O
51	O
patients	O
(	O
43	O
men	O
and	O
8	O
women	O
)	O
transplanted	O
for	O
benign	O
HBV-related	O
cirrhotic	B_Disease
diseases	I_Disease
between	O
June	O
2002	O
and	O
December	O
2004	O
who	O
had	O
survived	O
more	O
than	O
3	O
months	O
.	O

HBIg	O
was	O
administered	O
intravenously	O
during	O
the	O
first	O
week	O
and	O
intramuscularly	O
thereafter	O
.	O

RESULTS	O
:	O
At	O
a	O
median	O
follow-up	O
of	O
14.1	O
months	O
,	O
the	O
overall	O
recurrence	O
rate	O
in	O
the	O
51	O
patients	O
was	O
3.9	O
%	O
(	O
2/51	O
)	O
.	O

The	O
overall	O
patient	O
survival	O
was	O
88.3	O
%	O
,	O
and	O
82.4	O
%	O
after	O
1	O
and	O
2	O
years	O
,	O
respectively	O
.	O

A	O
daily	O
oral	O
dose	O
of	O
100	O
mg	O
lamivudine	B_Chemical
for	O
2	O
weeks	O
before	O
transplantation	O
for	O
10	O
patients	O
enabled	O
57.1	O
%	O
(	O
4/7	O
)	O
and	O
62.5	O
%	O
(	O
5/8	O
)	O
of	O
HBV-DNA	O
and	O
HBeAg	B_Chemical
positive	O
patients	O
respectively	O
to	O
convert	O
to	O
be	O
negative	O
.	O

Intramuscular	O
HBIg	O
was	O
well	O
tolerated	O
in	O
all	O
patients	O
.	O

CONCLUSION	O
:	O
Lamivudine	B_Chemical
combined	O
with	O
intramuscular	O
HBIg	O
can	O
effectively	O
prevent	O
allograft	O
from	O
the	O
recurrence	O
of	O
HBV	O
after	O
liver	O
transplantation	O
.	O

Anticonvulsant	O
effect	O
of	O
eslicarbazepine	B_Chemical
acetate	I_Chemical
(	O
BIA	B_Chemical
2	I_Chemical
-	I_Chemical
093	I_Chemical
)	O
on	O
seizures	B_Disease
induced	O
by	O
microperfusion	O
of	O
picrotoxin	B_Chemical
in	O
the	O
hippocampus	O
of	O
freely	O
moving	O
rats	O
.	O

Eslicarbazepine	B_Chemical
acetate	I_Chemical
(	O
BIA	B_Chemical
2	I_Chemical
-	I_Chemical
093	I_Chemical
,	O
S-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo/b	B_Chemical
,	I_Chemical
f/azepine-5-carboxamide	I_Chemical
)	O
is	O
a	O
novel	O
antiepileptic	O
drug	O
,	O
now	O
in	O
Phase	O
III	O
clinical	O
trials	O
,	O
designed	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
and	O
safety	O
in	O
comparison	O
with	O
the	O
structurally	O
related	O
drugs	O
carbamazepine	B_Chemical
(	O
CBZ	B_Chemical
)	O
and	O
oxcarbazepine	B_Chemical
(	O
OXC	B_Chemical
)	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
oral	O
treatment	O
with	O
eslicarbazepine	B_Chemical
acetate	I_Chemical
on	O
a	O
whole-animal	O
model	O
in	O
which	O
partial	O
seizures	B_Disease
can	O
be	O
elicited	O
repeatedly	O
on	O
different	O
days	O
without	O
changes	O
in	O
threshold	O
or	O
seizure	B_Disease
patterns	O
.	O

In	O
the	O
animals	O
treated	O
with	O
threshold	O
doses	O
of	O
picrotoxin	B_Chemical
,	O
the	O
average	O
number	O
of	O
seizures	B_Disease
was	O
2.3+/-1.2	O
,	O
and	O
average	O
seizure	B_Disease
duration	O
was	O
39.5+/-8.4s	O
.	O
Pre-treatment	O
with	O
a	O
dose	O
of	O
30	O
mg/kg	O
2h	O
before	O
picrotoxin	B_Chemical
microperfusion	O
prevented	O
seizures	B_Disease
in	O
the	O
75	O
%	O
of	O
the	O
rats	O
.	O

Lower	O
doses	O
(	O
3	O
and	O
10mg/kg	O
)	O
did	O
not	O
suppress	O
seizures	B_Disease
,	O
however	O
,	O
after	O
administration	O
of	O
10mg/kg	O
,	O
significant	O
reductions	O
in	O
seizures	B_Disease
duration	O
(	O
24.3+/-6.8s	O
)	O
and	O
seizure	B_Disease
number	O
(	O
1.6+/-0.34	O
)	O
were	O
found	O
.	O

No	O
adverse	O
effects	O
of	O
eslicarbazepine	B_Chemical
acetate	I_Chemical
were	O
observed	O
in	O
the	O
behavioral/EEG	O
patterns	O
studied	O
,	O
including	O
sleep/wakefulness	O
cycle	O
,	O
at	O
the	O
doses	O
studied	O
.	O

Acute	B_Disease
renal	I_Disease
failure	I_Disease
associated	O
with	O
prolonged	O
intake	O
of	O
slimming	O
pills	O
containing	O
anthraquinones	B_Chemical
.	O

Chinese	B_Chemical
herbal	I_Chemical
medicine	O
preparations	O
are	O
widely	O
available	O
and	O
often	O
regarded	O
by	O
the	O
public	O
as	O
natural	O
and	O
safe	O
remedies	O
for	O
a	O
variety	O
of	O
medical	O
conditions	O
.	O

Nephropathy	B_Disease
caused	O
by	O
Chinese	B_Chemical
herbs	I_Chemical
has	O
previously	O
been	O
reported	O
,	O
usually	O
involving	O
the	O
use	O
of	O
aristolochic	B_Chemical
acids	I_Chemical
.	O

We	O
report	O
a	O
23-year-old	O
woman	O
who	O
developed	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
following	O
prolonged	O
use	O
of	O
a	O
proprietary	O
Chinese	B_Chemical
herbal	I_Chemical
slimming	O
pill	O
that	O
contained	O
anthraquinone	B_Chemical
derivatives	O
,	O
extracted	O
from	O
Rhizoma	O
Rhei	O
(	O
rhubarb	O
)	O
.	O

The	O
renal	B_Disease
injury	I_Disease
was	O
probably	O
aggravated	O
by	O
the	O
concomitant	O
intake	O
of	O
a	O
non-steroidal	O
anti-inflammatory	O
drug	O
,	O
diclofenac	B_Chemical
.	O

Renal	O
pathology	O
was	O
that	O
of	O
hypocellular	O
interstitial	O
fibrosis	B_Disease
.	O

Spontaneous	O
renal	O
recovery	O
occurred	O
upon	O
cessation	O
of	O
the	O
slimming	O
pills	O
,	O
but	O
mild	O
interstitial	O
fibrosis	B_Disease
and	O
tubular	O
atrophy	B_Disease
was	O
still	O
evident	O
histologically	O
4	O
months	O
later	O
.	O

Although	O
a	O
causal	O
relationship	O
between	O
the	O
use	O
of	O
an	O
anthraquinone-containing	O
herbal	O
agent	O
and	O
renal	B_Disease
injury	I_Disease
remains	O
to	O
be	O
proven	O
,	O
phytotherapy-associated	O
interstitial	O
nephropathy	B_Disease
should	O
be	O
considered	O
in	O
patients	O
who	O
present	O
with	O
unexplained	O
renal	B_Disease
failure	I_Disease
.	O

Chloroacetaldehyde	B_Chemical
as	O
a	O
sulfhydryl	B_Chemical
reagent	O
:	O
the	O
role	O
of	O
critical	O
thiol	B_Chemical
groups	O
in	O
ifosfamide	B_Chemical
nephropathy	B_Disease
.	O

Chloroacetaldehyde	B_Chemical
(	O
CAA	B_Chemical
)	O
is	O
a	O
metabolite	O
of	O
the	O
alkylating	O
agent	O
ifosfamide	B_Chemical
(	O
IFO	B_Chemical
)	O
and	O
putatively	O
responsible	O
for	O
renal	B_Disease
damage	I_Disease
following	O
anti-tumor	O
therapy	O
with	O
IFO	B_Chemical
.	O

Depletion	O
of	O
sulfhydryl	B_Chemical
(	O
SH	B_Chemical
)	O
groups	O
has	O
been	O
reported	O
from	O
cell	O
culture	O
,	O
animal	O
and	O
clinical	O
studies	O
.	O

In	O
this	O
work	O
the	O
effect	O
of	O
CAA	B_Chemical
on	O
human	O
proximal	O
tubule	O
cells	O
in	O
primary	O
culture	O
(	O
hRPTEC	O
)	O
was	O
investigated	O
.	O

Toxicity	B_Disease
of	O
CAA	B_Chemical
was	O
determined	O
by	O
protein	O
content	O
,	O
cell	O
number	O
,	O
LDH	O
release	O
,	O
trypan	B_Chemical
blue	I_Chemical
exclusion	O
assay	O
and	O
caspase-3	O
activity	O
.	O

Free	O
thiols	B_Chemical
were	O
measured	O
by	O
the	O
method	O
of	O
Ellman	O
.	O

CAA	B_Chemical
reduced	O
hRPTEC	O
cell	O
number	O
and	O
protein	O
,	O
induced	O
a	O
loss	O
in	O
free	O
intracellular	O
thiols	B_Chemical
and	O
an	O
increase	O
in	O
necrosis	B_Disease
markers	O
.	O

CAA	B_Chemical
but	O
not	O
acrolein	B_Chemical
inhibited	O
the	O
cysteine	B_Chemical
proteases	O
caspase-3	O
,	O
caspase-8	O
and	O
cathepsin	O
B.	O
Caspase	O
activation	O
by	O
cisplatin	B_Chemical
was	O
inhibited	O
by	O
CAA	B_Chemical
.	O

In	O
cells	O
stained	O
with	O
fluorescent	O
dyes	O
targeting	O
lysosomes	O
,	O
CAA	B_Chemical
induced	O
an	O
increase	O
in	O
lysosomal	O
size	O
and	O
lysosomal	O
leakage	O
.	O

The	O
effects	O
of	O
CAA	B_Chemical
on	O
cysteine	B_Chemical
protease	O
activities	O
and	O
thiols	B_Chemical
could	O
be	O
reproduced	O
in	O
cell	O
lysate	O
.	O

Acidification	O
,	O
which	O
slowed	O
the	O
reaction	O
of	O
CAA	B_Chemical
with	O
thiol	B_Chemical
donors	O
,	O
could	O
also	O
attenuate	O
effects	O
of	O
CAA	B_Chemical
on	O
necrosis	B_Disease
markers	O
,	O
thiol	B_Chemical
depletion	O
and	O
cysteine	B_Chemical
protease	O
inhibition	O
in	O
living	O
cells	O
.	O

Thus	O
,	O
CAA	B_Chemical
directly	O
reacts	O
with	O
cellular	O
protein	O
and	O
non-protein	O
thiols	B_Chemical
,	O
mediating	O
its	O
toxicity	B_Disease
on	O
hRPTEC	O
.	O

This	O
effect	O
can	O
be	O
reduced	O
by	O
acidification	O
.	O

Therefore	O
,	O
urinary	O
acidification	O
could	O
be	O
an	O
option	O
to	O
prevent	O
IFO	B_Chemical
nephropathy	B_Disease
in	O
patients	O
.	O

Stereological	O
methods	O
reveal	O
the	O
robust	O
size	O
and	O
stability	O
of	O
ectopic	O
hilar	O
granule	O
cells	O
after	O
pilocarpine-induced	O
status	B_Disease
epilepticus	I_Disease
in	O
the	O
adult	O
rat	O
.	O

Following	O
status	B_Disease
epilepticus	I_Disease
in	O
the	O
rat	O
,	O
dentate	O
granule	O
cell	O
neurogenesis	O
increases	O
greatly	O
,	O
and	O
many	O
of	O
the	O
new	O
neurons	O
appear	O
to	O
develop	O
ectopically	O
,	O
in	O
the	O
hilar	O
region	O
of	O
the	O
hippocampal	O
formation	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
ectopic	O
hilar	O
granule	O
cells	O
could	O
contribute	O
to	O
the	O
spontaneous	O
seizures	B_Disease
that	O
ultimately	O
develop	O
after	O
status	B_Disease
epilepticus	I_Disease
.	O

However	O
,	O
the	O
population	O
has	O
never	O
been	O
quantified	O
,	O
so	O
it	O
is	O
unclear	O
whether	O
it	O
is	O
substantial	O
enough	O
to	O
have	O
a	O
strong	O
influence	O
on	O
epileptogenesis	O
.	O

To	O
quantify	O
this	O
population	O
,	O
the	O
total	O
number	O
of	O
ectopic	O
hilar	O
granule	O
cells	O
was	O
estimated	O
using	O
unbiased	O
stereology	O
at	O
different	O
times	O
after	O
pilocarpine-induced	O
status	B_Disease
epilepticus	I_Disease
.	O

The	O
number	O
of	O
hilar	O
neurons	O
immunoreactive	O
for	O
Prox-1	O
,	O
a	O
granule-cell-specific	O
marker	O
,	O
was	O
estimated	O
using	O
the	O
optical	O
fractionator	O
method	O
.	O

The	O
results	O
indicate	O
that	O
the	O
size	O
of	O
the	O
hilar	O
ectopic	O
granule	O
cell	O
population	O
after	O
status	B_Disease
epilepticus	I_Disease
is	O
substantial	O
,	O
and	O
stable	O
over	O
time	O
.	O

Interestingly	O
,	O
the	O
size	O
of	O
the	O
population	O
appears	O
to	O
be	O
correlated	O
with	O
the	O
frequency	O
of	O
behavioral	O
seizures	B_Disease
,	O
because	O
animals	O
with	O
more	O
ectopic	O
granule	O
cells	O
in	O
the	O
hilus	O
have	O
more	O
frequent	O
behavioral	O
seizures	B_Disease
.	O

The	O
hilar	O
ectopic	O
granule	O
cell	O
population	O
does	O
not	O
appear	O
to	O
vary	O
systematically	O
across	O
the	O
septotemporal	O
axis	O
,	O
although	O
it	O
is	O
associated	O
with	O
an	O
increase	O
in	O
volume	O
of	O
the	O
hilus	O
.	O

The	O
results	O
provide	O
new	O
insight	O
into	O
the	O
potential	O
role	O
of	O
ectopic	O
hilar	O
granule	O
cells	O
in	O
the	O
pilocarpine	B_Chemical
model	O
of	O
temporal	B_Disease
lobe	I_Disease
epilepsy	I_Disease
.	O

A	O
prospective	O
,	O
open-label	O
trial	O
of	O
galantamine	B_Chemical
in	O
autistic	B_Disease
disorder	I_Disease
.	O

OBJECTIVE	O
:	O
Post-mortem	O
studies	O
have	O
reported	O
abnormalities	O
of	O
the	O
cholinergic	O
system	O
in	O
autism	B_Disease
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
use	O
of	O
galantamine	B_Chemical
,	O
an	O
acetylcholinesterase	O
inhibitor	O
and	O
nicotinic	O
receptor	O
modulator	O
,	O
in	O
the	O
treatment	O
of	O
interfering	O
behaviors	O
in	O
children	O
with	O
autism	B_Disease
.	O

METHODS	O
:	O
Thirteen	O
medication-free	O
children	O
with	O
autism	B_Disease
(	O
mean	O
age	O
,	O
8.8	O
+	O
/-	O
3.5	O
years	O
)	O
participated	O
in	O
a	O
12-week	O
,	O
open-label	O
trial	O
of	O
galantamine	B_Chemical
.	O

Patients	O
were	O
rated	O
monthly	O
by	O
parents	O
on	O
the	O
Aberrant	O
Behavior	O
Checklist	O
(	O
ABC	O
)	O
and	O
the	O
Conners	O
'	O
Parent	O
Rating	O
Scale-Revised	O
,	O
and	O
by	O
a	O
physician	O
using	O
the	O
Children	O
's	O
Psychiatric	O
Rating	O
Scale	O
and	O
the	O
Clinical	O
Global	O
Impressions	O
scale	O
.	O

RESULTS	O
:	O
Patients	O
showed	O
a	O
significant	O
reduction	O
in	O
parent-rated	O
irritability	B_Disease
and	O
social	O
withdrawal	O
on	O
the	O
ABC	O
as	O
well	O
as	O
significant	O
improvements	O
in	O
emotional	O
lability	O
and	O
inattention	O
on	O
the	O
Conners	O
'	O
Parent	O
Rating	O
Scale	O
--	O
Revised	O
.	O

Similarly	O
,	O
clinician	O
ratings	O
showed	O
reductions	O
in	O
the	O
anger	O
subscale	O
of	O
the	O
Children	O
's	O
Psychiatric	O
Rating	O
Scale	O
.	O

Eight	O
of	O
13	O
participants	O
were	O
rated	O
as	O
responders	O
on	O
the	O
basis	O
of	O
their	O
improvement	O
scores	O
on	O
the	O
Clinical	O
Global	O
Impressions	O
scale	O
.	O

Overall	O
,	O
galantamine	B_Chemical
was	O
well-tolerated	O
,	O
with	O
no	O
significant	O
adverse	O
effects	O
apart	O
from	O
headaches	B_Disease
in	O
one	O
patient	O
.	O

CONCLUSION	O
:	O
In	O
this	O
open	O
trial	O
,	O
galantamine	B_Chemical
was	O
well-tolerated	O
and	O
appeared	O
to	O
be	O
beneficial	O
for	O
the	O
treatment	O
of	O
interfering	O
behaviors	O
in	O
children	O
with	O
autism	B_Disease
,	O
particularly	O
aggression	B_Disease
,	O
behavioral	B_Disease
dyscontrol	I_Disease
,	O
and	O
inattention	B_Disease
.	O

Further	O
controlled	O
trials	O
are	O
warranted	O
.	O

Randomized	O
comparison	O
of	O
olanzapine	B_Chemical
versus	O
risperidone	B_Chemical
for	O
the	O
treatment	O
of	O
first-episode	O
schizophrenia	B_Disease
:	O
4-month	O
outcomes	O
.	O

OBJECTIVE	O
:	O
The	O
authors	O
compared	O
4-month	O
treatment	O
outcomes	O
for	O
olanzapine	B_Chemical
versus	O
risperidone	B_Chemical
in	O
patients	O
with	O
first-episode	O
schizophrenia	B_Disease
spectrum	O
disorders	O
.	O

METHOD	O
:	O
One	O
hundred	O
twelve	O
subjects	O
(	O
70	O
%	O
male	O
;	O
mean	O
age=23.3	O
years	O
[	O
SD	O
=	O
5.1	O
]	O
)	O
with	O
first-episode	O
schizophrenia	B_Disease
(	O
75	O
%	O
)	O
,	O
schizophreniform	B_Disease
disorder	I_Disease
(	O
17	O
%	O
)	O
,	O
or	O
schizoaffective	B_Disease
disorder	I_Disease
(	O
8	O
%	O
)	O
were	O
randomly	O
assigned	O
to	O
treatment	O
with	O
olanzapine	B_Chemical
(	O
2.5	O
-	O
20	O
mg/day	O
)	O
or	O
risperidone	B_Chemical
(	O
1	O
-	O
6	O
mg/day	O
)	O
.	O

RESULTS	O
:	O
Response	O
rates	O
did	O
not	O
significantly	O
differ	O
between	O
olanzapine	B_Chemical
(	O
43.7	O
%	O
,	O
95	O
%	O
CI=28.8%-58.6	O
%	O
)	O
and	O
risperidone	B_Chemical
(	O
54.3	O
%	O
,	O
95	O
%	O
CI=39.9%-68.7	O
%	O
)	O
.	O

Among	O
those	O
responding	O
to	O
treatment	O
,	O
more	O
subjects	O
in	O
the	O
olanzapine	B_Chemical
group	O
(	O
40.9	O
%	O
,	O
95	O
%	O
CI=16.8%-65.0	O
%	O
)	O
than	O
in	O
the	O
risperidone	B_Chemical
group	O
(	O
18.9	O
%	O
,	O
95	O
%	O
CI=0%-39.2	O
%	O
)	O
had	O
subsequent	O
ratings	O
not	O
meeting	O
response	O
criteria	O
.	O

Negative	O
symptom	O
outcomes	O
and	O
measures	O
of	O
parkinsonism	B_Disease
and	O
akathisia	B_Disease
did	O
not	O
differ	O
between	O
medications	O
.	O

Extrapyramidal	B_Disease
symptom	I_Disease
severity	O
scores	O
were	O
1.4	O
(	O
95	O
%	O
CI=1.2	O
-	O
1.6	O
)	O
with	O
risperidone	B_Chemical
and	O
1.2	O
(	O
95	O
%	O
CI=1.0	O
-	O
1.4	O
)	O
with	O
olanzapine	B_Chemical
.	O

Significantly	O
more	O
weight	B_Disease
gain	I_Disease
occurred	O
with	O
olanzapine	B_Chemical
than	O
with	O
risperidone	B_Chemical
:	O
the	O
increase	O
in	O
weight	O
at	O
4	O
months	O
relative	O
to	O
baseline	O
weight	O
was	O
17.3	O
%	O
(	O
95	O
%	O
CI=14.2%-20.5	O
%	O
)	O
with	O
olanzapine	B_Chemical
and	O
11.3	O
%	O
(	O
95	O
%	O
CI=8.4%-14.3	O
%	O
)	O
with	O
risperidone	B_Chemical
.	O

Body	O
mass	O
index	O
at	O
baseline	O
and	O
at	O
4	O
months	O
was	O
24.3	O
(	O
95	O
%	O
CI=22.8	O
-	O
25.7	O
)	O
versus	O
28.2	O
(	O
95	O
%	O
CI=26.7	O
-	O
29.7	O
)	O
with	O
olanzapine	B_Chemical
and	O
23.9	O
(	O
95	O
%	O
CI=22.5	O
-	O
25.3	O
)	O
versus	O
26.7	O
(	O
95	O
%	O
CI=25.2	O
-	O
28.2	O
)	O
with	O
risperidone	B_Chemical
.	O

CONCLUSIONS	O
:	O
Clinical	O
outcomes	O
with	O
risperidone	B_Chemical
were	O
equal	O
to	O
those	O
with	O
olanzapine	B_Chemical
,	O
and	O
response	O
may	O
be	O
more	O
stable	O
.	O

Olanzapine	B_Chemical
may	O
have	O
an	O
advantage	O
for	O
motor	O
side	O
effects	O
.	O

Both	O
medications	O
caused	O
substantial	O
rapid	O
weight	B_Disease
gain	I_Disease
,	O
but	O
weight	B_Disease
gain	I_Disease
was	O
greater	O
with	O
olanzapine	B_Chemical
.	O

Early	O
paracentral	O
visual	B_Disease
field	I_Disease
loss	I_Disease
in	O
patients	O
taking	O
hydroxychloroquine	B_Chemical
.	O

OBJECTIVE	O
:	O
To	O
review	O
the	O
natural	O
history	O
and	O
ocular	O
and	O
systemic	O
adverse	O
effects	O
of	O
patients	O
taking	O
hydroxychloroquine	B_Chemical
sulfate	I_Chemical
who	O
attended	O
an	O
ophthalmic	O
screening	O
program	O
.	O

DESIGN	O
:	O
Retrospective	O
study	O
.	O

RESULTS	O
:	O
Records	O
of	O
262	O
patients	O
who	O
were	O
taking	O
hydroxychloroquine	B_Chemical
and	O
screened	O
in	O
the	O
Department	O
of	O
Ophthalmology	O
were	O
reviewed	O
.	O

Of	O
the	O
262	O
patients	O
,	O
14	O
(	O
18	O
%	O
)	O
of	O
76	O
who	O
had	O
stopped	O
treatment	O
at	O
the	O
time	O
of	O
the	O
study	O
experienced	O
documented	O
adverse	O
effects	O
.	O

Systemic	O
adverse	O
effects	O
occurred	O
in	O
8	O
patients	O
(	O
10.5	O
%	O
)	O
and	O
ocular	O
adverse	O
effects	O
,	O
in	O
5	O
(	O
6.5	O
%	O
)	O
.	O

Thirty-five	O
patients	O
(	O
13.4	O
%	O
)	O
had	O
visual	B_Disease
field	I_Disease
abnormalities	I_Disease
,	O
which	O
were	O
attributed	O
to	O
hydroxychloroquine	B_Chemical
treatment	O
in	O
4	O
patients	O
(	O
1.5	O
%	O
)	O
.	O

Three	O
of	O
the	O
4	O
patients	O
were	O
taking	O
less	O
than	O
6.5	O
mg/kg	O
per	O
day	O
and	O
all	O
patients	O
had	O
normal	O
renal	O
and	O
liver	O
function	O
test	O
results	O
.	O

CONCLUSIONS	O
:	O
The	O
current	O
study	O
used	O
a	O
protocol	O
of	O
visual	O
acuity	O
and	O
color	O
vision	O
assessment	O
,	O
funduscopy	O
,	O
and	O
Humphrey	O
10	O
-	O
2	O
visual	O
field	O
testing	O
and	O
shows	O
that	O
visual	B_Disease
field	I_Disease
defects	I_Disease
appeared	O
before	O
any	O
corresponding	O
changes	O
in	O
any	O
other	O
tested	O
clinical	O
parameters	O
;	O
the	O
defects	O
were	O
reproducible	O
and	O
the	O
test	O
parameters	O
were	O
reliable	O
.	O

Patients	O
taking	O
hydroxychloroquine	B_Chemical
can	O
demonstrate	O
a	O
toxic	O
reaction	O
in	O
the	O
retina	O
despite	O
the	O
absence	O
of	O
known	O
risk	O
factors	O
.	O

Screening	O
,	O
including	O
Humphrey	O
10	O
-	O
2	O
visual	O
field	O
assessment	O
,	O
is	O
recommended	O
2	O
years	O
after	O
the	O
initial	O
baseline	O
and	O
yearly	O
thereafter	O
.	O

Peri-operative	O
atrioventricular	B_Disease
block	I_Disease
as	O
a	O
result	O
of	O
chemotherapy	O
with	O
epirubicin	B_Chemical
and	O
paclitaxel	B_Chemical
.	O

A	O
47-year-old	O
woman	O
presented	O
for	O
mastectomy	O
and	O
immediate	O
latissimus	O
dorsi	O
flap	O
reconstruction	O
having	O
been	O
diagnosed	O
with	O
carcinoma	B_Disease
of	I_Disease
the	I_Disease
breast	I_Disease
6	O
months	O
previously	O
.	O

In	O
the	O
preceding	O
months	O
she	O
had	O
received	O
neo-adjuvant	O
chemotherapy	O
with	O
epirubicin	B_Chemical
,	O
paclitaxel	B_Chemical
(	O
Taxol	B_Chemical
)	O
and	O
cyclophosphamide	B_Chemical
.	O

This	O
had	O
been	O
apparently	O
uncomplicated	O
and	O
she	O
had	O
maintained	O
a	O
remarkably	O
high	O
level	O
of	O
physical	O
activity	O
.	O

She	O
was	O
found	O
to	O
be	O
bradycardic	B_Disease
at	O
pre-operative	O
assessment	O
but	O
had	O
no	O
cardiac	O
symptoms	O
.	O

Second	O
degree	O
Mobitz	O
type	O
II	O
atrioventricular	B_Disease
block	I_Disease
was	O
diagnosed	O
on	O
electrocardiogram	O
,	O
and	O
temporary	O
transvenous	O
ventricular	O
pacing	O
instituted	O
in	O
the	O
peri-operative	O
period	O
.	O

We	O
discuss	O
how	O
evidence-based	O
guidelines	O
would	O
not	O
have	O
been	O
helpful	O
in	O
this	O
case	O
,	O
and	O
how	O
chemotherapy	O
can	O
exhibit	O
substantial	O
cardiotoxicity	B_Disease
that	O
may	O
develop	O
over	O
many	O
years	O
.	O

We	O
suggest	O
that	O
patients	O
who	O
have	O
received	O
chemotherapy	O
at	O
any	O
time	O
should	O
have	O
a	O
pre-operative	O
electrocardiogram	O
even	O
if	O
they	O
are	O
asymptomatic	O
.	O

Risks	O
and	O
benefits	O
of	O
COX-2	O
inhibitors	O
vs	O
non-selective	O
NSAIDs	O
:	O
does	O
their	O
cardiovascular	O
risk	O
exceed	O
their	O
gastrointestinal	O
benefit	O
?	O
A	O
retrospective	O
cohort	O
study	O
.	O

OBJECTIVES	O
:	O
The	O
risk	O
of	O
acute	B_Disease
myocardial	I_Disease
infarction	I_Disease
(	O
AMI	B_Disease
)	O
with	O
COX-2	B_Chemical
inhibitors	I_Chemical
may	O
offset	O
their	O
gastrointestinal	O
(	O
GI	O
)	O
benefit	O
compared	O
with	O
non-selective	O
(	O
NS	O
)	O
non-steroidal	B_Chemical
anti-inflammatory	I_Chemical
drugs	I_Chemical
(	O
NSAIDs	O
)	O
.	O

We	O
aimed	O
to	O
compare	O
the	O
risks	O
of	O
hospitalization	O
for	O
AMI	B_Disease
and	O
GI	B_Disease
bleeding	I_Disease
among	O
elderly	O
patients	O
using	O
COX-2	B_Chemical
inhibitors	I_Chemical
,	O
NS-NSAIDs	O
and	O
acetaminophen	B_Chemical
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
cohort	O
study	O
using	O
administrative	O
data	O
of	O
patients	O
>	O
or	O
=	O
65	O
years	O
of	O
age	O
who	O
filled	O
a	O
prescription	O
for	O
NSAID	O
or	O
acetaminophen	B_Chemical
during	O
1999	O
-	O
2002	O
.	O

Outcomes	O
were	O
compared	O
using	O
Cox	O
regression	O
models	O
with	O
time-dependent	O
exposures	O
.	O

RESULTS	O
:	O
Person-years	O
of	O
exposure	O
among	O
non-users	O
of	O
aspirin	B_Chemical
were	O
:	O
75,761	O
to	O
acetaminophen	B_Chemical
,	O
42,671	O
to	O
rofecoxib	B_Chemical
65,860	O
to	O
celecoxib	B_Chemical
,	O
and	O
37,495	O
to	O
NS-NSAIDs	O
.	O

Among	O
users	O
of	O
aspirin	B_Chemical
,	O
they	O
were	O
:	O
14,671	O
to	O
rofecoxib	B_Chemical
,	O
22,875	O
to	O
celecoxib	B_Chemical
,	O
9,832	O
to	O
NS-NSAIDs	O
and	O
38,048	O
to	O
acetaminophen	B_Chemical
.	O

Among	O
non-users	O
of	O
aspirin	B_Chemical
,	O
the	O
adjusted	O
hazard	O
ratios	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
of	O
hospitalization	O
for	O
AMI/GI	O
vs	O
the	O
acetaminophen	B_Chemical
(	O
with	O
no	O
aspirin	B_Chemical
)	O
group	O
were	O
:	O
rofecoxib	B_Chemical
1.27	O
(	O
1.13	O
,	O
1.42	O
)	O
,	O
celecoxib	B_Chemical
0.93	O
(	O
0.83	O
,	O
1.03	O
)	O
,	O
naproxen	B_Chemical
1.59	O
(	O
1.31	O
,	O
1.93	O
)	O
,	O
diclofenac	B_Chemical
1.17	O
(	O
0.99	O
,	O
1.38	O
)	O
and	O
ibuprofen	B_Chemical
1.05	O
(	O
0.74	O
,	O
1.51	O
)	O
.	O

Among	O
users	O
of	O
aspirin	B_Chemical
,	O
they	O
were	O
:	O
rofecoxib	B_Chemical
1.73	O
(	O
1.52	O
,	O
1.98	O
)	O
,	O
celecoxib	B_Chemical
1.34	O
(	O
1.19	O
,	O
1.52	O
)	O
,	O
ibuprofen	B_Chemical
1.51	O
(	O
0.95	O
,	O
2.41	O
)	O
,	O
diclofenac	B_Chemical
1.69	O
(	O
1.35	O
,	O
2.10	O
)	O
,	O
naproxen	B_Chemical
1.35	O
(	O
0.97	O
,	O
1.88	O
)	O
and	O
acetaminophen	B_Chemical
1.29	O
(	O
1.17	O
,	O
1.42	O
)	O
.	O

CONCLUSION	O
:	O
Among	O
non-users	O
of	O
aspirin	B_Chemical
,	O
naproxen	B_Chemical
seemed	O
to	O
carry	O
the	O
highest	O
risk	O
for	O
AMI/GI	O
bleeding	O
.	O

The	O
AMI/GI	O
toxicity	B_Disease
of	O
celecoxib	B_Chemical
was	O
similar	O
to	O
that	O
of	O
acetaminophen	B_Chemical
and	O
seemed	O
to	O
be	O
better	O
than	O
those	O
of	O
rofecoxib	B_Chemical
and	O
NS-NSAIDs	O
.	O

Among	O
users	O
of	O
aspirin	B_Chemical
,	O
both	O
celecoxib	B_Chemical
and	O
naproxen	B_Chemical
seemed	O
to	O
be	O
the	O
least	O
toxic	O
.	O

Quinine-induced	O
arrhythmia	B_Disease
in	O
a	O
patient	O
with	O
severe	B_Disease
malaria	I_Disease
.	O

It	O
was	O
reported	O
that	O
there	O
was	O
a	O
case	O
of	O
severe	B_Disease
malaria	I_Disease
patient	O
with	O
jaundice	B_Disease
who	O
presented	O
with	O
arrhythmia	B_Disease
(	O
premature	B_Disease
ventricular	I_Disease
contraction	I_Disease
)	O
while	O
getting	O
quinine	B_Chemical
infusion	O
was	O
reported	O
.	O

A	O
man	O
,	O
25	O
years	O
old	O
,	O
was	O
admitted	O
to	O
hospital	O
with	O
high	O
fever	B_Disease
,	O
chill	B_Disease
,	O
vomiting	B_Disease
,	O
jaundice	B_Disease
.	O

The	O
patient	O
was	O
fully	O
conscious	O
,	O
blood	O
pressure	O
120/80	O
mmHg	O
,	O
pulse	O
rate	O
100	O
x/minute	O
,	O
regular	O
.	O

On	O
admission	O
,	O
laboratory	O
examination	O
showed	O
Plasmodium	O
falciparum	O
(	O
+	O
+	O
+	O
+	O
)	O
,	O
total	O
bilirubin	B_Chemical
8.25	O
mg/dL	O
,	O
conjugated	O
bilirubin	B_Chemical
4.36	O
mg/dL	O
,	O
unconjugated	O
bilirubin	B_Chemical
3.89	O
mg/dL	O
,	O
potassium	B_Chemical
3.52	O
meq/L	O
Patient	O
was	O
diagnosed	O
as	O
severe	B_Disease
malaria	I_Disease
with	O
jaundice	B_Disease
and	O
got	O
quinine	B_Chemical
infusion	O
in	O
dextrose	B_Chemical
5	O
%	O
500	O
mg/8	O
hour	O
.	O

On	O
the	O
second	O
day	O
the	O
patient	O
had	O
vomitus	B_Disease
,	O
diarrhea	B_Disease
,	O
tinnitus	B_Disease
,	O
loss	B_Disease
of	I_Disease
hearing	I_Disease
.	O

After	O
30	O
hours	O
of	O
quinine	B_Chemical
infusion	O
the	O
patient	O
felt	O
palpitation	B_Disease
and	O
electrocardiography	O
(	O
ECG	O
)	O
recording	O
showed	O
premature	B_Disease
ventricular	I_Disease
contraction	I_Disease
(	O
PVC	B_Disease
)	O
>	O
5	O
x/minute	O
,	O
trigemini	O
,	O
constant	O
type	O
--	O
sinoatrial	B_Disease
block	I_Disease
,	O
positive	O
U	O
wave	O
.	O

He	O
was	O
treated	O
with	O
lidocaine	B_Chemical
50	O
mg	O
intravenously	O
followed	O
by	O
infusion	O
1500	O
mg	O
in	O
dextrose	B_Chemical
5%/24	O
hour	O
and	O
potassium	B_Chemical
aspartate	I_Chemical
tablet	O
.	O

Quinine	B_Chemical
infusion	O
was	O
discontinued	O
and	O
changed	O
with	O
sulfate	O
quinine	B_Chemical
tablets	O
.	O

Three	O
hours	O
later	O
the	O
patient	O
felt	O
better	O
,	O
the	O
frequency	O
of	O
PVC	B_Disease
reduced	O
to	O
4	O
-	O
5	O
x/minute	O
and	O
on	O
the	O
third	O
day	O
ECG	O
was	O
normal	O
,	O
potassium	B_Chemical
level	O
was	O
3.34	O
meq/L.	O
He	O
was	O
discharged	O
on	O
7th	O
day	O
in	O
good	O
condition	O
.	O

Quinine	B_Chemical
,	O
like	O
quinidine	B_Chemical
,	O
is	O
a	O
chincona	O
alkaloid	O
that	O
has	O
anti-arrhythmic	O
property	O
,	O
although	O
it	O
also	O
pro-arrhythmic	O
that	O
can	O
cause	O
various	O
arrhythmias	B_Disease
,	O
including	O
severe	O
arrhythmia	B_Disease
such	O
as	O
multiple	O
PVC	B_Disease
.	O

Administration	O
of	O
parenteral	O
quinine	B_Chemical
must	O
be	O
done	O
carefully	O
and	O
with	O
good	O
observation	O
because	O
of	O
its	O
pro-arrhythmic	O
effect	O
,	O
especially	O
in	O
older	O
patients	O
who	O
have	O
heart	B_Disease
diseases	I_Disease
or	O
patients	O
with	O
electrolyte	B_Disease
disorder	I_Disease
(	O
hypokalemia	B_Disease
)	O
which	O
frequently	O
occurs	O
due	O
to	O
vomiting	B_Disease
and	O
or	O
diarrhea	B_Disease
in	O
malaria	B_Disease
cases	O
.	O

Penicillamine-related	O
lichenoid	B_Disease
dermatitis	I_Disease
and	O
utility	O
of	O
zinc	B_Chemical
acetate	I_Chemical
in	O
a	O
Wilson	B_Disease
disease	I_Disease
patient	O
with	O
hepatic	O
presentation	O
,	O
anxiety	B_Disease
and	O
SPECT	O
abnormalities	O
.	O

Wilson	B_Disease
's	I_Disease
disease	I_Disease
is	O
an	O
autosomal	O
recessive	O
disorder	O
of	O
hepatic	O
copper	B_Chemical
metabolism	O
with	O
consequent	O
copper	B_Chemical
accumulation	O
and	O
toxicity	B_Disease
in	O
many	O
tissues	O
and	O
consequent	O
hepatic	B_Disease
,	I_Disease
neurologic	I_Disease
and	I_Disease
psychiatric	B_Disease
disorders	I_Disease
.	O

We	O
report	O
a	O
case	O
of	O
Wilson	B_Disease
's	I_Disease
disease	I_Disease
with	O
chronic	B_Disease
liver	I_Disease
disease	I_Disease
;	O
moreover	O
,	O
in	O
our	O
patient	O
,	O
presenting	O
also	O
with	O
high	O
levels	O
of	O
state	O
anxiety	B_Disease
without	O
depression	B_Disease
,	O
99mTc-ECD-SPECT	O
showed	O
cortical	O
hypoperfusion	O
in	O
frontal	O
lobes	O
,	O
more	O
marked	O
on	O
the	O
left	O
frontal	O
lobe	O
.	O

During	O
the	O
follow-up	O
of	O
our	O
patient	O
,	O
penicillamine	B_Chemical
was	O
interrupted	O
after	O
the	O
appearance	O
of	O
a	O
lichenoid	B_Disease
dermatitis	I_Disease
,	O
and	O
zinc	B_Chemical
acetate	I_Chemical
permitted	O
to	O
continue	O
the	O
successful	O
treatment	O
of	O
the	O
patient	O
without	O
side-effects	O
.	O

In	O
our	O
case	O
the	O
therapy	O
with	O
zinc	B_Chemical
acetate	I_Chemical
represented	O
an	O
effective	O
treatment	O
for	O
a	O
Wilson	B_Disease
's	I_Disease
disease	I_Disease
patient	O
in	O
which	O
penicillamine-related	O
side	O
effects	O
appeared	O
.	O

The	O
safety	O
of	O
the	O
zinc	B_Chemical
acetate	I_Chemical
allowed	O
us	O
to	O
avoid	O
other	O
potentially	O
toxic	O
chelating	O
drugs	O
;	O
this	O
observation	O
is	O
in	O
line	O
with	O
the	O
growing	O
evidence	O
on	O
the	O
efficacy	O
of	O
the	O
drug	O
in	O
the	O
treatment	O
of	O
Wilson	B_Disease
's	I_Disease
disease	I_Disease
.	O

Since	O
most	O
of	O
Wilson	B_Disease
's	I_Disease
disease	I_Disease
penicillamine-treated	O
patients	O
do	O
not	O
seem	O
to	O
develop	O
this	O
skin	B_Disease
lesion	I_Disease
,	O
it	O
could	O
be	O
conceivable	O
that	O
a	O
specific	O
genetic	O
factor	O
is	O
involved	O
in	O
drug	O
response	O
.	O

Further	O
studies	O
are	O
needed	O
for	O
a	O
better	O
clarification	O
of	O
Wilson	B_Disease
's	I_Disease
disease	I_Disease
therapy	O
,	O
and	O
in	O
particular	O
to	O
differentiate	O
specific	O
therapies	O
for	O
different	O
Wilson	B_Disease
's	I_Disease
disease	I_Disease
phenotypes	O
.	O

A	O
dramatic	O
drop	B_Disease
in	I_Disease
blood	I_Disease
pressure	I_Disease
following	O
prehospital	O
GTN	B_Chemical
administration	O
.	O

A	O
male	O
in	O
his	O
sixties	O
with	O
no	O
history	O
of	O
cardiac	O
chest	B_Disease
pain	I_Disease
awoke	O
with	O
chest	B_Disease
pain	I_Disease
following	O
an	O
afternoon	O
sleep	O
.	O

The	O
patient	O
did	O
not	O
self	O
medicate	O
.	O

The	O
patient	O
's	O
observations	O
were	O
within	O
normal	O
limits	O
,	O
he	O
was	O
administered	O
oxygen	B_Chemical
via	O
a	O
face	O
mask	O
and	O
glyceryl	B_Chemical
trinitrate	I_Chemical
(	O
GTN	B_Chemical
)	O
.	O

Several	O
minutes	O
after	O
the	O
GTN	B_Chemical
the	O
patient	O
experienced	O
a	O
sudden	O
drop	B_Disease
in	I_Disease
blood	I_Disease
pressure	I_Disease
and	O
heart	O
rate	O
,	O
this	O
was	O
rectified	O
by	O
atropine	B_Chemical
sulphate	I_Chemical
and	O
a	O
fluid	O
challenge	O
.	O

There	O
was	O
no	O
further	O
deterioration	O
in	O
the	O
patient	O
's	O
condition	O
during	O
transport	O
to	O
hospital	O
.	O

There	O
are	O
very	O
few	O
documented	O
case	O
like	O
this	O
in	O
the	O
prehospital	O
scientific	O
literature	O
.	O

The	O
cause	O
appears	O
to	O
be	O
the	O
Bezold-Jarish	O
reflex	O
,	O
stimulation	O
of	O
the	O
ventricular	O
walls	O
which	O
in	O
turn	O
decreases	O
sympathetic	O
outflow	O
from	O
the	O
vasomotor	O
centre	O
.	O

Prehospital	O
care	O
providers	O
who	O
are	O
managing	O
any	O
patient	O
with	O
a	O
syncopal	B_Disease
episode	I_Disease
that	O
fails	O
to	O
recover	O
within	O
a	O
reasonable	O
time	O
frame	O
should	O
consider	O
the	O
Bezold-Jarisch	O
reflex	O
as	O
the	O
cause	O
and	O
manage	O
the	O
patient	O
accordingly	O
.	O

Chronic	O
lesion	O
of	O
rostral	O
ventrolateral	O
medulla	O
in	O
spontaneously	O
hypertensive	O
rats	O
.	O

We	O
studied	O
the	O
effects	O
of	O
chronic	O
selective	O
neuronal	O
lesion	O
of	O
rostral	O
ventrolateral	O
medulla	O
on	O
mean	O
arterial	O
pressure	O
,	O
heart	O
rate	O
,	O
and	O
neurogenic	O
tone	O
in	O
conscious	O
,	O
unrestrained	O
spontaneously	O
hypertensive	B_Disease
rats	O
.	O

The	O
lesions	O
were	O
placed	O
via	O
bilateral	O
microinjections	O
of	O
30	O
nmol/200	O
nl	O
N-methyl-D-aspartic	B_Chemical
acid	I_Chemical
.	O

The	O
restimulation	O
of	O
this	O
area	O
with	O
N-methyl-D-aspartic	B_Chemical
acid	I_Chemical
15	O
days	O
postlesion	O
failed	O
to	O
produce	O
a	O
pressor	O
response	O
.	O

One	O
day	O
postlesion	O
,	O
the	O
resting	O
mean	O
arterial	O
pressure	O
was	O
significantly	O
decreased	O
in	O
lesioned	O
rats	O
when	O
compared	O
with	O
sham	O
rats	O
(	O
100	O
+	O
/-	O
7	O
versus	O
173	O
+	O
/-	O
4	O
mm	O
Hg	O
,	O
p	O
less	O
than	O
0.05	O
)	O
.	O

Fifteen	O
days	O
later	O
,	O
the	O
lesioned	O
group	O
still	O
showed	O
values	O
significantly	O
lower	O
than	O
the	O
sham	O
group	O
(	O
150	O
+	O
/-	O
6	O
versus	O
167	O
+	O
/-	O
5	O
mm	O
Hg	O
,	O
p	O
less	O
than	O
0.05	O
)	O
.	O

No	O
significant	O
heart	O
rate	O
differences	O
were	O
observed	O
between	O
the	O
sham	O
and	O
lesioned	O
groups	O
.	O

The	O
ganglionic	O
blocker	O
trimethaphan	B_Chemical
(	O
5	O
mg/kg	O
i.v	O
.	O
)	O
caused	O
similar	O
reductions	O
in	O
mean	O
arterial	O
pressure	O
in	O
both	O
lesioned	O
and	O
sham	O
groups	O
.	O

The	O
trimethaphan-induced	O
hypotension	B_Disease
was	O
accompanied	O
by	O
a	O
significant	O
bradycardia	B_Disease
in	O
lesioned	O
rats	O
(	O
-32	O
+	O
/-	O
13	O
beats	O
per	O
minute	O
)	O
but	O
a	O
tachycardia	B_Disease
in	O
sham	O
rats	O
(	O
+	O
33	O
+	O
/-	O
12	O
beats	O
per	O
minute	O
)	O
1	O
day	O
postlesion	O
.	O

Therefore	O
,	O
rostral	O
ventrolateral	O
medulla	O
neurons	O
appear	O
to	O
play	O
a	O
significant	O
role	O
in	O
maintaining	O
hypertension	B_Disease
in	O
conscious	O
spontaneously	O
hypertensive	B_Disease
rats	O
.	O

Spinal	O
or	O
suprabulbar	O
structures	O
could	O
be	O
responsible	O
for	O
the	O
gradual	O
recovery	O
of	O
the	O
hypertension	B_Disease
in	O
the	O
lesioned	O
rats	O
.	O

Acute	B_Disease
encephalopathy	I_Disease
and	O
cerebral	B_Disease
vasospasm	I_Disease
after	O
multiagent	O
chemotherapy	O
including	O
PEG-asparaginase	B_Chemical
and	O
intrathecal	O
cytarabine	B_Chemical
for	O
the	O
treatment	O
of	O
acute	B_Disease
lymphoblastic	I_Disease
leukemia	I_Disease
.	O

A	O
7-year-old	O
girl	O
with	O
an	O
unusual	O
reaction	O
to	O
induction	O
chemotherapy	O
for	O
precursor	O
B-cell	O
acute	B_Disease
lymphoblastic	I_Disease
leukemia	I_Disease
(	O
ALL	B_Disease
)	O
is	O
described	O
.	O

The	O
patient	O
developed	O
acute	B_Disease
encephalopathy	I_Disease
evidenced	O
by	O
behavioral	O
changes	O
,	O
aphasia	B_Disease
,	O
incontinence	B_Disease
,	O
visual	B_Disease
hallucinations	I_Disease
,	O
and	O
right-sided	O
weakness	B_Disease
with	O
diffuse	O
cerebral	B_Disease
vasospasm	I_Disease
on	O
magnetic	O
resonance	O
angiography	O
after	O
the	O
administration	O
of	O
intrathecal	O
cytarabine	B_Chemical
.	O

Vincristine	B_Chemical
,	O
dexamethasone	B_Chemical
,	O
and	O
polyethylene	B_Chemical
glycol-asparaginase	I_Chemical
were	O
also	O
administered	O
before	O
the	O
episode	O
as	O
part	O
of	O
induction	O
therapy	O
.	O

Neurologic	O
status	O
returned	O
to	O
baseline	O
within	O
10	O
days	O
of	O
the	O
acute	O
event	O
,	O
and	O
magnetic	O
resonance	O
angiography	O
findings	O
returned	O
to	O
normal	O
4	O
months	O
later	O
.	O

Comparison	O
of	O
valsartan/hydrochlorothiazide	O
combination	O
therapy	O
at	O
doses	O
up	O
to	O
320/25	O
mg	O
versus	O
monotherapy	O
:	O
a	O
double-blind	O
,	O
placebo-controlled	O
study	O
followed	O
by	O
long-term	O
combination	O
therapy	O
in	O
hypertensive	B_Disease
adults	O
.	O

BACKGROUND	O
:	O
One	O
third	O
of	O
patients	O
treated	O
for	O
hypertension	B_Disease
attain	O
adequate	O
blood	O
pressure	O
(	O
BP	O
)	O
control	O
,	O
and	O
multidrug	O
regimens	O
are	O
often	O
required	O
.	O

Given	O
the	O
lifelong	O
nature	O
of	O
hypertension	B_Disease
,	O
there	O
is	O
a	O
need	O
to	O
evaluate	O
the	O
long-term	O
efficacy	O
and	O
tolerability	O
of	O
higher	O
doses	O
of	O
combination	O
anti-hypertensive	O
therapies	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
investigated	O
the	O
efficacy	O
and	O
tolerability	O
of	O
valsartan	B_Chemical
(	O
VAL	B_Chemical
)	O
or	O
hydrochlorothiazide	B_Chemical
(HCTZ)-monotherapy	O
and	O
higher-dose	O
combinations	O
in	O
patients	O
with	O
essential	B_Disease
hypertension	I_Disease
.	O

METHODS	O
:	O
The	O
first	O
part	O
of	O
this	O
study	O
was	O
an	O
8-week	O
,	O
multicenter	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo	O
controlled	O
,	O
parallel-group	O
trial	O
.	O

Patients	O
with	O
essential	B_Disease
hypertension	I_Disease
(	O
mean	O
sitting	O
diastolic	O
BP	O
[	O
MSDBP	O
]	O
,	O
>	O
or	O
=	O
95	O
mm	O
Hg	O
and	O
<	O
110	O
mm	O
Hg	O
)	O
were	O
randomized	O
to	O
1	O
of	O
8	O
treatment	O
groups	O
:	O
VAL	B_Chemical
160	O
or	O
320	O
mg	O
;	O
HCTZ	B_Chemical
12.5	O
or	O
25	O
mg	O
;	O
VAL/HCTZ	O
160/12.5	O
,	O
320/12.5	O
,	O
or	O
320/25	O
mg	O
;	O
or	O
placebo	O
.	O

Mean	O
changes	O
in	O
MSDBP	O
and	O
mean	O
sitting	O
systolic	O
BP	O
(	O
MSSBP	O
)	O
were	O
analyzed	O
at	O
the	O
8-week	O
core	O
study	O
end	O
point	O
.	O

VAL/HCTZ	O
320/12.5	O
and	O
320/25	O
mg	O
were	O
further	O
investigated	O
in	O
a	O
54-week	O
,	O
open-label	O
extension	O
.	O

Response	O
was	O
defined	O
as	O
MSDBP	O
<	O
90	O
mm	O
Hg	O
or	O
a	O
>	O
or	O
=	O
10	O
mm	O
Hg	O
decrease	O
compared	O
to	O
baseline	O
.	O

Control	O
was	O
defined	O
as	O
MSDBP	O
<	O
90	O
mm	O
Hg	O
compared	O
with	O
baseline	O
.	O

Tolerability	O
was	O
assessed	O
by	O
monitoring	O
adverse	O
events	O
at	O
randomization	O
and	O
all	O
subsequent	O
study	O
visits	O
and	O
regular	O
evaluation	O
of	O
hematology	O
and	O
blood	O
chemistry	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
1346	O
patients	O
were	O
randomized	O
into	O
the	O
8-week	O
core	O
study	O
(	O
734	O
men	O
,	O
612	O
women	O
;	O
924	O
white	O
,	O
291	O
black	O
,	O
23	O
Asian	O
,	O
108	O
other	O
;	O
mean	O
age	O
,	O
52.7	O
years	O
;	O
mean	O
weight	O
,	O
92.6	O
kg	O
)	O
.	O

All	O
active	O
treatments	O
were	O
associated	O
with	O
significantly	O
reduced	O
MSSBP	O
and	O
MSDBP	O
during	O
the	O
core	O
8-week	O
study	O
,	O
with	O
each	O
monotherapy	O
significantly	O
contributing	O
to	O
the	O
overall	O
effect	O
of	O
combination	O
therapy	O
(	O
VAL	B_Chemical
and	O
HCTZ	B_Chemical
,	O
P	O
<	O
0.001	O
)	O
.	O

Each	O
combination	O
was	O
associated	O
with	O
significantly	O
greater	O
reductions	O
in	O
MSSBP	O
and	O
MSDBP	O
compared	O
with	O
the	O
monotherapies	O
and	O
placebo	O
(	O
all	O
,	O
P	O
<	O
0.001	O
)	O
.	O

The	O
mean	O
reduction	O
in	O
MSSBP/MSDBP	O
with	O
VAL/HCTZ	O
320/25	O
mg	O
was	O
24.7/16.6	O
mm	O
Hg	O
,	O
compared	O
with	O
5.9/7.0	O
mm	O
Hg	O
with	O
placebo	O
.	O

The	O
reduction	O
in	O
MSSBP	O
was	O
significantly	O
greater	O
with	O
VAL/HCTZ	O
320/25	O
mg	O
compared	O
with	O
VAL/HCTZ	O
160/12.5	O
mg	O
(	O
P	O
<	O
0.002	O
)	O
.	O

Rates	O
of	O
response	O
and	O
BP	O
control	O
were	O
significantly	O
higher	O
in	O
the	O
groups	O
that	O
received	O
combination	O
treatment	O
compared	O
with	O
those	O
that	O
received	O
monotherapy	O
.	O

The	O
incidence	O
of	O
hypokalemia	B_Disease
was	O
lower	O
with	O
VAL/HCTZ	O
combinations	O
(	O
1.8%-6.1	O
%	O
)	O
than	O
with	O
HCTZ	B_Chemical
monotherapies	O
(	O
7.1%-13.3	O
%	O
)	O
.	O

The	O
majority	O
of	O
adverse	O
events	O
in	O
the	O
core	O
study	O
were	O
of	O
mild	O
to	O
moderate	O
severity	O
.	O

The	O
efficacy	O
and	O
tolerability	O
of	O
VAL/HCTZ	O
combinations	O
were	O
maintained	O
during	O
the	O
extension	O
(	O
797	O
patients	O
)	O
.	O

CONCLUSIONS	O
:	O
In	O
this	O
study	O
population	O
,	O
combination	O
therapies	O
with	O
VAL/HCTZ	O
were	O
associated	O
with	O
significantly	O
greater	O
BP	O
reductions	O
compared	O
with	O
either	O
monotherapy	O
,	O
were	O
well	O
tolerated	O
,	O
and	O
were	O
associated	O
with	O
less	O
hypokalemia	B_Disease
than	O
HCTZ	B_Chemical
alone	O
.	O

Succimer	B_Chemical
chelation	O
improves	O
learning	O
,	O
attention	O
,	O
and	O
arousal	O
regulation	O
in	O
lead-exposed	O
rats	O
but	O
produces	O
lasting	O
cognitive	B_Disease
impairment	I_Disease
in	O
the	O
absence	O
of	O
lead	B_Chemical
exposure	O
.	O

BACKGROUND	O
:	O
There	O
is	O
growing	O
pressure	O
for	O
clinicians	O
to	O
prescribe	O
chelation	O
therapy	O
at	O
only	O
slightly	O
elevated	O
blood	O
lead	B_Chemical
levels	O
.	O

However	O
,	O
very	O
few	O
studies	O
have	O
evaluated	O
whether	O
chelation	O
improves	O
cognitive	O
outcomes	O
in	O
Pb-exposed	O
children	O
,	O
or	O
whether	O
these	O
agents	O
have	O
adverse	O
effects	O
that	O
may	O
affect	O
brain	O
development	O
in	O
the	O
absence	O
of	O
Pb	B_Chemical
exposure	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
study	O
was	O
designed	O
to	O
answer	O
these	O
questions	O
,	O
using	O
a	O
rodent	O
model	O
of	O
early	O
childhood	O
Pb	B_Chemical
exposure	O
and	O
treatment	O
with	O
succimer	B_Chemical
,	O
a	O
widely	O
used	O
chelating	O
agent	O
for	O
the	O
treatment	O
of	O
Pb	B_Disease
poisoning	I_Disease
.	O

RESULTS	O
:	O
Pb	B_Chemical
exposure	O
produced	O
lasting	O
impairments	B_Disease
in	I_Disease
learning	I_Disease
,	I_Disease
attention	I_Disease
,	I_Disease
inhibitory	I_Disease
control	I_Disease
,	I_Disease
and	I_Disease
arousal	I_Disease
regulation	I_Disease
,	O
paralleling	O
the	O
areas	O
of	O
dysfunction	O
seen	O
in	O
Pb-exposed	O
children	O
.	O

Succimer	B_Chemical
treatment	O
of	O
the	O
Pb-exposed	O
rats	O
significantly	O
improved	O
learning	O
,	O
attention	O
,	O
and	O
arousal	O
regulation	O
,	O
although	O
the	O
efficacy	O
of	O
the	O
treatment	O
varied	O
as	O
a	O
function	O
of	O
the	O
Pb	B_Chemical
exposure	O
level	O
and	O
the	O
specific	O
functional	O
deficit	O
.	O

In	O
contrast	O
,	O
succimer	B_Chemical
treatment	O
of	O
rats	O
not	O
previously	O
exposed	O
to	O
Pb	B_Chemical
produced	O
lasting	O
and	O
pervasive	O
cognitive	B_Disease
and	I_Disease
affective	B_Disease
dysfunction	I_Disease
comparable	O
in	O
magnitude	O
to	O
that	O
produced	O
by	O
the	O
higher	O
Pb	B_Chemical
exposure	O
regimen	O
.	O
CONCLUSIONS	O
:	O
These	O
are	O
the	O
first	O
data	O
,	O
to	O
our	O
knowledge	O
,	O
to	O
show	O
that	O
treatment	O
with	O
any	O
chelating	O
agent	O
can	O
alleviate	O
cognitive	B_Disease
deficits	I_Disease
due	O
to	O
Pb	B_Chemical
exposure	O
.	O

These	O
findings	O
suggest	O
that	O
it	O
may	O
be	O
possible	O
to	O
identify	O
a	O
succimer	B_Chemical
treatment	O
protocol	O
that	O
improves	O
cognitive	O
outcomes	O
in	O
Pb-exposed	O
children	O
.	O

However	O
,	O
they	O
also	O
suggest	O
that	O
succimer	B_Chemical
treatment	O
should	O
be	O
strongly	O
discouraged	O
for	O
children	O
who	O
do	O
not	O
have	O
elevated	O
tissue	O
levels	O
of	O
Pb	B_Chemical
or	O
other	O
heavy	O
metals	O
.	O

Caffeine	B_Chemical
challenge	O
test	O
in	O
panic	B_Disease
disorder	I_Disease
and	O
depression	B_Disease
with	O
panic	B_Disease
attacks	I_Disease
.	O

Our	O
aim	O
was	O
to	O
observe	O
if	O
patients	O
with	O
panic	B_Disease
disorder	I_Disease
(	O
PD	B_Disease
)	O
and	O
patients	O
with	O
major	B_Disease
depression	I_Disease
with	O
panic	B_Disease
attacks	I_Disease
(	O
MDP	B_Disease
)	O
(	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	B_Disease
Disorders	I_Disease
,	O
Fourth	O
Edition	O
criteria	O
)	O
respond	O
in	O
a	O
similar	O
way	O
to	O
the	O
induction	O
of	O
panic	B_Disease
attacks	I_Disease
by	O
an	O
oral	O
caffeine	B_Chemical
challenge	O
test	O
.	O

We	O
randomly	O
selected	O
29	O
patients	O
with	O
PD	B_Disease
,	O
27	O
with	O
MDP	B_Disease
,	O
25	O
with	O
major	B_Disease
depression	I_Disease
without	O
panic	B_Disease
attacks	I_Disease
(	O
MD	B_Disease
)	O
,	O
and	O
28	O
healthy	O
volunteers	O
.	O

The	O
patients	O
had	O
no	O
psychotropic	O
drug	O
for	O
at	O
least	O
a	O
4-week	O
period	O
.	O

In	O
a	O
randomized	O
double-blind	O
experiment	O
performed	O
in	O
2	O
occasions	O
7	O
days	O
apart	O
,	O
480	O
mg	O
caffeine	B_Chemical
and	O
a	O
caffeine-free	O
(	O
placebo	O
)	O
solution	O
were	O
administered	O
in	O
a	O
coffee	O
form	O
and	O
anxiety	B_Disease
scales	O
were	O
applied	O
before	O
and	O
after	O
each	O
test	O
.	O

A	O
total	O
of	O
58.6	O
%	O
(	O
n	O
=	O
17	O
)	O
of	O
patients	O
with	O
PD	B_Disease
,	O
44.4	O
%	O
(	O
n	O
=	O
12	O
)	O
of	O
patients	O
with	O
MDP	B_Disease
,	O
12.0	O
%	O
(	O
n	O
=	O
3	O
)	O
of	O
patients	O
with	O
MD	B_Disease
,	O
and	O
7.1	O
%	O
(	O
n=	O
2	O
)	O
of	O
control	O
subjects	O
had	O
a	O
panic	B_Disease
attack	I_Disease
after	O
the	O
480-mg	O
caffeine	B_Chemical
challenge	O
test	O
(	O
chi(2)(3	O
)	O
=	O
16.22	O
,	O
P	O
=	O
.001	O
)	O
.	O

The	O
patients	O
with	O
PD	B_Disease
and	O
MDP	B_Disease
were	O
more	O
sensitive	O
to	O
caffeine	B_Chemical
than	O
were	O
patients	O
with	O
MD	B_Disease
and	O
healthy	O
volunteers	O
.	O

No	O
panic	B_Disease
attack	I_Disease
was	O
observed	O
after	O
the	O
caffeine-free	O
solution	O
intake	O
.	O

The	O
patients	O
with	O
MD	B_Disease
had	O
a	O
lower	O
heart	O
rate	O
response	O
to	O
the	O
test	O
than	O
all	O
the	O
other	O
groups	O
(	O
2-way	O
analysis	O
of	O
variance	O
,	O
group	O
by	O
time	O
interaction	O
with	O
Greenhouse-Geisser	O
correction	O
:	O
F(3,762	O
)	O
=	O
2.85	O
,	O
P	O
=	O
.026	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
there	O
is	O
an	O
association	O
between	O
panic	B_Disease
attacks	I_Disease
,	O
no	O
matter	O
if	O
associated	O
with	O
PD	B_Disease
or	O
MDP	B_Disease
,	O
and	O
hyperreactivity	O
to	O
an	O
oral	O
caffeine	B_Chemical
challenge	O
test	O
.	O

Mitral	O
annuloplasty	O
as	O
a	O
ventricular	O
restoration	O
method	O
for	O
the	O
failing	O
left	O
ventricle	O
:	O
a	O
pilot	O
study	O
.	O

BACKGROUND	O
AND	O
AIM	O
OF	O
THE	O
STUDY	O
:	O
Undersized	O
mitral	O
annuloplasty	O
(	O
MAP	O
)	O
is	O
effective	O
in	O
patients	O
with	O
dilated	B_Disease
cardiomyopathy	I_Disease
and	O
functional	O
mitral	B_Disease
regurgitation	I_Disease
(	O
MR	B_Disease
)	O
since	O
,	O
as	O
well	O
as	O
addressing	O
the	O
MR	B_Disease
,	O
the	O
MAP	O
may	O
also	O
reshape	O
the	O
dilated	O
left	O
ventricular	O
(	O
LV	O
)	O
base	O
.	O

However	O
,	O
the	O
direct	O
benefits	O
of	O
this	O
possible	O
reshaping	O
on	O
LV	O
function	O
in	O
the	O
absence	O
of	O
underlying	O
MR	B_Disease
remain	O
incompletely	O
understood	O
.	O

The	O
study	O
aim	O
was	O
to	O
identify	O
these	O
benefits	O
in	O
a	O
canine	O
model	O
of	O
acute	O
heart	B_Disease
failure	I_Disease
.	O

METHODS	O
:	O
Six	O
dogs	O
underwent	O
MAP	O
with	O
a	O
prosthetic	O
band	O
on	O
the	O
posterior	O
mitral	O
annulus	O
,	O
using	O
four	O
mattress	O
sutures	O
.	O

The	O
sutures	O
were	O
passed	O
individually	O
through	O
four	O
tourniquets	O
and	O
exteriorized	O
untied	O
via	O
the	O
left	O
atriotomy	O
.	O

Sonomicrometry	O
crystals	O
were	O
implanted	O
around	O
the	O
mitral	O
annulus	O
and	O
left	O
ventricle	O
to	O
measure	O
geometry	O
and	O
regional	O
function	O
.	O

Acute	O
heart	B_Disease
failure	I_Disease
was	O
induced	O
by	O
propranolol	B_Chemical
and	O
volume	O
loading	O
after	O
weaning	O
from	O
cardiopulmonary	O
bypass	O
;	O
an	O
absence	O
of	O
MR	B_Disease
was	O
confirmed	O
by	O
echocardiography	O
.	O

MAP	O
was	O
accomplished	O
by	O
cinching	O
the	O
tourniquets	O
.	O

Data	O
were	O
acquired	O
at	O
baseline	O
,	O
after	O
induction	O
of	O
acute	O
heart	B_Disease
failure	I_Disease
,	O
and	O
after	O
MAP	O
.	O

RESULTS	O
:	O
MAP	O
decreased	O
mitral	O
annular	O
dimensions	O
in	O
both	O
commissure-commissure	O
and	O
septal-lateral	O
directions	O
.	O

Concomitantly	O
,	O
the	O
diastolic	O
diameter	O
of	O
the	O
LV	O
base	O
and	O
LV	O
sphericity	O
decreased	O
(	O
i.e.	O
,	O
improved	O
)	O
from	O
37.4	O
+	O
/-	O
9.3	O
to	O
35.9	O
+	O
/-	O
10	O
mm	O
(	O
p	O
=	O
0.063	O
)	O
,	O
and	O
from	O
67.9	O
+	O
/-	O
18.6	O
%	O
to	O
65.3	O
+	O
/-	O
18.9	O
%	O
(	O
p	O
=	O
0.016	O
)	O
,	O
respectively	O
.	O

Decreases	O
were	O
evident	O
in	O
both	O
LV	O
end-diastolic	O
pressure	O
(	O
from	O
17	O
+	O
/-	O
7	O
to	O
15	O
+	O
/-	O
6	O
mmHg	O
,	O
p	O
=	O
0.0480	O
and	O
Tau	O
(	O
from	O
48	O
+	O
/-	O
8	O
to	O
45	O
+	O
/-	O
8	O
ms	O
,	O
p	O
<	O
0.01	O
)	O
,	O
while	O
fractional	O
shortening	O
at	O
the	O
LV	O
base	O
increased	O
from	O
7.7	O
+	O
/-	O
4.5	O
%	O
to	O
9.4	O
+	O
/-	O
4.5	O
%	O
(	O
p	O
=	O
0.045	O
)	O
.	O

After	O
MAP	O
,	O
increases	O
were	O
identified	O
in	O
both	O
cardiac	O
output	O
(	O
from	O
1.54	O
+	O
/-	O
0.57	O
to	O
1.65	O
+	O
/-	O
0.57	O
1/min	O
)	O
and	O
Emax	O
(	O
from	O
1.86	O
+	O
/-	O
0.9	O
to	O
2.41	O
+	O
/-	O
1.31	O
mmHg/ml	O
)	O
.	O

CONCLUSION	O
:	O
The	O
data	O
acquired	O
suggest	O
that	O
isolated	O
MAP	O
may	O
have	O
certain	O
benefits	O
on	O
LV	O
dimension/function	O
in	O
acute	O
heart	B_Disease
failure	I_Disease
,	O
even	O
in	O
the	O
absence	O
of	O
MR	B_Disease
.	O

However	O
,	O
further	O
investigations	O
are	O
warranted	O
in	O
a	O
model	O
of	O
chronic	O
heart	B_Disease
failure	I_Disease
.	O

Piperacillin/tazobactam-induced	O
seizure	B_Disease
rapidly	O
reversed	O
by	O
high	O
flux	O
hemodialysis	O
in	O
a	O
patient	O
on	O
peritoneal	O
dialysis	O
.	O

Despite	O
popular	O
use	O
of	O
piperacillin	B_Chemical
,	O
the	O
dire	O
neurotoxicity	B_Disease
associated	O
with	O
piperacillin	B_Chemical
still	O
goes	O
unrecognized	O
,	O
leading	O
to	O
a	O
delay	O
in	O
appropriate	O
management	O
.	O

We	O
report	O
a	O
57-year-old	O
woman	O
with	O
end-stage	B_Disease
renal	I_Disease
disease	I_Disease
receiving	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
(	O
CAPD	O
)	O
,	O
who	O
developed	O
slurred	O
speech	O
,	O
tremor	B_Disease
,	O
bizarre	O
behavior	O
,	O
progressive	O
mental	O
confusion	B_Disease
,	O
and	O
2	O
episodes	O
of	O
generalized	O
tonic-clonic	B_Disease
seizure	I_Disease
(	O
GTCS	B_Disease
)	O
after	O
5	O
doses	O
of	O
piperacillin/tazobactam	B_Chemical
(	O
2	O
g/250	O
mg	O
)	O
were	O
given	O
for	O
bronchiectasis	B_Disease
with	O
secondary	B_Disease
infection	I_Disease
.	O

The	O
laboratory	O
data	O
revealed	O
normal	O
plasma	O
electrolyte	O
and	O
ammonia	B_Chemical
levels	O
but	O
leukocytosis	B_Disease
.	O

Neurologic	O
examinations	O
showed	O
dysarthria	B_Disease
and	O
bilateral	O
Babinski	O
sign	O
.	O

Computed	O
tomography	O
of	O
brain	O
and	O
electroencephalogram	O
were	O
unremarkable	O
.	O

Despite	O
the	O
use	O
of	O
antiepileptic	O
agents	O
,	O
another	O
GTCS	B_Disease
episode	O
recurred	O
after	O
the	O
sixth	O
dose	O
of	O
piperacillin/tazobactam	B_Chemical
.	O

Brain	O
magnetic	O
resonance	O
imaging	O
did	O
not	O
demonstrate	O
acute	O
infarction	B_Disease
and	O
organic	B_Disease
brain	I_Disease
lesions	I_Disease
.	O

Initiation	O
of	O
high-flux	O
hemodialysis	O
rapidly	O
reversed	O
the	O
neurologic	O
symptoms	O
within	O
4	O
hours	O
.	O

Piperacillin-induced	O
encephalopathy	B_Disease
should	O
be	O
considered	O
in	O
any	O
uremic	B_Disease
patients	O
with	O
unexplained	O
neurological	O
manifestations	O
.	O

CAPD	O
is	O
inefficient	O
in	O
removing	O
piperacillin	B_Chemical
,	O
whereas	O
hemodialysis	O
can	O
rapidly	O
terminate	O
the	O
piperacillin-induced	O
encephalopathy	B_Disease
.	O

Frequency	O
of	O
transient	O
ipsilateral	O
vocal	O
cord	O
paralysis	O
in	O
patients	O
undergoing	O
carotid	O
endarterectomy	O
under	O
local	O
anesthesia	O
.	O

BACKGROUND	O
:	O
Especially	O
because	O
of	O
improvements	O
in	O
clinical	O
neurologic	O
monitoring	O
,	O
carotid	O
endarterectomy	O
done	O
under	O
local	O
anesthesia	O
has	O
become	O
the	O
technique	O
of	O
choice	O
in	O
several	O
centers	O
.	O

Temporary	O
ipsilateral	O
vocal	B_Disease
nerve	I_Disease
palsies	I_Disease
due	O
to	O
local	O
anesthetics	O
have	O
been	O
described	O
,	O
however	O
.	O

Such	O
complications	O
are	O
most	O
important	O
in	O
situations	O
where	O
there	O
is	O
a	O
pre-existing	O
contralateral	O
paralysis	B_Disease
.	O

We	O
therefore	O
examined	O
the	O
effect	O
of	O
local	O
anesthesia	O
on	O
vocal	O
cord	O
function	O
to	O
better	O
understand	O
its	O
possible	O
consequences	O
.	O

METHODS	O
:	O
This	O
prospective	O
study	O
included	O
28	O
patients	O
undergoing	O
carotid	O
endarterectomy	O
under	O
local	O
anesthesia	O
.	O

Vocal	O
cord	O
function	O
was	O
evaluated	O
before	O
,	O
during	O
,	O
and	O
after	O
surgery	O
(	O
postoperative	O
day	O
1	O
)	O
using	O
flexible	O
laryngoscopy	O
.	O

Anesthesia	O
was	O
performed	O
by	O
injecting	O
20	O
to	O
40	O
mL	O
of	O
a	O
mixture	O
of	O
long-acting	O
(	O
ropivacaine	B_Chemical
)	O
and	O
short-acting	O
(	O
prilocaine	B_Chemical
)	O
anesthetic	O
.	O

RESULTS	O
:	O
All	O
patients	O
had	O
normal	O
vocal	O
cord	O
function	O
preoperatively	O
.	O

Twelve	O
patients	O
(	O
43	O
%	O
)	O
were	O
found	O
to	O
have	O
intraoperative	O
ipsilateral	O
vocal	B_Disease
cord	I_Disease
paralysis	I_Disease
.	O

It	O
resolved	O
in	O
all	O
cases	O
<	O
or	O
=	O
24	O
hours	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
operating	O
time	O
or	O
volume	O
or	O
frequency	O
of	O
anesthetic	O
administration	O
in	O
patients	O
with	O
temporary	O
vocal	B_Disease
cord	I_Disease
paralysis	I_Disease
compared	O
with	O
those	O
without	O
.	O

CONCLUSION	O
:	O
Local	O
anesthesia	O
led	O
to	O
temporary	O
ipsilateral	O
vocal	B_Disease
cord	I_Disease
paralysis	I_Disease
in	O
almost	O
half	O
of	O
these	O
patients	O
.	O

Because	O
pre-existing	O
paralysis	B_Disease
is	O
of	O
a	O
relevant	O
frequency	O
(	O
up	O
to	O
3	O
%	O
)	O
,	O
a	O
preoperative	O
evaluation	O
of	O
vocal	O
cord	O
function	O
before	O
carotid	O
endarterectomy	O
under	O
local	O
anesthesia	O
is	O
recommended	O
to	O
avoid	O
intraoperative	O
bilateral	O
paralysis	B_Disease
.	O

In	O
patients	O
with	O
preoperative	O
contralateral	O
vocal	B_Disease
cord	I_Disease
paralysis	I_Disease
,	O
surgery	O
under	O
general	O
anesthesia	O
should	O
be	O
considered	O
.	O

Impaired	B_Disease
fear	I_Disease
recognition	I_Disease
in	O
regular	O
recreational	O
cocaine	B_Chemical
users	O
.	O

INTRODUCTION	O
:	O
The	O
ability	O
to	O
read	O
facial	O
expressions	O
is	O
essential	O
for	O
normal	O
human	O
social	O
interaction	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
conduct	O
the	O
first	O
investigation	O
of	O
facial	O
expression	O
recognition	O
performance	O
in	O
recreational	O
cocaine	B_Chemical
users	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Three	O
groups	O
,	O
comprised	O
of	O
21	O
cocaine	B_Chemical
naive	O
participants	O
(	O
CN	O
)	O
,	O
 	O
30	O
occasional	O
cocaine	B_Chemical
(	O
OC	O
)	O
,	O
and	O
48	O
regular	O
recreational	O
cocaine	B_Chemical
(	O
RC	O
)	O
users	O
,	O
were	O
compared	O
.	O

An	O
emotional	O
facial	O
expression	O
(	O
EFE	O
)	O
task	O
consisting	O
of	O
a	O
male	O
and	O
female	O
face	O
expressing	O
six	O
basic	O
emotions	O
(	O
happiness	O
,	O
surprise	O
,	O
sadness	O
,	O
anger	O
,	O
fear	O
,	O
and	O
disgust	O
)	O
was	O
administered	O
.	O

Mean	O
percent	O
accuracy	O
and	O
latencies	O
for	O
correct	O
responses	O
across	O
eight	O
presentations	O
of	O
each	O
basic	O
emotion	O
were	O
derived	O
.	O

Participants	O
were	O
also	O
assessed	O
with	O
the	O
"	O
Eyes	O
task	O
"	O
to	O
investigate	O
their	O
ability	O
to	O
recognize	O
more	O
complex	O
emotional	O
states	O
and	O
the	O
Symptom	O
CheckList-90-Revised	O
to	O
measure	O
psychopathology	O
.	O

RESULTS	O
:	O
There	O
were	O
no	O
group	O
differences	O
in	O
psychopathology	O
or	O
"	O
eyes	O
task	O
"	O
performance	O
,	O
but	O
the	O
RC	O
group	O
,	O
who	O
otherwise	O
had	O
similar	O
illicit	O
substance	O
use	O
histories	O
to	O
the	O
OC	O
group	O
,	O
exhibited	O
impaired	B_Disease
fear	I_Disease
recognition	I_Disease
accuracy	O
compared	O
to	O
the	O
OC	O
and	O
CN	O
groups	O
.	O

The	O
RC	O
group	O
also	O
correctly	O
identified	O
anger	O
,	O
fear	O
,	O
happiness	O
,	O
and	O
surprise	O
,	O
more	O
slowly	O
than	O
CN	O
,	O
but	O
not	O
OC	O
participants	O
.	O

The	O
OC	O
group	O
was	O
slower	O
than	O
CN	O
when	O
correctly	O
identifying	O
disgust	O
.	O

The	O
selective	O
deficit	B_Disease
in	I_Disease
fear	I_Disease
recognition	I_Disease
accuracy	O
manifested	O
by	O
the	O
RC	O
group	O
can	O
not	O
be	O
explained	O
by	O
the	O
subacute	O
effects	O
of	O
cocaine	B_Chemical
,	O
or	O
ecstasy	B_Chemical
,	O
because	O
recent	O
and	O
less	O
recent	O
users	O
of	O
these	O
drugs	O
within	O
this	O
group	O
were	O
similarly	O
impaired	O
.	O

Possible	O
parallels	O
between	O
RC	O
users	O
and	O
psychopaths	B_Disease
with	O
respect	O
to	O
impaired	B_Disease
fear	I_Disease
recognition	I_Disease
,	O
amygdala	B_Disease
dysfunction	I_Disease
,	O
and	O
etiology	O
are	O
discussed	O
.	O

Damage	B_Disease
of	I_Disease
substantia	I_Disease
nigra	I_Disease
pars	I_Disease
reticulata	I_Disease
during	O
pilocarpine-induced	O
status	B_Disease
epilepticus	I_Disease
in	O
the	O
rat	O
:	O
immunohistochemical	O
study	O
of	O
neurons	O
,	O
astrocytes	O
and	O
serum-protein	O
extravasation	O
.	O

The	O
substantia	O
nigra	O
has	O
a	O
gating	O
function	O
controlling	O
the	O
spread	O
of	O
epileptic	B_Disease
seizure	I_Disease
activity	O
.	O

Additionally	O
,	O
in	O
models	O
of	O
prolonged	B_Disease
status	I_Disease
epilepticus	I_Disease
the	O
pars	O
reticulata	O
of	O
substantia	O
nigra	O
(	O
SNR	O
)	O
suffers	O
from	O
a	O
massive	O
lesion	O
which	O
may	O
arise	O
from	O
a	O
massive	O
metabolic	B_Disease
derangement	I_Disease
and	O
hyperexcitation	O
developing	O
in	O
the	O
activated	O
SNR	O
.	O

In	O
this	O
study	O
,	O
status	B_Disease
epilepticus	I_Disease
was	O
induced	O
by	O
systemic	O
injection	O
of	O
pilocarpine	B_Chemical
in	O
rats	O
.	O

The	O
neuropathology	O
of	O
SNR	O
was	O
investigated	O
using	O
immunohistochemical	O
techniques	O
with	O
the	O
major	O
emphasis	O
on	O
the	O
time-course	O
of	O
changes	O
in	O
neurons	O
and	O
astrocytes	O
.	O

Animals	O
surviving	O
20	O
,	O
30	O
,	O
40	O
,	O
60	O
min	O
,	O
2	O
,	O
3	O
,	O
6	O
hours	O
,	O
1	O
,	O
2	O
,	O
and	O
3	O
days	O
after	O
induction	O
of	O
status	B_Disease
epilepticus	I_Disease
were	O
perfusion-fixed	O
,	O
and	O
brains	O
processed	O
for	O
immunohistochemical	O
staining	O
of	O
SNR	O
.	O

Nissl-staining	O
and	O
antibodies	O
against	O
the	O
neuron-specific	O
calcium-binding	O
protein	O
,	O
parvalbumin	O
,	O
served	O
to	O
detect	O
neuronal	B_Disease
damage	I_Disease
in	O
SNR	O
.	O

Antibodies	O
against	O
the	O
astroglia-specific	O
cytoskeletal	O
protein	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
,	O
and	O
against	O
the	O
glial	O
calcium-binding	O
protein	O
,	O
S-100	O
protein	O
,	O
were	O
used	O
to	O
assess	O
the	O
status	O
of	O
astrocytes	O
.	O

Immunohistochemical	O
staining	O
for	O
serum-albumin	O
and	O
immunoglobulins	O
in	O
brain	O
tissue	O
was	O
taken	O
as	O
indicator	O
of	O
blood-brain	O
barrier	O
disturbances	O
and	O
vasogenic	B_Disease
edema	I_Disease
formation	O
.	O

Immunohistochemical	O
staining	O
indicated	O
loss	O
of	O
GFAP-staining	O
already	O
at	O
30	O
min	O
after	O
induction	O
of	O
seizures	B_Disease
in	O
an	O
oval	O
focus	O
situated	O
in	O
the	O
center	O
of	O
SNR	O
while	O
sparing	O
medial	O
and	O
lateral	O
aspects	O
.	O

At	O
1	O
h	O
there	O
was	O
additional	O
vacuolation	O
in	O
S-100	O
protein	O
staining	O
.	O

By	O
2	O
hours	O
,	O
parvalbumin-staining	O
changed	O
in	O
the	O
central	O
SNR	O
indicating	O
neuronal	B_Disease
damage	I_Disease
,	O
and	O
Nissl-staining	O
visualized	O
some	O
neuronal	O
distortion	O
.	O

Staining	O
for	O
serum-proteins	O
occurred	O
in	O
a	O
patchy	O
manner	O
throughout	O
the	O
forebrain	O
during	O
the	O
first	O
hours	O
.	O

By	O
6	O
h	O
,	O
vasogenic	B_Disease
edema	I_Disease
covered	O
the	O
lesioned	B_Disease
SNR	I_Disease
.	O

By	O
24	O
h	O
,	O
glial	O
and	O
neuronal	O
markers	O
indicated	O
a	O
massive	O
lesion	O
in	O
the	O
center	O
of	O
SNR	O
.	O

By	O
48	O
-	O
72	O
h	O
,	O
astrocytes	O
surrounding	O
the	O
lesion	O
increased	O
in	O
size	O
,	O
and	O
polymorphic	O
phagocytotic	O
cells	O
invaded	O
the	O
damaged	O
area	O
.	O

In	O
a	O
further	O
group	O
of	O
animals	O
surviving	O
1	O
to	O
5	O
days	O
,	O
conventional	O
paraffin-sections	O
confirmed	O
the	O
neuronal	O
and	O
glial	O
damage	B_Disease
of	I_Disease
SNR	I_Disease
.	O

Additional	O
pathology	O
of	O
similar	O
quality	O
was	O
found	O
in	O
the	O
globus	O
pallidus	O
.	O

Since	O
astrocytes	O
were	O
always	O
damaged	O
in	O
parallel	O
with	O
neurons	O
in	O
SNR	O
it	O
is	O
proposed	O
that	O
the	O
anatomical	O
and	O
functional	O
interrelationship	O
between	O
neurons	O
and	O
astrocytes	O
is	O
particularly	O
tight	O
in	O
SNR	O
.	O

Both	O
cell	O
elements	O
may	O
suffer	O
in	O
common	O
from	O
metabolic	O
disturbance	O
and	O
neurotransmitter	B_Disease
dysfunction	I_Disease
as	O
occur	O
during	O
massive	O
status	B_Disease
epilepticus	I_Disease
.	O

Neuroprotective	O
effects	O
of	O
melatonin	B_Chemical
upon	O
the	O
offspring	O
cerebellar	O
cortex	O
in	O
the	O
rat	O
model	O
of	O
BCNU-induced	O
cortical	B_Disease
dysplasia	I_Disease
.	O

Cortical	B_Disease
dysplasia	I_Disease
is	O
a	O
malformation	O
characterized	O
by	O
defects	O
in	O
proliferation	O
,	O
migration	O
and	O
maturation	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
alterations	O
in	O
offspring	O
rat	O
cerebellum	O
induced	O
by	O
maternal	O
exposure	O
to	O
carmustine-[1,3-bis	O
(2-chloroethyl)-1-nitrosoure	O
]	O
(	O
BCNU	B_Chemical
)	O
and	O
to	O
investigate	O
the	O
effects	O
of	O
exogenous	O
melatonin	B_Chemical
upon	O
cerebellar	O
BCNU-induced	O
cortical	B_Disease
dysplasia	I_Disease
,	O
using	O
histological	O
and	O
biochemical	O
analyses	O
.	O

Pregnant	O
Wistar	O
rats	O
were	O
assigned	O
to	O
five	O
groups	O
:	O
intact-control	O
,	O
saline-control	O
,	O
melatonin-treated	O
,	O
BCNU-exposed	O
and	O
BCNU-exposed	O
plus	O
melatonin	B_Chemical
.	O

Rats	O
were	O
exposed	O
to	O
BCNU	B_Chemical
on	O
embryonic	O
day	O
15	O
and	O
melatonin	B_Chemical
was	O
given	O
until	O
delivery	O
.	O

Immuno/histochemistry	O
and	O
electron	O
microscopy	O
were	O
carried	O
out	O
on	O
the	O
offspring	O
cerebellum	O
,	O
and	O
levels	O
of	O
malondialdehyde	B_Chemical
and	O
superoxide	B_Chemical
dismutase	O
were	O
determined	O
.	O

Histopathologically	O
,	O
typical	O
findings	O
were	O
observed	O
in	O
the	O
cerebella	O
from	O
the	O
control	O
groups	O
,	O
but	O
the	O
findings	O
consistent	O
with	O
early	O
embryonic	O
development	O
were	O
noted	O
in	O
BCNU-exposed	O
cortical	B_Disease
dysplasia	I_Disease
group	O
.	O

There	O
was	O
a	O
marked	O
increase	O
in	O
the	O
number	O
of	O
TUNEL	O
positive	O
cells	O
and	O
nestin	O
positive	O
cells	O
in	O
BCNU-exposed	O
group	O
,	O
but	O
a	O
decreased	O
immunoreactivity	O
to	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
synaptophysin	O
and	O
transforming	O
growth	O
factor	O
beta1	O
was	O
observed	O
,	O
indicating	O
a	O
delayed	O
maturation	O
,	O
and	O
melatonin	B_Chemical
significantly	O
reversed	O
these	O
changes	O
.	O

Malondialdehyde	B_Chemical
level	O
in	O
BCNU-exposed	O
group	O
was	O
higher	O
than	O
those	O
in	O
control	O
groups	O
and	O
melatonin	B_Chemical
decreased	O
malondialdehyde	B_Chemical
levels	O
in	O
BCNU	B_Chemical
group	O
(	O
P<0.01	O
)	O
,	O
while	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
superoxide	B_Chemical
dismutase	O
levels	O
between	O
these	O
groups	O
.	O

These	O
data	O
suggest	O
that	O
exposure	O
of	O
animals	O
to	O
BCNU	B_Chemical
during	O
pregnancy	O
leads	O
to	O
delayed	O
maturation	O
of	O
offspring	O
cerebellum	O
and	O
melatonin	B_Chemical
protects	O
the	O
cerebellum	O
against	O
the	O
effects	O
of	O
BCNU	B_Chemical
.	O

Reduced	O
cardiotoxicity	B_Disease
of	O
doxorubicin	B_Chemical
given	O
in	O
the	O
form	O
of	O
N-(2-hydroxypropyl)methacrylamide	B_Chemical
conjugates	O
:	O
and	O
experimental	O
study	O
in	O
the	O
rat	O
.	O

A	O
rat	O
model	O
was	O
used	O
to	O
evaluate	O
the	O
general	O
acute	O
toxicity	B_Disease
and	O
the	O
late	O
cardiotoxicity	B_Disease
of	O
4	O
mg/kg	O
doxorubicin	B_Chemical
(	O
DOX	B_Chemical
)	O
given	O
either	O
as	O
free	O
drug	O
or	O
in	O
the	O
form	O
of	O
three	O
N-(2-hydroxypropyl)methacrylamide	B_Chemical
(	O
HPMA	B_Chemical
)	O
copolymer	O
conjugates	O
.	O

In	O
these	O
HPMA	B_Chemical
copolymers	O
,	O
DOX	B_Chemical
was	O
covalently	O
bound	O
via	O
peptide	O
linkages	O
that	O
were	O
either	O
non-biodegradable	O
(	O
Gly-Gly	O
)	O
or	O
degradable	O
by	O
lysosomal	O
proteinases	O
(	O
Gly-Phe-Leu-Gly	B_Chemical
)	O
.	O

In	O
addition	O
,	O
one	O
biodegradable	O
conjugate	O
containing	O
galactosamine	B_Chemical
was	O
used	O
;	O
this	O
residue	O
was	O
targeted	O
to	O
the	O
liver	O
.	O

Over	O
the	O
first	O
3	O
weeks	O
after	O
the	O
i.v	O
.	O

administration	O
of	O
free	O
and	O
polymer-bound	O
DOX	B_Chemical
,	O
all	O
animals	O
showed	O
a	O
transient	O
reduction	O
in	O
body	O
weight	O
.	O

However	O
,	O
the	O
maximal	O
reduction	O
in	O
body	O
weight	O
seen	O
in	O
animals	O
that	O
received	O
polymer-bound	O
DOX	B_Chemical
(	O
4	O
mg/kg	O
)	O
was	O
significantly	O
lower	O
than	O
that	O
observed	O
in	O
those	O
that	O
received	O
free	O
DOX	B_Chemical
(	O
4	O
mg/kg	O
)	O
or	O
a	O
mixture	O
of	O
the	O
unmodified	O
parent	O
HPMA	B_Chemical
copolymer	O
and	O
free	O
DOX	B_Chemical
(	O
4	O
mg/kg	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O

Throughout	O
the	O
study	O
(	O
20	O
weeks	O
)	O
,	O
deaths	O
related	O
to	O
cardiotoxicity	B_Disease
were	O
observed	O
only	O
in	O
animals	O
that	O
received	O
either	O
free	O
DOX	B_Chemical
or	O
the	O
mixture	O
of	O
HPMA	B_Chemical
copolymer	O
and	O
free	O
DOX	B_Chemical
;	O
in	O
these	O
cases	O
,	O
histological	O
investigations	O
revealed	O
marked	O
changes	O
in	O
the	O
heart	O
that	O
were	O
consistent	O
with	O
DOX-induced	O
cardiotoxicity	B_Disease
.	O

Sequential	O
measurements	O
of	O
cardiac	O
output	O
in	O
surviving	O
animals	O
that	O
received	O
either	O
free	O
DOX	B_Chemical
or	O
the	O
mixture	O
of	O
HPMA	B_Chemical
copolymer	O
and	O
free	O
DOX	B_Chemical
showed	O
a	O
reduction	O
of	O
approximately	O
30	O
%	O
in	O
function	O
beginning	O
at	O
the	O
4th	O
week	O
after	O
drug	O
administration	O
.	O

The	O
heart	O
rate	O
in	O
these	O
animals	O
was	O
approximately	O
12	O
%	O
lower	O
than	O
that	O
measured	O
in	O
age-matched	O
control	O
rats	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

Animals	O
that	O
were	O
given	O
the	O
HPMA	B_Chemical
copolymer	O
conjugates	O
containing	O
DOX	B_Chemical
exhibited	O
no	O
significant	O
change	O
in	O
cardiac	O
output	O
throughout	O
the	O
study	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

In	O
addition	O
,	O
no	O
significant	O
histological	O
change	O
was	O
observed	O
in	O
the	O
heart	O
of	O
animals	O
that	O
received	O
DOX	B_Chemical
in	O
the	O
form	O
of	O
HPMA	B_Chemical
copolymer	O
conjugates	O
and	O
were	O
killed	O
at	O
the	O
end	O
of	O
the	O
study	O
.	O

However	O
,	O
these	O
animals	O
had	O
shown	O
a	O
significant	O
increase	O
in	O
heart	O
rate	O
beginning	O
at	O
8	O
weeks	O
after	O
drug	O
administration	O
(	O
P	O
less	O
than	O
0.01).(ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Corneal	B_Disease
ulcers	I_Disease
associated	O
with	O
aerosolized	O
crack	B_Chemical
cocaine	I_Chemical
use	O
.	O

PURPOSE	O
:	O
We	O
report	O
4	O
cases	O
of	O
corneal	B_Disease
ulcers	I_Disease
associated	O
with	O
drug	B_Disease
abuse	I_Disease
.	O

The	O
pathogenesis	O
of	O
these	O
ulcers	B_Disease
and	O
management	O
of	O
these	O
patients	O
are	O
also	O
reviewed	O
.	O

METHODS	O
:	O
Review	O
of	O
all	O
cases	O
of	O
corneal	B_Disease
ulcers	I_Disease
associated	O
with	O
drug	B_Disease
abuse	I_Disease
seen	O
at	O
our	O
institution	O
from	O
July	O
2006	O
to	O
December	O
2006	O
.	O

RESULTS	O
:	O
Four	O
patients	O
with	O
corneal	B_Disease
ulcers	I_Disease
associated	O
with	O
crack	B_Chemical
cocaine	I_Chemical
use	O
were	O
reviewed	O
.	O

All	O
corneal	B_Disease
ulcers	I_Disease
were	O
cultured	O
,	O
and	O
the	O
patients	O
were	O
admitted	O
to	O
the	O
hospital	O
for	O
intensive	O
topical	O
antibiotic	O
treatment	O
.	O

Each	O
patient	O
received	O
comprehensive	O
health	O
care	O
,	O
including	O
medical	O
and	O
substance	B_Disease
abuse	I_Disease
consultations	O
.	O

Streptococcal	O
organisms	O
were	O
found	O
in	O
3	O
cases	O
and	O
Capnocytophaga	O
and	O
Brevibacterium	O
casei	O
in	O
1	O
patient	O
.	O

The	O
infections	B_Disease
responded	O
to	O
antibiotic	O
treatment	O
.	O

Two	O
patients	O
needed	O
a	O
lateral	O
tarsorrhaphy	O
for	O
persistent	O
epithelial	B_Disease
defects	I_Disease
.	O

CONCLUSIONS	O
:	O
Aerosolized	O
crack	B_Chemical
cocaine	I_Chemical
use	O
can	O
be	O
associated	O
with	O
the	O
development	O
of	O
corneal	B_Disease
ulcers	I_Disease
.	O

Drug	B_Disease
abuse	I_Disease
provides	O
additional	O
challenges	O
for	O
management	O
.	O

Not	O
only	O
treatment	O
of	O
their	O
infections	B_Disease
but	O
also	O
the	O
overall	O
poor	O
health	O
of	O
the	O
patients	O
and	O
increased	O
risk	O
of	O
noncompliance	O
need	O
to	O
be	O
addressed	O
.	O

Comprehensive	O
care	O
may	O
provide	O
the	O
patient	O
the	O
opportunity	O
to	O
discontinue	O
their	O
substance	B_Disease
abuse	I_Disease
,	O
improve	O
their	O
overall	O
health	O
,	O
and	O
prevent	O
future	O
corneal	O
complications	O
.	O

Topical	O
0.025	O
%	O
capsaicin	B_Chemical
in	O
chronic	O
post-herpetic	B_Disease
neuralgia	I_Disease
:	O
efficacy	O
,	O
predictors	O
of	O
response	O
and	O
long-term	O
course	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
efficacy	O
,	O
time-course	O
of	O
action	O
and	O
predictors	O
of	O
response	O
to	O
topical	O
capsaicin	B_Chemical
,	O
39	O
patients	O
with	O
chronic	O
post-herpetic	B_Disease
neuralgia	I_Disease
(	O
PHN	B_Disease
)	O
,	O
median	O
duration	O
24	O
months	O
,	O
were	O
treated	O
with	O
0.025	O
%	O
capsaicin	B_Chemical
cream	O
for	O
8	O
weeks	O
.	O

During	O
therapy	O
the	O
patients	O
rated	O
their	O
pain	B_Disease
on	O
a	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
and	O
a	O
verbal	O
outcome	O
scale	O
.	O

A	O
follow-up	O
investigation	O
was	O
performed	O
10	O
-	O
12	O
months	O
after	O
study	O
onset	O
on	O
the	O
patients	O
who	O
had	O
improved	O
.	O

Nineteen	O
patients	O
(	O
48.7	O
%	O
)	O
substantially	O
improved	O
after	O
the	O
8-week	O
trial	O
;	O
5	O
(	O
12.8	O
%	O
)	O
discontinued	O
therapy	O
due	O
to	O
side-effects	O
such	O
as	O
intolerable	O
capsaicin-induced	O
burning	O
sensations	O
(	O
4	O
)	O
or	O
mastitis	B_Disease
(	O
1	O
)	O
;	O
15	O
(	O
38.5	O
%	O
)	O
reported	O
no	O
benefit	O
.	O

The	O
decrease	O
in	O
VAS	O
ratings	O
was	O
significant	O
after	O
2	O
weeks	O
of	O
continuous	O
application	O
.	O

Of	O
the	O
responders	O
72.2	O
%	O
were	O
still	O
improved	O
at	O
the	O
follow-up	O
;	O
only	O
one-third	O
of	O
them	O
had	O
continued	O
application	O
irregularly	O
.	O

Treatment	O
effect	O
was	O
not	O
dependent	O
on	O
patient	O
's	O
age	O
,	O
duration	O
or	O
localization	O
of	O
PHN	B_Disease
(	O
trigeminal	O
involvement	O
was	O
excluded	O
)	O
,	O
sensory	B_Disease
disturbance	I_Disease
or	O
pain	B_Disease
character	O
.	O

Treatment	O
response	O
was	O
not	O
correlated	O
with	O
the	O
incidence	O
,	O
time-course	O
or	O
severity	O
of	O
capsaicin-induced	O
burning	O
.	O

If	O
confirmed	O
in	O
controlled	O
trials	O
,	O
the	O
long-term	O
results	O
of	O
this	O
open	O
,	O
non-randomized	O
study	O
might	O
indicate	O
that	O
the	O
analgesic	O
effect	O
of	O
capsaicin	B_Chemical
in	O
PHN	B_Disease
is	O
mediated	O
by	O
both	O
interference	O
with	O
neuropeptide	O
metabolism	O
and	O
morphological	O
changes	O
(	O
perhaps	O
degeneration	O
)	O
of	O
nociceptive	O
afferents	O
.	O

Myo-inositol-1-phosphate	B_Chemical
(	O
MIP	B_Chemical
)	O
synthase	O
inhibition	O
:	O
in-vivo	O
study	O
in	O
rats	O
.	O

Lithium	B_Chemical
and	O
valproate	B_Chemical
are	O
the	O
prototypic	O
mood	O
stabilizers	O
and	O
have	O
diverse	O
structures	O
and	O
targets	O
.	O

Both	O
drugs	O
influence	O
inositol	B_Chemical
metabolism	O
.	O

Lithium	B_Chemical
inhibits	O
IMPase	O
and	O
valproate	B_Chemical
inhibits	O
MIP	B_Chemical
synthase	O
.	O

This	O
study	O
shows	O
that	O
MIP	B_Chemical
synthase	O
inhibition	O
does	O
not	O
replicate	O
or	O
augment	O
the	O
effects	O
of	O
lithium	B_Chemical
in	O
the	O
inositol	B_Chemical
sensitive	O
pilocarpine-induced	O
seizures	B_Disease
model	O
.	O

This	O
lack	O
of	O
effects	O
may	O
stem	O
from	O
the	O
low	O
contribution	O
of	O
de-novo	O
synthesis	O
to	O
cellular	O
inositol	B_Chemical
supply	O
or	O
to	O
the	O
inhibition	O
of	O
the	O
de-novo	O
synthesis	O
by	O
lithium	B_Chemical
itself	O
.	O

Non-steroidal	O
anti-inflammatory	O
drugs-associated	O
acute	O
interstitial	O
nephritis	O
with	O
granular	O
tubular	O
basement	O
membrane	O
deposits	O
.	O

Acute	B_Disease
tubulo-interstitial	I_Disease
nephritis	I_Disease
(	O
ATIN	B_Disease
)	O
is	O
an	O
important	O
cause	O
of	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
resulting	O
from	O
a	O
variety	O
of	O
insults	O
,	O
including	O
immune	O
complex-mediated	O
tubulo-interstitial	B_Disease
injury	I_Disease
,	O
but	O
drugs	O
such	O
as	O
non-steroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
are	O
a	O
far	O
more	O
frequent	O
cause	O
.	O

Overall	O
,	O
as	O
an	O
entity	O
,	O
ATIN	B_Disease
remains	O
under-diagnosed	O
,	O
as	O
symptoms	O
resolve	O
spontaneously	O
if	O
the	O
medication	O
is	O
stopped	O
.	O

We	O
report	O
on	O
a	O
14-year-old	O
boy	O
who	O
developed	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
2	O
weeks	O
after	O
aortic	O
valve	O
surgery	O
.	O

He	O
was	O
put	O
on	O
aspirin	B_Chemical
following	O
surgery	O
and	O
took	O
ibuprofen	B_Chemical
for	O
fever	B_Disease
for	O
nearly	O
a	O
week	O
prior	O
to	O
presentation	O
.	O

He	O
then	O
presented	O
to	O
the	O
emergency	O
department	O
feeling	O
quite	O
ill	O
and	O
was	O
found	O
to	O
have	O
a	O
blood	B_Chemical
urea	I_Chemical
nitrogen	I_Chemical
(	O
BUN	B_Chemical
)	O
concentration	O
of	O
of	O
147	O
mg/dl	O
,	O
creatinine	B_Chemical
of	O
15.3	O
mg/dl	O
and	O
serum	O
potassium	B_Chemical
of	O
8.7	O
mEq/l	O
.	O

Dialysis	O
was	O
immediately	O
initiated	O
.	O

A	O
kidney	O
biopsy	O
showed	O
inflammatory	O
infiltrate	O
consistent	O
with	O
ATIN	B_Disease
.	O

However	O
,	O
in	O
the	O
tubular	O
basement	O
membrane	O
(	O
TBM	O
)	O
,	O
very	O
intense	O
granular	O
deposits	O
of	O
polyclonal	O
IgG	O
and	O
C3	O
were	O
noted	O
.	O

He	O
needed	O
dialysis	O
for	O
2	O
weeks	O
and	O
was	O
treated	O
successfully	O
with	O
steroids	B_Chemical
for	O
6	O
months	O
.	O

His	O
renal	O
recovery	O
and	O
disappearance	O
of	O
proteinuria	B_Disease
took	O
a	O
year	O
.	O

In	O
conclusion	O
,	O
this	O
is	O
a	O
first	O
report	O
of	O
NSAIDs-associated	O
ATIN	B_Disease
,	O
showing	O
deposits	O
of	O
granular	O
immune	O
complex	O
present	O
only	O
in	O
the	O
TBM	O
and	O
not	O
in	O
the	O
glomeruli	O
.	O

Rifampicin-associated	O
segmental	O
necrotizing	O
glomerulonephritis	B_Disease
in	O
staphylococcal	B_Disease
endocarditis	B_Disease
.	O

Segmental	O
necrotising	O
glomerulonephritis	B_Disease
has	O
been	O
reported	O
as	O
complication	O
of	O
rifampicin	B_Chemical
therapy	O
in	O
patients	O
receiving	O
treatment	O
for	O
tuberculosis	B_Disease
.	O

Changing	O
epidemiology	O
of	O
infections	B_Disease
such	O
as	O
infective	B_Disease
endocarditis	I_Disease
(	O
IE	B_Disease
)	O
has	O
led	O
to	O
an	O
increase	O
in	O
the	O
use	O
of	O
rifampicin	B_Chemical
for	O
Staphylococcal	B_Disease
infections	I_Disease
.	O

We	O
describe	O
a	O
case	O
of	O
a	O
patient	O
with	O
Staphylococcal	B_Disease
IE	B_Disease
who	O
developed	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
secondary	O
to	O
a	O
segmental	O
necrotising	O
glomerulonephritis	B_Disease
while	O
being	O
treated	O
with	O
rifampicin	B_Chemical
,	O
and	O
review	O
the	O
literature	O
regarding	O
this	O
complication	O
of	O
rifampicin	B_Chemical
therapy	O
.	O

Rate	O
of	O
YMDD	O
motif	O
mutants	O
in	O
lamivudine-untreated	O
Iranian	O
patients	O
with	O
chronic	B_Disease
hepatitis	I_Disease
B	I_Disease
virus	I_Disease
infection	I_Disease
.	O

BACKGROUND	O
:	O
Lamivudine	B_Chemical
is	O
used	O
for	O
the	O
treatment	O
of	O
chronic	B_Disease
hepatitis	I_Disease
B	I_Disease
patients	O
.	O

Recent	O
studies	O
show	O
that	O
the	O
YMDD	O
motif	O
mutants	O
(	O
resistant	O
hepatitis	B_Disease
B	I_Disease
virus	O
)	O
occur	O
as	O
natural	O
genome	O
variability	O
in	O
lamivudine-untreated	O
chronic	B_Disease
hepatitis	I_Disease
B	I_Disease
patients	O
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
determine	O
the	O
rate	O
of	O
YMDD	O
motif	O
mutants	O
in	O
lamivudine-untreated	O
chronic	B_Disease
hepatitis	I_Disease
B	I_Disease
patients	O
in	O
Iran	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
77	O
chronic	B_Disease
hepatitis	I_Disease
B	I_Disease
patients	O
who	O
had	O
not	O
been	O
treated	O
with	O
lamivudine	B_Chemical
were	O
included	O
in	O
the	O
study	O
.	O

Serum	O
samples	O
from	O
patients	O
were	O
tested	O
by	O
polymerase	O
chain	O
reaction-restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR-RFLP	O
)	O
for	O
detection	O
of	O
YMDD	O
motif	O
mutants	O
.	O

All	O
patients	O
were	O
also	O
tested	O
for	O
liver	O
enzymes	O
,	O
anti-HCV	O
,	O
HBeAg	B_Chemical
,	O
and	O
anti-HBe	O
.	O

RESULTS	O
:	O
Of	O
the	O
77	O
patients	O
enrolled	O
in	O
the	O
study	O
,	O
73	O
%	O
were	O
male	O
and	O
27	O
%	O
were	O
female	O
.	O

Mean	O
ALT	O
and	O
AST	O
levels	O
were	O
124.4+/-73.4	O
and	O
103.1+/-81	O
IU/l	O
,	O
respectively	O
.	O

HBeAg	B_Chemical
was	O
positive	O
in	O
40	O
%	O
and	O
anti-HBe	O
in	O
60	O
%	O
of	O
the	O
patients	O
.	O

Anti-HCV	O
was	O
negative	O
in	O
all	O
of	O
them	O
.	O

YMDD	O
motif	O
mutants	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
patients	O
despite	O
the	O
liver	O
enzyme	O
levels	O
and	O
the	O
presence	O
of	O
HBeAg	B_Chemical
or	O
anti-HBe	O
.	O

CONCLUSION	O
:	O
Although	O
the	O
natural	O
occurrence	O
of	O
YMDD	O
motif	O
mutants	O
in	O
lamivudine-untreated	O
patients	O
with	O
chronic	B_Disease
hepatitis	I_Disease
B	I_Disease
has	O
been	O
reported	O
,	O
these	O
mutants	O
were	O
not	O
detected	O
in	O
Iranian	O
lamivudine-untreated	O
chronic	B_Disease
hepatitis	I_Disease
B	I_Disease
patients	O
.	O

Branch	O
retinal	B_Disease
vein	I_Disease
occlusion	I_Disease
and	O
fluoxetine	B_Chemical
.	O

A	O
case	O
of	O
branch	O
retinal	B_Disease
vein	I_Disease
occlusion	I_Disease
associated	O
with	O
fluoxetine-induced	O
secondary	O
hypertension	B_Disease
is	O
described	O
.	O

Although	O
an	O
infrequent	O
complication	O
of	O
selective	O
serotonin	B_Chemical
reuptake	O
inhibitor	O
therapy	O
,	O
it	O
is	O
important	O
that	O
ophthalmologists	O
are	O
aware	O
that	O
these	O
agents	O
can	O
cause	O
hypertension	B_Disease
because	O
this	O
class	O
of	O
drugs	O
is	O
widely	O
prescribed	O
.	O

The	O
differential	O
effects	O
of	O
bupivacaine	B_Chemical
and	O
lidocaine	B_Chemical
on	O
prostaglandin	B_Chemical
E2	I_Chemical
release	O
,	O
cyclooxygenase	O
gene	O
expression	O
and	O
pain	B_Disease
in	O
a	O
clinical	O
pain	B_Disease
model	O
.	O

BACKGROUND	O
:	O
In	O
addition	O
to	O
blocking	O
nociceptive	O
input	O
from	O
surgical	O
sites	O
,	O
long-acting	O
local	O
anesthetics	O
might	O
directly	O
modulate	O
inflammation	B_Disease
.	O

In	O
the	O
present	O
study	O
,	O
we	O
describe	O
the	O
proinflammatory	O
effects	O
of	O
bupivacaine	B_Chemical
on	O
local	O
prostaglandin	B_Chemical
E2	I_Chemical
(	O
PGE2	B_Chemical
)	O
production	O
and	O
cyclooxygenase	O
(	O
COX	O
)	O
gene	O
expression	O
that	O
increases	O
postoperative	B_Disease
pain	I_Disease
in	O
human	O
subjects	O
.	O

METHODS	O
:	O
Subjects	O
(	O
n	O
=	O
114	O
)	O
undergoing	O
extraction	O
of	O
impacted	O
third	O
molars	O
received	O
either	O
2	O
%	O
lidocaine	B_Chemical
or	O
0.5	O
%	O
bupivacaine	B_Chemical
before	O
surgery	O
and	O
either	O
rofecoxib	B_Chemical
50	O
mg	O
or	O
placebo	O
orally	O
90	O
min	O
before	O
surgery	O
and	O
for	O
the	O
following	O
48	O
h.	O
Oral	O
mucosal	O
biopsies	O
were	O
taken	O
before	O
surgery	O
and	O
48	O
h	O
after	O
surgery	O
.	O

After	O
extraction	O
,	O
a	O
microdialysis	O
probe	O
was	O
placed	O
at	O
the	O
surgical	O
site	O
for	O
PGE2	B_Chemical
and	O
thromboxane	B_Chemical
B2	I_Chemical
(	O
TXB2	B_Chemical
)	O
measurements	O
.	O

RESULTS	O
:	O
The	O
bupivacaine/rofecoxib	O
group	O
reported	O
significantly	O
less	O
pain	B_Disease
,	O
as	O
assessed	O
by	O
a	O
visual	O
analog	O
scale	O
,	O
compared	O
with	O
the	O
other	O
three	O
treatment	O
groups	O
over	O
the	O
first	O
4	O
h.	O
However	O
,	O
the	O
bupivacaine/placebo	O
group	O
reported	O
significantly	O
more	O
pain	B_Disease
at	O
24	O
h	O
and	O
PGE2	B_Chemical
levels	O
during	O
the	O
first	O
4	O
h	O
were	O
significantly	O
higher	O
than	O
the	O
other	O
three	O
treatment	O
groups	O
.	O

Moreover	O
,	O
bupivacaine	B_Chemical
significantly	O
increased	O
COX-2	O
gene	O
expression	O
at	O
48	O
h	O
as	O
compared	O
with	O
the	O
lidocaine/placebo	O
group	O
.	O

Thromboxane	B_Chemical
levels	O
were	O
not	O
significantly	O
affected	O
by	O
any	O
of	O
the	O
treatments	O
,	O
indicating	O
that	O
the	O
effects	O
seen	O
were	O
attributable	O
to	O
inhibition	O
of	O
COX-2	O
,	O
but	O
not	O
COX-1	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
bupivacaine	B_Chemical
stimulates	O
COX-2	O
gene	O
expression	O
after	O
tissue	B_Disease
injury	I_Disease
,	O
which	O
is	O
associated	O
with	O
higher	O
PGE2	B_Chemical
production	O
and	O
pain	B_Disease
after	O
the	O
local	O
anesthetic	O
effect	O
dissipates	O
.	O

p75NTR	O
expression	O
in	O
rat	O
urinary	O
bladder	O
sensory	O
neurons	O
and	O
spinal	O
cord	O
with	O
cyclophosphamide-induced	O
cystitis	B_Disease
.	O

A	O
role	O
for	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
in	O
contributing	O
to	O
increased	O
voiding	O
frequency	O
and	O
altered	O
sensation	O
from	O
the	O
urinary	O
bladder	O
has	O
been	O
suggested	O
.	O

Previous	O
studies	O
have	O
examined	O
the	O
expression	O
and	O
regulation	O
of	O
tyrosine	B_Chemical
kinase	O
receptors	O
(	O
Trks	O
)	O
in	O
micturition	O
reflexes	O
with	O
urinary	B_Disease
bladder	I_Disease
inflammation	I_Disease
.	O

The	O
present	O
studies	O
examine	O
the	O
expression	O
and	O
regulation	O
of	O
another	O
receptor	O
known	O
to	O
bind	O
NGF	O
,	O
p75(NTR	O
)	O
,	O
after	O
various	O
durations	O
of	O
bladder	B_Disease
inflammation	I_Disease
induced	O
by	O
cyclophosphamide	B_Chemical
(	O
CYP	B_Chemical
)	O
.	O

CYP-induced	O
cystitis	B_Disease
increased	O
(	O
P	O
<	O
or	O
=	O
0.001	O
)	O
p75(NTR	O
)	O
expression	O
in	O
the	O
superficial	O
lateral	O
and	O
medial	O
dorsal	O
horn	O
in	O
L1-L2	O
and	O
L6-S1	O
spinal	O
segments	O
.	O

The	O
number	O
of	O
p75(NTR)-immunoreactive	O
(	O
-IR	O
)	O
cells	O
in	O
the	O
lumbosacral	O
dorsal	O
root	O
ganglia	O
(	O
DRG	O
)	O
also	O
increased	O
(	O
P	O
<	O
or	O
=	O
0.05	O
)	O
with	O
CYP-induced	O
cystitis	B_Disease
(	O
acute	O
,	O
intermediate	O
,	O
and	O
chronic	O
)	O
.	O

Quantitative	O
,	O
real-time	O
polymerase	O
chain	O
reaction	O
also	O
demonstrated	O
significant	O
increases	O
(	O
P	O
<	O
or	O
=	O
0.01	O
)	O
in	O
p75(NTR	O
)	O
mRNA	O
in	O
DRG	O
with	O
intermediate	O
and	O
chronic	O
CYP-induced	O
cystitis	B_Disease
.	O

Retrograde	O
dye-tracing	O
techniques	O
with	O
Fastblue	O
were	O
used	O
to	O
identify	O
presumptive	O
bladder	O
afferent	O
cells	O
in	O
the	O
lumbosacral	O
DRG	O
.	O

In	O
bladder	O
afferent	O
cells	O
in	O
DRG	O
,	O
p75(NTR)-IR	O
was	O
also	O
increased	O
(	O
P	O
<	O
or	O
=	O
0.01	O
)	O
with	O
cystitis	B_Disease
.	O

In	O
addition	O
to	O
increases	O
in	O
p75(NTR)-IR	O
in	O
DRG	O
cell	O
bodies	O
,	O
increases	O
(	O
P	O
<	O
or	O
=	O
0.001	O
)	O
in	O
pericellular	O
(	O
encircling	O
DRG	O
cells	O
)	O
p75(NTR)-IR	O
in	O
DRG	O
also	O
increased	O
.	O

Confocal	O
analyses	O
demonstrated	O
that	O
pericellular	O
p75(NTR)-IR	O
was	O
not	O
colocalized	O
with	O
the	O
glial	O
marker	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
.	O

These	O
studies	O
demonstrate	O
that	O
p75(NTR	O
)	O
expression	O
in	O
micturition	O
reflexes	O
is	O
present	O
constitutively	O
and	O
modified	O
by	O
bladder	B_Disease
inflammation	I_Disease
.	O

The	O
functional	O
significance	O
of	O
p75(NTR	O
)	O
expression	O
in	O
micturition	O
reflexes	O
remains	O
to	O
be	O
determined	O
.	O

Azathioprine-induced	O
suicidal	O
erythrocyte	O
death	O
.	O

BACKGROUND	O
:	O
Azathioprine	B_Chemical
is	O
widely	O
used	O
as	O
an	O
immunosuppressive	O
drug	O
.	O

The	O
side	O
effects	O
of	O
azathioprine	B_Chemical
include	O
anemia	B_Disease
,	O
which	O
has	O
been	O
attributed	O
to	O
bone	O
marrow	O
suppression	O
.	O

Alternatively	O
,	O
anemia	B_Disease
could	O
result	O
from	O
accelerated	O
suicidal	O
erythrocyte	O
death	O
or	O
eryptosis	O
,	O
which	O
is	O
characterized	O
by	O
exposure	O
of	O
phosphatidylserine	B_Chemical
(	O
PS	B_Chemical
)	O
at	O
the	O
erythrocyte	O
surface	O
and	O
by	O
cell	O
shrinkage	O
.	O

METHODS	O
:	O
The	O
present	O
experiments	O
explored	O
whether	O
azathioprine	B_Chemical
influences	O
eryptosis	O
.	O

According	O
to	O
annexin	O
V	O
binding	O
,	O
erythrocytes	O
from	O
patients	O
indeed	O
showed	O
a	O
significant	O
increase	O
of	O
PS	B_Chemical
exposure	O
within	O
1	O
week	O
of	O
treatment	O
with	O
azathioprine	B_Chemical
.	O

In	O
a	O
second	O
series	O
,	O
cytosolic	O
Ca2	O
+	O
activity	O
(	O
Fluo3	B_Chemical
fluorescence	O
)	O
,	O
cell	O
volume	O
(	O
forward	O
scatter	O
)	O
,	O
and	O
PS-exposure	O
(	O
annexin	O
V	O
binding	O
)	O
were	O
determined	O
by	O
FACS	O
analysis	O
in	O
erythrocytes	O
from	O
healthy	O
volunteers	O
.	O

RESULTS	O
:	O
Exposure	O
to	O
azathioprine	B_Chemical
(	O
>	O
or	O
=	O
2	O
microg/mL	O
)	O
for	O
48	O
hours	O
increased	O
cytosolic	O
Ca2	O
+	O
activity	O
and	O
annexin	O
V	O
binding	O
and	O
decreased	O
forward	O
scatter	O
.	O

The	O
effect	O
of	O
azathioprine	B_Chemical
on	O
both	O
annexin	O
V	O
binding	O
and	O
forward	O
scatter	O
was	O
significantly	O
blunted	O
in	O
the	O
nominal	O
absence	O
of	O
extracellular	O
Ca2	O
+	O
.	O

CONCLUSIONS	O
:	O
Azathioprine	B_Chemical
triggers	O
suicidal	O
erythrocyte	O
death	O
,	O
an	O
effect	O
presumably	O
contributing	O
to	O
azathioprine-induced	O
anemia	B_Disease
.	O

Levetiracetam	B_Chemical
as	O
an	O
adjunct	O
to	O
phenobarbital	B_Chemical
treatment	O
in	O
cats	O
with	O
suspected	O
idiopathic	B_Disease
epilepsy	I_Disease
.	O

OBJECTIVE	O
:	O
To	O
assess	O
pharmacokinetics	O
,	O
efficacy	O
,	O
and	O
tolerability	O
of	O
oral	O
levetiracetam	B_Chemical
administered	O
as	O
an	O
adjunct	O
to	O
phenobarbital	B_Chemical
treatment	O
in	O
cats	O
with	O
poorly	O
controlled	O
suspected	O
idiopathic	B_Disease
epilepsy	I_Disease
.	O

DESIGN-Open-label	O
,	O
noncomparative	O
clinical	O
trial	O
.	O

ANIMALS	O
:	O
12	O
cats	O
suspected	O
to	O
have	O
idiopathic	B_Disease
epilepsy	I_Disease
that	O
was	O
poorly	O
controlled	O
with	O
phenobarbital	B_Chemical
or	O
that	O
had	O
unacceptable	O
adverse	O
effects	O
when	O
treated	O
with	O
phenobarbital	B_Chemical
.	O

PROCEDURES	O
:	O
Cats	O
were	O
treated	O
with	O
levetiracetam	B_Chemical
(	O
20	O
mg/kg	O
[	O
9.1	O
mg/lb	O
]	O
,	O
PO	O
,	O
q	O
8	O
h	O
)	O
.	O

After	O
a	O
minimum	O
of	O
1	O
week	O
of	O
treatment	O
,	O
serum	O
levetiracetam	B_Chemical
concentrations	O
were	O
measured	O
before	O
and	O
2	O
,	O
4	O
,	O
and	O
6	O
hours	O
after	O
drug	O
administration	O
,	O
and	O
maximum	O
and	O
minimum	O
serum	O
concentrations	O
and	O
elimination	O
half-life	O
were	O
calculated	O
.	O

Seizure	B_Disease
frequencies	O
before	O
and	O
after	O
initiation	O
of	O
levetiracetam	B_Chemical
treatment	O
were	O
compared	O
,	O
and	O
adverse	O
effects	O
were	O
recorded	O
.	O

RESULTS	O
:	O
Median	O
maximum	O
serum	O
levetiracetam	B_Chemical
concentration	O
was	O
25.5	O
microg/mL	O
,	O
median	O
minimum	O
serum	O
levetiracetam	B_Chemical
concentration	O
was	O
8.3	O
microg/mL	O
,	O
and	O
median	O
elimination	O
half-life	O
was	O
2.9	O
hours	O
.	O

Median	O
seizure	B_Disease
frequency	O
prior	O
to	O
treatment	O
with	O
levetiracetam	B_Chemical
(	O
2.1	O
seizures/mo	O
)	O
was	O
significantly	O
higher	O
than	O
median	O
seizure	B_Disease
frequency	O
after	O
initiation	O
of	O
levetiracetam	B_Chemical
treatment	O
(	O
0.42	O
seizures/mo	O
)	O
,	O
and	O
7	O
of	O
10	O
cats	O
were	O
classified	O
as	O
having	O
responded	O
to	O
levetiracetam	B_Chemical
treatment	O
(	O
ie	O
,	O
reduction	O
in	O
seizure	B_Disease
frequency	O
of	O
>	O
or=50	O
%	O
)	O
.	O

Two	O
cats	O
had	O
transient	O
lethargy	B_Disease
and	O
inappetence	B_Disease
.	O

CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
:	O
Results	O
suggested	O
that	O
levetiracetam	B_Chemical
is	O
well	O
tolerated	O
in	O
cats	O
and	O
may	O
be	O
useful	O
as	O
an	O
adjunct	O
to	O
phenobarbital	B_Chemical
treatment	O
in	O
cats	O
with	O
idiopathic	B_Disease
epilepsy	I_Disease
.	O

Serotonin	B_Chemical
reuptake	O
inhibitors	O
,	O
paranoia	B_Disease
,	O
and	O
the	O
ventral	O
basal	O
ganglia	O
.	O

Antidepressants	O
have	O
previously	O
been	O
associated	O
with	O
paranoid	B_Disease
reactions	O
in	O
psychiatric	O
patients	O
.	O

Five	O
cases	O
of	O
paranoid	B_Disease
exacerbation	O
with	O
the	O
serotonin	B_Chemical
reuptake	O
inhibitors	O
fluoxetine	B_Chemical
and	O
amitriptyline	B_Chemical
are	O
reported	O
here	O
.	O

Elements	O
common	O
to	O
these	O
cases	O
included	O
a	O
history	O
of	O
paranoid	B_Disease
symptomatology	O
and	O
the	O
concomitant	O
occurrence	O
of	O
depressive	B_Disease
and	I_Disease
psychotic	B_Disease
symptoms	I_Disease
.	O

Complicated	O
depressive	B_Disease
disorders	I_Disease
(	O
including	O
atypicality	O
of	O
course	O
and	O
symptomatology	O
,	O
chronicity	O
,	O
psychosis	B_Disease
,	O
bipolarity	O
,	O
and	O
secondary	O
onset	O
in	O
the	O
course	O
of	O
a	O
primary	O
psychosis	B_Disease
)	O
may	O
present	O
particular	O
vulnerability	O
to	O
paranoid	B_Disease
exacerbations	O
associated	O
with	O
serotonin	B_Chemical
reuptake	O
inhibitors	O
.	O

Although	O
the	O
pharmacology	O
and	O
neurobiology	O
of	O
paranoia	B_Disease
remain	O
cryptic	O
,	O
several	O
mechanisms	O
,	O
including	O
5HT3	O
receptor-mediated	O
dopamine	B_Chemical
release	O
,	O
beta-noradrenergic	O
receptor	O
downregulation	O
,	O
or	O
GABAB	O
receptor	O
upregulation	O
acting	O
in	O
the	O
vicinity	O
of	O
the	O
ventral	O
basal	O
ganglia	O
(	O
possibly	O
in	O
lateral	O
orbitofrontal	O
or	O
anterior	O
cingulate	O
circuits	O
)	O
,	O
might	O
apply	O
to	O
this	O
phenomenon	O
.	O

These	O
cases	O
call	O
attention	O
to	O
possible	O
paranoid	B_Disease
exacerbations	O
with	O
serotonin	B_Chemical
reuptake	O
blockers	O
in	O
select	O
patients	O
and	O
raise	O
neurobiological	O
considerations	O
regarding	O
paranoia	B_Disease
.	O

Clinical	O
comparison	O
of	O
cardiorespiratory	O
effects	O
during	O
unilateral	O
and	O
conventional	O
spinal	O
anaesthesia	O
.	O

BACKGROUND	O
:	O
Spinal	O
anaesthesia	O
is	O
widely	O
employed	O
in	O
clinical	O
practice	O
but	O
has	O
the	O
main	O
drawback	O
of	O
post-spinal	O
block	O
hypotension	B_Disease
.	O

Efforts	O
must	O
therefore	O
continue	O
to	O
be	O
made	O
to	O
obviate	O
this	O
setback	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
cardiovascular	O
and	O
respiratory	O
changes	O
during	O
unilateral	O
and	O
conventional	O
spinal	O
anaesthesia	O
.	O

METHODS	O
:	O
With	O
ethical	O
approval	O
,	O
we	O
studied	O
74	O
American	O
Society	O
of	O
Anesthesiologists	O
(	O
ASA	O
)	O
,	O
physical	O
status	O
class	O
1	O
and	O
2	O
patients	O
scheduled	O
for	O
elective	O
unilateral	O
lower	O
limb	O
surgery	O
.	O

Patients	O
were	O
randomly	O
allocated	O
into	O
one	O
of	O
two	O
groups	O
:	O
lateral	O
and	O
conventional	O
spinal	O
anaesthesia	O
groups	O
.	O

In	O
the	O
lateral	O
position	O
with	O
operative	O
side	O
down	O
,	O
patients	O
recived	O
10	O
mg	O
(	O
2mls	O
)	O
of	O
0.5	O
%	O
hyperbaric	O
bupivacaine	B_Chemical
through	O
a	O
25-gauge	O
spinal	O
needle	O
.	O

Patients	O
in	O
the	O
unilateral	O
group	O
were	O
maintained	O
in	O
the	O
lateral	O
position	O
for	O
15	O
minutes	O
following	O
spinal	O
injection	O
while	O
those	O
in	O
the	O
conventional	O
group	O
were	O
turned	O
supine	O
immediately	O
after	O
injection	O
.	O

Blood	O
pressure	O
,	O
heart	O
rate	O
,	O
respiratory	O
rate	O
and	O
oxygen	B_Chemical
saturation	O
were	O
monitored	O
over	O
1	O
hour	O
.	O

RESULTS	O
:	O
Three	O
patients	O
(	O
8.1	O
%	O
)	O
in	O
the	O
unilateral	O
group	O
and	O
5	O
(	O
13.5	O
%	O
)	O
in	O
the	O
conventional	O
group	O
developed	O
hypotension	B_Disease
,	O
P=	O
0.71	O
.	O

Four	O
(	O
10.8	O
%	O
)	O
patients	O
in	O
the	O
conventional	O
group	O
and	O
1	O
(	O
2.7	O
%	O
)	O
in	O
the	O
unilateral	O
group	O
,	O
P=	O
0.17	O
required	O
epinephrine	B_Chemical
infusion	O
to	O
treat	O
hypotension	B_Disease
.	O

Patients	O
in	O
the	O
conventional	O
group	O
had	O
statistically	O
significant	O
greater	O
fall	O
in	O
the	O
systolic	O
blood	O
pressures	O
at	O
15	O
,	O
30	O
and	O
45	O
minutes	O
when	O
compared	O
to	O
the	O
baseline	O
(	O
P=	O
0.003	O
,	O
0.001	O
and	O
0.004	O
)	O
.	O

The	O
mean	O
respiratory	O
rate	O
and	O
oxygen	B_Chemical
saturations	O
in	O
the	O
two	O
groups	O
were	O
similar	O
.	O

CONCLUSION	O
:	O
Compared	O
to	O
conventional	O
spinal	O
anaesthesia	O
,	O
unilateral	O
spinal	O
anaesthesia	O
was	O
associated	O
with	O
fewer	O
cardiovascular	O
perturbations	O
.	O

Also	O
,	O
the	O
type	O
of	O
spinal	O
block	O
instituted	O
affected	O
neither	O
the	O
respiratory	O
rate	O
nor	O
the	O
arterial	O
oxygen	B_Chemical
saturation	O
.	O

Spectrum	O
of	O
adverse	O
events	O
after	O
generic	O
HAART	O
in	O
southern	O
Indian	O
HIV-infected	O
patients	O
.	O

To	O
determine	O
the	O
incidence	O
of	O
clinically	O
significant	O
adverse	O
events	O
after	O
long-term	O
,	O
fixed-dose	O
,	O
generic	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
use	O
among	O
HIV-infected	B_Disease
individuals	O
in	O
South	O
India	O
,	O
we	O
examined	O
the	O
experiences	O
of	O
3154	O
HIV-infected	B_Disease
individuals	O
who	O
received	O
a	O
minimum	O
of	O
3	O
months	O
of	O
generic	O
HAART	O
between	O
February	O
1996	O
and	O
December	O
2006	O
at	O
a	O
tertiary	O
HIV	O
care	O
referral	O
center	O
in	O
South	O
India	O
.	O

The	O
most	O
common	O
regimens	O
were	O
3TC	B_Chemical
+	O
d4	B_Chemical
T	I_Chemical
+	O
nevirapine	B_Chemical
(	O
NVP	B_Chemical
)	O
(	O
54.8	O
%	O
)	O
,	O
zidovudine	B_Chemical
(	O
AZT	B_Chemical
)	O
+	O
3TC	B_Chemical
+	O
NVP	B_Chemical
(	O
14.5	O
%	O
)	O
,	O
3TC	B_Chemical
+	O
d4	B_Chemical
T	I_Chemical
+	O
efavirenz	B_Chemical
(	O
EFV	B_Chemical
)	O
(	O
20.1	O
%	O
)	O
,	O
and	O
AZT	B_Chemical
+	O
3TC	B_Chemical
+	O
EFV	B_Chemical
(	O
5.4	O
%	O
)	O
.	O

The	O
most	O
common	O
adverse	O
events	O
and	O
median	O
CD4	O
at	O
time	O
of	O
event	O
were	O
rash	B_Disease
(	O
15.2	O
%	O
;	O
CD4	O
,	O
285	O
cells/microL	O
)	O
and	O
peripheral	B_Disease
neuropathy	I_Disease
(	O
9.0	O
%	O
and	O
348	O
cells/microL	O
)	O
.	O

Clinically	O
significant	O
anemia	B_Disease
(	O
hemoglobin	O
<	O
7	O
g/dL	O
)	O
was	O
observed	O
in	O
5.4	O
%	O
of	O
patients	O
(	O
CD4	O
,	O
165	O
cells/microL	O
)	O
and	O
hepatitis	B_Disease
(	O
clinical	O
jaundice	B_Disease
with	O
alanine	B_Chemical
aminotransferase	O
>	O
5	O
times	O
upper	O
limits	O
of	O
normal	O
)	O
in	O
3.5	O
%	O
of	O
patients	O
(	O
CD4	O
,	O
260	O
cells/microL	O
)	O
.	O

Women	O
were	O
significantly	O
more	O
likely	O
to	O
experience	O
lactic	B_Disease
acidosis	I_Disease
,	O
while	O
men	O
were	O
significantly	O
more	O
likely	O
to	O
experience	O
immune	B_Disease
reconstitution	I_Disease
syndrome	I_Disease
(	O
p	O
<	O
0.05	O
)	O
.	O

Among	O
the	O
patients	O
with	O
1	O
year	O
of	O
follow-up	O
,	O
NVP	B_Chemical
therapy	O
was	O
significantly	O
associated	O
with	O
developing	O
rash	B_Disease
and	O
d4	B_Chemical
T	I_Chemical
therapy	O
with	O
developing	O
peripheral	B_Disease
neuropathy	I_Disease
(	O
p	O
<	O
0.05	O
)	O
.	O

Anemia	B_Disease
and	O
hepatitis	B_Disease
often	O
occur	O
within	O
12	O
weeks	O
of	O
initiating	O
generic	O
HAART	O
.	O

Frequent	O
and	O
early	O
monitoring	O
for	O
these	O
toxicities	B_Disease
is	O
warranted	O
in	O
developing	O
countries	O
where	O
generic	O
HAART	O
is	O
increasingly	O
available	O
.	O

Thalidomide	B_Chemical
and	O
sensory	B_Disease
neurotoxicity	I_Disease
:	O
a	O
neurophysiological	O
study	O
.	O

BACKGROUND	O
:	O
Recent	O
studies	O
confirmed	O
a	O
high	O
incidence	O
of	O
sensory	B_Disease
axonal	I_Disease
neuropathy	I_Disease
in	O
patients	O
treated	O
with	O
different	O
doses	O
of	O
thalidomide	B_Chemical
.	O

The	O
study	O
's	O
aims	O
were	O
to	O
measure	O
variations	O
in	O
sural	O
nerve	O
sensory	O
action	O
potential	O
(	O
SAP	O
)	O
amplitude	O
in	O
patients	O
with	O
refractory	O
cutaneous	B_Disease
lupus	I_Disease
erythematosus	I_Disease
(	O
CLE	B_Disease
)	O
treated	O
with	O
thalidomide	B_Chemical
and	O
use	O
these	O
findings	O
to	O
identify	O
the	O
neurotoxic	B_Disease
potential	O
of	O
thalidomide	B_Chemical
and	O
the	O
recovery	O
capacity	O
of	O
sensory	O
fibres	O
after	O
discontinuation	O
of	O
treatment	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Clinical	O
and	O
electrophysiological	O
data	O
in	O
12	O
female	O
patients	O
with	O
CLE	B_Disease
during	O
treatment	O
with	O
thalidomide	B_Chemical
and	O
up	O
to	O
47	O
months	O
after	O
discontinuation	O
of	O
treatment	O
were	O
analysed	O
.	O

Sural	O
nerve	O
SAP	O
amplitude	O
reduction	O
>	O
or	O
=	O
40	O
%	O
was	O
the	O
criteria	O
for	O
discontinuing	O
therapy	O
.	O

RESULTS	O
:	O
During	O
treatment	O
,	O
11	O
patients	O
showed	O
a	O
reduction	O
in	O
sural	O
nerve	O
SAP	O
amplitude	O
compared	O
to	O
baseline	O
values	O
(	O
9	O
with	O
a	O
reduction	O
>	O
or	O
=	O
50	O
%	O
and	O
2	O
<	O
50	O
%	O
)	O
.	O

One	O
patient	O
showed	O
no	O
changes	O
in	O
SAP	O
amplitude	O
.	O

Five	O
patients	O
complained	O
of	O
paresthesias	B_Disease
and	O
leg	O
cramps	B_Disease
.	O

After	O
thalidomide	B_Chemical
treatment	O
,	O
sural	O
SAP	O
amplitude	O
recovered	O
in	O
3	O
patients	O
.	O

At	O
detection	O
of	O
reduction	O
in	O
sural	O
nerve	O
SAP	O
amplitude	O
,	O
the	O
median	O
thalidomide	B_Chemical
cumulative	O
dose	O
was	O
21.4	O
g.	O
The	O
threshold	O
neurotoxic	B_Disease
dosage	O
is	O
lower	O
than	O
previously	O
reported	O
.	O

CONCLUSIONS	O
:	O
Sural	O
nerve	O
SAP	O
amplitude	O
reduction	O
is	O
a	O
reliable	O
and	O
sensitive	O
marker	O
of	O
degeneration	O
and	O
recovery	O
of	O
sensory	O
fibres	O
.	O

This	O
electrophysiological	O
parameter	O
provides	O
information	O
about	O
subclinical	O
neurotoxic	B_Disease
potential	O
of	O
thalidomide	B_Chemical
but	O
is	O
not	O
helpful	O
in	O
predicting	O
the	O
appearance	O
of	O
sensory	O
symptoms	O
.	O

Five	O
cases	O
of	O
encephalitis	B_Disease
during	O
treatment	O
of	O
loiasis	B_Disease
with	O
diethylcarbamazine	B_Chemical
.	O

Five	O
cases	O
of	O
encephalitis	B_Disease
following	O
treatment	O
with	O
diethylcarbamazine	B_Chemical
(	O
DEC	B_Chemical
)	O
were	O
observed	O
in	O
Congolese	O
patients	O
with	O
Loa	O
loa	O
filariasis	B_Disease
.	O

Two	O
cases	O
had	O
a	O
fatal	O
outcome	O
and	O
one	O
resulted	O
in	O
severe	O
sequelae	O
.	O

The	O
notable	O
fact	O
was	O
that	O
this	O
complication	O
occurred	O
in	O
three	O
patients	O
hospitalized	O
before	O
treatment	O
began	O
,	O
with	O
whom	O
particularly	O
strict	O
therapeutic	O
precautions	O
were	O
taken	O
,	O
i.e.	O
,	O
initial	O
dose	O
less	O
than	O
10	O
mg	O
of	O
DEC	B_Chemical
,	O
very	O
gradual	O
dose	O
increases	O
,	O
and	O
associated	O
anti-allergic	O
treatment	O
.	O

This	O
type	O
of	O
drug-induced	O
complication	O
may	O
not	O
be	O
that	O
uncommon	O
in	O
highly	O
endemic	O
regions	O
.	O

It	O
occurs	O
primarily	O
,	O
but	O
not	O
exclusively	O
,	O
in	O
subjects	O
presenting	O
with	O
a	O
high	O
microfilarial	O
load	O
.	O

The	O
relationship	O
between	O
the	O
occurrence	O
of	O
encephalitis	B_Disease
and	O
the	O
decrease	O
in	O
microfilaremia	B_Disease
is	O
evident	O
.	O

The	O
pathophysiological	O
mechanisms	O
are	O
discussed	O
in	O
the	O
light	O
of	O
these	O
observations	O
and	O
the	O
few	O
other	O
comments	O
on	O
this	O
subject	O
published	O
in	O
the	O
literature	O
.	O

Amiodarone-related	O
pulmonary	B_Disease
mass	I_Disease
and	O
unique	O
membranous	B_Disease
glomerulonephritis	I_Disease
in	O
a	O
patient	O
with	O
valvular	B_Disease
heart	I_Disease
disease	I_Disease
:	O
Diagnostic	O
pitfall	O
and	O
new	O
findings	O
.	O

Amiodarone	B_Chemical
is	O
an	O
anti-arrhythmic	O
drug	O
for	O
life-threatening	O
tachycardia	B_Disease
,	O
but	O
various	O
adverse	O
effects	O
have	O
been	O
reported	O
.	O

Reported	O
herein	O
is	O
an	O
autopsy	O
case	O
of	O
valvular	B_Disease
heart	I_Disease
disease	I_Disease
,	O
in	O
a	O
patient	O
who	O
developed	O
a	O
lung	B_Disease
mass	I_Disease
(	O
1.5	O
cm	O
in	O
diameter	O
)	O
and	O
proteinuria	B_Disease
(	O
2.76	O
g/day	O
)	O
after	O
treatment	O
with	O
amiodarone	B_Chemical
for	O
a	O
long	O
time	O
.	O

The	O
lung	B_Disease
mass	I_Disease
was	O
highly	O
suspected	O
to	O
be	O
lung	B_Disease
cancer	I_Disease
on	O
CT	O
and	O
positron	O
emission	O
tomography	O
,	O
but	O
histologically	O
the	O
lesion	O
was	O
composed	O
of	O
lymphoplasmacytic	O
infiltrates	O
in	O
alveolar	O
walls	O
and	O
intra-alveolar	O
accumulation	O
of	O
foamy	O
macrophages	O
containing	O
characteristic	O
myelinoid	O
bodies	O
,	O
indicating	O
that	O
it	O
was	O
an	O
amiodarone-related	O
lesion	O
.	O

In	O
addition	O
,	O
the	O
lung	O
tissue	O
had	O
unevenly	O
distributed	O
hemosiderin	B_Disease
deposition	O
,	O
and	O
abnormally	O
tortuous	O
capillaries	O
were	O
seen	O
in	O
the	O
mass	O
and	O
in	O
heavily	O
hemosiderotic	B_Disease
lung	O
portions	O
outside	O
the	O
mass	O
.	O

In	O
the	O
kidneys	O
,	O
glomeruli	O
had	O
membrane	O
spikes	O
,	O
prominent	O
swelling	O
of	O
podocytes	O
and	O
subepithelial	O
deposits	O
,	O
which	O
were	O
sometimes	O
large	O
and	O
hump-like	O
.	O

Autoimmune	B_Disease
diseases	I_Disease
,	O
viral	B_Disease
hepatitis	I_Disease
,	O
malignant	O
neoplasms	B_Disease
or	O
other	O
diseases	O
with	O
a	O
known	O
relationship	O
to	O
membranous	B_Disease
glomerulonephritis	I_Disease
were	O
not	O
found	O
.	O

The	O
present	O
case	O
highlights	O
the	O
possibility	O
that	O
differential	O
diagnosis	O
between	O
an	O
amiodarone-related	O
pulmonary	B_Disease
lesion	I_Disease
and	O
a	O
neoplasm	B_Disease
can	O
be	O
very	O
difficult	O
radiologically	O
,	O
and	O
suggests	O
that	O
membranous	B_Disease
glomerulonephritis	I_Disease
might	O
be	O
another	O
possible	O
complication	O
of	O
amiodarone	B_Chemical
treatment	O
.	O

Risk	O
of	O
coronary	B_Disease
artery	I_Disease
disease	I_Disease
associated	O
with	O
initial	O
sulphonylurea	B_Chemical
treatment	O
of	O
patients	O
with	O
type	B_Disease
2	I_Disease
diabetes	I_Disease
:	O
a	O
matched	O
case-control	O
study	O
.	O

AIMS	O
:	O
This	O
study	O
sought	O
to	O
assess	O
the	O
risk	O
of	O
developing	O
coronary	B_Disease
artery	I_Disease
disease	I_Disease
(	O
CAD	B_Disease
)	O
associated	O
with	O
initial	O
treatment	O
of	O
type	B_Disease
2	I_Disease
diabetes	I_Disease
with	O
different	O
sulphonylureas	B_Chemical
.	O

METHODS	O
:	O
In	O
type	B_Disease
2	I_Disease
diabetic	I_Disease
patients	O
,	O
cases	O
who	O
developed	O
CAD	B_Disease
were	O
compared	O
retrospectively	O
with	O
controls	O
that	O
did	O
not	O
.	O

The	O
20-year	O
risk	O
of	O
CAD	B_Disease
at	O
diagnosis	O
of	O
diabetes	B_Disease
,	O
using	O
the	O
UKPDS	O
risk	O
engine	O
,	O
was	O
used	O
to	O
match	O
cases	O
with	O
controls	O
.	O

RESULTS	O
:	O
The	O
76	O
cases	O
of	O
CAD	B_Disease
were	O
compared	O
with	O
152	O
controls	O
.	O

The	O
hazard	O
of	O
developing	O
CAD	B_Disease
(	O
95	O
%	O
CI	O
)	O
associated	O
with	O
initial	O
treatment	O
increased	O
by	O
2.4-fold	O
(	O
1.3	O
-	O
4.3	O
,	O
P=0.004	O
)	O
with	O
glibenclamide	B_Chemical
;	O
2-fold	O
(	O
0.9	O
-	O
4.6	O
,	O
P=0.099	O
)	O
with	O
glipizide	B_Chemical
;	O
2.9-fold	O
(	O
1.6	O
-	O
5.1	O
,	O
P=0.000	O
)	O
with	O
either	O
,	O
and	O
was	O
unchanged	O
with	O
metformin	B_Chemical
.	O

The	O
hazard	O
decreased	O
0.3-fold	O
(	O
0.7	O
-	O
1.7	O
,	O
P=0.385	O
)	O
with	O
glimepiride	B_Chemical
,	O
0.4-fold	O
(	O
0.7	O
-	O
1.3	O
,	O
P=0.192	O
)	O
with	O
gliclazide	B_Chemical
,	O
and	O
0.4-fold	O
(	O
0.7	O
-	O
1.1	O
,	O
P=0.09	O
)	O
with	O
either	O
.	O

CONCLUSIONS	O
:	O
Initiating	O
treatment	O
of	O
type	B_Disease
2	I_Disease
diabetes	I_Disease
with	O
glibenclamide	B_Chemical
or	O
glipizide	B_Chemical
is	O
associated	O
with	O
increased	O
risk	O
of	O
CAD	B_Disease
in	O
comparison	O
to	O
gliclazide	B_Chemical
or	O
glimepiride	B_Chemical
.	O

If	O
confirmed	O
,	O
this	O
may	O
be	O
important	O
because	O
most	O
Indian	O
patients	O
receive	O
the	O
cheaper	O
older	O
sulphonylureas	B_Chemical
,	O
and	O
present	O
guidelines	O
do	O
not	O
distinguish	O
between	O
individual	O
agents	O
.	O

Reduced	O
progression	O
of	O
adriamycin	B_Chemical
nephropathy	B_Disease
in	O
spontaneously	O
hypertensive	B_Disease
rats	O
treated	O
by	O
losartan	B_Chemical
.	O

BACKGROUND	O
:	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
antihypertensive	O
effects	O
of	O
angiotensin	B_Chemical
II	I_Chemical
type-1	O
receptor	O
blocker	O
,	O
losartan	B_Chemical
,	O
and	O
its	O
potential	O
in	O
slowing	O
down	O
renal	B_Disease
disease	I_Disease
progression	O
in	O
spontaneously	O
hypertensive	B_Disease
rats	O
(	O
SHR	O
)	O
with	O
adriamycin	B_Chemical
(	O
ADR	B_Chemical
)	O
nephropathy	B_Disease
.	O

METHODS	O
:	O
Six-month-old	O
female	O
SHR	O
were	O
randomly	O
selected	O
in	O
six	O
groups	O
.	O

Two	O
control	O
groups	O
(	O
SH(6	O
)	O
,	O
SH(12	O
)	O
)	O
received	O
vehicle	O
.	O

Groups	O
ADR(6	O
)	O
,	O
ADR+LOS(6	O
)	O
and	O
ADR(12	O
)	O
,	O
and	O
ADR+LOS(12	O
)	O
received	O
ADR	B_Chemical
(	O
2	O
mg/kg/b.w	O
.	O

i.v	O
.	O
)	O
twice	O
in	O
a	O
3-week	O
interval	O
.	O

Group	O
ADR+LOS(6	O
)	O
received	O
losartan	B_Chemical
(	O
10	O
mg/kg/b.w./day	O
by	O
gavages	O
)	O
for	O
6	O
weeks	O
and	O
group	O
ADR+LOS(12	O
)	O
for	O
12	O
weeks	O
after	O
second	O
injection	O
of	O
ADR	B_Chemical
.	O

Animals	O
were	O
killed	O
after	O
6	O
or	O
12	O
weeks	O
,	O
respectively	O
.	O

Haemodynamic	O
measurements	O
were	O
performed	O
on	O
anaesthetized	O
animals	O
,	O
blood	O
and	O
urine	O
samples	O
were	O
taken	O
for	O
biochemical	O
analysis	O
and	O
the	O
left	O
kidney	O
was	O
processed	O
for	O
morphological	O
studies	O
.	O

RESULTS	O
:	O
Short-term	O
losartan	B_Chemical
treatment	O
,	O
besides	O
antihypertensive	O
effect	O
,	O
improved	O
glomerular	O
filtration	O
rate	O
and	O
ameliorated	O
glomerulosclerosis	B_Disease
resulting	O
in	O
decreased	O
proteinuria	B_Disease
.	O

Prolonged	O
treatment	O
with	O
losartan	B_Chemical
showed	O
further	O
reduction	O
of	O
glomerulosclerosis	B_Disease
associated	O
with	O
reduced	O
progression	O
of	O
tubular	O
atrophy	B_Disease
and	O
interstitial	B_Disease
fibrosis	I_Disease
,	O
thus	O
preventing	O
heavy	O
proteinuria	B_Disease
and	O
chronic	B_Disease
renal	I_Disease
failure	I_Disease
.	O

Losartan	B_Chemical
reduced	O
uraemia	B_Disease
and	O
increased	O
urea	B_Chemical
clearance	O
in	O
advanced	O
ADR	B_Chemical
nephropathy	B_Disease
in	O
SHR	O
.	O

Histological	O
examination	O
showed	O
that	O
losartan	B_Chemical
could	O
prevent	O
tubular	O
atrophy	B_Disease
,	O
interstitial	O
infiltration	O
and	O
fibrosis	B_Disease
in	O
ADR	B_Chemical
nephropathy	B_Disease
.	O

CONCLUSION	O
:	O
Losartan	B_Chemical
reduces	O
the	O
rate	O
of	O
progression	O
of	O
ADR-induced	O
focal	B_Disease
segmental	I_Disease
glomerulosclerosis	I_Disease
to	O
end-stage	B_Disease
renal	I_Disease
disease	I_Disease
in	O
SHR	O
.	O

The	O
risks	O
of	O
aprotinin	O
and	O
tranexamic	O
acid	O
in	O
cardiac	O
surgery	O
:	O
a	O
one-year	O
follow-up	O
of	O
1188	O
consecutive	O
patients	O
.	O

BACKGROUND	O
:	O
Our	O
aim	O
was	O
to	O
investigate	O
postoperative	O
complications	O
and	O
mortality	O
after	O
administration	O
of	O
aprotinin	O
compared	O
to	O
tranexamic	B_Chemical
acid	I_Chemical
in	O
an	O
unselected	O
,	O
consecutive	O
cohort	O
.	O

METHODS	O
:	O
Perioperative	O
data	O
from	O
consecutive	O
cardiac	O
surgery	O
patients	O
were	O
prospectively	O
collected	O
between	O
September	O
2005	O
and	O
June	O
2006	O
in	O
a	O
university-affiliated	O
clinic	O
(	O
n	O
=	O
1188	O
)	O
.	O

During	O
the	O
first	O
5	O
mo	O
,	O
596	O
patients	O
received	O
aprotinin	O
(	O
Group	O
A	O
)	O
;	O
in	O
the	O
next	O
5	O
mo	O
,	O
592	O
patients	O
were	O
treated	O
with	O
tranexamic	B_Chemical
acid	I_Chemical
(	O
Group	O
T	O
)	O
.	O

Except	O
for	O
antifibrinolytic	O
therapy	O
,	O
the	O
anesthetic	O
and	O
surgical	O
protocols	O
remained	O
unchanged	O
.	O

RESULTS	O
:	O
The	O
pre-	O
and	O
intraoperative	O
variables	O
were	O
comparable	O
between	O
the	O
treatment	O
groups	O
.	O

Postoperatively	O
,	O
a	O
significantly	O
higher	O
incidence	O
of	O
seizures	B_Disease
was	O
found	O
in	O
Group	O
T	O
(	O
4.6	O
%	O
vs	O
1.2	O
%	O
,	O
P	O
<	O
0.001	O
)	O
.	O

This	O
difference	O
was	O
also	O
significant	O
in	O
the	O
primary	O
valve	O
surgery	O
and	O
the	O
high	O
risk	O
surgery	O
subgroups	O
(	O
7.9	O
%	O
vs	O
1.2	O
%	O
,	O
P	O
=	O
0.003	O
;	O
7.3	O
%	O
vs	O
2.4	O
%	O
,	O
P	O
=	O
0.035	O
,	O
respectively	O
)	O
.	O

Persistent	O
atrial	O
fibrillation	O
(	O
7.9	O
%	O
vs	O
2.3	O
%	O
,	O
P	O
=	O
0.020	O
)	O
and	O
renal	B_Disease
failure	I_Disease
(	O
9.7	O
%	O
vs	O
1.7	O
%	O
,	O
P	O
=	O
0.002	O
)	O
were	O
also	O
more	O
common	O
in	O
Group	O
T	O
,	O
in	O
the	O
primary	O
valve	O
surgery	O
subgroup	O
.	O

On	O
the	O
contrary	O
,	O
among	O
primary	O
coronary	O
artery	O
bypass	O
surgery	O
patients	O
,	O
there	O
were	O
more	O
acute	O
myocardial	B_Disease
infarctions	I_Disease
and	O
renal	B_Disease
dysfunction	I_Disease
in	O
Group	O
A	O
(	O
5.8	O
%	O
vs	O
2.0	O
%	O
,	O
P	O
=	O
0.027	O
;	O
22.5	O
%	O
vs	O
15.2	O
%	O
,	O
P	O
=	O
0.036	O
,	O
respectively	O
)	O
.	O

The	O
1-yr	O
mortality	O
was	O
significantly	O
higher	O
after	O
aprotinin	O
treatment	O
in	O
the	O
high	O
risk	O
surgery	O
group	O
(	O
17.7	O
%	O
vs	O
9.8	O
%	O
,	O
P	O
=	O
0.034	O
)	O
.	O

CONCLUSION	O
:	O
Both	O
antifibrinolytic	O
drugs	O
bear	O
the	O
risk	O
of	O
adverse	O
outcome	O
depending	O
on	O
the	O
type	O
of	O
cardiac	O
surgery	O
.	O

Administration	O
of	O
aprotinin	O
should	O
be	O
avoided	O
in	O
coronary	O
artery	O
bypass	O
graft	O
and	O
high	O
risk	O
patients	O
,	O
whereas	O
administration	O
of	O
tranexamic	B_Chemical
acid	I_Chemical
is	O
not	O
recommended	O
in	O
valve	O
surgery	O
.	O

Delirium	B_Disease
in	O
an	O
elderly	O
woman	O
possibly	O
associated	O
with	O
administration	O
of	O
misoprostol	B_Chemical
.	O

Misoprostol	B_Chemical
has	O
been	O
associated	O
with	O
adverse	O
reactions	O
,	O
including	O
gastrointestinal	O
symptoms	O
,	O
gynecologic	O
problems	O
,	O
and	O
headache	B_Disease
.	O

Changes	O
in	O
mental	O
status	O
,	O
however	O
,	O
have	O
not	O
been	O
reported	O
.	O

We	O
present	O
a	O
case	O
in	O
which	O
an	O
89-year-old	O
woman	O
in	O
a	O
long-term	O
care	O
facility	O
became	O
confused	O
after	O
the	O
initiation	O
of	O
misoprostol	B_Chemical
therapy	O
.	O

The	O
patient	O
's	O
change	O
in	O
mental	O
status	O
was	O
first	O
reported	O
nine	O
days	O
after	O
the	O
initiation	O
of	O
therapy	O
.	O

Her	O
delirium	B_Disease
significantly	O
improved	O
after	O
misoprostol	B_Chemical
was	O
discontinued	O
and	O
her	O
mental	O
status	O
returned	O
to	O
normal	O
within	O
a	O
week	O
.	O
Because	O
no	O
other	O
factors	O
related	O
to	O
this	O
patient	O
changed	O
significantly	O
,	O
the	O
delirium	B_Disease
experienced	O
by	O
this	O
patient	O
possibly	O
resulted	O
from	O
misoprostol	B_Chemical
therapy	O
.	O

The	O
biological	O
properties	O
of	O
the	O
optical	O
isomers	O
of	O
propranolol	B_Chemical
and	O
their	O
effects	O
on	O
cardiac	O
arrhythmias.1	O
.	O

The	O
optical	O
isomers	O
of	O
propranolol	B_Chemical
have	O
been	O
compared	O
for	O
their	O
beta-blocking	O
and	O
antiarrhythmic	O
activities.2	O
.	O

In	O
blocking	O
the	O
positive	O
inotropic	O
and	O
chronotropic	O
responses	O
to	O
isoprenaline	B_Chemical
,	O
(+)-propranolol	O
had	O
less	O
than	O
one	O
hundredth	O
the	O
potency	O
of	O
(-)-propranolol	O
.	O

At	O
dose	O
levels	O
of	O
(+)-propranolol	O
which	O
attenuated	O
the	O
responses	O
to	O
isoprenaline	B_Chemical
,	O
there	O
was	O
a	O
significant	O
prolongation	O
of	O
the	O
PR	O
interval	O
of	O
the	O
electrocardiogram.3	O
.	O

The	O
metabolic	O
responses	O
to	O
isoprenaline	B_Chemical
in	O
dogs	O
(	O
an	O
increase	O
in	O
circulating	O
glucose	B_Chemical
,	O
lactate	B_Chemical
and	O
free	O
fatty	B_Chemical
acids	I_Chemical
)	O
were	O
all	O
blocked	O
by	O
(-)-propranolol	O
.	O

(+)-Propranolol	O
had	O
no	O
effect	O
on	O
fatty	B_Chemical
acid	I_Chemical
mobilization	O
but	O
significantly	O
reduced	O
the	O
increments	O
in	O
both	O
lactate	B_Chemical
and	O
glucose.4	O
.	O

Both	O
isomers	O
of	O
propranolol	B_Chemical
possessed	O
similar	O
depressant	O
potency	O
on	O
isolated	O
atrial	O
muscle	O
taken	O
from	O
guinea-pigs.5	O
.	O

The	O
isomers	O
of	O
propranolol	B_Chemical
exhibited	O
similar	O
local	O
anaesthetic	O
potencies	O
on	O
an	O
isolated	O
frog	O
nerve	O
preparation	O
at	O
a	O
level	O
approximately	O
three	O
times	O
that	O
of	O
procaine	B_Chemical
.	O

The	O
racemic	O
compound	O
was	O
significantly	O
less	O
potent	O
than	O
either	O
isomer.6	O
.	O

Both	O
isomers	O
of	O
propranolol	B_Chemical
were	O
capable	O
of	O
preventing	O
adrenaline-induced	O
cardiac	B_Disease
arrhythmias	I_Disease
in	O
cats	O
anaesthetized	O
with	O
halothane	B_Chemical
,	O
but	O
the	O
mean	O
dose	O
of	O
(-)-propranolol	O
was	O
0.09+/-0.02	O
mg/kg	O
whereas	O
that	O
of	O
(+)-propranolol	O
was	O
4.2+/-1.2	O
mg/kg	O
.	O

At	O
the	O
effective	O
dose	O
level	O
of	O
(+)-propranolol	O
there	O
was	O
a	O
significant	O
prolongation	O
of	O
the	O
PR	O
interval	O
of	O
the	O
electrocardiogram	O
.	O

Blockade	O
of	O
arrhythmias	B_Disease
with	O
both	O
isomers	O
was	O
surmountable	O
by	O
increasing	O
the	O
dose	O
of	O
adrenaline.7	O
.	O

Both	O
isomers	O
of	O
propranolol	B_Chemical
were	O
also	O
capable	O
of	O
reversing	O
ventricular	B_Disease
tachycardia	I_Disease
caused	O
by	O
ouabain	B_Chemical
in	O
anaesthetized	O
cats	O
and	O
dogs	O
.	O

The	O
dose	O
of	O
(-)-propranolol	O
was	O
significantly	O
smaller	O
than	O
that	O
of	O
(+)-propranolol	O
in	O
both	O
species	O
but	O
much	O
higher	O
than	O
that	O
required	O
to	O
produce	O
evidence	O
of	O
beta-blockade.8	O
.	O

The	O
implications	O
of	O
these	O
results	O
are	O
discussed	O
.	O

Topotecan	B_Chemical
in	O
combination	O
with	O
radiotherapy	O
in	O
unresectable	O
glioblastoma	B_Disease
:	O
a	O
phase	O
2	O
study	O
.	O

Improving	O
glioblastoma	B_Disease
multiforme	I_Disease
(	O
GBM	B_Disease
)	O
treatment	O
with	O
radio-chemotherapy	O
remains	O
a	O
challenge	O
.	O

Topotecan	B_Chemical
is	O
an	O
attractive	O
option	O
as	O
it	O
exhibits	O
growth	O
inhibition	O
of	O
human	O
glioma	B_Disease
as	O
well	O
as	O
brain	O
penetration	O
.	O

The	O
present	O
study	O
assessed	O
the	O
combination	O
of	O
radiotherapy	O
(	O
60	O
Gy/30	O
fractions/40	O
days	O
)	O
and	O
topotecan	B_Chemical
(	O
0.9	O
mg/m(2)/day	O
on	O
days	O
1	O
-	O
5	O
on	O
weeks	O
1	O
,	O
3	O
and	O
5	O
)	O
in	O
50	O
adults	O
with	O
histologically	O
proven	O
and	O
untreated	O
GBM	B_Disease
.	O

The	O
incidence	O
of	O
non-hematological	O
toxicities	B_Disease
was	O
low	O
and	O
grade	O
3	O
-	O
4	O
hematological	O
toxicities	B_Disease
were	O
reported	O
in	O
20	O
patients	O
(	O
mainly	O
lymphopenia	B_Disease
and	O
neutropenia	B_Disease
)	O
.	O

Partial	O
response	O
and	O
stabilization	O
rates	O
were	O
2	O
%	O
and	O
32	O
%	O
,	O
respectively	O
,	O
with	O
an	O
overall	O
time	O
to	O
progression	O
of	O
12	O
weeks	O
.	O

One-year	O
overall	O
survival	O
(	O
OS	O
)	O
rate	O
was	O
42	O
%	O
,	O
with	O
a	O
median	O
OS	O
of	O
40	O
weeks	O
.	O

Topotecan	B_Chemical
in	O
combination	O
with	O
radiotherapy	O
was	O
well	O
tolerated	O
.	O

However	O
,	O
while	O
response	O
and	O
stabilization	O
concerned	O
one-third	O
of	O
the	O
patients	O
,	O
the	O
study	O
did	O
not	O
show	O
increased	O
benefits	O
in	O
terms	O
of	O
survival	O
in	O
patients	O
with	O
unresectable	O
GBM	B_Disease
.	O

Long-term	O
lithium	B_Chemical
therapy	O
leading	O
to	O
hyperparathyroidism	B_Disease
:	O
a	O
case	O
report	O
.	O

PURPOSE	O
:	O
This	O
paper	O
reviews	O
the	O
effect	O
of	O
chronic	O
lithium	B_Chemical
therapy	O
on	O
serum	O
calcium	B_Chemical
level	O
and	O
parathyroid	O
glands	O
,	O
its	O
pathogenesis	O
,	O
and	O
treatment	O
options	O
.	O

We	O
examined	O
the	O
case	O
of	O
a	O
lithium-treated	O
patient	O
who	O
had	O
recurrent	O
hypercalcemia	B_Disease
to	O
better	O
understand	O
the	O
disease	O
process	O
.	O

CONCLUSION	O
:	O
Primary	B_Disease
hyperparathyroidism	I_Disease
is	O
a	O
rare	O
but	O
potentially	O
life-threatening	O
side	O
effect	O
of	O
long-term	O
lithium	B_Chemical
therapy	O
.	O

Careful	O
patient	O
selection	O
and	O
long-term	O
follow-up	O
can	O
reduce	O
morbidity	O
.	O

PRACTICAL	O
IMPLICATIONS	O
:	O
As	O
much	O
as	O
15	O
%	O
of	O
lithium-treated	O
patients	O
become	O
hypercalcemic	B_Disease
.	O

By	O
routinely	O
monitoring	O
serum	O
calcium	B_Chemical
levels	O
,	O
healthcare	O
providers	O
can	O
improve	O
the	O
quality	O
of	O
life	O
of	O
this	O
patient	O
group	O
.	O

Comparison	O
of	O
laryngeal	O
mask	O
with	O
endotracheal	O
tube	O
for	O
anesthesia	O
in	O
endoscopic	O
sinus	O
surgery	O
.	O

BACKGROUND	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
surgical	O
conditions	O
,	O
including	O
the	O
amount	O
of	O
intraoperative	O
bleeding	B_Disease
as	O
well	O
as	O
intraoperative	O
blood	O
pressure	O
,	O
during	O
functional	O
endoscopic	O
sinus	O
surgery	O
(	O
FESS	O
)	O
using	O
flexible	O
reinforced	O
laryngeal	O
mask	O
airway	O
(	O
FRLMA	O
)	O
versus	O
endotracheal	O
tube	O
(	O
ETT	O
)	O
in	O
maintaining	O
controlled	O
hypotension	B_Disease
anesthesia	O
induced	O
by	O
propofol-remifentanil	O
total	O
i.v	O
.	O
anesthesia	O
(	O
TIVA	O
)	O
.	O

METHODS	O
:	O
Sixty	O
normotensive	O
American	O
Society	O
of	O
Anesthesiologists	O
I-II	O
adult	O
patients	O
undergoing	O
FESS	O
under	O
controlled	O
hypotension	B_Disease
anesthesia	O
caused	O
by	O
propofol-remifentanil-TIVA	O
were	O
randomly	O
assigned	O
into	O
two	O
groups	O
:	O
group	O
I	O
,	O
FRLMA	O
;	O
group	O
II	O
,	O
ETT	O
.	O

Hemorrhage	B_Disease
was	O
measured	O
and	O
the	O
visibility	O
of	O
the	O
operative	O
field	O
was	O
evaluated	O
according	O
to	O
a	O
six-point	O
scale	O
.	O

RESULTS	O
:	O
Controlled	O
hypotension	B_Disease
was	O
achieved	O
within	O
a	O
shorter	O
period	O
using	O
laryngeal	O
mask	O
using	O
lower	O
rates	O
of	O
remifentanil	B_Chemical
infusion	O
and	O
lower	O
total	O
dose	O
of	O
remifentanil	B_Chemical
.	O

CONCLUSION	O
:	O
In	O
summary	O
,	O
our	O
results	O
indicate	O
that	O
airway	O
management	O
using	O
FRLMA	O
during	O
controlled	O
hypotension	B_Disease
anesthesia	O
provided	O
better	O
surgical	O
conditions	O
in	O
terms	O
of	O
quality	O
of	O
operative	O
field	O
and	O
blood	O
loss	O
and	O
allowed	O
for	O
convenient	O
induced	O
hypotension	B_Disease
with	O
low	O
doses	O
of	O
remifentanil	B_Chemical
during	O
TIVA	O
in	O
patients	O
undergoing	O
FESS	O
.	O

Nonalcoholic	B_Disease
fatty	I_Disease
liver	I_Disease
disease	I_Disease
during	O
valproate	B_Chemical
therapy	O
.	O

Valproic	B_Chemical
acid	I_Chemical
(	O
VPA	B_Chemical
)	O
is	O
effective	O
for	O
the	O
treatment	O
of	O
many	O
types	O
of	O
epilepsy	B_Disease
,	O
but	O
its	O
use	O
can	O
be	O
associated	O
with	O
an	O
increase	O
in	O
body	O
weight	O
.	O

We	O
report	O
a	O
case	O
of	O
nonalcoholic	B_Disease
fatty	I_Disease
liver	I_Disease
disease	I_Disease
(	O
NAFLD	B_Disease
)	O
arising	O
in	O
a	O
child	O
who	O
developed	O
obesity	B_Disease
during	O
VPA	B_Chemical
treatment	O
.	O

Laboratory	O
data	O
revealed	O
hyperinsulinemia	B_Disease
with	O
insulin	B_Disease
resistance	I_Disease
.	O

After	O
the	O
withdrawal	O
of	O
VPA	B_Chemical
therapy	O
,	O
our	O
patient	O
showed	O
a	O
significant	O
weight	B_Disease
loss	I_Disease
,	O
a	O
decrease	O
of	O
body	O
mass	O
index	O
,	O
and	O
normalization	O
of	O
metabolic	O
and	O
endocrine	O
parameters	O
;	O
moreover	O
,	O
ultrasound	O
measurements	O
showed	O
a	O
complete	O
normalization	O
.	O

The	O
present	O
case	O
suggests	O
that	O
obesity	B_Disease
,	O
hyperinsulinemia	B_Disease
,	O
insulin	B_Disease
resistance	I_Disease
,	O
and	O
long-term	O
treatment	O
with	O
VPA	B_Chemical
may	O
be	O
all	O
associated	O
with	O
the	O
development	O
of	O
NAFLD	B_Disease
;	O
this	O
side	O
effect	O
is	O
reversible	O
after	O
VPA	B_Chemical
withdrawal	O
.	O

Carbimazole	B_Chemical
induced	O
ANCA	B_Disease
positive	I_Disease
vasculitis	I_Disease
.	O

Anti-thyroid	B_Chemical
drugs	I_Chemical
,	O
like	O
carbimazole	B_Chemical
and	O
propylthiouracil	B_Chemical
(	O
PTU	B_Chemical
)	O
are	O
commonly	O
prescribed	O
for	O
the	O
treatment	O
of	O
hyperthyroidism	B_Disease
.	O

One	O
should	O
be	O
aware	O
of	O
the	O
side	O
effects	O
of	O
antithyroid	B_Chemical
medications	I_Chemical
.	O

Antineutrophil	B_Disease
cytoplasmic	I_Disease
antibody	I_Disease
(ANCA)--associated	I_Disease
vasculitis	I_Disease
is	O
a	O
potentially	O
life-threatening	O
adverse	O
effect	O
of	O
antithyroidmedications	B_Chemical
.	O

We	O
report	O
a	O
patient	O
with	O
Graves	B_Disease
'	I_Disease
disease	I_Disease
who	O
developed	O
ANCA	O
positive	O
carbimazole	B_Chemical
induced	O
vasculitis	B_Disease
.	O

The	O
episode	O
was	O
characterized	O
by	O
a	O
vasculitic	B_Disease
skin	B_Disease
rash	I_Disease
associated	O
with	O
large	O
joint	O
arthritis	B_Disease
,	O
pyrexia	B_Disease
and	O
parotiditis	B_Disease
but	O
no	O
renal	O
or	O
pulmonary	O
involvement	O
.	O

He	O
was	O
referred	O
to	O
us	O
for	O
neurological	O
evaluation	O
because	O
he	O
had	O
difficulty	O
in	O
getting	O
up	O
from	O
squatting	O
position	O
and	O
was	O
suspected	O
to	O
have	O
myositis	B_Disease
.	O

Carbimazole	B_Chemical
and	O
methimazole	B_Chemical
have	O
a	O
lower	O
incidence	O
of	O
reported	O
ANCA	O
positive	O
side	O
effects	O
than	O
PUT	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
ANCA	O
positive	O
carbimazole	B_Chemical
induced	O
vasculitis	B_Disease
case	O
reported	O
from	O
India	O
.	O

Aspirin	O
for	O
the	O
primary	O
prevention	O
of	O
cardiovascular	O
events	O
:	O
an	O
update	O
of	O
the	O
evidence	O
for	O
the	O
U.S.	O
Preventive	O
Services	O
Task	O
Force	O
.	O

BACKGROUND	O
:	O
Coronary	B_Disease
heart	I_Disease
disease	I_Disease
and	O
cerebrovascular	B_Disease
disease	I_Disease
are	O
leading	O
causes	O
of	O
death	O
in	O
the	O
United	O
States	O
.	O

In	O
2002	O
,	O
the	O
U.S.	O
Preventive	O
Services	O
Task	O
Force	O
(	O
USPSTF	O
)	O
strongly	O
recommended	O
that	O
clinicians	O
discuss	O
aspirin	B_Chemical
with	O
adults	O
who	O
are	O
at	O
increased	O
risk	O
for	O
coronary	B_Disease
heart	I_Disease
disease	I_Disease
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
benefits	O
and	O
harms	O
of	O
taking	O
aspirin	B_Chemical
for	O
the	O
primary	O
prevention	O
of	O
myocardial	B_Disease
infarctions	I_Disease
,	O
strokes	B_Disease
,	O
and	O
death	O
.	O

DATA	O
SOURCES	O
:	O
MEDLINE	O
and	O
Cochrane	O
Library	O
(	O
search	O
dates	O
,	O
1	O
January	O
2001	O
to	O
28	O
August	O
2008	O
)	O
,	O
recent	O
systematic	O
reviews	O
,	O
reference	O
lists	O
of	O
retrieved	O
articles	O
,	O
and	O
suggestions	O
from	O
experts	O
.	O

STUDY	O
SELECTION	O
:	O
English-language	O
randomized	O
,	O
controlled	O
trials	O
(	O
RCTs	O
)	O
;	O
case-control	O
studies	O
;	O
meta-analyses	O
;	O
and	O
systematic	O
reviews	O
of	O
aspirin	B_Chemical
versus	O
control	O
for	O
the	O
primary	O
prevention	O
of	O
cardiovascular	B_Disease
disease	I_Disease
(	O
CVD	B_Disease
)	O
were	O
selected	O
to	O
answer	O
the	O
following	O
questions	O
:	O
Does	O
aspirin	B_Chemical
decrease	O
coronary	O
heart	O
events	O
,	O
strokes	B_Disease
,	O
death	O
from	O
coronary	O
heart	O
events	O
or	O
stroke	B_Disease
,	O
or	O
all-cause	O
mortality	O
in	O
adults	O
without	O
known	O
CVD	B_Disease
?	O
Does	O
aspirin	B_Chemical
increase	O
gastrointestinal	B_Disease
bleeding	I_Disease
or	O
hemorrhagic	B_Disease
strokes	B_Disease
?	O
DATA	O
EXTRACTION	O
:	O
All	O
studies	O
were	O
reviewed	O
,	O
abstracted	O
,	O
and	O
rated	O
for	O
quality	O
by	O
using	O
predefined	O
USPSTF	O
criteria	O
.	O

DATA	O
SYNTHESIS	O
:	O
New	O
evidence	O
from	O
1	O
good-quality	O
RCT	O
,	O
1	O
good-quality	O
meta-analysis	O
,	O
and	O
2	O
fair-quality	O
subanalyses	O
of	O
RCTs	O
demonstrates	O
that	O
aspirin	B_Chemical
use	O
reduces	O
the	O
number	O
of	O
CVD	B_Disease
events	O
in	O
patients	O
without	O
known	O
CVD	B_Disease
.	O

Men	O
in	O
these	O
studies	O
experienced	O
fewer	O
myocardial	B_Disease
infarctions	I_Disease
and	O
women	O
experienced	O
fewer	O
ischemic	O
strokes	B_Disease
.	O

Aspirin	B_Chemical
does	O
not	O
seem	O
to	O
affect	O
CVD	B_Disease
mortality	O
or	O
all-cause	O
mortality	O
in	O
either	O
men	O
or	O
women	O
.	O

The	O
use	O
of	O
aspirin	B_Chemical
for	O
primary	O
prevention	O
increases	O
the	O
risk	O
for	O
major	O
bleeding	B_Disease
events	O
,	O
primarily	O
gastrointestinal	B_Disease
bleeding	I_Disease
events	O
,	O
in	O
both	O
men	O
and	O
women	O
.	O

Men	O
have	O
an	O
increased	O
risk	O
for	O
hemorrhagic	B_Disease
strokes	B_Disease
with	O
aspirin	B_Chemical
use	O
.	O

A	O
new	O
RCT	O
and	O
meta-analysis	O
suggest	O
that	O
the	O
risk	O
for	O
hemorrhagic	B_Disease
strokes	B_Disease
in	O
women	O
is	O
not	O
statistically	O
significantly	O
increased	O
.	O

LIMITATIONS	O
:	O
New	O
evidence	O
on	O
aspirin	B_Chemical
for	O
the	O
primary	O
prevention	O
of	O
CVD	B_Disease
is	O
limited	O
.	O

The	O
dose	O
of	O
aspirin	B_Chemical
used	O
in	O
the	O
RCTs	O
varied	O
,	O
which	O
prevented	O
the	O
estimation	O
of	O
the	O
most	O
appropriate	O
dose	O
for	O
primary	O
prevention	O
.	O

Several	O
of	O
the	O
RCTs	O
were	O
conducted	O
within	O
populations	O
of	O
health	O
professionals	O
,	O
which	O
potentially	O
limits	O
generalizability	O
.	O

CONCLUSION	O
:	O
Aspirin	B_Chemical
reduces	O
the	O
risk	O
for	O
myocardial	B_Disease
infarction	I_Disease
in	O
men	O
and	O
strokes	B_Disease
in	O
women	O
.	O

Aspirin	B_Chemical
use	O
increases	O
the	O
risk	O
for	O
serious	O
bleeding	B_Disease
events	O
.	O

Reducing	O
harm	O
associated	O
with	O
anticoagulation	O
:	O
practical	O
considerations	O
of	O
argatroban	B_Chemical
therapy	O
in	O
heparin-induced	O
thrombocytopenia	B_Disease
.	O

Argatroban	B_Chemical
is	O
a	O
hepatically	O
metabolized	O
,	O
direct	O
thrombin	O
inhibitor	O
used	O
for	O
prophylaxis	O
or	O
treatment	O
of	O
thrombosis	B_Disease
in	O
heparin-induced	O
thrombocytopenia	B_Disease
(	O
HIT	B_Disease
)	O
and	O
for	O
patients	O
with	O
or	O
at	O
risk	O
of	O
HIT	B_Disease
undergoing	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
.	O

The	O
objective	O
of	O
this	O
review	O
is	O
to	O
summarize	O
practical	O
considerations	O
of	O
argatroban	B_Chemical
therapy	O
in	O
HIT	B_Disease
.	O

The	O
US	O
FDA-recommended	O
argatroban	B_Chemical
dose	O
in	O
HIT	B_Disease
is	O
2	O
microg/kg/min	O
(	O
reduced	O
in	O
patients	O
with	O
hepatic	B_Disease
impairment	I_Disease
and	O
in	O
paediatric	O
patients	O
)	O
,	O
adjusted	O
to	O
achieve	O
activated	O
partial	O
thromboplastin	O
times	O
(	O
aPTTs	O
)	O
1.5	O
-	O
3	O
times	O
baseline	O
(	O
not	O
>	O
100	O
seconds	O
)	O
.	O

Contemporary	O
experiences	O
indicate	O
that	O
reduced	O
doses	O
are	O
also	O
needed	O
in	O
patients	O
with	O
conditions	O
associated	O
with	O
hepatic	O
hypoperfusion	O
,	O
e.g.	O
heart	B_Disease
failure	I_Disease
,	O
yet	O
are	O
unnecessary	O
for	O
renal	B_Disease
dysfunction	I_Disease
,	O
adult	O
age	O
,	O
sex	O
,	O
race/ethnicity	O
or	O
obesity	B_Disease
.	O

Argatroban	B_Chemical
0.5	O
-	O
1.2	O
microg/kg/min	O
typically	O
supports	O
therapeutic	O
aPTTs	O
.	O

The	O
FDA-recommended	O
dose	O
during	O
PCI	O
is	O
25	O
microg/kg/min	O
(	O
350	O
microg/kg	O
initial	O
bolus	O
)	O
,	O
adjusted	O
to	O
achieve	O
activated	O
clotting	O
times	O
(	O
ACTs	O
)	O
of	O
300	O
-	O
450	O
sec.	O
For	O
PCI	O
,	O
argatroban	B_Chemical
has	O
not	O
been	O
investigated	O
in	O
hepatically	O
impaired	O
patients	O
;	O
dose	O
adjustment	O
is	O
unnecessary	O
for	O
adult	O
age	O
,	O
sex	O
,	O
race/ethnicity	O
or	O
obesity	B_Disease
,	O
and	O
lesser	O
doses	O
may	O
be	O
adequate	O
with	O
concurrent	O
glycoprotein	O
IIb/IIIa	O
inhibition	O
.	O

Argatroban	B_Chemical
prolongs	O
the	O
International	O
Normalized	O
Ratio	O
,	O
and	O
published	O
approaches	O
for	O
monitoring	O
the	O
argatroban-to-warfarin	O
transition	O
should	O
be	O
followed	O
.	O

Major	O
bleeding	B_Disease
with	O
argatroban	B_Chemical
is	O
0	O
-	O
10	O
%	O
in	O
the	O
non-interventional	O
setting	O
and	O
0	O
-	O
5.8	O
%	O
periprocedurally	O
.	O

Argatroban	B_Chemical
has	O
no	O
specific	O
antidote	O
,	O
and	O
if	O
excessive	O
anticoagulation	O
occurs	O
,	O
argatroban	B_Chemical
infusion	O
should	O
be	O
stopped	O
or	O
reduced	O
.	O

Improved	O
familiarity	O
of	O
healthcare	O
professionals	O
with	O
argatroban	B_Chemical
therapy	O
in	O
HIT	B_Disease
,	O
including	O
in	O
special	O
populations	O
and	O
during	O
PCI	O
,	O
may	O
facilitate	O
reduction	O
of	O
harm	O
associated	O
with	O
HIT	B_Disease
(	O
e.g.	O
fewer	O
thromboses	O
)	O
or	O
its	O
treatment	O
(	O
e.g.	O
fewer	O
argatroban	B_Chemical
medication	O
errors	O
)	O
.	O

Rhabdomyolysis	B_Disease
and	O
brain	O
ischemic	B_Disease
stroke	I_Disease
in	O
a	O
heroin-dependent	O
male	O
under	O
methadone	B_Chemical
maintenance	O
therapy	O
.	O

OBJECTIVE	O
:	O
There	O
are	O
several	O
complications	O
associated	O
with	O
heroin	B_Disease
abuse	I_Disease
,	O
some	O
of	O
which	O
are	O
life-threatening	O
.	O

Methadone	B_Chemical
may	O
aggravate	O
this	O
problem	O
.	O

METHOD	O
:	O
A	O
clinical	O
case	O
description	O
.	O

RESULTS	O
:	O
A	O
33-year-old	O
man	O
presented	O
with	O
rhabdomyolysis	B_Disease
and	O
cerebral	O
ischemic	B_Disease
stroke	I_Disease
after	O
intravenous	O
heroin	B_Chemical
.	O

He	O
had	O
used	O
heroin	B_Chemical
since	O
age	O
20	O
,	O
and	O
had	O
used	O
150	O
mg	O
methadone	B_Chemical
daily	O
for	O
6	O
months	O
.	O

He	O
was	O
found	O
unconsciousness	B_Disease
at	O
home	O
and	O
was	O
sent	O
to	O
our	O
hospital	O
.	O

In	O
the	O
ER	O
,	O
his	O
opiate	O
level	O
was	O
4497	O
ng/ml	O
.	O

In	O
the	O
ICU	O
,	O
we	O
found	O
rhabdomyolysis	B_Disease
,	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
and	O
acute	O
respiratory	B_Disease
failure	I_Disease
.	O

After	O
transfer	O
to	O
an	O
internal	O
ward	O
,	O
we	O
noted	O
aphasia	B_Disease
and	O
weakness	B_Disease
of	O
his	O
left	O
limbs	O
.	O

After	O
MRI	O
,	O
we	O
found	O
cerebral	B_Disease
ischemic	I_Disease
infarction	I_Disease
.	O

CONCLUSION	O
:	O
Those	O
using	O
methadone	B_Chemical
and	O
heroin	B_Chemical
simultaneously	O
may	O
increase	O
risk	O
of	O
rhabdomyolysis	B_Disease
and	O
ischemic	B_Disease
stroke	I_Disease
.	O

Patients	O
under	O
methadone	B_Chemical
maintenance	O
therapy	O
should	O
be	O
warned	O
regarding	O
these	O
serious	O
adverse	O
events	O
.	O

Hypotheses	O
of	O
heroin-related	O
rhabdomyolysis	B_Disease
and	O
stroke	B_Disease
in	O
heroin	B_Chemical
abusers	O
are	O
discussed	O
.	O

Increased	O
vulnerability	O
to	O
6-hydroxydopamine	B_Chemical
lesion	O
and	O
reduced	O
development	O
of	O
dyskinesias	B_Disease
in	O
mice	O
lacking	O
CB1	O
cannabinoid	O
receptors	O
.	O

Motor	O
impairment	O
,	O
dopamine	B_Chemical
(	O
DA	B_Chemical
)	O
neuronal	O
activity	O
and	O
proenkephalin	B_Chemical
(	O
PENK	B_Chemical
)	O
gene	O
expression	O
in	O
the	O
caudate-putamen	O
(	O
CPu	O
)	O
were	O
measured	O
in	O
6-OHDA-lesioned	O
and	O
treated	O
(	O
L-DOPA+benserazide	B_Chemical
)	O
CB1	O
KO	O
and	O
WT	O
mice	O
.	O

A	O
lesion	O
induced	O
by	O
6-OHDA	B_Chemical
produced	O
more	O
severe	O
motor	O
deterioration	O
in	O
CB1	O
KO	O
mice	O
accompanied	O
by	O
more	O
loss	O
of	O
DA	B_Chemical
neurons	O
and	O
increased	O
PENK	B_Chemical
gene	O
expression	O
in	O
the	O
CPu	O
.	O

Oxidative/nitrosative	O
and	O
neuroinflammatory	O
parameters	O
were	O
estimated	O
in	O
the	O
CPu	O
and	O
cingulate	O
cortex	O
(	O
Cg	O
)	O
.	O

CB1	O
KO	O
mice	O
exhibited	O
higher	O
MDA	B_Chemical
levels	O
and	O
iNOS	O
protein	O
expression	O
in	O
the	O
CPu	O
and	O
Cg	O
compared	O
to	O
WT	O
mice	O
.	O

Treatment	O
with	O
L-DOPA+benserazide	B_Chemical
(	O
12	O
weeks	O
)	O
resulted	O
in	O
less	O
severe	O
dyskinesias	B_Disease
in	O
CB1	O
KO	O
than	O
in	O
WT	O
mice	O
.	O

The	O
results	O
revealed	O
that	O
the	O
lack	O
of	O
cannabinoid	O
CB1	O
receptors	O
increased	O
the	O
severity	O
of	O
motor	O
impairment	O
and	O
DA	B_Chemical
lesion	O
,	O
and	O
reduced	O
L-DOPA-induced	O
dyskinesias	B_Disease
.	O

These	O
results	O
suggest	O
that	O
activation	O
of	O
CB1	O
receptors	O
offers	O
neuroprotection	O
against	O
dopaminergic	O
lesion	O
and	O
the	O
development	O
of	O
L-DOPA-induced	O
dyskinesias	B_Disease
.	O

Hepatocellular	O
oxidant	O
stress	O
following	O
intestinal	O
ischemia-reperfusion	O
injury	O
.	O

Reperfusion	O
of	O
ischemic	B_Disease
intestine	O
results	O
in	O
acute	O
liver	B_Disease
dysfunction	I_Disease
characterized	O
by	O
hepatocellular	O
enzyme	O
release	O
into	O
plasma	O
,	O
reduction	O
in	O
bile	O
flow	O
rate	O
,	O
and	O
neutrophil	O
sequestration	O
within	O
the	O
liver	O
.	O

The	O
pathophysiology	O
underlying	O
this	O
acute	O
hepatic	B_Disease
injury	I_Disease
is	O
unknown	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
oxidants	O
are	O
associated	O
with	O
the	O
hepatic	B_Disease
injury	I_Disease
and	O
to	O
determine	O
the	O
relative	O
value	O
of	O
several	O
indirect	O
methods	O
of	O
assessing	O
oxidant	O
exposure	O
in	O
vivo	O
.	O

Rats	O
were	O
subjected	O
to	O
a	O
standardized	O
intestinal	O
ischemia-reperfusion	O
injury	O
.	O

Hepatic	O
tissue	O
was	O
assayed	O
for	O
lipid	O
peroxidation	O
products	O
and	O
oxidized	B_Chemical
and	I_Chemical
reduced	B_Chemical
glutathione	I_Chemical
.	O

There	O
was	O
no	O
change	O
in	O
hepatic	O
tissue	O
total	O
glutathione	B_Chemical
following	O
intestinal	O
ischemia-reperfusion	O
injury	O
.	O

Oxidized	B_Chemical
glutathione	I_Chemical
(	O
GSSG	B_Chemical
)	O
increased	O
significantly	O
following	O
30	O
and	O
60	O
min	O
of	O
reperfusion	O
.	O

There	O
was	O
no	O
increase	O
in	O
any	O
of	O
the	O
products	O
of	O
lipid	O
peroxidation	O
associated	O
with	O
this	O
injury	O
.	O

An	O
increase	O
in	O
GSSG	B_Chemical
within	O
hepatic	O
tissue	O
during	O
intestinal	O
reperfusion	O
suggests	O
exposure	O
of	O
hepatocytes	O
to	O
an	O
oxidant	O
stress	O
.	O

The	O
lack	O
of	O
a	O
significant	O
increase	O
in	O
products	O
of	O
lipid	O
peroxidation	O
suggests	O
that	O
the	O
oxidant	O
stress	O
is	O
of	O
insufficient	O
magnitude	O
to	O
result	O
in	O
irreversible	O
injury	O
to	O
hepatocyte	O
cell	O
membranes	O
.	O

These	O
data	O
also	O
suggest	O
that	O
the	O
measurement	O
of	O
tissue	O
GSSG	B_Chemical
may	O
be	O
a	O
more	O
sensitive	O
indicator	O
of	O
oxidant	O
stress	O
than	O
measurement	O
of	O
products	O
of	O
lipid	O
peroxidation	O
.	O

Animal	O
model	O
of	O
mania	B_Disease
induced	O
by	O
ouabain	B_Chemical
:	O
Evidence	O
of	O
oxidative	O
stress	O
in	O
submitochondrial	O
particles	O
of	O
the	O
rat	O
brain	O
.	O

The	O
intracerebroventricular	O
(	O
ICV	O
)	O
administration	O
of	O
ouabain	B_Chemical
(	O
a	O
Na(+)/K(+)-ATPase	O
inhibitor	O
)	O
in	O
rats	O
has	O
been	O
suggested	O
to	O
mimic	O
some	O
symptoms	O
of	O
human	O
bipolar	B_Disease
mania	I_Disease
.	O

Clinical	O
studies	O
have	O
shown	O
that	O
bipolar	B_Disease
disorder	I_Disease
may	O
be	O
related	O
to	O
mitochondrial	B_Disease
dysfunction	I_Disease
.	O

Herein	O
,	O
we	O
investigated	O
the	O
behavioral	O
and	O
biochemical	O
effects	O
induced	O
by	O
the	O
ICV	O
administration	O
of	O
ouabain	B_Chemical
in	O
rats	O
.	O

To	O
achieve	O
this	O
aim	O
,	O
the	O
effects	O
of	O
ouabain	B_Chemical
injection	O
immediately	O
after	O
and	O
7	O
days	O
following	O
a	O
single	O
ICV	O
administration	O
(	O
at	O
concentrations	O
of	O
10(-2	O
)	O
and	O
10(-3)M	O
)	O
on	O
locomotion	O
was	O
measured	O
using	O
the	O
open-field	O
test	O
.	O

Additionally	O
,	O
thiobarbituric	B_Chemical
acid	I_Chemical
reactive	O
substances	O
(	O
TBARSs	O
)	O
and	O
superoxide	B_Chemical
production	O
were	O
measured	O
in	O
submitochondrial	O
particles	O
of	O
the	O
prefrontal	O
cortex	O
,	O
hippocampus	O
,	O
striatum	O
and	O
amygdala	O
.	O

Our	O
findings	O
demonstrated	O
that	O
ouabain	B_Chemical
at	O
10(-2	O
)	O
and	O
10(-3)M	O
induced	O
hyperlocomotion	B_Disease
in	O
rats	O
,	O
and	O
this	O
response	O
remained	O
up	O
to	O
7	O
days	O
following	O
a	O
single	O
ICV	O
injection	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
the	O
persistent	O
increase	O
in	O
the	O
rat	O
spontaneous	O
locomotion	O
is	O
associated	O
with	O
increased	O
TBARS	O
levels	O
and	O
superoxide	B_Chemical
generation	O
in	O
submitochondrial	O
particles	O
in	O
the	O
prefrontal	O
cortex	O
,	O
striatum	O
and	O
amygdala	O
.	O

In	O
conclusion	O
,	O
ouabain-induced	O
mania-like	O
behavior	O
may	O
provide	O
a	O
useful	O
animal	O
model	O
to	O
test	O
the	O
hypothesis	O
of	O
the	O
involvement	O
of	O
oxidative	O
stress	O
in	O
bipolar	B_Disease
disorder	I_Disease
.	O

Intraoperative	O
dialysis	O
during	O
liver	O
transplantation	O
with	O
citrate	O
dialysate	O
.	O

Liver	O
transplantation	O
for	O
acutely	O
ill	O
patients	O
with	O
fulminant	B_Disease
liver	I_Disease
failure	I_Disease
carries	O
high	O
intraoperative	O
and	O
immediate	O
postoperative	O
risks	O
.	O

These	O
are	O
increased	O
with	O
the	O
presence	O
of	O
concomitant	O
acute	B_Disease
kidney	I_Disease
injury	I_Disease
(	O
AKI	B_Disease
)	O
and	O
intraoperative	O
dialysis	O
is	O
sometimes	O
required	O
to	O
allow	O
the	O
transplant	O
to	O
proceed	O
.	O

The	O
derangements	O
in	O
the	O
procoagulant	O
and	O
anticoagulant	O
pathways	O
during	O
fulminant	B_Disease
liver	I_Disease
failure	I_Disease
can	O
lead	O
to	O
difficulties	O
with	O
anticoagulation	O
during	O
dialysis	O
,	O
especially	O
when	O
continued	O
in	O
the	O
operating	O
room	O
.	O

Systemic	O
anticoagulation	O
is	O
unsafe	O
and	O
regional	O
citrate	B_Chemical
anticoagulation	O
in	O
the	O
absence	O
of	O
a	O
functional	O
liver	O
carries	O
the	O
risk	O
of	O
citrate	B_Chemical
toxicity	B_Disease
.	O

Citrate	B_Chemical
dialysate	O
,	O
a	O
new	O
dialysate	O
with	O
citric	B_Chemical
acid	I_Chemical
can	O
be	O
used	O
for	O
anticoagulation	O
in	O
patients	O
who	O
can	O
not	O
tolerate	O
heparin	B_Chemical
or	O
regional	O
citrate	B_Chemical
.	O

We	O
report	O
a	O
case	O
of	O
a	O
40-year-old	O
female	O
with	O
acetaminophen-induced	O
fulminant	B_Disease
liver	I_Disease
failure	I_Disease
with	O
associated	O
AKI	B_Disease
who	O
underwent	O
intraoperative	O
dialytic	O
support	O
during	O
liver	O
transplantation	O
anticoagulated	O
with	O
citrate	B_Chemical
dialysate	O
during	O
the	O
entire	O
procedure	O
.	O

The	O
patient	O
tolerated	O
the	O
procedure	O
well	O
without	O
any	O
signs	O
of	O
citrate	B_Chemical
toxicity	B_Disease
and	O
maintained	O
adequate	O
anticoagulation	O
for	O
patency	O
of	O
the	O
dialysis	O
circuit	O
.	O

Citrate	B_Chemical
dialysate	O
is	O
a	O
safe	O
alternative	O
for	O
intradialytic	O
support	O
of	O
liver	O
transplantation	O
in	O
fulminant	B_Disease
liver	I_Disease
failure	I_Disease
.	O

Delirium	B_Disease
in	O
a	O
patient	O
with	O
toxic	O
flecainide	B_Chemical
plasma	O
concentrations	O
:	O
the	O
role	O
of	O
a	O
pharmacokinetic	O
drug	O
interaction	O
with	O
paroxetine	B_Chemical
.	O

OBJECTIVE	O
:	O
To	O
describe	O
a	O
case	O
of	O
flecainide-induced	O
delirium	B_Disease
associated	O
with	O
a	O
pharmacokinetic	O
drug	O
interaction	O
with	O
paroxetine	B_Chemical
.	O

CASE	O
SUMMARY	O
:	O
A	O
69-year-old	O
white	O
female	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
a	O
history	O
of	O
confusion	B_Disease
and	O
paranoia	B_Disease
over	O
the	O
past	O
several	O
days	O
.	O

On	O
admission	O
the	O
patient	O
was	O
taking	O
carvedilol	B_Chemical
12	O
mg	O
twice	O
daily	O
,	O
warfarin	B_Chemical
2	O
mg/day	O
,	O
folic	B_Chemical
acid	I_Chemical
1	O
mg/day	O
,	O
levothyroxine	B_Chemical
100	O
microg/day	O
,	O
pantoprazole	B_Chemical
40	O
mg/day	O
,	O
paroxetine	B_Chemical
40	O
mg/day	O
,	O
and	O
flecainide	B_Chemical
100	O
mg	O
twice	O
daily	O
.	O

Flecainide	B_Chemical
had	O
been	O
started	O
2	O
weeks	O
prior	O
for	O
atrial	B_Disease
fibrillation	I_Disease
.	O

Laboratory	O
test	O
findings	O
on	O
admission	O
were	O
notable	O
only	O
for	O
a	O
flecainide	B_Chemical
plasma	O
concentration	O
of	O
1360	O
microg/L	O
(	O
reference	O
range	O
200	O
-	O
1000	O
)	O
.	O

A	O
metabolic	O
drug	O
interaction	O
between	O
flecainide	B_Chemical
and	O
paroxetine	B_Chemical
,	O
which	O
the	O
patient	O
had	O
been	O
taking	O
for	O
more	O
than	O
5	O
years	O
,	O
was	O
considered	O
.	O

Paroxetine	B_Chemical
was	O
discontinued	O
and	O
the	O
dose	O
of	O
flecainide	B_Chemical
was	O
reduced	O
to	O
50	O
mg	O
twice	O
daily	O
.	O

Her	O
delirium	B_Disease
resolved	O
3	O
days	O
later	O
.	O

DISCUSSION	O
:	O
Flecainide	B_Chemical
and	O
pharmacologically	O
similar	O
agents	O
that	O
interact	O
with	O
sodium	B_Chemical
channels	O
may	O
cause	O
delirium	B_Disease
in	O
susceptible	O
patients	O
.	O

A	O
MEDLINE	O
search	O
(	O
1966-January	O
2009	O
)	O
revealed	O
one	O
in	O
vivo	O
pharmacokinetic	O
study	O
on	O
the	O
interaction	O
between	O
flecainide	B_Chemical
,	O
a	O
CYP2D6	O
substrate	O
,	O
and	O
paroxetine	B_Chemical
,	O
a	O
CYP2D6	O
inhibitor	O
,	O
as	O
well	O
as	O
3	O
case	O
reports	O
of	O
flecainide-induced	O
delirium	B_Disease
.	O

According	O
to	O
the	O
Naranjo	O
probability	O
scale	O
,	O
flecainide	B_Chemical
was	O
the	O
probable	O
cause	O
of	O
the	O
patient	O
's	O
delirium	B_Disease
;	O
the	O
Horn	O
Drug	O
Interaction	O
Probability	O
Scale	O
indicates	O
a	O
possible	O
pharmacokinetic	O
drug	O
interaction	O
between	O
flecainide	B_Chemical
and	O
paroxetine	B_Chemical
.	O

CONCLUSIONS	O
:	O
Supratherapeutic	O
flecainide	B_Chemical
plasma	O
concentrations	O
may	O
cause	O
delirium	B_Disease
.	O

Because	O
toxicity	B_Disease
may	O
occur	O
when	O
flecainide	B_Chemical
is	O
prescribed	O
with	O
paroxetine	B_Chemical
and	O
other	O
potent	O
CYP2D6	O
inhibitors	O
,	O
flecainide	B_Chemical
plasma	O
concentrations	O
should	O
be	O
monitored	O
closely	O
with	O
commencement	O
of	O
CYP2D6	O
inhibitors	O
.	O

Efficacy	O
of	O
everolimus	B_Chemical
(	O
RAD001	B_Chemical
)	O
in	O
patients	O
with	O
advanced	O
NSCLC	B_Disease
previously	O
treated	O
with	O
chemotherapy	O
alone	O
or	O
with	O
chemotherapy	O
and	O
EGFR	O
inhibitors	O
.	O

BACKGROUND	O
:	O
Treatment	O
options	O
are	O
scarce	O
in	O
pretreated	O
advanced	O
non-small-cell	B_Disease
lung	I_Disease
cancer	I_Disease
(	O
NSCLC	B_Disease
)	O
patients	O
.	O

RAD001	B_Chemical
,	O
an	O
oral	O
inhibitor	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	B_Chemical
(	O
mTOR	O
)	O
,	O
has	O
shown	O
phase	O
I	O
efficacy	O
in	O
NSCLC	B_Disease
.	O

METHODS	O
:	O
Stage	O
IIIb	O
or	O
IV	O
NSCLC	B_Disease
patients	O
,	O
with	O
two	O
or	O
fewer	O
prior	O
chemotherapy	O
regimens	O
,	O
one	O
platinum	B_Chemical
based	O
(	O
stratum	O
1	O
)	O
or	O
both	O
chemotherapy	O
and	O
epidermal	O
growth	O
factor	O
receptor	O
tyrosine	B_Chemical
kinase	O
inhibitors	O
(	O
stratum	O
2	O
)	O
,	O
received	O
RAD001	B_Chemical
10	O
mg/day	O
until	O
progression	O
or	O
unacceptable	O
toxicity	B_Disease
.	O

Primary	O
objective	O
was	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
.	O

Analyses	O
of	O
markers	O
associated	O
with	O
the	O
mTOR	O
pathway	O
were	O
carried	O
out	O
on	O
archival	O
tumor	B_Disease
from	O
a	O
subgroup	O
using	O
immunohistochemistry	O
(	O
IHC	O
)	O
and	O
direct	O
mutation	O
sequencing	O
.	O

RESULTS	O
:	O
Eighty-five	O
patients	O
were	O
enrolled	O
,	O
42	O
in	O
stratum	O
1	O
and	O
43	O
in	O
stratum	O
.	O

ORR	O
was	O
4.7	O
%	O
(	O
7.1	O
%	O
stratum	O
1	O
;	O
2.3	O
%	O
stratum	O
2	O
)	O
.	O

Overall	O
disease	O
control	O
rate	O
was	O
47.1	O
%	O
.	O

Median	O
progression-free	O
survivals	O
(	O
PFSs	O
)	O
were	O
2.6	O
(	O
stratum	O
1	O
)	O
and	O
2.7	O
months	O
(	O
stratum	O
2	O
)	O
.	O

Common	O
>	O
or	O
=	O
grade	O
3	O
events	O
were	O
fatigue	B_Disease
,	O
dyspnea	B_Disease
,	O
stomatitis	B_Disease
,	O
anemia	B_Disease
,	O
and	O
thrombocytopenia	B_Disease
.	O

Pneumonitis	B_Disease
,	O
probably	O
or	O
possibly	O
related	O
,	O
mainly	O
grade	O
1/2	O
,	O
occurred	O
in	O
25	O
%	O
.	O

Cox	O
regression	O
analysis	O
of	O
IHC	O
scores	O
found	O
that	O
only	O
phospho	O
AKT	O
(	O
pAKT	O
)	O
was	O
a	O
significant	O
independent	O
predictor	O
of	O
worse	O
PFS	O
.	O

CONCLUSIONS	O
:	O
RAD001	B_Chemical
10	O
mg/day	O
was	O
well	O
tolerated	O
,	O
showing	O
modest	O
clinical	O
activity	O
in	O
pretreated	O
NSCLC	B_Disease
.	O

Evaluation	O
of	O
RAD001	B_Chemical
plus	O
standard	O
therapy	O
for	O
metastatic	O
NSCLC	B_Disease
continues	O
.	O

Posttransplant	O
anemia	B_Disease
:	O
the	O
role	O
of	O
sirolimus	B_Chemical
.	O

Posttransplant	O
anemia	B_Disease
is	O
a	O
common	O
problem	O
that	O
may	O
hinder	O
patients	O
'	O
quality	O
of	O
life	O
.	O

It	O
occurs	O
in	O
12	O
to	O
76	O
%	O
of	O
patients	O
,	O
and	O
is	O
most	O
common	O
in	O
the	O
immediate	O
posttransplant	O
period	O
.	O

A	O
variety	O
of	O
factors	O
have	O
been	O
identified	O
that	O
increase	O
the	O
risk	O
of	O
posttransplant	O
anemia	B_Disease
,	O
of	O
which	O
the	O
level	O
of	O
renal	O
function	O
is	O
most	O
important	O
.	O

Sirolimus	B_Chemical
,	O
a	O
mammalian	O
target	O
of	O
rapamycin	B_Chemical
inhibitor	O
,	O
has	O
been	O
implicated	O
as	O
playing	O
a	O
special	O
role	O
in	O
posttransplant	O
anemia	B_Disease
.	O

This	O
review	O
considers	O
anemia	B_Disease
associated	O
with	O
sirolimus	B_Chemical
,	O
including	O
its	O
presentation	O
,	O
mechanisms	O
,	O
and	O
management	O
.	O

Coronary	O
computerized	O
tomography	O
angiography	O
for	O
rapid	O
discharge	O
of	O
low-risk	O
patients	O
with	O
cocaine-associated	O
chest	B_Disease
pain	I_Disease
.	O

BACKGROUND	O
:	O
Most	O
patients	O
presenting	O
to	O
emergency	O
departments	O
(	O
EDs	O
)	O
with	O
cocaine-associated	O
chest	B_Disease
pain	I_Disease
are	O
admitted	O
for	O
at	O
least	O
12	O
hours	O
and	O
receive	O
a	O
"	O
rule	O
out	O
acute	B_Disease
coronary	I_Disease
syndrome	I_Disease
"	O
protocol	O
,	O
often	O
with	O
noninvasive	O
testing	O
prior	O
to	O
discharge	O
.	O

In	O
patients	O
without	O
cocaine	B_Chemical
use	O
,	O
coronary	O
computerized	O
tomography	O
angiography	O
(	O
CTA	O
)	O
has	O
been	O
shown	O
to	O
be	O
useful	O
for	O
identifying	O
a	O
group	O
of	O
patients	O
at	O
low	O
risk	O
for	O
cardiac	O
events	O
who	O
can	O
be	O
safely	O
discharged	O
.	O

It	O
is	O
unclear	O
whether	O
a	O
coronary	O
CTA	O
strategy	O
would	O
be	O
efficacious	O
in	O
cocaine-associated	O
chest	B_Disease
pain	I_Disease
,	O
as	O
coronary	B_Disease
vasospasm	I_Disease
may	O
account	O
for	O
some	O
of	O
the	O
ischemia	B_Disease
.	O

We	O
studied	O
whether	O
a	O
negative	O
coronary	O
CTA	O
in	O
patients	O
with	O
cocaine-associated	O
chest	B_Disease
pain	I_Disease
could	O
identify	O
a	O
subset	O
safe	O
for	O
discharge	O
.	O

METHODS	O
:	O
We	O
prospectively	O
evaluated	O
the	O
safety	O
of	O
coronary	O
CTA	O
for	O
low-risk	O
patients	O
who	O
presented	O
to	O
the	O
ED	O
with	O
cocaineassociated	O
chest	B_Disease
pain	I_Disease
(	O
self-reported	O
or	O
positive	O
urine	O
test	O
)	O
.	O

Consecutive	O
patients	O
received	O
either	O
immediate	O
coronary	O
CTA	O
in	O
the	O
ED	O
(	O
without	O
serial	O
markers	O
)	O
or	O
underwent	O
coronary	O
CTA	O
after	O
a	O
brief	O
observation	O
period	O
with	O
serial	O
cardiac	O
marker	O
measurements	O
.	O

Patients	O
with	O
negative	O
coronary	O
CTA	O
(	O
maximal	O
stenosis	B_Disease
less	O
than	O
50	O
%	O
)	O
were	O
discharged	O
.	O

The	O
main	O
outcome	O
was	O
30-day	O
cardiovascular	O
death	O
or	O
myocardial	B_Disease
infarction	I_Disease
.	O

RESULTS	O
:	O
A	O
total	O
of	O
59	O
patients	O
with	O
cocaine-associated	O
chest	B_Disease
pain	I_Disease
were	O
evaluated	O
.	O

Patients	O
had	O
a	O
mean	O
age	O
of	O
45.6	O
+	O
/-	O
6.6	O
yrs	O
and	O
were	O
86	O
%	O
black	O
,	O
66	O
%	O
male	O
.	O

Seventy-nine	O
percent	O
had	O
a	O
normal	O
or	O
nonspecific	O
ECG	O
and	O
85	O
%	O
had	O
a	O
TIMI	O
score	O
<	O
2	O
.	O

Twenty	O
patients	O
received	O
coronary	O
CTA	O
immediately	O
in	O
the	O
ED	O
,	O
18	O
of	O
whom	O
were	O
discharged	O
following	O
CTA	O
(	O
90	O
%	O
)	O
.	O

Thirty-nine	O
received	O
coronary	O
CTA	O
after	O
a	O
brief	O
observation	O
period	O
,	O
with	O
37	O
discharged	O
home	O
following	O
CTA	O
(	O
95	O
%	O
)	O
.	O

Six	O
patients	O
had	O
coronary	B_Disease
stenosis	I_Disease
>	O
or=50	O
%	O
.	O

During	O
the	O
30-day	O
follow-up	O
period	O
,	O
no	O
patients	O
died	O
of	O
a	O
cardiovascular	O
event	O
(	O
0	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
-	O
6.1	O
%	O
)	O
and	O
no	O
patient	O
sustained	O
a	O
nonfatal	O
myocardial	B_Disease
infarction	I_Disease
(	O
0	O
%	O
;	O
95	O
%	O
CI	O
,	O
0	O
-	O
6.1	O
%	O
)	O
.	O

CONCLUSIONS	O
:	O
Although	O
cocaine-associated	O
myocardial	B_Disease
ischemia	I_Disease
can	O
result	O
from	O
coronary	O
vasoconstriction	O
,	O
patients	O
with	O
cocaine	B_Chemical
associated	O
chest	B_Disease
pain	I_Disease
,	O
a	O
non-ischemic	O
ECG	O
,	O
and	O
a	O
TIMI	O
risk	O
score	O
<	O
2	O
may	O
be	O
safely	O
discharged	O
from	O
the	O
ED	O
after	O
a	O
negative	O
coronary	O
CTA	O
with	O
a	O
low	O
risk	O
of	O
30-day	O
adverse	O
events	O
.	O

Bilateral	O
haemorrhagic	B_Disease
infarction	B_Disease
of	I_Disease
the	I_Disease
globus	I_Disease
pallidus	I_Disease
after	O
cocaine	B_Chemical
and	O
alcohol	B_Chemical
intoxication	O
.	O

Cocaine	B_Chemical
is	O
a	O
risk	O
factor	O
for	O
both	O
ischemic	B_Disease
and	I_Disease
haemorrhagic	B_Disease
stroke	I_Disease
.	O

We	O
present	O
the	O
case	O
of	O
a	O
31-year-old	O
man	O
with	O
bilateral	O
ischemia	B_Disease
of	I_Disease
the	I_Disease
globus	I_Disease
pallidus	I_Disease
after	O
excessive	O
alcohol	B_Chemical
and	O
intranasal	O
cocaine	B_Chemical
use	O
.	O

Drug-related	O
globus	B_Disease
pallidus	I_Disease
infarctions	I_Disease
are	O
most	O
often	O
associated	O
with	O
heroin	B_Chemical
.	O

Bilateral	O
basal	B_Disease
ganglia	I_Disease
infarcts	I_Disease
after	O
the	O
use	O
of	O
cocaine	B_Chemical
,	O
without	O
concurrent	O
heroin	B_Chemical
use	O
,	O
have	O
never	O
been	O
reported	O
.	O

In	O
our	O
patient	O
,	O
transient	O
cardiac	B_Disease
arrhythmia	I_Disease
or	O
respiratory	B_Disease
dysfunction	I_Disease
related	O
to	O
cocaine	B_Chemical
and/or	O
ethanol	B_Chemical
use	O
were	O
the	O
most	O
likely	O
causes	O
of	O
cerebral	B_Disease
hypoperfusion	I_Disease
.	O

Late	O
fulminant	O
posterior	O
reversible	O
encephalopathy	O
syndrome	O
after	O
liver	O
transplant	O
.	O

OBJECTIVES	O
:	O
Posterior	B_Disease
leukoencephalopathy	I_Disease
due	O
to	O
calcineurin-inhibitor-related	O
neurotoxicity	B_Disease
is	O
a	O
rare	O
but	O
severe	O
complication	O
that	O
results	O
from	O
treatment	O
with	O
immunosuppressive	O
agents	O
(	O
primarily	O
those	O
administered	O
after	O
a	O
liver	O
or	O
kidney	O
transplant	O
)	O
.	O

The	O
pathophysiologic	O
mechanisms	O
of	O
that	O
disorder	O
remain	O
unknown	O
.	O

CASE	O
:	O
We	O
report	O
the	O
case	O
of	O
a	O
46-year-old	O
woman	O
who	O
received	O
a	O
liver	O
transplant	O
in	O
our	O
center	O
as	O
treatment	O
for	O
alcoholic	B_Disease
cirrhosis	I_Disease
and	O
in	O
whom	O
either	O
a	O
fulminant	O
course	O
of	O
posterior	B_Disease
leukoencephalopathy	I_Disease
or	O
posterior	B_Disease
reversible	I_Disease
encephalopathy	I_Disease
syndrome	I_Disease
developed	O
110	O
days	O
after	O
transplant	O
.	O

After	O
an	O
initially	O
uneventful	O
course	O
after	O
the	O
transplant	O
,	O
the	O
patient	O
rapidly	O
fell	O
into	O
deep	O
coma	O
.	O

RESULTS	O
:	O
Cerebral	O
MRI	O
scan	O
showed	O
typical	O
signs	O
of	O
enhancement	O
in	O
the	O
pontine	O
and	O
posterior	O
regions	O
.	O

Switching	O
the	O
immunosuppressive	O
regimen	O
from	O
tacrolimus	B_Chemical
to	O
cyclosporine	B_Chemical
did	O
not	O
improve	O
the	O
clinical	O
situation	O
.	O

The	O
termination	O
of	O
treatment	O
with	O
any	O
calcineurin	O
inhibitor	O
resulted	O
in	O
a	O
complete	O
resolution	O
of	O
that	O
complication	O
.	O

CONCLUSIONS	O
:	O
Posterior	B_Disease
reversible	I_Disease
encephalopathy	I_Disease
syndrome	I_Disease
after	O
liver	O
transplant	O
is	O
rare	O
.	O

We	O
recommend	O
a	O
complete	O
cessation	O
of	O
any	O
calcineurin	O
inhibitor	O
rather	O
than	O
a	O
dose	O
reduction	O
.	O

Prolonged	O
hypothermia	B_Disease
as	O
a	O
bridge	O
to	O
recovery	O
for	O
cerebral	B_Disease
edema	I_Disease
and	O
intracranial	B_Disease
hypertension	I_Disease
associated	O
with	O
fulminant	B_Disease
hepatic	I_Disease
failure	I_Disease
.	O

BACKGROUND	O
:	O
To	O
review	O
evidence-based	O
treatment	O
options	O
in	O
patients	O
with	O
cerebral	B_Disease
edema	I_Disease
complicating	O
fulminant	B_Disease
hepatic	I_Disease
failure	I_Disease
(	O
FHF	B_Disease
)	O
and	O
discuss	O
the	O
potential	O
applications	O
of	O
hypothermia	B_Disease
.	O

METHOD	O
:	O
Case-based	O
observations	O
from	O
a	O
medical	O
intensive	O
care	O
unit	O
(	O
MICU	O
)	O
in	O
a	O
tertiary	O
care	O
facility	O
in	O
a	O
27-year-old	O
female	O
with	O
FHF	B_Disease
from	O
acetaminophen	B_Chemical
and	O
resultant	O
cerebral	B_Disease
edema	I_Disease
.	O

RESULTS	O
:	O
Our	O
patient	O
was	O
admitted	O
to	O
the	O
MICU	O
after	O
being	O
found	O
unresponsive	O
with	O
presumed	O
toxicity	B_Disease
from	O
acetaminophen	B_Chemical
which	O
was	O
ingested	O
over	O
a	O
2-day	O
period	O
.	O

The	O
patient	O
had	O
depressed	O
of	O
mental	O
status	O
lasting	O
at	O
least	O
24	O
h	O
prior	O
to	O
admission	O
.	O

Initial	O
evaluation	O
confirmed	O
FHF	B_Disease
from	O
acetaminophen	B_Chemical
and	O
cerebral	B_Disease
edema	I_Disease
.	O

The	O
patient	O
was	O
treated	O
with	O
hyperosmolar	O
therapy	O
,	O
hyperventilation	B_Disease
,	O
sedation	O
,	O
and	O
chemical	O
paralysis	B_Disease
.	O

Her	O
intracranial	O
pressure	O
remained	O
elevated	O
despite	O
maximal	O
medical	O
therapy	O
.	O

We	O
then	O
initiated	O
therapeutic	O
hypothermia	B_Disease
which	O
was	O
continued	O
for	O
5	O
days	O
.	O

At	O
re-warming	O
,	O
patient	O
had	O
resolution	O
of	O
her	O
cerebral	B_Disease
edema	I_Disease
and	O
intracranial	B_Disease
hypertension	I_Disease
.	O

At	O
discharge	O
,	O
she	O
had	O
complete	O
recovery	O
of	O
neurological	O
and	O
hepatic	O
functions	O
.	O

CONCLUSION	O
:	O
In	O
patients	O
with	O
FHF	B_Disease
and	O
cerebral	B_Disease
edema	I_Disease
from	O
acetaminophen	B_Chemical
overdose	B_Disease
,	O
prolonged	O
therapeutic	O
hypothermia	B_Disease
could	O
potentially	O
be	O
used	O
as	O
a	O
life	O
saving	O
therapy	O
and	O
a	O
bridge	O
to	O
hepatic	O
and	O
neurological	O
recovery	O
.	O

A	O
clinical	O
trial	O
of	O
hypothermia	B_Disease
in	O
patients	O
with	O
this	O
condition	O
is	O
warranted	O
.	O

Binasal	B_Disease
visual	I_Disease
field	I_Disease
defects	I_Disease
are	O
not	O
specific	O
to	O
vigabatrin	B_Chemical
.	O

This	O
study	O
investigated	O
the	O
visual	B_Disease
defects	I_Disease
associated	O
with	O
the	O
antiepileptic	O
drug	O
vigabatrin	B_Chemical
(	O
VGB	B_Chemical
)	O
.	O

Two	O
hundred	O
four	O
people	O
with	O
epilepsy	B_Disease
were	O
grouped	O
on	O
the	O
basis	O
of	O
antiepileptic	O
drug	O
therapy	O
(	O
current	O
,	O
previous	O
,	O
or	O
no	O
exposure	O
to	O
VGB	B_Chemical
)	O
.	O

Groups	O
were	O
matched	O
with	O
respect	O
to	O
age	O
,	O
gender	O
,	O
and	O
seizure	B_Disease
frequency	O
.	O

All	O
patients	O
underwent	O
objective	O
assessment	O
of	O
electrophysiological	O
function	O
(	O
wide-field	O
multifocal	O
electroretinography	O
)	O
and	O
conventional	O
visual	O
field	O
testing	O
(	O
static	O
perimetry	O
)	O
.	O

Bilateral	O
visual	O
field	O
constriction	O
was	O
observed	O
in	O
59	O
%	O
of	O
patients	O
currently	O
taking	O
VGB	B_Chemical
,	O
43	O
%	O
of	O
patients	O
who	O
previously	O
took	O
VGB	B_Chemical
,	O
and	O
24	O
%	O
of	O
patients	O
with	O
no	O
exposure	O
to	O
VGB	B_Chemical
.	O

Assessment	O
of	O
retinal	O
function	O
revealed	O
abnormal	O
responses	O
in	O
48	O
%	O
of	O
current	O
VGB	B_Chemical
users	O
and	O
22	O
%	O
of	O
prior	O
VGB	B_Chemical
users	O
,	O
but	O
in	O
none	O
of	O
the	O
patients	O
without	O
previous	O
exposure	O
to	O
VGB	B_Chemical
.	O

Bilateral	B_Disease
visual	I_Disease
field	I_Disease
abnormalities	I_Disease
are	O
common	O
in	O
the	O
treated	O
epilepsy	B_Disease
population	O
,	O
irrespective	O
of	O
drug	O
history	O
.	O

Assessment	O
by	O
conventional	O
static	O
perimetry	O
may	O
neither	O
be	O
sufficiently	O
sensitive	O
nor	O
specific	O
to	O
reliably	O
identify	O
retinal	B_Disease
toxicity	I_Disease
associated	O
with	O
VGB	B_Chemical
.	O

Smoking	O
of	O
crack	B_Chemical
cocaine	I_Chemical
as	O
a	O
risk	O
factor	O
for	O
HIV	B_Disease
infection	I_Disease
among	O
people	O
who	O
use	O
injection	O
drugs	O
.	O

BACKGROUND	O
:	O
Little	O
is	O
known	O
about	O
the	O
possible	O
role	O
that	O
smoking	O
crack	B_Chemical
cocaine	I_Chemical
has	O
on	O
the	O
incidence	O
of	O
HIV	B_Disease
infection	I_Disease
.	O

Given	O
the	O
increasing	O
use	O
of	O
crack	B_Chemical
cocaine	I_Chemical
,	O
we	O
sought	O
to	O
examine	O
whether	O
use	O
of	O
this	O
illicit	O
drug	O
has	O
become	O
a	O
risk	O
factor	O
for	O
HIV	B_Disease
infection	I_Disease
.	O

METHODS	O
:	O
We	O
included	O
data	O
from	O
people	O
participating	O
in	O
the	O
Vancouver	O
Injection	O
Drug	O
Users	O
Study	O
who	O
reported	O
injecting	O
illicit	O
drugs	O
at	O
least	O
once	O
in	O
the	O
month	O
before	O
enrolment	O
,	O
lived	O
in	O
the	O
greater	O
Vancouver	O
area	O
,	O
were	O
HIV-negative	O
at	O
enrolment	O
and	O
completed	O
at	O
least	O
1	O
follow-up	O
study	O
visit	O
.	O

To	O
determine	O
whether	O
the	O
risk	O
of	O
HIV	B_Disease
seroconversion	I_Disease
among	O
daily	O
smokers	O
of	O
crack	B_Chemical
cocaine	I_Chemical
changed	O
over	O
time	O
,	O
we	O
used	O
Cox	O
proportional	O
hazards	O
regression	O
and	O
divided	O
the	O
study	O
into	O
3	O
periods	O
:	O
May	O
1	O
,	O
1996-Nov	O
.	O

30	O
,	O
1999	O
(	O
period	O
1	O
)	O
,	O
Dec.	O
1	O
,	O
1999-Nov	O
.	O

30	O
,	O
2002	O
(	O
period	O
2	O
)	O
,	O
and	O
Dec.	O
1	O
,	O
2002-Dec	O
.	O
30	O
,	O
2005	O
(	O
period	O
3	O
)	O
.	O

RESULTS	O
:	O
Overall	O
,	O
1048	O
eligible	O
injection	O
drug	O
users	O
were	O
included	O
in	O
our	O
study	O
.	O

Of	O
these	O
,	O
137	O
acquired	O
HIV	B_Disease
infection	I_Disease
during	O
follow-up	O
.	O

The	O
mean	O
proportion	O
of	O
participants	O
who	O
reported	O
daily	O
smoking	O
of	O
crack	B_Chemical
cocaine	I_Chemical
increased	O
from	O
11.6	O
%	O
in	O
period	O
1	O
to	O
39.7	O
%	O
in	O
period	O
3	O
.	O

After	O
adjusting	O
for	O
potential	O
confounders	O
,	O
we	O
found	O
that	O
the	O
risk	O
of	O
HIV	B_Disease
seroconversion	I_Disease
among	O
participants	O
who	O
were	O
daily	O
smokers	O
of	O
crack	B_Chemical
cocaine	I_Chemical
increased	O
over	O
time	O
(	O
period	O
1	O
:	O
hazard	O
ratio	O
[	O
HR	O
]	O
1.03	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
0.57	O
-	O
1.85	O
;	O
period	O
2	O
:	O
HR	O
1.68	O
,	O
95	O
%	O
CI	O
1.01	O
-	O
2.80	O
;	O
and	O
period	O
3	O
:	O
HR	O
2.74	O
,	O
95	O
%	O
CI	O
1.06	O
-	O
7.11	O
)	O
.	O

INTERPRETATION	O
:	O
Smoking	O
of	O
crack	B_Chemical
cocaine	I_Chemical
was	O
found	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
HIV	B_Disease
seroconversion	I_Disease
among	O
people	O
who	O
were	O
injection	O
drug	O
users	O
.	O

This	O
finding	O
points	O
to	O
the	O
urgent	O
need	O
for	O
evidence-based	O
public	O
health	O
initiatives	O
targeted	O
at	O
people	O
who	O
smoke	O
crack	B_Chemical
cocaine	I_Chemical
.	O

Fluoxetine	B_Chemical
improves	O
the	O
memory	B_Disease
deficits	I_Disease
caused	O
by	O
the	O
chemotherapy	O
agent	O
5-fluorouracil	B_Chemical
.	O

Cancer	B_Disease
patients	O
who	O
have	O
been	O
treated	O
with	O
systemic	O
adjuvant	O
chemotherapy	O
have	O
described	O
experiencing	O
deteriorations	O
in	O
cognition	O
.	O

A	O
widely	O
used	O
chemotherapeutic	O
agent	O
,	O
5-fluorouracil	B_Chemical
(	O
5-FU	B_Chemical
)	O
,	O
readily	O
crosses	O
the	O
blood-brain	O
barrier	O
and	O
so	O
could	O
have	O
a	O
direct	O
effect	O
on	O
brain	O
function	O
.	O

In	O
particular	O
this	O
anti	O
mitotic	O
drug	O
could	O
reduce	O
cell	O
proliferation	O
in	O
the	O
neurogenic	O
regions	O
of	O
the	O
adult	O
brain	O
.	O

In	O
contrast	O
reports	O
indicate	O
that	O
hippocampal	O
dependent	O
neurogenesis	O
and	O
cognition	O
are	O
enhanced	O
by	O
the	O
SSRI	B_Chemical
antidepressant	O
Fluoxetine	B_Chemical
.	O

In	O
this	O
investigation	O
the	O
behavioural	O
effects	O
of	O
chronic	O
(	O
two	O
week	O
)	O
treatment	O
with	O
5-FU	B_Chemical
and	O
(	O
three	O
weeks	O
)	O
with	O
Fluoxetine	B_Chemical
either	O
separately	O
or	O
in	O
combination	O
with	O
5-FU	B_Chemical
were	O
tested	O
on	O
adult	O
Lister	O
hooded	O
rats	O
.	O

Behavioural	O
effects	O
were	O
tested	O
using	O
a	O
context	O
dependent	O
conditioned	O
emotional	O
response	O
test	O
(	O
CER	O
)	O
which	O
showed	O
that	O
animals	O
treated	O
with	O
5-FU	B_Chemical
had	O
a	O
significant	O
reduction	O
in	O
freezing	O
time	O
compared	O
to	O
controls	O
.	O

A	O
separate	O
group	O
of	O
animals	O
was	O
tested	O
using	O
a	O
hippocampal	O
dependent	O
spatial	O
working	O
memory	O
test	O
,	O
the	O
object	O
location	O
recognition	O
test	O
(	O
OLR	O
)	O
.	O

Animals	O
treated	O
only	O
with	O
5-FU	B_Chemical
showed	O
significant	O
deficits	O
in	O
their	O
ability	O
to	O
carry	O
out	O
the	O
OLR	O
task	O
but	O
co	O
administration	O
of	O
Fluoxetine	B_Chemical
improved	O
their	O
performance	O
.	O

5-FU	B_Chemical
chemotherapy	O
caused	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
proliferating	O
cells	O
in	O
the	O
sub	O
granular	O
zone	O
of	O
the	O
dentate	O
gyrus	O
compared	O
to	O
controls	O
.	O

This	O
reduction	O
was	O
eliminated	O
when	O
Fluoxetine	B_Chemical
was	O
co	O
administered	O
with	O
5-FU	B_Chemical
.	O

Fluoxetine	B_Chemical
on	O
its	O
own	O
had	O
no	O
effect	O
on	O
proliferating	O
cell	O
number	O
or	O
behaviour	O
.	O

These	O
findings	O
suggest	O
that	O
5-FU	B_Chemical
can	O
negatively	O
affect	O
both	O
cell	O
proliferation	O
and	O
hippocampal	O
dependent	O
working	O
memory	O
and	O
that	O
these	O
deficits	O
can	O
be	O
reversed	O
by	O
the	O
simultaneous	O
administration	O
of	O
the	O
antidepressant	O
Fluoxetine	B_Chemical
.	O

Liver-specific	O
ablation	O
of	O
integrin-linked	O
kinase	O
in	O
mice	O
results	O
in	O
enhanced	O
and	O
prolonged	O
cell	O
proliferation	O
and	O
hepatomegaly	B_Disease
after	O
phenobarbital	B_Chemical
administration	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
disruption	O
of	O
extracellular	O
matrix	O
(ECM)/integrin	O
signaling	O
via	O
elimination	O
of	O
integrin-linked	O
kinase	O
(	O
ILK	O
)	O
in	O
hepatocytes	O
interferes	O
with	O
signals	O
leading	O
to	O
termination	O
of	O
liver	O
regeneration	O
.	O

This	O
study	O
investigates	O
the	O
role	O
of	O
ILK	O
in	O
liver	O
enlargement	O
induced	O
by	O
phenobarbital	B_Chemical
(	O
PB	B_Chemical
)	O
.	O

Wild-type	O
(	O
WT	O
)	O
and	O
ILK	O
:	O
liver-/-	O
mice	O
were	O
given	O
PB	B_Chemical
(	O
0.1	O
%	O
in	O
drinking	O
water	O
)	O
for	O
10	O
days	O
.	O

Livers	O
were	O
harvested	O
on	O
2	O
,	O
5	O
,	O
and	O
10	O
days	O
during	O
PB	B_Chemical
administration	O
.	O

In	O
the	O
hepatocyte-specific	O
ILK/liver-/-	O
mice	O
,	O
the	O
liver	O
:	O
body	O
weight	O
ratio	O
was	O
more	O
than	O
double	O
as	O
compared	O
to	O
0	O
h	O
at	O
day	O
2	O
(	O
2.5	O
times	O
)	O
,	O
while	O
at	O
days	O
5	O
and	O
10	O
,	O
it	O
was	O
enlarged	O
three	O
times	O
.	O

In	O
the	O
WT	O
mice	O
,	O
the	O
increase	O
was	O
as	O
expected	O
from	O
previous	O
literature	O
(	O
1.8	O
times	O
)	O
and	O
seems	O
to	O
have	O
leveled	O
off	O
after	O
day	O
2	O
.	O

There	O
were	O
slightly	O
increased	O
proliferating	O
cell	O
nuclear	O
antigen-positive	O
cells	O
in	O
the	O
ILK/liver-/-	O
animals	O
at	O
day	O
2	O
as	O
compared	O
to	O
WT	O
after	O
PB	B_Chemical
administration	O
.	O

In	O
the	O
WT	O
animals	O
,	O
the	O
proliferative	O
response	O
had	O
come	O
back	O
to	O
normal	O
by	O
days	O
5	O
and	O
10	O
.	O

Hepatocytes	O
of	O
the	O
ILK/liver-/-	O
mice	O
continued	O
to	O
proliferate	O
up	O
until	O
day	O
10	O
.	O

ILK/liver-/-	O
mice	O
also	O
showed	O
increased	O
expression	O
of	O
key	O
genes	O
involved	O
in	O
hepatocyte	O
proliferation	O
at	O
different	O
time	O
points	O
during	O
PB	B_Chemical
administration	O
.	O

In	O
summary	O
,	O
ECM	O
proteins	O
communicate	O
with	O
the	O
signaling	O
machinery	O
of	O
dividing	O
cells	O
via	O
ILK	O
to	O
regulate	O
hepatocyte	O
proliferation	O
and	O
termination	O
of	O
the	O
proliferative	O
response	O
.	O

Lack	O
of	O
ILK	O
in	O
the	O
hepatocytes	O
imparts	O
prolonged	O
proliferative	O
response	O
not	O
only	O
to	O
stimuli	O
related	O
to	O
liver	O
regeneration	O
but	O
also	O
to	O
xenobiotic	O
chemical	O
mitogens	O
,	O
such	O
as	O
PB	B_Chemical
.	O

Decreased	O
Expression	O
of	O
Na/K-ATPase	O
,	O
NHE3	O
,	O
NBC1	O
,	O
AQP1	O
and	O
OAT	O
in	O
Gentamicin-induced	O
Nephropathy	B_Disease
.	O

The	O
present	O
study	O
was	O
aimed	O
to	O
determine	O
whether	O
there	O
is	O
an	O
altered	O
regulation	O
of	O
tubular	O
transporters	O
in	O
gentamicin-induced	O
nephropathy	B_Disease
.	O

Sprague-Dawley	O
male	O
rats	O
(	O
200~250	O
g	O
)	O
were	O
subcutaneously	O
injected	O
with	O
gentamicin	B_Chemical
(	O
100	O
mg/kg	O
per	O
day	O
)	O
for	O
7	O
days	O
,	O
and	O
the	O
expression	O
of	O
tubular	O
transporters	O
was	O
determined	O
by	O
immunoblotting	O
and	O
immunohistochemistry	O
.	O

The	O
mRNA	O
and	O
protein	O
expression	O
of	O
OAT	O
was	O
also	O
determined	O
.	O

Gentamicin-treated	O
rats	O
exhibited	O
significantly	O
decreased	O
creatinine	B_Chemical
clearance	O
along	O
with	O
increased	O
plasma	O
creatinine	B_Chemical
levels	O
.	O

Accordingly	O
,	O
the	O
fractional	O
excretion	O
of	O
sodium	B_Chemical
increased	O
.	O

Urine	O
volume	O
was	O
increased	O
,	O
while	O
urine	O
osmolality	O
and	O
free	O
water	O
reabsorption	O
were	O
decreased	O
.	O

Immunoblotting	O
and	O
immunohistochemistry	O
revealed	O
decreased	O
expression	O
of	O
Na(+)/K(+)-ATPase	O
,	O
NHE3	O
,	O
NBC1	O
,	O
and	O
AQP1	O
in	O
the	O
kidney	O
of	O
gentamicin-treated	O
rats	O
.	O

The	O
expression	O
of	O
OAT1	O
and	O
OAT3	O
was	O
also	O
decreased	O
.	O

Gentamicin-induced	O
nephropathy	B_Disease
may	O
at	O
least	O
in	O
part	O
be	O
causally	O
related	O
with	O
a	O
decreased	O
expression	O
of	O
Na(+)/K(+)-ATPase	O
,	O
NHE3	O
,	O
NBC1	O
,	O
AQP1	O
and	O
OAT	O
.	O

Acute	B_Disease
renal	I_Disease
failure	I_Disease
after	O
high-dose	O
methotrexate	B_Chemical
therapy	O
in	O
a	O
patient	O
with	O
ileostomy	O
.	O

High-dose	O
methotrexate	B_Chemical
(	O
HD-MTX	O
)	O
is	O
an	O
important	O
treatment	O
for	O
Burkitt	B_Disease
lymphoma	I_Disease
,	O
but	O
can	O
cause	O
hepatic	B_Disease
and	I_Disease
renal	B_Disease
toxicity	I_Disease
when	O
its	O
clearance	O
is	O
delayed	O
.	O

We	O
report	O
a	O
case	O
of	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
after	O
HD-MTX	O
therapy	O
in	O
a	O
patient	O
with	O
ileostomy	O
,	O
The	O
patient	O
was	O
a	O
3-year-old	O
boy	O
who	O
had	O
received	O
a	O
living-related	O
liver	O
transplantation	O
for	O
congenital	O
biliary	B_Disease
atresia	I_Disease
.	O

At	O
day	O
833	O
after	O
the	O
transplantation	O
,	O
he	O
was	O
diagnosed	O
with	O
PTLD	B_Disease
(	O
post-transplantation	B_Disease
lymphoproliferative	I_Disease
disorder	I_Disease
,	O
Burkitt-type	B_Disease
malignant	I_Disease
lymphoma	I_Disease
)	O
.	O

During	O
induction	O
therapy	O
,	O
he	O
suffered	O
ileal	O
perforation	O
and	O
ileostomy	O
was	O
performed	O
.	O

Subsequent	O
HD-MTX	O
therapy	O
caused	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
that	O
required	O
continuous	O
hemodialysis	O
.	O

We	O
supposed	O
that	O
intravascular	O
hypovolemia	B_Disease
due	O
to	O
substantial	O
drainage	O
from	O
the	O
ileostoma	O
caused	O
acute	B_Disease
prerenal	I_Disease
failure	I_Disease
.	O

After	O
recovery	O
of	O
his	O
renal	O
function	O
,	O
we	O
could	O
safely	O
treat	O
the	O
patient	O
with	O
HD-MTX	O
therapy	O
by	O
controlling	O
drainage	O
from	O
ileostoma	O
with	O
total	O
parenteral	O
nutrition	O
.	O

Longitudinal	O
association	O
of	O
alcohol	B_Chemical
use	O
with	O
HIV	B_Disease
disease	I_Disease
progression	O
and	O
psychological	O
health	O
of	O
women	O
with	O
HIV.We	O
evaluated	O
the	O
association	O
of	O
alcohol	B_Chemical
consumption	O
and	O
depression	B_Disease
,	O
and	O
their	O
effects	O
on	O
HIV	B_Disease
disease	I_Disease
progression	O
among	O
women	O
with	O
HIV	O
.	O

The	O
study	O
included	O
871	O
women	O
with	O
HIV	O
who	O
were	O
recruited	O
from	O
1993	O
-	O
1995	O
in	O
four	O
US	O
cities	O
.	O

The	O
participants	O
had	O
physical	O
examination	O
,	O
medical	O
record	O
extraction	O
,	O
and	O
venipuncture	O
,	O
CD4+T-cell	O
counts	O
determination	O
,	O
measurement	O
of	O
depression	B_Disease
symptoms	O
(	O
using	O
the	O
self-report	O
Center	O
for	O
Epidemiological	O
Studies-Depression	O
Scale	O
)	O
,	O
and	O
alcohol	B_Chemical
use	O
assessment	O
at	O
enrollment	O
,	O
and	O
semiannually	O
until	O
March	O
2000	O
.	O

Multilevel	O
random	O
coefficient	O
ordinal	O
models	O
as	O
well	O
as	O
multilevel	O
models	O
with	O
joint	O
responses	O
were	O
used	O
in	O
the	O
analysis	O
.	O

There	O
was	O
no	O
significant	O
association	O
between	O
level	O
of	O
alcohol	B_Chemical
use	O
and	O
CD4	O
+	O
T-cell	O
counts	O
.	O

When	O
participants	O
were	O
stratified	O
by	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
use	O
,	O
the	O
association	O
between	O
alcohol	B_Chemical
and	O
CD4	O
+	O
T-cell	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

The	O
association	O
between	O
alcohol	B_Chemical
consumption	O
and	O
depression	B_Disease
was	O
significant	O
(	O
p<0.001	O
)	O
.	O

Depression	B_Disease
had	O
a	O
significant	O
negative	O
effect	O
on	O
CD4	O
+	O
T-cell	O
counts	O
over	O
time	O
regardless	O
of	O
ART	O
use	O
.	O

Our	O
findings	O
suggest	O
that	O
alcohol	B_Chemical
consumption	O
has	O
a	O
direct	O
association	O
with	O
depression	B_Disease
.	O

Moreover	O
,	O
depression	B_Disease
is	O
associated	O
with	O
HIV	B_Disease
disease	I_Disease
progression	O
.	O

Our	O
findings	O
have	O
implications	O
for	O
the	O
provision	O
of	O
alcohol	B_Chemical
use	O
interventions	O
and	O
psychological	O
resources	O
to	O
improve	O
the	O
health	O
of	O
women	O
with	O
HIV	O
.	O

Chemokine	O
CCL2	O
and	O
its	O
receptor	O
CCR2	O
are	O
increased	O
in	O
the	O
hippocampus	O
following	O
pilocarpine-induced	O
status	B_Disease
epilepticus	I_Disease
.	O

BACKGROUND	O
:	O
Neuroinflammation	B_Disease
occurs	O
after	O
seizures	B_Disease
and	O
is	O
implicated	O
in	O
epileptogenesis	O
.	O

CCR2	O
is	O
a	O
chemokine	O
receptor	O
for	O
CCL2	O
and	O
their	O
interaction	O
mediates	O
monocyte	O
infiltration	O
in	O
the	O
neuroinflammatory	B_Disease
cascade	O
triggered	O
in	O
different	O
brain	O
pathologies	O
.	O

In	O
this	O
work	O
CCR2	O
and	O
CCL2	O
expression	O
were	O
examined	O
following	O
status	B_Disease
epilepticus	I_Disease
(	O
SE	B_Disease
)	O
induced	O
by	O
pilocarpine	B_Chemical
injection	O
.	O

METHODS	O
:	O
SE	B_Disease
was	O
induced	O
by	O
pilocarpine	B_Chemical
injection	O
.	O

Control	O
rats	O
were	O
injected	O
with	O
saline	O
instead	O
of	O
pilocarpine	B_Chemical
.	O

Five	O
days	O
after	O
SE	B_Disease
,	O
CCR2	O
staining	O
in	O
neurons	O
and	O
glial	O
cells	O
was	O
examined	O
using	O
imunohistochemical	O
analyses	O
.	O

The	O
number	O
of	O
CCR2	O
positive	O
cells	O
was	O
determined	O
using	O
stereology	O
probes	O
in	O
the	O
hippocampus	O
.	O

CCL2	O
expression	O
in	O
the	O
hippocampus	O
was	O
examined	O
by	O
molecular	O
assay	O
.	O

RESULTS	O
:	O
Increased	O
CCR2	O
was	O
observed	O
in	O
the	O
hippocampus	O
after	O
SE	B_Disease
.	O

Seizures	B_Disease
also	O
resulted	O
in	O
alterations	O
to	O
the	O
cell	O
types	O
expressing	O
CCR2	O
.	O

Increased	O
numbers	O
of	O
neurons	O
that	O
expressed	O
CCR2	O
was	O
observed	O
following	O
SE	B_Disease
.	O

Microglial	O
cells	O
were	O
more	O
closely	O
apposed	O
to	O
the	O
CCR2-labeled	O
cells	O
in	O
SE	B_Disease
rats	O
.	O

In	O
addition	O
,	O
rats	O
that	O
experienced	O
SE	B_Disease
exhibited	O
CCR2-labeling	O
in	O
populations	O
of	O
hypertrophied	B_Disease
astrocytes	O
,	O
especially	O
in	O
CA1	O
and	O
dentate	O
gyrus	O
.	O

These	O
CCR2	O
+	O
astroctytes	O
were	O
not	O
observed	O
in	O
control	O
rats	O
.	O

Examination	O
of	O
CCL2	O
expression	O
showed	O
that	O
it	O
was	O
elevated	O
in	O
the	O
hippocampus	O
following	O
SE	B_Disease
.	O

CONCLUSION	O
:	O
The	O
data	O
show	O
that	O
CCR2	O
and	O
CCL2	O
are	O
up-regulated	O
in	O
the	O
hippocampus	O
after	O
pilocarpine-induced	O
SE	B_Disease
.	O

Seizures	B_Disease
also	O
result	O
in	O
changes	O
to	O
CCR2	O
receptor	O
expression	O
in	O
neurons	O
and	O
astrocytes	O
.	O

These	O
changes	O
might	O
be	O
involved	O
in	O
detrimental	O
neuroplasticity	O
and	O
neuroinflammatory	B_Disease
changes	O
that	O
occur	O
following	O
seizures	B_Disease
.	O

Metallothionein	B_Chemical
induction	O
reduces	O
caspase-3	O
activity	O
and	O
TNFalpha	O
levels	O
with	O
preservation	O
of	O
cognitive	O
function	O
and	O
intact	O
hippocampal	O
neurons	O
in	O
carmustine-treated	O
rats	O
.	O

Hippocampal	O
integrity	O
is	O
essential	O
for	O
cognitive	O
functions	O
.	O

On	O
the	O
other	O
hand	O
,	O
induction	O
of	O
metallothionein	B_Chemical
(	O
MT	B_Chemical
)	O
by	O
ZnSO(4	B_Chemical
)	I_Chemical
and	O
its	O
role	O
in	O
neuroprotection	O
has	O
been	O
documented	O
.	O

The	O
present	O
study	O
aimed	O
to	O
explore	O
the	O
effect	O
of	O
MT	B_Chemical
induction	O
on	O
carmustine	B_Chemical
(BCNU)-induced	O
hippocampal	O
cognitive	B_Disease
dysfunction	I_Disease
in	O
rats	O
.	O

A	O
total	O
of	O
60	O
male	O
Wistar	O
albino	O
rats	O
were	O
randomly	O
divided	O
into	O
four	O
groups	O
(	O
15/group	O
):	O
The	O
control	O
group	O
injected	O
with	O
single	O
doses	O
of	O
normal	O
saline	O
(	O
i.c.v	O
)	O
followed	O
24	O
h	O
later	O
by	O
BCNU	B_Chemical
solvent	O
(	O
i.v	O
)	O
.	O

The	O
second	O
group	O
administered	O
ZnSO(4	B_Chemical
)	I_Chemical
(	O
0.1	O
micromol/10	O
microl	O
normal	O
saline	O
,	O
i.c.v	O
,	O
once	O
)	O
then	O
BCNU	B_Chemical
solvent	O
(	O
i.v	O
)	O
after	O
24	O
h.	O
Third	O
group	O
received	O
BCNU	B_Chemical
(	O
20	O
mg/kg	O
,	O
i.v	O
,	O
once	O
)	O
24	O
h	O
after	O
injection	O
with	O
normal	O
saline	O
(	O
i.c.v	O
)	O
.	O

Fourth	O
group	O
received	O
a	O
single	O
dose	O
of	O
ZnSO(4	B_Chemical
)	I_Chemical
(	O
0.1	O
micromol/10	O
microl	O
normal	O
saline	O
,	O
i.c.v	O
)	O
then	O
BCNU	B_Chemical
(	O
20	O
mg/kg	O
,	O
i.v	O
,	O
once	O
)	O
after	O
24	O
h.	O
The	O
obtained	O
data	O
revealed	O
that	O
BCNU	B_Chemical
administration	O
resulted	O
in	O
deterioration	B_Disease
of	I_Disease
learning	I_Disease
and	I_Disease
short-term	I_Disease
memory	I_Disease
(	O
STM	O
)	O
,	O
as	O
measured	O
by	O
using	O
radial	O
arm	O
water	O
maze	O
,	O
accompanied	O
with	O
decreased	O
hippocampal	O
glutathione	B_Chemical
reductase	O
(	O
GR	O
)	O
activity	O
and	O
reduced	O
glutathione	B_Chemical
(	O
GSH	B_Chemical
)	O
content	O
.	O

Also	O
,	O
BCNU	B_Chemical
administration	O
increased	O
serum	O
tumor	B_Disease
necrosis	B_Disease
factor-alpha	O
(	O
TNFalpha	O
)	O
,	O
hippocampal	O
MT	B_Chemical
and	O
malondialdehyde	B_Chemical
(	O
MDA	B_Chemical
)	O
contents	O
as	O
well	O
as	O
caspase-3	O
activity	O
in	O
addition	O
to	O
histological	O
alterations	O
.	O

ZnSO(4	B_Chemical
)	I_Chemical
pretreatment	O
counteracted	O
BCNU-induced	O
inhibition	O
of	O
GR	O
and	O
depletion	O
of	O
GSH	B_Chemical
and	O
resulted	O
in	O
significant	O
reduction	O
in	O
the	O
levels	O
of	O
MDA	B_Chemical
and	O
TNFalpha	O
as	O
well	O
as	O
the	O
activity	O
of	O
caspase-3	O
.	O

The	O
histological	O
features	O
were	O
improved	O
in	O
hippocampus	O
of	O
rats	O
treated	O
with	O
ZnSO(4	B_Chemical
)	I_Chemical
+	O
BCNU	B_Chemical
compared	O
to	O
only	O
BCNU-treated	O
animals	O
.	O

In	O
conclusion	O
,	O
MT	B_Chemical
induction	O
halts	O
BCNU-induced	O
hippocampal	O
toxicity	B_Disease
as	O
it	O
prevented	O
GR	O
inhibition	O
and	O
GSH	B_Chemical
depletion	O
and	O
counteracted	O
the	O
increased	O
levels	O
of	O
TNFalpha	O
,	O
MDA	B_Chemical
and	O
caspase-3	O
activity	O
with	O
subsequent	O
preservation	O
of	O
cognition	O
.	O

Fatal	O
carbamazepine	B_Chemical
induced	O
fulminant	B_Disease
eosinophilic	I_Disease
(	O
hypersensitivity	B_Disease
)	O
myocarditis	B_Disease
:	O
emphasis	O
on	O
anatomical	O
and	O
histological	O
characteristics	O
,	O
mechanisms	O
and	O
genetics	O
of	O
drug	B_Disease
hypersensitivity	I_Disease
and	O
differential	O
diagnosis	O
.	O

The	O
most	O
severe	O
adverse	O
reactions	O
to	O
carbamazepine	B_Chemical
have	O
been	O
observed	O
in	O
the	O
haemopoietic	O
system	O
,	O
the	O
liver	O
and	O
the	O
cardiovascular	O
system	O
.	O

A	O
frequently	O
fatal	O
,	O
although	O
exceptionally	O
rare	O
side	O
effect	O
of	O
carbamazepine	B_Chemical
is	O
necrotizing	O
eosinophilic	O
(	O
hypersensitivity	B_Disease
)	O
myocarditis	B_Disease
.	O

We	O
report	O
a	O
case	O
of	O
hypersensitivity	B_Disease
myocarditis	B_Disease
secondary	O
to	O
administration	O
of	O
carbamazepine	B_Chemical
.	O

Acute	O
hypersensitivity	B_Disease
myocarditis	B_Disease
was	O
not	O
suspected	O
clinically	O
,	O
and	O
the	O
diagnosis	O
was	O
made	O
post-mortem	O
.	O

Histology	O
revealed	O
diffuse	O
infiltration	O
of	O
the	O
myocardium	O
by	O
eosinophils	O
and	O
lymphocytes	O
with	O
myocyte	O
damage	O
.	O

Clinically	O
,	O
death	O
was	O
due	O
to	O
cardiogenic	B_Disease
shock	I_Disease
.	O

To	O
best	O
of	O
our	O
knowledge	O
this	O
is	O
the	O
second	O
case	O
of	O
fatal	O
carbamazepine	B_Chemical
induced	O
myocarditis	B_Disease
reported	O
in	O
English	O
literature	O
.	O

Neuropsychiatric	O
behaviors	O
in	O
the	O
MPTP	B_Chemical
marmoset	O
model	O
of	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
.	O

OBJECTIVES	O
:	O
Neuropsychiatric	O
symptoms	O
are	O
increasingly	O
recognised	O
as	O
a	O
significant	O
problem	O
in	O
patients	O
with	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
(	O
PD	B_Disease
)	O
.	O

These	O
symptoms	O
may	O
be	O
due	O
to	O
'	O
sensitisation	O
'	O
following	O
repeated	O
levodopa	B_Chemical
treatment	O
or	O
a	O
direct	O
effect	O
of	O
dopamine	B_Chemical
on	O
the	O
disease	O
state	O
.	O

The	O
levodopa-treated	O
MPTP-lesioned	O
marmoset	O
was	O
used	O
as	O
a	O
model	O
of	O
neuropsychiatric	B_Disease
symptoms	I_Disease
in	O
PD	B_Disease
patients	O
.	O

Here	O
we	O
compare	O
the	O
time	O
course	O
of	O
levodopa-induced	O
motor	O
fluctuations	O
and	O
neuropsychiatric-like	B_Disease
behaviors	I_Disease
to	O
determine	O
the	O
relationship	O
between	O
duration	O
of	O
treatment	O
and	O
onset	O
of	O
symptoms	O
.	O

METHODS	O
:	O
Marmosets	O
were	O
administered	O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	B_Chemical
(	O
2.0	O
mg/kg	O
s.c	O
.	O
)	O
for	O
five	O
days	O
,	O
resulting	O
in	O
stable	O
parkinsonism	B_Disease
.	O

Levodopa	B_Chemical
(	O
15	O
mg/kg	O
and	O
benserazide	B_Chemical
,	O
3.75	O
mg/kg	O
)	O
p.o	O
.	O

b.i.d	O
,	O
was	O
administered	O
for	O
30	O
days	O
.	O

Animals	O
were	O
evaluated	O
for	O
parkinsonian	B_Disease
disability	I_Disease
,	O
dyskinesia	B_Disease
and	O
on-time	O
(	O
motor	O
fluctuations	O
)	O
and	O
neuropsychiatric-like	B_Disease
behaviors	I_Disease
on	O
Day	O
0	O
(	O
prior	O
to	O
levodopa	B_Chemical
)	O
and	O
on	O
Days	O
1	O
,	O
7	O
,	O
13	O
,	O
27	O
and	O
30	O
of	O
treatment	O
using	O
post	O
hoc	O
DVD	O
analysis	O
by	O
a	O
trained	O
rater	O
,	O
blind	O
to	O
the	O
treatment	O
day	O
.	O

RESULTS	O
:	O
The	O
neuropsychiatric-like	B_Disease
behavior	I_Disease
rating	O
scale	O
demonstrated	O
high	O
interrater	O
reliability	O
between	O
three	O
trained	O
raters	O
of	O
differing	O
professional	O
backgrounds	O
.	O

As	O
anticipated	O
,	O
animals	O
exhibited	O
a	O
progressive	O
increase	O
in	O
levodopa-induced	O
motor	O
fluctuations	O
,	O
dyskinesia	B_Disease
and	O
wearing-off	O
,	O
that	O
correlated	O
with	O
the	O
duration	O
of	O
levodopa	B_Chemical
therapy	O
.	O

In	O
contrast	O
,	O
levodopa-induced	O
neuropsychiatric-like	B_Disease
behaviors	I_Disease
were	O
present	O
on	O
Day	O
1	O
of	O
levodopa	B_Chemical
treatment	O
and	O
their	O
severity	O
did	O
not	O
correlate	O
with	O
duration	O
of	O
treatment	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
suggest	O
that	O
neuropsychiatric	B_Disease
disorders	I_Disease
in	O
PD	B_Disease
are	O
more	O
likely	O
an	O
interaction	O
between	O
levodopa	B_Chemical
and	O
the	O
disease	O
state	O
than	O
a	O
consequence	O
of	O
sensitisation	O
to	O
repeated	O
dopaminergic	O
therapy	O
.	O

Contrast	B_Chemical
medium	I_Chemical
nephrotoxicity	B_Disease
after	O
renal	O
artery	O
and	O
coronary	O
angioplasty	O
.	O

BACKGROUND	O
:	O
Renal	B_Disease
dysfunction	I_Disease
induced	O
by	O
iodinated	O
contrast	B_Chemical
medium	I_Chemical
(	O
CM	B_Chemical
)	O
administration	O
can	O
minimize	O
the	O
benefit	O
of	O
the	O
interventional	O
procedure	O
in	O
patients	O
undergoing	O
renal	O
angioplasty	O
(	O
PTRA	O
)	O
.	O

PURPOSE	O
:	O
To	O
compare	O
the	O
susceptibility	O
to	O
nephrotoxic	B_Disease
effect	O
of	O
CM	B_Chemical
in	O
patients	O
undergoing	O
PTRA	O
with	O
that	O
of	O
patients	O
submitted	O
to	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
33	O
patients	O
successfully	O
treated	O
with	O
PTRA	O
(	O
PTRA	O
group	O
,	O
mean	O
age	O
70+/-12	O
years	O
,	O
23	O
female	O
,	O
basal	O
creatinine	B_Chemical
1.46+/-0.79	O
,	O
range	O
0.7	O
-	O
4.9	O
mg/dl	O
)	O
were	O
compared	O
with	O
33	O
patients	O
undergoing	O
successful	O
PCI	O
(	O
PCI	O
group	O
)	O
,	O
matched	O
for	O
basal	O
creatinine	B_Chemical
(	O
1.44+/-0.6	O
,	O
range	O
0.7	O
-	O
3.4	O
mg/dl	O
)	O
,	O
gender	O
,	O
and	O
age	O
.	O

In	O
both	O
groups	O
postprocedural	O
(	O
48	O
h	O
)	O
serum	O
creatinine	B_Chemical
was	O
measured	O
.	O

RESULTS	O
:	O
Postprocedural	O
creatinine	B_Chemical
level	O
decreased	O
nonsignificantly	O
in	O
the	O
PTRA	O
group	O
(	O
1.46+/-0.8	O
vs.	O
1.34+/-0.5	O
mg/dl	O
,	O
P	O
=	O
NS	O
)	O
and	O
increased	O
significantly	O
in	O
the	O
PCI	O
group	O
(	O
1.44+/-0.6	O
vs.	O
1.57+/-0.7	O
mg/dl	O
,	O
P<0.02	O
)	O
.	O

Changes	O
in	O
serum	O
creatinine	B_Chemical
after	O
intervention	O
(	O
after-before	O
)	O
were	O
significantly	O
different	O
between	O
the	O
PTRA	O
and	O
PCI	O
groups	O
(	O
-0.12+/-0.5	O
vs.	O
0.13+/-0.3	O
,	O
P=0.014	O
)	O
.	O

This	O
difference	O
was	O
not	O
related	O
to	O
either	O
a	O
different	O
clinical	O
risk	O
profile	O
or	O
to	O
the	O
volume	O
of	O
CM	B_Chemical
administered	O
.	O

CONCLUSION	O
:	O
In	O
this	O
preliminary	O
study	O
patients	O
submitted	O
to	O
PTRA	O
showed	O
a	O
lower	O
susceptibility	O
to	O
renal	B_Disease
damage	I_Disease
induced	O
by	O
CM	B_Chemical
administration	O
than	O
PCI	O
patients	O
.	O

The	O
effectiveness	O
of	O
PTRA	O
on	O
renal	O
function	O
seems	O
to	O
be	O
barely	O
influenced	O
by	O
CM	B_Chemical
toxicity	B_Disease
.	O

Diphenhydramine	B_Chemical
prevents	O
the	O
haemodynamic	O
changes	O
of	O
cimetidine	B_Chemical
in	O
ICU	O
patients	O
.	O

Cimetidine	B_Chemical
,	O
a	O
histamine	B_Chemical
2	O
(	O
H2	O
)	O
antagonist	O
,	O
produces	O
a	O
decrease	O
in	O
arterial	O
pressure	O
due	O
to	O
vasodilatation	O
,	O
especially	O
in	O
critically	O
ill	O
patients	O
.	O

This	O
may	O
be	O
because	O
cimetidine	B_Chemical
acts	O
as	O
a	O
histamine	B_Chemical
agonist	O
.	O

We	O
,	O
therefore	O
,	O
investigated	O
the	O
effects	O
of	O
the	O
histamine	B_Chemical
1(H1	O
)	O
receptor	O
antagonist	O
,	O
diphenhydramine	B_Chemical
,	O
on	O
the	O
haemodynamic	O
changes	O
observed	O
after	O
cimetidine	B_Chemical
in	O
ICU	O
patients	O
.	O

Each	O
patient	O
was	O
studied	O
on	O
two	O
separate	O
days	O
.	O

In	O
a	O
random	O
fashion	O
,	O
they	O
received	O
cimetidine	B_Chemical
200	O
mg	O
iv	O
on	O
one	O
day	O
,	O
and	O
on	O
the	O
other	O
,	O
a	O
pretreatment	O
of	O
diphenhydramine	B_Chemical
40	O
mg	O
iv	O
with	O
cimetidine	B_Chemical
200	O
mg	O
iv	O
.	O

In	O
the	O
non-pretreatment	O
group	O
,	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
decreased	O
from	O
107.4	O
+	O
/-	O
8.4	O
mmHg	O
to	O
86.7	O
+	O
/-	O
11.4	O
mmHg	O
(	O
P	O
less	O
than	O
0.01	O
)	O
two	O
minutes	O
after	O
cimetidine	B_Chemical
.	O

Also	O
,	O
systemic	O
vascular	O
resistance	O
(	O
SVR	O
)	O
decreased	O
during	O
the	O
eight-minute	O
observation	O
period	O
(	O
P	O
less	O
than	O
0.01	O
)	O
.	O

In	O
contrast	O
,	O
in	O
the	O
pretreatment	O
group	O
,	O
little	O
haemodynamic	O
change	O
was	O
seen	O
.	O

We	O
conclude	O
that	O
an	O
H1	O
antagonist	O
may	O
be	O
useful	O
in	O
preventing	O
hypotension	B_Disease
caused	O
by	O
iv	O
cimetidine	B_Chemical
,	O
since	O
the	O
vasodilating	O
activity	O
of	O
cimetidine	B_Chemical
is	O
mediated	O
,	O
in	O
part	O
,	O
through	O
the	O
H1	O
receptor	O
.	O

Medical	O
and	O
psychiatric	O
outcomes	O
for	O
patients	O
transplanted	O
for	O
acetaminophen-induced	O
acute	B_Disease
liver	I_Disease
failure	I_Disease
:	O
a	O
case-control	O
study	O
.	O

BACKGROUND	O
:	O
Acetaminophen-induced	O
hepatotoxicity	B_Disease
is	O
the	O
most	O
common	O
cause	O
of	O
acute	B_Disease
liver	I_Disease
failure	I_Disease
(	O
ALF	B_Disease
)	O
in	O
the	O
UK	O
.	O

Patients	O
often	O
consume	O
the	O
drug	O
with	O
suicidal	O
intent	O
or	O
with	O
a	O
background	O
of	O
substance	O
dependence	O
.	O

AIMS	O
AND	O
METHODS	O
:	O
We	O
compared	O
the	O
severity	O
of	O
pretransplant	O
illness	O
,	O
psychiatric	O
co-morbidity	O
,	O
medical	O
and	O
psychosocial	O
outcomes	O
of	O
all	O
patients	O
who	O
had	O
undergone	O
liver	O
transplantation	O
(	O
LT	O
)	O
emergently	O
between	O
1999	O
-	O
2004	O
for	O
acetaminophen-induced	O
ALF	B_Disease
(	O
n=36	O
)	O
with	O
age-	O
and	O
sex-matched	O
patients	O
undergoing	O
emergent	O
LT	O
for	O
non-acetaminophen-induced	O
ALF	B_Disease
(	O
n=35	O
)	O
and	O
elective	O
LT	O
for	O
chronic	B_Disease
liver	I_Disease
disease	I_Disease
(	O
CLD	B_Disease
,	O
n=34	O
)	O
.	O

RESULTS	O
:	O
Acetaminophen-induced	O
ALF	B_Disease
patients	O
undergoing	O
LT	O
had	O
a	O
greater	O
severity	O
of	O
pre-LT	O
illness	O
reflected	O
by	O
higher	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
II	O
scores	O
and	O
requirement	O
for	O
organ	O
support	O
compared	O
with	O
the	O
other	O
two	O
groups	O
.	O

Twenty	O
(	O
56	O
%	O
)	O
acetaminophen-induced	O
ALF	B_Disease
patients	O
had	O
a	O
formal	O
psychiatric	O
diagnosis	O
before	O
LT	O
(	O
non-acetaminophen-induced	O
ALF=0/35	O
,	O
CLD=2/34	O
;	O
P<0.01	O
for	O
all	O
)	O
and	O
nine	O
(	O
25	O
%	O
)	O
had	O
a	O
previous	O
suicide	O
attempt	O
.	O

During	O
follow-up	O
(	O
median	O
5	O
years	O
)	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
rejection	O
(	O
acute	O
and	O
chronic	O
)	O
,	O
graft	O
failure	O
or	O
survival	O
between	O
the	O
groups	O
(	O
acetaminophen-induced	O
ALF	B_Disease
1	O
year	O
87	O
%	O
,	O
5	O
years	O
75	O
%	O
;	O
non-acetaminophen-induced	O
ALF	B_Disease
88	O
%	O
,	O
78	O
%	O
;	O
CLD	B_Disease
93	O
%	O
,	O
82	O
%	O
:	O
P>0.6	O
log	O
rank	O
)	O
.	O

Two	O
acetaminophen-induced	O
ALF	B_Disease
patients	O
reattempted	O
suicide	O
post-LT	O
(	O
one	O
died	O
8	O
years	O
post-LT	O
)	O
.	O

CONCLUSIONS	O
:	O
Despite	O
a	O
high	O
prevalence	O
of	O
psychiatric	O
disturbance	O
,	O
outcomes	O
for	O
patients	O
transplanted	O
emergently	O
for	O
acetaminophen-induced	O
ALF	B_Disease
were	O
comparable	O
to	O
those	O
transplanted	O
for	O
non-acetaminophen-induced	O
ALF	B_Disease
and	O
electively	O
for	O
CLD	B_Disease
.	O

Multidisciplinary	O
approaches	O
with	O
long-term	O
psychiatric	O
follow-up	O
may	O
contribute	O
to	O
low	O
post-transplant	O
suicide	O
rates	O
seen	O
and	O
low	O
rates	O
of	O
graft	O
loss	O
because	O
of	O
non-compliance	O
.	O

Antithrombotic	O
drug	O
use	O
,	O
cerebral	B_Disease
microbleeds	I_Disease
,	O
and	O
intracerebral	B_Disease
hemorrhage	I_Disease
:	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
studies	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
Cerebral	B_Disease
microbleeds	I_Disease
(	O
MB	B_Disease
)	O
are	O
potential	O
risk	O
factors	O
for	O
intracerebral	B_Disease
hemorrhage	I_Disease
(	O
ICH	B_Disease
)	O
,	O
but	O
it	O
is	O
unclear	O
if	O
they	O
are	O
a	O
contraindication	O
to	O
using	O
antithrombotic	O
drugs	O
.	O

Insights	O
could	O
be	O
gained	O
by	O
pooling	O
data	O
on	O
MB	B_Disease
frequency	O
stratified	O
by	O
antithrombotic	O
use	O
in	O
cohorts	O
with	O
ICH	B_Disease
and	O
ischemic	B_Disease
stroke	I_Disease
(IS)/transient	O
ischemic	O
attack	O
(	O
TIA	B_Disease
)	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
data	O
from	O
cohorts	O
with	O
stroke	B_Disease
or	O
TIA	B_Disease
to	O
compare	O
the	O
presence	O
of	O
MB	B_Disease
in	O
:	O
(	O
1	O
)	O
antithrombotic	O
users	O
vs	O
nonantithrombotic	O
users	O
with	O
ICH	B_Disease
;	O
(	O
2	O
)	O
antithrombotic	O
users	O
vs	O
nonusers	O
with	O
IS/TIA	O
;	O
and	O
(	O
3	O
)	O
ICH	B_Disease
vs	O
ischemic	B_Disease
events	O
stratified	O
by	O
antithrombotic	O
use	O
.	O

We	O
also	O
analyzed	O
published	O
and	O
unpublished	O
follow-up	O
data	O
to	O
determine	O
the	O
risk	O
of	O
ICH	B_Disease
in	O
antithrombotic	O
users	O
with	O
MB	B_Disease
.	O

RESULTS	O
:	O
In	O
a	O
pooled	O
analysis	O
of	O
1460	O
ICH	B_Disease
and	O
3817	O
IS/TIA	O
,	O
MB	B_Disease
were	O
more	O
frequent	O
in	O
ICH	B_Disease
vs	O
IS/TIA	O
in	O
all	O
treatment	O
groups	O
,	O
but	O
the	O
excess	O
increased	O
from	O
2.8	O
(	O
odds	O
ratio	O
;	O
range	O
,	O
2.3	O
-	O
3.5	O
)	O
in	O
nonantithrombotic	O
users	O
to	O
5.7	O
(	O
range	O
,	O
3.4	O
-	O
9.7	O
)	O
in	O
antiplatelet	O
users	O
and	O
8.0	O
(	O
range	O
,	O
3.5	O
-	O
17.8	O
)	O
in	O
warfarin	B_Chemical
users	O
(	O
P	O
difference=0.01	O
)	O
.	O

There	O
was	O
also	O
an	O
excess	O
of	O
MB	B_Disease
in	O
warfarin	B_Chemical
users	O
vs	O
nonusers	O
with	O
ICH	B_Disease
(	O
OR	O
,	O
2.7	O
;	O
95	O
%	O
CI	O
,	O
1.6	O
-	O
4.4	O
;	O
P<0.001	O
)	O
but	O
none	O
in	O
warfarin	B_Chemical
users	O
with	O
IS/TIA	O
(	O
OR	O
,	O
1.3	O
;	O
95	O
%	O
CI	O
,	O
0.9	O
-	O
1.7	O
;	O
P=0.33	O
;	O
P	O
difference=0.01	O
)	O
.	O

There	O
was	O
a	O
smaller	O
excess	O
of	O
MB	B_Disease
in	O
antiplatelet	O
users	O
vs	O
nonusers	O
with	O
ICH	B_Disease
(	O
OR	O
,	O
1.7	O
;	O
95	O
%	O
CI	O
,	O
1.3	O
-	O
2.3	O
;	O
P<0.001	O
)	O
,	O
but	O
findings	O
were	O
similar	O
for	O
antiplatelet	O
users	O
with	O
IS/TIA	O
(	O
OR	O
,	O
1.4	O
;	O
95	O
%	O
CI	O
,	O
1.2	O
-	O
1.7	O
;	O
P<0.001	O
;	O
P	O
difference=0.25	O
)	O
.	O

In	O
pooled	O
follow-up	O
data	O
for	O
768	O
antithrombotic	O
users	O
,	O
presence	O
of	O
MB	B_Disease
at	O
baseline	O
was	O
associated	O
with	O
a	O
substantially	O
increased	O
risk	O
of	O
subsequent	O
ICH	B_Disease
(	O
OR	O
,	O
12.1	O
;	O
95	O
%	O
CI	O
,	O
3.4	O
-	O
42.5	O
;	O
P<0.001	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
excess	O
of	O
MB	B_Disease
in	O
warfarin	B_Chemical
users	O
with	O
ICH	B_Disease
compared	O
to	O
other	O
groups	O
suggests	O
that	O
MB	B_Disease
increase	O
the	O
risk	O
of	O
warfarin-associated	O
ICH	B_Disease
.	O

Limited	O
prospective	O
data	O
corroborate	O
these	O
findings	O
,	O
but	O
larger	O
prospective	O
studies	O
are	O
urgently	O
required	O
.	O

Studies	O
of	O
synergy	O
between	O
morphine	B_Chemical
and	O
a	O
novel	O
sodium	B_Chemical
channel	O
blocker	O
,	O
CNSB002	B_Chemical
,	O
in	O
rat	O
models	O
of	O
inflammatory	O
and	O
neuropathic	B_Disease
pain	I_Disease
.	O

OBJECTIVE	O
:	O
This	O
study	O
determined	O
the	O
antihyperalgesic	O
effect	O
of	O
CNSB002	B_Chemical
,	O
a	O
sodium	B_Chemical
channel	O
blocker	O
with	O
antioxidant	O
properties	O
given	O
alone	O
and	O
in	O
combinations	O
with	O
morphine	B_Chemical
in	O
rat	O
models	O
of	O
inflammatory	O
and	O
neuropathic	B_Disease
pain	I_Disease
.	O

DESIGN	O
:	O
Dose	O
response	O
curves	O
for	O
nonsedating	O
doses	O
of	O
morphine	B_Chemical
and	O
CNSB002	B_Chemical
given	O
intraperitoneally	O
alone	O
and	O
together	O
in	O
combinations	O
were	O
constructed	O
for	O
antihyperalgesic	O
effect	O
using	O
paw	O
withdrawal	O
from	O
noxious	O
heat	O
in	O
two	O
rat	O
pain	B_Disease
models	O
:	O
carrageenan-induced	O
paw	O
inflammation	B_Disease
and	O
streptozotocin	B_Chemical
(STZ)-induced	O
diabetic	B_Disease
neuropathy	I_Disease
.	O

RESULTS	O
:	O
The	O
maximum	O
nonsedating	O
doses	O
were	O
:	O
morphine	B_Chemical
,	O
3.2	O
mg/kg	O
;	O
CNSB002	B_Chemical
10.0	O
mg/kg	O
;	O
5.0	O
mg/kg	O
CNSB002	B_Chemical
with	O
morphine	B_Chemical
3.2	O
mg/kg	O
in	O
combination	O
.	O

The	O
doses	O
calculated	O
to	O
cause	O
50	O
%	O
reversal	O
of	O
hyperalgesia	B_Disease
(	O
ED50	O
)	O
were	O
7.54	O
(	O
1.81	O
)	O
and	O
4.83	O
(	O
1.54	O
)	O
in	O
the	O
carrageenan	B_Chemical
model	O
and	O
44.18	O
(	O
1.37	O
)	O
and	O
9.14	O
(	O
1.24	O
)	O
in	O
the	O
STZ-induced	O
neuropathy	B_Disease
model	O
for	O
CNSB002	B_Chemical
and	O
morphine	B_Chemical
,	O
respectively	O
(	O
mg/kg	O
;	O
mean	O
,	O
SEM	O
)	O
.	O

These	O
values	O
were	O
greater	O
than	O
the	O
maximum	O
nonsedating	O
doses	O
.	O

The	O
ED50	O
values	O
for	O
morphine	B_Chemical
when	O
given	O
in	O
combination	O
with	O
CNSB002	B_Chemical
(	O
5	O
mg/kg	O
)	O
were	O
less	O
than	O
the	O
maximum	O
nonsedating	O
dose	O
:	O
0.56	O
(	O
1.55	O
)	O
in	O
the	O
carrageenan	B_Chemical
model	O
and	O
1.37	O
(	O
1.23	O
)	O
in	O
the	O
neuropathy	B_Disease
model	O
(	O
mg/kg	O
;	O
mean	O
,	O
SEM	O
)	O
.	O

The	O
antinociception	O
after	O
morphine	B_Chemical
(	O
3.2	O
mg/kg	O
)	O
was	O
increased	O
by	O
co-administration	O
with	O
CNSB002	B_Chemical
from	O
28.0	O
and	O
31.7	O
%	O
to	O
114.6	O
and	O
56.9	O
%	O
reversal	O
of	O
hyperalgesia	B_Disease
in	O
the	O
inflammatory	O
and	O
neuropathic	B_Disease
models	O
,	O
respectively	O
(	O
P	O
<	O
0.01	O
;	O
one-way	O
analysis	O
of	O
variance-significantly	O
greater	O
than	O
either	O
drug	O
given	O
alone	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
maximum	O
antihyperalgesic	O
effect	O
achievable	O
with	O
nonsedating	O
doses	O
of	O
morphine	B_Chemical
may	O
be	O
increased	O
significantly	O
when	O
the	O
drug	O
is	O
used	O
in	O
combination	O
with	O
CNSB002	B_Chemical
.	O

Heparin-induced	O
thrombocytopenia	B_Disease
:	O
a	O
practical	O
review	O
.	O

Heparin-induced	O
thrombocytopenia	B_Disease
(	O
HIT	B_Disease
)	O
remains	O
under-recognized	O
despite	O
its	O
potentially	O
devastating	O
outcomes	O
.	O

It	O
begins	O
when	O
heparin	B_Chemical
exposure	O
stimulates	O
the	O
formation	O
of	O
heparin-platelet	O
factor	O
4	O
antibodies	O
,	O
which	O
in	O
turn	O
triggers	O
the	O
release	O
of	O
procoagulant	O
platelet	O
particles	O
.	O

Thrombosis	B_Disease
and	O
thrombocytopenia	B_Disease
that	O
follow	O
comprise	O
the	O
2	O
hallmark	O
traits	O
of	O
HIT	B_Disease
,	O
with	O
the	O
former	O
largely	O
responsible	O
for	O
significant	O
vascular	O
complications	O
.	O

The	O
prevalence	O
of	O
HIT	B_Disease
varies	O
among	O
several	O
subgroups	O
,	O
with	O
greater	O
incidence	O
in	O
surgical	O
as	O
compared	O
with	O
medical	O
populations	O
.	O

HIT	B_Disease
must	O
be	O
acknowledged	O
for	O
its	O
intense	O
predilection	O
for	O
thrombosis	B_Disease
and	O
suspected	O
whenever	O
thrombosis	B_Disease
occurs	O
after	O
heparin	B_Chemical
exposure	O
.	O

Early	O
recognition	O
that	O
incorporates	O
the	O
clinical	O
and	O
serologic	O
clues	O
is	O
paramount	O
to	O
timely	O
institution	O
of	O
treatment	O
,	O
as	O
its	O
delay	O
may	O
result	O
in	O
catastrophic	O
outcomes	O
.	O

The	O
treatment	O
of	O
HIT	B_Disease
mandates	O
an	O
immediate	O
cessation	O
of	O
all	O
heparin	B_Chemical
exposure	O
and	O
the	O
institution	O
of	O
an	O
antithrombotic	O
therapy	O
,	O
most	O
commonly	O
using	O
a	O
direct	B_Chemical
thrombin	I_Chemical
inhibitor	I_Chemical
.	O

Current	O
"	O
diagnostic	O
"	O
tests	O
,	O
which	O
primarily	O
include	O
functional	O
and	O
antigenic	O
assays	O
,	O
have	O
more	O
of	O
a	O
confirmatory	O
than	O
diagnostic	O
role	O
in	O
the	O
management	O
of	O
HIT	B_Disease
.	O

Special	O
attention	O
must	O
be	O
paid	O
to	O
cardiac	O
patients	O
who	O
are	O
often	O
exposed	O
to	O
heparin	B_Chemical
multiple	O
times	O
during	O
their	O
course	O
of	O
treatment	O
.	O

Direct	B_Chemical
thrombin	I_Chemical
inhibitors	I_Chemical
are	O
appropriate	O
,	O
evidence-based	O
alternatives	O
to	O
heparin	B_Chemical
in	O
patients	O
with	O
a	O
history	O
of	O
HIT	B_Disease
,	O
who	O
need	O
to	O
undergo	O
percutaneous	O
coronary	O
intervention	O
.	O

As	O
heparin	B_Chemical
remains	O
one	O
of	O
the	O
most	O
frequently	O
used	O
medications	O
today	O
with	O
potential	O
for	O
HIT	B_Disease
with	O
every	O
heparin	B_Chemical
exposure	O
,	O
a	O
close	O
vigilance	O
of	O
platelet	O
counts	O
must	O
be	O
practiced	O
whenever	O
heparin	B_Chemical
is	O
initiated	O
.	O

Abductor	O
paralysis	B_Disease
after	O
botox	B_Chemical
injection	O
for	O
adductor	B_Disease
spasmodic	I_Disease
dysphonia	I_Disease
.	O

OBJECTIVES/HYPOTHESIS	O
:	O
Botulinum	O
toxin	O
(	O
Botox	B_Chemical
)	O
injections	O
into	O
the	O
thyroarytenoid	O
muscles	O
are	O
the	O
current	O
standard	O
of	O
care	O
for	O
adductor	B_Disease
spasmodic	I_Disease
dysphonia	I_Disease
(	O
ADSD	B_Disease
)	O
.	O

Reported	O
adverse	O
effects	O
include	O
a	O
period	O
of	O
breathiness	O
,	O
throat	B_Disease
pain	I_Disease
,	O
and	O
difficulty	O
with	O
swallowing	O
liquids	O
.	O

Here	O
we	O
report	O
multiple	O
cases	O
of	O
bilateral	O
abductor	O
paralysis	B_Disease
following	O
Botox	B_Chemical
injections	O
for	O
ADSD	B_Disease
,	O
a	O
complication	O
previously	O
unreported	O
.	O

STUDY	O
DESIGN	O
:	O
Retrospective	O
case	O
series	O
.	O

METHODS	O
:	O
Patients	O
that	O
received	O
Botox	B_Chemical
injections	O
for	O
spasmodic	B_Disease
dysphonia	I_Disease
between	O
January	O
2000	O
and	O
October	O
2009	O
were	O
evaluated	O
.	O

Patients	O
with	O
ADSD	B_Disease
were	O
identified	O
.	O

The	O
number	O
of	O
treatments	O
received	O
and	O
adverse	O
effects	O
were	O
noted	O
.	O

For	O
patients	O
with	O
bilateral	O
abductor	O
paralysis	B_Disease
,	O
age	O
,	O
sex	O
,	O
paralytic	O
Botox	B_Chemical
dose	O
,	O
prior	O
Botox	B_Chemical
dose	O
,	O
and	O
course	O
following	O
paralysis	B_Disease
were	O
noted	O
.	O

RESULTS	O
:	O
From	O
a	O
database	O
of	O
452	O
patients	O
receiving	O
Botox	B_Chemical
,	O
352	O
patients	O
had	O
been	O
diagnosed	O
with	O
ADSD	B_Disease
.	O

Of	O
these	O
352	O
patients	O
,	O
eight	O
patients	O
suffered	O
bilateral	O
abductor	O
paralysis	B_Disease
,	O
and	O
two	O
suffered	O
this	O
complication	O
twice	O
.	O

All	O
affected	O
patients	O
were	O
females	O
over	O
the	O
age	O
of	O
50	O
years	O
.	O

Most	O
patients	O
had	O
received	O
treatments	O
prior	O
to	O
abductor	O
paralysis	B_Disease
and	O
continued	O
receiving	O
after	O
paralysis	B_Disease
.	O

Seven	O
patients	O
recovered	O
after	O
a	O
brief	O
period	O
of	O
activity	O
restrictions	O
,	O
and	O
one	O
underwent	O
a	O
tracheotomy	O
.	O

The	O
incidence	O
of	O
abductor	O
paralysis	B_Disease
after	O
Botox	B_Chemical
injection	O
for	O
ADSD	B_Disease
was	O
0.34	O
%	O
.	O

CONCLUSIONS	O
:	O
Bilateral	O
abductor	O
paralysis	B_Disease
is	O
a	O
rare	O
complication	O
of	O
Botox	B_Chemical
injections	O
for	O
ADSD	B_Disease
,	O
causing	O
difficulty	O
with	O
breathing	O
upon	O
exertion	O
.	O

The	O
likely	O
mechanism	O
of	O
paralysis	B_Disease
is	O
diffusion	O
of	O
Botox	B_Chemical
around	O
the	O
muscular	O
process	O
of	O
the	O
arytenoid	O
to	O
the	O
posterior	O
cricoarytenoid	O
muscles	O
.	O

The	O
paralysis	B_Disease
is	O
temporary	O
,	O
and	O
watchful	O
waiting	O
with	O
restriction	O
of	O
activity	O
is	O
the	O
recommended	O
management	O
.	O

Mitochondrial	B_Disease
impairment	I_Disease
contributes	O
to	O
cocaine-induced	O
cardiac	B_Disease
dysfunction	I_Disease
:	O
Prevention	O
by	O
the	O
targeted	O
antioxidant	O
MitoQ.The	O
goal	O
of	O
this	O
study	O
was	O
to	O
assess	O
mitochondrial	O
function	O
and	O
ROS	O
production	O
in	O
an	O
experimental	O
model	O
of	O
cocaine-induced	O
cardiac	B_Disease
dysfunction	I_Disease
.	O

We	O
hypothesized	O
that	O
cocaine	B_Disease
abuse	I_Disease
may	O
lead	O
to	O
altered	O
mitochondrial	O
function	O
that	O
in	O
turn	O
may	O
cause	O
left	B_Disease
ventricular	I_Disease
dysfunction	I_Disease
.	O

Seven	O
days	O
of	O
cocaine	B_Chemical
administration	O
to	O
rats	O
led	O
to	O
an	O
increased	O
oxygen	B_Chemical
consumption	O
detected	O
in	O
cardiac	O
fibers	O
,	O
specifically	O
through	O
complex	O
I	O
and	O
complex	O
III	O
.	O

ROS	O
levels	O
were	O
increased	O
,	O
specifically	O
in	O
interfibrillar	O
mitochondria	O
.	O

In	O
parallel	O
there	O
was	O
a	O
decrease	O
in	O
ATP	B_Chemical
synthesis	O
,	O
whereas	O
no	O
difference	O
was	O
observed	O
in	O
subsarcolemmal	O
mitochondria	O
.	O

This	O
uncoupling	O
effect	O
on	O
oxidative	O
phosphorylation	O
was	O
not	O
detectable	O
after	O
short-term	O
exposure	O
to	O
cocaine	B_Chemical
,	O
suggesting	O
that	O
these	O
mitochondrial	B_Disease
abnormalities	I_Disease
were	O
a	O
late	O
rather	O
than	O
a	O
primary	O
event	O
in	O
the	O
pathological	O
response	O
to	O
cocaine	B_Chemical
.	O

MitoQ	B_Chemical
,	O
a	O
mitochondrial-targeted	O
antioxidant	O
,	O
was	O
shown	O
to	O
completely	O
prevent	O
these	O
mitochondrial	B_Disease
abnormalities	I_Disease
as	O
well	O
as	O
cardiac	B_Disease
dysfunction	I_Disease
characterized	O
here	O
by	O
a	O
diastolic	B_Disease
dysfunction	I_Disease
studied	O
with	O
a	O
conductance	O
catheter	O
to	O
obtain	O
pressure-volume	O
data	O
.	O

Taken	O
together	O
,	O
these	O
results	O
extend	O
previous	O
studies	O
and	O
demonstrate	O
that	O
cocaine-induced	O
cardiac	B_Disease
dysfunction	I_Disease
may	O
be	O
due	O
to	O
a	O
mitochondrial	B_Disease
defect	I_Disease
.	O

Trimethoprim-induced	O
immune	O
hemolytic	B_Disease
anemia	I_Disease
in	O
a	O
pediatric	O
oncology	O
patient	O
presenting	O
as	O
an	O
acute	O
hemolytic	O
transfusion	O
reaction	O
.	O

A	O
10-year-old	O
male	O
with	O
acute	B_Disease
leukemia	I_Disease
presented	O
with	O
post-chemotherapy	O
anemia	B_Disease
.	O

During	O
red	O
cell	O
transfusion	O
,	O
he	O
developed	O
hemoglobinuria	B_Disease
.	O

Transfusion	O
reaction	O
workup	O
was	O
negative	O
.	O

Drug-induced	O
immune	O
hemolytic	B_Disease
anemia	I_Disease
was	O
suspected	O
because	O
of	O
positive	O
direct	O
antiglobulin	O
test	O
,	O
negative	O
eluate	O
,	O
and	O
microspherocytes	O
on	O
smear	O
pre-	O
and	O
post-transfusion	O
.	O

Drug	O
studies	O
using	O
the	O
indirect	O
antiglobulin	O
test	O
were	O
strongly	O
positive	O
with	O
trimethoprim	B_Chemical
and	O
trimethoprim-sulfamethoxazole	B_Chemical
but	O
negative	O
with	O
sulfamethoxazole	B_Chemical
.	O

The	O
patient	O
recovered	O
after	O
discontinuing	O
the	O
drug	O
,	O
with	O
no	O
recurrence	O
in	O
2	O
years	O
.	O

Other	O
causes	O
of	O
anemia	B_Disease
should	O
be	O
considered	O
in	O
patients	O
with	O
worse-than-expected	O
anemia	B_Disease
after	O
chemotherapy	O
.	O

Furthermore	O
,	O
hemolysis	B_Disease
during	O
transfusion	O
is	O
not	O
always	O
a	O
transfusion	O
reaction	O
.	O

Verapamil	B_Chemical
stimulation	O
test	O
in	O
hyperprolactinemia	B_Disease
:	O
loss	O
of	O
prolactin	O
response	O
in	O
anatomic	O
or	O
functional	O
stalk	O
effect	O
.	O

AIM	O
:	O
Verapamil	B_Chemical
stimulation	O
test	O
was	O
previously	O
investigated	O
as	O
a	O
tool	O
for	O
differential	O
diagnosis	O
of	O
hyperprolactinemia	B_Disease
,	O
but	O
with	O
conflicting	O
results	O
.	O

Macroprolactinemia	B_Disease
was	O
never	O
considered	O
in	O
those	O
previous	O
studies	O
.	O

Here	O
,	O
we	O
aimed	O
to	O
re-investigate	O
the	O
diagnostic	O
value	O
of	O
verapamil	B_Chemical
in	O
a	O
population	O
who	O
were	O
all	O
screened	O
for	O
macroprolactinemia	B_Disease
.	O

Prolactin	O
responses	O
to	O
verapamil	B_Chemical
in	O
65	O
female	O
patients	O
(	O
age	O
:	O
29.9	O
+	O
/-	O
8.1	O
years	O
)	O
with	O
hyperprolactinemia	B_Disease
were	O
tested	O
in	O
a	O
descriptive	O
,	O
matched	O
case-control	O
study	O
.	O

METHODS	O
:	O
Verapamil	B_Chemical
80	O
mg	O
,	O
p.o	O
.	O
was	O
administered	O
,	O
and	O
then	O
PRL	O
levels	O
were	O
measured	O
at	O
8th	O
and	O
16th	O
hours	O
,	O
by	O
immunometric	O
chemiluminescence	O
.	O

Verapamil	B_Chemical
responsiveness	O
was	O
determined	O
by	O
peak	O
percent	O
change	O
in	O
basal	O
prolactin	O
levels	O
(	O
PRL	O
)	O
.	O

RESULTS	O
:	O
Verapamil	B_Chemical
significantly	O
increased	O
PRL	O
levels	O
in	O
healthy	O
controls	O
(	O
N.	O
8	O
,	O
PRL	O
:	O
183	O
%	O
)	O
,	O
macroprolactinoma	B_Disease
(	O
N.	O
8	O
,	O
PRL	O
:	O
7	O
%	O
)	O
,	O
microprolactinoma	B_Disease
(	O
N.	O
19	O
,	O
PRL	O
:	O
21	O
%	O
)	O
,	O
macroprolactinemia	B_Disease
(	O
N.	O
23	O
,	O
PRL	O
:	O
126	O
%	O
)	O
,	O
but	O
not	O
in	O
pseudoprolactinoma	B_Disease
(	O
N.	O
8	O
,	O
PRL	O
:	O
0.8	O
%	O
)	O
,	O
and	O
risperidone-induced	O
hyperprolactinemia	B_Disease
(	O
N.	O
7	O
,	O
PRL	O
:	O
3	O
%	O
)	O
.	O

ROC	O
curve	O
analysis	O
revealed	O
that	O
unresponsiveness	O
to	O
verapamil	B_Chemical
defined	O
as	O
PRL	O
<	O
7	O
%	O
,	O
discriminated	O
anatomical	O
or	O
functional	O
stalk	O
effect	O
(	O
sensitivity	O
:	O
74	O
%	O
,	O
specificity	O
:	O
73	O
%	O
,	O
AUC	O
:	O
0.855+/-0.04	O
,	O
P	O
<	O
0.001	O
,	O
CI	O
:	O
0.768	O
-	O
0.942	O
)	O
associated	O
with	O
pseudoprolactinoma	B_Disease
or	O
risperidone-induced	O
hyperprolactinemia	B_Disease
,	O
respectively	O
.	O

CONCLUSION	O
:	O
Verapamil	B_Chemical
responsiveness	O
is	O
not	O
a	O
reliable	O
finding	O
for	O
the	O
differential	O
diagnosis	O
of	O
hyperprolactinemia	B_Disease
.	O

However	O
,	O
verapamil	B_Chemical
unresponsiveness	O
discriminates	O
stalk	O
effect	O
(	O
i.e.	O
,	O
anatomically	O
or	O
functionally	O
inhibited	O
dopaminergic	O
tonus	O
)	O
from	O
other	O
causes	O
of	O
hyperprolactinemia	B_Disease
with	O
varying	O
degrees	O
of	O
responsiveness	O
.	O

Blockade	O
of	O
endothelial-mesenchymal	O
transition	O
by	O
a	O
Smad3	O
inhibitor	O
delays	O
the	O
early	O
development	O
of	O
streptozotocin-induced	O
diabetic	B_Disease
nephropathy	I_Disease
.	O

OBJECTIVE	O
:	O
A	O
multicenter	O
,	O
controlled	O
trial	O
showed	O
that	O
early	O
blockade	O
of	O
the	O
renin-angiotensin	O
system	O
in	O
patients	O
with	O
type	B_Disease
1	I_Disease
diabetes	I_Disease
and	O
normoalbuminuria	O
did	O
not	O
retard	O
the	O
progression	O
of	O
nephropathy	B_Disease
,	O
suggesting	O
that	O
other	O
mechanism(s	O
)	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
early	O
diabetic	B_Disease
nephropathy	I_Disease
(	O
diabetic	B_Disease
nephropathy	I_Disease
)	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
endothelial-mesenchymal-transition	O
(	O
EndoMT	O
)	O
contributes	O
to	O
the	O
early	O
development	O
of	O
renal	O
interstitial	O
fibrosis	B_Disease
independently	O
of	O
microalbuminuria	O
in	O
mice	O
with	O
streptozotocin	B_Chemical
(STZ)-induced	O
diabetes	B_Disease
.	O

In	O
the	O
present	O
study	O
,	O
we	O
hypothesized	O
that	O
blocking	O
EndoMT	O
reduces	O
the	O
early	O
development	O
of	O
diabetic	B_Disease
nephropathy	I_Disease
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
EndoMT	O
was	O
induced	O
in	O
a	O
mouse	O
pancreatic	O
microvascular	O
endothelial	O
cell	O
line	O
(	O
MMEC	O
)	O
in	O
the	O
presence	O
of	O
advanced	O
glycation	O
end	O
products	O
(	O
AGEs	O
)	O
and	O
in	O
the	O
endothelial	O
lineage-traceble	O
mouse	O
line	O
Tie2-Cre;Loxp-EGFP	O
by	O
administration	O
of	O
AGEs	O
,	O
with	O
nonglycated	O
mouse	O
albumin	O
serving	O
as	O
a	O
control	O
.	O

Phosphorylated	O
Smad3	O
was	O
detected	O
by	O
immunoprecipitation/Western	O
blotting	O
and	O
confocal	O
microscopy	O
.	O

Blocking	O
studies	O
using	O
receptor	O
for	O
AGE	O
siRNA	O
and	O
a	O
specific	O
inhibitor	O
of	O
Smad3	O
(	O
SIS3	O
)	O
were	O
performed	O
in	O
MMECs	O
and	O
in	O
STZ-induced	O
diabetic	B_Disease
nephropathy	I_Disease
in	O
Tie2-Cre;Loxp-EGFP	O
mice	O
.	O

RESULTS	O
:	O
Confocal	O
microscopy	O
and	O
real-time	O
PCR	O
demonstrated	O
that	O
AGEs	O
induced	O
EndoMT	O
in	O
MMECs	O
and	O
in	O
Tie2-Cre;Loxp-EGFP	O
mice	O
.	O

Immunoprecipitation/Western	O
blotting	O
showed	O
that	O
Smad3	O
was	O
activated	O
by	O
AGEs	O
but	O
was	O
inhibited	O
by	O
SIS3	O
in	O
MMECs	O
and	O
in	O
STZ-induced	O
diabetic	B_Disease
nephropathy	I_Disease
.	O

Confocal	O
microscopy	O
and	O
real-time	O
PCR	O
further	O
demonstrated	O
that	O
SIS3	O
abrogated	O
EndoMT	O
,	O
reduced	O
renal	O
fibrosis	B_Disease
,	O
and	O
retarded	O
progression	O
of	O
nephropathy	B_Disease
.	O

CONCLUSIONS	O
:	O
EndoMT	O
is	O
a	O
novel	O
pathway	O
leading	O
to	O
early	O
development	O
of	O
diabetic	B_Disease
nephropathy	I_Disease
.	O

Blockade	O
of	O
EndoMT	O
by	O
SIS3	O
may	O
provide	O
a	O
new	O
strategy	O
to	O
retard	O
the	O
progression	O
of	O
diabetic	B_Disease
nephropathy	I_Disease
and	O
other	O
diabetes	B_Disease
complications	I_Disease
.	O

Cytostatic	O
and	O
anti-angiogenic	O
effects	O
of	O
temsirolimus	B_Chemical
in	O
refractory	O
mantle	B_Disease
cell	I_Disease
lymphoma	I_Disease
.	O

Mantle	B_Disease
cell	I_Disease
lymphoma	I_Disease
(	O
MCL	B_Disease
)	O
is	O
a	O
rare	O
and	O
aggressive	O
type	O
of	O
B-cell	B_Disease
non-Hodgkin	I_Disease
's	I_Disease
lymphoma	I_Disease
.	O

Patients	O
become	O
progressively	O
refractory	O
to	O
conventional	O
chemotherapy	O
,	O
and	O
their	O
prognosis	O
is	O
poor	O
.	O

However	O
,	O
a	O
38	O
%	O
remission	O
rate	O
has	O
been	O
recently	O
reported	O
in	O
refractory	O
MCL	B_Disease
treated	O
with	O
temsirolimus	B_Chemical
,	O
a	O
mTOR	O
inhibitor	O
.	O

Here	O
we	O
had	O
the	O
opportunity	O
to	O
study	O
a	O
case	O
of	O
refractory	O
MCL	B_Disease
who	O
had	O
tumor	B_Disease
regression	O
two	O
months	O
after	O
temsirolimus	B_Chemical
treatment	O
,	O
and	O
a	O
progression-free	O
survival	O
of	O
10	O
months	O
.	O

In	O
this	O
case	O
,	O
lymph	O
node	O
biopsies	O
were	O
performed	O
before	O
and	O
six	O
months	O
after	O
temsirolimus	B_Chemical
therapy	O
.	O

Comparison	O
of	O
the	O
two	O
biopsies	O
showed	O
that	O
temsirolimus	B_Chemical
inhibited	O
tumor	B_Disease
cell	O
proliferation	O
through	O
cell	O
cycle	O
arrest	O
,	O
but	O
did	O
not	O
induce	O
any	O
change	O
in	O
the	O
number	O
of	O
apoptotic	O
tumor	B_Disease
cells	O
.	O

Apart	O
from	O
this	O
cytostatic	O
effect	O
,	O
temsirolimus	B_Chemical
had	O
an	O
antiangiogenic	O
effect	O
with	O
decrease	O
of	O
tumor	B_Disease
microvessel	O
density	O
and	O
of	O
VEGF	O
expression	O
.	O

Moreover	O
,	O
numerous	O
patchy	O
,	O
well-limited	O
fibrotic	O
areas	O
,	O
compatible	O
with	O
post-necrotic	O
tissue	O
repair	O
,	O
were	O
found	O
after	O
6-month	O
temsirolimus	B_Chemical
therapy	O
.	O

Thus	O
,	O
temsirolimus	B_Chemical
reduced	O
tumor	B_Disease
burden	O
through	O
associated	O
cytostatic	O
and	O
anti-angiogenic	O
effects	O
.	O

This	O
dual	O
effect	O
of	O
temsirolimus	B_Chemical
on	O
tumor	B_Disease
tissue	O
could	O
contribute	O
to	O
its	O
recently	O
reported	O
efficiency	O
in	O
refractory	O
MCL	B_Disease
resistant	O
to	O
conventional	O
chemotherapy	O
.	O

Acute	B_Disease
renal	I_Disease
failure	I_Disease
due	O
to	O
rifampicin	B_Chemical
.	O

A	O
23-year-old	O
male	O
patient	O
with	O
bacteriologically	O
proven	O
pulmonary	B_Disease
tuberculosis	I_Disease
was	O
treated	O
with	O
the	O
various	O
regimens	O
of	O
antituberculosis	O
drugs	O
for	O
nearly	O
15	O
months	O
.	O

Rifampicin	B_Chemical
was	O
administered	O
thrice	O
as	O
one	O
of	O
the	O
3	O
-	O
4	O
drug	O
regimen	O
and	O
each	O
time	O
he	O
developed	O
untoward	O
side	O
effects	O
like	O
nausea	B_Disease
,	O
vomiting	B_Disease
and	O
fever	B_Disease
with	O
chills	O
and	O
rigors	O
.	O

The	O
last	O
such	O
episode	O
was	O
of	O
acute	O
renal	O
failure	O
at	O
which	O
stage	O
the	O
patient	O
was	O
seen	O
by	O
the	O
authors	O
of	O
this	O
report	O
.	O

The	O
patient	O
,	O
however	O
,	O
made	O
a	O
full	O
recovery	O
.	O

Syncope	B_Disease
caused	O
by	O
hyperkalemia	B_Disease
during	O
use	O
of	O
a	O
combined	O
therapy	O
with	O
the	O
angiotensin-converting	O
enzyme	O
inhibitor	O
and	O
spironolactone	B_Chemical
.	O

A	O
76	O
year-old	O
woman	O
with	O
a	O
history	O
of	O
coronary	O
artery	O
bypass	O
grafting	O
and	O
prior	O
myocardial	B_Disease
infarction	I_Disease
was	O
transferred	O
to	O
the	O
emergency	O
room	O
with	O
loss	B_Disease
of	I_Disease
consciousness	I_Disease
due	O
to	O
marked	O
bradycardia	B_Disease
caused	O
by	O
hyperkalemia	B_Disease
.	O

The	O
concentration	O
of	O
serum	O
potassium	B_Chemical
was	O
high	O
,	O
and	O
normal	O
sinus	O
rhythm	O
was	O
restored	O
after	O
correction	O
of	O
the	O
serum	O
potassium	B_Chemical
level	O
.	O

The	O
cause	O
of	O
hyperkalemia	B_Disease
was	O
considered	O
to	O
be	O
several	O
doses	O
of	O
spiranolactone	B_Chemical
,	O
an	O
aldosterone	B_Chemical
antagonist	O
,	O
in	O
addition	O
to	O
the	O
long-term	O
intake	O
of	O
ramipril	B_Chemical
,	O
an	O
ACE	O
inhibitor	O
.	O

This	O
case	O
is	O
a	O
good	O
example	O
of	O
electrolyte	O
imbalance	O
causing	O
acute	O
life-threatening	O
cardiac	O
events	O
.	O

Clinicians	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
hyperkalemia	B_Disease
,	O
especially	O
in	O
elderly	O
patients	O
using	O
ACE/ARB	O
in	O
combination	O
with	O
potassium	B_Chemical
sparing	O
agents	O
and	O
who	O
have	O
mild	O
renal	B_Disease
disturbance	I_Disease
.	O

Diffuse	O
skeletal	O
pain	B_Disease
after	O
administration	O
of	O
alendronate	B_Chemical
.	O

BACKGROUND	O
:	O
Osteoporosis	B_Disease
is	O
caused	O
by	O
bone	O
resorption	O
in	O
excess	O
of	O
bone	O
formation	O
,	O
and	O
bisphosphonates	B_Chemical
,	O
are	O
used	O
to	O
inhibit	O
bone	O
resorption	O
.	O

Alendronate	B_Chemical
,	O
a	O
biphosphonate	B_Chemical
,	O
is	O
effective	O
for	O
both	O
the	O
treatment	O
and	O
prevention	O
of	O
osteoporosis	B_Disease
in	O
postmenopausal	O
women	O
.	O

Side	O
effects	O
are	O
relatively	O
few	O
and	O
prominently	O
gastrointestinal	O
.	O

Musculoskeletal	B_Disease
pain	I_Disease
may	O
be	O
an	O
important	O
side	O
effect	O
in	O
these	O
patients	O
.	O

We	O
presented	O
a	O
patient	O
admitted	O
to	O
our	O
out-patient	O
clinic	O
with	O
diffuse	O
skeletal	O
pain	B_Disease
after	O
three	O
consecutive	O
administration	O
of	O
alendronate	B_Chemical
.	O

CONCLUSION	O
:	O
We	O
conclude	O
that	O
patients	O
with	O
osteoporosis	B_Disease
can	O
report	O
pain	B_Disease
,	O
and	O
bisphosphonate-related	O
pain	B_Disease
should	O
also	O
be	O
considered	O
before	O
ascribing	O
this	O
complaint	O
to	O
osteoporosis	B_Disease
.	O

Cerebrospinal	O
fluid	O
penetration	O
of	O
high-dose	O
daptomycin	B_Chemical
in	O
suspected	O
Staphylococcus	O
aureus	O
meningitis	B_Disease
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
methicillin-sensitive	O
Staphylococcus	O
aureus	O
(	O
MSSA	O
)	O
bacteremia	B_Disease
with	O
suspected	O
MSSA	O
meningitis	B_Disease
treated	O
with	O
high-dose	O
daptomycin	B_Chemical
assessed	O
with	O
concurrent	O
serum	O
and	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
concentrations	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
54-year-old	O
male	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
generalized	O
weakness	B_Disease
and	O
presumed	O
health-care-associated	O
pneumonia	B_Disease
shown	O
on	O
chest	O
radiograph	O
.	O

Treatment	O
was	O
empirically	O
initiated	O
with	O
vancomycin	B_Chemical
,	O
levofloxacin	B_Chemical
,	O
and	O
piperacillin/tazobactam	O
.	O

Blood	O
cultures	O
revealed	O
S.	O
aureus	O
susceptible	O
to	O
oxacillin	B_Chemical
.	O

Empiric	O
antibiotic	O
treatment	O
was	O
narrowed	O
to	O
nafcillin	B_Chemical
on	O
day	O
4	O
.	O

On	O
day	O
8	O
,	O
the	O
patient	O
developed	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
(	O
serum	O
creatinine	B_Chemical
1.9	O
mg/dL	O
,	O
increased	O
from	O
1.2	O
mg/dL	O
the	O
previous	O
day	O
and	O
0.8	O
mg/dL	O
on	O
admission	O
)	O
.	O

The	O
patient	O
's	O
Glasgow	O
Coma	O
Score	O
was	O
3	O
,	O
with	O
normal	O
findings	O
shown	O
on	O
computed	O
tomography	O
scan	O
of	O
the	O
head	O
72	O
hours	O
following	O
an	O
episode	O
of	O
cardiac	B_Disease
arrest	I_Disease
on	O
day	O
10	O
.	O

The	O
patient	O
experienced	O
relapsing	O
MSSA	O
bacteremia	B_Disease
on	O
day	O
9	O
,	O
increasing	O
the	O
suspicion	O
for	O
a	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
infection	B_Disease
.	O

Nafcillin	B_Chemical
was	O
discontinued	O
and	O
daptomycin	B_Chemical
9	O
mg/kg	O
daily	O
was	O
initiated	O
for	O
suspected	O
meningitis	B_Disease
and	O
was	O
continued	O
until	O
the	O
patient	O
's	O
death	O
on	O
day	O
16	O
.	O

Daptomycin	B_Chemical
serum	O
and	O
CSF	O
trough	O
concentrations	O
were	O
11.21	O
ug/mL	O
and	O
0.52	O
ug/mL	O
,	O
respectively	O
,	O
prior	O
to	O
the	O
third	O
dose	O
.	O

Lumbar	O
puncture	O
results	O
were	O
inconclusive	O
and	O
no	O
further	O
blood	O
cultures	O
were	O
positive	O
for	O
MSSA	O
.	O

Creatine	B_Chemical
kinase	O
levels	O
were	O
normal	O
prior	O
to	O
daptomycin	B_Chemical
therapy	O
and	O
were	O
not	O
reassessed	O
.	O

DISCUSSION	O
:	O
Daptomycin	B_Chemical
was	O
initiated	O
in	O
our	O
patient	O
secondary	O
to	O
possible	O
nafcillin-induced	O
acute	O
interstitial	B_Disease
nephritis	I_Disease
and	O
relapsing	O
bacteremia	B_Disease
.	O

At	O
a	O
dose	O
of	O
9	O
mg/kg	O
,	O
resultant	O
penetration	O
of	O
5	O
%	O
was	O
higher	O
than	O
in	O
previous	O
reports	O
,	O
more	O
consistent	O
with	O
inflamed	O
meninges	O
.	O

CONCLUSIONS	O
:	O
High-dose	O
daptomycin	B_Chemical
may	O
be	O
an	O
alternative	O
option	O
for	O
MSSA	O
bacteremia	B_Disease
with	O
or	O
without	O
a	O
CNS	O
source	O
in	O
patients	O
who	O
have	O
failed	O
or	O
can	O
not	O
tolerate	O
standard	O
therapy	O
.	O

Further	O
clinical	O
evaluation	O
in	O
patients	O
with	O
confirmed	O
meningitis	B_Disease
is	O
warranted	O
.	O

The	O
role	O
of	O
nitric	B_Chemical
oxide	I_Chemical
in	O
convulsions	B_Disease
induced	O
by	O
lindane	B_Chemical
in	O
rats	O
.	O

Lindane	B_Chemical
is	O
an	O
organochloride	O
pesticide	O
and	O
scabicide	O
.	O

It	O
evokes	O
convulsions	B_Disease
mainly	O
trough	O
the	O
blockage	O
of	O
GABA(A	O
)	O
receptors	O
.	O

Nitric	B_Chemical
oxide	I_Chemical
(	O
NO	B_Chemical
)	O
,	O
gaseous	O
neurotransmitter	O
,	O
has	O
contradictor	O
role	O
in	O
epileptogenesis	O
due	O
to	O
opposite	O
effects	O
of	O
L-arginine	B_Chemical
,	O
precursor	O
of	O
NO	B_Chemical
syntheses	O
(	O
NOS	O
)	O
,	O
and	O
L-NAME	B_Chemical
(	O
NOS	O
inhibitor	O
)	O
observed	O
in	O
different	O
epilepsy	B_Disease
models	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
NO	B_Chemical
on	O
the	O
behavioral	O
and	O
EEG	O
characteristics	O
of	O
lindane-induced	O
epilepsy	B_Disease
in	O
male	O
Wistar	O
albino	O
rats	O
.	O

The	O
administration	O
of	O
L-arginine	B_Chemical
(	O
600	O
,	O
800	O
and	O
1000	O
mg/kg	O
,	O
i.p	O
.	O
)	O
in	O
dose-dependent	O
manner	O
significantly	O
increased	O
convulsion	B_Disease
incidence	O
and	O
severity	O
and	O
shortened	O
latency	O
time	O
to	O
first	O
convulsion	B_Disease
elicited	O
by	O
lower	O
lindane	B_Chemical
dose	O
(	O
4	O
mg/kg	O
,	O
i.p	O
.	O
)	O
.	O

On	O
the	O
contrary	O
,	O
pretreatment	O
with	O
L-NAME	B_Chemical
(	O
500	O
,	O
700	O
and	O
900	O
mg/kg	O
,	O
i.p	O
.	O
)	O
decreased	O
convulsion	B_Disease
incidence	O
and	O
severity	O
and	O
prolonged	O
latency	O
time	O
to	O
convulsion	B_Disease
following	O
injection	O
with	O
a	O
convulsive	B_Disease
dose	O
of	O
lindane	B_Chemical
(	O
8	O
mg/kg	O
,	O
i.p	O
.	O
)	O
.	O

EEG	O
analyses	O
showed	O
increase	O
of	O
number	O
and	O
duration	O
of	O
ictal	O
periods	O
in	O
EEG	O
of	O
rats	O
receiving	O
l-arginine	B_Chemical
prior	O
to	O
lindane	B_Chemical
and	O
decrease	O
of	O
this	O
number	O
in	O
rats	O
pretreated	O
with	O
L-NAME	B_Chemical
.	O

These	O
results	O
support	O
the	O
conclusion	O
that	O
NO	B_Chemical
plays	O
a	O
role	O
of	O
endogenous	O
convulsant	O
in	O
rat	O
model	O
of	O
lindane	B_Chemical
seizures	B_Disease
.	O

Severe	O
polyneuropathy	B_Disease
and	O
motor	O
loss	O
after	O
intrathecal	O
thiotepa	B_Chemical
combination	O
chemotherapy	O
:	O
description	O
of	O
two	O
cases	O
.	O

Two	O
cases	O
of	O
severe	O
delayed	O
neurologic	B_Disease
toxicity	I_Disease
related	O
to	O
the	O
administration	O
of	O
intrathecal	O
(	O
IT	O
)	O
combination	O
chemotherapy	O
including	O
thiotepa	B_Chemical
(	O
TSPA	B_Chemical
)	O
are	O
presented	O
.	O

Both	O
cases	O
developed	O
axonal	B_Disease
neuropathy	I_Disease
with	O
motor	O
predominance	O
in	O
the	O
lower	O
extremities	O
1	O
and	O
6	O
months	O
after	O
IT	O
chemotherapy	O
was	O
administered	O
.	O

Neurologic	B_Disease
toxicities	I_Disease
have	O
been	O
described	O
with	O
IT-methotrexate	O
,	O
IT-cytosine	O
arabinoside	O
and	O
IT-TSPA	O
.	O

To	O
our	O
knowledge	O
,	O
however	O
,	O
axonal	B_Disease
neuropathy	I_Disease
following	O
administration	O
of	O
these	O
three	O
agents	O
has	O
not	O
been	O
previously	O
described	O
.	O

In	O
spite	O
of	O
the	O
fact	O
that	O
TSPA	B_Chemical
is	O
a	O
useful	O
IT	O
agent	O
,	O
its	O
combination	O
with	O
MTX	B_Chemical
,	O
ara-C	B_Chemical
and	O
radiotherapy	O
could	O
cause	O
severe	O
neurotoxicity	B_Disease
.	O

This	O
unexpected	O
complication	O
indicates	O
the	O
need	O
for	O
further	O
toxicology	O
research	O
on	O
IT-TSPA	O
.	O

Effects	O
of	O
cromakalim	B_Chemical
and	O
pinacidil	B_Chemical
on	O
large	O
epicardial	O
and	O
small	O
coronary	O
arteries	O
in	O
conscious	O
dogs	O
.	O

The	O
effects	O
of	O
i.v	O
.	O

bolus	O
administration	O
of	O
cromakalim	B_Chemical
(	O
1	O
-	O
10	O
micrograms/kg	O
)	O
and	O
pinacidil	B_Chemical
(	O
3	O
-	O
100	O
micrograms/kg	O
)	O
on	O
large	O
(	O
circumflex	O
artery	O
)	O
and	O
small	O
coronary	O
arteries	O
and	O
on	O
systemic	O
hemodynamics	O
were	O
investigated	O
in	O
chronically	O
instrumented	O
conscious	O
dogs	O
and	O
compared	O
to	O
those	O
of	O
nitroglycerin	B_Chemical
(	O
0.03	O
-	O
10	O
micrograms/kg	O
)	O
.	O

Nitroglycerin	B_Chemical
,	O
up	O
to	O
0.3	O
micrograms/kg	O
,	O
selectively	O
increased	O
circumflex	O
artery	O
diameter	O
(	O
CxAD	O
)	O
without	O
simultaneously	O
affecting	O
any	O
other	O
cardiac	O
or	O
systemic	O
hemodynamic	O
parameter	O
.	O

In	O
contrast	O
,	O
cromakalim	B_Chemical
and	O
pinacidil	B_Chemical
at	O
all	O
doses	O
and	O
nitroglycerin	B_Chemical
at	O
doses	O
higher	O
than	O
0.3	O
micrograms/kg	O
simultaneously	O
and	O
dose-dependently	O
increased	O
CxAD	O
,	O
coronary	O
blood	O
flow	O
and	O
heart	O
rate	O
and	O
decreased	O
coronary	O
vascular	O
resistance	O
and	O
aortic	O
pressure	O
.	O

Cromakalim	B_Chemical
was	O
approximately	O
8-	O
to	O
9.5-fold	O
more	O
potent	O
than	O
pinacidil	B_Chemical
in	O
increasing	O
CxAD	O
.	O

Vasodilation	O
of	O
large	O
and	O
small	O
coronary	O
vessels	O
and	O
hypotension	B_Disease
induced	O
by	O
cromakalim	B_Chemical
and	O
pinacidil	B_Chemical
were	O
not	O
affected	O
by	O
prior	O
combined	O
beta	B_Chemical
adrenergic	I_Chemical
and	I_Chemical
muscarinic	B_Chemical
receptors	I_Chemical
blockade	I_Chemical
but	O
drug-induced	O
tachycardia	B_Disease
was	O
abolished	O
.	O

When	O
circumflex	O
artery	O
blood	O
flow	O
was	O
maintained	O
constant	O
,	O
the	O
increases	O
in	O
CxAD	O
induced	O
by	O
cromakalim	B_Chemical
(	O
10	O
micrograms/kg	O
)	O
,	O
pinacidil	B_Chemical
(	O
30	O
micrograms/kg	O
)	O
and	O
nitroglycerin	B_Chemical
(	O
10	O
micrograms/kg	O
)	O
were	O
reduced	O
by	O
68	O
+	O
/-	O
7	O
,	O
54	O
+	O
/-	O
9	O
and	O
1	O
+	O
/-	O
1	O
%	O
,	O
respectively	O
.	O

Thus	O
,	O
whereas	O
nitroglycerin	B_Chemical
preferentially	O
and	O
flow-independently	O
dilates	O
large	O
coronary	O
arteries	O
,	O
cromakalim	B_Chemical
and	O
pinacidil	B_Chemical
dilate	O
both	O
large	O
and	O
small	O
coronary	O
arteries	O
and	O
this	O
effect	O
is	O
not	O
dependent	O
upon	O
the	O
simultaneous	O
beta	O
adrenoceptors-mediated	O
rise	O
in	O
myocardial	O
metabolic	O
demand	O
.	O

Finally	O
,	O
two	O
mechanisms	O
at	O
least	O
,	O
direct	O
vasodilation	O
and	O
flow	O
dependency	O
,	O
are	O
involved	O
in	O
the	O
cromakalim-	O
and	O
pinacidil-induced	O
increase	O
in	O
CxAD	O
.	O

Mefenamic	O
acid-induced	O
neutropenia	B_Disease
and	O
renal	B_Disease
failure	I_Disease
in	O
elderly	O
females	O
with	O
hypothyroidism	B_Disease
.	O

We	O
report	O
mefenamic	O
acid-induced	O
non-oliguric	O
renal	B_Disease
failure	I_Disease
and	O
severe	O
neutropenia	B_Disease
occurring	O
simultaneously	O
in	O
two	O
elderly	O
females	O
.	O

The	O
neutropenia	B_Disease
was	O
due	O
to	O
maturation	O
arrest	O
of	O
the	O
myeloid	O
series	O
in	O
one	O
patient	O
.	O

Both	O
patients	O
were	O
also	O
hypothyroid	B_Disease
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
this	O
was	O
a	O
predisposing	O
factor	O
to	O
the	O
development	O
of	O
these	O
adverse	O
reactions	O
.	O

However	O
,	O
it	O
would	O
seem	O
prudent	O
not	O
to	O
use	O
mefenamic	B_Chemical
acid	I_Chemical
in	O
hypothyroid	B_Disease
patients	O
until	O
the	O
hypothyroidism	B_Disease
has	O
been	O
corrected	O
.	O

Etiology	O
of	O
hypercalcemia	B_Disease
in	O
hemodialysis	O
patients	O
on	O
calcium	B_Chemical
carbonate	I_Chemical
therapy	O
.	O

Fourteen	O
of	O
39	O
dialysis	O
patients	O
(	O
36	O
%	O
)	O
became	O
hypercalcemic	B_Disease
after	O
switching	O
to	O
calcium	B_Chemical
carbonate	I_Chemical
as	O
their	O
principal	O
phosphate	B_Chemical
binder	O
.	O

In	O
order	O
to	O
identify	O
risk	O
factors	O
associated	O
with	O
the	O
development	O
of	O
hypercalcemia	B_Disease
,	O
indirect	O
parameters	O
of	O
intestinal	O
calcium	B_Chemical
reabsorption	O
and	O
bone	O
turnover	O
rate	O
in	O
these	O
14	O
patients	O
were	O
compared	O
with	O
results	O
in	O
14	O
eucalcemic	O
patients	O
matched	O
for	O
age	O
,	O
sex	O
,	O
length	O
of	O
time	O
on	O
dialysis	O
,	O
and	O
etiology	O
of	O
renal	B_Disease
disease	I_Disease
.	O

In	O
addition	O
to	O
experiencing	O
hypercalcemic	B_Disease
episodes	O
with	O
peak	O
calcium	B_Chemical
values	O
of	O
2.7	O
to	O
3.8	O
mmol/L	O
(	O
10.7	O
to	O
15.0	O
mg/dL	O
)	O
,	O
patients	O
in	O
the	O
hypercalcemic	B_Disease
group	O
exhibited	O
a	O
significant	O
increase	O
in	O
the	O
mean	O
calcium	B_Chemical
concentration	O
obtained	O
during	O
6	O
months	O
before	O
the	O
switch	O
,	O
compared	O
with	O
the	O
mean	O
value	O
obtained	O
during	O
the	O
7	O
months	O
of	O
observation	O
after	O
the	O
switch	O
(	O
2.4	O
+	O
/-	O
0.03	O
to	O
2.5	O
+	O
/-	O
0.03	O
mmol/L	O
[	O
9.7	O
+	O
/-	O
0.2	O
to	O
10.2	O
+	O
/-	O
0.1	O
mg/dL	O
]	O
,	O
P	O
=	O
0.006	O
)	O
.	O

In	O
contrast	O
,	O
eucalcemic	O
patients	O
exhibited	O
no	O
change	O
in	O
mean	O
calcium	B_Chemical
values	O
over	O
the	O
same	O
time	O
period	O
(	O
2.3	O
+	O
/-	O
0.05	O
to	O
2.3	O
+	O
/-	O
0.05	O
mmol/L	O
[	O
9.2	O
+	O
/-	O
0.2	O
to	O
9.2	O
+	O
/-	O
0.2	O
mg/dL	O
]	O
)	O
.	O

CaCO3	B_Chemical
dosage	O
,	O
calculated	O
dietary	O
calcium	B_Chemical
intake	O
,	O
and	O
circulating	O
levels	O
of	O
vitamin	B_Chemical
D	I_Chemical
metabolites	O
were	O
similar	O
in	O
both	O
groups	O
.	O

Physical	O
activity	O
index	O
and	O
predialysis	O
serum	O
bicarbonate	B_Chemical
levels	O
also	O
were	O
similar	O
in	O
both	O
groups	O
.	O

However	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
parameters	O
reflecting	O
bone	O
turnover	O
rates	O
between	O
groups.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Late-onset	O
scleroderma	B_Disease
renal	I_Disease
crisis	I_Disease
induced	O
by	O
tacrolimus	B_Chemical
and	O
prednisolone	B_Chemical
:	O
a	O
case	O
report	O
.	O

Scleroderma	B_Disease
renal	I_Disease
crisis	I_Disease
(	O
SRC	B_Disease
)	O
is	O
a	O
rare	O
complication	O
of	O
systemic	B_Disease
sclerosis	I_Disease
(	O
SSc	B_Disease
)	O
but	O
can	O
be	O
severe	O
enough	O
to	O
require	O
temporary	O
or	O
permanent	O
renal	O
replacement	O
therapy	O
.	O

Moderate	O
to	O
high	O
dose	O
corticosteroid	B_Chemical
use	O
is	O
recognized	O
as	O
a	O
major	O
risk	O
factor	O
for	O
SRC	B_Disease
.	O

Furthermore	O
,	O
there	O
have	O
been	O
reports	O
of	O
thrombotic	B_Disease
microangiopathy	I_Disease
precipitated	O
by	O
cyclosporine	B_Chemical
in	O
patients	O
with	O
SSc	B_Disease
.	O

In	O
this	O
article	O
,	O
we	O
report	O
a	O
patient	O
with	O
SRC	B_Disease
induced	O
by	O
tacrolimus	B_Chemical
and	O
corticosteroids	B_Chemical
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
call	O
attention	O
to	O
the	O
risk	O
of	O
tacrolimus	B_Chemical
use	O
in	O
patients	O
with	O
SSc	B_Disease
.	O

Methyldopa-induced	O
hemolytic	B_Disease
anemia	I_Disease
in	O
a	O
15	O
year	O
old	O
presenting	O
as	O
near-syncope	O
.	O

Methyldopa	B_Chemical
is	O
an	O
antihypertensive	O
medication	O
which	O
is	O
available	O
generically	O
and	O
under	O
the	O
trade	O
name	O
Aldomet	B_Chemical
that	O
is	O
widely	O
prescribed	O
in	O
the	O
adult	O
population	O
and	O
infrequently	O
used	O
in	O
children	O
.	O

Methyldopa	B_Chemical
causes	O
an	O
autoimmune	B_Disease
hemolytic	I_Disease
anemia	I_Disease
in	O
a	O
small	O
percentage	O
of	O
patients	O
who	O
take	O
the	O
drug	O
.	O

We	O
report	O
a	O
case	O
of	O
methyldopa-induced	O
hemolytic	B_Disease
anemia	I_Disease
in	O
a	O
15-year-old	O
boy	O
who	O
presented	O
to	O
the	O
emergency	B_Disease
department	I_Disease
with	O
near-syncope	O
.	O

The	O
boy	O
had	O
been	O
treated	O
with	O
intravenous	O
methyldopa	B_Chemical
during	O
a	O
trauma	B_Disease
admission	O
seven	O
weeks	O
prior	O
to	O
presentation	O
.	O

Evaluation	O
revealed	O
a	O
hemoglobin	O
of	O
three	O
grams	O
,	O
3	O
+	O
Coombs	O
'	O
test	O
with	O
polyspecific	O
anti-human	O
globulin	O
and	O
monospecific	O
IgG	O
reagents	O
,	O
and	O
a	O
warm	O
reacting	O
autoantibody	O
.	O

Transfusion	O
and	O
corticosteroid	B_Chemical
therapy	O
resulted	O
in	O
a	O
complete	O
recovery	O
of	O
the	O
patient	O
.	O

Emergency	O
physicians	O
treating	O
children	O
must	O
be	O
aware	O
of	O
this	O
syndrome	O
in	O
order	O
to	O
diagnose	O
and	O
treat	O
it	O
correctly	O
.	O

A	O
brief	O
review	O
of	O
autoimmune	O
and	O
drug-induced	O
hemolytic	B_Disease
anemias	I_Disease
is	O
provided	O
.	O

The	O
risk	O
and	O
associated	O
factors	O
of	O
methamphetamine	B_Chemical
psychosis	B_Disease
in	O
methamphetamine-dependent	O
patients	O
in	O
Malaysia	O
.	O

OBJECTIVE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
risk	O
of	O
lifetime	O
and	O
current	O
methamphetamine-induced	O
psychosis	B_Disease
in	O
patients	O
with	O
methamphetamine	B_Chemical
dependence	O
.	O

The	O
association	O
between	O
psychiatric	O
co-morbidity	O
and	O
methamphetamine-induced	O
psychosis	B_Disease
was	O
also	O
studied	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
cross-sectional	O
study	O
conducted	O
concurrently	O
at	O
a	O
teaching	O
hospital	O
and	O
a	O
drug	O
rehabilitation	O
center	O
in	O
Malaysia	O
.	O

Patients	O
with	O
the	O
diagnosis	O
of	O
methamphetamine	B_Chemical
based	O
on	O
DSM-IV	O
were	O
interviewed	O
using	O
the	O
Mini	O
International	O
Neuropsychiatric	O
Interview	O
(	O
M.I.N.I.	O
)	O
for	O
methamphetamine-induced	O
psychosis	B_Disease
and	O
other	O
Axis	O
I	O
psychiatric	B_Disease
disorders	I_Disease
.	O

The	O
information	O
on	O
sociodemographic	O
background	O
and	O
drug	O
use	O
history	O
was	O
obtained	O
from	O
interview	O
or	O
medical	O
records	O
.	O

RESULTS	O
:	O
Of	O
292	O
subjects	O
,	O
47.9	O
%	O
of	O
the	O
subjects	O
had	O
a	O
past	O
history	O
of	O
psychotic	B_Disease
symptoms	I_Disease
and	O
13.0	O
%	O
of	O
the	O
patients	O
were	O
having	O
current	O
psychotic	B_Disease
symptoms	I_Disease
.	O

Co-morbid	O
major	O
depressive	B_Disease
disorder	I_Disease
(	O
OR=7.18	O
,	O
95	O
CI=2.612	O
-	O
19.708	O
)	O
,	O
bipolar	B_Disease
disorder	I_Disease
(	O
OR=13.807	O
,	O
95	O
CI=5.194	O
-	O
36.706	O
)	O
,	O
antisocial	B_Disease
personality	I_Disease
disorder	I_Disease
(	O
OR=12.619	O
,	O
95	O
CI=6.702	O
-	O
23.759	O
)	O
and	O
heavy	O
methamphetamine	B_Chemical
uses	O
were	O
significantly	O
associated	O
with	O
lifetime	O
methamphetamine-induced	O
psychosis	B_Disease
after	O
adjusted	O
for	O
other	O
factors	O
.	O

Major	B_Disease
depressive	I_Disease
disorder	I_Disease
(	O
OR=2.870	O
,	O
CI=1.154	O
-	O
7.142	O
)	O
and	O
antisocial	B_Disease
personality	I_Disease
disorder	I_Disease
(	O
OR=3.299	O
,	O
95	O
CI=1.375	O
-	O
7.914	O
)	O
were	O
the	O
only	O
factors	O
associated	O
with	O
current	O
psychosis	B_Disease
.	O

CONCLUSION	O
:	O
There	O
was	O
a	O
high	O
risk	O
of	O
psychosis	B_Disease
in	O
patients	O
with	O
methamphetamine	B_Chemical
dependence	O
.	O

It	O
was	O
associated	O
with	O
co-morbid	O
affective	B_Disease
disorder	I_Disease
,	O
antisocial	B_Disease
personality	I_Disease
,	O
and	O
heavy	O
methamphetamine	B_Chemical
use	O
.	O

It	O
is	O
recommended	O
that	O
all	O
cases	O
of	O
methamphetamine	B_Chemical
dependence	O
should	O
be	O
screened	O
for	O
psychotic	B_Disease
symptoms	I_Disease
.	O

Cerebellar	O
sensory	O
processing	O
alterations	O
impact	O
motor	O
cortical	O
plasticity	O
in	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
:	O
clues	O
from	O
dyskinetic	B_Disease
patients	O
.	O

The	O
plasticity	O
of	O
primary	O
motor	O
cortex	O
(	O
M1	O
)	O
in	O
patients	O
with	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
(	O
PD	B_Disease
)	O
and	O
levodopa-induced	O
dyskinesias	B_Disease
(	O
LIDs	B_Disease
)	O
is	O
severely	O
impaired	O
.	O

We	O
recently	O
reported	O
in	O
young	O
healthy	O
subjects	O
that	O
inhibitory	O
cerebellar	O
stimulation	O
enhanced	O
the	O
sensorimotor	O
plasticity	O
of	O
M1	O
that	O
was	O
induced	O
by	O
paired	O
associative	O
stimulation	O
(	O
PAS	O
)	O
.	O

This	O
study	O
demonstrates	O
that	O
the	O
deficient	O
sensorimotor	O
M1	O
plasticity	O
in	O
16	O
patients	O
with	O
LIDs	B_Disease
could	O
be	O
reinstated	O
by	O
a	O
single	O
session	O
of	O
real	O
inhibitory	O
cerebellar	O
stimulation	O
but	O
not	O
sham	O
stimulation	O
.	O

This	O
was	O
evident	O
only	O
when	O
a	O
sensory	O
component	O
was	O
involved	O
in	O
the	O
induction	O
of	O
plasticity	O
,	O
indicating	O
that	O
cerebellar	O
sensory	O
processing	O
function	O
is	O
involved	O
in	O
the	O
resurgence	O
of	O
M1	O
plasticity	O
.	O

The	O
benefit	O
of	O
inhibitory	O
cerebellar	O
stimulation	O
on	O
LIDs	B_Disease
is	O
known	O
.	O

To	O
explore	O
whether	O
this	O
benefit	O
is	O
linked	O
to	O
the	O
restoration	O
of	O
sensorimotor	O
plasticity	O
of	O
M1	O
,	O
we	O
conducted	O
an	O
additional	O
study	O
looking	O
at	O
changes	O
in	O
LIDs	B_Disease
and	O
PAS-induced	O
plasticity	O
after	O
10	O
sessions	O
of	O
either	O
bilateral	O
,	O
real	O
inhibitory	O
cerebellar	O
stimulation	O
or	O
sham	O
stimulation	O
.	O

Only	O
real	O
and	O
not	O
sham	O
stimulation	O
had	O
an	O
antidyskinetic	O
effect	O
and	O
it	O
was	O
paralleled	O
by	O
a	O
resurgence	O
in	O
the	O
sensorimotor	O
plasticity	O
of	O
M1	O
.	O

These	O
results	O
suggest	O
that	O
alterations	O
in	O
cerebellar	O
sensory	O
processing	O
function	O
,	O
occurring	O
secondary	O
to	O
abnormal	O
basal	O
ganglia	O
signals	O
reaching	O
it	O
,	O
may	O
be	O
an	O
important	O
element	O
contributing	O
to	O
the	O
maladaptive	O
sensorimotor	O
plasticity	O
of	O
M1	O
and	O
the	O
emergence	O
of	O
abnormal	B_Disease
involuntary	I_Disease
movements	I_Disease
.	O

The	O
long-term	O
safety	O
of	O
danazol	B_Chemical
in	O
women	O
with	O
hereditary	B_Disease
angioedema	I_Disease
.	O

Although	O
the	O
short-term	O
safety	O
(	O
less	O
than	O
or	O
equal	O
to	O
6	O
months	O
)	O
of	O
danazol	B_Chemical
has	O
been	O
established	O
in	O
a	O
variety	O
of	O
settings	O
,	O
no	O
information	O
exists	O
as	O
to	O
its	O
long-term	O
safety	O
.	O

We	O
therefore	O
investigated	O
the	O
long-term	O
safety	O
of	O
danazol	B_Chemical
by	O
performing	O
a	O
retrospective	O
chart	O
review	O
of	O
60	O
female	O
patients	O
with	O
hereditary	B_Disease
angioedema	I_Disease
treated	O
with	O
danazol	B_Chemical
for	O
a	O
continuous	O
period	O
of	O
6	O
months	O
or	O
longer	O
.	O

The	O
mean	O
age	O
of	O
the	O
patients	O
was	O
35.2	O
years	O
and	O
the	O
mean	O
duration	O
of	O
therapy	O
was	O
59.7	O
months	O
.	O

Virtually	O
all	O
patients	O
experienced	O
one	O
or	O
more	O
adverse	O
reactions	O
.	O

Menstrual	B_Disease
abnormalities	I_Disease
(	O
79	O
%	O
)	O
,	O
weight	B_Disease
gain	I_Disease
(	O
60	O
%	O
)	O
,	O
muscle	O
cramps/myalgias	O
(	O
40	O
%	O
)	O
,	O
and	O
transaminase	O
elevations	O
(	O
40	O
%	O
)	O
were	O
the	O
most	O
common	O
adverse	O
reactions	O
.	O

The	O
drug	O
was	O
discontinued	O
due	O
to	O
adverse	O
reactions	O
in	O
8	O
patients	O
.	O

No	O
patient	O
has	O
died	O
or	O
suffered	O
any	O
apparent	O
long-term	O
sequelae	O
that	O
were	O
directly	O
attributable	O
to	O
the	O
drug	O
.	O

We	O
conclude	O
that	O
,	O
despite	O
a	O
relatively	O
high	O
incidence	O
of	O
adverse	O
reactions	O
,	O
danazol	B_Chemical
has	O
proven	O
to	O
be	O
remarkably	O
safe	O
over	O
the	O
long-term	O
in	O
this	O
group	O
of	O
patients	O
.	O

The	O
function	O
of	O
P2X3	O
receptor	O
and	O
NK1	O
receptor	O
antagonists	O
on	O
cyclophosphamide-induced	O
cystitis	B_Disease
in	O
rats	O
.	O

PURPOSE	O
:	O
The	O
purpose	O
of	O
the	O
study	O
is	O
to	O
explore	O
the	O
function	O
of	O
P2X3	O
and	O
NK1	O
receptors	O
antagonists	O
on	O
cyclophosphamide	B_Chemical
(CYP)-induced	O
cystitis	B_Disease
in	O
rats	O
.	O

METHODS	O
:	O
Sixty	O
female	O
Sprague-Dawley	O
(	O
SD	O
)	O
rats	O
were	O
randomly	O
divided	O
into	O
three	O
groups	O
.	O

The	O
rats	O
in	O
the	O
control	O
group	O
were	O
intraperitoneally	O
(	O
i.p	O
.	O
)	O
injected	O
with	O
0.9	O
%	O
saline	O
(	O
4	O
ml/kg	O
)	O
;	O
the	O
rats	O
in	O
the	O
model	O
group	O
were	O
i.p	O
.	O
injected	O
with	O
CYP	B_Chemical
(	O
150	O
mg/kg	O
)	O
;	O
and	O
the	O
rats	O
in	O
the	O
intervention	O
group	O
were	O
i.p	O
.	O
injected	O
with	O
CYP	B_Chemical
with	O
subsequently	O
perfusion	O
of	O
bladder	O
with	O
P2X3	O
and	O
NK1	O
receptors	O
'	O
antagonists	O
,	O
Suramin	B_Chemical
and	O
GR	B_Chemical
82334	I_Chemical
.	O

Spontaneous	O
pain	B_Disease
behaviors	O
following	O
the	O
administration	O
of	O
CYP	B_Chemical
were	O
observed	O
.	O

Urodynamic	O
parameters	O
,	O
bladder	O
pressure-volume	O
curve	O
,	O
maximum	O
voiding	O
pressure	O
(	O
MVP	O
)	O
,	O
and	O
maximum	O
cystometric	O
capacity	O
(	O
MCC	O
)	O
,	O
were	O
recorded	O
.	O

Pathological	O
changes	O
in	O
bladder	O
tissue	O
were	O
observed	O
.	O

Immunofluorescence	O
was	O
used	O
to	O
detect	O
the	O
expression	O
of	O
P2X3	O
and	O
NK1	O
receptors	O
in	O
bladder	O
.	O

RESULTS	O
:	O
Cyclophosphamide	B_Chemical
treatment	O
increased	O
the	O
spontaneous	O
pain	B_Disease
behaviors	O
scores	O
.	O

The	O
incidence	O
of	O
bladder	O
instability	O
during	O
urine	O
storage	O
period	O
of	O
model	O
group	O
was	O
significantly	O
higher	O
than	O
intervention	O
group	O
(	O
X(2	O
)	O
=	O
7.619	O
,	O
P	O
=	O
0.007	O
)	O
and	O
control	O
group	O
(	O
X(2	O
)	O
=	O
13.755	O
,	O
P	O
=	O
0.000	O
)	O
.	O

MCC	O
in	O
the	O
model	O
group	O
was	O
lower	O
than	O
the	O
control	O
and	O
intervention	O
groups	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Histological	O
changes	O
evident	O
in	O
model	O
and	O
intervention	O
groups	O
rats	O
'	O
bladder	O
included	O
edema	B_Disease
,	O
vasodilation	O
,	O
and	O
infiltration	O
of	O
inflammatory	O
cells	O
.	O

In	O
model	O
group	O
,	O
the	O
expression	O
of	O
P2X3	O
receptor	O
increased	O
in	O
urothelium	O
and	O
suburothelium	O
,	O
and	O
NK1	O
receptor	O
increased	O
in	O
suburothelium	O
,	O
while	O
the	O
expression	O
of	O
them	O
in	O
intervention	O
group	O
was	O
lower	O
.	O

CONCLUSIONS	O
:	O
In	O
CYP-induced	O
cystitis	B_Disease
,	O
the	O
expression	O
of	O
P2X3	O
and	O
NK1	O
receptors	O
increased	O
in	O
urothelium	O
and/or	O
suburothelium	O
.	O

Perfusion	O
of	O
bladder	O
with	O
P2X3	O
and	O
NK1	O
receptors	O
antagonists	O
ameliorated	O
the	O
bladder	O
function	O
.	O

Patient	O
tolerance	O
study	O
of	O
topical	O
chlorhexidine	B_Chemical
diphosphanilate	I_Chemical
:	O
a	O
new	O
topical	O
agent	O
for	O
burns	B_Disease
.	O

Effective	O
topical	O
antimicrobial	O
agents	O
decrease	O
infection	B_Disease
and	O
mortality	O
in	O
burn	B_Disease
patients	O
.	O

Chlorhexidine	B_Chemical
phosphanilate	I_Chemical
(	O
CHP	B_Chemical
)	O
,	O
a	O
new	O
broad-spectrum	O
antimicrobial	O
agent	O
,	O
has	O
been	O
evaluated	O
as	O
a	O
topical	O
burn	B_Disease
wound	O
dressing	O
in	O
cream	O
form	O
,	O
but	O
preliminary	O
clinical	O
trials	O
reported	O
that	O
it	O
was	O
painful	O
upon	O
application	O
.	O

This	O
study	O
compared	O
various	O
concentrations	O
of	O
CHP	B_Chemical
to	O
determine	O
if	O
a	O
tolerable	O
concentration	O
could	O
be	O
identified	O
with	O
retention	O
of	O
antimicrobial	O
efficacy	O
.	O

Twenty-nine	O
burn	B_Disease
patients	O
,	O
each	O
with	O
two	O
similar	O
burns	B_Disease
which	O
could	O
be	O
separately	O
treated	O
,	O
were	O
given	O
pairs	O
of	O
treatments	O
at	O
successive	O
12-h	O
intervals	O
over	O
a	O
3-day	O
period	O
.	O

One	O
burn	B_Disease
site	O
was	O
treated	O
with	O
each	O
of	O
four	O
different	O
CHP	B_Chemical
concentrations	O
,	O
from	O
0.25	O
per	O
cent	O
to	O
2	O
per	O
cent	O
,	O
their	O
vehicle	O
,	O
and	O
1	O
per	O
cent	O
silver	B_Chemical
sulphadiazine	I_Chemical
(	O
AgSD	B_Chemical
)	O
cream	O
,	O
an	O
antimicrobial	O
agent	O
frequently	O
used	O
for	O
topical	O
treatment	O
of	O
burn	B_Disease
wounds	O
.	O

The	O
other	O
site	O
was	O
always	O
treated	O
with	O
AgSD	B_Chemical
cream	O
.	O

There	O
was	O
a	O
direct	O
relationship	O
between	O
CHP	B_Chemical
concentration	O
and	O
patients	O
'	O
ratings	O
of	O
pain	B_Disease
on	O
an	O
analogue	O
scale	O
.	O

The	O
0.25	O
per	O
cent	O
CHP	B_Chemical
cream	O
was	O
closest	O
to	O
AgSD	B_Chemical
in	O
pain	B_Disease
tolerance	O
;	O
however	O
,	O
none	O
of	O
the	O
treatments	O
differed	O
statistically	O
from	O
AgSD	B_Chemical
or	O
from	O
each	O
other	O
.	O

In	O
addition	O
,	O
ease	O
of	O
application	O
of	O
CHP	B_Chemical
creams	O
was	O
less	O
satisfactory	O
than	O
that	O
of	O
AgSD	B_Chemical
.	O

It	O
was	O
concluded	O
that	O
formulations	O
at	O
or	O
below	O
0.5	O
per	O
cent	O
CHP	B_Chemical
may	O
prove	O
acceptable	O
for	O
wound	O
care	O
,	O
but	O
the	O
vehicle	O
system	O
needs	O
pharmaceutical	O
improvement	O
to	O
render	O
it	O
more	O
tolerable	O
and	O
easier	O
to	O
use	O
.	O

Acute	O
hepatitis	B_Disease
associated	O
with	O
clopidogrel	B_Chemical
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

Drug-induced	O
hepatotoxicity	B_Disease
is	O
a	O
common	O
cause	O
of	O
acute	O
hepatitis	B_Disease
,	O
and	O
the	O
recognition	O
of	O
the	O
responsible	O
drug	O
may	O
be	O
difficult	O
.	O

We	O
describe	O
a	O
case	O
of	O
clopidogrel-related	O
acute	O
hepatitis	B_Disease
.	O

The	O
diagnosis	O
is	O
strongly	O
suggested	O
by	O
an	O
accurate	O
medical	O
history	O
and	O
liver	O
biopsy	O
.	O

Reports	O
about	O
cases	O
of	O
hepatotoxicity	B_Disease
due	O
to	O
clopidogrel	B_Chemical
are	O
increasing	O
in	O
the	O
last	O
few	O
years	O
,	O
after	O
the	O
increased	O
use	O
of	O
this	O
drug	O
.	O

In	O
conclusion	O
,	O
we	O
believe	O
that	O
physicians	O
should	O
carefully	O
consider	O
the	O
risk	O
of	O
drug-induced	O
hepatic	B_Disease
injury	I_Disease
when	O
clopidogrel	B_Chemical
is	O
prescribed	O
.	O

Bortezomib	B_Chemical
and	O
dexamethasone	B_Chemical
as	O
salvage	O
therapy	O
in	O
patients	O
with	O
relapsed/refractory	O
multiple	B_Disease
myeloma	I_Disease
:	O
analysis	O
of	O
long-term	O
clinical	O
outcomes	O
.	O

Bortezomib	B_Chemical
(bort)-dexamethasone	O
(	O
dex	B_Chemical
)	O
is	O
an	O
effective	O
therapy	O
for	O
relapsed/refractory	O
(	O
R/R	O
)	O
multiple	B_Disease
myeloma	I_Disease
(	O
MM	B_Disease
)	O
.	O

This	O
retrospective	O
study	O
investigated	O
the	O
combination	O
of	O
bort	B_Chemical
(	O
1.3	O
mg/m(2	O
)	O
on	O
days	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
11	O
every	O
3	O
weeks	O
)	O
and	O
dex	B_Chemical
(	O
20	O
mg	O
on	O
the	O
day	O
of	O
and	O
the	O
day	O
after	O
bort	B_Chemical
)	O
as	O
salvage	O
treatment	O
in	O
85	O
patients	O
with	O
R/R	O
MM	B_Disease
after	O
prior	O
autologous	O
stem	O
cell	O
transplantation	O
or	O
conventional	O
chemotherapy	O
.	O

The	O
median	O
number	O
of	O
prior	O
lines	O
of	O
therapy	O
was	O
2	O
.	O

Eighty-seven	O
percent	O
of	O
the	O
patients	O
had	O
received	O
immunomodulatory	O
drugs	O
included	O
in	O
some	O
line	O
of	O
therapy	O
before	O
bort-dex	O
.	O

The	O
median	O
number	O
of	O
bort-dex	O
cycles	O
was	O
6	O
,	O
up	O
to	O
a	O
maximum	O
of	O
12	O
cycles	O
.	O

On	O
an	O
intention-to-treat	O
basis	O
,	O
55	O
%	O
of	O
the	O
patients	O
achieved	O
at	O
least	O
partial	O
response	O
,	O
including	O
19	O
%	O
CR	O
and	O
35	O
%	O
achieved	O
at	O
least	O
very	O
good	O
partial	O
response	O
.	O

Median	O
durations	O
of	O
response	O
,	O
time	O
to	O
next	O
therapy	O
and	O
treatment-free	O
interval	O
were	O
8	O
,	O
11.2	O
,	O
and	O
5.1	O
months	O
,	O
respectively	O
.	O

The	O
most	O
relevant	O
adverse	O
event	O
was	O
peripheral	B_Disease
neuropathy	I_Disease
,	O
which	O
occurred	O
in	O
78	O
%	O
of	O
the	O
patients	O
(	O
grade	O
II	O
,	O
38	O
%	O
;	O
grade	O
III	O
,	O
21	O
%	O
)	O
and	O
led	O
to	O
treatment	O
discontinuation	O
in	O
6	O
%	O
.	O

With	O
a	O
median	O
follow	O
up	O
of	O
22	O
months	O
,	O
median	O
time	O
to	O
progression	O
,	O
progression-free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
were	O
8.9	O
,	O
8.7	O
,	O
and	O
22	O
months	O
,	O
respectively	O
.	O

Prolonged	O
PFS	O
and	O
OS	O
were	O
observed	O
in	O
patients	O
achieving	O
CR	O
and	O
receiving	O
bort-dex	O
a	O
single	O
line	O
of	O
prior	O
therapy	O
.	O

Bort-dex	O
was	O
an	O
effective	O
salvage	O
treatment	O
for	O
MM	B_Disease
patients	O
,	O
particularly	O
for	O
those	O
in	O
first	O
relapse	O
.	O

Pubertal	O
exposure	O
to	O
Bisphenol	B_Chemical
A	I_Chemical
increases	O
anxiety-like	O
behavior	O
and	O
decreases	O
acetylcholinesterase	O
activity	O
of	O
hippocampus	O
in	O
adult	O
male	O
mice	O
.	O

The	O
negative	O
effects	O
of	O
Bisphenol	B_Chemical
A	I_Chemical
(	O
BPA	B_Chemical
)	O
on	O
neurodevelopment	O
and	O
behaviors	O
have	O
been	O
well	O
established	O
.	O

Acetylcholinesterase	O
(	O
AChE	O
)	O
is	O
a	O
regulatory	O
enzyme	O
which	O
is	O
involved	O
in	O
anxiety-like	O
behavior	O
.	O

This	O
study	O
investigated	O
behavioral	O
phenotypes	O
and	O
AChE	O
activity	O
in	O
male	O
mice	O
following	O
BPA	B_Chemical
exposure	O
during	O
puberty	O
.	O

On	O
postnatal	O
day	O
(	O
PND	O
)	O
35	O
,	O
male	O
mice	O
were	O
exposed	O
to	O
50	O
mg	O
BPA/kg	O
diet	O
per	O
day	O
for	O
a	O
period	O
of	O
35	O
days	O
.	O

On	O
PND71	O
,	O
a	O
behavioral	O
assay	O
was	O
performed	O
using	O
the	O
elevated	O
plus	O
maze	O
(	O
EPM	O
)	O
and	O
the	O
light/dark	O
test	O
.	O

In	O
addition	O
,	O
AChE	O
activity	O
was	O
measured	O
in	O
the	O
prefrontal	O
cortex	O
,	O
hypothalamus	O
,	O
cerebellum	O
and	O
hippocampus	O
.	O

Results	O
from	O
our	O
behavioral	O
phenotyping	O
indicated	O
that	O
anxiety-like	O
behavior	O
was	O
increased	O
in	O
mice	O
exposed	O
to	O
BPA	B_Chemical
.	O

AChE	O
activity	O
was	O
significantly	O
decreased	O
in	O
the	O
hippocampus	O
of	O
mice	O
with	O
BPA	B_Chemical
compared	O
to	O
control	O
mice	O
,	O
whereas	O
no	O
difference	O
was	O
found	O
in	O
the	O
prefrontal	O
cortex	O
,	O
hypothalamus	O
and	O
cerebellum	O
.	O

Our	O
findings	O
showed	O
that	O
pubertal	O
BPA	B_Chemical
exposure	O
increased	O
anxiety-like	O
behavior	O
,	O
which	O
may	O
be	O
associated	O
with	O
decreased	O
AChE	O
activity	O
of	O
the	O
hippocampus	O
in	O
adult	O
male	O
mice	O
.	O

Further	O
studies	O
are	O
necessary	O
to	O
investigate	O
the	O
cholinergic	O
signaling	O
of	O
the	O
hippocampus	O
in	O
PBE	O
induced	O
anxiety-like	O
behaviors	O
.	O

Biochemical	O
effects	O
of	O
Solidago	O
virgaurea	O
extract	O
on	O
experimental	O
cardiotoxicity	O
.	O

Cardiovascular	B_Disease
diseases	I_Disease
(	O
CVDs	B_Disease
)	O
are	O
the	O
major	O
health	O
problem	O
of	O
advanced	O
as	O
well	O
as	O
developing	O
countries	O
of	O
the	O
world	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
the	O
Solidago	O
virgaurea	O
extract	O
on	O
isoproterenol-induced	O
cardiotoxicity	B_Disease
in	O
rats	O
.	O

The	O
subcutaneous	O
injection	O
of	O
isoproterenol	B_Chemical
(	O
30	O
mg/kg	O
)	O
into	O
rats	O
twice	O
at	O
an	O
interval	O
of	O
24	O
h	O
,	O
for	O
two	O
consecutive	O
days	O
,	O
led	O
to	O
a	O
significant	O
increase	O
in	O
serum	O
lactate	B_Chemical
dehydrogenase	O
,	O
creatine	B_Chemical
phosphokinase	O
,	O
alanine	B_Chemical
transaminase	O
,	O
aspartate	B_Chemical
transaminase	O
,	O
and	O
angiotensin-converting	O
enzyme	O
activities	O
,	O
total	O
cholesterol	B_Chemical
,	O
triglycerides	B_Chemical
,	O
free	O
serum	O
fatty	B_Chemical
acid	I_Chemical
,	O
cardiac	O
tissue	O
malondialdehyde	B_Chemical
(	O
MDA	B_Chemical
)	O
,	O
and	O
nitric	B_Chemical
oxide	I_Chemical
levels	O
and	O
a	O
significant	O
decrease	O
in	O
levels	O
of	O
glutathione	B_Chemical
and	O
superoxide	B_Chemical
dismutase	O
in	O
cardiac	O
tissue	O
as	O
compared	O
to	O
the	O
normal	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Pretreatment	O
with	O
S.	O
virgaurea	O
extract	O
for	O
5	O
weeks	O
at	O
a	O
dose	O
of	O
250	O
mg/kg	O
followed	O
by	O
isoproterenol	B_Chemical
injection	O
significantly	O
prevented	O
the	O
observed	O
alterations	O
.	O

Captopril	B_Chemical
(	O
50	O
mg/kg/day	O
,	O
given	O
orally	O
)	O
,	O
an	O
inhibitor	O
of	O
angiotensin-converting	O
enzyme	O
used	O
as	O
a	O
standard	O
cardioprotective	O
drug	O
,	O
was	O
used	O
as	O
a	O
positive	O
control	O
in	O
this	O
study	O
.	O

The	O
data	O
of	O
the	O
present	O
study	O
suggest	O
that	O
S.	O
virgaurea	O
extract	O
exerts	O
its	O
protective	O
effect	O
by	O
decreasing	O
MDA	B_Chemical
level	O
and	O
increasing	O
the	O
antioxidant	O
status	O
in	O
isoproterenol-treated	O
rats	O
.	O

The	O
study	O
emphasizes	O
the	O
beneficial	O
action	O
of	O
S.	O
virgaurea	O
extract	O
as	O
a	O
cardioprotective	O
agent	O
.	O

"	O
Real-world	O
"	O
data	O
on	O
the	O
efficacy	O
and	O
safety	O
of	O
lenalidomide	B_Chemical
and	O
dexamethasone	B_Chemical
in	O
patients	O
with	O
relapsed/refractory	O
multiple	B_Disease
myeloma	I_Disease
who	O
were	O
treated	O
according	O
to	O
the	O
standard	O
clinical	O
practice	O
:	O
a	O
study	O
of	O
the	O
Greek	O
Myeloma	B_Disease
Study	O
Group	O
.	O

Lenalidomide	B_Chemical
and	O
dexamethasone	B_Chemical
(	O
RD	B_Chemical
)	O
is	O
a	O
standard	O
of	O
care	O
for	O
relapsed/refractory	O
multiple	B_Disease
myeloma	I_Disease
(	O
RRMM	B_Disease
)	O
,	O
but	O
there	O
is	O
limited	O
published	O
data	O
on	O
its	O
efficacy	O
and	O
safety	O
in	O
the	O
"	O
real	O
world	O
"	O
(	O
RW	O
)	O
,	O
according	O
to	O
the	O
International	O
Society	O
of	O
Pharmacoeconomics	O
and	O
Outcomes	O
Research	O
definition	O
.	O

We	O
studied	O
212	O
RRMM	B_Disease
patients	O
who	O
received	O
RD	B_Chemical
in	O
RW	O
.	O

Objective	O
response	O
(	O
>	O
PR	O
(	O
partial	O
response	O
)	O
)	O
rate	O
was	O
77.4	O
%	O
(	O
complete	O
response	O
(	O
CR	O
)	O
,	O
20.2	O
%	O
)	O
.	O

Median	O
time	O
to	O
first	O
and	O
best	O
response	O
was	O
2	O
and	O
5	O
months	O
,	O
respectively	O
.	O

Median	O
time	O
to	O
CR	O
when	O
RD	B_Chemical
was	O
given	O
as	O
2nd	O
or	O
>	O
2(nd)-line	O
treatment	O
at	O
4	O
and	O
11	O
months	O
,	O
respectively	O
.	O

Quality	O
of	O
response	O
was	O
independent	O
of	O
previous	O
lines	O
of	O
therapies	O
or	O
previous	O
exposure	O
to	O
thalidomide	B_Chemical
or	O
bortezomib	B_Chemical
.	O

Median	O
duration	O
of	O
response	O
was	O
34.4	O
months	O
,	O
and	O
it	O
was	O
higher	O
in	O
patients	O
who	O
received	O
RD	B_Chemical
until	O
progression	O
(	O
not	O
reached	O
versus	O
19	O
months	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Improvement	O
of	O
humoral	O
immunity	O
occurred	O
in	O
60	O
%	O
of	O
responders	O
(	O
p	O
<	O
0.001	O
)	O
and	O
in	O
the	O
majority	O
of	O
patients	O
who	O
achieved	O
stable	O
disease	O
.	O

Adverse	O
events	O
were	O
reported	O
in	O
68.9	O
%	O
of	O
patients	O
(	O
myelosuppression	B_Disease
in	O
49.4	O
%	O
)	O
and	O
12.7	O
%	O
of	O
patients	O
needed	O
hospitalization	O
.	O

Peripheral	B_Disease
neuropathy	I_Disease
was	O
observed	O
only	O
in	O
2.5	O
%	O
of	O
patients	O
and	O
deep	B_Disease
vein	I_Disease
thrombosis	I_Disease
in	O
5.7	O
%	O
.	O

Dose	O
reductions	O
were	O
needed	O
in	O
31	O
%	O
of	O
patients	O
and	O
permanent	O
discontinuation	O
in	O
38.9	O
%	O
.	O

Median	O
time	O
to	O
treatment	O
discontinuation	O
was	O
16.8	O
months	O
.	O

Performance	O
status	O
(	O
PS	O
)	O
and	O
initial	O
lenalidomide	B_Chemical
dose	O
predicted	O
for	O
treatment	O
discontinuation	O
.	O

Extra-medullary	O
relapses	O
occurred	O
in	O
3.8	O
%	O
of	O
patients	O
.	O

Our	O
study	O
confirms	O
that	O
RD	B_Chemical
is	O
effective	O
and	O
safe	O
in	O
RRMM	B_Disease
in	O
the	O
RW	O
;	O
it	O
produces	O
durable	O
responses	O
especially	O
in	O
patients	O
who	O
continue	O
on	O
treatment	O
till	O
progression	O
and	O
improves	O
humoral	O
immunity	O
even	O
in	O
patients	O
with	O
stable	O
disease	O
.	O

The	O
cytogenetic	O
action	O
of	O
ifosfamide	B_Chemical
,	O
mesna	B_Chemical
,	O
and	O
their	O
combination	O
on	O
peripheral	O
rabbit	O
lymphocytes	O
:	O
an	O
in	O
vivo/in	O
vitro	O
cytogenetic	O
study	O
.	O

Ifosfamide	B_Chemical
(	O
IFO	B_Chemical
)	O
is	O
an	O
alkylating	O
nitrogen	B_Chemical
mustard	O
,	O
administrated	O
as	O
an	O
antineoplasmic	O
agent	O
.	O

It	O
is	O
characterized	O
by	O
its	O
intense	O
urotoxic	O
action	O
,	O
leading	O
to	O
hemorrhagic	B_Disease
cystitis	B_Disease
.	O

This	O
side	O
effect	O
of	O
IFO	B_Chemical
raises	O
the	O
requirement	O
for	O
the	O
co-administration	O
with	O
sodium	B_Chemical
2-sulfanylethanesulfonate	I_Chemical
(	O
Mesna	B_Chemical
)	O
aiming	O
to	O
avoid	O
or	O
minimize	O
this	O
effect	O
.	O

IFO	B_Chemical
and	O
Mesna	B_Chemical
were	O
administrated	O
separately	O
on	O
rabbit	O
's	O
lymphocytes	O
in	O
vivo	O
,	O
which	O
were	O
later	O
developed	O
in	O
vitro	O
.	O

Cytogenetic	O
markers	O
for	O
sister	O
chromatid	O
exchanges	O
(	O
SCEs	O
)	O
,	O
proliferation	O
rate	O
index	O
(	O
PRI	O
)	O
and	O
Mitotic	O
Index	O
were	O
recorded	O
.	O

Mesna	B_Chemical
's	O
action	O
,	O
in	O
conjunction	O
with	O
IFO	B_Chemical
reduces	O
the	O
frequency	O
of	O
SCEs	O
,	O
in	O
comparison	O
with	O
the	O
SCEs	O
recordings	O
obtained	O
when	O
IFO	B_Chemical
is	O
administered	O
alone	O
.	O

In	O
addition	O
to	O
this	O
,	O
when	O
high	O
concentrations	O
of	O
Mesna	B_Chemical
were	O
administered	O
alone	O
significant	O
reductions	O
of	O
the	O
PRI	O
were	O
noted	O
,	O
than	O
with	O
IFO	B_Chemical
acting	O
at	O
the	O
same	O
concentration	O
on	O
the	O
lymphocytes	O
.	O

Mesna	B_Chemical
significantly	O
reduces	O
IFO	B_Chemical
's	O
genotoxicity	B_Disease
,	O
while	O
when	O
administered	O
in	O
high	O
concentrations	O
it	O
acts	O
in	O
an	O
inhibitory	O
fashion	O
on	O
the	O
cytostatic	O
action	O
of	O
the	O
drug	O
.	O

Risk	O
factors	O
and	O
predictors	O
of	O
levodopa-induced	O
dyskinesia	B_Disease
among	O
multiethnic	O
Malaysians	O
with	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
.	O

Chronic	O
pulsatile	O
levodopa	B_Chemical
therapy	O
for	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
(	O
PD	B_Disease
)	O
leads	O
to	O
the	O
development	O
of	O
motor	O
fluctuations	O
and	O
dyskinesia	B_Disease
.	O

We	O
studied	O
the	O
prevalence	O
and	O
predictors	O
of	O
levodopa-induced	O
dyskinesia	B_Disease
among	O
multiethnic	O
Malaysian	O
patients	O
with	O
PD	B_Disease
.	O

METHODS	O
:	O
This	O
is	O
a	O
cross-sectional	O
study	O
involving	O
95	O
patients	O
with	O
PD	B_Disease
on	O
uninterrupted	O
levodopa	B_Chemical
therapy	O
for	O
at	O
least	O
6	O
months	O
.	O

The	O
instrument	O
used	O
was	O
the	O
UPDRS	O
questionnaires	O
.	O

The	O
predictors	O
of	O
dyskinesia	B_Disease
were	O
determined	O
using	O
multivariate	O
logistic	O
regression	O
analysis	O
.	O

RESULTS	O
:	O
The	O
mean	O
age	O
was	O
65.6	O
+	O
8.5	O
years	O
.	O

The	O
mean	O
onset	O
age	O
was	O
58.5	O
+	O
9.8	O
years	O
.	O

The	O
median	O
disease	O
duration	O
was	O
6	O
(	O
7	O
)	O
years	O
.	O

Dyskinesia	B_Disease
was	O
present	O
in	O
44	O
%	O
(	O
n	O
=	O
42	O
)	O
with	O
median	O
levodopa	B_Chemical
therapy	O
of	O
3	O
years	O
.	O

There	O
were	O
64.3	O
%	O
Chinese	O
,	O
31	O
%	O
Malays	O
,	O
and	O
3.7	O
%	O
Indians	O
and	O
other	O
ethnic	O
groups	O
.	O

Eighty-one	O
percent	O
of	O
patients	O
with	O
dyskinesia	B_Disease
had	O
clinical	O
fluctuations	O
.	O

Patients	O
with	O
dyskinesia	B_Disease
had	O
lower	O
onset	O
age	O
(	O
p	O
<	O
0.001	O
)	O
,	O
longer	O
duration	O
of	O
levodopa	B_Chemical
therapy	O
(	O
p	O
<	O
0.001	O
)	O
,	O
longer	O
disease	O
duration	O
(	O
p	O
<	O
0.001	O
)	O
,	O
higher	O
total	O
daily	O
levodopa	B_Chemical
dose	O
(	O
p	O
<	O
0.001	O
)	O
,	O
and	O
higher	O
total	O
UPDRS	O
scores	O
(	O
p	O
=	O
0.005	O
)	O
than	O
patients	O
without	O
dyskinesia	B_Disease
.	O

The	O
three	O
significant	O
predictors	O
of	O
dyskinesia	B_Disease
were	O
duration	O
of	O
levodopa	B_Chemical
therapy	O
,	O
onset	O
age	O
,	O
and	O
total	O
daily	O
levodopa	B_Chemical
dose	O
.	O

CONCLUSIONS	O
:	O
The	O
prevalence	O
of	O
levodopa-induced	O
dyskinesia	B_Disease
in	O
our	O
patients	O
was	O
44	O
%	O
.	O

The	O
most	O
significant	O
predictors	O
were	O
duration	O
of	O
levodopa	B_Chemical
therapy	O
,	O
total	O
daily	O
levodopa	B_Chemical
dose	O
,	O
and	O
onset	O
age	O
.	O

Dose-dependent	O
neurotoxicity	B_Disease
of	O
high-dose	O
busulfan	B_Chemical
in	O
children	O
:	O
a	O
clinical	O
and	O
pharmacological	O
study	O
.	O

Busulfan	B_Chemical
is	O
known	O
to	O
be	O
neurotoxic	B_Disease
in	O
animals	O
and	O
humans	O
,	O
but	O
its	O
acute	O
neurotoxicity	B_Disease
remains	O
poorly	O
characterized	O
in	O
children	O
.	O

We	O
report	O
here	O
a	O
retrospective	O
study	O
of	O
123	O
children	O
(	O
median	O
age	O
,	O
6.5	O
years	O
)	O
receiving	O
high-dose	O
busulfan	B_Chemical
in	O
combined	O
chemotherapy	O
before	O
bone	O
marrow	O
transplantation	O
for	O
malignant	O
solid	O
tumors	B_Disease
,	O
brain	B_Disease
tumors	I_Disease
excluded	O
.	O

Busulfan	B_Chemical
was	O
given	O
p.o	O
.	O
,	O
every	O
6	O
hours	O
for	O
16	O
doses	O
over	O
4	O
days	O
.	O

Two	O
total	O
doses	O
were	O
consecutively	O
used	O
:	O
16	O
mg/kg	O
,	O
then	O
600	O
mg/m2	O
.	O

The	O
dose	O
calculation	O
on	O
the	O
basis	O
of	O
body	O
surface	O
area	O
results	O
in	O
higher	O
doses	O
in	O
young	O
children	O
than	O
in	O
older	O
patients	O
(	O
16	O
to	O
28	O
mg/kg	O
)	O
.	O

Ninety-six	O
patients	O
were	O
not	O
given	O
anticonvulsive	O
prophylaxis	O
;	O
7	O
(	O
7.5	O
%	O
)	O
developed	O
seizures	B_Disease
during	O
the	O
4	O
days	O
of	O
the	O
busulfan	B_Chemical
course	O
or	O
within	O
24	O
h	O
after	O
the	O
last	O
dosing	O
.	O

When	O
the	O
total	O
busulfan	B_Chemical
dose	O
was	O
taken	O
into	O
account	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
terms	O
of	O
neurotoxicity	B_Disease
incidence	O
among	O
patients	O
under	O
16	O
mg/kg	O
(	O
1	O
of	O
57	O
,	O
1.7	O
%	O
)	O
and	O
patients	O
under	O
600	O
mg/m2	O
(	O
6	O
of	O
39	O
,	O
15.4	O
%	O
)	O
(	O
P	O
less	O
than	O
0.02	O
)	O
.	O

Twenty-seven	O
patients	O
were	O
given	O
a	O
600-mg/m2	O
busulfan	B_Chemical
total	O
dose	O
with	O
continuous	O
i.v	O
.	O

infusion	O
of	O
clonazepam	B_Chemical
;	O
none	O
had	O
any	O
neurological	B_Disease
symptoms	I_Disease
.	O

Busulfan	B_Chemical
levels	O
were	O
measured	O
by	O
a	O
gas	O
chromatographic-mass	O
spectrometry	O
assay	O
in	O
the	O
plasma	O
and	O
cerebrospinal	O
fluid	O
of	O
9	O
children	O
without	O
central	B_Disease
nervous	I_Disease
system	I_Disease
disease	I_Disease
under	O
600	O
mg/m2	O
busulfan	B_Chemical
with	O
clonazepam	B_Chemical
:	O
busulfan	B_Chemical
cerebrospinal	O
fluid	O
:	O
plasma	O
ratio	O
was	O
1.39	O
.	O

This	O
was	O
significantly	O
different	O
(	O
P	O
less	O
than	O
0.02	O
)	O
from	O
the	O
cerebrospinal	O
fluid	O
:	O
plasma	O
ratio	O
previously	O
defined	O
in	O
children	O
receiving	O
a	O
16-mg/kg	O
total	O
dose	O
of	O
busulfan	B_Chemical
.	O

This	O
study	O
shows	O
that	O
busulfan	B_Chemical
neurotoxicity	B_Disease
is	O
dose-dependent	O
in	O
children	O
and	O
efficiently	O
prevented	O
by	O
clonazepam	B_Chemical
.	O

A	O
busulfan	B_Chemical
dose	O
calculated	O
on	O
the	O
basis	O
of	O
body	O
surface	O
area	O
,	O
resulting	O
in	O
higher	O
doses	O
in	O
young	O
children	O
,	O
was	O
followed	O
by	O
increased	O
neurotoxicity	B_Disease
,	O
close	O
to	O
neurotoxicity	B_Disease
incidence	O
observed	O
in	O
adults	O
.	O

Since	O
plasma	O
pharmacokinetic	O
studies	O
showed	O
a	O
faster	O
busulfan	B_Chemical
clearance	O
in	O
children	O
than	O
in	O
adults	O
,	O
this	O
new	O
dose	O
may	O
approximate	O
more	O
closely	O
the	O
adult	O
systemic	O
exposure	O
obtained	O
after	O
the	O
usual	O
16-mg/kg	O
total	O
dose	O
,	O
with	O
potential	O
inferences	O
in	O
terms	O
of	O
anticancer	O
or	O
myeloablative	O
effects	O
.	O

The	O
busulfan	B_Chemical
dose	O
in	O
children	O
and	O
infants	O
undergoing	O
bone	O
marrow	O
transplantation	O
should	O
be	O
reconsidered	O
on	O
the	O
basis	O
of	O
pharmacokinetic	O
studies	O
.	O

An	O
unexpected	O
diagnosis	O
in	O
a	O
renal-transplant	O
patient	O
with	O
proteinuria	B_Disease
treated	O
with	O
everolimus	B_Chemical
:	O
AL	B_Disease
amyloidosis	B_Disease
.	O

Proteinuria	B_Disease
is	O
an	O
expected	O
complication	O
in	O
transplant	O
patients	O
treated	O
with	O
mammalian	O
target	O
of	O
rapamycin	B_Chemical
inhibitors	O
(	O
mTOR-i	O
)	O
.	O

However	O
,	O
clinical	O
suspicion	O
should	O
always	O
be	O
supported	O
by	O
histological	O
evidence	O
in	O
order	O
to	O
investigate	O
potential	O
alternate	O
diagnoses	O
such	O
as	O
acute	O
or	O
chronic	O
rejection	O
,	O
interstitial	O
fibrosis	B_Disease
and	O
tubular	O
atrophy	B_Disease
,	O
or	O
recurrent	O
or	O
de	O
novo	O
glomerulopathy	B_Disease
.	O

In	O
this	O
case	O
we	O
report	O
the	O
unexpected	O
diagnosis	O
of	O
amyloidosis	B_Disease
in	O
a	O
renal-transplant	O
patient	O
with	O
pre-transplant	O
monoclonal	O
gammapathy	O
of	O
undetermined	O
significance	O
who	O
developed	O
proteinuria	B_Disease
after	O
conversion	O
from	O
tacrolimus	B_Chemical
to	O
everolimus	B_Chemical
.	O

Long-term	O
oral	O
galactose	B_Chemical
treatment	O
prevents	O
cognitive	B_Disease
deficits	I_Disease
in	O
male	O
Wistar	O
rats	O
treated	O
intracerebroventricularly	O
with	O
streptozotocin	B_Chemical
.	O

Basic	O
and	O
clinical	O
research	O
has	O
demonstrated	O
that	O
dementia	B_Disease
of	O
sporadic	O
Alzheimer	B_Disease
's	I_Disease
disease	I_Disease
(	O
sAD	O
)	O
type	O
is	O
associated	O
with	O
dysfunction	O
of	O
the	O
insulin-receptor	O
(	O
IR	O
)	O
system	O
followed	O
by	O
decreased	O
glucose	B_Chemical
transport	O
via	O
glucose	B_Chemical
transporter	O
GLUT4	O
and	O
decreased	O
glucose	B_Chemical
metabolism	O
in	O
brain	O
cells	O
.	O

An	O
alternative	O
source	O
of	O
energy	O
is	O
d-galactose	B_Chemical
(	O
the	O
C-4-epimer	O
of	O
d-glucose	B_Chemical
)	O
which	O
is	O
transported	O
into	O
the	O
brain	O
by	O
insulin-independent	O
GLUT3	O
transporter	O
where	O
it	O
might	O
be	O
metabolized	O
to	O
glucose	B_Chemical
via	O
the	O
Leloir	O
pathway	O
.	O

Exclusively	O
parenteral	O
daily	O
injections	O
of	O
galactose	B_Chemical
induce	O
memory	B_Disease
deterioration	I_Disease
in	O
rodents	O
and	O
are	O
used	O
to	O
generate	O
animal	O
aging	O
model	O
,	O
but	O
the	O
effects	O
of	O
oral	O
galactose	B_Chemical
treatment	O
on	O
cognitive	O
functions	O
have	O
never	O
been	O
tested	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
continuous	O
daily	O
oral	O
galactose	B_Chemical
(	O
200	O
mg/kg/day	O
)	O
treatment	O
on	O
cognitive	B_Disease
deficits	I_Disease
in	O
streptozotocin-induced	O
(	O
STZ-icv	O
)	O
rat	O
model	O
of	O
sAD	O
,	O
tested	O
by	O
Morris	O
Water	O
Maze	O
and	O
Passive	O
Avoidance	O
test	O
,	O
respectively	O
.	O

One	O
month	O
of	O
oral	O
galactose	B_Chemical
treatment	O
initiated	O
immediately	O
after	O
the	O
STZ-icv	O
administration	O
,	O
successfully	O
prevented	O
development	O
of	O
the	O
STZ-icv-induced	O
cognitive	B_Disease
deficits	I_Disease
.	O

Beneficial	O
effect	O
of	O
oral	O
galactose	B_Chemical
was	O
independent	O
of	O
the	O
rat	O
age	O
and	O
of	O
the	O
galactose	B_Chemical
dose	O
ranging	O
from	O
100	O
to	O
300	O
mg/kg/day	O
.	O

Additionally	O
,	O
oral	O
galactose	B_Chemical
administration	O
led	O
to	O
the	O
appearance	O
of	O
galactose	B_Chemical
in	O
the	O
blood	O
.	O

The	O
increase	O
of	O
galactose	B_Chemical
concentration	O
in	O
the	O
cerebrospinal	O
fluid	O
was	O
several	O
times	O
lower	O
after	O
oral	O
than	O
after	O
parenteral	O
administration	O
of	O
the	O
same	O
galactose	B_Chemical
dose	O
.	O

Oral	O
galactose	B_Chemical
exposure	O
might	O
have	O
beneficial	O
effects	O
on	O
learning	O
and	O
memory	O
ability	O
and	O
could	O
be	O
worth	O
investigating	O
for	O
improvement	O
of	O
cognitive	B_Disease
deficits	I_Disease
associated	O
with	O
glucose	B_Disease
hypometabolism	I_Disease
in	O
AD	B_Disease
.	O

An	O
investigation	O
of	O
the	O
pattern	O
of	O
kidney	B_Disease
injury	I_Disease
in	O
HIV-positive	O
persons	O
exposed	O
to	O
tenofovir	B_Chemical
disoproxil	I_Chemical
fumarate	I_Chemical
:	O
an	O
examination	O
of	O
a	O
large	O
population	O
database	O
(	O
MHRA	O
database).The	O
potential	O
for	O
tenofovir	B_Chemical
to	O
cause	O
a	O
range	O
of	O
kidney	O
syndromes	O
has	O
been	O
established	O
from	O
mechanistic	O
and	O
randomised	O
clinical	O
trials	O
.	O

However	O
,	O
the	O
exact	O
pattern	O
of	O
kidney	O
involvement	O
is	O
still	O
uncertain	O
.	O

We	O
undertook	O
a	O
descriptive	O
analysis	O
of	O
Yellow	O
Card	O
records	O
of	O
407	O
HIV-positive	O
persons	O
taking	O
tenofovir	B_Chemical
disoproxil	I_Chemical
fumarate	I_Chemical
(	O
TDF	B_Chemical
)	O
as	O
part	O
of	O
their	O
antiretroviral	O
therapy	O
regimen	O
and	O
submitted	O
to	O
the	O
Medicines	O
and	O
Healthcare	O
Products	O
Regulatory	O
Agency	O
(	O
MHRA	O
)	O
with	O
suspected	O
kidney	O
adverse	O
effects	O
.	O

Reports	O
that	O
satisfy	O
defined	O
criteria	O
were	O
classified	O
as	O
acute	B_Disease
kidney	I_Disease
injury	I_Disease
,	O
kidney	B_Disease
tubular	I_Disease
dysfunction	I_Disease
and	O
Fanconi	B_Disease
syndrome	I_Disease
.	O

Of	O
the	O
407	O
Yellow	O
Card	O
records	O
analysed	O
,	O
106	O
satisfied	O
criteria	O
for	O
TDF-related	O
kidney	B_Disease
disease	I_Disease
,	O
of	O
which	O
53	O
(	O
50	O
%	O
)	O
had	O
features	O
of	O
kidney	B_Disease
tubular	I_Disease
dysfunction	I_Disease
,	O
35	O
(	O
33	O
%	O
)	O
were	O
found	O
to	O
have	O
features	O
of	O
glomerular	B_Disease
dysfunction	I_Disease
and	O
18	O
(	O
17	O
%	O
)	O
had	O
Fanconi	B_Disease
syndrome	I_Disease
.	O

The	O
median	O
TDF	B_Chemical
exposure	O
was	O
316	O
days	O
(	O
interquartile	O
range	O
120	O
-	O
740	O
)	O
.	O

The	O
incidence	O
of	O
hospitalisation	O
for	O
TDF	B_Chemical
kidney	O
adverse	O
effects	O
was	O
high	O
,	O
particularly	O
amongst	O
patients	O
with	O
features	O
of	O
Fanconi	B_Disease
syndrome	I_Disease
.	O

The	O
pattern	O
of	O
kidney	O
syndromes	O
in	O
this	O
population	O
series	O
mirrors	O
that	O
reported	O
in	O
randomised	O
clinical	O
trials	O
.	O

Cessation	O
of	O
TDF	B_Chemical
was	O
associated	O
with	O
complete	O
restoration	O
of	O
kidney	O
function	O
in	O
up	O
half	O
of	O
the	O
patients	O
in	O
this	O
report	O
.	O

Incidence	O
of	O
postoperative	O
delirium	O
is	O
high	O
even	O
in	O
a	O
population	O
without	O
known	O
risk	O
factors	O
.	O

PURPOSE	O
:	O
Postoperative	B_Disease
delirium	I_Disease
is	O
a	O
recognized	O
complication	O
in	O
populations	O
at	O
risk	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
assess	O
the	O
prevalence	O
of	O
early	O
postoperative	B_Disease
delirium	I_Disease
in	O
a	O
population	O
without	O
known	O
risk	O
factors	O
admitted	O
to	O
the	O
ICU	O
for	O
postoperative	O
monitoring	O
after	O
elective	O
major	O
surgery	O
.	O

The	O
secondary	O
outcome	O
investigated	O
is	O
to	O
identify	O
eventual	O
independent	O
risk	O
factors	O
among	O
demographic	O
data	O
and	O
anesthetic	O
drugs	O
used	O
.	O

METHODS	O
:	O
An	O
observational	O
,	O
prospective	O
study	O
was	O
conducted	O
on	O
a	O
consecutive	O
cohort	O
of	O
patients	O
admitted	O
to	O
our	O
ICU	O
within	O
and	O
for	O
at	O
least	O
24	O
h	O
after	O
major	O
surgical	O
procedures	O
.	O

Exclusion	O
criteria	O
were	O
any	O
preexisting	O
predisposing	O
factor	O
for	O
delirium	B_Disease
or	O
other	O
potentially	O
confounding	O
neurological	B_Disease
dysfunctions	I_Disease
.	O

Patients	O
were	O
assessed	O
daily	O
using	O
the	O
confusion	B_Disease
assessment	O
method	O
for	O
the	O
ICU	O
scale	O
for	O
3	O
days	O
after	O
the	O
surgical	O
procedure	O
.	O

Early	O
postoperative	B_Disease
delirium	I_Disease
incidence	O
risk	O
factors	O
were	O
then	O
assessed	O
through	O
three	O
different	O
multiple	O
regression	O
models	O
.	O

RESULTS	O
:	O
According	O
to	O
the	O
confusion	O
assessment	O
method	O
for	O
the	O
ICU	O
scale	O
,	O
28	O
%	O
of	O
patients	O
were	O
diagnosed	O
with	O
early	O
postoperative	B_Disease
delirium	I_Disease
.	O

The	O
use	O
of	O
thiopentone	B_Chemical
was	O
significantly	O
associated	O
with	O
an	O
eight-fold-higher	O
risk	O
for	O
delirium	B_Disease
compared	O
to	O
propofol	B_Chemical
(	O
57.1	O
%	O
vs.	O
7.1	O
%	O
,	O
RR	O
=	O
8.0	O
,	O
X2	O
=	O
4.256	O
;	O
df	O
=	O
1	O
;	O
0.05	O
<	O
p	O
<	O
0.02	O
)	O
.	O

CONCLUSION	O
:	O
In	O
this	O
study	O
early	O
postoperative	B_Disease
delirium	I_Disease
was	O
found	O
to	O
be	O
a	O
very	O
common	O
complication	O
after	O
major	O
surgery	O
,	O
even	O
in	O
a	O
population	O
without	O
known	O
risk	O
factors	O
.	O

Thiopentone	B_Chemical
was	O
independently	O
associated	O
with	O
an	O
increase	O
in	O
its	O
relative	O
risk	O
.	O

A	O
single	O
neurotoxic	B_Disease
dose	O
of	O
methamphetamine	B_Chemical
induces	O
a	O
long-lasting	O
depressive-like	O
behaviour	O
in	O
mice	O
.	O

Methamphetamine	B_Chemical
(	O
METH	B_Chemical
)	O
triggers	O
a	O
disruption	O
of	O
the	O
monoaminergic	O
system	O
and	O
METH	B_Chemical
abuse	O
leads	O
to	O
negative	O
emotional	O
states	O
including	O
depressive	B_Disease
symptoms	I_Disease
during	O
drug	O
withdrawal	O
.	O

However	O
,	O
it	O
is	O
currently	O
unknown	O
if	O
the	O
acute	O
toxic	O
dosage	O
of	O
METH	B_Chemical
also	O
causes	O
a	O
long-lasting	O
depressive	B_Disease
phenotype	O
and	O
persistent	O
monoaminergic	O
deficits	O
.	O

Thus	O
,	O
we	O
now	O
assessed	O
the	O
depressive-like	O
behaviour	O
in	O
mice	O
at	O
early	O
and	O
long-term	O
periods	O
following	O
a	O
single	O
high	O
METH	B_Chemical
dose	O
(	O
30	O
mg/kg	O
,	O
i.p	O
.	O
)	O
.	O

METH	B_Chemical
did	O
not	O
alter	O
the	O
motor	O
function	O
and	O
procedural	O
memory	O
of	O
mice	O
as	O
assessed	O
by	O
swimming	O
speed	O
and	O
escape	O
latency	O
to	O
find	O
the	O
platform	O
in	O
a	O
cued	O
version	O
of	O
the	O
water	O
maze	O
task	O
.	O

However	O
,	O
METH	B_Chemical
significantly	O
increased	O
the	O
immobility	O
time	O
in	O
the	O
tail	O
suspension	O
test	O
at	O
3	O
and	O
49	O
days	O
post-administration	O
.	O

This	O
depressive-like	O
profile	O
induced	O
by	O
METH	B_Chemical
was	O
accompanied	O
by	O
a	O
marked	O
depletion	O
of	O
frontostriatal	O
dopaminergic	O
and	O
serotonergic	O
neurotransmission	O
,	O
indicated	O
by	O
a	O
reduction	O
in	O
the	O
levels	O
of	O
dopamine	B_Chemical
,	O
DOPAC	B_Chemical
and	O
HVA	B_Chemical
,	O
tyrosine	B_Chemical
hydroxylase	O
and	O
serotonin	B_Chemical
,	O
observed	O
at	O
both	O
3	O
and	O
49	O
days	O
post-administration	O
.	O

In	O
parallel	O
,	O
another	O
neurochemical	O
feature	O
of	O
depression	B_Disease
--	O
astroglial	O
dysfunction	O
--	O
was	O
unaffected	O
in	O
the	O
cortex	O
and	O
the	O
striatal	O
levels	O
of	O
the	O
astrocytic	O
protein	O
marker	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
were	O
only	O
transiently	O
increased	O
at	O
3	O
days	O
.	O

These	O
findings	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
a	O
single	O
high	O
dose	O
of	O
METH	B_Chemical
induces	O
long-lasting	O
depressive-like	O
behaviour	O
in	O
mice	O
associated	O
with	O
a	O
persistent	O
disruption	O
of	O
frontostriatal	O
dopaminergic	O
and	O
serotonergic	O
homoeostasis	O
.	O

Linezolid-induced	O
optic	B_Disease
neuropathy	I_Disease
.	O

Many	O
systemic	O
antimicrobials	O
have	O
been	O
implicated	O
to	O
cause	O
ocular	O
adverse	O
effects	O
.	O

This	O
is	O
especially	O
relevant	O
in	O
multidrug	O
therapy	O
where	O
more	O
than	O
one	O
drug	O
can	O
cause	O
a	O
similar	O
ocular	O
adverse	O
effect	O
.	O

We	O
describe	O
a	O
case	O
of	O
progressive	O
loss	B_Disease
of	I_Disease
vision	I_Disease
associated	O
with	O
linezolid	B_Chemical
therapy	O
.	O

A	O
45-year-old	O
male	O
patient	O
who	O
was	O
on	O
treatment	O
with	O
multiple	O
second-line	O
anti-tuberculous	O
drugs	O
including	O
linezolid	B_Chemical
and	O
ethambutol	B_Chemical
for	O
extensively	B_Disease
drug-resistant	I_Disease
tuberculosis	I_Disease
(	O
XDR-TB	B_Disease
)	O
presented	O
to	O
us	O
with	O
painless	O
progressive	O
loss	B_Disease
of	I_Disease
vision	I_Disease
in	O
both	O
eyes	O
.	O

Color	O
vision	O
was	O
defective	O
and	O
fundus	O
examination	O
revealed	O
optic	B_Disease
disc	I_Disease
edema	I_Disease
in	O
both	O
eyes	O
.	O

Ethambutol-induced	O
toxic	B_Disease
optic	I_Disease
neuropathy	I_Disease
was	O
suspected	O
and	O
tablet	O
ethambutol	B_Chemical
was	O
withdrawn	O
.	O

Deterioration	B_Disease
of	I_Disease
vision	I_Disease
occurred	O
despite	O
withdrawal	O
of	O
ethambutol	B_Chemical
.	O

Discontinuation	O
of	O
linezolid	B_Chemical
resulted	O
in	O
marked	O
improvement	O
of	O
vision	O
.	O

Our	O
report	O
emphasizes	O
the	O
need	O
for	O
monitoring	O
of	O
visual	O
function	O
in	O
patients	O
on	O
long-term	O
linezolid	B_Chemical
treatment	O
.	O

Resuscitation	O
with	O
lipid	O
,	O
epinephrine	B_Chemical
,	O
or	O
both	O
in	O
levobupivacaine-induced	O
cardiac	B_Disease
toxicity	I_Disease
in	O
newborn	O
piglets	O
.	O

BACKGROUND	O
:	O
The	O
optimal	O
dosing	O
regimens	O
of	O
lipid	O
emulsion	O
,	O
epinephrine	B_Chemical
,	O
or	O
both	O
are	O
not	O
yet	O
determined	O
in	O
neonates	O
in	O
cases	O
of	O
local	O
anaesthetic	O
systemic	O
toxicity	B_Disease
(	O
LAST	O
)	O
.	O

METHODS	O
:	O
Newborn	O
piglets	O
received	O
levobupivacaine	B_Chemical
until	O
cardiovascular	B_Disease
collapse	I_Disease
occurred	O
.	O

Standard	O
cardiopulmonary	O
resuscitation	O
was	O
started	O
and	O
electrocardiogram	O
(	O
ECG	O
)	O
was	O
monitored	O
for	O
ventricular	B_Disease
tachycardia	I_Disease
,	O
fibrillation	B_Disease
,	O
or	O
QRS	O
prolongation	O
.	O

Piglets	O
were	O
then	O
randomly	O
allocated	O
to	O
four	O
groups	O
:	O
control	O
(	O
saline	O
)	O
,	O
Intralipid	O
(	O
)	O
alone	O
,	O
epinephrine	B_Chemical
alone	O
,	O
or	O
a	O
combination	O
of	O
Intralipd	O
plus	O
epinephrine	B_Chemical
.	O

Resuscitation	O
continued	O
for	O
30	O
min	O
or	O
until	O
there	O
was	O
a	O
return	O
of	O
spontaneous	O
circulation	O
(	O
ROSC	O
)	O
accompanied	O
by	O
a	O
mean	O
arterial	O
pressure	O
at	O
or	O
superior	O
to	O
the	O
baseline	O
pressure	O
and	O
normal	O
sinus	O
rhythm	O
for	O
a	O
period	O
of	O
30	O
min	O
.	O

RESULTS	O
:	O
ROSC	O
was	O
achieved	O
in	O
only	O
one	O
of	O
the	O
control	O
piglets	O
compared	O
with	O
most	O
of	O
the	O
treated	O
piglets	O
.	O

Mortality	O
was	O
not	O
significantly	O
different	O
between	O
the	O
three	O
treatment	O
groups	O
,	O
but	O
was	O
significantly	O
lower	O
in	O
all	O
the	O
treatment	O
groups	O
compared	O
with	O
control	O
.	O

The	O
number	O
of	O
ECG	O
abnormalities	O
was	O
zero	O
in	O
the	O
Intralipid	O
only	O
group	O
,	O
but	O
14	O
and	O
17	O
,	O
respectively	O
,	O
in	O
the	O
epinephrine	B_Chemical
and	O
epinephrine	B_Chemical
plus	O
lipid	O
groups	O
(	O
P<0.05	O
)	O
.	O

CONCLUSIONS	O
:	O
Lipid	O
emulsion	O
with	O
or	O
without	O
epinephrine	B_Chemical
,	O
or	O
epinephrine	B_Chemical
alone	O
were	O
equally	O
effective	O
in	O
achieving	O
a	O
return	O
to	O
spontaneous	O
circulation	O
in	O
this	O
model	O
of	O
LAST	O
.	O

Epinephrine	B_Chemical
alone	O
or	O
in	O
combination	O
with	O
lipid	O
was	O
associated	O
with	O
an	O
increased	O
number	O
of	O
ECG	O
abnormalities	O
compared	O
with	O
lipid	O
emulsion	O
alone	O
.	O

Incidence	O
of	O
heparin-induced	O
thrombocytopenia	B_Disease
type	I_Disease
II	I_Disease
and	O
postoperative	O
recovery	O
of	O
platelet	O
count	O
in	O
liver	O
graft	O
recipients	O
:	O
a	O
retrospective	O
cohort	O
analysis	O
.	O

BACKGROUND	O
:	O
Thrombocytopenia	B_Disease
in	O
patients	O
with	O
end-stage	B_Disease
liver	I_Disease
disease	I_Disease
is	O
a	O
common	O
disorder	O
caused	O
mainly	O
by	O
portal	B_Disease
hypertension	I_Disease
,	O
low	O
levels	O
of	O
thrombopoetin	O
,	O
and	O
endotoxemia	B_Disease
.	O

The	O
impact	O
of	O
immune-mediated	O
heparin-induced	O
thrombocytopenia	B_Disease
type	I_Disease
II	I_Disease
(	O
HIT	B_Disease
type	I_Disease
II	I_Disease
)	O
as	O
a	O
cause	O
of	O
thrombocytopenia	B_Disease
after	O
liver	O
transplantation	O
is	O
not	O
yet	O
understood	O
,	O
with	O
few	O
literature	O
citations	O
reporting	O
contradictory	O
results	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
demonstrate	O
the	O
perioperative	O
course	O
of	O
thrombocytopenia	B_Disease
after	O
liver	O
transplantation	O
and	O
determine	O
the	O
occurrence	O
of	O
clinical	O
HIT	B_Disease
type	I_Disease
II	I_Disease
.	O

METHOD	O
:	O
We	O
retrospectively	O
evaluated	O
the	O
medical	O
records	O
of	O
205	O
consecutive	O
adult	O
patients	O
who	O
underwent	O
full-size	O
liver	O
transplantation	O
between	O
January	O
2006	O
and	O
December	O
2010	O
due	O
to	O
end-stage	B_Disease
or	I_Disease
malignant	B_Disease
liver	I_Disease
disease	I_Disease
.	O

Preoperative	O
platelet	O
count	O
,	O
postoperative	O
course	O
of	O
platelets	O
,	O
and	O
clinical	O
signs	O
of	O
HIT	B_Disease
type	I_Disease
II	I_Disease
were	O
analyzed	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
155	O
(	O
75.6	O
%	O
)	O
of	O
205	O
patients	O
had	O
thrombocytopenia	B_Disease
before	O
transplantation	O
,	O
significantly	O
influenced	O
by	O
Model	O
of	O
End-Stage	B_Disease
Liver	I_Disease
Disease	I_Disease
score	O
and	O
liver	B_Disease
cirrhosis	I_Disease
.	O

The	O
platelet	O
count	O
exceeded	O
100,000/uL	O
in	O
most	O
of	O
the	O
patients	O
(	O
n	O
=	O
193	O
)	O
at	O
a	O
medium	O
of	O
7	O
d.	O
Regarding	O
HIT	B_Disease
II	I_Disease
,	O
there	O
were	O
four	O
(	O
1.95	O
%	O
)	O
patients	O
with	O
a	O
background	O
of	O
HIT	B_Disease
type	I_Disease
II	I_Disease
.	O

CONCLUSIONS	O
:	O
The	O
incidence	O
of	O
HIT	B_Disease
in	O
patients	O
with	O
end-stage	B_Disease
hepatic	I_Disease
failure	I_Disease
is	O
,	O
with	O
about	O
1.95	O
%	O
,	O
rare	O
.	O

For	O
further	O
reduction	O
of	O
HIT	B_Disease
type	I_Disease
II	I_Disease
,	O
the	O
use	O
of	O
intravenous	O
heparin	B_Chemical
should	O
be	O
avoided	O
and	O
the	O
prophylactic	O
anticoagulation	O
should	O
be	O
performed	O
with	O
low-molecular-weight	O
heparin	B_Chemical
after	O
normalization	O
of	O
platelet	O
count	O
.	O

Takotsubo	B_Disease
syndrome	I_Disease
(	O
or	O
apical	B_Disease
ballooning	I_Disease
syndrome	I_Disease
)	O
secondary	O
to	O
Zolmitriptan	B_Chemical
.	O

Takotsubo	B_Disease
syndrome	I_Disease
(	O
TS	B_Disease
)	O
,	O
also	O
known	O
as	O
broken	B_Disease
heart	I_Disease
syndrome	I_Disease
,	O
is	O
characterized	O
by	O
left	O
ventricle	O
apical	O
ballooning	O
with	O
elevated	O
cardiac	O
biomarkers	O
and	O
electrocardiographic	O
changes	O
suggestive	O
of	O
an	O
acute	B_Disease
coronary	I_Disease
syndrome	I_Disease
(	O
ie	O
,	O
ST-segment	O
elevation	O
,	O
T	O
wave	O
inversions	O
,	O
and	O
pathologic	O
Q	O
waves	O
)	O
.	O

We	O
report	O
a	O
case	O
of	O
54-year-old	O
woman	O
with	O
medical	O
history	O
of	O
mitral	B_Disease
valve	I_Disease
prolapse	I_Disease
and	O
migraines	B_Disease
,	O
who	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
substernal	O
chest	B_Disease
pain	I_Disease
and	O
electrocardiogram	O
demonstrated	O
1/2	O
mm	O
ST-segment	O
elevation	O
in	O
leads	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V5	O
,	O
and	O
V6	O
and	O
positive	O
troponin	O
I.	O
Emergent	O
coronary	O
angiogram	O
revealed	O
normal	O
coronary	O
arteries	O
with	O
moderately	O
reduced	O
left	O
ventricular	O
ejection	O
fraction	O
with	O
wall	O
motion	O
abnormalities	O
consistent	O
with	O
TS	B_Disease
.	O

Detailed	O
history	O
obtained	O
retrospectively	O
revealed	O
that	O
the	O
patient	O
took	O
zolmitriptan	B_Chemical
sparingly	O
only	O
when	O
she	O
had	O
migraines	B_Disease
.	O

But	O
before	O
this	O
event	O
,	O
she	O
was	O
taking	O
zolmitriptan	B_Chemical
2	O
-	O
3	O
times	O
daily	O
for	O
several	O
days	O
because	O
of	O
a	O
persistent	O
migraine	B_Disease
headache	I_Disease
.	O

She	O
otherwise	O
reported	O
that	O
she	O
is	O
quite	O
active	O
,	O
rides	O
horses	O
,	O
and	O
does	O
show	O
jumping	O
without	O
any	O
limitations	O
in	O
her	O
physical	O
activity	O
.	O

There	O
was	O
no	O
evidence	O
of	O
any	O
recent	O
stress	O
or	O
status	B_Disease
migrainosus	I_Disease
.	O

Extensive	O
literature	O
search	O
revealed	O
multiple	O
cases	O
of	O
coronary	B_Disease
artery	I_Disease
vasospasm	I_Disease
secondary	O
to	O
zolmitriptan	B_Chemical
,	O
but	O
none	O
of	O
the	O
cases	O
were	O
associated	O
with	O
TS	B_Disease
.	O

Depression	B_Disease
,	O
impulsiveness	B_Disease
,	O
sleep	O
,	O
and	O
memory	O
in	O
past	O
and	O
present	O
polydrug	O
users	O
of	O
3,4-methylenedioxymethamphetamine	B_Chemical
(	O
MDMA	B_Chemical
,	O
ecstasy).RATIONALE	O
:	O
Ecstasy	B_Chemical
(	O
3,4-methylenedioxymethamphetamine	B_Chemical
,	O
MDMA	B_Chemical
)	O
is	O
a	O
worldwide	O
recreational	O
drug	O
of	O
abuse	O
.	O

Unfortunately	O
,	O
the	O
results	O
from	O
human	O
research	O
investigating	O
its	O
psychological	O
effects	O
have	O
been	O
inconsistent	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
study	O
aimed	O
to	O
be	O
the	O
largest	O
to	O
date	O
in	O
sample	O
size	O
and	O
5HT-related	O
behaviors	O
;	O
the	O
first	O
to	O
compare	O
present	O
ecstasy	B_Chemical
users	O
with	O
past	O
users	O
after	O
an	O
abstinence	O
of	O
4	O
or	O
more	O
years	O
,	O
and	O
the	O
first	O
to	O
include	O
robust	O
controls	O
for	O
other	O
recreational	O
substances	O
.	O

METHODS	O
:	O
A	O
sample	O
of	O
997	O
participants	O
(	O
52	O
%	O
male	O
)	O
was	O
recruited	O
to	O
four	O
control	O
groups	O
(	O
non-drug	O
(	O
ND	O
)	O
,	O
alcohol/nicotine	O
(	O
AN	B_Chemical
)	O
,	O
cannabis/alcohol/nicotine	O
(	O
CAN	B_Chemical
)	O
,	O
non-ecstasy	O
polydrug	O
(	O
PD	O
)	O
)	O
,	O
and	O
two	O
ecstasy	B_Chemical
polydrug	O
groups	O
(	O
present	O
(	O
MDMA	B_Chemical
)	O
and	O
past	O
users	O
(	O
EX-MDMA	O
)	O
.	O

Participants	O
completed	O
a	O
drug	O
history	O
questionnaire	O
,	O
Beck	O
Depression	B_Disease
Inventory	O
,	O
Barratt	O
Impulsiveness	B_Disease
Scale	O
,	O
Pittsburgh	O
Sleep	O
Quality	O
Index	O
,	O
and	O
Wechsler	O
Memory	O
Scale-Revised	O
which	O
,	O
in	O
total	O
,	O
provided	O
13	O
psychometric	O
measures	O
.	O

RESULTS	O
:	O
While	O
the	O
CAN	B_Chemical
and	O
PD	O
groups	O
tended	O
to	O
record	O
greater	O
deficits	O
than	O
the	O
non-drug	O
controls	O
,	O
the	O
MDMA	B_Chemical
and	O
EX-MDMA	O
groups	O
recorded	O
greater	O
deficits	O
than	O
all	O
the	O
control	O
groups	O
on	O
ten	O
of	O
the	O
13	O
psychometric	O
measures	O
.	O

Strikingly	O
,	O
despite	O
prolonged	O
abstinence	O
(	O
mean	O
,	O
4.98	O
;	O
range	O
,	O
4	O
-	O
9	O
years	O
)	O
,	O
past	O
ecstasy	B_Chemical
users	O
showed	O
few	O
signs	O
of	O
recovery	O
.	O

Compared	O
with	O
present	O
ecstasy	B_Chemical
users	O
,	O
the	O
past	O
users	O
showed	O
no	O
change	O
for	O
ten	O
measures	O
,	O
increased	O
impairment	O
for	O
two	O
measures	O
,	O
and	O
improvement	O
on	O
just	O
one	O
measure	O
.	O

CONCLUSIONS	O
:	O
Given	O
this	O
record	O
of	O
impaired	B_Disease
memory	I_Disease
and	O
clinically	O
significant	O
levels	O
of	O
depression	B_Disease
,	O
impulsiveness	B_Disease
,	O
and	O
sleep	B_Disease
disturbance	I_Disease
,	O
the	O
prognosis	O
for	O
the	O
current	O
generation	O
of	O
ecstasy	B_Chemical
users	O
is	O
a	O
major	O
cause	O
for	O
concern	O
.	O

Association	O
of	O
common	O
genetic	O
variants	O
of	O
HOMER1	O
gene	O
with	O
levodopa	B_Chemical
adverse	O
effects	O
in	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
patients	O
.	O

Levodopa	B_Chemical
is	O
the	O
most	O
effective	O
symptomatic	O
therapy	O
for	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
,	O
but	O
its	O
chronic	O
use	O
could	O
lead	O
to	O
chronic	O
adverse	O
outcomes	O
,	O
such	O
as	O
motor	O
fluctuations	O
,	O
dyskinesia	B_Disease
and	O
visual	B_Disease
hallucinations	I_Disease
.	O

HOMER1	O
is	O
a	O
protein	O
with	O
pivotal	O
function	O
in	O
glutamate	B_Chemical
transmission	O
,	O
which	O
has	O
been	O
related	O
to	O
the	O
pathogenesis	O
of	O
these	O
complications	O
.	O

This	O
study	O
investigates	O
whether	O
polymorphisms	O
in	O
the	O
HOMER1	O
gene	O
promoter	O
region	O
are	O
associated	O
with	O
the	O
occurrence	O
of	O
the	O
chronic	O
complications	O
of	O
levodopa	B_Chemical
therapy	O
.	O

A	O
total	O
of	O
205	O
patients	O
with	O
idiopathic	B_Disease
Parkinson	I_Disease
's	I_Disease
disease	I_Disease
were	O
investigated	O
.	O

Patients	O
were	O
genotyped	O
for	O
rs4704559	O
,	O
rs10942891	O
and	O
rs4704560	O
by	O
allelic	O
discrimination	O
with	O
Taqman	O
assays	O
.	O

The	O
rs4704559	O
G	O
allele	O
was	O
associated	O
with	O
a	O
lower	O
prevalence	O
of	O
dyskinesia	B_Disease
(	O
prevalence	O
ratio	O
(PR)=0.615	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.426	O
-	O
0.887	O
,	O
P=0.009	O
)	O
and	O
visual	B_Disease
hallucinations	I_Disease
(	O
PR=0.515	O
,	O
95	O
%	O
CI	O
0.295	O
-	O
0.899	O
,	O
P=0.020	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
HOMER1	O
rs4704559	O
G	O
allele	O
has	O
a	O
protective	O
role	O
for	O
the	O
development	O
of	O
levodopa	B_Chemical
adverse	O
effects	O
.	O

Crocin	B_Chemical
improves	O
lipid	O
dysregulation	O
in	O
subacute	O
diazinon	B_Chemical
exposure	O
through	O
ERK1/2	O
pathway	O
in	O
rat	O
liver	O
.	O

INTRODUCTION	O
:	O
Diazinon	B_Chemical
Yis	O
one	O
of	O
the	O
most	O
broadly	O
used	O
organophosphorus	B_Chemical
insecticides	O
in	O
agriculture	O
.	O

It	O
has	O
been	O
shown	O
that	O
exposure	O
to	O
diazinon	B_Chemical
may	O
interfere	O
with	O
lipid	O
metabolism	O
.	O

Moreover	O
,	O
the	O
hypolipidemic	O
effect	O
of	O
crocin	B_Chemical
has	O
been	O
established	O
.	O

Earlier	O
studies	O
revealed	O
the	O
major	O
role	O
of	O
Extracellular	O
signal-regulated	O
kinase	O
(	O
ERK	O
)	O
pathways	O
in	O
low-density	O
lipoprotein	O
receptor	O
(	O
LDLr	O
)	O
expression	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
changes	O
in	O
the	O
regulation	O
of	O
lipid	O
metabolism	O
,	O
ERK	O
and	O
LDLr	O
expression	O
in	O
the	O
liver	O
of	O
rats	O
exposed	O
to	O
subacute	O
diazinon	B_Chemical
.	O

Furthermore	O
ameliorating	O
effect	O
of	O
crocin	B_Chemical
on	O
diazinon	B_Chemical
induced	O
disturbed	O
cholesterol	B_Chemical
homeostasis	O
was	O
studied	O
.	O

METHODS	O
:	O
24	O
Rats	O
were	O
divided	O
into	O
4	O
groups	O
and	O
received	O
following	O
treatments	O
for	O
4	O
weeks	O
;	O
Corn	O
oil	O
(	O
control	O
)	O
,	O
diazinon	B_Chemical
(	O
15mg/kg	O
per	O
day	O
,	O
orally	O
)	O
and	O
crocin	B_Chemical
(	O
12.5	O
and	O
25mg/kg	O
per	O
day	O
,	O
intraperitoneally	O
)	O
in	O
combination	O
with	O
diazinon	B_Chemical
(	O
15	O
mg/kg	O
)	O
.	O

The	O
levels	O
of	O
cholesterol	B_Chemical
,	O
triglyceride	B_Chemical
and	O
LDL	O
in	O
blood	O
of	O
rats	O
were	O
analyzed	O
.	O

Moreover	O
mRNA	O
levels	O
of	O
LDLr	O
and	O
ERK1/2	O
as	O
well	O
as	O
protein	O
levels	O
of	O
total	O
and	O
activated	O
forms	O
of	O
ERK1/2	O
in	O
rat	O
liver	O
were	O
evaluated	O
by	O
Western	O
blotting	O
and	O
quantitative	O
real	O
time	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

RESULTS	O
:	O
Our	O
data	O
showed	O
that	O
subacute	O
exposure	O
to	O
diazinon	B_Chemical
significantly	O
increased	O
concentrations	O
of	O
cholesterol	B_Chemical
,	O
triglyceride	B_Chemical
and	O
LDL	O
.	O

Moreover	O
diazinon	B_Chemical
decreased	O
ERK1/2	O
protein	O
phosphorylation	O
and	O
LDLr	O
transcript	O
.	O

Crocin	B_Chemical
reduced	O
inhibition	O
of	O
ERK	O
activation	O
and	O
diazinon-induced	O
hyperlipemia	B_Disease
and	O
increased	O
levels	O
of	O
LDLr	O
transcript	O
.	O

CONCLUSIONS	O
:	O
Crocin	B_Chemical
may	O
be	O
considered	O
as	O
a	O
novel	O
protective	O
agent	O
in	O
diazinon-induced	O
hyperlipemia	B_Disease
through	O
modulating	O
of	O
ERK	O
pathway	O
and	O
increase	O
of	O
LDLr	O
expression	O
.	O

GEM-P	O
chemotherapy	O
is	O
active	O
in	O
the	O
treatment	O
of	O
relapsed	O
Hodgkin	B_Disease
lymphoma	I_Disease
.	O

Hodgkin	B_Disease
lymphoma	I_Disease
(	O
HL	B_Disease
)	O
is	O
a	O
relatively	O
chemosensitive	O
malignancy	B_Disease
.	O

However	O
,	O
for	O
those	O
who	O
relapse	O
,	O
high-dose	O
chemotherapy	O
with	O
autologous	O
stem	O
cell	O
transplant	O
is	O
the	O
treatment	O
of	O
choice	O
which	O
relies	O
on	O
adequate	O
disease	O
control	O
with	O
salvage	O
chemotherapy	O
.	O

Regimens	O
commonly	O
used	O
often	O
require	O
inpatient	O
administration	O
and	O
can	O
be	O
difficult	O
to	O
deliver	O
due	O
to	O
toxicity	B_Disease
.	O

Gemcitabine	B_Chemical
and	O
cisplatin	B_Chemical
have	O
activity	O
in	O
HL	B_Disease
,	O
non-overlapping	O
toxicity	B_Disease
with	O
first-line	O
chemotherapeutics	O
,	O
and	O
may	O
be	O
delivered	O
in	O
an	O
outpatient	O
setting	O
.	O

In	O
this	O
retrospective	O
single-centre	O
analysis	O
,	O
patients	O
with	O
relapsed	O
or	O
refractory	O
HL	B_Disease
treated	O
with	O
gemcitabine	B_Chemical
1,000	O
mg/m(2	O
)	O
day	O
(D)1	O
,	O
D8	O
and	O
D15	O
;	O
methylprednisolone	B_Chemical
1,000	O
mg	O
D1	O
-	O
5	O
;	O
and	O
cisplatin	B_Chemical
100	O
mg/m(2	O
)	O
D15	O
,	O
every	O
28	O
days	O
(	O
GEM-P	O
)	O
were	O
included	O
.	O

Demographic	O
,	O
survival	O
,	O
response	O
and	O
toxicity	B_Disease
data	O
were	O
recorded	O
.	O

Forty-one	O
eligible	O
patients	O
were	O
identified	O
:	O
median	O
age	O
27	O
.	O

One	O
hundred	O
and	O
twenty-two	O
cycles	O
of	O
GEM-P	O
were	O
administered	O
in	O
total	O
(	O
median	O
3	O
cycles	O
;	O
range	O
1	O
-	O
6	O
)	O
.	O

Twenty	O
of	O
41	O
(	O
48	O
%	O
)	O
patients	O
received	O
GEM-P	O
as	O
second-line	O
treatment	O
and	O
11/41	O
(	O
27	O
%	O
)	O
as	O
third-line	O
therapy	O
.	O

Overall	O
response	O
rate	O
(	O
ORR	O
)	O
to	O
GEM-P	O
in	O
the	O
entire	O
cohort	O
was	O
80	O
%	O
(	O
complete	O
response	O
(	O
CR	O
)	O
37	O
%	O
,	O
partial	O
response	O
44	O
%	O
)	O
with	O
14/15	O
CR	O
confirmed	O
as	O
a	O
metabolic	O
CR	O
on	O
PET	O
and	O
ORR	O
of	O
85	O
%	O
in	O
the	O
20	O
second-line	O
patients	O
.	O

The	O
most	O
common	O
grade	O
3/4	O
toxicities	B_Disease
were	O
haematological	O
:	O
neutropenia	B_Disease
54	O
%	O
and	O
thrombocytopenia	B_Disease
51	O
%	O
.	O

Median	O
follow-up	O
from	O
the	O
start	O
of	O
GEM-P	O
was	O
4.5	O
years	O
.	O

Following	O
GEM-P	O
,	O
5-year	O
progression-free	O
survival	O
was	O
46	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
30	O
-	O
62	O
%	O
)	O
and	O
5-year	O
overall	O
survival	O
was	O
59	O
%	O
(	O
95	O
%	O
CI	O
,	O
43	O
-	O
74	O
%	O
)	O
.	O

Fourteen	O
of	O
41	O
patients	O
proceeded	O
directly	O
to	O
autologous	O
transplant	O
.	O

GEM-P	O
is	O
a	O
salvage	O
chemotherapy	O
with	O
relatively	O
high	O
response	O
rates	O
,	O
leading	O
to	O
successful	O
transplantation	O
in	O
appropriate	O
patients	O
,	O
in	O
the	O
treatment	O
of	O
relapsed	O
or	O
refractory	O
HL	B_Disease
.	O

Basal	O
functioning	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
axis	O
and	O
psychological	O
distress	O
in	O
recreational	O
ecstasy	O
polydrug	O
users	O
.	O

RATIONALE	O
:	O
Ecstasy	B_Chemical
(	O
MDMA	B_Chemical
)	O
is	O
a	O
psychostimulant	O
drug	O
which	O
is	O
increasingly	O
associated	O
with	O
psychobiological	B_Disease
dysfunction	I_Disease
.	O

While	O
some	O
recent	O
studies	O
suggest	O
acute	O
changes	O
in	O
neuroendocrine	O
function	O
,	O
less	O
is	O
known	O
about	O
long-term	O
changes	O
in	O
HPA	O
functionality	O
in	O
recreational	O
users	O
.	O

OBJECTIVES	O
:	O
The	O
current	O
study	O
is	O
the	O
first	O
to	O
explore	O
the	O
effects	O
of	O
ecstasy-polydrug	O
use	O
on	O
psychological	O
distress	O
and	O
basal	O
functioning	O
of	O
the	O
HPA	O
axis	O
through	O
assessing	O
the	O
secretion	O
of	O
cortisol	B_Chemical
across	O
the	O
diurnal	O
period	O
.	O

METHOD	O
:	O
Seventy-six	O
participants	O
(	O
21	O
nonusers	O
,	O
29	O
light	O
ecstasy-polydrug	O
users	O
,	O
26	O
heavy	O
ecstasy-polydrug	O
users	O
)	O
completed	O
a	O
substance	O
use	O
inventory	O
and	O
measures	O
of	O
psychological	O
distress	O
at	O
baseline	O
,	O
then	O
two	O
consecutive	O
days	O
of	O
cortisol	B_Chemical
sampling	O
(	O
on	O
awakening	O
,	O
30	O
min	O
post	O
awakening	O
,	O
between	O
1400	O
and	O
1600	O
hours	O
and	O
pre	O
bedtime	O
)	O
.	O

On	O
day	O
2	O
,	O
participants	O
also	O
attended	O
the	O
laboratory	O
to	O
complete	O
a	O
20-min	O
multitasking	O
stressor	O
.	O

RESULTS	O
:	O
Both	O
user	O
groups	O
exhibited	O
significantly	O
greater	O
levels	O
of	O
anxiety	B_Disease
and	O
depression	B_Disease
than	O
nonusers	O
.	O

On	O
day	O
1	O
,	O
all	O
participants	O
exhibited	O
a	O
typical	O
cortisol	B_Chemical
profile	O
,	O
though	O
light	O
users	O
had	O
significantly	O
elevated	O
levels	O
pre-bed	O
.	O

On	O
day	O
2	O
,	O
heavy	O
users	O
demonstrated	O
elevated	O
levels	O
upon	O
awakening	O
and	O
all	O
ecstasy-polydrug	O
users	O
demonstrated	O
elevated	O
pre-bed	O
levels	O
compared	O
to	O
non-users	O
.	O

Significant	O
between	O
group	O
differences	O
were	O
also	O
observed	O
in	O
afternoon	O
cortisol	B_Chemical
levels	O
and	O
in	O
overall	O
cortisol	B_Chemical
secretion	O
across	O
the	O
day	O
.	O

CONCLUSIONS	O
:	O
The	O
increases	O
in	O
anxiety	B_Disease
and	O
depression	B_Disease
are	O
in	O
line	O
with	O
previous	O
observations	O
in	O
recreational	O
ecstasy-polydrug	O
users	O
.	O

Dysregulated	O
diurnal	O
cortisol	B_Chemical
may	O
be	O
indicative	O
of	O
inappropriate	O
anticipation	O
of	O
forthcoming	O
demands	O
and	O
hypersecretion	O
may	O
lead	O
to	O
the	O
increased	O
psychological	O
and	O
physical	O
morbidity	O
associated	O
with	O
heavy	O
recreational	O
use	O
of	O
ecstasy	B_Chemical
.	O

Ifosfamide	B_Chemical
related	O
encephalopathy	B_Disease
:	O
the	O
need	O
for	O
a	O
timely	O
EEG	O
evaluation	O
.	O

BACKGROUND	O
:	O
Ifosfamide	B_Chemical
is	O
an	O
alkylating	O
agent	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
wide	O
range	O
of	O
cancers	B_Disease
including	O
sarcomas	B_Disease
,	O
lymphoma	B_Disease
,	O
gynecologic	B_Disease
and	I_Disease
testicular	I_Disease
cancers	I_Disease
.	O

Encephalopathy	B_Disease
has	O
been	O
reported	O
in	O
10	O
-	O
40	O
%	O
of	O
patients	O
receiving	O
high-dose	O
IV	O
ifosfamide	B_Chemical
.	O

OBJECTIVE	O
:	O
To	O
highlight	O
the	O
role	O
of	O
electroencephalogram	O
(	O
EEG	O
)	O
in	O
the	O
early	O
detection	O
and	O
management	O
of	O
ifosfamide	B_Chemical
related	O
encephalopathy	B_Disease
.	O

METHODS	O
:	O
Retrospective	O
chart	O
review	O
including	O
clinical	O
data	O
and	O
EEG	O
recordings	O
was	O
done	O
on	O
five	O
patients	O
,	O
admitted	O
to	O
MD	O
Anderson	O
Cancer	B_Disease
Center	O
between	O
years	O
2009	O
and	O
2012	O
,	O
who	O
developed	O
ifosfamide	B_Chemical
related	O
acute	O
encephalopathy	B_Disease
.	O

RESULTS	O
:	O
All	O
five	O
patients	O
experienced	O
symptoms	O
of	O
encephalopathy	B_Disease
soon	O
after	O
(	O
within	O
12	O
h-2	O
days	O
)	O
receiving	O
ifosfamide	B_Chemical
.	O

Two	O
patients	O
developed	O
generalized	O
convulsions	B_Disease
while	O
one	O
patient	O
developed	O
continuous	O
non-convulsive	B_Disease
status	I_Disease
epilepticus	I_Disease
(	O
NCSE	B_Disease
)	O
that	O
required	O
ICU	O
admission	O
and	O
intubation	O
.	O

Initial	O
EEG	O
showed	O
epileptiform	O
discharges	O
in	O
three	O
patients	O
;	O
run	O
of	O
triphasic	O
waves	O
in	O
one	O
patient	O
and	O
moderate	O
degree	O
diffuse	O
generalized	O
slowing	O
.	O

Mixed	O
pattern	O
with	O
the	O
presence	O
of	O
both	O
sharps	O
and	O
triphasic	O
waves	O
were	O
also	O
noted	O
.	O

Repeat	O
EEGs	O
within	O
24_h	O
of	O
symptom	O
onset	O
showed	O
marked	O
improvement	O
that	O
was	O
correlated	O
with	O
clinical	O
improvement	O
.	O

CONCLUSIONS	O
:	O
Severity	O
of	O
ifosfamide	B_Chemical
related	O
encephalopathy	B_Disease
correlates	O
with	O
EEG	O
changes	O
.	O

We	O
suggest	O
a	O
timely	O
EEG	O
evaluation	O
for	O
patients	O
receiving	O
ifosfamide	B_Chemical
who	O
develop	O
features	O
of	O
encephalopathy	B_Disease
.	O

Incidence	O
of	O
contrast-induced	O
nephropathy	B_Disease
in	O
hospitalised	O
patients	O
with	O
cancer	B_Disease
.	O

OBJECTIVES	O
:	O
To	O
determine	O
the	O
frequency	O
of	O
and	O
possible	O
factors	O
related	O
to	O
contrast-induced	O
nephropathy	B_Disease
(	O
CIN	O
)	O
in	O
hospitalised	O
patients	O
with	O
cancer	B_Disease
.	O

METHODS	O
:	O
Ninety	O
adult	O
patients	O
were	O
enrolled	O
.	O

Patients	O
with	O
risk	O
factors	O
for	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
were	O
excluded	O
.	O

Blood	O
samples	O
were	O
examined	O
the	O
day	O
before	O
contrast-enhanced	O
computed	O
tomography	O
(	O
CT	O
)	O
and	O
serially	O
for	O
3	O
days	O
thereafter	O
.	O

CIN	O
was	O
defined	O
as	O
an	O
increase	O
in	O
serum	O
creatinine	B_Chemical
(	O
Cr	B_Chemical
)	O
of	O
0.5	O
mg/dl	O
or	O
more	O
,	O
or	O
elevation	O
of	O
Cr	B_Chemical
to	O
25	O
%	O
over	O
baseline	O
.	O

Relationships	O
between	O
CIN	O
and	O
possible	O
risk	O
factors	O
were	O
investigated	O
.	O

RESULTS	O
:	O
CIN	O
was	O
detected	O
in	O
18/90	O
(	O
20	O
%	O
)	O
patients	O
.	O

CIN	O
developed	O
in	O
25.5	O
%	O
patients	O
who	O
underwent	O
chemotherapy	O
and	O
in	O
11	O
%	O
patients	O
who	O
did	O
not	O
(	O
P	O
=	O
0.1	O
)	O
.	O

CIN	O
more	O
frequently	O
developed	O
in	O
patients	O
who	O
had	O
undergone	O
CT	O
within	O
45	O
days	O
after	O
the	O
last	O
chemotherapy	O
(	O
P	O
=	O
0.005	O
)	O
;	O
it	O
was	O
also	O
an	O
independent	O
risk	O
factor	O
(	O
P	O
=	O
0.017	O
)	O
.	O

CIN	O
was	O
significantly	O
more	O
after	O
treatment	O
with	O
bevacizumab/irinotecan	O
(	O
P	O
=	O
0.021	O
)	O
and	O
in	O
patients	O
with	O
hypertension	B_Disease
(	O
P	O
=	O
0.044	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
incidence	O
of	O
CIN	O
after	O
CT	O
in	O
hospitalised	O
oncological	O
patients	O
was	O
20	O
%	O
.	O

CIN	O
developed	O
4.5-times	O
more	O
frequently	O
in	O
patients	O
with	O
cancer	B_Disease
who	O
had	O
undergone	O
recent	O
chemotherapy	O
.	O

Hypertension	B_Disease
and	O
the	O
combination	O
of	O
bevacizumab/irinotecan	O
may	O
be	O
additional	O
risk	O
factors	O
for	O
CIN	O
development	O
.	O

KEY	O
POINTS	O
:	O
.	O

Contrast-induced	O
nephropathy	B_Disease
(	O
CIN	O
)	O
is	O
a	O
concern	O
for	O
oncological	O
patients	O
undergoing	O
CT	O
.	O
.	O

CIN	O
occurs	O
more	O
often	O
when	O
CT	O
is	O
performed	O
<	O
45	O
days	O
after	O
chemotherapy	O
.	O
.	O

Hypertension	B_Disease
and	O
treatment	O
with	O
bevacizumab	B_Chemical
appear	O
to	O
be	O
additional	O
risk	O
factors	O
.	O

Syndrome	B_Disease
of	I_Disease
inappropriate	I_Disease
antidiuretic	I_Disease
hormone	I_Disease
secretion	O
associated	O
with	O
desvenlafaxine	B_Chemical
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
syndrome	B_Disease
of	I_Disease
inappropriate	I_Disease
anti-diuretic	I_Disease
hormone	I_Disease
(	O
SIADH	B_Disease
)	O
secretion	O
associated	O
with	O
desvenlafaxine	B_Chemical
.	O

CASE	O
SUMMARY	O
:	O
A	O
57-year	O
old	O
female	O
with	O
hyponatraemia	B_Disease
.	O

Her	O
medications	O
included	O
desvenlafaxine	B_Chemical
,	O
and	O
symptoms	O
included	O
nausea	B_Disease
,	O
anxiety	B_Disease
and	O
confusion	B_Disease
.	O

The	O
serum	O
sodium	B_Chemical
at	O
this	O
time	O
was	O
120	O
mmol/L	O
,	O
serum	O
osmolality	O
was	O
263	O
mosmol/kg	O
,	O
urine	O
osmolality	O
410	O
mosmol/kg	O
and	O
urine	O
sodium	B_Chemical
63	O
mmol/L	O
,	O
consistent	O
with	O
a	O
diagnosis	O
of	O
SIADH	B_Disease
.	O

Desvenlafaxine	B_Chemical
was	O
ceased	O
and	O
fluid	O
restriction	O
implemented	O
.	O

After	O
4	O
days	O
the	O
sodium	B_Chemical
increased	O
to	O
128	O
mmol/L	O
and	O
fluid	O
restriction	O
was	O
relaxed	O
.	O

During	O
her	O
further	O
3	O
weeks	O
inpatient	O
admission	O
the	O
serum	O
sodium	B_Chemical
ranged	O
from	O
134	O
to	O
137	O
mmol/L	O
during	O
treatment	O
with	O
mirtazapine	B_Chemical
.	O

DISCUSSION	O
:	O
SIADH	B_Disease
has	O
been	O
widely	O
reported	O
with	O
a	O
range	O
of	O
antidepressants	O
.	O

This	O
case	O
report	O
suggests	O
that	O
desvenlafaxine	B_Chemical
might	O
cause	O
clinically	O
significant	O
hyponatremia	B_Disease
.	O

CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
antidepressants	O
to	O
cause	O
hyponatremia	B_Disease
,	O
and	O
take	O
appropriate	O
corrective	O
action	O
where	O
necessary	O
.	O

Oxidative	O
stress	O
on	O
cardiotoxicity	B_Disease
after	O
treatment	O
with	O
single	O
and	O
multiple	O
doses	O
of	O
doxorubicin	B_Chemical
.	O

The	O
mechanism	O
of	O
doxorubicin	B_Chemical
(DOX)-induced	O
cardiotoxicity	B_Disease
remains	O
controversial	O
.	O

Wistar	O
rats	O
(	O
n	O
=	O
66	O
)	O
received	O
DOX	B_Chemical
injections	O
intraperitoneally	O
and	O
were	O
randomly	O
assigned	O
to	O
2	O
experimental	O
protocols	O
:	O
(	O
1	O
)	O
rats	O
were	O
killed	O
before	O
(	O
-24	O
h	O
,	O
n	O
=	O
8)	O
and	O
24	O
h	O
after	O
(	O
+	O
24	O
h	O
,	O
n	O
=	O
8)	O
a	O
single	O
dose	O
of	O
DOX	B_Chemical
(	O
4	O
mg/kg	O
body	O
weight	O
)	O
to	O
determine	O
the	O
DOX	B_Chemical
acute	O
effect	O
and	O
(	O
2	O
)	O
rats	O
(	O
n	O
=	O
58	O
)	O
received	O
4	O
injections	O
of	O
DOX	B_Chemical
(	O
4	O
mg/kg	O
body	O
weight/week	O
)	O
and	O
were	O
killed	O
before	O
the	O
first	O
injection	O
(	O
M0	O
)	O
and	O
1	O
week	O
after	O
each	O
injection	O
(	O
M1	O
,	O
M2	O
,	O
M3	O
,	O
and	O
M4	O
)	O
to	O
determine	O
the	O
chronological	O
effects	O
.	O

Animals	O
used	O
at	O
M0	O
(	O
n	O
=	O
8)	O
were	O
also	O
used	O
at	O
moment	O
-24	O
h	O
of	O
acute	O
study	O
.	O

Cardiac	O
total	O
antioxidant	O
performance	O
(	O
TAP	O
)	O
,	O
DNA	O
damage	O
,	O
and	O
morphology	O
analyses	O
were	O
carried	O
out	O
at	O
each	O
time	O
point	O
.	O

Single	O
dose	O
of	O
DOX	B_Chemical
was	O
associated	O
with	O
increased	O
cardiac	B_Disease
disarrangement	I_Disease
,	O
necrosis	B_Disease
,	O
and	O
DNA	O
damage	O
(	O
strand	O
breaks	O
(	O
SBs	O
)	O
and	O
oxidized	O
pyrimidines	O
)	O
and	O
decreased	O
TAP	O
.	O

The	O
chronological	O
study	O
showed	O
an	O
effect	O
of	O
a	O
cumulative	O
dose	O
on	O
body	O
weight	O
(	O
R	O
=	O
-0.99	O
,	O
p	O
=	O
0.011	O
)	O
,	O
necrosis	B_Disease
(	O
R	O
=	O
1.00	O
,	O
p	O
=	O
0.004	O
)	O
,	O
TAP	O
(	O
R	O
=	O
0.95	O
,	O
p	O
=	O
0.049	O
)	O
,	O
and	O
DNA	O
SBs	O
(	O
R	O
=	O
-0.95	O
,	O
p	O
=	O
0.049	O
)	O
.	O

DNA	O
SBs	O
damage	O
was	O
negatively	O
associated	O
with	O
TAP	O
(	O
R	O
=	O
-0.98	O
,	O
p	O
=	O
0.018	O
)	O
,	O
and	O
necrosis	B_Disease
(	O
R	O
=	O
-0.97	O
,	O
p	O
=	O
0.027	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
oxidative	O
damage	O
is	O
associated	O
with	O
acute	O
cardiotoxicity	B_Disease
induced	O
by	O
a	O
single	O
dose	O
of	O
DOX	B_Chemical
only	O
.	O

Increased	O
resistance	O
to	O
the	O
oxidative	O
stress	O
is	O
plausible	O
for	O
the	O
multiple	O
dose	O
of	O
DOX	B_Chemical
.	O

Thus	O
,	O
different	O
mechanisms	O
may	O
be	O
involved	O
in	O
acute	O
toxicity	B_Disease
versus	O
chronic	O
toxicity	B_Disease
.	O

Tacrolimus-related	O
seizure	B_Disease
after	O
pediatric	O
liver	O
transplantation	O
--	O
a	O
single-center	O
experience	O
.	O

To	O
identify	O
the	O
risk	O
factors	O
for	O
new-onset	O
seizures	B_Disease
after	O
pediatric	O
LT	O
and	O
to	O
assess	O
their	O
clinical	O
implications	O
and	O
long-term	O
prognosis	O
.	O

The	O
clinical	O
and	O
laboratory	O
data	O
of	O
27	O
consecutive	O
children	O
who	O
underwent	O
LT	O
from	O
January	O
2007	O
to	O
December	O
2010	O
in	O
our	O
center	O
were	O
analyzed	O
retrospectively	O
.	O

Patients	O
were	O
divided	O
into	O
seizures	B_Disease
group	O
and	O
a	O
non-seizures	O
group	O
.	O

Pre-operative	O
,	O
intra-operative	O
,	O
and	O
post-operative	O
data	O
were	O
collected	O
.	O

Seizures	B_Disease
occurred	O
in	O
four	O
children	O
,	O
an	O
incidence	O
of	O
14.8	O
%	O
.	O

All	O
exhibited	O
generalized	O
tonic-clonic	B_Disease
seizures	I_Disease
within	O
the	O
first	O
two	O
wk	O
after	O
LT	O
.	O

Univariate	O
analysis	O
showed	O
that	O
the	O
risk	O
factors	O
associated	O
with	O
seizures	B_Disease
after	O
pediatric	O
LT	O
included	O
gender	O
,	O
pediatric	O
end-stage	B_Disease
liver	I_Disease
disease	I_Disease
score	O
before	O
surgery	O
,	O
Child-Pugh	O
score	O
before	O
surgery	O
,	O
serum	O
total	O
bilirubin	B_Chemical
after	O
surgery	O
,	O
and	O
trough	O
TAC	B_Chemical
level	O
.	O

Multivariate	O
analysis	O
showed	O
that	O
trough	O
TAC	B_Chemical
level	O
was	O
the	O
only	O
independent	O
risk	O
factor	O
associated	O
with	O
the	O
seizures	B_Disease
.	O

All	O
children	O
who	O
experienced	O
seizures	B_Disease
survived	O
with	O
good	O
graft	O
function	O
and	O
remained	O
seizure-free	O
without	O
anti-epileptic	O
drugs	O
over	O
a	O
mean	O
follow-up	O
period	O
of	O
33.7	O
+	O
14.6	O
months	O
.	O

High	O
trough	O
TAC	B_Chemical
level	O
was	O
the	O
predominant	O
factor	O
that	O
contributed	O
to	O
seizures	B_Disease
in	O
the	O
early	O
post-operative	O
period	O
after	O
pediatric	O
LT	O
.	O

High	O
PELD	O
and	O
Child-Pugh	O
scores	O
before	O
LT	O
and	O
high	O
post-operative	O
serum	O
Tbil	O
may	O
be	O
contributory	O
risk	O
factors	O
for	O
TAC-related	O
seizures	B_Disease
.	O

The	O
flavonoid	B_Chemical
apigenin	B_Chemical
delays	O
forgetting	O
of	O
passive	O
avoidance	O
conditioning	O
in	O
rats	O
.	O

The	O
present	O
experiments	O
were	O
performed	O
to	O
study	O
the	O
effect	O
of	O
the	O
flavonoid	B_Chemical
apigenin	B_Chemical
(	O
20	O
mg/kg	O
intraperitoneally	O
(	O
i.p	O
.	O
)	O
,	O
1	O
h	O
before	O
acquisition	O
)	O
,	O
on	O
24	O
h	O
retention	O
performance	O
and	O
forgetting	O
of	O
a	O
step-through	O
passive	O
avoidance	O
task	O
,	O
in	O
young	O
male	O
Wistar	O
rats	O
.	O

There	O
were	O
no	O
differences	O
between	O
saline-	O
and	O
apigenin-treated	O
groups	O
in	O
the	O
24	O
h	O
retention	O
trial	O
.	O

Furthermore	O
,	O
apigenin	B_Chemical
did	O
not	O
prevent	O
the	O
amnesia	B_Disease
induced	O
by	O
scopolamine	B_Chemical
(	O
1mg/kg	O
,	O
i.p	O
.	O
,	O
30	O
min	O
before	O
the	O
acquisition	O
)	O
.	O

The	O
saline-	O
and	O
apigenin-treated	O
rats	O
that	O
did	O
not	O
step	O
through	O
into	O
the	O
dark	O
compartment	O
during	O
the	O
cut-off	O
time	O
(	O
540	O
s	O
)	O
were	O
retested	O
weekly	O
for	O
up	O
to	O
eight	O
weeks	O
.	O

In	O
the	O
saline	O
treated	O
group	O
,	O
the	O
first	O
significant	O
decline	O
in	O
passive	O
avoidance	O
response	O
was	O
observed	O
at	O
four	O
weeks	O
,	O
and	O
complete	O
memory	B_Disease
loss	I_Disease
was	O
found	O
five	O
weeks	O
after	O
the	O
acquisition	O
of	O
the	O
passive	O
avoidance	O
task	O
.	O

At	O
the	O
end	O
of	O
the	O
experimental	O
period	O
,	O
60	O
%	O
of	O
the	O
animals	O
treated	O
with	O
apigenin	B_Chemical
still	O
did	O
not	O
step	O
through	O
.	O

These	O
data	O
suggest	O
that	O
1	O
)	O
apigenin	B_Chemical
delays	O
the	O
long-term	O
forgetting	O
but	O
did	O
not	O
modulate	O
the	O
24	O
h	O
retention	O
of	O
fear	O
memory	O
and	O
2	O
)	O
the	O
obtained	O
beneficial	O
effect	O
of	O
apigenin	B_Chemical
on	O
the	O
passive	O
avoidance	O
conditioning	O
is	O
mediated	O
by	O
mechanisms	O
that	O
do	O
not	O
implicate	O
its	O
action	O
on	O
the	O
muscarinic	O
cholinergic	O
system	O
.	O

Histamine	B_Chemical
antagonists	O
and	O
d-tubocurarine-induced	O
hypotension	B_Disease
in	O
cardiac	O
surgical	O
patients	O
.	O

Hemodynamic	O
effects	O
and	O
histamine	B_Chemical
release	O
by	O
bolus	O
injection	O
of	O
0.35	O
mg/kg	O
of	O
d-tubocurarine	B_Chemical
were	O
studied	O
in	O
24	O
patients	O
.	O

H1-	O
and	O
H2-histamine	O
antagonists	O
or	O
placebo	O
were	O
given	O
before	O
dosing	O
with	O
d-tubocurarine	B_Chemical
in	O
a	O
randomized	O
double-blind	O
fashion	O
to	O
four	O
groups	O
:	O
group	O
1	O
-	O
-placebo	O
;	O
group	O
2	O
-	O
-cimetidine	O
,	O
4	O
mg/kg	O
,	O
plus	O
placebo	O
;	O
group	O
3	O
-	O
-chlorpheniramine	O
,	O
0.1	O
mg/kg	O
,	O
plus	O
placebo	O
;	O
and	O
group	O
4	O
-	O
-cimetidine	O
plus	O
chlorpheniramine	B_Chemical
.	O

Histamine	B_Chemical
release	O
occurred	O
in	O
most	O
patients	O
,	O
the	O
highest	O
level	O
2	O
minutes	O
after	O
d-tubocurarine	B_Chemical
dosing	O
.	O

Group	O
1	O
had	O
a	O
moderate	O
negative	O
correlation	O
between	O
plasma	O
histamine	B_Chemical
change	O
and	O
systemic	O
vascular	O
resistance	O
(	O
r	O
=	O
0.58	O
;	O
P	O
less	O
than	O
0.05	O
)	O
not	O
present	O
in	O
group	O
4	O
.	O

Prior	O
dosing	O
with	O
antagonists	O
partially	O
prevented	O
the	O
fall	O
in	O
systemic	O
vascular	O
resistance	O
.	O

These	O
data	O
demonstrate	O
that	O
the	O
hemodynamic	O
changes	O
associated	O
with	O
d-tubocurarine	B_Chemical
dosing	O
are	O
only	O
partially	O
explained	O
by	O
histamine	B_Chemical
release	O
.	O

Thus	O
prior	O
dosing	O
with	O
H1-	O
and	O
H2-antagonists	O
provides	O
only	O
partial	O
protection	O
.	O

Cholecystokinin-octapeptide	B_Chemical
restored	O
morphine-induced	O
hippocampal	O
long-term	O
potentiation	O
impairment	O
in	O
rats	O
.	O

Cholecystokinin-octapeptide	B_Chemical
(	O
CCK-8	B_Chemical
)	O
,	O
which	O
is	O
a	O
typical	O
brain-gut	O
peptide	O
,	O
exerts	O
a	O
wide	O
range	O
of	O
biological	O
activities	O
on	O
the	O
central	O
nervous	O
system	O
.	O

We	O
have	O
previously	O
reported	O
that	O
CCK-8	B_Chemical
significantly	O
alleviated	O
morphine-induced	O
amnesia	B_Disease
and	O
reversed	O
spine	O
density	O
decreases	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
in	O
morphine-treated	O
animals	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
CCK-8	B_Chemical
on	O
long-term	O
potentiation	O
(	O
LTP	O
)	O
in	O
the	O
lateral	O
perforant	O
path	O
(LPP)-granule	O
cell	O
synapse	O
of	O
rat	O
dentate	O
gyrus	O
(	O
DG	O
)	O
in	O
acute	O
saline	O
or	O
morphine-treated	O
rats	O
.	O

Population	O
spikes	O
(	O
PS	O
)	O
,	O
which	O
were	O
evoked	O
by	O
stimulation	O
of	O
the	O
LPP	O
,	O
were	O
recorded	O
in	O
the	O
DG	O
region	O
.	O

Acute	O
morphine	B_Chemical
(	O
30mg/kg	O
,	O
s.c	O
.	O
)	O
treatment	O
significantly	O
attenuated	O
hippocampal	O
LTP	O
and	O
CCK-8	B_Chemical
(	O
1ug	O
,	O
i.c.v	O
.	O
)	O
restored	O
the	O
amplitude	O
of	O
PS	O
that	O
was	O
attenuated	O
by	O
morphine	B_Chemical
injection	O
.	O

Furthermore	O
,	O
microinjection	O
of	O
CCK-8	B_Chemical
(	O
0.1	O
and	O
1ug	O
,	O
i.c.v	O
.	O
)	O
also	O
significantly	O
augmented	O
hippocampal	O
LTP	O
in	O
saline-treated	O
(	O
1ml/kg	O
,	O
s.c	O
.	O
)	O
rats	O
.	O

Pre-treatment	O
of	O
the	O
CCK2	O
receptor	O
antagonist	O
L-365,260	O
(	O
10ug	O
,	O
i.c.v	O
)	O
reversed	O
the	O
effects	O
of	O
CCK-8	B_Chemical
,	O
but	O
the	O
CCK1	O
receptor	O
antagonist	O
L-364,718	O
(	O
10ug	O
,	O
i.c.v	O
)	O
did	O
not	O
.	O

The	O
present	O
results	O
demonstrate	O
that	O
CCK-8	B_Chemical
attenuates	O
the	O
effect	O
of	O
morphine	B_Chemical
on	O
hippocampal	O
LTP	O
through	O
CCK2	O
receptors	O
and	O
suggest	O
an	O
ameliorative	O
function	O
of	O
CCK-8	B_Chemical
on	O
morphine-induced	O
memory	B_Disease
impairment	I_Disease
.	O

Glial	O
activation	O
and	O
post-synaptic	O
neurotoxicity	B_Disease
:	O
the	O
key	O
events	O
in	O
Streptozotocin	B_Chemical
(	O
ICV	O
)	O
induced	O
memory	B_Disease
impairment	I_Disease
in	O
rats	O
.	O

In	O
the	O
present	O
study	O
the	O
role	O
of	O
glial	O
activation	O
and	O
post	O
synaptic	O
toxicity	B_Disease
in	O
ICV	O
Streptozotocin	B_Chemical
(	O
STZ	B_Chemical
)	O
induced	O
memory	B_Disease
impaired	I_Disease
rats	O
was	O
explored	O
.	O

In	O
experiment	O
set	O
up	O
1	O
:	O
Memory	B_Disease
deficit	I_Disease
was	O
found	O
in	O
Morris	O
water	O
maze	O
test	O
on	O
14	O
-	O
16	O
days	O
after	O
STZ	B_Chemical
(	O
ICV	O
;	O
3mg/Kg	O
)	O
administration	O
.	O

STZ	B_Chemical
causes	O
increased	O
expression	O
of	O
GFAP	O
,	O
CD11b	O
and	O
TNF-a	O
indicating	O
glial	O
activation	O
and	O
neuroinflammation	B_Disease
.	O

STZ	B_Chemical
also	O
significantly	O
increased	O
the	O
level	O
of	O
ROS	O
,	O
nitrite	B_Chemical
,	O
Ca(2	O
+	O
)	O
and	O
reduced	O
the	O
mitochondrial	O
activity	O
in	O
synaptosomal	O
preparation	O
illustrating	O
free	O
radical	O
generation	O
and	O
excitotoxicity	B_Disease
.	O

Increased	O
expression	O
and	O
activity	O
of	O
Caspase-3	O
was	O
also	O
observed	O
in	O
STZ	B_Chemical
treated	O
rat	O
which	O
specify	O
apoptotic	O
cell	O
death	O
in	O
hippocampus	O
and	O
cortex	O
.	O

STZ	B_Chemical
treatment	O
showed	O
decrease	O
expression	O
of	O
post	O
synaptic	O
markers	O
CaMKIIa	O
and	O
PSD-95	O
,	O
while	O
,	O
expression	O
of	O
pre	O
synaptic	O
markers	O
(	O
synaptophysin	O
and	O
SNAP-25	O
)	O
remains	O
unaltered	O
indicating	O
selective	O
post	O
synaptic	O
neurotoxicity	B_Disease
.	O

Oral	O
treatment	O
with	O
Memantine	B_Chemical
(	O
10mg/kg	O
)	O
and	O
Ibuprofen	B_Chemical
(	O
50	O
mg/kg	O
)	O
daily	O
for	O
13	O
days	O
attenuated	O
STZ	B_Chemical
induced	O
glial	O
activation	O
,	O
apoptotic	O
cell	O
death	O
and	O
post	O
synaptic	O
neurotoxicity	B_Disease
in	O
rat	O
brain	O
.	O

Further	O
,	O
in	O
experiment	O
set	O
up	O
2	O
:	O
where	O
memory	O
function	O
was	O
not	O
affected	O
i.e.	O
7	O
-	O
9	O
days	O
after	O
STZ	B_Chemical
treatment	O
.	O

The	O
level	O
of	O
GFAP	O
,	O
CD11b	O
,	O
TNF-a	O
,	O
ROS	O
and	O
nitrite	B_Chemical
levels	O
were	O
increased	O
.	O

On	O
the	O
other	O
hand	O
,	O
apoptotic	O
marker	O
,	O
synaptic	O
markers	O
,	O
mitochondrial	O
activity	O
and	O
Ca(2	O
+	O
)	O
levels	O
remained	O
unaffected	O
.	O

Collective	O
data	O
indicates	O
that	O
neuroinflammatory	B_Disease
process	O
and	O
oxidative	O
stress	O
occurs	O
earlier	O
to	O
apoptosis	O
and	O
does	O
not	O
affect	O
memory	O
function	O
.	O

Present	O
study	O
clearly	O
suggests	O
that	O
glial	O
activation	O
and	O
post	O
synaptic	O
neurotoxicity	B_Disease
are	O
the	O
key	O
factors	O
in	O
STZ	B_Chemical
induced	O
memory	B_Disease
impairment	I_Disease
and	O
neuronal	O
cell	O
death	O
.	O

Comparison	O
of	O
effects	O
of	O
isotonic	O
sodium	B_Chemical
chloride	I_Chemical
with	O
diltiazem	B_Chemical
in	O
prevention	O
of	O
contrast-induced	O
nephropathy	B_Disease
.	O

INTRODUCTION	O
AND	O
OBJECTIVE	O
:	O
Contrast-induced	O
nephropathy	B_Disease
(	O
CIN	O
)	O
significantly	O
increases	O
the	O
morbidity	O
and	O
mortality	O
of	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
and	O
compare	O
the	O
protective	O
effects	O
of	O
isotonic	O
sodium	B_Chemical
chloride	I_Chemical
with	O
sodium	B_Chemical
bicarbonate	I_Chemical
infusion	O
and	O
isotonic	O
sodium	B_Chemical
chloride	I_Chemical
infusion	O
with	O
diltiazem	B_Chemical
,	O
a	O
calcium	B_Chemical
channel	O
blocker	O
,	O
in	O
preventing	O
CIN	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Our	O
study	O
included	O
patients	O
who	O
were	O
administered	O
30	O
-	O
60	O
mL	O
of	O
iodinated	O
contrast	B_Chemical
agent	O
for	O
percutaneous	O
coronary	O
angiography	O
(	O
PCAG	O
)	O
,	O
all	O
with	O
creatinine	B_Chemical
values	O
between	O
1.1	O
and	O
3.1	O
mg/dL.	O
Patients	O
were	O
divided	O
into	O
three	O
groups	O
and	O
each	O
group	O
had	O
20	O
patients	O
.	O

The	O
first	O
group	O
of	O
patients	O
was	O
administered	O
isotonic	O
sodium	B_Chemical
chloride	I_Chemical
;	O
the	O
second	O
group	O
was	O
administered	O
a	O
solution	O
that	O
of	O
5	O
%	O
dextrose	B_Chemical
and	O
sodium	B_Chemical
bicarbonate	I_Chemical
,	O
while	O
the	O
third	O
group	O
was	O
administered	O
isotonic	O
sodium	B_Chemical
chloride	I_Chemical
before	O
and	O
after	O
the	O
contrast	B_Chemical
injection	O
.	O

The	O
third	O
group	O
received	O
an	O
additional	O
injection	O
of	O
diltiazem	B_Chemical
the	O
day	O
before	O
and	O
first	O
2	O
days	O
after	O
the	O
contrast	B_Chemical
injection	O
.	O

All	O
of	O
the	O
patients	O
'	O
plasma	O
blood	B_Chemical
urea	I_Chemical
nitrogen	I_Chemical
(	O
BUN	B_Chemical
)	O
and	O
creatinine	B_Chemical
levels	O
were	O
measured	O
on	O
the	O
second	O
and	O
seventh	O
day	O
after	O
the	O
administration	O
of	O
intravenous	O
contrast	B_Chemical
material	O
.	O

RESULTS	O
:	O
The	O
basal	O
creatinine	B_Chemical
levels	O
were	O
similar	O
for	O
all	O
three	O
groups	O
(	O
p	O
>	O
0.05	O
)	O
.	O

Among	O
a	O
total	O
of	O
60	O
patients	O
included	O
in	O
the	O
study	O
,	O
16	O
patients	O
developed	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
(	O
ARF	B_Disease
)	O
on	O
the	O
second	O
day	O
after	O
contrast	B_Chemical
material	O
was	O
injected	O
(	O
26.6	O
%	O
)	O
.	O

The	O
number	O
of	O
patients	O
who	O
developed	O
ARF	B_Disease
on	O
the	O
second	O
day	O
after	O
the	O
injection	O
in	O
the	O
first	O
group	O
was	O
five	O
(	O
25	O
%	O
)	O
,	O
in	O
the	O
second	O
group	O
was	O
six	O
(	O
30	O
%	O
)	O
and	O
the	O
third	O
group	O
was	O
five	O
(	O
25	O
%	O
)	O
(	O
p	O
>	O
0.05	O
)	O
.	O

CONCLUSION	O
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
isotonic	O
sodium	B_Chemical
chloride	I_Chemical
,	O
sodium	B_Chemical
bicarbonate	I_Chemical
and	O
isotonic	O
sodium	B_Chemical
chloride	I_Chemical
with	O
diltiazem	B_Chemical
application	O
in	O
prevention	O
of	O
CIN	O
.	O

Neurocognitive	O
and	O
neuroradiologic	O
central	O
nervous	O
system	O
late	O
effects	O
in	O
children	O
treated	O
on	O
Pediatric	O
Oncology	O
Group	O
(	O
POG	O
)	O
P9605	O
(	O
standard	O
risk	O
)	O
and	O
P9201	O
(	O
lesser	O
risk	O
)	O
acute	B_Disease
lymphoblastic	I_Disease
leukemia	I_Disease
protocols	O
(	O
ACCL0131	O
):	O
a	O
methotrexate	B_Chemical
consequence	O
?	O

A	O
report	O
from	O
the	O
Children	O
's	O
Oncology	O
Group	O
.	O

Concerns	O
about	O
long-term	O
methotrexate	B_Chemical
(	O
MTX	B_Chemical
)	O
neurotoxicity	B_Disease
in	O
the	O
1990s	O
led	O
to	O
modifications	O
in	O
intrathecal	O
(	O
IT	O
)	O
therapy	O
,	O
leucovorin	O
rescue	O
,	O
and	O
frequency	O
of	O
systemic	O
MTX	B_Chemical
administration	O
in	O
children	O
with	O
acute	B_Disease
lymphoblastic	I_Disease
leukemia	I_Disease
.	O

In	O
this	O
study	O
,	O
neurocognitive	O
outcomes	O
and	O
neuroradiologic	O
evidence	O
of	O
leukoencephalopathy	B_Disease
were	O
compared	O
in	O
children	O
treated	O
with	O
intense	O
central	O
nervous	O
system	O
(CNS)-directed	O
therapy	O
(	O
P9605	O
)	O
versus	O
those	O
receiving	O
fewer	O
CNS-directed	O
treatment	O
days	O
during	O
intensive	O
consolidation	O
(	O
P9201	O
)	O
.	O

A	O
total	O
of	O
66	O
children	O
from	O
16	O
Pediatric	O
Oncology	O
Group	O
institutions	O
with	O
"	O
standard-risk	O
"	O
acute	B_Disease
lymphoblastic	I_Disease
leukemia	I_Disease
,	O
1.00	O
to	O
9.99	O
years	O
at	O
diagnosis	O
,	O
without	O
evidence	O
of	O
CNS	O
leukemia	B_Disease
at	O
diagnosis	O
were	O
enrolled	O
on	O
ACCL0131	O
:	O
28	O
from	O
P9201	O
and	O
38	O
from	O
P9605	O
.	O

Magnetic	O
resonance	O
imaging	O
scans	O
and	O
standard	O
neuropsychological	O
tests	O
were	O
performed	O
>	O
2.6	O
years	O
after	O
the	O
end	O
of	O
treatment	O
.	O

Significantly	O
more	O
P9605	O
patients	O
developed	O
leukoencephalopathy	B_Disease
compared	O
with	O
P9201	O
patients	O
(	O
68	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
49%-83	O
%	O
vs.	O
22	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
5%-44	O
%	O
;	O
P=0.001	O
)	O
identified	O
as	O
late	O
as	O
7.7	O
years	O
after	O
the	O
end	O
of	O
treatment	O
.	O

Overall	O
,	O
40	O
%	O
of	O
patients	O
scored	O
<	O
85	O
on	O
either	O
Verbal	O
or	O
Performance	O
IQ	O
.	O

Children	O
on	O
both	O
studies	O
had	O
significant	O
attention	B_Disease
problems	I_Disease
,	O
but	O
P9605	O
children	O
scored	O
below	O
average	O
on	O
more	O
neurocognitive	O
measures	O
than	O
those	O
treated	O
on	O
P9201	O
(	O
82	O
%	O
,	O
14/17	O
measures	O
vs.	O
24	O
%	O
,	O
4/17	O
measures	O
)	O
.	O

This	O
supports	O
ongoing	O
concerns	O
about	O
intensive	O
MTX	B_Chemical
exposure	O
as	O
a	O
major	O
contributor	O
to	O
CNS	O
late	O
effects	O
.	O

Tranexamic	B_Chemical
acid	I_Chemical
overdosage-induced	O
generalized	O
seizure	B_Disease
in	O
renal	B_Disease
failure	I_Disease
.	O

We	O
report	O
a	O
45-year-old	O
lady	O
with	O
chronic	B_Disease
kidney	I_Disease
disease	I_Disease
stage	O
4	O
due	O
to	O
chronic	O
tubulointerstial	B_Disease
disease	I_Disease
.	O

She	O
was	O
admitted	O
to	O
our	O
center	O
for	O
severe	O
anemia	B_Disease
due	O
to	O
menorrhagia	B_Disease
and	O
deterioration	B_Disease
of	I_Disease
renal	I_Disease
function	I_Disease
.	O

She	O
was	O
infused	O
three	O
units	O
of	O
packed	O
cells	O
during	O
a	O
session	O
of	O
hemodialysis	O
.	O

Tranexamic	B_Chemical
acid	I_Chemical
(	O
TNA	B_Chemical
)	O
1	O
g	O
8-hourly	O
was	O
administered	O
to	O
her	O
to	O
control	O
bleeding	B_Disease
per	O
vaginum	O
.	O

Two	O
hours	O
after	O
the	O
sixth	O
dose	O
of	O
TNA	B_Chemical
,	O
she	O
had	O
an	O
episode	O
of	O
generalized	O
tonic	B_Disease
clonic	I_Disease
convulsions	I_Disease
.	O

TNA	B_Chemical
was	O
discontinued	O
.	O

Investigations	O
of	O
the	O
patient	O
revealed	O
no	O
biochemical	O
or	O
structural	O
central	O
nervous	B_Disease
system	I_Disease
abnormalities	I_Disease
that	O
could	O
have	O
provoked	O
the	O
convulsions	B_Disease
.	O

She	O
did	O
not	O
require	O
any	O
further	O
dialytic	O
support	O
.	O

She	O
had	O
no	O
further	O
episodes	O
of	O
convulsion	B_Disease
till	O
dis-charge	O
and	O
during	O
the	O
two	O
months	O
of	O
follow-up	O
.	O

Thus	O
,	O
the	O
precipitating	O
cause	O
of	O
convulsions	B_Disease
was	O
believed	O
to	O
be	O
an	O
overdose	B_Disease
of	O
TNA	B_Chemical
.	O

Pre-treatment	O
of	O
bupivacaine-induced	O
cardiovascular	B_Disease
depression	I_Disease
using	O
different	O
lipid	O
formulations	O
of	O
propofol	B_Chemical
.	O

BACKGROUND	O
:	O
Pre-treatment	O
with	O
lipid	O
emulsions	O
has	O
been	O
shown	O
to	O
increase	O
lethal	O
doses	O
of	O
bupivacaine	B_Chemical
,	O
and	O
the	O
lipid	O
content	O
of	O
propofol	B_Chemical
may	O
alleviate	O
bupivacaine-induced	O
cardiotoxicity	B_Disease
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
effects	O
of	O
propofol	B_Chemical
in	O
intralipid	O
or	O
medialipid	O
emulsions	O
on	O
bupivacaine-induced	O
cardiotoxicity	B_Disease
.	O

METHODS	O
:	O
Rats	O
were	O
anaesthetised	O
with	O
ketamine	B_Chemical
and	O
were	O
given	O
0.5	O
mg/kg/min	O
propofol	B_Chemical
in	O
intralipid	O
(	O
Group	O
P	O
)	O
,	O
propofol	B_Chemical
in	O
medialipid	O
(	O
Group	O
L	O
)	O
,	O
or	O
saline	O
(	O
Group	O
C	O
)	O
over	O
20	O
min	O
.	O

Thereafter	O
,	O
2	O
mg/kg/min	O
bupivacaine	B_Chemical
0.5	O
%	O
was	O
infused	O
.	O

We	O
recorded	O
time	O
to	O
first	O
dysrhythmia	B_Disease
occurrence	O
,	O
respective	O
times	O
to	O
25	O
%	O
and	O
50	O
%	O
reduction	O
of	O
the	O
heart	O
rate	O
(	O
HR	O
)	O
and	O
mean	O
arterial	O
pressure	O
,	O
and	O
time	O
to	O
asystole	B_Disease
and	O
total	O
amount	O
of	O
bupivacaine	B_Chemical
consumption	O
.	O

Blood	O
and	O
tissue	O
samples	O
were	O
collected	O
following	O
asystole	B_Disease
.	O

RESULTS	O
:	O
The	O
time	O
to	O
first	O
dysrhythmia	B_Disease
occurrence	O
,	O
time	O
to	O
25	O
%	O
and	O
50	O
%	O
reductions	O
in	O
HR	O
,	O
and	O
time	O
to	O
asystole	B_Disease
were	O
longer	O
in	O
Group	O
P	O
than	O
the	O
other	O
groups	O
.	O

The	O
cumulative	O
bupivacaine	B_Chemical
dose	O
given	O
at	O
those	O
time	O
points	O
was	O
higher	O
in	O
Group	O
P.	O
Plasma	O
bupivacaine	B_Chemical
levels	O
were	O
significantly	O
lower	O
in	O
Group	O
P	O
than	O
in	O
Group	O
C.	O
Bupivacaine	B_Chemical
levels	O
in	O
the	O
brain	O
and	O
heart	O
were	O
significantly	O
lower	O
in	O
Group	O
P	O
and	O
Group	O
L	O
than	O
in	O
Group	O
C.	O
CONCLUSION	O
:	O
We	O
conclude	O
that	O
pre-treatment	O
with	O
propofol	B_Chemical
in	O
intralipid	O
,	O
compared	O
with	O
propofol	B_Chemical
in	O
medialipid	O
or	O
saline	O
,	O
delayed	O
the	O
onset	O
of	O
bupivacaine-induced	O
cardiotoxic	B_Disease
effects	O
as	O
well	O
as	O
reduced	O
plasma	O
bupivacaine	B_Chemical
levels	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
explore	O
tissue	O
bupivacaine	B_Chemical
levels	O
of	O
propofol	B_Chemical
in	O
medialipid	O
and	O
adapt	O
these	O
results	O
to	O
clinical	O
practice	O
.	O

Drug-Induced	B_Disease
Acute	I_Disease
Liver	I_Disease
Injury	I_Disease
Within	O
12	O
Hours	O
After	O
Fluvastatin	B_Chemical
Therapy	O
.	O

Although	O
statins	B_Chemical
are	O
generally	O
well-tolerated	O
drugs	O
,	O
recent	O
cases	O
of	O
drug-induced	B_Disease
liver	I_Disease
injury	I_Disease
associated	O
with	O
their	O
use	O
have	O
been	O
reported	O
.	O

A	O
52-year-old	O
Chinese	O
man	O
reported	O
with	O
liver	B_Disease
damage	I_Disease
,	O
which	O
appeared	O
12	O
hours	O
after	O
beginning	O
treatment	O
with	O
fluvastatin	B_Chemical
.	O

Patient	O
presented	O
with	O
complaints	O
of	O
increasing	O
nausea	B_Disease
,	O
anorexia	B_Disease
,	O
and	O
upper	O
abdominal	B_Disease
pain	I_Disease
.	O

His	O
laboratory	O
values	O
showed	O
elevated	O
creatine	B_Chemical
kinase	O
and	O
transaminases	O
.	O

Testing	O
for	O
autoantibodies	O
was	O
also	O
negative	O
.	O

The	O
liver	O
biochemistries	O
eventually	O
normalized	O
within	O
3	O
weeks	O
of	O
stopping	O
the	O
fluvastatin	B_Chemical
.	O

Therefore	O
,	O
when	O
prescribing	O
statins	O
,	O
the	O
possibility	O
of	O
hepatic	B_Disease
damage	I_Disease
should	O
be	O
taken	O
into	O
account	O
.	O

Fluconazole	B_Chemical
associated	O
agranulocytosis	B_Disease
and	O
thrombocytopenia	B_Disease
.	O

CASE	O
:	O
We	O
describe	O
a	O
second	O
case	O
of	O
fluconazole	B_Chemical
associated	O
agranulocytosis	B_Disease
with	O
thrombocytopenia	B_Disease
and	O
recovery	O
upon	O
discontinuation	O
of	O
therapy	O
.	O

The	O
patient	O
began	O
to	O
have	O
changes	O
in	O
white	O
blood	O
cells	O
and	O
platelets	O
within	O
48	O
h	O
of	O
administration	O
of	O
fluconazole	B_Chemical
and	O
began	O
to	O
recover	O
with	O
48	O
h	O
of	O
discontinuation	O
.	O

This	O
case	O
highlights	O
that	O
drug-induced	O
blood	B_Disease
dyscrasias	I_Disease
can	O
occur	O
unexpectedly	O
as	O
a	O
result	O
of	O
treatment	O
with	O
a	O
commonly	O
used	O
drug	O
thought	O
to	O
be	O
"	O
safe	O
"	O
.	O

CONCLUSION	O
:	O
According	O
to	O
Naranjo	O
's	O
algorithm	O
the	O
likelihood	O
that	O
our	O
patient	O
's	O
agranulocytosis	B_Disease
and	O
thrombocytopenia	B_Disease
occurred	O
as	O
a	O
result	O
of	O
therapy	O
with	O
fluconazole	B_Chemical
is	O
probable	O
,	O
with	O
a	O
total	O
of	O
six	O
points	O
.	O

We	O
feel	O
that	O
the	O
weight	O
of	O
the	O
overall	O
evidence	O
of	O
this	O
evidence	O
is	O
strong	O
.	O

In	O
particular	O
the	O
temporal	O
relationship	O
of	O
bone	B_Disease
marrow	I_Disease
suppression	I_Disease
to	O
the	O
initiation	O
of	O
fluconazole	B_Chemical
and	O
the	O
abatement	O
of	O
symptoms	O
that	O
rapidly	O
reversed	O
immediately	O
following	O
discontinuation	O
.	O

Two-dimensional	O
speckle	O
tracking	O
echocardiography	O
combined	O
with	O
high-sensitive	O
cardiac	O
troponin	O
T	O
in	O
early	O
detection	O
and	O
prediction	O
of	O
cardiotoxicity	B_Disease
during	O
epirubicine-based	O
chemotherapy	O
.	O

AIMS	O
:	O
To	O
investigate	O
whether	O
alterations	O
of	O
myocardial	B_Disease
strain	I_Disease
and	O
high-sensitive	O
cardiac	O
troponin	O
T	O
(	O
cTnT	O
)	O
could	O
predict	O
future	O
cardiac	B_Disease
dysfunction	I_Disease
in	O
patients	O
after	O
epirubicin	B_Chemical
exposure	O
.	O

METHODS	O
:	O
Seventy-five	O
patients	O
with	O
non-Hodgkin	B_Disease
lymphoma	I_Disease
treated	O
with	O
epirubicin	B_Chemical
were	O
studied	O
.	O

Blood	O
collection	O
and	O
echocardiography	O
were	O
performed	O
at	O
baseline	O
,	O
1	O
day	O
after	O
the	O
third	O
cycle	O
,	O
and	O
1	O
day	O
after	O
completion	O
of	O
chemotherapy	O
.	O

Patients	O
were	O
studied	O
using	O
echocardiography	O
during	O
follow-up	O
.	O

Global	O
longitudinal	O
(	O
GLS	O
)	O
,	O
circumferential	O
(	O
GCS	O
)	O
,	O
and	O
radial	O
strain	O
(	O
GRS	O
)	O
were	O
calculated	O
using	O
speckle	O
tracking	O
echocardiography	O
.	O

Left	O
ventricular	O
ejection	O
fraction	O
was	O
analysed	O
by	O
real-time	O
3D	O
echocardiography	O
.	O

Cardiotoxicity	B_Disease
was	O
defined	O
as	O
a	O
reduction	O
of	O
the	O
LVEF	O
of	O
>	O
5	O
%	O
to	O
<	O
55	O
%	O
with	O
symptoms	O
of	O
heart	B_Disease
failure	I_Disease
or	O
an	O
asymptomatic	O
reduction	O
of	O
the	O
LVEF	O
of	O
>	O
10	O
%	O
to	O
<	O
55	O
%	O
.	O

RESULTS	O
:	O
Fourteen	O
patients	O
(	O
18.67	O
%	O
)	O
developed	O
cardiotoxicity	B_Disease
after	O
treatment	O
.	O

GLS	O
(	O
-18.48	O
+	O
1.72	O
%	O
vs.	O
-15.96	O
+	O
1.6	O
%	O
)	O
,	O
GCS	O
(	O
-20.93	O
+	O
2.86	O
%	O
vs.	O
-19.20	O
+	O
3.21	O
%	O
)	O
,	O
and	O
GRS	O
(	O
39.23	O
+	O
6.44	O
%	O
vs.	O
34.98	O
+	O
6.2	O
%	O
)	O
were	O
markedly	O
reduced	O
and	O
cTnT	O
was	O
elevated	O
from	O
0.0010	O
+	O
0.0020	O
to	O
0.0073	O
+	O
0.0038	O
ng/mL	O
(	O
P	O
all	O
<	O
0.01	O
)	O
at	O
the	O
completion	O
of	O
chemotherapy	O
compared	O
with	O
baseline	O
values	O
.	O

A	O
>	O
15.9	O
%	O
decrease	O
in	O
GLS	O
[	O
sensitivity	O
,	O
86	O
%	O
;	O
specificity	O
,	O
75	O
%	O
;	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
=	O
0.815	O
;	O
P	O
=	O
0.001	O
]	O
and	O
a	O
>	O
0.004	O
ng/mL	O
elevation	O
in	O
cTnT	O
(	O
sensitivity	O
,	O
79	O
%	O
;	O
specificity	O
,	O
64	O
%	O
;	O
AUC	O
=	O
0.757	O
;	O
P	O
=	O
0.005	O
)	O
from	O
baseline	O
to	O
the	O
third	O
cycle	O
of	O
chemotherapy	O
predicted	O
later	O
cardiotoxicity	B_Disease
.	O

The	O
decrease	O
in	O
GLS	O
remained	O
the	O
only	O
independent	O
predictor	O
of	O
cardiotoxicity	B_Disease
(	O
P	O
=	O
0.000	O
)	O
.	O

CONCLUSIONS	O
:	O
GLS	O
combined	O
with	O
cTnT	O
may	O
provide	O
a	O
reliable	O
and	O
non-invasive	O
method	O
to	O
predict	O
cardiac	B_Disease
dysfunction	I_Disease
in	O
patients	O
receiving	O
anthracycline-based	O
chemotherapy	O
.	O

Prevention	O
of	O
etomidate-induced	O
myoclonus	B_Disease
:	O
which	O
is	O
superior	O
:	O
Fentanyl	B_Chemical
,	O
midazolam	B_Chemical
,	O
or	O
a	O
combination	O
?	O
A	O
Retrospective	O
comparative	O
study	O
.	O

BACKGROUND	O
:	O
In	O
this	O
retrospective	O
comparative	O
study	O
,	O
we	O
aimed	O
to	O
compare	O
the	O
effectiveness	O
of	O
fentanyl	B_Chemical
,	O
midazolam	B_Chemical
,	O
and	O
a	O
combination	O
of	O
fentanyl	B_Chemical
and	O
midazolam	B_Chemical
to	O
prevent	O
etomidate-induced	O
myoclonus	B_Disease
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
This	O
study	O
was	O
performed	O
based	O
on	O
anesthesia	O
records	O
.	O

Depending	O
on	O
the	O
drugs	O
that	O
would	O
be	O
given	O
before	O
the	O
induction	O
of	O
anesthesia	O
with	O
etomidate	B_Chemical
,	O
the	O
patients	O
were	O
separated	O
into	O
4	O
groups	O
:	O
no	O
pretreatment	O
(	O
Group	O
NP	O
)	O
,	O
fentanyl	B_Chemical
1	O
ug.kg-1	O
(	O
Group	O
F	O
)	O
,	O
midazolam	B_Chemical
0.03	O
mg.kg-1	O
(	O
Group	O
M	O
)	O
,	O
and	O
midazolam	B_Chemical
0.015	O
mg.kg-1	O
+	O
fentanyl	B_Chemical
0.5	O
ug.kg-1	O
(	O
Group	O
FM	O
)	O
.	O

Patients	O
who	O
received	O
the	O
same	O
anesthetic	O
procedure	O
were	O
selected	O
:	O
2	O
minutes	O
after	O
intravenous	O
injections	O
of	O
the	O
pretreatment	O
drugs	O
,	O
anesthesia	O
is	O
induced	O
with	O
0.3	O
mg.kg-1	O
etomidate	B_Chemical
injected	O
intravenously	O
over	O
a	O
period	O
of	O
20	O
-	O
30	O
seconds	O
.	O

Myoclonic	B_Disease
movements	I_Disease
are	O
evaluated	O
,	O
which	O
were	O
observed	O
and	O
graded	O
according	O
to	O
clinical	O
severity	O
during	O
the	O
2	O
minutes	O
after	O
etomidate	B_Chemical
injection	O
.	O

The	O
severity	O
of	O
pain	B_Disease
due	O
to	O
etomidate	B_Chemical
injection	O
,	O
mean	O
arterial	O
pressure	O
,	O
heart	O
rate	O
,	O
and	O
adverse	O
effects	O
were	O
also	O
evaluated	O
.	O

RESULTS	O
:	O
Study	O
results	O
showed	O
that	O
myoclonus	B_Disease
incidence	O
was	O
85	O
%	O
,	O
40	O
%	O
,	O
70	O
%	O
,	O
and	O
25	O
%	O
in	O
Group	O
NP	O
,	O
Group	O
F	O
,	O
Group	O
M	O
,	O
and	O
Group	O
FM	O
,	O
respectively	O
,	O
and	O
were	O
significantly	O
lower	O
in	O
Group	O
F	O
and	O
Group	O
FM	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
pretreatment	O
with	O
fentanyl	B_Chemical
or	O
combination	O
of	O
fentanyl	B_Chemical
and	O
midazolam	B_Chemical
was	O
effective	O
in	O
preventing	O
etomidate-induced	O
myoclonus	B_Disease
.	O

Convulsant	O
effect	O
of	O
lindane	B_Chemical
and	O
regional	O
brain	O
concentration	O
of	O
GABA	B_Chemical
and	O
dopamine	B_Chemical
.	O

Lindane	B_Chemical
(	O
gamma-hexachlorocyclohexane	B_Chemical
)	O
is	O
an	O
organochlorine	O
insecticide	O
with	O
known	O
neurotoxic	B_Disease
effects	O
.	O

Its	O
mechanism	O
of	O
action	O
is	O
not	O
well	O
understood	O
although	O
it	O
has	O
been	O
proposed	O
that	O
lindane	B_Chemical
acts	O
as	O
a	O
non-competitive	O
antagonist	O
at	O
the	O
gamma-aminobutyric	B_Chemical
acid	I_Chemical
(GABA)-A	O
receptor	O
.	O

We	O
studied	O
the	O
effect	O
of	O
lindane	B_Chemical
(	O
150	O
mg/kg	O
)	O
on	O
the	O
GABAergic	O
and	O
dopaminergic	O
systems	O
by	O
measuring	O
the	O
concentration	O
of	O
GABA	B_Chemical
,	O
dopamine	B_Chemical
and	O
its	O
metabolites	O
in	O
7	O
brain	O
areas	O
at	O
the	O
onset	O
of	O
seizures	B_Disease
.	O

All	O
animals	O
suffered	O
tonic	O
convulsions	B_Disease
at	O
18.3	O
+	O
/-	O
1.4	O
min	O
after	O
lindane	B_Chemical
administration	O
.	O

The	O
concentration	O
of	O
GABA	B_Chemical
was	O
only	O
slightly	O
but	O
significantly	O
decreased	O
in	O
the	O
colliculi	O
without	O
modifications	O
in	O
the	O
other	O
areas	O
.	O

The	O
concentration	O
of	O
dopamine	B_Chemical
was	O
increased	O
in	O
the	O
mesencephalon	O
and	O
that	O
of	O
its	O
metabolite	O
DOPAC	B_Chemical
was	O
also	O
increased	O
in	O
the	O
mesencephalon	O
and	O
the	O
striatum	O
.	O

Cholestatic	B_Disease
presentation	O
of	O
yellow	O
phosphorus	B_Chemical
poisoning	B_Disease
.	O

Yellow	O
phosphorus	B_Chemical
,	O
a	O
component	O
of	O
certain	O
pesticide	O
pastes	O
and	O
fireworks	O
,	O
is	O
well	O
known	O
to	O
cause	O
hepatotoxicity	B_Disease
.	O

Poisoning	B_Disease
with	O
yellow	O
phosphorus	B_Chemical
classically	O
manifests	O
with	O
acute	B_Disease
hepatitis	I_Disease
leading	O
to	O
acute	B_Disease
liver	I_Disease
failure	I_Disease
which	O
may	O
need	O
liver	O
transplantation	O
.	O

We	O
present	O
a	O
case	O
of	O
yellow	O
phosphorus	B_Chemical
poisoning	B_Disease
in	O
which	O
a	O
patient	O
presented	O
with	O
florid	O
clinical	O
features	O
of	O
cholestasis	B_Disease
highlighting	O
the	O
fact	O
that	O
cholestasis	B_Disease
can	O
rarely	O
be	O
a	O
presenting	O
feature	O
of	O
yellow	O
phosphorus	B_Chemical
hepatotoxicity	B_Disease
.	O

Vasovagal	B_Disease
syncope	I_Disease
and	O
severe	O
bradycardia	B_Disease
following	O
intranasal	O
dexmedetomidine	B_Chemical
for	O
pediatric	O
procedural	O
sedation	O
.	O

We	O
report	O
syncope	B_Disease
and	O
bradycardia	B_Disease
in	O
an	O
11-year-old	O
girl	O
following	O
administration	O
of	O
intranasal	O
dexmedetomidine	B_Chemical
for	O
sedation	O
for	O
a	O
voiding	O
cystourethrogram	O
.	O

Following	O
successful	O
completion	O
of	O
VCUG	O
and	O
a	O
60-min	O
recovery	O
period	O
,	O
the	O
patient	O
's	O
level	O
of	O
consciousness	O
and	O
vital	O
signs	O
returned	O
to	O
presedation	O
levels	O
.	O

Upon	O
leaving	O
the	O
sedation	O
area	O
,	O
the	O
patient	O
collapsed	O
,	O
with	O
no	O
apparent	O
inciting	O
event	O
.	O

The	O
patient	O
quickly	O
regained	O
consciousness	O
and	O
no	O
injury	O
occurred	O
.	O

The	O
primary	O
abnormality	O
found	O
was	O
persistent	O
bradycardia	B_Disease
,	O
and	O
she	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
telemetric	O
observation	O
.	O

The	O
bradycardia	B_Disease
lasted	O
~2	O
h	O
,	O
and	O
further	O
cardiac	O
workup	O
revealed	O
no	O
underlying	O
abnormality	O
.	O

Unanticipated	O
and	O
previously	O
unreported	O
outcomes	O
may	O
be	O
witnessed	O
as	O
we	O
expand	O
the	O
use	O
of	O
certain	O
sedatives	O
to	O
alternative	O
routes	O
of	O
administration	O
.	O

Paradoxical	O
severe	O
agitation	B_Disease
induced	O
by	O
add-on	O
high-doses	O
quetiapine	B_Chemical
in	O
schizo-affective	B_Disease
disorder	I_Disease
.	O

We	O
report	O
the	O
case	O
of	O
a	O
35-year-old	O
patient	O
suffering	O
from	O
schizo-affective	B_Disease
disorder	I_Disease
since	O
the	O
age	O
of	O
19	O
years	O
,	O
treated	O
by	O
a	O
combination	O
of	O
first-generation	O
antipsychotics	O
,	O
zuclopenthixol	B_Chemical
(	O
100	O
mg/day	O
)	O
and	O
lithium	B_Chemical
(	O
1200	O
mg/day	O
)	O
(	O
serum	O
lithium=0.85	O
mEq/l	O
)	O
.	O

This	O
patient	O
had	O
no	O
associated	O
personality	B_Disease
disorder	I_Disease
(	O
particularly	O
no	O
antisocial	B_Disease
disorder	I_Disease
)	O
and	O
no	O
substance	B_Disease
abuse	I_Disease
disorder	I_Disease
.	O

Within	O
the	O
48	O
h	O
following	O
the	O
gradual	O
introduction	O
of	O
quetiapine	B_Chemical
(	O
up	O
to	O
600	O
mg/day	O
)	O
,	O
the	O
patient	O
presented	O
severe	O
agitation	B_Disease
without	O
an	O
environmental	O
explanation	O
,	O
contrasting	O
with	O
the	O
absence	O
of	O
a	O
history	O
of	O
aggressiveness	B_Disease
or	O
personality	B_Disease
disorder	I_Disease
.	O

The	O
diagnoses	O
of	O
manic	B_Disease
shift	O
and	O
akathisia	B_Disease
were	O
dismissed	O
.	O

The	O
withdrawal	O
and	O
the	O
gradual	O
reintroduction	O
of	O
quetiapine	B_Chemical
2	O
weeks	O
later	O
,	O
which	O
led	O
to	O
another	O
severe	O
agitation	B_Disease
,	O
enabled	O
us	O
to	O
attribute	O
the	O
agitation	B_Disease
specifically	O
to	O
quetiapine	B_Chemical
.	O

Antioxidant	O
effects	O
of	O
bovine	O
lactoferrin	O
on	O
dexamethasone-induced	O
hypertension	B_Disease
in	O
rat	O
.	O

Dexamethasone-	O
(	O
Dex-	O
)	O
induced	O
hypertension	B_Disease
is	O
associated	O
with	O
enhanced	O
oxidative	O
stress	O
.	O

Lactoferrin	O
(	O
LF	O
)	O
is	O
an	O
iron-binding	O
glycoprotein	O
with	O
antihypertensive	O
properties	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
chronic	O
administration	O
of	O
LF	O
on	O
oxidative	O
stress	O
and	O
hypertension	B_Disease
upon	O
Dex	B_Chemical
administration	O
.	O

Male	O
Wistar	O
rats	O
were	O
treated	O
by	O
Dex	B_Chemical
(	O
30	O
 	O
u	O
g/kg/day	O
subcutaneously	O
)	O
or	O
saline	O
for	O
14	O
days	O
.	O

Oral	O
bovine	O
LF	O
(	O
30	O
,	O
100	O
,	O
300	O
mg/kg	O
)	O
was	O
given	O
from	O
day	O
8	O
to	O
14	O
in	O
a	O
reversal	O
study	O
.	O

In	O
a	O
prevention	O
study	O
,	O
rats	O
received	O
4	O
days	O
of	O
LF	O
treatment	O
followed	O
by	O
Dex	B_Chemical
and	O
continued	O
during	O
the	O
test	O
period	O
.	O

Systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
was	O
measured	O
using	O
tail-cuff	O
method	O
.	O

Thymus	O
weight	O
was	O
used	O
as	O
a	O
marker	O
of	O
glucocorticoid	O
activity	O
.	O

Plasma	O
hydrogen	B_Chemical
peroxide	I_Chemical
(	O
H2O2	B_Chemical
)	O
concentration	O
and	O
ferric	O
reducing	O
antioxidant	O
power	O
(	O
FRAP	O
)	O
value	O
were	O
determined	O
.	O

Dexamethasone	B_Chemical
significantly	O
increased	O
SBP	O
and	O
plasma	O
H2O2	B_Chemical
level	O
and	O
decreased	O
thymus	O
and	O
body	O
weights	O
.	O

LF	O
lowered	O
(	O
P	O
<	O
0.01	O
)	O
and	O
dose	O
dependently	O
prevented	O
(	O
P	O
<	O
0.001	O
)	O
Dex-induced	O
hypertension	B_Disease
.	O

LF	O
prevented	O
body	O
weight	B_Disease
loss	I_Disease
and	O
significantly	O
reduced	O
the	O
elevated	O
plasma	O
H2O2	B_Chemical
and	O
increased	O
FRAP	O
values	O
.	O

Chronic	O
administration	O
of	O
LF	O
strongly	O
reduced	O
the	O
blood	O
pressure	O
and	O
production	O
of	O
ROS	O
and	O
improved	O
antioxidant	O
capacity	O
in	O
Dex-induced	O
hypertension	B_Disease
,	O
suggesting	O
the	O
role	O
of	O
inhibition	O
of	O
oxidative	O
stress	O
as	O
another	O
mechanism	O
of	O
antihypertensive	O
action	O
of	O
LF	O
.	O

The	O
association	O
between	O
tranexamic	B_Chemical
acid	I_Chemical
and	O
convulsive	B_Disease
seizures	B_Disease
after	O
cardiac	O
surgery	O
:	O
a	O
multivariate	O
analysis	O
in	O
11	O
529	O
patients	O
.	O

Because	O
of	O
a	O
lack	O
of	O
contemporary	O
data	O
regarding	O
seizures	B_Disease
after	O
cardiac	O
surgery	O
,	O
we	O
undertook	O
a	O
retrospective	O
analysis	O
of	O
prospectively	O
collected	O
data	O
from	O
11	O
529	O
patients	O
in	O
whom	O
cardiopulmonary	O
bypass	O
was	O
used	O
from	O
January	O
2004	O
to	O
December	O
2010	O
.	O

A	O
convulsive	B_Disease
seizure	B_Disease
was	O
defined	O
as	O
a	O
transient	O
episode	O
of	O
disturbed	O
brain	O
function	O
characterised	O
by	O
abnormal	B_Disease
involuntary	I_Disease
motor	I_Disease
movements	I_Disease
.	O

Multivariate	O
regression	O
analysis	O
was	O
performed	O
to	O
identify	O
independent	O
predictors	O
of	O
postoperative	O
seizures	B_Disease
.	O

A	O
total	O
of	O
100	O
(	O
0.9	O
%	O
)	O
patients	O
developed	O
postoperative	O
convulsive	B_Disease
seizures	B_Disease
.	O

Generalised	B_Disease
and	I_Disease
focal	I_Disease
seizures	I_Disease
were	O
identified	O
in	O
68	O
and	O
32	O
patients	O
,	O
respectively	O
.	O

The	O
median	O
(	O
IQR	O
[	O
range	O
]	O
)	O
time	O
after	O
surgery	O
when	O
the	O
seizure	B_Disease
occurred	O
was	O
7	O
(	O
6	O
-	O
12	O
[	O
1	O
-	O
216	O
]	O
)	O
h	O
and	O
8	O
(	O
6	O
-	O
11	O
[	O
4	O
-	O
18	O
]	O
)	O
h	O
,	O
respectively	O
.	O

Epileptiform	O
findings	O
on	O
electroencephalography	O
were	O
seen	O
in	O
19	O
patients	O
.	O

Independent	O
predictors	O
of	O
postoperative	O
seizures	B_Disease
included	O
age	O
,	O
female	O
sex	O
,	O
redo	O
cardiac	O
surgery	O
,	O
calcification	O
of	O
ascending	O
aorta	O
,	O
congestive	B_Disease
heart	I_Disease
failure	I_Disease
,	O
deep	O
hypothermic	B_Disease
circulatory	O
arrest	O
,	O
duration	O
of	O
aortic	O
cross-clamp	O
and	O
tranexamic	B_Chemical
acid	I_Chemical
.	O

When	O
tested	O
in	O
a	O
multivariate	O
regression	O
analysis	O
,	O
tranexamic	B_Chemical
acid	I_Chemical
was	O
a	O
strong	O
independent	O
predictor	O
of	O
seizures	B_Disease
(	O
OR	O
14.3	O
,	O
95	O
%	O
CI	O
5.5	O
-	O
36.7	O
;	O
p	O
<	O
0.001	O
)	O
.	O

Patients	O
with	O
convulsive	B_Disease
seizures	B_Disease
had	O
2.5	O
times	O
higher	O
in-hospital	O
mortality	O
rates	O
and	O
twice	O
the	O
length	O
of	O
hospital	O
stay	O
compared	O
with	O
patients	O
without	O
convulsive	B_Disease
seizures	B_Disease
.	O

Mean	O
(	O
IQR	O
[	O
range	O
]	O
)	O
length	O
of	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
was	O
115	O
(	O
49	O
-	O
228	O
[	O
32	O
-	O
481	O
]	O
)	O
h	O
in	O
patients	O
with	O
convulsive	B_Disease
seizures	B_Disease
compared	O
with	O
26	O
(	O
22	O
-	O
69	O
[	O
14	O
-	O
1080	O
]	O
)	O
h	O
in	O
patients	O
without	O
seizures	B_Disease
(	O
p	O
<	O
0.001	O
)	O
.	O

Convulsive	B_Disease
seizures	B_Disease
are	O
a	O
serious	O
postoperative	B_Disease
complication	I_Disease
after	O
cardiac	O
surgery	O
.	O

As	O
tranexamic	B_Chemical
acid	I_Chemical
is	O
the	O
only	O
modifiable	O
factor	O
,	O
its	O
administration	O
,	O
particularly	O
in	O
doses	O
exceeding	O
80	O
mg.kg(-1	O
)	O
,	O
should	O
be	O
weighed	O
against	O
the	O
risk	O
of	O
postoperative	O
seizures	B_Disease
.	O

Dysfunctional	B_Disease
overnight	I_Disease
memory	I_Disease
consolidation	O
in	O
ecstasy	B_Chemical
users	O
.	O

Sleep	O
plays	O
an	O
important	O
role	O
in	O
the	O
consolidation	O
and	O
integration	O
of	O
memory	O
in	O
a	O
process	O
called	O
overnight	O
memory	O
consolidation	O
.	O

Previous	O
studies	O
indicate	O
that	O
ecstasy	B_Chemical
users	O
have	O
marked	O
and	O
persistent	O
neurocognitive	O
and	O
sleep-related	B_Disease
impairments	I_Disease
.	O

We	O
extend	O
past	O
research	O
by	O
examining	O
overnight	O
memory	O
consolidation	O
among	O
regular	O
ecstasy	B_Chemical
users	O
(	O
n=12	O
)	O
and	O
drug	O
naive	O
healthy	O
controls	O
(	O
n=26	O
)	O
.	O

Memory	O
recall	O
of	O
word	O
pairs	O
was	O
evaluated	O
before	O
and	O
after	O
a	O
period	O
of	O
sleep	O
,	O
with	O
and	O
without	O
interference	O
prior	O
to	O
testing	O
.	O

In	O
addition	O
,	O
we	O
assessed	O
neurocognitive	O
performances	O
across	O
tasks	O
of	O
learning	O
,	O
memory	O
and	O
executive	O
functioning	O
.	O

Ecstasy	B_Chemical
users	O
demonstrated	O
impaired	B_Disease
overnight	I_Disease
memory	I_Disease
consolidation	O
,	O
a	O
finding	O
that	O
was	O
more	O
pronounced	O
following	O
associative	O
interference	O
.	O

Additionally	O
,	O
ecstasy	B_Chemical
users	O
demonstrated	O
impairments	O
on	O
tasks	O
recruiting	O
frontostriatal	O
and	O
hippocampal	O
neural	O
circuitry	O
,	O
in	O
the	O
domains	O
of	O
proactive	O
interference	O
memory	O
,	O
long-term	O
memory	O
,	O
encoding	O
,	O
working	O
memory	O
and	O
complex	O
planning	O
.	O

We	O
suggest	O
that	O
ecstasy-associated	O
dysfunction	O
in	O
fronto-temporal	O
circuitry	O
may	O
underlie	O
overnight	O
consolidation	O
memory	B_Disease
impairments	I_Disease
in	O
regular	O
ecstasy	B_Chemical
users	O
.	O

Normoammonemic	O
encephalopathy	B_Disease
:	O
solely	O
valproate	B_Chemical
induced	O
or	O
multiple	O
mechanisms?A	O
77-year-old	O
woman	O
presented	O
with	O
subacute	O
onset	O
progressive	O
confusion	B_Disease
,	O
aggression	B_Disease
,	O
auditory	B_Disease
hallucinations	I_Disease
and	O
delusions	B_Disease
.	O

In	O
the	O
preceding	O
months	O
,	O
the	O
patient	O
had	O
a	O
number	O
of	O
admissions	O
with	O
transient	O
unilateral	O
hemiparesis	B_Disease
with	O
facial	O
droop	O
,	O
and	O
had	O
been	O
started	O
on	O
valproate	B_Chemical
for	O
presumed	O
hemiplegic	B_Disease
migraine	I_Disease
.	O

Valproate	B_Chemical
was	O
withdrawn	O
soon	O
after	O
admission	O
and	O
her	O
cognitive	O
abilities	O
have	O
gradually	O
improved	O
over	O
3	O
months	O
of	O
follow-up	O
.	O

Valproate	B_Chemical
levels	O
taken	O
prior	O
to	O
withdrawal	O
were	O
subtherapeutic	O
and	O
the	O
patient	O
was	O
normoammonaemic	O
.	O

EEG	O
undertaken	O
during	O
inpatient	O
stay	O
showed	O
changes	O
consistent	O
with	O
encephalopathy	B_Disease
,	O
and	O
low	O
titre	O
N-methyl-D-aspartate	B_Chemical
(	O
NMDA	B_Chemical
)	O
receptor	O
antibodies	O
were	O
present	O
in	O
this	O
patient	O
.	O

The	O
possible	O
aetiologies	O
of	O
valproate-induced	O
encephalopathy	B_Disease
and	O
NMDA	B_Chemical
receptor-associated	O
encephalitis	B_Disease
present	O
a	O
diagnostic	O
dilemma	O
.	O

We	O
present	O
a	O
putative	O
combinatorial	O
hypothesis	O
to	O
explain	O
this	O
patient	O
's	O
symptoms	O
.	O

Cerebellar	B_Disease
and	I_Disease
oculomotor	B_Disease
dysfunction	I_Disease
induced	O
by	O
rapid	O
infusion	O
of	O
pethidine	B_Chemical
.	O

Pethidine	B_Chemical
is	O
an	O
opioid	O
that	O
gains	O
its	O
popularity	O
for	O
the	O
effective	O
pain	B_Disease
control	O
through	O
acting	O
on	O
the	O
opioid-receptors	O
.	O

However	O
,	O
rapid	O
pain	B_Disease
relief	O
sometimes	O
brings	O
about	O
unfavourable	O
side	O
effects	O
that	O
largely	O
limit	O
its	O
clinical	O
utility	O
.	O

Common	O
side	O
effects	O
include	O
nausea	B_Disease
,	O
vomiting	B_Disease
and	O
hypotension	B_Disease
.	O

In	O
patients	O
with	O
impaired	B_Disease
renal	I_Disease
and	I_Disease
liver	I_Disease
function	I_Disease
,	O
and	O
those	O
who	O
need	O
long-term	O
pain	B_Disease
control	O
,	O
pethidine	B_Chemical
may	O
cause	O
excitatory	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
effects	O
through	O
its	O
neurotoxic	B_Disease
metabolite	O
,	O
norpethidine	B_Chemical
,	O
resulting	O
in	O
irritability	B_Disease
and	O
seizure	B_Disease
attack	O
.	O

On	O
the	O
contrary	O
,	O
though	O
not	O
clinically	O
apparent	O
,	O
pethidine	B_Chemical
potentially	O
causes	O
inhibitory	O
impacts	O
on	O
the	O
CNS	O
and	O
impairs	O
normal	O
cerebellar	O
and	O
oculomotor	O
function	O
in	O
the	O
short	O
term	O
.	O

In	O
this	O
case	O
report	O
,	O
we	O
highlight	O
opioid	O
's	O
inhibitory	O
side	O
effects	O
on	O
the	O
cerebellar	O
structure	O
that	O
causes	O
dysmetria	B_Disease
,	O
dysarthria	B_Disease
,	O
reduced	O
smooth	O
pursuit	O
gain	O
and	O
decreased	O
saccadic	O
velocity	O
.	O

Baboon	B_Disease
syndrome	I_Disease
induced	O
by	O
ketoconazole	B_Chemical
.	O

A	O
27-year-old	O
male	O
patient	O
presented	O
with	O
a	O
maculopapular	B_Disease
eruption	I_Disease
on	O
the	O
flexural	O
areas	O
and	O
buttocks	O
after	O
using	O
oral	O
ketoconazole	B_Chemical
.	O

The	O
patient	O
was	O
diagnosed	O
with	O
drug-induced	O
baboon	B_Disease
syndrome	I_Disease
based	O
on	O
his	O
history	O
,	O
which	O
included	O
prior	O
sensitivity	O
to	O
topical	O
ketoconazole	B_Chemical
,	O
a	O
physical	O
examination	O
,	O
and	O
histopathological	O
findings	O
.	O

Baboon	B_Disease
syndrome	I_Disease
is	O
a	O
drug-	O
or	O
contact	O
allergen-related	O
maculopapular	B_Disease
eruption	I_Disease
that	O
typically	O
involves	O
the	O
flexural	O
and	O
gluteal	O
areas	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
ketoconazole-induced	O
baboon	B_Disease
syndrome	I_Disease
in	O
the	O
English	O
literature	O
.	O

A	O
Case	O
of	O
Sudden	B_Disease
Cardiac	I_Disease
Death	I_Disease
due	O
to	O
Pilsicainide-Induced	O
Torsades	B_Disease
de	I_Disease
Pointes	I_Disease
.	O

An	O
84-year-old	O
male	O
received	O
oral	O
pilsicainide	B_Chemical
,	O
a	O
pure	O
sodium	B_Chemical
channel	O
blocker	O
with	O
slow	O
recovery	O
kinetics	O
,	O
to	O
convert	O
his	O
paroxysmal	O
atrial	B_Disease
fibrillation	I_Disease
to	O
a	O
sinus	O
rhythm	O
;	O
the	O
patient	O
developed	O
sudden	B_Disease
cardiac	I_Disease
death	I_Disease
two	O
days	O
later	O
.	O

The	O
Holter	O
electrocardiogram	O
,	O
which	O
was	O
worn	O
by	O
chance	O
,	O
revealed	O
torsade	B_Disease
de	I_Disease
pointes	I_Disease
with	O
gradually	O
prolonged	O
QT	O
intervals	O
.	O

This	O
drug	O
is	O
rapidly	O
absorbed	O
from	O
the	O
gastrointestinal	O
tract	O
,	O
and	O
most	O
of	O
it	O
is	O
excreted	O
from	O
the	O
kidney	O
.	O

Although	O
the	O
patient	O
's	O
renal	O
function	O
was	O
not	O
highly	O
impaired	O
and	O
the	O
dose	O
of	O
pilsicainide	B_Chemical
was	O
low	O
,	O
the	O
plasma	O
concentration	O
of	O
pilsicainide	B_Chemical
may	O
have	O
been	O
high	O
,	O
which	O
can	O
produce	O
torsades	B_Disease
de	I_Disease
pointes	I_Disease
in	O
the	O
octogenarian	O
.	O

Although	O
the	O
oral	O
administration	O
of	O
class	O
IC	O
drugs	O
,	O
including	O
pilsicainide	B_Chemical
,	O
is	O
effective	O
to	O
terminate	O
atrial	B_Disease
fibrillation	I_Disease
,	O
careful	O
consideration	O
must	O
be	O
taken	O
before	O
giving	O
these	O
drugs	O
to	O
octogenarians	O
.	O

All-trans	O
retinoic	O
acid-induced	O
inflammatory	O
myositis	B_Disease
in	O
a	O
patient	O
with	O
acute	B_Disease
promyelocytic	I_Disease
leukemia	I_Disease
.	O

All-trans	B_Chemical
retinoic	I_Chemical
acid	I_Chemical
(	O
ATRA	B_Chemical
)	O
,	O
a	O
component	O
of	O
standard	O
therapy	O
for	O
acute	B_Disease
promyelocytic	I_Disease
leukemia	I_Disease
(	O
APL	B_Disease
)	O
,	O
is	O
associated	O
with	O
potentially	O
serious	O
but	O
treatable	O
adverse	O
effects	O
involving	O
numerous	O
organ	O
systems	O
,	O
including	O
rare	O
skeletal	O
muscle	O
involvement	O
.	O

Only	O
a	O
handful	O
of	O
cases	O
of	O
ATRA-induced	O
myositis	B_Disease
in	O
children	O
have	O
been	O
reported	O
,	O
and	O
none	O
in	O
the	O
radiology	O
literature	O
.	O

We	O
present	O
such	O
a	O
case	O
in	O
a	O
15-year-old	O
boy	O
with	O
APL	B_Disease
,	O
where	O
recognition	O
of	O
imaging	O
findings	O
played	O
a	O
crucial	O
role	O
in	O
making	O
the	O
diagnosis	O
and	O
facilitated	O
prompt	O
,	O
effective	O
treatment	O
.	O

Tolerability	O
of	O
lomustine	B_Chemical
in	O
combination	O
with	O
cyclophosphamide	B_Chemical
in	O
dogs	O
with	O
lymphoma	B_Disease
.	O

This	O
retrospective	O
study	O
describes	O
toxicity	B_Disease
associated	O
with	O
a	O
protocol	O
of	O
lomustine	B_Chemical
(	O
CCNU	B_Chemical
)	O
and	O
cyclophosphamide	B_Chemical
(	O
CTX	B_Chemical
)	O
in	O
dogs	O
with	O
lymphoma	B_Disease
.	O

CCNU	B_Chemical
was	O
administered	O
per	O
os	O
(	O
PO	O
)	O
at	O
a	O
targeted	O
dosage	O
of	O
60	O
mg/m(2	O
)	O
body	O
surface	O
area	O
on	O
day	O
0	O
,	O
CTX	B_Chemical
was	O
administered	O
PO	O
at	O
a	O
targeted	O
dosage	O
of	O
250	O
mg/m(2	O
)	O
divided	O
over	O
days	O
0	O
through	O
4	O
,	O
and	O
all	O
dogs	O
received	O
prophylactic	O
antibiotics	O
.	O

Ninety	O
treatments	O
were	O
given	O
to	O
the	O
57	O
dogs	O
included	O
in	O
the	O
study	O
.	O

Neutropenia	B_Disease
was	O
the	O
principal	O
toxic	O
effect	O
,	O
and	O
the	O
overall	O
frequency	O
of	O
grade	O
4	O
neutropenia	B_Disease
after	O
the	O
first	O
treatment	O
of	O
CCNU/CTX	O
was	O
30	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
19	O
-	O
43	O
%	O
)	O
.	O

The	O
mean	O
body	O
weight	O
of	O
dogs	O
with	O
grade	O
4	O
neutropenia	B_Disease
(	O
19.7	O
kg	O
+	O
13.4	O
kg	O
)	O
was	O
significantly	O
less	O
than	O
the	O
mean	O
body	O
weight	O
of	O
dogs	O
that	O
did	O
not	O
develop	O
grade	O
4	O
neutropenia	B_Disease
(	O
31.7	O
kg	O
+	O
12.4	O
kg	O
;	O
P	O
=	O
.005	O
)	O
.	O

One	O
dog	O
(	O
3	O
%	O
)	O
developed	O
hematologic	O
changes	O
suggestive	O
of	O
hepatotoxicity	B_Disease
.	O

No	O
dogs	O
had	O
evidence	O
of	O
either	O
renal	B_Disease
toxicity	I_Disease
or	O
hemorrhagic	B_Disease
cystitis	B_Disease
.	O

Adverse	O
gastrointestinal	O
effects	O
were	O
uncommon	O
.	O

On	O
the	O
basis	O
of	O
the	O
findings	O
reported	O
herein	O
,	O
a	O
dose	O
of	O
60	O
mg/m(2	O
)	O
of	O
CCNU	B_Chemical
combined	O
with	O
250	O
mg/m(2	O
)	O
of	O
CTX	B_Chemical
(	O
divided	O
over	O
5	O
days	O
)	O
q	O
4	O
wk	O
is	O
tolerable	O
in	O
tumor-bearing	O
dogs	O
.	O

Nelarabine	B_Chemical
neurotoxicity	B_Disease
with	O
concurrent	O
intrathecal	O
chemotherapy	O
:	O
Case	O
report	O
and	O
review	O
of	O
literature	O
.	O

Severe	O
nelarabine	B_Chemical
neurotoxicity	B_Disease
in	O
a	O
patient	O
who	O
received	O
concurrent	O
intrathecal	O
(	O
IT	O
)	O
chemotherapy	O
is	O
reported	O
.	O

A	O
37-year-old	O
Caucasian	O
woman	O
with	O
a	O
history	O
of	O
T-cell	B_Disease
lymphoblastic	I_Disease
lymphoma	I_Disease
was	O
admitted	O
for	O
relapsed	O
disease	O
.	O

She	O
was	O
originally	O
treated	O
with	O
induction	O
chemotherapy	O
followed	O
by	O
an	O
autologous	O
transplant	O
.	O

She	O
developed	O
relapsed	O
disease	O
10	O
months	O
later	O
with	O
leukemic	B_Disease
involvement	O
.	O

She	O
was	O
re-induced	O
with	O
nelarabine	B_Chemical
1500	O
mg/m(2	O
)	O
on	O
days	O
1	O
,	O
3	O
,	O
and	O
5	O
with	O
1	O
dose	O
of	O
IT	O
cytarabine	B_Chemical
100	O
mg	O
on	O
day	O
2	O
as	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
prophylaxis	O
.	O

At	O
the	O
time	O
of	O
treatment	O
,	O
she	O
was	O
on	O
continuous	O
renal	O
replacement	O
therapy	O
due	O
to	O
sequelae	O
of	O
tumor	B_Disease
lysis	I_Disease
syndrome	I_Disease
(	O
TLS	B_Disease
)	O
.	O

She	O
tolerated	O
therapy	O
well	O
,	O
entered	O
a	O
complete	O
remission	O
,	O
and	O
recovered	O
her	O
renal	O
function	O
.	O

She	O
received	O
a	O
second	O
cycle	O
of	O
nelarabine	B_Chemical
without	O
additional	O
IT	O
prophylaxis	O
one	O
month	O
later	O
.	O

A	O
week	O
after	O
this	O
second	O
cycle	O
,	O
she	O
noted	O
numbness	O
in	O
her	O
lower	O
extremities	O
.	O

Predominantly	O
sensory	O
,	O
though	O
also	O
motor	O
and	O
autonomic	O
,	O
peripheral	B_Disease
neuropathy	I_Disease
started	O
in	O
her	O
feet	O
,	O
ascended	O
proximally	O
to	O
the	O
mid-thoracic	O
region	O
,	O
and	O
eventually	O
included	O
her	O
distal	O
upper	O
extremities	O
.	O

A	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
of	O
her	O
spine	O
demonstrated	O
changes	O
from	O
C2	O
to	O
C6	O
consistent	O
with	O
subacute	O
combined	O
degeneration	O
.	O

Nelarabine	B_Chemical
was	O
felt	O
to	O
be	O
the	O
cause	O
of	O
her	O
symptoms	O
.	O

Her	O
neuropathy	B_Disease
stabilized	O
and	O
showed	O
slight	O
improvement	O
and	O
ultimately	O
received	O
an	O
unrelated	O
,	O
reduced-intensity	O
allogeneic	O
transplant	O
while	O
in	O
complete	O
remission	O
,	O
but	O
relapsed	O
disease	O
10	O
weeks	O
later	O
.	O

She	O
is	O
currently	O
being	O
treated	O
with	O
best	O
supportive	O
care	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
published	O
case	O
report	O
of	O
severe	O
neurotoxicity	B_Disease
caused	O
by	O
nelarabine	B_Chemical
in	O
a	O
patient	O
who	O
received	O
concurrent	O
IT	O
chemotherapy	O
.	O

Valproate-induced	O
hyperammonemic	B_Disease
encephalopathy	B_Disease
in	O
a	O
renal	O
transplanted	O
patient	O
.	O

Neurological	B_Disease
complications	I_Disease
after	O
renal	O
transplantation	O
constitute	O
an	O
important	O
cause	O
of	O
morbidity	O
and	O
mortality	O
.	O

Their	O
differential	O
diagnosis	O
is	O
difficult	O
and	O
essential	O
for	O
subsequent	O
patient	O
's	O
management	O
.	O

Valproate-induced	O
hyperammonemic	B_Disease
encephalopathy	B_Disease
is	O
an	O
uncommon	O
but	O
serious	O
effect	O
of	O
valproate	B_Chemical
treatment	O
.	O

Here	O
,	O
we	O
describe	O
the	O
case	O
of	O
a	O
15-year-old	O
girl	O
who	O
was	O
on	O
a	O
long-term	O
therapy	O
with	O
valproate	B_Chemical
due	O
to	O
epilepsy	B_Disease
and	O
revealed	O
impaired	B_Disease
consciousness	I_Disease
with	O
hyperammonemia	B_Disease
12	O
days	O
after	O
renal	O
transplantation	O
.	O

After	O
withdraw	O
of	O
valproate	B_Chemical
,	O
patients	O
'	O
symptoms	O
resolved	O
within	O
24	O
h.	O
Clinicians	O
should	O
increase	O
their	O
awareness	O
for	O
potential	O
complication	O
of	O
valproate	B_Chemical
,	O
especially	O
in	O
transplanted	O
patients	O
.	O

Necrotising	B_Disease
fasciitis	I_Disease
after	O
bortezomib	B_Chemical
and	O
dexamethasone-containing	O
regimen	O
in	O
an	O
elderly	O
patient	O
of	O
Waldenstrom	B_Disease
macroglobulinaemia	I_Disease
.	O

Bortezomib	B_Chemical
and	O
high-dose	O
dexamethasone-containing	O
regimens	O
are	O
considered	O
to	O
be	O
generally	O
tolerable	O
with	O
few	O
severe	O
bacterial	B_Disease
infections	I_Disease
in	O
patients	O
with	O
B-cell	O
malignancies	B_Disease
.	O

However	O
,	O
information	O
is	O
limited	O
concerning	O
the	O
safety	O
of	O
the	O
regimen	O
in	O
elderly	O
patients	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
76-year-old	O
man	O
with	O
Waldenstrom	B_Disease
macroglobulinaemia	I_Disease
who	O
suffered	O
necrotising	B_Disease
fasciitis	I_Disease
without	O
neutropenia	B_Disease
after	O
the	O
combination	O
treatment	O
with	O
bortezomib	B_Chemical
,	O
high-dose	O
dexamethasone	B_Chemical
and	O
rituximab	O
.	O

Despite	O
immediate	O
intravenous	O
antimicrobial	O
therapy	O
,	O
he	O
succumbed	O
23	O
h	O
after	O
the	O
onset	O
.	O

Physicians	O
should	O
recognise	O
the	O
possibility	O
of	O
fatal	O
bacterial	B_Disease
infections	I_Disease
related	O
to	O
bortezomib	B_Chemical
plus	O
high-dose	O
dexamethasone	B_Chemical
in	O
elderly	O
patients	O
,	O
and	O
we	O
believe	O
this	O
case	O
warrants	O
further	O
investigation	O
.	O

An	O
integrated	O
characterization	O
of	O
serological	O
,	O
pathological	O
,	O
and	O
functional	O
events	O
in	O
doxorubicin-induced	O
cardiotoxicity	B_Disease
.	O

Many	O
efficacious	O
cancer	B_Disease
treatments	O
cause	O
significant	O
cardiac	O
morbidity	O
,	O
yet	O
biomarkers	O
or	O
functional	O
indices	O
of	O
early	O
damage	O
,	O
which	O
would	O
allow	O
monitoring	O
and	O
intervention	O
,	O
are	O
lacking	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
utilized	O
a	O
rat	O
model	O
of	O
progressive	O
doxorubicin	B_Chemical
(DOX)-induced	O
cardiomyopathy	B_Disease
,	O
applying	O
multiple	O
approaches	O
,	O
including	O
cardiac	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
,	O
to	O
provide	O
the	O
most	O
comprehensive	O
characterization	O
to	O
date	O
of	O
the	O
timecourse	O
of	O
serological	O
,	O
pathological	O
,	O
and	O
functional	O
events	O
underlying	O
this	O
toxicity	B_Disease
.	O

Hannover	O
Wistar	O
rats	O
were	O
dosed	O
with	O
1.25	O
mg/kg	O
DOX	B_Chemical
weekly	O
for	O
8	O
weeks	O
followed	O
by	O
a	O
4	O
week	O
off-dosing	O
"	O
recovery	O
"	O
period	O
.	O

Electron	O
microscopy	O
of	O
the	O
myocardium	O
revealed	O
subcellular	B_Disease
degeneration	I_Disease
and	O
marked	O
mitochondrial	O
changes	O
after	O
a	O
single	O
dose	O
.	O

Histopathological	O
analysis	O
revealed	O
progressive	O
cardiomyocyte	B_Disease
degeneration	I_Disease
,	O
hypertrophy/cytomegaly	O
,	O
and	O
extensive	O
vacuolation	O
after	O
two	O
doses	O
.	O

Extensive	O
replacement	O
fibrosis	B_Disease
(	O
quantified	O
by	O
Sirius	O
red	O
staining	O
)	O
developed	O
during	O
the	O
off-dosing	O
period	O
.	O

Functional	O
indices	O
assessed	O
by	O
cardiac	O
MRI	O
(	O
including	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
,	O
cardiac	O
output	O
,	O
and	O
E/A	O
ratio	O
)	O
declined	O
progressively	O
,	O
reaching	O
statistical	O
significance	O
after	O
two	O
doses	O
and	O
culminating	O
in	O
"	O
clinical	O
"	O
LV	B_Disease
dysfunction	I_Disease
by	O
12	O
weeks	O
.	O

Significant	O
increases	O
in	O
peak	O
myocardial	O
contrast	O
enhancement	O
and	O
serological	O
cardiac	O
troponin	O
I	O
(	O
cTnI	O
)	O
emerged	O
after	O
eight	O
doses	O
,	O
importantly	O
preceding	O
the	O
LVEF	O
decline	O
to	O
<	O
50	O
%	O
.	O

Troponin	O
I	O
levels	O
positively	O
correlated	O
with	O
delayed	O
and	O
peak	O
gadolinium	B_Chemical
contrast	O
enhancement	O
,	O
histopathological	O
grading	O
,	O
and	O
diastolic	B_Disease
dysfunction	I_Disease
.	O

In	O
summary	O
,	O
subcellular	O
cardiomyocyte	B_Disease
degeneration	I_Disease
was	O
the	O
earliest	O
marker	O
,	O
followed	O
by	O
progressive	O
functional	O
decline	O
and	O
histopathological	O
manifestations	O
.	O

Myocardial	O
contrast	O
enhancement	O
and	O
elevations	O
in	O
cTnI	O
occurred	O
later	O
.	O

However	O
,	O
all	O
indices	O
predated	O
"	O
clinical	O
"	O
LV	B_Disease
dysfunction	I_Disease
and	O
thus	O
warrant	O
further	O
evaluation	O
as	O
predictive	O
biomarkers	O
.	O

Intradermal	O
glutamate	B_Chemical
and	O
capsaicin	B_Chemical
injections	O
:	O
intra-	O
and	O
interindividual	O
variability	O
of	O
provoked	O
hyperalgesia	B_Disease
and	O
allodynia	B_Disease
.	O

Intradermal	O
injections	O
of	O
glutamate	B_Chemical
and	O
capsaicin	B_Chemical
are	O
attractive	O
to	O
use	O
in	O
human	O
experimental	O
pain	B_Disease
models	O
because	O
hyperalgesia	B_Disease
and	O
allodynia	B_Disease
mimic	O
isolated	O
aspects	O
of	O
clinical	O
pain	B_Disease
disorders	I_Disease
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
reproducibility	O
of	O
these	O
models	O
.	O

Twenty	O
healthy	O
male	O
volunteers	O
(	O
mean	O
age	O
24	O
years	O
;	O
range	O
18	O
-	O
38	O
years	O
)	O
received	O
intradermal	O
injections	O
of	O
glutamate	B_Chemical
and	O
capsaicin	B_Chemical
in	O
the	O
volar	O
forearm	O
.	O

Magnitudes	O
of	O
secondary	O
pinprick	O
hyperalgesia	B_Disease
and	O
brush-evoked	O
allodynia	B_Disease
were	O
investigated	O
using	O
von	O
Frey	O
filaments	O
(	O
gauges	O
10	O
,	O
15	O
,	O
60	O
and	O
100	O
g	O
)	O
and	O
brush	O
strokes	O
.	O

Areas	O
of	O
secondary	B_Disease
hyperalgesia	I_Disease
and	O
allodynia	B_Disease
were	O
quantified	O
immediately	O
after	O
injection	O
and	O
after	O
15	O
,	O
30	O
and	O
60	O
min	O
.	O

Two	O
identical	O
experiments	O
separated	O
by	O
at	O
least	O
7	O
days	O
were	O
performed	O
.	O

Reproducibility	O
across	O
and	O
within	O
volunteers	O
(	O
inter-	O
and	O
intra-individual	O
variation	O
,	O
respectively	O
)	O
was	O
assessed	O
using	O
intraclass	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
and	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
.	O

Secondary	O
pinprick	O
hyperalgesia	B_Disease
was	O
observed	O
as	O
a	O
marked	O
increase	O
in	O
the	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
response	O
to	O
von	O
Frey	O
gauges	O
60	O
and	O
100	O
g	O
(	O
P	O
<	O
0.001	O
)	O
after	O
glutamate	B_Chemical
injection	O
.	O

For	O
capsaicin	B_Chemical
,	O
secondary	O
pinprick	O
hyperalgesia	B_Disease
was	O
detected	O
with	O
all	O
von	O
Frey	O
gauges	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Glutamate	B_Chemical
evoked	O
reproducible	O
VAS	O
response	O
to	O
all	O
von	O
Frey	O
gauges	O
(	O
ICC	O
>	O
0.60	O
)	O
and	O
brush	O
strokes	O
(	O
ICC	O
>	O
0.83	O
)	O
.	O

Capsaicin	B_Chemical
injection	O
was	O
reproducible	O
for	O
secondary	B_Disease
hyperalgesia	I_Disease
(	O
ICC	O
>	O
0.70	O
)	O
and	O
allodynia	B_Disease
(	O
ICC	O
>	O
0.71	O
)	O
.	O

Intra-individual	O
variability	O
was	O
generally	O
lower	O
for	O
the	O
VAS	O
response	O
to	O
von	O
Frey	O
and	O
brush	O
compared	O
with	O
areas	O
of	O
secondary	B_Disease
hyperalgesia	I_Disease
and	O
allodynia	B_Disease
.	O

In	O
conclusion	O
,	O
glutamate	B_Chemical
and	O
capsaicin	B_Chemical
yield	O
reproducible	O
hyperalgesic	B_Disease
and	O
allodynic	B_Disease
responses	O
,	O
and	O
the	O
present	O
model	O
is	O
well	O
suited	O
for	O
basic	O
research	O
,	O
as	O
well	O
as	O
for	O
assessing	O
the	O
modulation	O
of	O
central	O
phenomena	O
.	O

Ocular-specific	O
ER	O
stress	O
reduction	O
rescues	O
glaucoma	B_Disease
in	O
murine	O
glucocorticoid-induced	O
glaucoma	B_Disease
.	O

Administration	O
of	O
glucocorticoids	O
induces	O
ocular	B_Disease
hypertension	I_Disease
in	O
some	O
patients	O
.	O

If	O
untreated	O
,	O
these	O
patients	O
can	O
develop	O
a	O
secondary	O
glaucoma	B_Disease
that	O
resembles	O
primary	B_Disease
open-angle	I_Disease
glaucoma	I_Disease
(	O
POAG	B_Disease
)	O
.	O

The	O
underlying	O
pathology	O
of	O
glucocorticoid-induced	O
glaucoma	B_Disease
is	O
not	O
fully	O
understood	O
,	O
due	O
in	O
part	O
to	O
lack	O
of	O
an	O
appropriate	O
animal	O
model	O
.	O

Here	O
,	O
we	O
developed	O
a	O
murine	O
model	O
of	O
glucocorticoid-induced	O
glaucoma	B_Disease
that	O
exhibits	O
glaucoma	B_Disease
features	O
that	O
are	O
observed	O
in	O
patients	O
.	O

Treatment	O
of	O
WT	O
mice	O
with	O
topical	O
ocular	O
0.1	O
%	O
dexamethasone	B_Chemical
led	O
to	O
elevation	O
of	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
,	O
functional	O
and	O
structural	O
loss	O
of	O
retinal	B_Disease
ganglion	I_Disease
cells	O
,	O
and	O
axonal	B_Disease
degeneration	I_Disease
,	O
resembling	O
glucocorticoid-induced	O
glaucoma	B_Disease
in	O
human	O
patients	O
.	O

Furthermore	O
,	O
dexamethasone-induced	O
ocular	B_Disease
hypertension	I_Disease
was	O
associated	O
with	O
chronic	O
ER	O
stress	O
of	O
the	O
trabecular	O
meshwork	O
(	O
TM	O
)	O
.	O

Similar	O
to	O
patients	O
,	O
withdrawal	O
of	O
dexamethasone	B_Chemical
treatment	O
reduced	O
elevated	O
IOP	O
and	O
ER	O
stress	O
in	O
this	O
animal	O
model	O
.	O

Dexamethasone	B_Chemical
induced	O
the	O
transcriptional	O
factor	O
CHOP	O
,	O
a	O
marker	O
for	O
chronic	O
ER	O
stress	O
,	O
in	O
the	O
anterior	O
segment	O
tissues	O
,	O
and	O
Chop	O
deletion	O
reduced	O
ER	O
stress	O
in	O
these	O
tissues	O
and	O
prevented	O
dexamethasone-induced	O
ocular	B_Disease
hypertension	I_Disease
.	O

Furthermore	O
,	O
reduction	O
of	O
ER	O
stress	O
in	O
the	O
TM	O
with	O
sodium	B_Chemical
4-phenylbutyrate	I_Chemical
prevented	O
dexamethasone-induced	O
ocular	B_Disease
hypertension	I_Disease
in	O
WT	O
mice	O
.	O

Our	O
data	O
indicate	O
that	O
ER	O
stress	O
contributes	O
to	O
glucocorticoid-induced	O
ocular	B_Disease
hypertension	I_Disease
and	O
suggest	O
that	O
reducing	O
ER	O
stress	O
has	O
potential	O
as	O
a	O
therapeutic	O
strategy	O
for	O
treating	O
glucocorticoid-induced	O
glaucoma	B_Disease
.	O

Effects	O
of	O
ginsenosides	B_Chemical
on	O
opioid-induced	O
hyperalgesia	B_Disease
in	O
mice	O
.	O

Opioid-induced	O
hyperalgesia	B_Disease
(	O
OIH	B_Disease
)	O
is	O
characterized	O
by	O
nociceptive	O
sensitization	O
caused	O
by	O
the	O
cessation	O
of	O
chronic	O
opioid	O
use	O
.	O

OIH	B_Disease
can	O
limit	O
the	O
clinical	O
use	O
of	O
opioid	O
analgesics	O
and	O
complicate	O
withdrawal	O
from	O
opioid	B_Disease
addiction	I_Disease
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
Re	B_Chemical
,	I_Chemical
Rg1	I_Chemical
,	I_Chemical
and	I_Chemical
Rb1	B_Chemical
ginsenosides	I_Chemical
,	O
the	O
bioactive	O
components	O
of	O
ginseng	O
,	O
on	O
OIH	B_Disease
.	O

OIH	B_Disease
was	O
achieved	O
in	O
mice	O
after	O
subcutaneous	O
administration	O
of	O
morphine	B_Chemical
for	O
7	O
consecutive	O
days	O
three	O
times	O
per	O
day	O
.	O

During	O
withdrawal	O
(	O
days	O
8	O
and	O
9	O
)	O
,	O
these	O
mice	O
were	O
administered	O
Re	B_Chemical
,	O
Rg1	B_Chemical
,	O
or	O
Rb1	B_Chemical
intragastrically	O
two	O
times	O
per	O
day	O
.	O

On	O
the	O
test	O
day	O
(	O
day	O
10	O
)	O
,	O
mice	O
were	O
subjected	O
to	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	O
acid-induced	O
writhing	O
test	O
.	O

Re	B_Chemical
(	O
300	O
mg/kg	O
)	O
inhibited	O
OIH	B_Disease
in	O
both	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	O
acid-induced	O
writhing	O
test	O
.	O

However	O
,	O
the	O
Rg1	B_Chemical
and	I_Chemical
Rb1	B_Chemical
ginsenosides	I_Chemical
failed	O
to	O
prevent	O
OIH	B_Disease
in	O
either	O
test	O
.	O

Furthermore	O
,	O
Rg1	B_Chemical
showed	O
a	O
tendency	O
to	O
aggravate	O
OIH	B_Disease
in	O
the	O
acetic	O
acid-induced	O
writhing	O
test	O
.	O

Our	O
data	O
suggested	O
that	O
the	O
ginsenoside	B_Chemical
Re	I_Chemical
,	O
but	O
not	O
Rg1	B_Chemical
or	O
Rb1	B_Chemical
,	O
may	O
contribute	O
toward	O
reversal	O
of	O
OIH	B_Disease
.	O

A	O
comparison	O
of	O
severe	O
hemodynamic	O
disturbances	O
between	O
dexmedetomidine	B_Chemical
and	O
propofol	B_Chemical
for	O
sedation	O
in	O
neurocritical	O
care	O
patients	O
.	O

OBJECTIVE	O
:	O
Dexmedetomidine	B_Chemical
and	O
propofol	B_Chemical
are	O
commonly	O
used	O
sedatives	O
in	O
neurocritical	O
care	O
as	O
they	O
allow	O
for	O
frequent	O
neurologic	O
examinations	O
.	O

However	O
,	O
both	O
agents	O
are	O
associated	O
with	O
significant	O
hemodynamic	O
side	O
effects	O
.	O

The	O
primary	O
objective	O
of	O
this	O
study	O
is	O
to	O
compare	O
the	O
prevalence	O
of	O
severe	O
hemodynamic	O
effects	O
in	O
neurocritical	O
care	O
patients	O
receiving	O
dexmedetomidine	B_Chemical
and	O
propofol	B_Chemical
.	O

DESIGN	O
:	O
Multicenter	O
,	O
retrospective	O
,	O
propensity-matched	O
cohort	O
study	O
.	O

SETTING	O
:	O
Neurocritical	O
care	O
units	O
at	O
two	O
academic	O
medical	O
centers	O
with	O
dedicated	O
neurocritical	O
care	O
teams	O
and	O
board-certified	O
neurointensivists	O
.	O

PATIENTS	O
:	O
Neurocritical	O
care	O
patients	O
admitted	O
between	O
July	O
2009	O
and	O
September	O
2012	O
were	O
evaluated	O
and	O
then	O
matched	O
1:1	O
based	O
on	O
propensity	O
scoring	O
of	O
baseline	O
characteristics	O
.	O

INTERVENTIONS	O
:	O
Continuous	O
sedation	O
with	O
dexmedetomidine	B_Chemical
or	O
propofol	B_Chemical
.	O

MEASUREMENTS	O
AND	O
MAIN	O
RESULTS	O
:	O
A	O
total	O
of	O
342	O
patients	O
(	O
105	O
dexmedetomidine	B_Chemical
and	O
237	O
propofol	B_Chemical
)	O
were	O
included	O
in	O
the	O
analysis	O
,	O
with	O
190	O
matched	O
(	O
95	O
in	O
each	O
group	O
)	O
by	O
propensity	O
score	O
.	O

The	O
primary	O
outcome	O
of	O
this	O
study	O
was	O
a	O
composite	O
of	O
severe	O
hypotension	B_Disease
(	O
mean	O
arterial	O
pressure	O
<	O
60	O
mm	O
Hg	O
)	O
and	O
bradycardia	B_Disease
(	O
heart	O
rate	O
<	O
50	O
beats/min	O
)	O
during	O
sedative	O
infusion	O
.	O

No	O
difference	O
in	O
the	O
primary	O
composite	O
outcome	O
in	O
both	O
the	O
unmatched	O
(	O
30	O
%	O
vs	O
30	O
%	O
,	O
p	O
=	O
0.94	O
)	O
or	O
matched	O
cohorts	O
(	O
28	O
%	O
vs	O
34	O
%	O
,	O
p	O
=	O
0.35	O
)	O
could	O
be	O
found	O
.	O

When	O
analyzed	O
separately	O
,	O
no	O
differences	O
could	O
be	O
found	O
in	O
the	O
prevalence	O
of	O
severe	O
hypotension	B_Disease
or	O
bradycardia	B_Disease
in	O
either	O
the	O
unmatched	O
or	O
matched	O
cohorts	O
.	O

CONCLUSIONS	O
:	O
Severe	O
hypotension	B_Disease
and	O
bradycardia	B_Disease
occur	O
at	O
similar	O
prevalence	O
in	O
neurocritical	O
care	O
patients	O
who	O
receive	O
dexmedetomidine	B_Chemical
or	O
propofol	B_Chemical
.	O

Providers	O
should	O
similarly	O
consider	O
the	O
likelihood	O
of	O
hypotension	B_Disease
or	O
bradycardia	B_Disease
before	O
starting	O
either	O
sedative	O
.	O

Hydroxytyrosol	B_Chemical
ameliorates	O
oxidative	O
stress	O
and	O
mitochondrial	B_Disease
dysfunction	I_Disease
in	O
doxorubicin-induced	O
cardiotoxicity	B_Disease
in	O
rats	O
with	O
breast	B_Disease
cancer	I_Disease
.	O

Oxidative	O
stress	O
is	O
involved	O
in	O
several	O
processes	O
including	O
cancer	B_Disease
,	O
aging	O
and	O
cardiovascular	B_Disease
disease	I_Disease
,	O
and	O
has	O
been	O
shown	O
to	O
potentiate	O
the	O
therapeutic	O
effect	O
of	O
drugs	O
such	O
as	O
doxorubicin	B_Chemical
.	O

Doxorubicin	B_Chemical
causes	O
significant	O
cardiotoxicity	B_Disease
characterized	O
by	O
marked	O
increases	O
in	O
oxidative	O
stress	O
and	O
mitochondrial	B_Disease
dysfunction	I_Disease
.	O

Herein	O
,	O
we	O
investigate	O
whether	O
doxorubicin-associated	O
chronic	O
cardiac	B_Disease
toxicity	I_Disease
can	O
be	O
ameliorated	O
with	O
the	O
antioxidant	O
hydroxytyrosol	B_Chemical
in	O
rats	O
with	O
breast	B_Disease
cancer	I_Disease
.	O

Thirty-six	O
rats	O
bearing	O
breast	B_Disease
tumors	I_Disease
induced	O
chemically	O
were	O
divided	O
into	O
4	O
groups	O
:	O
control	O
,	O
hydroxytyrosol	B_Chemical
(	O
0.5mg/kg	O
,	O
5days/week	O
)	O
,	O
doxorubicin	B_Chemical
(	O
1mg/kg/week	O
)	O
,	O
and	O
doxorubicin	B_Chemical
plus	O
hydroxytyrosol	B_Chemical
.	O

Cardiac	B_Disease
disturbances	I_Disease
at	O
the	O
cellular	O
and	O
mitochondrial	O
level	O
,	O
mitochondrial	O
electron	O
transport	O
chain	O
complexes	O
I-IV	O
and	O
apoptosis-inducing	O
factor	O
,	O
and	O
oxidative	O
stress	O
markers	O
have	O
been	O
analyzed	O
.	O

Hydroxytyrosol	B_Chemical
improved	O
the	O
cardiac	B_Disease
disturbances	I_Disease
enhanced	O
by	O
doxorubicin	B_Chemical
by	O
significantly	O
reducing	O
the	O
percentage	O
of	O
altered	O
mitochondria	O
and	O
oxidative	O
damage	O
.	O

These	O
results	O
suggest	O
that	O
hydroxytyrosol	B_Chemical
improve	O
the	O
mitochondrial	O
electron	O
transport	O
chain	O
.	O

This	O
study	O
demonstrates	O
that	O
hydroxytyrosol	B_Chemical
protect	O
rat	O
heart	B_Disease
damage	I_Disease
provoked	O
by	O
doxorubicin	B_Chemical
decreasing	O
oxidative	O
damage	O
and	O
mitochondrial	O
alterations	O
.	O

Amiodarone-induced	O
myxoedema	B_Disease
coma	B_Disease
.	O

A	O
62-year-old	O
man	O
was	O
found	O
to	O
have	O
bradycardia	B_Disease
,	O
hypothermia	B_Disease
and	O
respiratory	B_Disease
failure	I_Disease
3	O
weeks	O
after	O
initiation	O
of	O
amiodarone	B_Chemical
therapy	O
for	O
atrial	B_Disease
fibrillation	I_Disease
.	O

Thyroid-stimulating	O
hormone	O
was	O
found	O
to	O
be	O
168	O
uIU/mL	O
(	O
nl	O
.	O
0.3	O
-	O
5	O
uIU/mL	O
)	O
and	O
free	O
thyroxine	B_Chemical
(	O
FT4	O
)	O
was	O
<	O
0.2	O
ng/dL	O
(	O
nl	O
.	O
0.8	O
-	O
1.8	O
ng/dL	O
)	O
.	O

He	O
received	O
intravenous	O
fluids	O
,	O
vasopressor	O
therapy	O
and	O
stress	O
dose	O
steroids	B_Chemical
;	O
he	O
was	O
intubated	O
and	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
.	O

He	O
received	O
500	O
ug	O
of	O
intravenous	O
levothyroxine	B_Chemical
in	O
the	O
first	O
18	O
h	O
of	O
therapy	O
,	O
and	O
150	O
ug	O
intravenous	O
daily	O
thereafter	O
.	O

Haemodynamic	O
improvement	O
,	O
along	O
with	O
complete	O
recovery	O
of	O
mental	O
status	O
,	O
occurred	O
after	O
48	O
h.	O
Twelve	O
hours	O
after	O
the	O
initiation	O
of	O
therapy	O
,	O
FT4	O
was	O
0.96	O
ng/dL.	O
The	O
patient	O
was	O
maintained	O
on	O
levothyroxine	B_Chemical
175	O
(	O
g	O
POorally	O
daily	O
.	O

A	O
thyroid	O
ultrasound	O
showed	O
diffuse	O
heterogeneity	O
.	O

The	O
24	O
hour	O
excretion	O
of	O
iodine	B_Chemical
was	O
3657	O
(	O
mcg	O
(	O
25	O
-	O
756	O
(	O
mcg	O
)	O
.	O

The	O
only	O
two	O
cases	O
of	O
amiodarone-induced	O
myxoedema	B_Disease
coma	B_Disease
in	O
the	O
literature	O
report	O
patient	O
death	O
despite	O
supportive	O
therapy	O
and	O
thyroid	O
hormone	O
replacement	O
.	O

This	O
case	O
represents	O
the	O
most	O
thoroughly	O
investigated	O
case	O
of	O
amiodarone-induced	O
myxoedema	B_Disease
coma	B_Disease
with	O
a	O
history	O
significant	O
for	O
subclinical	O
thyroid	B_Disease
disease	I_Disease
.	O

Use	O
of	O
argatroban	B_Chemical
and	O
catheter-directed	O
thrombolysis	B_Disease
with	O
alteplase	O
in	O
an	O
oncology	O
patient	O
with	O
heparin-induced	O
thrombocytopenia	B_Disease
with	O
thrombosis	B_Disease
.	O

PURPOSE	O
:	O
The	O
case	O
of	O
an	O
oncology	O
patient	O
who	O
developed	O
heparin-induced	O
thrombocytopenia	B_Disease
with	O
thrombosis	B_Disease
(	O
HITT	B_Disease
)	O
and	O
was	O
treated	O
with	O
argatroban	B_Chemical
plus	O
catheter-directed	O
thrombolysis	B_Disease
(	O
CDT	O
)	O
with	O
alteplase	O
is	O
presented	O
.	O

SUMMARY	O
:	O
A	O
63-year-old	O
Caucasian	O
man	O
with	O
renal	O
amyloidosis	B_Disease
undergoing	O
peripheral	O
blood	O
stem	O
cell	O
collection	O
for	O
an	O
autologous	O
stem	O
cell	O
transplant	O
developed	O
extensive	O
bilateral	O
upper-extremity	B_Disease
deep	I_Disease
venous	I_Disease
thrombosis	I_Disease
(	O
DVT	B_Disease
)	O
and	O
pulmonary	B_Disease
embolism	I_Disease
secondary	O
to	O
heparin-induced	O
thrombocytopenia	B_Disease
.	O

A	O
continuous	O
i.v	O
.	O

infusion	O
of	O
argatroban	B_Chemical
was	O
initiated	O
,	O
and	O
the	O
patient	O
was	O
managed	O
on	O
the	O
general	O
medical	O
floor	O
.	O

After	O
one	O
week	O
of	O
therapy	O
,	O
he	O
was	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
with	O
cardiopulmonary	O
compromise	O
related	O
to	O
superior	B_Disease
vena	I_Disease
cava	I_Disease
(	I_Disease
SVC	I_Disease
)	I_Disease
syndrome	I_Disease
.	O

A	O
percutaneous	O
mechanical	O
thrombectomy	O
and	O
CDT	O
with	O
alteplase	O
were	O
attempted	O
,	O
but	O
the	O
procedure	O
was	O
aborted	O
due	O
to	O
epistaxis	B_Disease
.	O

The	O
epistaxis	B_Disease
resolved	O
the	O
next	O
day	O
,	O
and	O
the	O
patient	O
was	O
restarted	O
on	O
argatroban	B_Chemical
.	O

A	O
second	O
percutaneous	O
mechanical	O
thrombectomy	O
was	O
performed	O
six	O
days	O
later	O
and	O
resulted	O
in	O
partial	O
revascularization	O
of	O
the	O
SVC	O
and	O
central	O
veins	O
.	O

Postthrombectomy	O
continuous	O
CDT	O
with	O
alteplase	O
was	O
commenced	O
while	O
argatroban	B_Chemical
was	O
withheld	O
,	O
and	O
complete	O
patency	O
of	O
the	O
SVC	O
and	O
central	O
veins	O
was	O
achieved	O
after	O
three	O
days	O
of	O
therapy	O
.	O

Alteplase	O
was	O
discontinued	O
,	O
and	O
the	O
patient	O
was	O
reinitiated	O
on	O
argatroban	B_Chemical
;	O
ultimately	O
,	O
he	O
was	O
transitioned	O
to	O
warfarin	B_Chemical
for	O
long-term	O
anticoagulation	O
.	O

Although	O
the	O
patient	O
recovered	O
,	O
he	O
experienced	O
permanent	O
vision	B_Disease
and	I_Disease
hearing	B_Disease
loss	I_Disease
,	O
as	O
well	O
as	O
end-stage	B_Disease
renal	I_Disease
disease	I_Disease
.	O

CONCLUSION	O
:	O
A	O
63-year-old	O
man	O
with	O
renal	O
amyloidosis	B_Disease
and	O
SVC	B_Disease
syndrome	I_Disease
secondary	O
to	O
HITT	B_Disease
was	O
successfully	O
treated	O
with	O
argatroban	B_Chemical
and	O
CDT	O
with	O
alteplase	O
.	O

Effects	O
of	O
dehydroepiandrosterone	B_Chemical
in	O
amphetamine-induced	O
schizophrenia	B_Disease
models	O
in	O
mice	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
effects	O
of	O
dehydroepiandrosterone	B_Chemical
(	O
DHEA	B_Chemical
)	O
on	O
animal	O
models	O
of	O
schizophrenia	B_Disease
.	O

METHODS	O
:	O
Seventy	O
Swiss	O
albino	O
female	O
mice	O
(	O
25	O
-	O
35	O
g	O
)	O
were	O
divided	O
into	O
4	O
groups	O
:	O
amphetamine-free	O
(	O
control	O
)	O
,	O
amphetamine	B_Chemical
,	O
50	O
,	O
and	O
100	O
mg/kg	O
DHEA	B_Chemical
.	O

The	O
DHEA	B_Chemical
was	O
administered	O
intraperitoneally	O
(	O
ip	O
)	O
for	O
5	O
days	O
.	O

Amphetamine	B_Chemical
(	O
3	O
mg/kg	O
ip	O
)	O
induced	O
hyper	B_Disease
locomotion	O
,	O
apomorphine	B_Chemical
(	O
1.5	O
mg/kg	O
subcutaneously	O
[	O
sc	O
]	O
)	O
induced	O
climbing	O
,	O
and	O
haloperidol	B_Chemical
(	O
1.5	O
mg/kg	O
sc	O
)	O
induced	O
catalepsy	B_Disease
tests	O
were	O
used	O
as	O
animal	O
models	O
of	O
schizophrenia	B_Disease
.	O

The	O
study	O
was	O
conducted	O
at	O
the	O
Animal	O
Experiment	O
Laboratories	O
,	O
Department	O
of	O
Pharmacology	O
,	O
Medical	O
School	O
,	O
Eskisehir	O
Osmangazi	O
University	O
,	O
Eskisehir	O
,	O
Turkey	O
between	O
March	O
and	O
May	O
2012	O
.	O

Statistical	O
analysis	O
was	O
carried	O
out	O
using	O
Kruskal-Wallis	O
test	O
for	O
hyper	B_Disease
locomotion	O
,	O
and	O
one-way	O
ANOVA	O
for	O
climbing	O
and	O
catalepsy	B_Disease
tests	O
.	O

RESULTS	O
:	O
In	O
the	O
amphetamine-induced	O
locomotion	O
test	O
,	O
there	O
were	O
significant	O
increases	O
in	O
all	O
movements	O
compared	O
with	O
the	O
amphetamine-free	O
group	O
.	O

Both	O
DHEA	B_Chemical
50	O
mg/kg	O
(	O
p<0.05	O
)	O
,	O
and	O
100	O
mg/kg	O
(	O
p<0.01	O
)	O
significantly	O
decreased	O
all	O
movements	O
compared	O
with	O
the	O
amphetamine-induced	O
locomotion	O
group	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
groups	O
in	O
the	O
haloperidol-induced	O
catalepsy	B_Disease
test	O
(	O
p<0.05	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
groups	O
in	O
terms	O
of	O
total	O
climbing	O
time	O
in	O
the	O
apomorphine-induced	O
climbing	O
test	O
(	O
p>0.05	O
)	O
.	O

CONCLUSION	O
:	O
We	O
observed	O
that	O
DHEA	B_Chemical
reduced	O
locomotor	O
activity	O
and	O
increased	O
catalepsy	B_Disease
at	O
both	O
doses	O
,	O
while	O
it	O
had	O
no	O
effect	O
on	O
climbing	O
behavior	O
.	O

We	O
suggest	O
that	O
DHEA	B_Chemical
displays	O
typical	O
neuroleptic-like	O
effects	O
,	O
and	O
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
schizophrenia	B_Disease
.	O

Availability	O
of	O
human	O
induced	O
pluripotent	O
stem	O
cell-derived	O
cardiomyocytes	O
in	O
assessment	O
of	O
drug	O
potential	O
for	O
QT	O
prolongation	O
.	O

Field	O
potential	O
duration	O
(	O
FPD	O
)	O
in	O
human-induced	O
pluripotent	O
stem	O
cell-derived	O
cardiomyocytes	O
(	O
hiPS-CMs	O
)	O
,	O
which	O
can	O
express	O
QT	O
interval	O
in	O
an	O
electrocardiogram	O
,	O
is	O
reported	O
to	O
be	O
a	O
useful	O
tool	O
to	O
predict	O
K(+	O
)	O
channel	O
and	O
Ca(2	O
+	O
)	O
channel	O
blocker	O
effects	O
on	O
QT	O
interval	O
.	O

However	O
,	O
there	O
is	O
no	O
report	O
showing	O
that	O
this	O
technique	O
can	O
be	O
used	O
to	O
predict	O
multichannel	O
blocker	O
potential	O
for	O
QT	B_Disease
prolongation	I_Disease
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
show	O
that	O
FPD	O
from	O
MEA	O
(	O
Multielectrode	O
array	O
)	O
of	O
hiPS-CMs	O
can	O
detect	O
QT	B_Disease
prolongation	I_Disease
induced	O
by	O
multichannel	O
blockers	O
.	O

hiPS-CMs	O
were	O
seeded	O
onto	O
MEA	O
and	O
FPD	O
was	O
measured	O
for	O
2min	O
every	O
10min	O
for	O
30min	O
after	O
drug	O
exposure	O
for	O
the	O
vehicle	O
and	O
each	O
drug	O
concentration	O
.	O

IKr	O
and	O
IKs	O
blockers	O
concentration-dependently	O
prolonged	O
corrected	O
FPD	O
(	O
FPDc	O
)	O
,	O
whereas	O
Ca(2	O
+	O
)	O
channel	O
blockers	O
concentration-dependently	O
shortened	O
FPDc	O
.	O

Also	O
,	O
the	O
multichannel	O
blockers	O
Amiodarone	B_Chemical
,	O
Paroxetine	B_Chemical
,	O
Terfenadine	B_Chemical
and	O
Citalopram	B_Chemical
prolonged	O
FPDc	O
in	O
a	O
concentration	O
dependent	O
manner	O
.	O

Finally	O
,	O
the	O
IKr	O
blockers	O
,	O
Terfenadine	B_Chemical
and	O
Citalopram	B_Chemical
,	O
which	O
are	O
reported	O
to	O
cause	O
Torsade	B_Disease
de	I_Disease
Pointes	I_Disease
(	O
TdP	B_Disease
)	O
in	O
clinical	O
practice	O
,	O
produced	O
early	O
afterdepolarization	O
(	O
EAD	O
)	O
.	O

hiPS-CMs	O
using	O
MEA	O
system	O
and	O
FPDc	O
can	O
predict	O
the	O
effects	O
of	O
drug	O
candidates	O
on	O
QT	O
interval	O
.	O

This	O
study	O
also	O
shows	O
that	O
this	O
assay	O
can	O
help	O
detect	O
EAD	O
for	O
drugs	O
with	O
TdP	B_Disease
potential	O
.	O

Dermal	O
developmental	O
toxicity	O
of	O
N-phenylimide	O
herbicides	O
in	O
rats	O
.	O

BACKGROUND	O
:	O
S-53482	B_Chemical
and	O
S-23121	B_Chemical
are	O
N-phenylimide	O
herbicides	O
and	O
produced	O
embryolethality	B_Disease
,	O
teratogenicity	B_Disease
(	O
mainly	O
ventricular	B_Disease
septal	I_Disease
defects	I_Disease
and	O
wavy	O
ribs	O
)	O
,	O
and	O
growth	B_Disease
retardation	I_Disease
in	O
rats	O
in	O
conventional	O
oral	O
developmental	O
toxicity	B_Disease
studies	O
.	O

Our	O
objective	O
in	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
the	O
compounds	O
induce	O
developmental	O
toxicity	B_Disease
via	O
the	O
dermal	O
route	O
,	O
which	O
is	O
more	O
relevant	O
to	O
occupational	O
exposure	O
,	O
hence	O
better	O
addressing	O
human	O
health	O
risks	O
.	O

METHODS	O
:	O
S-53482	B_Chemical
was	O
administered	O
dermally	O
to	O
rats	O
at	O
30	O
,	O
100	O
,	O
and	O
300	O
mg/kg	O
during	O
organogenesis	O
,	O
and	O
S-23121	B_Chemical
was	O
administered	O
at	O
200	O
,	O
400	O
,	O
and	O
800	O
mg/kg	O
(	O
the	O
maximum	O
applicable	O
dose	O
level	O
)	O
.	O

Fetuses	O
were	O
obtained	O
by	O
a	O
Cesarean	O
section	O
and	O
examined	O
for	O
external	O
,	O
visceral	O
,	O
and	O
skeletal	O
alterations	O
.	O

RESULTS	O
:	O
Dermal	O
exposure	O
of	O
rats	O
to	O
S-53482	B_Chemical
at	O
300	O
mg/kg	O
produced	O
patterns	O
of	O
developmental	O
toxicity	B_Disease
similar	O
to	O
those	O
resulting	O
from	O
oral	O
exposure	O
.	O

Toxicity	B_Disease
included	O
embryolethality	B_Disease
,	O
teratogenicity	B_Disease
,	O
and	O
growth	B_Disease
retardation	I_Disease
.	O

Dermal	O
administration	O
of	O
S-23121	B_Chemical
at	O
800	O
mg/kg	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
embryonic	B_Disease
death	I_Disease
and	O
ventricular	B_Disease
septal	I_Disease
defect	I_Disease
,	O
but	O
retarded	O
fetal	O
growth	O
was	O
not	O
observed	O
as	O
it	O
was	O
following	O
oral	O
exposure	O
to	O
S-23121	B_Chemical
.	O

CONCLUSIONS	O
:	O
Based	O
on	O
the	O
results	O
,	O
S-53482	B_Chemical
and	O
S-23121	B_Chemical
were	O
teratogenic	B_Disease
when	O
administered	O
dermally	O
to	O
pregnant	O
rats	O
as	O
were	O
the	O
compounds	O
administered	O
orally	O
.	O

Thus	O
,	O
investigation	O
of	O
the	O
mechanism	O
and	O
its	O
human	O
relevancy	O
become	O
more	O
important	O
.	O

Rates	O
of	O
Renal	B_Disease
Toxicity	I_Disease
in	O
Cancer	B_Disease
Patients	O
Receiving	O
Cisplatin	B_Chemical
With	O
and	O
Without	O
Mannitol	B_Chemical
.	O

BACKGROUND	O
:	O
Cisplatin	B_Chemical
is	O
a	O
widely	O
used	O
antineoplastic	O
.	O

One	O
of	O
the	O
major	O
complications	O
of	O
cisplatin	B_Chemical
use	O
is	O
dose-limiting	O
nephrotoxicity	B_Disease
.	O

There	O
are	O
many	O
strategies	O
to	O
prevent	O
this	O
toxicity	B_Disease
,	O
including	O
the	O
use	O
of	O
mannitol	B_Chemical
as	O
a	O
nephroprotectant	O
in	O
combination	O
with	O
hydration	O
.	O

OBJECTIVE	O
:	O
We	O
aimed	O
to	O
evaluate	O
the	O
rates	O
of	O
cisplatin-induced	O
nephrotoxicity	B_Disease
in	O
cancer	B_Disease
patients	O
receiving	O
single-agent	O
cisplatin	B_Chemical
with	O
and	O
without	O
mannitol	B_Chemical
.	O

METHODS	O
:	O
This	O
single-center	O
retrospective	O
analysis	O
was	O
a	O
quasi	O
experiment	O
created	O
by	O
the	O
national	O
mannitol	B_Chemical
shortage	O
.	O

Data	O
were	O
collected	O
on	O
adult	O
cancer	B_Disease
patients	O
receiving	O
single-agent	O
cisplatin	B_Chemical
as	O
an	O
outpatient	O
from	O
January	O
2011	O
to	O
September	O
2012	O
.	O

The	O
primary	O
outcome	O
was	O
acute	B_Disease
kidney	I_Disease
injury	I_Disease
(	O
AKI	B_Disease
)	O
.	O

RESULTS	O
:	O
We	O
evaluated	O
143	O
patients	O
who	O
received	O
single-agent	O
cisplatin	B_Chemical
;	O
97.2	O
%	O
of	O
patients	O
had	O
head	B_Disease
and	I_Disease
neck	I_Disease
cancer	I_Disease
as	O
their	O
primary	O
malignancy	B_Disease
.	O

Patients	O
who	O
did	O
not	O
receive	O
mannitol	B_Chemical
were	O
more	O
likely	O
to	O
develop	O
nephrotoxicity	B_Disease
:	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
2.646	O
(	O
95	O
%	O
CI	O
=	O
1.008	O
,	O
6.944	O
;	O
P	O
=	O
0.048	O
)	O
.	O

Patients	O
who	O
received	O
the	O
100	O
mg/m(2	O
)	O
dosing	O
and	O
patients	O
who	O
had	O
a	O
history	O
of	O
hypertension	B_Disease
also	O
had	O
a	O
higher	O
likelihood	O
of	O
developing	O
nephrotoxicity	B_Disease
:	O
OR	O
=	O
11.494	O
(	O
95	O
%	O
CI	O
=	O
4.149	O
,	O
32.258	O
;	O
P	O
<	O
0.0001	O
)	O
and	O
OR	O
=	O
3.219	O
(	O
95	O
%	O
CI	O
=	O
1.228	O
,	O
8.439	O
;	O
P	O
=	O
0.017	O
)	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
When	O
limited	O
quantities	O
of	O
mannitol	B_Chemical
are	O
available	O
,	O
it	O
should	O
preferentially	O
be	O
given	O
to	O
patients	O
at	O
particularly	O
high	O
risk	O
of	O
nephrotoxicity	B_Disease
.	O

Our	O
analysis	O
suggests	O
that	O
those	O
patients	O
receiving	O
the	O
dosing	O
schedule	O
of	O
100	O
mg/m(2	O
)	O
cisplatin	B_Chemical
every	O
3	O
weeks	O
and	O
those	O
with	O
hypertension	B_Disease
are	O
at	O
the	O
greatest	O
risk	O
of	O
nephrotoxicity	B_Disease
and	O
would	O
benefit	O
from	O
the	O
addition	O
of	O
mannitol	B_Chemical
.	O

Metformin	B_Chemical
protects	O
against	O
seizures	B_Disease
,	O
learning	B_Disease
and	I_Disease
memory	B_Disease
impairments	I_Disease
and	O
oxidative	O
damage	O
induced	O
by	O
pentylenetetrazole-induced	O
kindling	O
in	O
mice	O
.	O

Cognitive	B_Disease
impairment	I_Disease
,	O
the	O
most	O
common	O
and	O
severe	O
comorbidity	O
of	O
epilepsy	B_Disease
,	O
greatly	O
diminishes	O
the	O
quality	O
of	O
life	O
.	O

However	O
,	O
current	O
therapeutic	O
interventions	O
for	O
epilepsy	B_Disease
can	O
also	O
cause	O
untoward	O
cognitive	O
effects	O
.	O

Thus	O
,	O
there	O
is	O
an	O
urgent	O
need	O
for	O
new	O
kinds	O
of	O
agents	O
targeting	O
both	O
seizures	B_Disease
and	O
cognition	B_Disease
deficits	I_Disease
.	O

Oxidative	O
stress	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
epileptogenesis	O
and	O
cognitive	B_Disease
deficits	I_Disease
,	O
and	O
antioxidants	O
have	O
a	O
putative	O
antiepileptic	O
potential	O
.	O

Metformin	B_Chemical
,	O
the	O
most	O
commonly	O
prescribed	O
antidiabetic	O
oral	O
drug	O
,	O
has	O
antioxidant	O
properties	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
ameliorative	O
effects	O
of	O
metformin	B_Chemical
on	O
seizures	B_Disease
,	O
cognitive	B_Disease
impairment	I_Disease
and	O
brain	O
oxidative	O
stress	O
markers	O
observed	O
in	O
pentylenetetrazole-induced	O
kindling	O
animals	O
.	O

Male	O
C57BL/6	O
mice	O
were	O
administered	O
with	O
subconvulsive	O
dose	O
of	O
pentylenetetrazole	B_Chemical
(	O
37	O
mg/kg	O
,	O
i.p	O
.	O
)	O
every	O
other	O
day	O
for	O
14	O
injections	O
.	O

Metformin	B_Chemical
was	O
injected	O
intraperitoneally	O
in	O
dose	O
of	O
200mg/kg	O
along	O
with	O
alternate-day	O
PTZ	B_Chemical
.	O

We	O
found	O
that	O
metformin	B_Chemical
suppressed	O
the	O
progression	O
of	O
kindling	O
,	O
ameliorated	O
the	O
cognitive	B_Disease
impairment	I_Disease
and	O
decreased	O
brain	O
oxidative	O
stress	O
.	O

Thus	O
the	O
present	O
study	O
concluded	O
that	O
metformin	B_Chemical
may	O
be	O
a	O
potential	O
agent	O
for	O
the	O
treatment	O
of	O
epilepsy	B_Disease
as	O
well	O
as	O
a	O
protective	O
medicine	O
against	O
cognitive	B_Disease
impairment	I_Disease
induced	O
by	O
seizures	B_Disease
.	O

P53	O
inhibition	O
exacerbates	O
late-stage	O
anthracycline	B_Chemical
cardiotoxicity	B_Disease
.	O

AIMS	O
:	O
Doxorubicin	B_Chemical
(	O
DOX	B_Chemical
)	O
is	O
an	O
effective	O
anti-cancer	O
therapeutic	O
,	O
but	O
is	O
associated	O
with	O
both	O
acute	O
and	O
late-stage	O
cardiotoxicity	B_Disease
.	O

Children	O
are	O
particularly	O
sensitive	O
to	O
DOX-induced	O
heart	B_Disease
failure	I_Disease
.	O

Here	O
,	O
the	O
impact	O
of	O
p53	O
inhibition	O
on	O
acute	O
vs.	O
late-stage	O
DOX	B_Chemical
cardiotoxicity	B_Disease
was	O
examined	O
in	O
a	O
juvenile	O
model	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Two-week-old	O
MHC-CB7	O
mice	O
(	O
which	O
express	O
dominant-interfering	O
p53	O
in	O
cardiomyocytes	O
)	O
and	O
their	O
non-transgenic	O
(	O
NON-TXG	O
)	O
littermates	O
received	O
weekly	O
DOX	B_Chemical
injections	O
for	O
5	O
weeks	O
(	O
25	O
mg/kg	O
cumulative	O
dose	O
)	O
.	O

One	O
week	O
after	O
the	O
last	O
DOX	B_Chemical
treatment	O
(	O
acute	O
stage	O
)	O
,	O
MHC-CB7	O
mice	O
exhibited	O
improved	O
cardiac	O
function	O
and	O
lower	O
levels	O
of	O
cardiomyocyte	O
apoptosis	O
when	O
compared	O
with	O
the	O
NON-TXG	O
mice	O
.	O

Surprisingly	O
,	O
by	O
13	O
weeks	O
following	O
the	O
last	O
DOX	B_Chemical
treatment	O
(	O
late	O
stage	O
)	O
,	O
MHC-CB7	O
exhibited	O
a	O
progressive	O
decrease	O
in	O
cardiac	O
function	O
and	O
higher	O
rates	O
of	O
cardiomyocyte	O
apoptosis	O
when	O
compared	O
with	O
NON-TXG	O
mice	O
.	O

p53	O
inhibition	O
blocked	O
transient	O
DOX-induced	O
STAT3	O
activation	O
in	O
MHC-CB7	O
mice	O
,	O
which	O
was	O
associated	O
with	O
enhanced	O
induction	O
of	O
the	O
DNA	O
repair	O
proteins	O
Ku70	O
and	O
Ku80	O
.	O

Mice	O
with	O
cardiomyocyte-restricted	O
deletion	O
of	O
STAT3	O
exhibited	O
worse	O
cardiac	O
function	O
,	O
higher	O
levels	O
of	O
cardiomyocyte	O
apoptosis	O
,	O
and	O
a	O
greater	O
induction	O
of	O
Ku70	O
and	O
Ku80	O
in	O
response	O
to	O
DOX	B_Chemical
treatment	O
during	O
the	O
acute	O
stage	O
when	O
compared	O
with	O
control	O
animals	O
.	O

CONCLUSION	O
:	O
These	O
data	O
support	O
a	O
model	O
wherein	O
a	O
p53-dependent	O
cardioprotective	O
pathway	O
,	O
mediated	O
via	O
STAT3	O
activation	O
,	O
mitigates	O
DOX-induced	O
myocardial	O
stress	O
during	O
drug	O
delivery	O
.	O

Furthermore	O
,	O
these	O
data	O
suggest	O
an	O
explanation	O
as	O
to	O
how	O
p53	O
inhibition	O
can	O
result	O
in	O
cardioprotection	O
during	O
drug	O
treatment	O
and	O
,	O
paradoxically	O
,	O
enhanced	O
cardiotoxicity	B_Disease
long	O
after	O
the	O
cessation	O
of	O
drug	O
treatment	O
.	O

Metronidazole-induced	O
encephalopathy	B_Disease
:	O
an	O
uncommon	O
scenario	O
.	O

Metronidazole	B_Chemical
can	O
produce	O
neurological	O
complications	O
although	O
it	O
is	O
not	O
a	O
common	O
scenario	O
.	O

We	O
present	O
a	O
case	O
where	O
a	O
patient	O
developed	O
features	O
of	O
encephalopathy	B_Disease
following	O
prolonged	O
metronidazole	B_Chemical
intake	O
.	O

Magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
brain	O
showed	O
abnormal	O
signal	O
intensity	O
involving	O
both	O
dentate	O
nuclei	O
of	O
cerebellum	O
and	O
splenium	O
of	O
corpus	O
callosum	O
.	O

The	O
diagnosis	O
of	O
metronidazole	B_Chemical
toxicity	B_Disease
was	O
made	O
by	O
the	O
MRI	O
findings	O
and	O
supported	O
clinically	O
.	O

Aconitine-induced	O
Ca2	O
+	O
overload	O
causes	O
arrhythmia	B_Disease
and	O
triggers	O
apoptosis	O
through	O
p38	O
MAPK	O
signaling	O
pathway	O
in	O
rats	O
.	O

Aconitine	B_Chemical
is	O
a	O
major	O
bioactive	O
diterpenoid	O
alkaloid	O
with	O
high	O
content	O
derived	O
from	O
herbal	O
aconitum	O
plants	O
.	O

Emerging	O
evidence	O
indicates	O
that	O
voltage-dependent	O
Na(+	O
)	O
channels	O
have	O
pivotal	O
roles	O
in	O
the	O
cardiotoxicity	B_Disease
of	O
aconitine	B_Chemical
.	O

However	O
,	O
no	O
reports	O
are	O
available	O
on	O
the	O
role	O
of	O
Ca(2	O
+	O
)	O
in	O
aconitine	B_Chemical
poisoning	B_Disease
.	O

In	O
this	O
study	O
,	O
we	O
explored	O
the	O
importance	O
of	O
pathological	O
Ca(2	O
+	O
)	O
signaling	O
in	O
aconitine	B_Chemical
poisoning	B_Disease
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
found	O
that	O
Ca(2	O
+	O
)	O
overload	O
lead	O
to	O
accelerated	O
beating	O
rhythm	O
in	O
adult	O
rat	O
ventricular	O
myocytes	O
and	O
caused	O
arrhythmia	B_Disease
in	O
conscious	O
freely	O
moving	O
rats	O
.	O

To	O
investigate	O
effects	O
of	O
aconitine	B_Chemical
on	O
myocardial	B_Disease
injury	I_Disease
,	O
we	O
performed	O
cytotoxicity	B_Disease
assay	O
in	O
neonatal	O
rat	O
ventricular	O
myocytes	O
(	O
NRVMs	O
)	O
,	O
as	O
well	O
as	O
measured	O
lactate	B_Chemical
dehydrogenase	O
level	O
in	O
the	O
culture	O
medium	O
of	O
NRVMs	O
and	O
activities	O
of	O
serum	O
cardiac	O
enzymes	O
in	O
rats	O
.	O

The	O
results	O
showed	O
that	O
aconitine	B_Chemical
resulted	O
in	O
myocardial	B_Disease
injury	I_Disease
and	O
reduced	O
NRVMs	O
viability	O
dose-dependently	O
.	O

To	O
confirm	O
the	O
pro-apoptotic	O
effects	O
,	O
we	O
performed	O
flow	O
cytometric	O
detection	O
,	O
cardiac	O
histology	O
,	O
transmission	O
electron	O
microscopy	O
and	O
terminal	O
deoxynucleotidyl	O
transferase-mediated	O
dUTP-biotin	O
nick	O
end	O
labeling	O
assay	O
.	O

The	O
results	O
showed	O
that	O
aconitine	B_Chemical
stimulated	O
apoptosis	O
time-dependently	O
.	O

The	O
expression	O
analysis	O
of	O
Ca(2	O
+	O
)	O
handling	O
proteins	O
demonstrated	O
that	O
aconitine	B_Chemical
promoted	O
Ca(2	O
+	O
)	O
overload	O
through	O
the	O
expression	O
regulation	O
of	O
Ca(2	O
+	O
)	O
handling	O
proteins	O
.	O

The	O
expression	O
analysis	O
of	O
apoptosis-related	O
proteins	O
revealed	O
that	O
pro-apoptotic	O
protein	O
expression	O
was	O
upregulated	O
,	O
and	O
anti-apoptotic	O
protein	O
BCL-2	O
expression	O
was	O
downregulated	O
.	O

Furthermore	O
,	O
increased	O
phosphorylation	O
of	O
MAPK	O
family	O
members	O
,	O
especially	O
the	O
P-P38/P38	O
ratio	O
was	O
found	O
in	O
cardiac	O
tissues	O
.	O

Hence	O
,	O
our	O
results	O
suggest	O
that	O
aconitine	B_Chemical
significantly	O
aggravates	O
Ca(2	O
+	O
)	O
overload	O
and	O
causes	O
arrhythmia	B_Disease
and	O
finally	O
promotes	O
apoptotic	O
development	O
via	O
phosphorylation	O
of	O
P38	O
mitogen-activated	O
protein	O
kinase	O
.	O

Chronic	O
treatment	O
with	O
metformin	B_Chemical
suppresses	O
toll-like	O
receptor	O
4	O
signaling	O
and	O
attenuates	O
left	B_Disease
ventricular	I_Disease
dysfunction	I_Disease
following	O
myocardial	B_Disease
infarction	I_Disease
.	O

Acute	O
treatment	O
with	O
metformin	B_Chemical
has	O
a	O
protective	O
effect	O
in	O
myocardial	B_Disease
infarction	I_Disease
by	O
suppression	O
of	O
inflammatory	O
responses	O
due	O
to	O
activation	O
of	O
AMP-activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
chronic	O
pre-treatment	O
with	O
metformin	B_Chemical
on	O
cardiac	B_Disease
dysfunction	I_Disease
and	O
toll-like	O
receptor	O
4	O
(	O
TLR4	O
)	O
activities	O
following	O
myocardial	B_Disease
infarction	I_Disease
and	O
their	O
relation	O
with	O
AMPK	O
were	O
assessed	O
.	O

Male	O
Wistar	O
rats	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
5	O
groups	O
(	O
n=6	O
):	O
normal	O
control	O
and	O
groups	O
were	O
injected	O
isoproterenol	B_Chemical
after	O
chronic	O
pre-treatment	O
with	O
0	O
,	O
25	O
,	O
50	O
,	O
or	O
100mg/kg	O
of	O
metformin	B_Chemical
twice	O
daily	O
for	O
14	O
days	O
.	O

Isoproterenol	B_Chemical
(	O
100mg/kg	O
)	O
was	O
injected	O
subcutaneously	O
on	O
the	O
13th	O
and	O
14th	O
days	O
to	O
induce	O
acute	B_Disease
myocardial	I_Disease
infarction	I_Disease
.	O

Isoproterenol	B_Chemical
alone	O
decreased	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
myocardial	O
contractility	O
indexed	O
as	O
LVdp/dtmax	O
and	O
LVdp/dtmin	O
.	O

The	O
left	B_Disease
ventricular	I_Disease
dysfunction	I_Disease
was	O
significantly	O
lower	O
in	O
the	O
groups	O
treated	O
with	O
25	O
and	O
50mg/kg	O
of	O
metformin	B_Chemical
.	O

Metfromin	O
markedly	O
lowered	O
isoproterenol-induced	O
elevation	O
in	O
the	O
levels	O
of	O
TLR4	O
mRNA	O
,	O
myeloid	O
differentiation	O
protein	O
88	O
(	O
MyD88	O
)	O
,	O
tumor	B_Disease
necrosis	B_Disease
factor-alpha	O
(	O
TNF-a	O
)	O
,	O
and	O
interleukin	O
6	O
(	O
IL-6	O
)	O
in	O
the	O
heart	O
tissues	O
.	O

Similar	O
changes	O
were	O
also	O
seen	O
in	O
the	O
serum	O
levels	O
of	O
TNF-a	O
and	O
IL-6	O
.	O

However	O
,	O
the	O
lower	O
doses	O
of	O
25	O
and	O
50mg/kg	O
were	O
more	O
effective	O
than	O
100mg/kg	O
.	O

Phosphorylated	O
AMPKa	O
(	O
p-AMPK	O
)	O
in	O
the	O
myocardium	O
was	O
significantly	O
elevated	O
by	O
25mg/kg	O
of	O
metformin	B_Chemical
,	O
slightly	O
by	O
50mg/kg	O
,	O
but	O
not	O
by	O
100mg/kg	O
.	O

Chronic	O
pre-treatment	O
with	O
metformin	B_Chemical
reduces	O
post-myocardial	O
infarction	O
cardiac	O
dysfunction	O
and	O
suppresses	O
inflammatory	O
responses	O
,	O
possibly	O
through	O
inhibition	O
of	O
TLR4	O
activities	O
.	O

This	O
mechanism	O
can	O
be	O
considered	O
as	O
a	O
target	O
to	O
protect	O
infarcted	O
myocardium	O
.	O

Unusual	O
complications	O
of	O
antithyroid	O
drug	O
therapy	O
:	O
four	O
case	O
reports	O
and	O
review	O
of	O
literature	O
.	O

Two	O
cases	O
of	O
propylthiouracil-associated	O
acute	O
hepatitis	B_Disease
,	O
one	O
case	O
of	O
fatal	O
methimazole-associated	O
hepatocellular	B_Disease
necrosis	I_Disease
and	O
one	O
case	O
of	O
propylthiouracil-associated	O
lupus-like	B_Disease
syndrome	I_Disease
are	O
described	O
.	O

The	O
literature	O
related	O
to	O
antithyroid	O
drug	O
side	O
effects	O
and	O
the	O
mechanisms	O
for	O
their	O
occurrence	O
are	O
reviewed	O
and	O
the	O
efficacy	O
and	O
complications	O
of	O
thyroidectomy	O
and	O
radioiodine	O
compared	O
to	O
those	O
of	O
antithyroid	O
drugs	O
.	O

It	O
is	O
concluded	O
that	O
in	O
most	O
circumstances	O
131I	O
is	O
the	O
therapy	O
of	O
choice	O
for	O
hyperthyroidism	B_Disease
.	O

Neuroleptic	B_Disease
malignant	I_Disease
syndrome	I_Disease
induced	O
by	O
combination	O
therapy	O
with	O
tetrabenazine	B_Chemical
and	O
tiapride	B_Chemical
in	O
a	O
Japanese	O
patient	O
with	O
Huntington	B_Disease
's	I_Disease
disease	I_Disease
at	O
the	O
terminal	O
stage	O
of	O
recurrent	O
breast	B_Disease
cancer	I_Disease
.	O

We	O
herein	O
describe	O
the	O
case	O
of	O
an	O
81-year-old	O
Japanese	O
woman	O
with	O
neuroleptic	B_Disease
malignant	I_Disease
syndrome	I_Disease
that	O
occurred	O
36	O
days	O
after	O
the	O
initiation	O
of	O
combination	O
therapy	O
with	O
tiapride	B_Chemical
(	O
75	O
mg/day	O
)	O
and	O
tetrabenazine	B_Chemical
(	O
12.5	O
mg/day	O
)	O
for	O
Huntington	B_Disease
's	I_Disease
disease	I_Disease
.	O

The	O
patient	O
had	O
been	O
treated	O
with	O
tiapride	B_Chemical
or	O
tetrabenazine	B_Chemical
alone	O
without	O
any	O
adverse	O
effects	O
before	O
the	O
administration	O
of	O
the	O
combination	O
therapy	O
.	O

She	O
also	O
had	O
advanced	O
breast	B_Disease
cancer	I_Disease
when	O
the	O
combination	O
therapy	O
was	O
initiated	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
occurrence	O
of	O
neuroleptic	B_Disease
malignant	I_Disease
syndrome	I_Disease
due	O
to	O
combination	O
therapy	O
with	O
tetrabenazine	B_Chemical
and	O
tiapride	B_Chemical
has	O
not	O
been	O
previously	O
reported	O
.	O

Tetrabenazine	B_Chemical
should	O
be	O
administered	O
very	O
carefully	O
in	O
combination	O
with	O
other	O
neuroleptic	B_Chemical
drugs	I_Chemical
,	O
particularly	O
in	O
patients	O
with	O
a	O
worsening	O
general	O
condition	O
.	O

A	O
metoprolol-terbinafine	O
combination	O
induced	O
bradycardia	B_Disease
.	O

To	O
report	O
a	O
sinus	B_Disease
bradycardia	I_Disease
induced	O
by	O
metoprolol	B_Chemical
and	O
terbinafine	B_Chemical
drug-drug	O
interaction	O
and	O
its	O
management	O
.	O

A	O
63	O
year-old	O
Caucasian	O
man	O
on	O
metoprolol	B_Chemical
200	O
mg/day	O
for	O
stable	O
coronary	B_Disease
artery	I_Disease
disease	I_Disease
was	O
prescribed	O
a	O
90-day	O
course	O
of	O
oral	O
terbinafine	B_Chemical
250	O
mg/day	O
for	O
onychomycosis	B_Disease
.	O

On	O
the	O
49th	O
day	O
of	O
terbinafine	B_Chemical
therapy	O
,	O
he	O
was	O
brought	O
to	O
the	O
emergency	O
room	O
for	O
a	O
decrease	O
of	O
his	O
global	O
health	O
status	O
,	O
confusion	B_Disease
and	O
falls	O
.	O

The	O
electrocardiogram	O
revealed	O
a	O
37	O
beats/min	O
sinus	B_Disease
bradycardia	I_Disease
.	O

A	O
score	O
of	O
7	O
on	O
the	O
Naranjo	O
adverse	B_Disease
drug	I_Disease
reaction	I_Disease
probability	O
scale	O
indicates	O
a	O
probable	O
relationship	O
between	O
the	O
patient	O
's	O
sinus	B_Disease
bradycardia	I_Disease
and	O
the	O
drug	O
interaction	O
between	O
metoprolol	B_Chemical
and	O
terbinafine	B_Chemical
.	O

The	O
heart	O
rate	O
ameliorated	O
first	O
with	O
a	O
decrease	O
in	O
the	O
dose	O
of	O
metoprolol	B_Chemical
.	O

It	O
was	O
subsequently	O
changed	O
to	O
bisoprolol	B_Chemical
and	O
the	O
heart	O
rate	O
remained	O
normal	O
.	O

By	O
inhibiting	O
the	O
cytochrome	O
P450	O
2D6	O
,	O
terbinafine	B_Chemical
had	O
decreased	O
metoprolol	B_Chemical
's	O
clearance	O
,	O
leading	O
in	O
metoprolol	B_Chemical
accumulation	O
which	O
has	O
resulted	O
in	O
clinically	O
significant	O
sinus	B_Disease
bradycardia	I_Disease
.	O

Optochiasmatic	O
and	O
peripheral	B_Disease
neuropathy	I_Disease
due	O
to	O
ethambutol	B_Chemical
overtreatment	O
.	O

Ethambutol	B_Chemical
is	O
known	O
to	O
cause	O
optic	B_Disease
neuropathy	I_Disease
and	O
,	O
more	O
rarely	O
,	O
axonal	O
polyneuropathy	B_Disease
.	O

We	O
characterize	O
the	O
clinical	O
,	O
neurophysiological	O
,	O
and	O
neuroimaging	O
findings	O
in	O
a	O
72-year-old	O
man	O
who	O
developed	O
visual	B_Disease
loss	I_Disease
and	O
paresthesias	B_Disease
after	O
11	O
weeks	O
of	O
exposure	O
to	O
a	O
supratherapeutic	O
dose	O
of	O
ethambutol	B_Chemical
.	O

This	O
case	O
demonstrates	O
the	O
selective	O
vulnerability	O
of	O
the	O
anterior	O
visual	O
pathways	O
and	O
peripheral	O
nerves	O
to	O
ethambutol	B_Chemical
toxicity	B_Disease
.	O

Testosterone	B_Chemical
ameliorates	O
streptozotocin-induced	O
memory	B_Disease
impairment	I_Disease
in	O
male	O
rats	O
.	O

AIM	O
:	O
To	O
study	O
the	O
effects	O
of	O
testosterone	B_Chemical
on	O
streptozotocin	B_Chemical
(STZ)-induced	O
memory	B_Disease
impairment	I_Disease
in	O
male	O
rats	O
.	O

METHODS	O
:	O
Adult	O
male	O
Wistar	O
rats	O
were	O
intracerebroventricularly	O
(	O
icv	O
)	O
infused	O
with	O
STZ	B_Chemical
(	O
750	O
ug	O
)	O
on	O
d	O
1	O
and	O
d	O
3	O
,	O
and	O
a	O
passive	O
avoidance	O
task	O
was	O
assessed	O
2	O
weeks	O
after	O
the	O
first	O
injection	O
of	O
STZ	B_Chemical
.	O

Castration	O
surgery	O
was	O
performed	O
in	O
another	O
group	O
of	O
rats	O
,	O
and	O
the	O
passive	O
avoidance	O
task	O
was	O
assessed	O
4	O
weeks	O
after	O
the	O
operation	O
.	O

Testosterone	B_Chemical
(	O
1	O
mg.kg(-1).d(-1	O
)	O
,	O
sc	O
)	O
,	O
the	O
androgen	B_Chemical
receptor	O
antagonist	O
flutamide	B_Chemical
(	O
10	O
mg.kg(-1).d(-1	O
)	O
,	O
ip	O
)	O
,	O
the	O
estrogen	B_Chemical
receptor	O
antagonist	O
tamoxifen	B_Chemical
(	O
1	O
mg.kg(-1).d(-1	O
)	O
,	O
ip	O
)	O
or	O
the	O
aromatase	O
inhibitor	O
letrozole	B_Chemical
(	O
4	O
mg.kg(-1).d(-1	O
)	O
,	O
ip	O
)	O
were	O
administered	O
for	O
6	O
d	O
after	O
the	O
first	O
injection	O
of	O
STZ	B_Chemical
.	O

RESULTS	O
:	O
STZ	B_Chemical
administration	O
and	O
castration	O
markedly	O
decreased	O
both	O
STL1	O
(	O
the	O
short	O
memory	O
)	O
and	O
STL2	O
(	O
the	O
long	O
memory	O
)	O
in	O
passive	O
avoidance	O
tests	O
.	O

Testosterone	B_Chemical
replacement	O
almost	O
restored	O
the	O
STL1	O
and	O
STL2	O
in	O
castrated	O
rats	O
,	O
and	O
significantly	O
prolonged	O
the	O
STL1	O
and	O
STL2	O
in	O
STZ-treated	O
rats	O
.	O

Administration	O
of	O
flutamide	B_Chemical
,	O
letrozole	B_Chemical
or	O
tamoxifen	B_Chemical
significantly	O
impaired	B_Disease
the	I_Disease
memory	I_Disease
in	O
intact	O
rats	O
,	O
and	O
significantly	O
attenuated	O
the	O
testosterone	B_Chemical
replacement	O
in	O
improving	O
STZ-	O
and	O
castration-induced	O
memory	B_Disease
impairment	I_Disease
.	O

CONCLUSION	O
:	O
Testosterone	B_Chemical
administration	O
ameliorates	O
STZ-	O
and	O
castration-induced	O
memory	B_Disease
impairment	I_Disease
in	O
male	O
Wistar	O
rats	O
.	O

Behavioral	O
and	O
neurochemical	O
studies	O
in	O
mice	O
pretreated	O
with	O
garcinielliptone	B_Chemical
FC	I_Chemical
in	O
pilocarpine-induced	O
seizures	B_Disease
.	O

Garcinielliptone	B_Chemical
FC	I_Chemical
(	O
GFC	B_Chemical
)	O
isolated	O
from	O
hexanic	O
fraction	O
seed	O
extract	O
of	O
species	O
Platonia	O
insignis	O
Mart	O
.	O
It	O
is	O
widely	O
used	O
in	O
folk	O
medicine	O
to	O
treat	O
skin	B_Disease
diseases	I_Disease
in	O
both	O
humans	O
and	O
animals	O
as	O
well	O
as	O
the	O
seed	O
decoction	O
has	O
been	O
used	O
to	O
treat	O
diarrheas	B_Disease
and	O
inflammatory	B_Disease
diseases	I_Disease
.	O

However	O
,	O
there	O
is	O
no	O
research	O
on	O
GFC	B_Chemical
effects	O
in	O
the	O
central	O
nervous	O
system	O
of	O
rodents	O
.	O

The	O
present	O
study	O
aimed	O
to	O
evaluate	O
the	O
GFC	B_Chemical
effects	O
at	O
doses	O
of	O
25	O
,	O
50	O
or	O
75	O
mg/kg	O
on	O
seizure	B_Disease
parameters	O
to	O
determine	O
their	O
anticonvulsant	O
activity	O
and	O
its	O
effects	O
on	O
amino	B_Chemical
acid	I_Chemical
(	O
r-aminobutyric	B_Chemical
acid	I_Chemical
(	O
GABA	B_Chemical
)	O
,	O
glutamine	B_Chemical
,	O
aspartate	B_Chemical
and	O
glutathione	B_Chemical
)	O
levels	O
as	O
well	O
as	O
on	O
acetylcholinesterase	O
(	O
AChE	O
)	O
activity	O
in	O
mice	O
hippocampus	O
after	O
seizures	B_Disease
.	O

GFC	B_Chemical
produced	O
an	O
increased	O
latency	O
to	O
first	O
seizure	B_Disease
,	O
at	O
doses	O
25mg/kg	O
(	O
20.12	O
+	O
2.20	O
min	O
)	O
,	O
50mg/kg	O
(	O
20.95	O
+	O
2.21	O
min	O
)	O
or	O
75	O
mg/kg	O
(	O
23.43	O
+	O
1.99	O
min	O
)	O
when	O
compared	O
with	O
seized	O
mice	O
.	O

In	O
addition	O
,	O
GABA	B_Chemical
content	O
of	O
mice	O
hippocampus	O
treated	O
with	O
GFC75	O
plus	O
P400	O
showed	O
an	O
increase	O
of	O
46.90	O
%	O
when	O
compared	O
with	O
seized	O
mice	O
.	O

In	O
aspartate	B_Chemical
,	O
glutamine	B_Chemical
and	O
glutamate	B_Chemical
levels	O
detected	O
a	O
decrease	O
of	O
5.21	O
%	O
,	O
13.55	O
%	O
and	O
21.80	O
%	O
,	O
respectively	O
in	O
mice	O
hippocampus	O
treated	O
with	O
GFC75	O
plus	O
P400	O
when	O
compared	O
with	O
seized	O
mice	O
.	O

Hippocampus	O
mice	O
treated	O
with	O
GFC75	O
plus	O
P400	O
showed	O
an	O
increase	O
in	O
AChE	O
activity	O
(	O
63.30	O
%	O
)	O
when	O
compared	O
with	O
seized	O
mice	O
.	O

The	O
results	O
indicate	O
that	O
GFC	B_Chemical
can	O
exert	O
anticonvulsant	O
activity	O
and	O
reduce	O
the	O
frequency	O
of	O
installation	O
of	O
pilocarpine-induced	O
status	B_Disease
epilepticus	I_Disease
,	O
as	O
demonstrated	O
by	O
increase	O
in	O
latency	O
to	O
first	O
seizure	B_Disease
and	O
decrease	O
in	O
mortality	O
rate	O
of	O
animals	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
GFC	B_Chemical
may	O
influence	O
in	O
epileptogenesis	O
and	O
promote	O
anticonvulsant	O
actions	O
in	O
pilocarpine	B_Chemical
model	O
by	O
modulating	O
the	O
GABA	B_Chemical
and	O
glutamate	B_Chemical
contents	O
and	O
of	O
AChE	O
activity	O
in	O
seized	O
mice	O
hippocampus	O
.	O

This	O
compound	O
may	O
be	O
useful	O
to	O
produce	O
neuronal	O
protection	O
and	O
it	O
can	O
be	O
considered	O
as	O
an	O
anticonvulsant	O
agent	O
.	O

Standard	O
operating	O
procedures	O
for	O
antibiotic	O
therapy	O
and	O
the	O
occurrence	O
of	O
acute	O
kidney	O
injury	O
:	O
a	O
prospective	O
,	O
clinical	O
,	O
non-interventional	O
,	O
observational	O
study	O
.	O

INTRODUCTION	O
:	O
Acute	B_Disease
kidney	I_Disease
injury	I_Disease
(	O
AKI	B_Disease
)	O
occurs	O
in	O
7	O
%	O
of	O
hospitalized	O
and	O
66	O
%	O
of	O
Intensive	O
Care	O
Unit	O
(	O
ICU	O
)	O
patients	O
.	O

It	O
increases	O
mortality	O
,	O
hospital	O
length	O
of	O
stay	O
,	O
and	O
costs	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
,	O
whether	O
there	O
is	O
an	O
association	O
between	O
adherence	O
to	O
guidelines	O
(	O
standard	O
operating	O
procedures	O
(	O
SOP	O
)	O
)	O
for	O
potentially	O
nephrotoxic	B_Disease
antibiotics	O
and	O
the	O
occurrence	O
of	O
AKI	B_Disease
.	O

METHODS	O
:	O
This	O
study	O
was	O
carried	O
out	O
as	O
a	O
prospective	O
,	O
clinical	O
,	O
non-interventional	O
,	O
observational	O
study	O
.	O

Data	O
collection	O
was	O
performed	O
over	O
a	O
total	O
of	O
170	O
days	O
in	O
three	O
ICUs	O
at	O
Charite	O
-	O
Universitaetsmedizin	O
Berlin	O
.	O

A	O
total	O
of	O
675	O
patients	O
were	O
included	O
;	O
163	O
of	O
these	O
had	O
therapy	O
with	O
vancomycin	B_Chemical
,	O
gentamicin	B_Chemical
,	O
or	O
tobramycin	B_Chemical
;	O
were	O
>	O
18	O
years	O
;	O
and	O
treated	O
in	O
the	O
ICU	O
for	O
>	O
24	O
hours	O
.	O

Patients	O
with	O
an	O
adherence	O
to	O
SOP	O
>	O
70	O
%	O
were	O
classified	O
into	O
the	O
high	O
adherence	O
group	O
(	O
HAG	O
)	O
and	O
patients	O
with	O
an	O
adherence	O
of	O
<	O
70	O
%	O
into	O
the	O
low	O
adherence	O
group	O
(	O
LAG	O
)	O
.	O

AKI	B_Disease
was	O
defined	O
according	O
to	O
RIFLE	O
criteria	O
.	O

Adherence	O
to	O
SOPs	O
was	O
evaluated	O
by	O
retrospective	O
expert	O
audit	O
.	O

Development	O
of	O
AKI	B_Disease
was	O
compared	O
between	O
groups	O
with	O
exact	O
Chi2-test	O
and	O
multivariate	O
logistic	O
regression	O
analysis	O
(	O
two-sided	O
P	O
<	O
0.05	O
)	O
.	O

RESULTS	O
:	O
LAG	O
consisted	O
of	O
75	O
patients	O
(	O
46	O
%	O
)	O
versus	O
88	O
HAG	O
patients	O
(	O
54	O
%	O
)	O
.	O

AKI	B_Disease
occurred	O
significantly	O
more	O
often	O
in	O
LAG	O
with	O
36	O
%	O
versus	O
21	O
%	O
in	O
HAG	O
(	O
P	O
=	O
0.035	O
)	O
.	O

Basic	O
characteristics	O
were	O
comparable	O
,	O
except	O
an	O
increased	O
rate	O
of	O
soft	O
tissue	O
infections	B_Disease
in	O
LAG	O
.	O

Multivariate	O
analysis	O
revealed	O
an	O
odds	O
ratio	O
of	O
2.5-fold	O
for	O
LAG	O
to	O
develop	O
AKI	B_Disease
compared	O
with	O
HAG	O
(	O
95	O
%	O
confidence	O
interval	O
1.195	O
to	O
5.124	O
,	O
P	O
=	O
0.039	O
)	O
.	O

CONCLUSION	O
:	O
Low	O
adherence	O
to	O
SOPs	O
for	O
potentially	O
nephrotoxic	B_Disease
antibiotics	O
was	O
associated	O
with	O
a	O
higher	O
occurrence	O
of	O
AKI	B_Disease
.	O

TRIAL	O
REGISTRATION	O
:	O
Current	O
Controlled	O
Trials	O
ISRCTN54598675	O
.	O

Registered	O
17	O
August	O
2007	O
.	O

Rhabdomyolysis	B_Disease
in	O
a	O
hepatitis	B_Disease
C	I_Disease
virus	I_Disease
infected	I_Disease
patient	O
treated	O
with	O
telaprevir	B_Chemical
and	O
simvastatin	B_Chemical
.	O

A	O
46-year	O
old	O
man	O
with	O
a	O
chronic	O
hepatitis	B_Disease
C	I_Disease
virus	I_Disease
infection	I_Disease
received	O
triple	O
therapy	O
with	O
ribavirin	B_Chemical
,	O
pegylated	B_Chemical
interferon	I_Chemical
and	O
telaprevir	B_Chemical
.	O

The	O
patient	O
also	O
received	O
simvastatin	B_Chemical
.	O

One	O
month	O
after	O
starting	O
the	O
antiviral	O
therapy	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
hospital	O
because	O
he	O
developed	O
rhabdomyolysis	B_Disease
.	O

At	O
admission	O
simvastatin	B_Chemical
and	O
all	O
antiviral	O
drugs	O
were	O
discontinued	O
because	O
toxicity	B_Disease
due	O
to	O
a	O
drug-drug	O
interaction	O
was	O
suspected	O
.	O

The	O
creatine	B_Chemical
kinase	O
peaked	O
at	O
62,246	O
IU/L	O
and	O
the	O
patient	O
was	O
treated	O
with	O
intravenous	O
normal	O
saline	O
.	O

The	O
patient	O
's	O
renal	O
function	O
remained	O
unaffected	O
.	O

Fourteen	O
days	O
after	O
hospitalization	O
,	O
creatine	B_Chemical
kinase	O
level	O
had	O
returned	O
to	O
230	O
IU/L	O
and	O
the	O
patient	O
was	O
discharged	O
.	O

Telaprevir	B_Chemical
was	O
considered	O
the	O
probable	O
causative	O
agent	O
of	O
an	O
interaction	O
with	O
simvastatin	B_Chemical
according	O
to	O
the	O
Drug	O
Interaction	O
Probability	O
Scale	O
.	O

The	O
interaction	O
is	O
due	O
to	O
inhibition	O
of	O
CYP3A4-mediated	O
simvastatin	B_Chemical
clearance	O
.	O

Simvastatin	B_Chemical
plasma	O
concentration	O
increased	O
30	O
times	O
in	O
this	O
patient	O
and	O
statin	B_Chemical
induced	O
muscle	B_Disease
toxicity	I_Disease
is	O
related	O
to	O
the	O
concentration	O
of	O
the	O
statin	B_Chemical
in	O
blood	O
.	O

In	O
conclusion	O
,	O
with	O
this	O
case	O
we	O
illustrate	O
that	O
telaprevir	B_Chemical
as	O
well	O
as	O
statins	B_Chemical
are	O
susceptible	O
to	O
clinical	O
relevant	O
drug-drug	O
interactions	O
.	O

Combination	O
of	O
bortezomib	B_Chemical
,	O
thalidomide	B_Chemical
,	O
and	O
dexamethasone	B_Chemical
(	O
VTD	O
)	O
as	O
a	O
consolidation	O
therapy	O
after	O
autologous	O
stem	O
cell	O
transplantation	O
for	O
symptomatic	O
multiple	B_Disease
myeloma	I_Disease
in	O
Japanese	O
patients	O
.	O

Consolidation	O
therapy	O
for	O
patients	O
with	O
multiple	B_Disease
myeloma	I_Disease
(	O
MM	B_Disease
)	O
has	O
been	O
widely	O
adopted	O
to	O
improve	O
treatment	O
response	O
following	O
autologous	O
stem	O
cell	O
transplantation	O
.	O

In	O
this	O
study	O
,	O
we	O
retrospectively	O
analyzed	O
the	O
safety	O
and	O
efficacy	O
of	O
combination	O
regimen	O
of	O
bortezomib	B_Chemical
,	O
thalidomide	B_Chemical
,	O
and	O
dexamethasone	B_Chemical
(	O
VTD	O
)	O
as	O
consolidation	O
therapy	O
in	O
24	O
Japanese	O
patients	O
with	O
newly	O
diagnosed	O
MM	B_Disease
.	O

VTD	O
consisted	O
of	O
bortezomib	B_Chemical
at	O
a	O
dose	O
of	O
1.3	O
mg/m(2	O
)	O
and	O
dexamethasone	B_Chemical
at	O
a	O
dose	O
of	O
40	O
mg/day	O
on	O
days	O
1	O
,	O
8	O
,	O
15	O
,	O
and	O
22	O
of	O
a	O
35-day	O
cycle	O
,	O
with	O
daily	O
oral	O
thalidomide	B_Chemical
at	O
a	O
dose	O
of	O
100	O
mg/day	O
.	O

Grade	O
3	O
-	O
4	O
neutropenia	B_Disease
and	O
thrombocytopenia	B_Disease
were	O
documented	O
in	O
four	O
and	O
three	O
patients	O
(	O
17	O
and	O
13	O
%	O
)	O
,	O
respectively	O
,	O
but	O
drug	O
dose	O
reduction	O
due	O
to	O
cytopenia	B_Disease
was	O
not	O
required	O
in	O
any	O
case	O
.	O

Peripheral	B_Disease
neuropathy	I_Disease
was	O
common	O
(	O
63	O
%	O
)	O
,	O
but	O
severe	O
grade	O
3	O
-	O
4	O
peripheral	B_Disease
neuropathy	I_Disease
was	O
not	O
observed	O
.	O

Very	O
good	O
partial	O
response	O
or	O
better	O
response	O
(	O
>	O
VGPR	O
)	O
rates	O
before	O
and	O
after	O
consolidation	O
therapy	O
were	O
54	O
and	O
79	O
%	O
,	O
respectively	O
.	O

Patients	O
had	O
a	O
significant	O
probability	O
of	O
improving	O
from	O
<	O
VGPR	O
before	O
consolidation	O
therapy	O
to	O
>	O
VGPR	O
after	O
consolidation	O
therapy	O
(	O
p	O
=	O
0.041	O
)	O
.	O

The	O
VTD	O
regimen	O
may	O
be	O
safe	O
and	O
effective	O
as	O
a	O
consolidation	O
therapy	O
in	O
the	O
treatment	O
of	O
MM	O
in	O
Japanese	O
population	O
.	O

Conversion	O
to	O
sirolimus	B_Chemical
ameliorates	O
cyclosporine-induced	O
nephropathy	B_Disease
in	O
the	O
rat	O
:	O
focus	O
on	O
serum	O
,	O
urine	O
,	O
gene	O
,	O
and	O
protein	O
renal	O
expression	O
biomarkers	O
.	O

Protocols	O
of	O
conversion	O
from	O
cyclosporin	B_Chemical
A	I_Chemical
(	O
CsA	B_Chemical
)	O
to	O
sirolimus	B_Chemical
(	O
SRL	B_Chemical
)	O
have	O
been	O
widely	O
used	O
in	O
immunotherapy	O
after	O
transplantation	O
to	O
prevent	O
CsA-induced	O
nephropathy	B_Disease
,	O
but	O
the	O
molecular	O
mechanisms	O
underlying	O
these	O
protocols	O
remain	O
nuclear	O
.	O

This	O
study	O
aimed	O
to	O
identify	O
the	O
molecular	O
pathways	O
and	O
putative	O
biomarkers	O
of	O
CsA-to-SRL	O
conversion	O
in	O
a	O
rat	O
model	O
.	O

Four	O
animal	O
groups	O
(	O
n	O
=	O
6	O
)	O
were	O
tested	O
during	O
9	O
weeks	O
:	O
control	O
,	O
CsA	B_Chemical
,	O
SRL	B_Chemical
,	O
and	O
conversion	O
(	O
CsA	B_Chemical
for	O
3	O
weeks	O
followed	O
by	O
SRL	B_Chemical
for	O
6	O
weeks	O
)	O
.	O

Classical	O
and	O
emergent	O
serum	O
,	O
urinary	O
,	O
and	O
kidney	O
tissue	O
(	O
gene	O
and	O
protein	O
expression	O
)	O
markers	O
were	O
assessed	O
.	O

Renal	B_Disease
lesions	I_Disease
were	O
analyzed	O
in	O
hematoxylin	B_Chemical
and	O
eosin	B_Chemical
,	O
periodic	O
acid-Schiff	O
,	O
and	O
Masson	O
's	O
trichrome	O
stains	O
.	O

SRL-treated	O
rats	O
presented	O
proteinuria	B_Disease
and	O
NGAL	O
(	O
serum	O
and	O
urinary	O
)	O
as	O
the	O
best	O
markers	O
of	O
renal	B_Disease
impairment	I_Disease
.	O

Short	O
CsA	B_Chemical
treatment	O
presented	O
slight	O
or	O
even	O
absent	O
kidney	B_Disease
lesions	I_Disease
and	O
TGF-b	O
,	O
NF-	O
kb	O
,	O
mTOR	O
,	O
PCNA	O
,	O
TP53	O
,	O
KIM-1	O
,	O
and	O
CTGF	O
as	O
relevant	O
gene	O
and	O
protein	O
changes	O
.	O

Prolonged	O
CsA	B_Chemical
exposure	O
aggravated	O
renal	B_Disease
damage	I_Disease
,	O
without	O
clear	O
changes	O
on	O
the	O
traditional	O
markers	O
,	O
but	O
with	O
changes	O
in	O
serums	O
TGF-	O
b	O
and	O
IL-7	O
,	O
TBARs	O
clearance	O
,	O
and	O
kidney	O
TGF-b	O
and	O
mTOR	O
.	O

Conversion	O
to	O
SRL	B_Chemical
prevented	O
CsA-induced	O
renal	B_Disease
damage	I_Disease
evolution	O
(	O
absent/mild	O
grade	O
lesions	O
)	O
,	O
while	O
NGAL	O
(	O
serum	O
versus	O
urine	O
)	O
seems	O
to	O
be	O
a	O
feasible	O
biomarker	O
of	O
CsA	B_Chemical
replacement	O
to	O
SRL	B_Chemical
.	O

Kinin	O
B2	O
receptor	O
deletion	O
and	O
blockage	O
ameliorates	O
cisplatin-induced	O
acute	B_Disease
renal	I_Disease
injury	I_Disease
.	O

Cisplatin	B_Chemical
treatment	O
has	O
been	O
adopted	O
in	O
some	O
chemotherapies	O
;	O
however	O
,	O
this	O
drug	O
can	O
induce	O
acute	B_Disease
kidney	I_Disease
injury	I_Disease
due	O
its	O
ability	O
to	O
negatively	O
affect	O
renal	O
function	O
,	O
augment	O
serum	O
levels	O
of	O
creatinine	B_Chemical
and	O
urea	B_Chemical
,	O
increase	O
the	O
acute	B_Disease
tubular	I_Disease
necrosis	I_Disease
score	O
and	O
up-regulate	O
cytokines	O
(	O
e.g.	O
,	O
IL-1b	O
and	O
TNF-a	O
)	O
.	O

The	O
kinin	O
B2	O
receptor	O
has	O
been	O
associated	O
with	O
the	O
inflammation	B_Disease
process	O
,	O
as	O
well	O
as	O
the	O
regulation	O
of	O
cytokine	O
expression	O
,	O
and	O
its	O
deletion	O
resulted	O
in	O
an	O
improvement	O
in	O
the	O
diabetic	B_Disease
nephropathy	I_Disease
status	O
.	O

To	O
examine	O
the	O
role	O
of	O
the	O
kinin	O
B2	O
receptor	O
in	O
cisplatin-induced	O
acute	B_Disease
kidney	I_Disease
injury	I_Disease
,	O
kinin	O
B2	O
receptor	O
knockout	O
mice	O
were	O
challenged	O
with	O
cisplatin	B_Chemical
.	O

Additionally	O
,	O
WT	O
mice	O
were	O
treated	O
with	O
a	O
B2	O
receptor	O
antagonist	O
after	O
cisplatin	B_Chemical
administration	O
.	O

B2	O
receptor-deficient	O
mice	O
were	O
less	O
sensitive	O
to	O
this	O
drug	O
than	O
the	O
WT	O
mice	O
,	O
as	O
shown	O
by	O
reduced	O
weight	B_Disease
loss	I_Disease
,	O
better	O
preservation	O
of	O
kidney	O
function	O
,	O
down	O
regulation	O
of	O
inflammatory	O
cytokines	O
and	O
less	O
acute	B_Disease
tubular	I_Disease
necrosis	I_Disease
.	O

Moreover	O
,	O
treatment	O
with	O
the	O
kinin	O
B2	O
receptor	O
antagonist	O
effectively	O
reduced	O
the	O
levels	O
of	O
serum	O
creatinine	B_Chemical
and	O
blood	O
urea	B_Chemical
after	O
cisplatin	B_Chemical
administration	O
.	O

Thus	O
,	O
our	O
data	O
suggest	O
that	O
the	O
kinin	O
B2	O
receptor	O
is	O
involved	O
in	O
cisplatin-induced	O
acute	B_Disease
kidney	I_Disease
injury	I_Disease
by	O
mediating	O
the	O
necrotic	B_Disease
process	O
and	O
the	O
expression	O
of	O
inflammatory	O
cytokines	O
,	O
thus	O
resulting	O
in	O
declined	O
renal	O
function	O
.	O

These	O
results	O
highlight	O
the	O
kinin	O
B2	O
receptor	O
antagonist	O
treatment	O
in	O
amelioration	O
of	O
nephrotoxicity	B_Disease
induced	O
by	O
cisplatin	B_Chemical
therapy	O
.	O

Safety	O
and	O
efficacy	O
of	O
fluocinolone	B_Chemical
acetonide	I_Chemical
intravitreal	O
implant	O
(	O
0.59	O
mg	O
)	O
in	O
birdshot	B_Disease
retinochoroidopathy	I_Disease
.	O

PURPOSE	O
:	O
To	O
report	O
the	O
treatment	O
outcomes	O
of	O
the	O
fluocinolone	B_Chemical
acetonide	I_Chemical
intravitreal	O
implant	O
(	O
0.59	O
mg	O
)	O
in	O
patients	O
with	O
birdshot	B_Disease
retinochoroidopathy	I_Disease
whose	O
disease	O
is	O
refractory	O
or	O
intolerant	O
to	O
conventional	O
immunomodulatory	O
therapy	O
.	O

METHODS	O
:	O
A	O
retrospective	O
case	O
series	O
involving	O
11	O
birdshot	B_Disease
retinochoroidopathy	I_Disease
patients	O
(	O
11	O
eyes	O
)	O
.	O

Eleven	O
patients	O
(	O
11	O
eyes	O
)	O
underwent	O
surgery	O
for	O
fluocinolone	B_Chemical
acetonide	I_Chemical
implant	O
(	O
0.59	O
mg	O
)	O
.	O

Treatment	O
outcomes	O
of	O
interest	O
were	O
noted	O
at	O
baseline	O
,	O
before	O
fluocinolone	B_Chemical
acetonide	I_Chemical
implant	O
,	O
and	O
then	O
at	O
6	O
months	O
,	O
1	O
year	O
,	O
2	O
years	O
,	O
3	O
years	O
,	O
and	O
beyond	O
3	O
years	O
.	O

Disease	O
activity	O
markers	O
,	O
including	O
signs	O
of	O
ocular	O
inflammation	B_Disease
,	O
evidence	O
of	O
retinal	B_Disease
vasculitis	I_Disease
,	O
Swedish	O
interactive	O
threshold	O
algorithm-short	O
wavelength	O
automated	O
perimetry	O
Humphrey	O
visual	O
field	O
analysis	O
,	O
electroretinographic	O
parameters	O
,	O
and	O
optical	O
coherence	O
tomography	O
were	O
recorded	O
.	O

Data	O
on	O
occurrence	O
of	O
cataract	B_Disease
and	O
raised	B_Disease
intraocular	I_Disease
pressure	I_Disease
were	O
collected	O
in	O
all	O
eyes	O
.	O

RESULTS	O
:	O
Intraocular	O
inflammation	B_Disease
was	O
present	O
in	O
54.5	O
,	O
9.9	O
,	O
11.1	O
,	O
and	O
0	O
%	O
of	O
patients	O
at	O
baseline	O
,	O
6	O
months	O
,	O
1	O
year	O
,	O
2	O
years	O
,	O
3	O
years	O
,	O
and	O
beyond	O
3	O
years	O
after	O
receiving	O
the	O
implant	O
,	O
respectively	O
.	O

Active	O
vasculitis	B_Disease
was	O
noted	O
in	O
36.3	O
%	O
patients	O
at	O
baseline	O
and	O
0	O
%	O
at	O
3	O
years	O
of	O
follow-up	O
.	O

More	O
than	O
20	O
%	O
(	O
47.61	O
-	O
67.2	O
%	O
)	O
reduction	O
in	O
central	O
retinal	O
thickness	O
was	O
noted	O
in	O
all	O
patients	O
with	O
cystoid	B_Disease
macular	I_Disease
edema	I_Disease
at	O
6	O
months	O
,	O
1	O
year	O
,	O
2	O
years	O
,	O
and	O
3	O
years	O
postimplant	O
.	O

At	O
baseline	O
,	O
54.5	O
%	O
patients	O
were	O
on	O
immunomodulatory	O
agents	O
.	O

This	O
percentage	O
decreased	O
to	O
45.45	O
,	O
44.4	O
,	O
and	O
14.28	O
%	O
at	O
1	O
year	O
,	O
2	O
years	O
,	O
and	O
3	O
years	O
postimplant	O
,	O
respectively	O
.	O

Adverse	O
events	O
included	O
increased	B_Disease
intraocular	I_Disease
pressure	I_Disease
(	O
54.5	O
%	O
)	O
and	O
cataract	B_Disease
formation	O
(	O
100	O
%	O
)	O
.	O

CONCLUSION	O
:	O
The	O
data	O
suggest	O
that	O
fluocinolone	B_Chemical
acetonide	I_Chemical
implant	O
(	O
0.59	O
mg	O
)	O
helps	O
to	O
control	O
inflammation	B_Disease
in	O
otherwise	O
treatment-refractory	O
cases	O
of	O
birdshot	B_Disease
retinochoroidopathy	I_Disease
.	O

It	O
is	O
associated	O
with	O
significant	O
side	O
effects	O
of	O
cataract	B_Disease
and	O
ocular	B_Disease
hypertension	I_Disease
requiring	O
treatment	O
.	O

Optimal	O
precurarizing	O
dose	O
of	O
rocuronium	B_Chemical
to	O
decrease	O
fasciculation	B_Disease
and	O
myalgia	B_Disease
following	O
succinylcholine	B_Chemical
administration	O
.	O

BACKGROUND	O
:	O
Succinylcholine	B_Chemical
commonly	O
produces	O
frequent	O
adverse	O
effects	O
,	O
including	O
muscle	B_Disease
fasciculation	I_Disease
and	O
myalgia	B_Disease
.	O

The	O
current	O
study	O
identified	O
the	O
optimal	O
dose	O
of	O
rocuronium	B_Chemical
to	O
prevent	O
succinylcholine-induced	O
fasciculation	B_Disease
and	O
myalgia	B_Disease
and	O
evaluated	O
the	O
influence	O
of	O
rocuronium	B_Chemical
on	O
the	O
speed	O
of	O
onset	O
produced	O
by	O
succinylcholine	B_Chemical
.	O

METHODS	O
:	O
This	O
randomized	O
,	O
double-blinded	O
study	O
was	O
conducted	O
in	O
100	O
patients	O
randomly	O
allocated	O
into	O
five	O
groups	O
of	O
20	O
patients	O
each	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
0.02	O
,	O
0.03	O
,	O
0.04	O
,	O
0.05	O
and	O
0.06	O
mg/kg	O
rocuronium	B_Chemical
as	O
a	O
precurarizing	O
dose	O
.	O

Neuromuscular	O
monitoring	O
after	O
each	O
precurarizing	O
dose	O
was	O
recorded	O
from	O
the	O
adductor	O
pollicis	O
muscle	O
using	O
acceleromyography	O
with	O
train-of-four	O
stimulation	O
of	O
the	O
ulnar	O
nerve	O
.	O

All	O
patients	O
received	O
succinylcholine	B_Chemical
1.5	O
mg/kg	O
at	O
2	O
minutes	O
after	O
the	O
precurarization	O
,	O
and	O
were	O
assessed	O
the	O
incidence	O
and	O
severity	O
of	O
fasciculations	B_Disease
,	O
while	O
myalgia	B_Disease
was	O
assessed	O
at	O
24	O
hours	O
after	O
surgery	O
.	O

RESULTS	O
:	O
The	O
incidence	O
and	O
severity	O
of	O
visible	O
muscle	B_Disease
fasciculation	I_Disease
was	O
significantly	O
less	O
with	O
increasing	O
the	O
amount	O
of	O
precurarizing	O
dose	O
of	O
rocuronium	B_Chemical
(	O
P	O
<	O
0.001	O
)	O
.	O

Those	O
of	O
myalgia	B_Disease
tend	O
to	O
decrease	O
according	O
to	O
increasing	O
the	O
amount	O
of	O
precurarizing	O
dose	O
of	O
rocuronium	B_Chemical
,	O
but	O
there	O
was	O
no	O
significance	O
(	O
P	O
=	O
0.072	O
)	O
.	O

The	O
onset	O
time	O
of	O
succinylcholine	B_Chemical
was	O
significantly	O
longer	O
with	O
increasing	O
the	O
amount	O
of	O
precurarizing	O
dose	O
of	O
rocuronium	B_Chemical
(	O
P	O
<	O
0.001	O
)	O
.	O

CONCLUSIONS	O
:	O
Precurarization	O
with	O
0.04	O
mg/kg	O
rocuronium	B_Chemical
was	O
the	O
optimal	O
dose	O
considering	O
the	O
reduction	O
in	O
the	O
incidence	O
and	O
severity	O
of	O
fasciculation	B_Disease
and	O
myalgia	B_Disease
with	O
acceptable	O
onset	O
time	O
,	O
and	O
the	O
safe	O
and	O
effective	O
precurarization	O
.	O

Absence	O
of	O
PKC-alpha	O
attenuates	O
lithium-induced	O
nephrogenic	B_Disease
diabetes	I_Disease
insipidus	I_Disease
.	O

Lithium	B_Chemical
,	O
an	O
effective	O
antipsychotic	O
,	O
induces	O
nephrogenic	B_Disease
diabetes	I_Disease
insipidus	I_Disease
(	O
NDI	B_Disease
)	O
in	O
 	O
40	O
%	O
of	O
patients	O
.	O

The	O
decreased	O
capacity	O
to	O
concentrate	O
urine	O
is	O
likely	O
due	O
to	O
lithium	B_Chemical
acutely	O
disrupting	O
the	O
cAMP	B_Chemical
pathway	O
and	O
chronically	O
reducing	O
urea	B_Chemical
transporter	O
(	O
UT-A1	O
)	O
and	O
water	O
channel	O
(	O
AQP2	O
)	O
expression	O
in	O
the	O
inner	O
medulla	O
.	O

Targeting	O
an	O
alternative	O
signaling	O
pathway	O
,	O
such	O
as	O
PKC-mediated	O
signaling	O
,	O
may	O
be	O
an	O
effective	O
method	O
of	O
treating	O
lithium-induced	O
polyuria	B_Disease
.	O

PKC-alpha	O
null	O
mice	O
(	O
PKCa	O
KO	O
)	O
and	O
strain-matched	O
wild	O
type	O
(	O
WT	O
)	O
controls	O
were	O
treated	O
with	O
lithium	B_Chemical
for	O
0	O
,	O
3	O
or	O
5	O
days	O
.	O

WT	O
mice	O
had	O
increased	O
urine	O
output	O
and	O
lowered	O
urine	O
osmolality	O
after	O
3	O
and	O
5	O
days	O
of	O
treatment	O
whereas	O
PKCa	O
KO	O
mice	O
had	O
no	O
change	O
in	O
urine	O
output	O
or	O
concentration	O
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
AQP2	O
expression	O
in	O
medullary	O
tissues	O
was	O
lowered	O
after	O
3	O
and	O
5	O
days	O
in	O
WT	O
mice	O
;	O
however	O
,	O
AQP2	O
was	O
unchanged	O
in	O
PKCa	O
KO	O
.	O

Similar	O
results	O
were	O
observed	O
with	O
UT-A1	O
expression	O
.	O

Animals	O
were	O
also	O
treated	O
with	O
lithium	B_Chemical
for	O
6	O
weeks	O
.	O

Lithium-treated	O
WT	O
mice	O
had	O
19-fold	O
increased	O
urine	O
output	O
whereas	O
treated	O
PKCa	O
KO	O
animals	O
had	O
a	O
4-fold	O
increase	O
in	O
output	O
.	O

AQP2	O
and	O
UT-A1	O
expression	O
was	O
lowered	O
in	O
6	O
week	O
lithium-treated	O
WT	O
animals	O
whereas	O
in	O
treated	O
PKCa	O
KO	O
mice	O
,	O
AQP2	O
was	O
only	O
reduced	O
by	O
2-fold	O
and	O
UT-A1	O
expression	O
was	O
unaffected	O
.	O

Urinary	O
sodium	B_Chemical
,	O
potassium	B_Chemical
and	O
calcium	B_Chemical
were	O
elevated	O
in	O
lithium-fed	O
WT	O
but	O
not	O
in	O
lithium-fed	O
PKCa	O
KO	O
mice	O
.	O

Our	O
data	O
show	O
that	O
ablation	O
of	O
PKCa	O
preserves	O
AQP2	O
and	O
UT-A1	O
protein	O
expression	O
and	O
localization	O
in	O
lithium-induced	O
NDI	B_Disease
,	O
and	O
prevents	O
the	O
development	O
of	O
the	O
severe	O
polyuria	B_Disease
associated	O
with	O
lithium	B_Chemical
therapy	O
.	O

Is	O
Dysguesia	B_Disease
Going	O
to	O
be	O
a	O
Rare	O
or	O
a	O
Common	O
Side-effect	O
of	O
Amlodipine?A	O
very	O
rare	O
side-effect	O
of	O
amlodipine	B_Chemical
is	O
dysguesia	B_Disease
.	O

A	O
review	O
of	O
the	O
literature	O
produced	O
only	O
one	O
case	O
.	O

We	O
report	O
a	O
case	O
about	O
a	O
female	O
with	O
essential	O
hypertension	B_Disease
on	O
drug	O
treatment	O
with	O
amlodipine	B_Chemical
developed	O
loss	B_Disease
of	I_Disease
taste	I_Disease
sensation	I_Disease
.	O

Condition	O
moderately	O
improved	O
on	O
stoppage	O
of	O
the	O
drug	O
for	O
25	O
days	O
.	O

We	O
conclude	O
that	O
amlodipine	B_Chemical
can	O
cause	O
dysguesia	B_Disease
.	O

Here	O
,	O
we	O
describe	O
the	O
clinical	O
presentation	O
and	O
review	O
the	O
relevant	O
literature	O
on	O
amlodipine	B_Chemical
and	O
dysguesia	B_Disease
.	O

Rhabdomyolysis	B_Disease
in	O
association	O
with	O
simvastatin	B_Chemical
and	O
dosage	O
increment	O
in	O
clarithromycin	B_Chemical
.	O

Clarithromycin	B_Chemical
is	O
the	O
most	O
documented	O
cytochrome	O
P450	O
3A4	O
(	O
CYP3A4	O
)	O
inhibitor	O
to	O
cause	O
an	O
adverse	O
interaction	O
with	O
simvastatin	B_Chemical
.	O

This	O
particular	O
case	O
is	O
of	O
interest	O
as	O
rhabdomyolysis	B_Disease
only	O
occurred	O
after	O
an	O
increase	O
in	O
the	O
dose	O
of	O
clarithromycin	B_Chemical
.	O

The	O
patient	O
developed	O
raised	O
cardiac	O
biomarkers	O
without	O
any	O
obvious	O
cardiac	O
issues	O
,	O
a	O
phenomenon	O
that	O
has	O
been	O
linked	O
to	O
rhabdomyolysis	B_Disease
previously	O
.	O

To	O
date	O
,	O
there	O
has	O
been	O
no	O
reported	O
effect	O
of	O
rhabdomyolysis	B_Disease
on	O
the	O
structure	O
and	O
function	O
of	O
cardiac	O
muscle	O
.	O

Clinicians	O
need	O
to	O
be	O
aware	O
of	O
prescribing	O
concomitant	O
medications	O
that	O
increase	O
the	O
risk	O
of	O
myopathy	B_Disease
or	O
inhibit	O
the	O
CYP3A4	O
enzyme	O
.	O

Our	O
case	O
suggests	O
that	O
troponin	O
elevation	O
could	O
be	O
associated	O
with	O
statin	B_Chemical
induced	O
rhabdomyolysis	B_Disease
,	O
which	O
may	O
warrant	O
further	O
studies	O
.	O

Characterization	O
of	O
a	O
novel	O
BCHE	O
"	O
silent	O
"	O
allele	O
:	O
point	O
mutation	O
(	O
p.	O
Val204Asp	O
)	O
causes	O
loss	O
of	O
activity	O
and	O
prolonged	O
apnea	B_Disease
with	O
suxamethonium	B_Chemical
.	O

Butyrylcholinesterase	B_Disease
deficiency	I_Disease
is	O
characterized	O
by	O
prolonged	O
apnea	B_Disease
after	O
the	O
use	O
of	O
muscle	O
relaxants	O
(	O
suxamethonium	B_Chemical
or	O
mivacurium	B_Chemical
)	O
in	O
patients	O
who	O
have	O
mutations	O
in	O
the	O
BCHE	O
gene	O
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
prolonged	O
neuromuscular	O
block	O
after	O
administration	O
of	O
suxamethonium	B_Chemical
leading	O
to	O
the	O
discovery	O
of	O
a	O
novel	O
BCHE	O
variant	O
(	O
c.695T	O
>	O
A	O
,	O
p.	O
Val204Asp	O
)	O
.	O

Inhibition	O
studies	O
,	O
kinetic	O
analysis	O
and	O
molecular	O
dynamics	O
were	O
undertaken	O
to	O
understand	O
how	O
this	O
mutation	O
disrupts	O
the	O
catalytic	O
triad	O
and	O
determines	O
a	O
"	O
silent	O
"	O
phenotype	O
.	O

Low	O
activity	O
of	O
patient	O
plasma	O
butyrylcholinesterase	O
with	O
butyrylthiocholine	B_Chemical
(	O
BTC	B_Chemical
)	O
and	O
benzoylcholine	B_Chemical
,	O
and	O
values	O
of	O
dibucaine	B_Chemical
and	O
fluoride	B_Chemical
numbers	O
fit	O
with	O
heterozygous	O
atypical	O
silent	O
genotype	O
.	O

Electrophoretic	O
analysis	O
of	O
plasma	O
BChE	O
of	O
the	O
proband	O
and	O
his	O
mother	O
showed	O
that	O
patient	O
has	O
a	O
reduced	O
amount	O
of	O
tetrameric	O
enzyme	O
in	O
plasma	O
and	O
that	O
minor	O
fast-moving	O
BChE	O
components	O
:	O
monomer	O
,	O
dimer	O
,	O
and	O
monomer-albumin	O
conjugate	O
are	O
missing	O
.	O

Kinetic	O
analysis	O
showed	O
that	O
the	O
p.	O
Val204Asp/p	O
.	O

Asp70Gly-p	O
.	O

Ala539Thr	O
BChE	O
displays	O
a	O
pure	O
Michaelian	O
behavior	O
with	O
BTC	B_Chemical
as	O
the	O
substrate	O
.	O

Both	O
catalytic	O
parameters	O
Km	O
=	O
265	O
uM	O
for	O
BTC	B_Chemical
,	O
two	O
times	O
higher	O
than	O
that	O
of	O
the	O
atypical	O
enzyme	O
,	O
and	O
a	O
low	O
Vmax	O
are	O
consistent	O
with	O
the	O
absence	O
of	O
activity	O
against	O
suxamethonium	B_Chemical
.	O

Molecular	O
dynamic	O
(	O
MD	O
)	O
simulations	O
showed	O
that	O
the	O
overall	O
effect	O
of	O
the	O
mutation	O
p.	O
Val204Asp	O
is	O
disruption	O
of	O
hydrogen	B_Chemical
bonding	O
between	O
Gln223	O
and	O
Glu441	O
,	O
leading	O
Ser198	O
and	O
His438	O
to	O
move	O
away	O
from	O
each	O
other	O
with	O
subsequent	O
disruption	O
of	O
the	O
catalytic	O
triad	O
functionality	O
regardless	O
of	O
the	O
type	O
of	O
substrate	O
.	O

MD	O
also	O
showed	O
that	O
the	O
enzyme	O
volume	O
is	O
increased	O
,	O
suggesting	O
a	O
pre-denaturation	O
state	O
.	O

This	O
fits	O
with	O
the	O
reduced	O
concentration	O
of	O
p.	O
Ala204Asp/p	O
.	O

Asp70Gly-p	O
.	O

Ala539Thr	O
tetrameric	O
enzyme	O
in	O
the	O
plasma	O
and	O
non-detectable	O
fast	O
moving-bands	O
on	O
electrophoresis	O
gels	O
.	O

Delayed	O
anemia	B_Disease
after	O
treatment	O
with	O
injectable	O
artesunate	B_Chemical
in	O
the	O
Democratic	O
Republic	O
of	O
the	O
Congo	O
:	O
a	O
manageable	O
issue	O
.	O

Cases	O
of	O
delayed	O
hemolytic	B_Disease
anemia	I_Disease
have	O
been	O
described	O
after	O
treatment	O
with	O
injectable	O
artesunate	B_Chemical
,	O
the	O
current	O
World	O
Health	O
Organization	O
(WHO)-recommended	O
first-line	O
drug	O
for	O
the	O
treatment	O
of	O
severe	O
malaria	B_Disease
.	O

A	O
total	O
of	O
350	O
patients	O
(	O
215	O
[	O
61.4	O
%	O
]	O
<	O
5	O
years	O
of	O
age	O
and	O
135	O
[	O
38.6	O
%	O
]	O
>	O
5	O
years	O
of	O
age	O
)	O
were	O
followed-up	O
after	O
treatment	O
with	O
injectable	O
artesunate	B_Chemical
for	O
severe	O
malaria	B_Disease
in	O
hospitals	O
and	O
health	O
centers	O
of	O
the	O
Democratic	O
Republic	O
of	O
the	O
Congo	O
.	O

Complete	O
series	O
of	O
hemoglobin	O
(	O
Hb	O
)	O
measurements	O
were	O
available	O
for	O
201	O
patients	O
.	O

A	O
decrease	O
in	O
Hb	O
levels	O
between	O
2	O
and	O
5	O
g/dL	O
was	O
detected	O
in	O
23	O
(	O
11.4	O
%	O
)	O
patients	O
during	O
the	O
follow-up	O
period	O
.	O

For	O
five	O
patients	O
,	O
Hb	O
levels	O
decreased	O
below	O
5	O
g/dL	O
during	O
at	O
least	O
one	O
follow-up	O
visit	O
.	O

All	O
cases	O
of	O
delayed	O
anemia	B_Disease
were	O
clinically	O
manageable	O
and	O
resolved	O
within	O
one	O
month	O
.	O

Regulation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
and	O
apoptotic	O
pathways	O
by	O
betaine	B_Chemical
attenuates	O
isoproterenol-induced	O
acute	O
myocardial	B_Disease
injury	I_Disease
in	O
rats	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
cardioprotective	O
effects	O
of	O
betaine	B_Chemical
on	O
acute	O
myocardial	B_Disease
ischemia	I_Disease
induced	O
experimentally	O
in	O
rats	O
focusing	O
on	O
regulation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
STAT3	O
)	O
and	O
apoptotic	O
pathways	O
as	O
the	O
potential	O
mechanism	O
underlying	O
the	O
drug	O
effect	O
.	O

Male	O
Sprague	O
Dawley	O
rats	O
were	O
treated	O
with	O
betaine	B_Chemical
(	O
100	O
,	O
200	O
,	O
and	O
400	O
mg/kg	O
)	O
orally	O
for	O
40	O
days	O
.	O

Acute	O
myocardial	B_Disease
ischemic	I_Disease
injury	I_Disease
was	O
induced	O
in	O
rats	O
by	O
subcutaneous	O
injection	O
of	O
isoproterenol	B_Chemical
(	O
85	O
mg/kg	O
)	O
,	O
for	O
two	O
consecutive	O
days	O
.	O

Serum	O
cardiac	O
marker	O
enzyme	O
,	O
histopathological	O
variables	O
and	O
expression	O
of	O
protein	O
levels	O
were	O
analyzed	O
.	O

Oral	O
administration	O
of	O
betaine	B_Chemical
(	O
200	O
and	O
400	O
mg/kg	O
)	O
significantly	O
reduced	O
the	O
level	O
of	O
cardiac	O
marker	O
enzyme	O
in	O
the	O
serum	O
and	O
prevented	O
left	O
ventricular	B_Disease
remodeling	I_Disease
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
isoproterenol-induced	O
phosphorylation	O
of	O
STAT3	O
was	O
maintained	O
or	O
further	O
enhanced	O
by	O
betaine	B_Chemical
treatment	O
in	O
myocardium	O
.	O

Furthermore	O
,	O
betaine	B_Chemical
(	O
200	O
and	O
400	O
mg/kg	O
)	O
treatment	O
increased	O
the	O
ventricular	O
expression	O
of	O
Bcl-2	O
and	O
reduced	O
the	O
level	O
of	O
Bax	O
,	O
therefore	O
causing	O
a	O
significant	O
increase	O
in	O
the	O
ratio	O
of	O
Bcl-2/Bax	O
.	O

The	O
protective	O
role	O
of	O
betaine	B_Chemical
on	O
myocardial	B_Disease
damage	I_Disease
was	O
further	O
confirmed	O
by	O
histopathological	O
examination	O
.	O

In	O
summary	O
,	O
our	O
results	O
showed	O
that	O
betaine	B_Chemical
pretreatment	O
attenuated	O
isoproterenol-induced	O
acute	O
myocardial	B_Disease
ischemia	I_Disease
via	O
the	O
regulation	O
of	O
STAT3	O
and	O
apoptotic	O
pathways	O
.	O

Quetiapine-induced	O
neutropenia	B_Disease
in	O
a	O
bipolar	B_Disease
patient	O
with	O
hepatocellular	B_Disease
carcinoma	I_Disease
.	O

OBJECTIVE	O
:	O
Quetiapine	B_Chemical
is	O
a	O
dibenzothiazepine	O
derivative	O
,	O
similar	O
to	O
clozapine	B_Chemical
,	O
which	O
has	O
the	O
highest	O
risk	O
of	O
causing	O
blood	B_Disease
dyscrasias	I_Disease
,	O
especially	O
neutropenia	B_Disease
.	O

There	O
are	O
some	O
case	O
reports	O
about	O
this	O
side	O
effect	O
of	O
quetiapine	B_Chemical
,	O
but	O
possible	O
risk	O
factors	O
are	O
seldom	O
discussed	O
and	O
identified	O
.	O

A	O
case	O
of	O
a	O
patient	O
with	O
hepatocellular	B_Disease
carcinoma	I_Disease
that	O
developed	O
neutropenia	B_Disease
after	O
treatment	O
with	O
quetiapine	B_Chemical
is	O
described	O
here	O
.	O

CASE	O
REPORT	O
:	O
A	O
62-year-old	O
Taiwanese	O
widow	O
with	O
bipolar	B_Disease
disorder	I_Disease
was	O
diagnosed	O
with	O
hepatocellular	B_Disease
carcinoma	I_Disease
at	O
age	O
60	O
.	O

She	O
developed	O
leucopenia	B_Disease
after	O
being	O
treated	O
with	O
quetiapine	B_Chemical
.	O
After	O
quetiapine	B_Chemical
was	O
discontinued	O
,	O
her	O
white	O
blood	O
cell	O
count	O
returned	O
to	O
normal	O
.	O

CONCLUSIONS	O
:	O
Although	O
neutropenia	B_Disease
is	O
not	O
a	O
common	O
side	O
effect	O
of	O
quetiapine	B_Chemical
,	O
physicians	O
should	O
be	O
cautious	O
about	O
its	O
presentation	O
and	O
associated	O
risk	O
factors	O
.	O

Hepatic	B_Disease
dysfunction	I_Disease
may	O
be	O
one	O
of	O
the	O
possible	O
risk	O
factors	O
,	O
and	O
concomitant	O
fever	B_Disease
may	O
be	O
a	O
diagnostic	O
marker	O
for	O
adverse	O
reaction	O
to	O
quetiapine	B_Chemical
.	O

Lateral	O
antebrachial	O
cutaneous	O
neuropathy	B_Disease
after	O
steroid	B_Chemical
injection	O
at	O
lateral	O
epicondyle	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
This	O
report	O
aimed	O
to	O
present	O
a	O
case	O
of	O
lateral	O
antebrachial	O
cutaneous	O
neuropathy	B_Disease
(	O
LACNP	O
)	O
that	O
occurred	O
after	O
a	O
steroid	B_Chemical
injection	O
in	O
the	O
lateral	O
epicondyle	O
to	O
treat	O
lateral	B_Disease
epicondylitis	I_Disease
in	O
a	O
40-year-old	O
woman	O
.	O

MATERIAL	O
AND	O
METHOD	O
:	O
A	O
40-year-old	O
woman	O
presented	O
with	O
decreased	O
sensation	O
and	O
paresthesia	B_Disease
over	O
her	O
right	O
lateral	O
forearm	O
;	O
the	O
paresthesia	B_Disease
had	O
occurred	O
after	O
a	O
steroid	B_Chemical
injection	O
in	O
the	O
right	O
lateral	O
epicondyle	O
3	O
months	O
before	O
.	O

Her	O
sensation	O
of	O
light	O
touch	O
and	O
pain	B_Disease
was	O
diminished	O
over	O
the	O
lateral	O
side	O
of	O
the	O
right	O
forearm	O
and	O
wrist	O
area	O
.	O

RESULTS	O
:	O
The	O
sensory	O
action	O
potential	O
amplitude	O
of	O
the	O
right	O
lateral	O
antebrachial	O
cutaneous	O
nerve	O
(	O
LACN	O
)	O
(	O
6.2	O
uV	O
)	O
was	O
lower	O
than	O
that	O
of	O
the	O
left	O
(	O
13.1	O
uV	O
)	O
.	O

The	O
difference	O
of	O
amplitude	O
between	O
both	O
sides	O
was	O
significant	O
because	O
there	O
was	O
more	O
than	O
a	O
50	O
%	O
reduction	O
.	O

She	O
was	O
diagnosed	O
with	O
right	O
LACNP	O
(	O
mainly	O
axonal	O
involvement	O
)	O
on	O
the	O
basis	O
of	O
the	O
clinical	O
manifestation	O
and	O
the	O
electrodiagnostic	O
findings	O
.	O

Her	O
symptoms	O
improved	O
through	O
physical	O
therapy	O
but	O
persisted	O
to	O
some	O
degree	O
.	O

CONCLUSION	O
:	O
This	O
report	O
describes	O
the	O
case	O
of	O
a	O
woman	O
with	O
LACNP	O
that	O
developed	O
after	O
a	O
steroid	B_Chemical
injection	O
for	O
the	O
treatment	O
of	O
lateral	B_Disease
epicondylitis	I_Disease
.	O

An	O
electrodiagnostic	O
study	O
,	O
including	O
a	O
nerve	O
conduction	O
study	O
of	O
the	O
LACN	O
,	O
was	O
helpful	O
to	O
diagnose	O
right	O
LACNP	O
and	O
to	O
find	O
the	O
passage	O
of	O
the	O
LACN	O
on	O
the	O
lateral	O
epicondyle	O
.	O

Curcumin	B_Chemical
prevents	O
maleate-induced	O
nephrotoxicity	B_Disease
:	O
relation	O
to	O
hemodynamic	O
alterations	O
,	O
oxidative	O
stress	O
,	O
mitochondrial	O
oxygen	B_Chemical
consumption	O
and	O
activity	O
of	O
respiratory	O
complex	O
I.The	O
potential	O
protective	O
effect	O
of	O
the	O
dietary	O
antioxidant	O
curcumin	B_Chemical
(	O
120	O
mg/Kg/day	O
for	O
6	O
days	O
)	O
against	O
the	O
renal	B_Disease
injury	I_Disease
induced	O
by	O
maleate	B_Chemical
was	O
evaluated	O
.	O

Tubular	O
proteinuria	B_Disease
and	O
oxidative	O
stress	O
were	O
induced	O
by	O
a	O
single	O
injection	O
of	O
maleate	B_Chemical
(	O
400	O
mg/kg	O
)	O
in	O
rats	O
.	O

Maleate-induced	O
renal	B_Disease
injury	I_Disease
included	O
increase	O
in	O
renal	O
vascular	O
resistance	O
and	O
in	O
the	O
urinary	O
excretion	O
of	O
total	O
protein	O
,	O
glucose	B_Chemical
,	O
sodium	B_Chemical
,	O
neutrophil	O
gelatinase-associated	O
lipocalin	O
(	O
NGAL	O
)	O
and	O
N-acetyl	O
b-D-glucosaminidase	O
(	O
NAG	O
)	O
,	O
upregulation	O
of	O
kidney	B_Disease
injury	I_Disease
molecule	O
(KIM)-1	O
,	O
decrease	O
in	O
renal	O
blood	O
flow	O
and	O
claudin-2	O
expression	O
besides	O
of	O
necrosis	B_Disease
and	O
apoptosis	O
of	O
tubular	O
cells	O
on	O
24	O
h.	O
Oxidative	O
stress	O
was	O
determined	O
by	O
measuring	O
the	O
oxidation	O
of	O
lipids	O
and	O
proteins	O
and	O
diminution	O
in	O
renal	O
Nrf2	O
levels	O
.	O

Studies	O
were	O
also	O
conducted	O
in	O
renal	O
epithelial	O
LLC-PK1	O
cells	O
and	O
in	O
mitochondria	O
isolated	O
from	O
kidneys	O
of	O
all	O
the	O
experimental	O
groups	O
.	O

Maleate	B_Chemical
induced	O
cell	O
damage	O
and	O
reactive	O
oxygen	B_Chemical
species	O
(	O
ROS	O
)	O
production	O
in	O
LLC-PK1	O
cells	O
in	O
culture	O
.	O

In	O
addition	O
,	O
maleate	B_Chemical
treatment	O
reduced	O
oxygen	B_Chemical
consumption	O
in	O
ADP-stimulated	O
mitochondria	O
and	O
diminished	O
respiratory	O
control	O
index	O
when	O
using	O
malate/glutamate	O
as	O
substrate	O
.	O

The	O
activities	O
of	O
both	O
complex	O
I	O
and	O
aconitase	O
were	O
also	O
diminished	O
.	O

All	O
the	O
above-described	O
alterations	O
were	O
prevented	O
by	O
curcumin	B_Chemical
.	O

It	O
is	O
concluded	O
that	O
curcumin	B_Chemical
is	O
able	O
to	O
attenuate	O
in	O
vivo	O
maleate-induced	O
nephropathy	B_Disease
and	O
in	O
vitro	O
cell	O
damage	O
.	O

The	O
in	O
vivo	O
protection	O
was	O
associated	O
to	O
the	O
prevention	O
of	O
oxidative	O
stress	O
and	O
preservation	O
of	O
mitochondrial	O
oxygen	B_Chemical
consumption	O
and	O
activity	O
of	O
respiratory	O
complex	O
I	O
,	O
and	O
the	O
in	O
vitro	O
protection	O
was	O
associated	O
to	O
the	O
prevention	O
of	O
ROS	O
production	O
.	O

Anticonvulsant	O
actions	O
of	O
MK-801	B_Chemical
on	O
the	O
lithium-pilocarpine	O
model	O
of	O
status	B_Disease
epilepticus	I_Disease
in	O
rats	O
.	O

MK-801	B_Chemical
,	O
a	O
noncompetitive	O
N-methyl-D-aspartate	B_Chemical
(	O
NMDA	B_Chemical
)	O
receptor	O
antagonist	O
,	O
was	O
tested	O
for	O
anticonvulsant	O
effects	O
in	O
rats	O
using	O
two	O
seizure	B_Disease
models	O
,	O
coadministration	O
of	O
lithium	B_Chemical
and	O
pilocarpine	B_Chemical
and	O
administration	O
of	O
a	O
high	O
dose	O
of	O
pilocarpine	B_Chemical
alone	O
.	O

Three	O
major	O
results	O
are	O
reported	O
.	O

First	O
,	O
pretreatment	O
with	O
MK-801	B_Chemical
produced	O
an	O
effective	O
and	O
dose-dependent	O
anticonvulsant	O
action	O
with	O
the	O
lithium-pilocarpine	O
model	O
but	O
not	O
with	O
rats	O
treated	O
with	O
pilocarpine	B_Chemical
alone	O
,	O
suggesting	O
that	O
different	O
biochemical	O
mechanisms	O
control	O
seizures	B_Disease
in	O
these	O
two	O
models	O
.	O

Second	O
,	O
the	O
anticonvulsant	O
effect	O
of	O
MK-801	B_Chemical
in	O
the	O
lithium-pilocarpine	O
model	O
only	O
occurred	O
after	O
initial	O
periods	O
of	O
seizure	B_Disease
activity	O
.	O

This	O
observation	O
is	O
suggested	O
to	O
be	O
an	O
in	O
vivo	O
demonstration	O
of	O
the	O
conclusion	O
derived	O
from	O
in	O
vitro	O
experiments	O
that	O
MK-801	B_Chemical
binding	O
requires	O
agonist-induced	O
opening	O
of	O
the	O
channel	O
sites	O
of	O
the	O
NMDA	B_Chemical
receptor	O
.	O

Third	O
,	O
although	O
it	O
is	O
relatively	O
easy	O
to	O
block	O
seizures	B_Disease
induced	O
by	O
lithium	B_Chemical
and	O
pilocarpine	B_Chemical
by	O
administration	O
of	O
anticonvulsants	O
prior	O
to	O
pilocarpine	B_Chemical
,	O
it	O
is	O
more	O
difficult	O
to	O
terminate	O
ongoing	O
status	B_Disease
epilepticus	I_Disease
and	O
block	O
the	O
lethality	O
of	O
the	O
seizures	B_Disease
.	O

Administration	O
of	O
MK-801	B_Chemical
30	O
or	O
60	O
min	O
after	O
pilocarpine	B_Chemical
,	O
i.e.	O
,	O
during	O
status	B_Disease
epilepticus	I_Disease
,	O
gradually	O
reduced	O
electrical	O
and	O
behavioral	O
seizure	B_Disease
activity	O
and	O
greatly	O
enhanced	O
the	O
survival	O
rate	O
.	O

These	O
results	O
suggest	O
that	O
activation	O
of	O
NMDA	B_Chemical
receptors	O
plays	O
an	O
important	O
role	O
in	O
status	B_Disease
epilepticus	I_Disease
and	O
brain	B_Disease
damage	I_Disease
in	O
the	O
lithium-pilocarpine	O
model	O
.	O

This	O
was	O
further	O
supported	O
by	O
results	O
showing	O
that	O
nonconvulsive	O
doses	O
of	O
NMDA	B_Chemical
and	O
pilocarpine	B_Chemical
were	O
synergistic	O
,	O
resulting	O
in	O
status	B_Disease
epilepticus	I_Disease
and	O
subsequent	O
mortality	O
.	O

Continuous	O
infusion	O
tobramycin	B_Chemical
combined	O
with	O
carbenicillin	B_Chemical
for	O
infections	B_Disease
in	O
cancer	B_Disease
patients	O
.	O

The	O
cure	O
rate	O
of	O
infections	B_Disease
in	O
cancer	B_Disease
patients	O
is	O
adversely	O
affected	O
by	O
neutropenia	B_Disease
(	O
less	O
than	O
1,000/mm3	O
)	O
.	O

In	O
particular	O
,	O
patients	O
with	O
severe	O
neutropenia	B_Disease
(	O
less	O
than	O
100/mm3	O
)	O
have	O
shown	O
a	O
poor	O
response	O
to	O
antibiotics	O
.	O

To	O
overcome	O
the	O
adverse	O
effects	O
of	O
neutropenia	B_Disease
,	O
tobramycin	B_Chemical
was	O
given	O
by	O
continuous	O
infusion	O
and	O
combined	O
with	O
intermittent	O
carbenicillin	B_Chemical
.	O

Tobramycin	B_Chemical
was	O
given	O
to	O
a	O
total	O
daily	O
dose	O
of	O
300	O
mg/m2	O
and	O
carbenicillin	B_Chemical
was	O
given	O
at	O
a	O
dose	O
of	O
5	O
gm	O
every	O
four	O
hours	O
.	O

There	O
were	O
125	O
infectious	O
episodes	O
in	O
116	O
cancer	B_Disease
patients	O
receiving	O
myelosuppressive	O
chemotherapy	O
.	O

The	O
overall	O
cure	O
rate	O
was	O
70	O
%	O
.	O

Pneumonia	B_Disease
was	O
the	O
most	O
common	O
infection	B_Disease
and	O
61	O
%	O
of	O
59	O
episodes	O
were	O
cured	O
.	O

Gram-negative	O
bacilli	O
were	O
the	O
most	O
common	O
causative	O
organisms	O
and	O
69	O
%	O
of	O
these	O
infections	B_Disease
were	O
cured	O
.	O

The	O
most	O
common	O
pathogen	O
was	O
Klebsiella	O
pneumoniae	B_Disease
and	O
this	O
,	O
together	O
with	O
Escherichia	O
coli	O
and	O
Pseudomonas	O
aeruginosa	O
,	O
accounted	O
for	O
74	O
%	O
of	O
all	O
gram-negative	B_Disease
bacillary	I_Disease
infections	I_Disease
.	O

Response	O
was	O
not	O
influenced	O
by	O
the	O
initial	O
neutrophil	O
count	O
,	O
with	O
a	O
62	O
%	O
cure	O
rate	O
for	O
39	O
episodes	O
associated	O
with	O
severe	O
neutropenia	B_Disease
.	O

However	O
,	O
failure	O
of	O
the	O
neutrophil	O
count	O
to	O
increase	O
during	O
therapy	O
adversely	O
affected	O
response	O
.	O

Azotemia	B_Disease
was	O
the	O
major	O
side	O
effect	O
recognized	O
,	O
and	O
it	O
occurred	O
in	O
11	O
%	O
of	O
episodes	O
.	O

Major	O
azotemia	B_Disease
(	O
serum	O
creatinine	B_Chemical
greater	O
than	O
2.5	O
mg/dl	O
or	O
BUN	O
greater	O
than	O
50	O
mg/dl	O
)	O
occurred	O
in	O
only	O
2	O
%	O
.	O

Azotemia	B_Disease
was	O
not	O
related	O
to	O
duration	O
of	O
therapy	O
or	O
serum	O
tobramycin	B_Chemical
concentration	O
.	O

This	O
antibiotic	O
regimen	O
showed	O
both	O
therapeutic	O
efficacy	O
and	O
acceptable	O
renal	B_Disease
toxicity	I_Disease
for	O
these	O
patients	O
.	O

Incidence	O
of	O
solid	O
tumours	B_Disease
among	O
pesticide	O
applicators	O
exposed	O
to	O
the	O
organophosphate	B_Chemical
insecticide	O
diazinon	B_Chemical
in	O
the	O
Agricultural	O
Health	O
Study	O
:	O
an	O
updated	O
analysis	O
.	O

OBJECTIVE	O
:	O
Diazinon	B_Chemical
,	O
a	O
common	O
organophosphate	B_Chemical
insecticide	O
with	O
genotoxic	O
properties	O
,	O
was	O
previously	O
associated	O
with	O
lung	B_Disease
cancer	I_Disease
in	O
the	O
Agricultural	O
Health	O
Study	O
(	O
AHS	O
)	O
cohort	O
,	O
but	O
few	O
other	O
epidemiological	O
studies	O
have	O
examined	O
diazinon-associated	O
cancer	B_Disease
risk	O
.	O

We	O
used	O
updated	O
diazinon	B_Chemical
exposure	O
and	O
cancer	B_Disease
incidence	O
information	O
to	O
evaluate	O
solid	O
tumour	B_Disease
risk	O
in	O
the	O
AHS	O
.	O

METHODS	O
:	O
Male	O
pesticide	O
applicators	O
in	O
Iowa	O
and	O
North	O
Carolina	O
reported	O
lifetime	O
diazinon	B_Chemical
use	O
at	O
enrolment	O
(	O
1993	O
-	O
1997	O
)	O
and	O
follow-up	O
(	O
1998	O
-	O
2005	O
)	O
;	O
cancer	B_Disease
incidence	O
was	O
assessed	O
through	O
2010(North	O
Carolina)/2011(Iowa	O
)	O
.	O

Among	O
applicators	O
with	O
usage	O
information	O
sufficient	O
to	O
evaluate	O
exposure-response	O
patterns	O
,	O
we	O
used	O
Poisson	O
regression	O
to	O
estimate	O
adjusted	O
rate	O
ratios	O
(	O
RRs	O
)	O
and	O
95	O
%	O
CI	O
for	O
cancer	B_Disease
sites	O
with	O
>	O
10	O
exposed	O
cases	O
for	O
both	O
lifetime	O
(	O
LT	O
)	O
exposure	O
days	O
and	O
intensity-weighted	O
(	O
IW	O
)	O
lifetime	O
exposure	O
days	O
(	O
accounting	O
for	O
factors	O
impacting	O
exposure	O
)	O
.	O

RESULTS	O
:	O
We	O
observed	O
elevated	O
lung	B_Disease
cancer	I_Disease
risks	O
(	O
N=283	O
)	O
among	O
applicators	O
with	O
the	O
greatest	O
number	O
of	O
LT	O
(	O
RR=1.60	O
;	O
95	O
%	O
CI	O
1.11	O
to	O
2.31	O
;	O
Ptrend=0.02	O
)	O
and	O
IW	O
days	O
of	O
diazinon	B_Chemical
use	O
(	O
RR=1.41	O
;	O
95	O
%	O
CI	O
0.98	O
to	O
2.04	O
;	O
Ptrend=0.08	O
)	O
.	O

Kidney	B_Disease
cancer	I_Disease
(	O
N=94	O
)	O
risks	O
were	O
non-significantly	O
elevated	O
(	O
RRLT	O
days=1.77	O
;	O
95	O
%	O
CI	O
0.90	O
to	O
3.51	O
;	O
Ptrend=0.09	O
;	O
RRIW	O
days	O
1.37	O
;	O
95	O
%	O
CI	O
0.64	O
to	O
2.92	O
;	O
Ptrend=0.50	O
)	O
,	O
as	O
were	O
risks	O
for	O
aggressive	O
prostate	B_Disease
cancer	I_Disease
(	O
N=656	O
)	O
.	O

CONCLUSIONS	O
:	O
Our	O
updated	O
evaluation	O
of	O
diazinon	B_Chemical
provides	O
additional	O
evidence	O
of	O
an	O
association	O
with	O
lung	B_Disease
cancer	I_Disease
risk	O
.	O

Newly	O
identified	O
links	O
to	O
kidney	B_Disease
cancer	I_Disease
and	O
associations	O
with	O
aggressive	O
prostate	B_Disease
cancer	I_Disease
require	O
further	O
evaluation	O
.	O

Associations	O
of	O
Ozone	B_Chemical
and	O
PM2.5	O
Concentrations	O
With	O
Parkinson	B_Disease
's	I_Disease
Disease	I_Disease
Among	O
Participants	O
in	O
the	O
Agricultural	O
Health	O
Study	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
describes	O
associations	O
of	O
ozone	B_Chemical
and	O
fine	O
particulate	B_Chemical
matter	I_Chemical
with	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
observed	O
among	O
farmers	O
in	O
North	O
Carolina	O
and	O
Iowa	O
.	O

METHODS	O
:	O
We	O
used	O
logistic	O
regression	O
to	O
determine	O
the	O
associations	O
of	O
these	O
pollutants	O
with	O
self-reported	O
,	O
doctor-diagnosed	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
.	O

Daily	O
predicted	O
pollutant	O
concentrations	O
were	O
used	O
to	O
derive	O
surrogates	O
of	O
long-term	O
exposure	O
and	O
link	O
them	O
to	O
study	O
participants	O
'	O
geocoded	O
addresses	O
.	O

RESULTS	O
:	O
We	O
observed	O
positive	O
associations	O
of	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
with	O
ozone	B_Chemical
(	O
odds	O
ratio	O
=	O
1.39	O
;	O
95	O
%	O
CI	O
:	O
0.98	O
to	O
1.98	O
)	O
and	O
fine	O
particulate	B_Chemical
matter	I_Chemical
(	O
odds	O
ratio	O
=	O
1.34	O
;	O
95	O
%	O
CI	O
:	O
0.93	O
to	O
1.93	O
)	O
in	O
North	O
Carolina	O
but	O
not	O
in	O
Iowa	O
.	O

CONCLUSIONS	O
:	O
The	O
plausibility	O
of	O
an	O
effect	O
of	O
ambient	O
concentrations	O
of	O
these	O
pollutants	O
on	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
risk	O
is	O
supported	O
by	O
experimental	O
data	O
demonstrating	O
damage	O
to	O
dopaminergic	O
neurons	O
at	O
relevant	O
concentrations	O
.	O

Additional	O
studies	O
are	O
needed	O
to	O
address	O
uncertainties	O
related	O
to	O
confounding	O
and	O
to	O
examine	O
temporal	O
aspects	O
of	O
the	O
associations	O
we	O
observed	O
.	O

Low	O
functional	O
programming	O
of	O
renal	O
AT2R	O
mediates	O
the	O
developmental	O
origin	O
of	O
glomerulosclerosis	B_Disease
in	O
adult	O
offspring	O
induced	O
by	O
prenatal	O
caffeine	B_Chemical
exposure	O
.	O

UNASSIGNED	O
:	O
Our	O
previous	O
study	O
has	O
indicated	O
that	O
prenatal	O
caffeine	B_Chemical
exposure	O
(	O
PCE	O
)	O
could	O
induce	O
intrauterine	B_Disease
growth	I_Disease
retardation	I_Disease
(	O
IUGR	B_Disease
)	O
of	O
offspring	O
.	O

Recent	O
research	O
suggested	O
that	O
IUGR	B_Disease
is	O
a	O
risk	O
factor	O
for	O
glomerulosclerosis	B_Disease
.	O

However	O
,	O
whether	O
PCE	O
could	O
induce	O
glomerulosclerosis	B_Disease
and	O
its	O
underlying	O
mechanisms	O
remain	O
unknown	O
.	O

This	O
study	O
aimed	O
to	O
demonstrate	O
the	O
induction	O
to	O
glomerulosclerosis	B_Disease
in	O
adult	O
offspring	O
by	O
PCE	O
and	O
its	O
intrauterine	O
programming	O
mechanisms	O
.	O

A	O
rat	O
model	O
of	O
IUGR	B_Disease
was	O
established	O
by	O
PCE	O
,	O
male	O
fetuses	O
and	O
adult	O
offspring	O
at	O
the	O
age	O
of	O
postnatal	O
week	O
24	O
were	O
euthanized	O
.	O

The	O
results	O
revealed	O
that	O
the	O
adult	O
offspring	O
kidneys	O
in	O
the	O
PCE	O
group	O
exhibited	O
glomerulosclerosis	B_Disease
as	O
well	O
as	O
interstitial	B_Disease
fibrosis	I_Disease
,	O
accompanied	O
by	O
elevated	O
levels	O
of	O
serum	O
creatinine	B_Chemical
and	O
urine	O
protein	O
.	O

Renal	O
angiotensin	B_Chemical
II	I_Chemical
receptor	O
type	O
2	O
(	O
AT2R	O
)	O
gene	O
expression	O
in	O
adult	O
offspring	O
was	O
reduced	O
by	O
PCE	O
,	O
whereas	O
the	O
renal	O
angiotensin	B_Chemical
II	I_Chemical
receptor	O
type	O
1a	O
(AT1aR)/AT2R	O
expression	O
ratio	O
was	O
increased	O
.	O

The	O
fetal	O
kidneys	O
in	O
the	O
PCE	O
group	O
displayed	O
an	O
enlarged	O
Bowman	O
's	O
space	O
and	O
a	O
shrunken	O
glomerular	O
tuft	O
,	O
accompanied	O
by	O
a	O
reduced	O
cortex	O
width	O
and	O
an	O
increase	O
in	O
the	O
nephrogenic	O
zone/cortical	O
zone	O
ratio	O
.	O

Observation	O
by	O
electronic	O
microscope	O
revealed	O
structural	O
damage	O
of	O
podocytes	O
;	O
the	O
reduced	O
expression	O
level	O
of	O
podocyte	O
marker	O
genes	O
,	O
nephrin	O
and	O
podocin	O
,	O
was	O
also	O
detected	O
by	O
q-PCR	O
.	O

Moreover	O
,	O
AT2R	O
gene	O
and	O
protein	O
expressions	O
in	O
fetal	O
kidneys	O
were	O
inhibited	O
by	O
PCE	O
,	O
associated	O
with	O
the	O
repression	O
of	O
the	O
gene	O
expression	O
of	O
glial-cell-line-derived	O
neurotrophic	O
factor	O
(GDNF)/tyrosine	O
kinase	O
receptor	O
(	O
c-Ret	O
)	O
signaling	O
pathway	O
.	O

These	O
results	O
demonstrated	O
that	O
PCE	O
could	O
induce	O
dysplasia	B_Disease
of	I_Disease
fetal	I_Disease
kidneys	I_Disease
as	O
well	O
as	O
glomerulosclerosis	B_Disease
of	O
adult	O
offspring	O
,	O
and	O
the	O
low	O
functional	O
programming	O
of	O
renal	O
AT2R	O
might	O
mediate	O
the	O
developmental	O
origin	O
of	O
adult	O
glomerulosclerosis	B_Disease
.	O

1,3-Butadiene	B_Chemical
,	O
CML	B_Disease
and	O
the	O
t(9:22	O
)	O
translocation	O
:	O
A	O
reality	O
check	O
.	O

UNASSIGNED	O
:	O
Epidemiological	O
studies	O
of	O
1,3-butadiene	B_Chemical
have	O
suggest	O
that	O
exposures	O
to	O
humans	O
are	O
associated	O
with	O
chronic	B_Disease
myeloid	I_Disease
leukemia	I_Disease
(	O
CML	B_Disease
)	O
.	O

CML	B_Disease
has	O
a	O
well-documented	O
association	O
with	O
ionizing	O
radiation	O
,	O
but	O
reports	O
of	O
associations	O
with	O
chemical	O
exposures	O
have	O
been	O
questioned	O
.	O

Ionizing	O
radiation	O
is	O
capable	O
of	O
inducing	O
the	O
requisite	O
CML-associated	O
t(9:22	O
)	O
translocation	O
(	O
Philadelphia	B_Disease
chromosome	I_Disease
)	O
in	O
appropriate	O
cells	O
in	O
vitro	O
but	O
,	O
thus	O
far	O
,	O
chemicals	O
have	O
not	O
shown	O
this	O
capacity	O
.	O

We	O
have	O
proposed	O
that	O
1,3-butadiene	B_Chemical
metabolites	O
be	O
so	O
tested	O
as	O
a	O
reality	O
check	O
on	O
the	O
epidemiological	O
reports	O
.	O

In	O
order	O
to	O
conduct	O
reliable	O
testing	O
in	O
this	O
regard	O
,	O
it	O
is	O
essential	O
that	O
a	O
positive	O
control	O
for	O
induction	O
be	O
available	O
.	O

We	O
have	O
used	O
ionizing	O
radiation	O
to	O
develop	O
such	O
a	O
control	O
.	O

Results	O
described	O
here	O
demonstrate	O
that	O
this	O
agent	O
does	O
in	O
fact	O
induce	O
pathogenic	O
t(9:22	O
)	O
translocations	O
in	O
a	O
human	O
myeloid	O
cell	O
line	O
in	O
vitro	O
,	O
but	O
does	O
so	O
at	O
low	O
frequencies	O
.	O

Conditions	O
that	O
will	O
be	O
required	O
for	O
studies	O
of	O
1,3-butadiene	B_Chemical
are	O
discussed	O
.	O

Cancer	B_Disease
incidence	O
and	O
metolachlor	B_Chemical
use	O
in	O
the	O
Agricultural	O
Health	O
Study	O
:	O
An	O
update	O
.	O

UNASSIGNED	O
:	O
Metolachlor	B_Chemical
,	O
a	O
widely	O
used	O
herbicide	O
,	O
is	O
classified	O
as	O
a	O
Group	O
C	O
carcinogen	O
by	O
the	O
U.S.	O
Environmental	O
Protection	O
Agency	O
based	O
on	O
increased	O
liver	B_Disease
neoplasms	I_Disease
in	O
female	O
rats	O
.	O

Epidemiologic	O
studies	O
of	O
the	O
health	O
effects	O
of	O
metolachlor	B_Chemical
have	O
been	O
limited	O
.	O

The	O
Agricultural	O
Health	O
Study	O
(	O
AHS	O
)	O
is	O
a	O
prospective	O
cohort	O
study	O
including	O
licensed	O
private	O
and	O
commercial	O
pesticide	O
applicators	O
in	O
Iowa	O
and	O
North	O
Carolina	O
enrolled	O
1993	O
-	O
1997	O
.	O

We	O
evaluated	O
cancer	B_Disease
incidence	O
through	O
2010/2011	O
(	O
NC/IA	O
)	O
for	O
49,616	O
applicators	O
,	O
53	O
%	O
of	O
whom	O
reported	O
ever	O
using	O
metolachlor	B_Chemical
.	O

We	O
used	O
Poisson	O
regression	O
to	O
evaluate	O
relations	O
between	O
two	O
metrics	O
of	O
metolachlor	B_Chemical
use	O
(	O
lifetime	O
days	O
,	O
intensity-weighted	O
lifetime	O
days	O
)	O
and	O
cancer	B_Disease
incidence	O
.	O

We	O
saw	O
no	O
association	O
between	O
metolachlor	B_Chemical
use	O
and	O
incidence	O
of	O
all	O
cancers	B_Disease
combined	O
(	O
n	O
=	O
5,701	O
with	O
a	O
5-year	O
lag	O
)	O
or	O
most	O
site-specific	O
cancers	B_Disease
.	O

For	O
liver	B_Disease
cancer	I_Disease
,	O
in	O
analyses	O
restricted	O
to	O
exposed	O
workers	O
,	O
elevations	O
observed	O
at	O
higher	O
categories	O
of	O
use	O
were	O
not	O
statistically	O
significant	O
.	O

However	O
,	O
trends	O
for	O
both	O
lifetime	O
and	O
intensity-weighted	O
lifetime	O
days	O
of	O
metolachor	B_Chemical
use	O
were	O
positive	O
and	O
statistically	O
significant	O
with	O
an	O
unexposed	O
reference	O
group	O
.	O

A	O
similar	O
pattern	O
was	O
observed	O
for	O
follicular	B_Disease
cell	I_Disease
lymphoma	I_Disease
,	O
but	O
no	O
other	O
lymphoma	B_Disease
subtypes	O
.	O

An	O
earlier	O
suggestion	O
of	O
increased	O
lung	B_Disease
cancer	I_Disease
risk	O
at	O
high	O
levels	O
of	O
metolachlor	B_Chemical
use	O
in	O
this	O
cohort	O
was	O
not	O
confirmed	O
in	O
this	O
update	O
.	O

This	O
suggestion	O
of	O
an	O
association	O
between	O
metolachlor	B_Chemical
and	O
liver	B_Disease
cancer	I_Disease
among	O
pesticide	O
applicators	O
is	O
a	O
novel	O
finding	O
and	O
echoes	O
observation	O
of	O
increased	O
liver	B_Disease
neoplasms	I_Disease
in	O
some	O
animal	O
studies	O
.	O

However	O
,	O
our	O
findings	O
for	O
both	O
liver	B_Disease
cancer	I_Disease
and	O
follicular	O
cell	O
lymphoma	B_Disease
warrant	O
follow-up	O
to	O
better	O
differentiate	O
effects	O
of	O
metolachlor	B_Chemical
use	O
from	O
other	O
factors	O
.	O

Mechanisms	O
Underlying	O
Latent	O
Disease	O
Risk	O
Associated	O
with	O
Early-Life	O
Arsenic	O
Exposure	O
:	O
Current	O
Research	O
Trends	O
and	O
Scientific	O
Gaps	O
.	O

BACKGROUND	O
:	O
Millions	O
of	O
individuals	O
worldwide	O
,	O
particularly	O
those	O
living	O
in	O
rural	O
and	O
developing	O
areas	O
,	O
are	O
exposed	O
to	O
harmful	O
levels	O
of	O
inorganic	B_Chemical
arsenic	I_Chemical
(	O
iAs	B_Chemical
)	O
in	O
their	O
drinking	O
water	O
.	O

Inorganic	B_Chemical
As	I_Chemical
exposure	O
during	O
key	O
developmental	O
periods	O
is	O
associated	O
with	O
a	O
variety	O
of	O
adverse	O
health	O
effects	O
including	O
those	O
that	O
are	O
evident	O
in	O
adulthood	O
.	O

There	O
is	O
considerable	O
interest	O
in	O
identifying	O
the	O
molecular	O
mechanisms	O
that	O
relate	O
early-life	O
iAs	B_Chemical
exposure	O
to	O
the	O
development	O
of	O
these	O
latent	O
diseases	O
,	O
particularly	O
in	O
relationship	O
to	O
cancer	B_Disease
.	O

OBJECTIVES	O
:	O
This	O
work	O
summarizes	O
research	O
on	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
the	O
increased	O
risk	O
of	O
cancer	B_Disease
development	O
in	O
adulthood	O
that	O
is	O
associated	O
with	O
early-life	O
iAs	B_Chemical
exposure	O
.	O

DISCUSSION	O
:	O
Epigenetic	O
reprogramming	O
that	O
imparts	O
functional	O
changes	O
in	O
gene	O
expression	O
,	O
the	O
development	O
of	O
cancer	B_Disease
stem	O
cells	O
,	O
and	O
immunomodulation	O
are	O
plausible	O
underlying	O
mechanisms	O
by	O
which	O
early-life	O
iAs	B_Chemical
exposure	O
elicits	O
latent	O
carcinogenic	O
effects	O
.	O

CONCLUSIONS	O
:	O
Evidence	O
is	O
mounting	O
that	O
relates	O
early-life	O
iAs	B_Chemical
exposure	O
and	O
cancer	B_Disease
development	O
later	O
in	O
life	O
.	O

Future	O
research	O
should	O
include	O
animal	O
studies	O
that	O
address	O
mechanistic	O
hypotheses	O
and	O
studies	O
of	O
human	O
populations	O
that	O
integrate	O
early-life	O
exposure	O
,	O
molecular	O
alterations	O
,	O
and	O
latent	O
disease	O
outcomes	O
.	O

Nifedipine	B_Chemical
induced	O
bradycardia	B_Disease
in	O
a	O
patient	O
with	O
autonomic	B_Disease
neuropathy	I_Disease
.	O

An	O
80	O
year	O
old	O
diabetic	B_Disease
male	O
with	O
evidence	O
of	O
peripheral	B_Disease
and	I_Disease
autonomic	B_Disease
neuropathy	I_Disease
was	O
admitted	O
with	O
chest	B_Disease
pain	I_Disease
.	O

He	O
was	O
found	O
to	O
have	O
atrial	B_Disease
flutter	I_Disease
at	O
a	O
ventricular	O
rate	O
of	O
70/min	O
which	O
slowed	O
down	O
to	O
30	O
-	O
40/min	O
when	O
nifedipine	B_Chemical
(	O
60	O
mg	O
)	O
in	O
3	O
divided	O
doses	O
,	O
during	O
which	O
he	O
was	O
paced	O
at	O
a	O
rate	O
of	O
70/min	O
.	O

This	O
is	O
inconsistent	O
with	O
the	O
well-established	O
finding	O
that	O
nifedipine	B_Chemical
induces	O
tachycardia	B_Disease
in	O
normally	O
innervated	O
hearts	O
.	O

However	O
,	O
in	O
hearts	O
deprived	O
of	O
compensatory	O
sympathetic	O
drive	O
,	O
it	O
may	O
lead	O
to	O
bradycardia	B_Disease
.	O

The	O
effect	O
of	O
haloperidol	B_Chemical
in	O
cocaine	B_Chemical
and	O
amphetamine	B_Chemical
intoxication	O
.	O

The	O
effectiveness	O
of	O
haloperidol	B_Chemical
pretreatment	O
in	O
preventing	O
the	O
toxic	O
effects	O
of	O
high	O
doses	O
of	O
amphetamine	B_Chemical
and	O
cocaine	B_Chemical
was	O
studied	O
in	O
rats	O
.	O

In	O
this	O
model	O
,	O
toxic	O
effects	O
were	O
induced	O
by	O
intraperitoneal	O
(	O
i.p	O
.	O
)	O
injection	O
of	O
amphetamine	B_Chemical
75	O
mg/kg	O
(	O
100	O
%	O
death	O
rate	O
)	O
or	O
cocaine	B_Chemical
70	O
mg/kg	O
(	O
82	O
%	O
death	O
rate	O
)	O
.	O

Haloperidol	B_Chemical
failed	O
to	O
prevent	O
amphetamine-induced	O
seizures	B_Disease
,	O
but	O
did	O
lower	O
the	O
mortality	O
rate	O
at	O
most	O
doses	O
tested	O
.	O

Haloperidol	B_Chemical
decreased	O
the	O
incidence	O
of	O
cocaine-induced	O
seizures	B_Disease
at	O
the	O
two	O
highest	O
doses	O
,	O
but	O
the	O
lowering	O
of	O
the	O
mortality	O
rate	O
did	O
not	O
reach	O
statistical	O
significance	O
at	O
any	O
dose	O
.	O

These	O
data	O
suggest	O
a	O
protective	O
role	O
for	O
the	O
central	O
dopamine	B_Chemical
blocker	O
haloperidol	B_Chemical
against	O
death	O
from	O
high-dose	O
amphetamine	B_Chemical
exposure	O
without	O
reducing	O
the	O
incidence	O
of	O
seizures	B_Disease
.	O

In	O
contrast	O
,	O
haloperidol	B_Chemical
demonstrated	O
an	O
ability	O
to	O
reduce	O
cocaine-induced	O
seizures	B_Disease
without	O
significantly	O
reducing	O
mortality	O
.	O

Autoradiographic	O
evidence	O
of	O
estrogen	B_Chemical
binding	O
sites	O
in	O
nuclei	O
of	O
diethylstilbesterol	B_Chemical
induced	O
hamster	O
renal	B_Disease
carcinomas	I_Disease
.	O

Estrogen	B_Chemical
binding	O
sites	O
were	O
demonstrated	O
by	O
autoradiography	O
in	O
one	O
transplantable	O
and	O
five	O
primary	O
diethylstilbesterol	B_Chemical
induced	O
renal	B_Disease
carcinomas	I_Disease
in	O
three	O
hamsters	O
.	O

Radiolabelling	O
,	O
following	O
the	O
in	O
vivo	O
injection	O
of	O
3H-17	O
beta	O
estradiol	B_Chemical
,	O
was	O
increased	O
only	O
over	O
the	O
nuclei	O
of	O
tumor	B_Disease
cells	O
;	O
stereologic	O
analysis	O
revealed	O
a	O
4.5-	O
to	O
6.7-times	O
higher	O
concentration	O
of	O
reduced	O
silver	B_Chemical
grains	O
over	O
nuclei	O
than	O
cytoplasm	O
of	O
these	O
cells	O
.	O

Despite	O
rapid	O
tubular	O
excretion	O
of	O
estradiol	B_Chemical
which	O
peaked	O
in	O
less	O
than	O
1	O
h	O
,	O
the	O
normal	O
cells	O
did	O
not	O
appear	O
to	O
bind	O
the	O
ligand	O
.	O

This	O
is	O
the	O
first	O
published	O
report	O
documenting	O
the	O
preferential	O
in	O
vivo	O
binding	O
of	O
estrogen	B_Chemical
to	O
nuclei	O
of	O
cells	O
in	O
estrogen	B_Chemical
induced	O
hamster	O
renal	B_Disease
carcinomas	I_Disease
.	O

Bradycardia	B_Disease
due	O
to	O
biperiden	B_Chemical
.	O

In	O
a	O
38-year-old	O
male	O
patient	O
suffering	O
from	O
a	O
severe	O
postzosteric	B_Disease
trigeminal	B_Disease
neuralgia	I_Disease
,	O
intravenous	O
application	O
of	O
10	O
mg	O
biperiden	B_Chemical
lactate	I_Chemical
led	O
to	O
a	O
long-lasting	O
paradoxical	O
reaction	O
characterized	O
by	O
considerable	O
bradycardia	B_Disease
,	O
dysarthria	B_Disease
,	O
and	O
dysphagia	B_Disease
.	O

The	O
heart	O
rate	O
was	O
back	O
to	O
normal	O
within	O
12	O
hours	O
upon	O
administration	O
of	O
orciprenaline	B_Chemical
under	O
cardiac	O
monitoring	O
in	O
an	O
intensive	O
care	O
unit	O
.	O

Bradycardia	B_Disease
induced	O
by	O
biperiden	B_Chemical
is	O
attributed	O
to	O
the	O
speed	O
of	O
injection	O
and	O
to	O
a	O
dose-related	O
dual	O
effect	O
of	O
atropine-like	O
drugs	O
on	O
muscarine	B_Chemical
receptors	O
.	O

Deliberate	O
hypotension	B_Disease
induced	O
by	O
labetalol	B_Chemical
with	O
halothane	B_Chemical
,	O
enflurane	B_Chemical
or	O
isoflurane	B_Chemical
for	O
middle-ear	O
surgery	O
.	O

The	O
feasibility	O
of	O
using	O
labetalol	B_Chemical
,	O
an	O
alpha-	O
and	O
beta-adrenergic	O
blocking	O
agent	O
,	O
as	O
a	O
hypotensive	B_Disease
agent	O
in	O
combination	O
with	O
inhalation	O
anaesthetics	O
(	O
halothane	B_Chemical
,	O
enflurane	B_Chemical
or	O
isoflurane	B_Chemical
)	O
was	O
studied	O
in	O
23	O
adult	O
patients	O
undergoing	O
middle-ear	O
surgery	O
.	O

The	O
mean	O
arterial	O
pressure	O
was	O
decreased	O
from	O
86	O
+	O
/-	O
5	O
(	O
s.e	O
.	O
mean	O
)	O
mmHg	O
to	O
52	O
+	O
/-	O
1	O
mmHg	O
(	O
11.5	O
+	O
/-	O
0.7	O
to	O
6.9	O
+	O
/-	O
0.1	O
kPa	O
)	O
for	O
98	O
+	O
/-	O
10	O
min	O
in	O
the	O
halothane	B_Chemical
(	O
H	B_Chemical
)	O
group	O
,	O
from	O
79	O
+	O
/-	O
5	O
to	O
53	O
+	O
/-	O
1	O
mmHg	O
(	O
10.5	O
+	O
/-	O
0.7	O
to	O
7.1	O
+	O
/-	O
0.1	O
kPa	O
)	O
for	O
129	O
+	O
/-	O
11	O
min	O
in	O
the	O
enflurane	B_Chemical
(	O
E	B_Chemical
)	O
group	O
,	O
and	O
from	O
80	O
+	O
/-	O
4	O
to	O
49	O
+	O
/-	O
1	O
mmHg	O
(	O
10.7	O
+	O
/-	O
0.5	O
to	O
6.5	O
+	O
/-	O
0.1	O
kPa	O
)	O
for	O
135	O
+	O
/-	O
15	O
min	O
in	O
the	O
isoflurane	B_Chemical
(	O
I	B_Chemical
)	O
group	O
.	O

The	O
mean	O
H	B_Chemical
concentration	O
during	O
hypotension	B_Disease
in	O
the	O
inspiratory	O
gas	O
was	O
0.7	O
+	O
/-	O
0.1	O
vol%	O
,	O
the	O
mean	O
E	B_Chemical
concentration	O
1.6	O
+	O
/-	O
0.2	O
vol%	O
,	O
and	O
the	O
mean	O
I	B_Chemical
concentration	O
1.0	O
+	O
/-	O
0.1	O
vol%	O
.	O

In	O
addition	O
,	O
the	O
patients	O
received	O
fentanyl	B_Chemical
and	O
d-tubocurarine	B_Chemical
.	O

The	O
initial	O
dose	O
of	O
labetalol	B_Chemical
for	O
lowering	O
blood	O
pressure	O
was	O
similar	O
,	O
0.52	O
-	O
0.59	O
mg/kg	O
,	O
in	O
all	O
the	O
groups	O
.	O

During	O
hypotension	B_Disease
,	O
the	O
heart	O
rate	O
was	O
stable	O
without	O
tachy-	B_Disease
or	I_Disease
bradycardia	I_Disease
.	O

The	O
operating	O
conditions	O
regarding	O
bleeding	B_Disease
were	O
estimated	O
in	O
a	O
double-blind	O
manner	O
,	O
and	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
groups	O
.	O

During	O
hypotension	B_Disease
,	O
the	O
serum	O
creatinine	B_Chemical
concentration	O
rose	O
significantly	O
in	O
all	O
groups	O
from	O
the	O
values	O
before	O
hypotension	B_Disease
and	O
returned	O
postoperatively	O
to	O
the	O
initial	O
level	O
in	O
the	O
other	O
groups	O
,	O
except	O
the	O
isoflurane	B_Chemical
group	O
.	O

After	O
hypotension	B_Disease
there	O
was	O
no	O
rebound	O
phenomenon	O
in	O
either	O
blood	O
pressure	O
or	O
heart	O
rate	O
.	O

These	O
results	O
indicate	O
that	O
labetalol	B_Chemical
induces	O
easily	O
adjustable	O
hypotension	B_Disease
without	O
compensatory	O
tachycardia	B_Disease
and	O
rebound	O
hypertension	B_Disease
.	O

Convulsion	B_Disease
following	O
intravenous	O
fluorescein	B_Chemical
angiography	O
.	O

Tonic-clonic	B_Disease
seizures	I_Disease
followed	O
intravenous	O
fluorescein	B_Chemical
injection	O
for	O
fundus	O
angiography	O
in	O
a	O
47-year-old	O
male	O
.	O

Despite	O
precautions	O
this	O
adverse	O
reaction	O
recurred	O
on	O
re-exposure	O
to	O
intravenous	O
fluorescein	B_Chemical
.	O

Pharmacology	O
of	O
ACC-9653	B_Chemical
(	O
phenytoin	B_Chemical
prodrug).ACC-9653	O
,	O
the	O
disodium	B_Chemical
phosphate	I_Chemical
ester	I_Chemical
of	O
3-hydroxymethyl-5,5-diphenylhydantoin	B_Chemical
,	O
is	O
a	O
prodrug	O
of	O
phenytoin	B_Chemical
with	O
advantageous	O
physicochemical	O
properties	O
.	O

ACC-9653	B_Chemical
is	O
rapidly	O
converted	O
enzymatically	O
to	O
phenytoin	B_Chemical
in	O
vivo	O
.	O

ACC-9653	B_Chemical
and	O
phenytoin	B_Chemical
sodium	I_Chemical
have	O
equivalent	O
anticonvulsant	O
activity	O
against	O
seizures	B_Disease
induced	O
by	O
maximal	O
electroshock	O
(	O
MES	O
)	O
in	O
mice	O
following	O
i.p	O
.	O
,	O
oral	O
,	O
or	O
i.v	O
.	O
administration	O
.	O

The	O
ED50	O
doses	O
were	O
16	O
mg/kg	O
for	O
i.v	O
.	O

ACC-9653	B_Chemical
and	O
8	O
mg/kg	O
for	O
i.v	O
.	O

phenytoin	B_Chemical
sodium	I_Chemical
.	O

ACC-9653	B_Chemical
and	O
phenytoin	B_Chemical
sodium	I_Chemical
have	O
similar	O
antiarrhythmic	O
activity	O
against	O
ouabain-induced	O
ventricular	B_Disease
tachycardia	I_Disease
in	O
anesthetized	O
dogs	O
.	O

The	O
total	O
doses	O
of	O
ACC-9653	B_Chemical
or	O
phenytoin	B_Chemical
sodium	I_Chemical
necessary	O
to	O
convert	O
the	O
arrhythmia	B_Disease
to	O
a	O
normal	O
sinus	O
rhythm	O
were	O
24	O
+	O
/-	O
6	O
and	O
14	O
+	O
/-	O
3	O
mg/kg	O
,	O
respectively	O
.	O

Only	O
phenytoin	B_Chemical
sodium	I_Chemical
displayed	O
in	O
vitro	O
antiarrhythmic	O
activity	O
against	O
strophanthidin-induced	O
arrhythmias	B_Disease
in	O
guinea	O
pig	O
right	O
atria	O
.	O

In	O
anesthetized	O
dogs	O
,	O
a	O
high	O
dose	O
of	O
ACC-9653	B_Chemical
(	O
31	O
mg/kg	O
)	O
was	O
infused	O
over	O
15	O
,	O
20	O
,	O
and	O
30	O
min	O
and	O
the	O
responses	O
were	O
compared	O
to	O
an	O
equimolar	O
dose	O
of	O
phenytoin	B_Chemical
sodium	I_Chemical
(	O
21	O
mg/kg	O
)	O
.	O

The	O
ACC-9653	B_Chemical
and	O
phenytoin	B_Chemical
sodium	I_Chemical
treatments	O
produced	O
similar	O
marked	O
reductions	O
in	O
diastolic	O
blood	O
pressure	O
and	O
contractile	O
force	O
(	O
LVdP/dt	O
)	O
.	O

The	O
maximum	O
effects	O
of	O
each	O
treatment	O
occurred	O
at	O
the	O
time	O
of	O
maximum	O
phenytoin	B_Chemical
sodium	I_Chemical
levels	O
.	O

Acute	O
toxicity	B_Disease
studies	O
of	O
ACC-9653	B_Chemical
and	O
phenytoin	B_Chemical
sodium	I_Chemical
were	O
carried	O
out	O
in	O
mice	O
,	O
rats	O
,	O
rabbits	O
,	O
and	O
dogs	O
by	O
i.v	O
.	O
,	O
i.m	O
.	O
,	O
and	O
i.p	O
.	O

routes	O
of	O
administration	O
.	O

The	O
systemic	O
toxic	O
signs	O
of	O
both	O
agents	O
were	O
similar	O
and	O
occurred	O
at	O
approximately	O
equivalent	O
doses	O
.	O

Importantly	O
,	O
the	O
local	O
irritation	O
of	O
ACC-9653	B_Chemical
was	O
markedly	O
less	O
than	O
phenytoin	B_Chemical
sodium	I_Chemical
following	O
i.m	O
.	O

administration.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Tachyphylaxis	O
to	O
systemic	O
but	O
not	O
to	O
airway	O
responses	O
during	O
prolonged	O
therapy	O
with	O
high	O
dose	O
inhaled	O
salbutamol	B_Chemical
in	O
asthmatics	B_Disease
.	O

High	O
doses	O
of	O
inhaled	O
salbutamol	B_Chemical
produce	O
substantial	O
improvements	O
in	O
airway	O
response	O
in	O
patients	O
with	O
asthma	B_Disease
,	O
and	O
are	O
associated	O
with	O
dose-dependent	O
systemic	O
beta-adrenoceptor	O
responses	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
tachyphylaxis	O
occurs	O
during	O
prolonged	O
treatment	O
with	O
high	O
dose	O
inhaled	O
salbutamol	B_Chemical
.	O

Twelve	O
asthmatic	B_Disease
patients	O
(	O
FEV1	O
,	O
81	O
+	O
/-	O
4	O
%	O
predicted	O
)	O
,	O
requiring	O
only	O
occasional	O
inhaled	O
beta-agonists	O
as	O
their	O
sole	O
therapy	O
,	O
were	O
given	O
a	O
14-day	O
treatment	O
with	O
high	O
dose	O
inhaled	O
salbutamol	B_Chemical
(	O
HDS	O
)	O
,	O
4,000	O
micrograms	O
daily	O
,	O
low	O
dose	O
inhaled	O
salbutamol	B_Chemical
(	O
LDS	O
)	O
,	O
800	O
micrograms	O
daily	O
,	O
or	O
placebo	O
(	O
PI	O
)	O
by	O
metered-dose	O
inhaler	O
in	O
a	O
double-blind	O
,	O
randomized	O
crossover	O
design	O
.	O

During	O
the	O
14-day	O
run-in	O
and	O
during	O
washout	O
periods	O
,	O
inhaled	O
beta-agonists	O
were	O
withheld	O
and	O
ipratropium	B_Chemical
bromide	I_Chemical
was	O
substituted	O
for	O
rescue	O
purposes	O
.	O

At	O
the	O
end	O
of	O
each	O
14-day	O
treatment	O
,	O
a	O
dose-response	O
curve	O
(	O
DRC	O
)	O
was	O
performed	O
,	O
and	O
airway	O
(	O
FEV1	O
,	O
FEF25	O
-	O
75	O
)	O
chronotropic	O
(	O
HR	O
)	O
,	O
tremor	B_Disease
,	O
and	O
metabolic	O
(	O
K	B_Chemical
,	O
Glu	B_Chemical
)	O
responses	O
were	O
measured	O
at	O
each	O
step	O
(	O
from	O
100	O
to	O
4,000	O
micrograms	O
)	O
.	O

Treatment	O
had	O
no	O
significant	O
effect	O
on	O
baseline	O
values	O
.	O

There	O
were	O
dose-dependent	O
increases	O
in	O
FEV1	O
and	O
FEF25	O
-	O
75	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
and	O
pretreatment	O
with	O
HDS	O
did	O
not	O
displace	O
the	O
DRC	O
to	O
the	O
right	O
.	O

DRC	O
for	O
HR	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
K	B_Chemical
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
and	O
Glu	B_Chemical
(	O
p	O
less	O
than	O
0.005	O
)	O
were	O
attenuated	O
after	O
treatment	O
with	O
HDS	O
compared	O
with	O
PI	O
.	O

There	O
were	O
also	O
differences	O
between	O
HDS	O
and	O
LDS	O
for	O
HR	O
(	O
p	O
less	O
than	O
0.001	O
)	O
and	O
Glu	B_Chemical
(	O
p	O
less	O
than	O
0.05	O
)	O
responses	O
.	O

Frequency	O
and	O
severity	O
of	O
subjective	O
adverse	O
effects	O
were	O
also	O
reduced	O
after	O
HDS	O
:	O
tremor	B_Disease
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
palpitations	B_Disease
(	O
p	O
less	O
than	O
0.001).(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Phenytoin	B_Chemical
induced	O
fatal	O
hepatic	B_Disease
injury	I_Disease
.	O

A	O
61	O
year	O
old	O
female	O
developed	O
fatal	O
hepatic	B_Disease
failure	I_Disease
after	O
phenytoin	B_Chemical
administration	O
.	O

A	O
typical	O
multisystem	O
clinical	O
pattern	O
precedes	O
the	O
manifestations	O
of	O
hepatic	B_Disease
injury	I_Disease
.	O

The	O
hematologic	O
,	O
biochemical	O
and	O
pathologic	O
features	O
indicate	O
a	O
mixed	O
hepatocellular	B_Disease
damage	I_Disease
due	O
to	O
drug	B_Disease
hypersensitivity	I_Disease
.	O

In	O
a	O
patient	O
receiving	O
phenytoin	B_Chemical
who	O
presents	O
a	O
viral-like	O
illness	O
,	O
early	O
recognition	O
and	O
discontinuation	O
of	O
the	O
drug	O
are	O
mandatory	O
.	O

Treatment	O
of	O
lethal	O
pertussis	B_Chemical
vaccine	I_Chemical
reaction	O
with	O
histamine	B_Chemical
H1	O
antagonists	O
.	O

We	O
studied	O
mortality	O
after	O
pertussis	B_Disease
immunization	O
in	O
the	O
mouse	O
.	O

Without	O
treatment	O
,	O
73	O
of	O
92	O
animals	O
(	O
80	O
%	O
)	O
died	O
after	O
injection	O
of	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
on	O
day	O
+	O
7	O
of	O
pertussis	B_Disease
immunization	O
.	O

After	O
pretreatment	O
with	O
3	O
mg	O
of	O
cyproheptadine	B_Chemical
,	O
2	O
mg	O
mianserin	B_Chemical
,	O
or	O
2	O
mg	O
chlorpheniramine	B_Chemical
,	O
only	O
5	O
of	O
105	O
animals	O
(	O
5	O
%	O
)	O
died	O
after	O
receiving	O
BSA	O
on	O
day	O
+	O
7	O
(	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Blockade	O
of	O
histamine	B_Chemical
H1	O
receptors	O
may	O
reduce	O
mortality	O
in	O
pertussis	B_Disease
immunization-induced	O
encephalopathy	B_Disease
in	O
mice	O
.	O

Support	O
for	O
adrenaline-hypertension	O
hypothesis	O
:	O
18	O
hour	O
pressor	O
effect	O
after	O
6	O
hours	O
adrenaline	B_Chemical
infusion	O
.	O

In	O
a	O
double	O
blind	O
,	O
crossover	O
study	O
6	O
h	O
infusions	O
of	O
adrenaline	B_Chemical
(	O
15	O
ng/kg/min	O
;	O
1	O
ng	O
=	O
5.458	O
pmol	O
)	O
,	O
noradrenaline	B_Chemical
(	O
30	O
ng/kg/min	O
;	O
1	O
ng	O
=	O
5.911	O
pmol	O
)	O
,	O
and	O
a	O
5	O
%	O
dextrose	B_Chemical
solution	O
(	O
5.4	O
ml/h	O
)	O
,	O
were	O
given	O
to	O
ten	O
healthy	O
volunteers	O
in	O
random	O
order	O
2	O
weeks	O
apart	O
.	O

By	O
means	O
of	O
intra-arterial	O
ambulatory	O
monitoring	O
the	O
haemodynamic	O
effects	O
were	O
followed	O
for	O
18	O
h	O
after	O
the	O
infusions	O
were	O
stopped	O
.	O

Adrenaline	B_Chemical
,	O
but	O
not	O
noradrenaline	B_Chemical
,	O
caused	O
a	O
delayed	O
and	O
protracted	O
pressor	O
effect	O
.	O

Over	O
the	O
total	O
postinfusion	O
period	O
systolic	O
and	O
diastolic	O
arterial	O
pressure	O
were	O
6	O
(	O
SEM	O
2)%	O
and	O
7	O
(2)%	O
,	O
respectively	O
,	O
higher	O
than	O
after	O
dextrose	B_Chemical
infusion	O
(	O
ANOVA	O
,	O
p	O
less	O
than	O
0.001	O
)	O
.	O

Thus	O
,	O
"	O
stress	O
"	O
levels	O
of	O
adrenaline	B_Chemical
(	O
230	O
pg/ml	O
)	O
for	O
6	O
h	O
cause	O
a	O
delayed	O
and	O
protracted	O
pressor	O
effect	O
.	O

These	O
findings	O
are	O
strong	O
support	O
for	O
the	O
adrenaline-hypertension	O
hypothesis	O
in	O
man	O
.	O

Effect	O
of	O
alkylxanthines	B_Chemical
on	O
gentamicin-induced	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
in	O
the	O
rat	O
.	O

Adenosine	B_Chemical
antagonists	O
have	O
been	O
previously	O
shown	O
to	O
be	O
of	O
benefit	O
in	O
some	O
ischaemic	B_Disease
and	O
nephrotoxic	B_Disease
models	O
of	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
(	O
ARF	B_Disease
)	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
three	O
alkylxanthines	B_Chemical
with	O
different	O
potencies	O
as	O
adenosine	B_Chemical
antagonists	O
8-phenyltheophylline	B_Chemical
,	O
theophylline	B_Chemical
and	O
enprofylline	B_Chemical
,	O
were	O
examined	O
in	O
rats	O
developing	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
after	O
4	O
daily	O
injections	O
of	O
gentamicin	B_Chemical
(	O
200	O
mg	O
kg-1	O
)	O
.	O

Renal	O
function	O
was	O
assessed	O
by	O
biochemical	O
(	O
plasma	O
urea	B_Chemical
and	O
creatinine	B_Chemical
)	O
,	O
functional	O
(	O
urine	O
analysis	O
and	O
[3H]inulin	O
and	O
[14C]p-aminohippuric	O
acid	O
clearances	O
)	O
and	O
morphological	O
(	O
degree	O
of	O
necrosis	B_Disease
)	O
indices	O
.	O

The	O
various	O
drug	O
treatments	O
produced	O
improvements	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
measurements	O
of	O
renal	O
function	O
.	O

However	O
,	O
any	O
improvement	O
produced	O
by	O
drug	O
treatment	O
was	O
largely	O
a	O
result	O
of	O
a	O
beneficial	O
effect	O
exerted	O
by	O
its	O
vehicle	O
(	O
polyethylene	B_Chemical
glycol	I_Chemical
and	O
NaOH	B_Chemical
)	O
.	O

The	O
lack	O
of	O
any	O
consistent	O
protective	O
effect	O
noted	O
with	O
the	O
alkylxanthines	B_Chemical
tested	O
in	O
the	O
present	O
study	O
indicates	O
that	O
adenosine	B_Chemical
plays	O
little	O
,	O
if	O
any	O
,	O
pathophysiological	O
role	O
in	O
gentamicin-induced	O
ARF	B_Disease
.	O

Adverse	O
ocular	O
reactions	O
possibly	O
associated	O
with	O
isotretinoin	O
.	O

A	O
total	O
of	O
261	O
adverse	O
ocular	O
reactions	O
occurred	O
in	O
237	O
patients	O
who	O
received	O
isotretinoin	B_Chemical
,	O
a	O
commonly	O
used	O
drug	O
in	O
the	O
treatment	O
of	O
severe	O
cystic	O
acne	B_Disease
.	O

Blepharoconjunctivitis	B_Disease
,	O
subjective	O
complaints	O
of	O
dry	B_Disease
eyes	I_Disease
,	O
blurred	B_Disease
vision	I_Disease
,	O
contact	O
lens	O
intolerance	O
,	O
and	O
photodermatitis	B_Disease
are	O
reversible	O
side	O
effects	O
.	O

More	O
serious	O
ocular	O
adverse	O
reactions	O
include	O
papilledema	B_Disease
,	O
pseudotumor	B_Disease
cerebri	I_Disease
,	O
and	O
white	O
or	O
gray	O
subepithelial	O
corneal	B_Disease
opacities	I_Disease
;	O
all	O
of	O
these	O
are	O
reversible	O
if	O
the	O
drug	O
is	O
discontinued	O
.	O

Reported	O
cases	O
of	O
decreased	O
dark	O
adaptation	O
are	O
under	O
investigation	O
.	O

Isotretinoin	B_Chemical
is	O
contraindicated	O
in	O
pregnancy	O
because	O
of	O
the	O
many	O
reported	O
congenital	B_Disease
abnormalities	I_Disease
after	O
maternal	O
use	O
(	O
including	O
microphthalmos	B_Disease
,	O
orbital	O
hypertelorism	B_Disease
,	O
and	O
optic	B_Disease
nerve	I_Disease
hypoplasia	I_Disease
)	O
.	O

Procaterol	B_Chemical
and	O
terbutaline	B_Chemical
in	O
bronchial	B_Disease
asthma	I_Disease
.	O

A	O
double-blind	O
,	O
placebo-controlled	O
,	O
cross-over	O
study	O
.	O

Procaterol	B_Chemical
,	O
a	O
new	O
beta-2	O
adrenoceptor	O
stimulant	O
,	O
was	O
studied	O
in	O
a	O
double-blind	O
,	O
placebo-controlled	O
,	O
cross-over	O
trial	O
in	O
patients	O
with	O
bronchial	B_Disease
asthma	I_Disease
.	O

Oral	O
procaterol	B_Chemical
50	O
micrograms	O
b.d	O
.	O
,	O
procaterol	B_Chemical
100	O
micrograms	O
b.d	O
.	O
,	O
and	O
terbutaline	B_Chemical
5	O
mg	O
t.i.d	O
.	O
,	O
were	O
compared	O
when	O
given	O
randomly	O
in	O
1-week	O
treatment	O
periods	O
.	O

The	O
best	O
clinical	O
effect	O
was	O
found	O
with	O
terbutaline	B_Chemical
.	O

Both	O
anti-asthmatic	O
and	O
tremorgenic	B_Disease
effects	O
of	O
procaterol	B_Chemical
were	O
dose-related	O
.	O

Procaterol	B_Chemical
appeared	O
effective	O
in	O
the	O
doses	O
tested	O
,	O
and	O
a	O
twice	O
daily	O
regimen	O
would	O
appear	O
to	O
be	O
suitable	O
with	O
this	O
drug	O
.	O

Subacute	O
effects	O
of	O
propranolol	B_Chemical
and	O
B	O
24/76	O
on	O
isoproterenol-induced	O
rat	O
heart	B_Disease
hypertrophy	I_Disease
in	O
correlation	O
with	O
blood	O
pressure	O
.	O

We	O
compared	O
the	O
potential	O
beta-receptor	O
blocker	O
,	O
B	O
24/76	O
i.e.	O
1-(2,4-dichlorophenoxy)-3[2	O
-	O
3,4-dimethoxyphenyl)ethanolamino]-prop	O
an-2-ol	O
,	O
which	O
is	O
characterized	O
by	O
beta	O
1-adrenoceptor	O
blocking	O
and	O
beta	O
2-adrenoceptor	O
stimulating	O
properties	O
with	O
propranolol	B_Chemical
.	O

The	O
studies	O
were	O
performed	O
using	O
an	O
experimental	O
model	O
of	O
isoproterenol-induced	O
heart	B_Disease
hypertrophy	I_Disease
in	O
rats	O
.	O

A	O
correlation	O
of	O
the	O
blood	O
pressure	O
was	O
neither	O
found	O
in	O
the	O
development	O
nor	O
in	O
the	O
attempt	O
to	O
suppress	O
the	O
development	O
of	O
heart	B_Disease
hypertrophy	I_Disease
with	O
the	O
two	O
beta-receptor	O
blockers	O
.	O

Both	O
beta-blockers	O
influenced	O
the	O
development	O
of	O
hypertrophy	B_Disease
to	O
a	O
different	O
,	O
but	O
not	O
reproducible	O
extent	O
.	O

It	O
was	O
possible	O
to	O
suppress	O
the	O
increased	O
ornithine	B_Chemical
decarboxylase	O
activity	O
with	O
both	O
beta-blockers	O
in	O
hypertrophied	B_Disease
hearts	I_Disease
,	O
but	O
there	O
was	O
no	O
effect	O
on	O
the	O
heart	O
mass	O
.	O

Neither	O
propranolol	B_Chemical
nor	O
B	O
24/76	O
could	O
stop	O
the	O
changes	O
in	O
the	O
characteristic	O
myosin	O
isoenzyme	O
pattern	O
of	O
the	O
hypertrophied	B_Disease
rat	O
heart	O
.	O

Thus	O
,	O
the	O
investigations	O
did	O
not	O
provide	O
any	O
evidence	O
that	O
the	O
beta-receptor	O
blockers	O
propranolol	B_Chemical
and	O
B	O
24/76	O
have	O
the	O
potency	O
to	O
prevent	O
isoproterenol	B_Chemical
from	O
producing	O
heart	B_Disease
hypertrophy	I_Disease
.	O

Increased	O
anxiogenic	O
effects	O
of	O
caffeine	B_Chemical
in	O
panic	B_Disease
disorders	I_Disease
.	O

The	O
effects	O
of	O
oral	O
administration	O
of	O
caffeine	B_Chemical
(	O
10	O
mg/kg	O
)	O
on	O
behavioral	O
ratings	O
,	O
somatic	O
symptoms	O
,	O
blood	O
pressure	O
and	O
plasma	O
levels	O
of	O
3-methoxy-4-hydroxyphenethyleneglycol	B_Chemical
(	O
MHPG	B_Chemical
)	O
and	O
cortisol	B_Chemical
were	O
determined	O
in	O
17	O
healthy	O
subjects	O
and	O
21	O
patients	O
meeting	O
DSM-III	O
criteria	O
for	O
agoraphobia	B_Disease
with	O
panic	B_Disease
attacks	I_Disease
or	O
panic	B_Disease
disorder	I_Disease
.	O

Caffeine	B_Chemical
produced	O
significantly	O
greater	O
increases	O
in	O
subject-rated	O
anxiety	B_Disease
,	O
nervousness	O
,	O
fear	O
,	O
nausea	B_Disease
,	O
palpitations	B_Disease
,	O
restlessness	B_Disease
,	O
and	O
tremors	B_Disease
in	O
the	O
patients	O
compared	O
with	O
healthy	O
subjects	O
.	O

In	O
the	O
patients	O
,	O
but	O
not	O
the	O
healthy	O
subjects	O
,	O
these	O
symptoms	O
were	O
significantly	O
correlated	O
with	O
plasma	O
caffeine	B_Chemical
levels	O
.	O

Seventy-one	O
percent	O
of	O
the	O
patients	O
reported	O
that	O
the	O
behavioral	O
effects	O
of	O
caffeine	B_Chemical
were	O
similar	O
to	O
those	O
experienced	O
during	O
panic	B_Disease
attacks	I_Disease
.	O

Caffeine	B_Chemical
did	O
not	O
alter	O
plasma	O
MHPG	B_Chemical
levels	O
in	O
either	O
the	O
healthy	O
subjects	O
or	O
patients	O
.	O

Caffeine	B_Chemical
increased	O
plasma	O
cortisol	B_Chemical
levels	O
equally	O
in	O
the	O
patient	O
and	O
healthy	O
groups	O
.	O

Because	O
caffeine	B_Chemical
is	O
an	O
adenosine	B_Chemical
receptor	O
antagonist	O
,	O
these	O
results	O
suggest	O
that	O
some	O
panic	B_Disease
disorder	I_Disease
patients	O
may	O
have	O
abnormalities	B_Disease
in	I_Disease
neuronal	I_Disease
systems	I_Disease
involving	O
adenosine	B_Chemical
.	O

Patients	O
with	O
anxiety	B_Disease
disorders	I_Disease
may	O
benefit	O
by	O
avoiding	O
caffeine-containing	O
foods	O
and	O
beverages	O
.	O

Comparison	O
of	O
the	O
effect	O
of	O
oxitropium	B_Chemical
bromide	I_Chemical
and	O
of	O
slow-release	O
theophylline	B_Chemical
on	O
nocturnal	O
asthma	B_Disease
.	O

The	O
effects	O
of	O
a	O
new	O
inhaled	O
antimuscarinic	O
drug	O
,	O
oxitropium	B_Chemical
bromide	I_Chemical
,	O
and	O
of	O
a	O
slow-release	O
theophylline	B_Chemical
preparation	O
upon	O
nocturnal	O
asthma	B_Disease
were	O
compared	O
in	O
a	O
placebo-controlled	O
double-blind	O
study	O
.	O

Two	O
samples	O
were	O
studied	O
:	O
12	O
patients	O
received	O
oxitropium	B_Chemical
at	O
600	O
micrograms	O
(	O
6	O
subjects	O
)	O
or	O
at	O
400	O
micrograms	O
t.i.d	O
.	O
(	O
6	O
subjects	O
)	O
whereas	O
11	O
received	O
theophylline	B_Chemical
at	O
300	O
mg	O
b.i.d	O
.	O

Morning	O
dipping	O
,	O
assessed	O
by	O
the	O
fall	O
in	O
peak	O
flow	O
overnight	O
,	O
was	O
significantly	O
reduced	O
in	O
the	O
periods	O
when	O
either	O
active	O
drug	O
was	O
taken	O
,	O
whereas	O
no	O
difference	O
was	O
noticed	O
during	O
the	O
placebo	O
administration	O
.	O

No	O
significant	O
difference	O
was	O
noticed	O
between	O
results	O
obtained	O
with	O
either	O
active	O
drug	O
,	O
as	O
well	O
as	O
with	O
either	O
dosage	O
of	O
oxitropium	B_Chemical
.	O

No	O
subject	O
reported	O
side	O
effects	O
of	O
oxitropium	B_Chemical
,	O
as	O
compared	O
to	O
three	O
subjects	O
reporting	O
nausea	B_Disease
,	O
vomiting	B_Disease
and	O
tremors	B_Disease
after	O
theophylline	B_Chemical
.	O

Oxitropium	B_Chemical
proves	O
to	O
be	O
a	O
valuable	O
alternative	O
to	O
theophylline	B_Chemical
in	O
nocturnal	O
asthma	B_Disease
,	O
since	O
it	O
is	O
equally	O
potent	O
,	O
safer	O
and	O
does	O
not	O
require	O
the	O
titration	O
of	O
dosage	O
.	O

Penicillin	B_Chemical
anaphylaxis	B_Disease
.	O

A	O
case	O
of	O
oral	O
penicillin	B_Chemical
anaphylaxis	B_Disease
is	O
described	O
,	O
and	O
the	O
terminology	O
,	O
occurrence	O
,	O
clinical	O
manifestations	O
,	O
pathogenesis	O
,	O
prevention	O
,	O
and	O
treatment	O
of	O
anaphylaxis	B_Disease
are	O
reviewed	O
.	O

Emergency	O
physicians	O
should	O
be	O
aware	O
of	O
oral	O
penicillin	B_Chemical
anaphylaxis	B_Disease
in	O
order	O
to	O
prevent	O
its	O
occurrence	O
by	O
prescribing	O
the	O
antibiotic	O
judiciously	O
and	O
knowledgeably	O
and	O
to	O
offer	O
optimal	O
medical	O
therapy	O
once	O
this	O
life-threatening	O
reaction	O
has	O
begun	O
.	O

Reversible	O
valproic	O
acid-induced	O
dementia	B_Disease
:	O
a	O
case	O
report	O
.	O

Reversible	O
valproic	O
acid-induced	O
dementia	B_Disease
was	O
documented	O
in	O
a	O
21-year-old	O
man	O
with	O
epilepsy	B_Disease
who	O
had	O
a	O
3-year	O
history	O
of	O
insidious	O
progressive	O
decline	O
in	O
global	O
cognitive	O
abilities	O
documented	O
by	O
serial	O
neuropsychological	O
studies	O
.	O

Repeat	O
neuropsychological	O
testing	O
7	O
weeks	O
after	O
discontinuation	O
of	O
the	O
drug	O
revealed	O
dramatic	O
improvement	O
in	O
IQ	O
,	O
memory	O
,	O
naming	O
,	O
and	O
other	O
tasks	O
commensurate	O
with	O
clinical	O
recovery	O
in	O
his	O
intellectual	O
capacity	O
.	O

Possible	O
pathophysiological	O
mechanisms	O
which	O
may	O
have	O
been	O
operative	O
in	O
this	O
case	O
include	O
:	O
a	O
direct	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
toxic	O
effect	O
of	O
valproic	B_Chemical
acid	I_Chemical
;	O
a	O
paradoxical	O
epileptogenic	O
effect	O
secondary	O
to	O
the	O
drug	O
;	O
and	O
an	O
indirect	O
CNS	O
toxic	O
effect	O
mediated	O
through	O
valproic	O
acid-induced	O
hyperammonemia	B_Disease
.	O

Reversal	O
of	O
scopolamine-induced	O
amnesia	B_Disease
of	O
passive	O
avoidance	O
by	O
pre-	O
and	O
post-training	O
naloxone	B_Chemical
.	O

In	O
a	O
series	O
of	O
five	O
experiments	O
,	O
the	O
modulating	O
role	O
of	O
naloxone	B_Chemical
on	O
a	O
scopolamine-induced	O
retention	B_Disease
deficit	I_Disease
in	O
a	O
passive	O
avoidance	O
paradigm	O
was	O
investigated	O
in	O
mice	O
.	O

Scopolamine	B_Chemical
,	O
but	O
not	O
methyl	B_Chemical
scopolamine	I_Chemical
(	O
1	O
and	O
3	O
mg/kg	O
)	O
,	O
induced	O
an	O
amnesia	B_Disease
as	O
measured	O
by	O
latency	O
and	O
duration	O
parameters	O
.	O

Naloxone	B_Chemical
(	O
0.3	O
,	O
1	O
,	O
3	O
,	O
and	O
10	O
mg/kg	O
)	O
injected	O
prior	O
to	O
training	O
attenuated	O
the	O
retention	B_Disease
deficit	I_Disease
with	O
a	O
peak	O
of	O
activity	O
at	O
3	O
mg/kg	O
.	O

The	O
effect	O
of	O
naloxone	B_Chemical
could	O
be	O
antagonized	O
with	O
morphine	B_Chemical
(	O
1	O
,	O
3	O
,	O
and	O
10	O
mg/kg	O
)	O
,	O
demonstrating	O
the	O
opioid	O
specificity	O
of	O
the	O
naloxone	B_Chemical
effect	O
.	O

Post-training	O
administration	O
of	O
naloxone	B_Chemical
(	O
3	O
mg/kg	O
)	O
as	O
a	O
single	O
or	O
as	O
a	O
split	O
dose	O
also	O
attenuated	O
the	O
scopolamine-induced	O
amnesia	B_Disease
.	O

Control	O
experiments	O
indicated	O
that	O
neither	O
an	O
increase	O
in	O
pain	B_Disease
sensitivity	O
(	O
pre-training	O
naloxone	B_Chemical
)	O
nor	O
an	O
induced	O
aversive	O
state	O
(	O
post-training	O
naloxone	B_Chemical
)	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
influence	O
of	O
naloxone	B_Chemical
on	O
the	O
scopolamine-induced	O
retention	B_Disease
deficit	I_Disease
.	O

These	O
results	O
extend	O
previous	O
findings	O
implicating	O
a	O
cholinergic-opioid	O
interaction	O
in	O
memory	O
processes	O
.	O

A	O
possible	O
mechanism	O
for	O
this	O
interaction	O
involving	O
the	O
septo-hippocampal	O
cholinergic	O
pathway	O
is	O
discussed	O
.	O

Electron	O
microscopic	O
investigations	O
of	O
the	O
cyclophosphamide-induced	O
lesions	B_Disease
of	I_Disease
the	I_Disease
urinary	I_Disease
bladder	I_Disease
of	O
the	O
rat	O
and	O
their	O
prevention	O
by	O
mesna	B_Chemical
.	O

Fully	O
developed	O
cyclophosphamide-induced	O
cystitis	B_Disease
is	O
characterized	O
by	O
nearly	O
complete	O
detachment	O
of	O
the	O
urothelium	O
,	O
severe	O
submucosal	O
edema	B_Disease
owing	O
to	O
damage	O
to	O
the	O
microvascular	O
bed	O
and	O
focal	O
muscle	O
necroses	B_Disease
.	O

The	O
initial	O
response	O
to	O
the	O
primary	O
attack	O
by	O
the	O
cyclophosphamide	B_Chemical
metabolites	O
seems	O
to	O
be	O
fragmentation	O
of	O
the	O
luminal	B_Chemical
membrane	O
.	O

This	O
damages	O
the	O
cellular	O
barrier	O
against	O
the	O
hypertonic	O
urine	O
.	O

Subsequent	O
breaks	O
in	O
the	O
lateral	O
cell	O
membranes	O
of	O
the	O
superficial	O
cells	O
and	O
in	O
all	O
the	O
plasma	O
membranes	O
of	O
the	O
intermediate	O
and	O
basal	O
cells	O
,	O
intercellular	O
and	O
intracellular	O
edema	B_Disease
and	O
disintegration	O
of	O
the	O
desmosomes	O
and	O
hemidesmosomes	O
lead	O
to	O
progressive	O
degeneration	O
and	O
detachment	O
of	O
the	O
epithelial	O
cells	O
with	O
exposure	O
and	O
splitting	O
of	O
the	O
basal	O
membrane	O
.	O

The	O
morphological	O
changes	O
of	O
the	O
endothelial	O
cells	O
,	O
which	O
become	O
more	O
pronounced	O
in	O
the	O
later	O
stages	O
of	O
the	O
experiment	O
,	O
the	O
involvement	O
of	O
blood	O
vessels	O
regardless	O
of	O
their	O
diameter	O
and	O
the	O
location-dependent	O
extent	O
of	O
the	O
damage	O
indicate	O
a	O
direct	O
type	O
of	O
damage	O
which	O
is	O
preceded	O
by	O
a	O
mediator-induced	O
increase	O
in	O
permeability	O
,	O
the	O
morphological	O
correlate	O
of	O
which	O
is	O
the	O
formation	O
of	O
gaps	O
in	O
the	O
interendothelial	O
cell	O
connections	O
on	O
the	O
venules	O
.	O

These	O
changes	O
can	O
be	O
effectively	O
prevented	O
by	O
mesna	B_Chemical
.	O

The	O
only	O
sign	O
of	O
a	O
possible	O
involvement	O
is	O
the	O
increase	O
in	O
the	O
number	O
of	O
specific	O
granules	O
with	O
a	O
presumed	O
lysosomal	O
function	O
in	O
the	O
superficial	O
cells	O
.	O

Increase	O
in	O
intragastric	O
pressure	O
during	O
suxamethonium-induced	O
muscle	B_Disease
fasciculations	I_Disease
in	O
children	O
:	O
inhibition	O
by	O
alfentanil	B_Chemical
.	O

Changes	O
in	O
intragastric	O
pressure	O
after	O
the	O
administration	O
of	O
suxamethonium	B_Chemical
1.5	O
mg	O
kg-1	O
i.v	O
.	O
were	O
studied	O
in	O
32	O
children	O
(	O
mean	O
age	O
6.9	O
yr	O
)	O
pretreated	O
with	O
either	O
physiological	O
saline	O
or	O
alfentanil	B_Chemical
50	O
micrograms	O
kg-1	O
.	O

Anaesthesia	O
was	O
induced	O
with	O
thiopentone	B_Chemical
5	O
mg	O
kg-1	O
.	O

The	O
incidence	O
and	O
intensity	O
of	O
muscle	B_Disease
fasciculations	I_Disease
caused	O
by	O
suxamethonium	B_Chemical
were	O
significantly	O
greater	O
in	O
the	O
control	O
than	O
in	O
the	O
alfentanil	B_Chemical
group	O
.	O

The	O
intragastric	O
pressure	O
during	O
muscle	B_Disease
fasciculations	I_Disease
was	O
significantly	O
higher	O
in	O
the	O
control	O
group	O
(	O
16	O
+	O
/-	O
0.7	O
(	O
SEM	O
)	O
cm	O
H2O	B_Chemical
)	O
than	O
in	O
the	O
alfentanil	B_Chemical
group	O
(	O
7.7	O
+	O
/-	O
1.5	O
(	O
SEM	O
)	O
cm	O
H2O	B_Chemical
)	O
.	O

The	O
increase	O
in	O
intragastric	O
pressure	O
was	O
directly	O
related	O
to	O
the	O
intensity	O
of	O
muscle	B_Disease
fasciculations	I_Disease
(	O
regression	O
line	O
:	O
y	O
=	O
0.5	O
+	O
4.78x	O
with	O
r	O
of	O
0.78	O
)	O
.	O

It	O
is	O
concluded	O
that	O
intragastric	O
pressure	O
increases	O
significantly	O
during	O
muscle	B_Disease
fasciculations	I_Disease
caused	O
by	O
suxamethonium	B_Chemical
in	O
healthy	O
children	O
.	O

Alfentanil	B_Chemical
50	O
micrograms	O
kg-1	O
effectively	O
inhibits	O
the	O
incidence	O
and	O
intensity	O
of	O
suxamethonium-induced	O
muscle	B_Disease
fasciculations	I_Disease
;	O
moreover	O
,	O
intragastric	O
pressure	O
remains	O
at	O
its	O
control	O
value	O
.	O

Acute	O
insulin	O
treatment	O
normalizes	O
the	O
resistance	O
to	O
the	O
cardiotoxic	B_Disease
effect	O
of	O
isoproterenol	B_Chemical
in	O
streptozotocin	B_Chemical
diabetic	B_Disease
rats	O
.	O

A	O
morphometric	O
study	O
of	O
isoproterenol	B_Chemical
induced	O
myocardial	O
fibrosis	B_Disease
.	O

The	O
acute	O
effect	O
of	O
insulin	O
treatment	O
on	O
the	O
earlier	O
reported	O
protective	O
effect	O
of	O
streptozotocin	B_Chemical
diabetes	B_Disease
against	O
the	O
cardiotoxic	B_Disease
effect	O
of	O
high	O
doses	O
of	O
isoproterenol	B_Chemical
(	O
ISO	B_Chemical
)	O
was	O
investigated	O
in	O
rats	O
.	O

Thirty	O
to	O
135	O
min	O
after	O
the	O
injection	O
of	O
crystalline	O
insulin	O
,	O
ISO	B_Chemical
was	O
given	O
subcutaneously	O
and	O
when	O
ISO	B_Chemical
induced	O
fibrosis	B_Disease
in	O
the	O
myocardium	O
was	O
morphometrically	O
analyzed	O
7	O
days	O
later	O
,	O
a	O
highly	O
significant	O
correlation	O
(	O
r	O
=	O
0.83	O
,	O
2	O
p	O
=	O
0.006	O
)	O
to	O
the	O
slope	O
of	O
the	O
fall	O
in	O
blood	O
glucose	B_Chemical
after	O
insulin	O
treatment	O
appeared	O
.	O

The	O
myocardial	O
content	O
of	O
catecholamines	B_Chemical
was	O
estimated	O
in	O
these	O
8	O
day	O
diabetic	B_Disease
rats	O
.	O

The	O
norepinephrine	B_Chemical
content	O
was	O
significantly	O
increased	O
while	O
epinephrine	B_Chemical
remained	O
unchanged	O
.	O

An	O
enhanced	O
sympathetic	O
nervous	O
system	O
activity	O
with	O
a	O
consequent	O
down	O
regulation	O
of	O
the	O
myocardial	O
beta-adrenergic	O
receptors	O
could	O
,	O
therefore	O
,	O
explain	O
this	O
catecholamine	B_Chemical
resistance	O
.	O

The	O
rapid	O
reversion	O
after	O
insulin	O
treatment	O
excludes	O
the	O
possibility	O
that	O
streptozotocin	B_Chemical
in	O
itself	O
causes	O
the	O
ISO	B_Chemical
resistance	O
and	O
points	O
towards	O
a	O
direct	O
insulin	O
effect	O
on	O
myocardial	O
catecholamine	B_Chemical
sensitivity	O
in	O
diabetic	B_Disease
rats	O
.	O

The	O
phenomenon	O
described	O
might	O
elucidate	O
pathogenetic	O
mechanisms	O
behind	O
toxic	O
myocardial	O
cell	O
degeneration	O
and	O
may	O
possibly	O
have	O
relevance	O
for	O
acute	O
cardiovascular	O
complications	O
in	O
diabetic	B_Disease
patients	O
.	O

Differential	O
effects	O
of	O
non-steroidal	O
anti-inflammatory	O
drugs	O
on	O
seizures	B_Disease
produced	O
by	O
pilocarpine	B_Chemical
in	O
rats	O
.	O

The	O
muscarinic	O
cholinergic	O
agonist	O
pilocarpine	B_Chemical
induces	O
in	O
rats	O
seizures	B_Disease
and	O
status	B_Disease
epilepticus	I_Disease
followed	O
by	O
widespread	O
damage	O
to	O
the	O
forebrain	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effect	O
of	O
5	O
non-steroidal	O
anti-inflammatory	O
drugs	O
,	O
sodium	B_Chemical
salicylate	I_Chemical
,	O
phenylbutazone	B_Chemical
,	O
indomethacin	B_Chemical
,	O
ibuprofen	B_Chemical
and	O
mefenamic	B_Chemical
acid	I_Chemical
,	O
on	O
seizures	B_Disease
produced	O
by	O
pilocarpine	B_Chemical
.	O

Pretreatment	O
of	O
rats	O
with	O
sodium	B_Chemical
salicylate	I_Chemical
,	O
ED50	O
103	O
mg/kg	O
(	O
60	O
-	O
174	O
)	O
,	O
and	O
phenylbutazone	B_Chemical
,	O
59	O
mg/kg	O
(	O
50	O
-	O
70	O
)	O
converted	O
the	O
non-convulsant	O
dose	O
of	O
pilocarpine	B_Chemical
,	O
200	O
mg/kg	O
,	O
to	O
a	O
convulsant	O
one	O
.	O

Indomethacin	B_Chemical
,	O
1	O
-	O
10	O
mg/kg	O
,	O
and	O
ibuprofen	B_Chemical
,	O
10	O
-	O
100	O
mg/kg	O
,	O
failed	O
to	O
modulate	O
seizures	B_Disease
produced	O
by	O
pilocarpine	B_Chemical
.	O

Mefenamic	B_Chemical
acid	I_Chemical
,	O
26	O
(	O
22	O
-	O
30	O
)	O
mg/kg	O
,	O
prevented	O
seizures	B_Disease
and	O
protected	O
rats	O
from	O
seizure-related	O
brain	B_Disease
damage	I_Disease
induced	O
by	O
pilocarpine	B_Chemical
,	O
380	O
mg/kg	O
.	O

These	O
results	O
indicate	O
that	O
non-steroidal	O
anti-inflammatory	O
drugs	O
differentially	O
modulate	O
the	O
threshold	O
for	O
pilocarpine-induced	O
seizures	B_Disease
.	O

Acute	B_Disease
neurologic	I_Disease
dysfunction	I_Disease
after	O
high-dose	O
etoposide	B_Chemical
therapy	O
for	O
malignant	B_Disease
glioma	I_Disease
.	O

Etoposide	B_Chemical
(	O
VP-16	B_Chemical
-	I_Chemical
213	I_Chemical
)	O
has	O
been	O
used	O
in	O
the	O
treatment	O
of	O
many	O
solid	O
tumors	B_Disease
and	O
hematologic	B_Disease
malignancies	I_Disease
.	O

When	O
used	O
in	O
high	O
doses	O
and	O
in	O
conjunction	O
with	O
autologous	O
bone	O
marrow	O
transplantation	O
,	O
this	O
agent	O
has	O
activity	O
against	O
several	O
treatment-resistant	O
cancers	B_Disease
including	O
malignant	B_Disease
glioma	I_Disease
.	O

In	O
six	O
of	O
eight	O
patients	O
(	O
75	O
%	O
)	O
who	O
we	O
treated	O
for	O
recurrent	O
or	O
resistant	O
glioma	B_Disease
,	O
sudden	O
severe	O
neurologic	B_Disease
deterioration	I_Disease
occurred	O
.	O

This	O
developed	O
a	O
median	O
of	O
9	O
days	O
after	O
initiation	O
of	O
high-dose	O
etoposide	B_Chemical
therapy	O
.	O

Significant	O
clinical	O
manifestations	O
have	O
included	O
confusion	B_Disease
,	O
papilledema	B_Disease
,	O
somnolence	B_Disease
,	O
exacerbation	O
of	O
motor	B_Disease
deficits	I_Disease
,	O
and	O
sharp	O
increase	O
in	O
seizure	B_Disease
activity	O
.	O

These	O
abnormalities	O
resolved	O
rapidly	O
after	O
initiation	O
of	O
high-dose	O
intravenous	O
dexamethasone	B_Chemical
therapy	O
.	O

In	O
all	O
patients	O
,	O
computerized	O
tomographic	O
(	O
CT	O
)	O
brain	O
scans	O
demonstrated	O
stability	O
in	O
tumor	B_Disease
size	O
and	O
peritumor	O
edema	B_Disease
when	O
compared	O
with	O
pretransplant	O
scans	O
.	O

This	O
complication	O
appears	O
to	O
represent	O
a	O
significant	O
new	O
toxicity	B_Disease
of	O
high-dose	O
etoposide	B_Chemical
therapy	O
for	O
malignant	B_Disease
glioma	I_Disease
.	O

Progressive	O
bile	B_Disease
duct	I_Disease
injury	I_Disease
after	O
thiabendazole	B_Chemical
administration	O
.	O

A	O
27-yr-old	O
man	O
developed	O
jaundice	B_Disease
2	O
wk	O
after	O
exposure	O
to	O
thiabendazole	B_Chemical
.	O

Cholestasis	B_Disease
persisted	O
for	O
3	O
yr	O
,	O
at	O
which	O
time	O
a	O
liver	O
transplant	O
was	O
performed	O
.	O

Two	O
liver	O
biopsy	O
specimens	O
and	O
the	O
hepatectomy	O
specimen	O
were	O
remarkable	O
for	O
almost	O
complete	O
disappearance	O
of	O
interlobular	O
bile	O
ducts	O
.	O

Prominent	O
fibrosis	B_Disease
and	O
hepatocellular	O
regeneration	O
were	O
also	O
present	O
;	O
however	O
,	O
the	O
lobular	O
architecture	O
was	O
preserved	O
.	O

This	O
case	O
represents	O
an	O
example	O
of	O
"	O
idiosyncratic	O
"	O
drug-induced	B_Disease
liver	I_Disease
damage	I_Disease
in	O
which	O
the	O
primary	O
target	O
of	O
injury	O
is	O
the	O
bile	O
duct	O
.	O

An	O
autoimmune	O
pathogenesis	O
of	O
the	O
bile	B_Disease
duct	I_Disease
destruction	I_Disease
is	O
suggested	O
.	O

Differential	O
effects	O
of	O
1,4-dihydropyridine	B_Chemical
calcium	B_Chemical
channel	I_Chemical
blockers	I_Chemical
:	O
therapeutic	O
implications	O
.	O

Increasing	O
recognition	O
of	O
the	O
importance	O
of	O
calcium	B_Chemical
in	O
the	O
pathogenesis	O
of	O
cardiovascular	B_Disease
disease	I_Disease
has	O
stimulated	O
research	O
into	O
the	O
use	O
of	O
calcium	B_Chemical
channel	I_Chemical
blocking	I_Chemical
agents	I_Chemical
for	O
treatment	O
of	O
a	O
variety	O
of	O
cardiovascular	B_Disease
diseases	I_Disease
.	O

The	O
favorable	O
efficacy	O
and	O
tolerability	O
profiles	O
of	O
these	O
agents	O
make	O
them	O
attractive	O
therapeutic	O
modalities	O
.	O

Clinical	O
applications	O
of	O
calcium	B_Chemical
channel	I_Chemical
blockers	I_Chemical
parallel	O
their	O
tissue	O
selectivity	O
.	O

In	O
contrast	O
to	O
verapamil	B_Chemical
and	O
diltiazem	B_Chemical
,	O
which	O
are	O
roughly	O
equipotent	O
in	O
their	O
actions	O
on	O
the	O
heart	O
and	O
vascular	O
smooth	O
muscle	O
,	O
the	O
dihydropyridine	B_Chemical
calcium	B_Chemical
channel	I_Chemical
blockers	I_Chemical
are	O
a	O
group	O
of	O
potent	O
peripheral	O
vasodilator	O
agents	O
that	O
exert	O
minimal	O
electrophysiologic	O
effects	O
on	O
cardiac	O
nodal	O
or	O
conduction	O
tissue	O
.	O

As	O
the	O
first	O
dihydropyridine	B_Chemical
available	O
for	O
use	O
in	O
the	O
United	O
States	O
,	O
nifedipine	B_Chemical
controls	O
angina	B_Disease
and	O
hypertension	B_Disease
with	O
minimal	O
depression	O
of	O
cardiac	O
function	O
.	O

Additional	O
members	O
of	O
this	O
group	O
of	O
calcium	B_Chemical
channel	I_Chemical
blockers	I_Chemical
have	O
been	O
studied	O
for	O
a	O
variety	O
of	O
indications	O
for	O
which	O
they	O
may	O
offer	O
advantages	O
over	O
current	O
therapy	O
.	O

Once	O
or	O
twice	O
daily	O
dosage	O
possible	O
with	O
nitrendipine	B_Chemical
and	O
nisoldipine	B_Chemical
offers	O
a	O
convenient	O
administration	O
schedule	O
,	O
which	O
encourages	O
patient	O
compliance	O
in	O
long-term	O
therapy	O
of	O
hypertension	B_Disease
.	O

The	O
coronary	O
vasodilating	O
properties	O
of	O
nisoldipine	B_Chemical
have	O
led	O
to	O
the	O
investigation	O
of	O
this	O
agent	O
for	O
use	O
in	O
angina	B_Disease
.	O

Selectivity	O
for	O
the	O
cerebrovascular	O
bed	O
makes	O
nimodipine	B_Chemical
potentially	O
useful	O
in	O
the	O
treatment	O
of	O
subarachnoid	B_Disease
hemorrhage	I_Disease
,	O
migraine	B_Disease
headache	I_Disease
,	O
dementia	B_Disease
,	O
and	O
stroke	B_Disease
.	O

In	O
general	O
,	O
the	O
dihydropyridine	B_Chemical
calcium	B_Chemical
channel	I_Chemical
blockers	I_Chemical
are	O
usually	O
well	O
tolerated	O
,	O
with	O
headache	B_Disease
,	O
facial	O
flushing	B_Disease
,	O
palpitations	B_Disease
,	O
edema	B_Disease
,	O
nausea	B_Disease
,	O
anorexia	B_Disease
,	O
and	O
dizziness	B_Disease
being	O
the	O
more	O
common	O
adverse	O
effects	O
.	O

The	O
enhancement	O
of	O
aminonucleoside	B_Chemical
nephrosis	B_Disease
by	O
the	O
co-administration	O
of	O
protamine	O
.	O

An	O
experimental	O
model	O
of	O
focal	B_Disease
segmental	I_Disease
glomerular	I_Disease
sclerosis	I_Disease
(	O
FSGS	B_Disease
)	O
was	O
developed	O
in	O
rats	O
by	O
the	O
combined	O
administration	O
of	O
puromycin-aminonucleoside	B_Chemical
(	O
AMNS	B_Chemical
)	O
and	O
protamine	B_Chemical
sulfate	I_Chemical
(	O
PS	B_Chemical
)	O
.	O

Male	O
Sprague-Dawley	O
rats	O
,	O
uninephrectomized	O
three	O
weeks	O
before	O
,	O
received	O
daily	O
injections	O
of	O
subcutaneous	O
AMNS	B_Chemical
(	O
1	O
mg/100	O
g	O
body	O
wt	O
)	O
and	O
intravenous	O
PS	B_Chemical
(	O
2	O
separated	O
doses	O
of	O
2.5	O
mg/100	O
g	O
body	O
wt	O
)	O
for	O
four	O
days	O
.	O

The	O
series	O
of	O
injections	O
were	O
repeated	O
another	O
three	O
times	O
at	O
10	O
day	O
intervals	O
.	O

The	O
animals	O
were	O
sacrificed	O
on	O
days	O
24	O
,	O
52	O
,	O
and	O
80	O
.	O

They	O
developed	O
nephrotic	B_Disease
syndrome	I_Disease
and	O
finally	O
renal	B_Disease
failure	I_Disease
.	O

The	O
time-course	O
curve	O
of	O
creatinine	B_Chemical
clearance	O
dropped	O
and	O
showed	O
significant	O
difference	O
(	O
P	O
less	O
than	O
0.01	O
)	O
from	O
that	O
of	O
each	O
control	O
group	O
,	O
such	O
as	O
,	O
AMNS	B_Chemical
alone	O
,	O
PS	B_Chemical
alone	O
or	O
saline	O
injected	O
.	O

Their	O
glomeruli	O
showed	O
changes	O
of	O
progressive	O
FSGS	B_Disease
.	O

The	O
ultrastructural	O
studies	O
in	O
the	O
initial	O
stage	O
revealed	O
significant	O
lack	O
of	O
particles	O
of	O
perfused	O
ruthenium	B_Chemical
red	O
on	O
the	O
lamina	O
rara	O
externa	O
and	O
marked	O
changes	O
in	O
epithelial	O
cell	O
cytoplasm	O
.	O

Therefore	O
,	O
it	O
is	O
suggested	O
that	O
the	O
administration	O
of	O
PS	B_Chemical
enhances	O
the	O
toxicity	B_Disease
of	O
AMNS	B_Chemical
on	O
the	O
glomerulus	O
and	O
readily	O
produces	O
progressive	O
FSGS	B_Disease
in	O
rats	O
resulting	O
in	O
the	O
end-stage	B_Disease
renal	I_Disease
disease	I_Disease
.	O

Theophylline	B_Chemical
neurotoxicity	B_Disease
in	O
pregnant	O
rats	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
determine	O
whether	O
the	O
neurotoxicity	B_Disease
of	O
theophylline	B_Chemical
is	O
altered	O
in	O
advanced	O
pregnancy	O
.	O

Sprague-Dawley	O
rats	O
that	O
were	O
20	O
days	O
pregnant	O
and	O
nonpregnant	O
rats	O
of	O
the	O
same	O
age	O
and	O
strain	O
received	O
infusions	O
of	O
aminophylline	B_Chemical
until	O
onset	O
of	O
maximal	O
seizures	B_Disease
which	O
occurred	O
after	O
28	O
and	O
30	O
minutes	O
respectively	O
.	O

Theophylline	B_Chemical
concentrations	O
at	O
this	O
endpoint	O
in	O
serum	O
(	O
total	O
)	O
and	O
CSF	O
were	O
similar	O
but	O
serum	O
(	O
free	O
)	O
and	O
brain	O
concentrations	O
were	O
slightly	O
different	O
in	O
pregnant	O
rats	O
.	O

Theophylline	B_Chemical
serum	O
protein	O
binding	O
determined	O
by	O
equilibrium	O
dialysis	O
was	O
lower	O
in	O
pregnant	O
rats	O
.	O

Fetal	O
serum	O
concentrations	O
at	O
onset	O
of	O
seizures	B_Disease
in	O
the	O
mother	O
were	O
similar	O
to	O
maternal	O
brain	O
and	O
CSF	O
concentrations	O
and	O
correlated	O
significantly	O
with	O
the	O
former	O
.	O

It	O
is	O
concluded	O
that	O
advanced	O
pregnancy	O
has	O
a	O
negligible	O
effect	O
on	O
the	O
neurotoxic	B_Disease
response	O
to	O
theophylline	B_Chemical
in	O
rats	O
.	O

Hyperkalemia	B_Disease
induced	O
by	O
indomethacin	B_Chemical
and	O
naproxen	B_Chemical
and	O
reversed	O
by	O
fludrocortisone	B_Chemical
.	O

We	O
have	O
described	O
a	O
patient	O
with	O
severe	O
rheumatoid	B_Disease
arthritis	I_Disease
and	O
a	O
history	O
of	O
mefenamic	B_Chemical
acid	I_Chemical
nephropathy	B_Disease
in	O
whom	O
hyperkalemia	B_Disease
and	O
inappropriate	O
hypoaldosteronism	B_Disease
were	O
caused	O
by	O
both	O
indomethacin	B_Chemical
and	O
naproxen	B_Chemical
,	O
without	O
major	O
decline	O
in	O
renal	O
function	O
.	O

It	O
is	O
likely	O
that	O
preexisting	O
renal	B_Disease
disease	I_Disease
predisposed	O
this	O
patient	O
to	O
type	B_Disease
IV	I_Disease
renal	I_Disease
tubular	I_Disease
acidosis	I_Disease
with	O
prostaglandin	B_Chemical
synthetase	O
inhibitors	O
.	O

Because	O
he	O
was	O
unable	O
to	O
discontinue	O
nonsteroidal	O
anti-inflammatory	O
drug	O
therapy	O
,	O
fludrocortisone	B_Chemical
was	O
added	O
,	O
correcting	O
the	O
hyperkalemia	B_Disease
and	O
allowing	O
indomethacin	B_Chemical
therapy	O
to	O
be	O
continued	O
safely	O
.	O

Hypotension	B_Disease
as	O
a	O
manifestation	O
of	O
cardiotoxicity	B_Disease
in	O
three	O
patients	O
receiving	O
cisplatin	B_Chemical
and	O
5-fluorouracil	B_Chemical
.	O

Cardiac	O
symptoms	O
,	O
including	O
hypotension	B_Disease
,	O
developed	O
in	O
three	O
patients	O
with	O
advanced	O
colorectal	B_Disease
carcinoma	I_Disease
while	O
being	O
treated	O
with	O
cisplatin	B_Chemical
(	O
CDDP	B_Chemical
)	O
and	O
5-fluorouracil	B_Chemical
(	O
5-FU	B_Chemical
)	O
.	O

In	O
two	O
patients	O
,	O
hypotension	B_Disease
was	O
associated	O
with	O
severe	O
left	B_Disease
ventricular	I_Disease
dysfunction	I_Disease
.	O

All	O
three	O
patients	O
required	O
therapy	O
discontinuation	O
.	O

Cardiac	O
enzymes	O
remained	O
normal	O
despite	O
transient	O
electrocardiographic	O
(	O
EKG	O
)	O
changes	O
.	O

The	O
presentation	O
and	O
cardiac	O
evaluation	O
(	O
hemodynamic	O
,	O
echocardiographic	O
,	O
and	O
scintigraphic	O
)	O
of	O
these	O
patients	O
suggest	O
new	O
manifestations	O
of	O
5-FU	B_Chemical
cardiotoxicity	B_Disease
that	O
may	O
be	O
influenced	O
by	O
CDDP	B_Chemical
.	O

The	O
possible	O
pathophysiologic	O
mechanisms	O
are	O
discussed	O
.	O

Fatal	O
aplastic	B_Disease
anemia	I_Disease
in	O
a	O
patient	O
treated	O
with	O
carbamazepine	B_Chemical
.	O

A	O
case	O
of	O
fatal	O
aplastic	B_Disease
anemia	I_Disease
due	O
to	O
carbamazepine	B_Chemical
treatment	O
in	O
an	O
epileptic	B_Disease
woman	O
is	O
reported	O
.	O

Despite	O
concerns	O
of	O
fatal	O
bone	B_Disease
marrow	I_Disease
toxicity	I_Disease
due	O
to	O
carbamazepine	B_Chemical
,	O
this	O
is	O
only	O
the	O
fourth	O
documented	O
and	O
published	O
report	O
.	O

Carbamazepine	B_Chemical
is	O
a	O
safe	O
drug	O
,	O
but	O
physicians	O
and	O
patients	O
should	O
be	O
aware	O
of	O
the	O
exceedingly	O
rare	O
but	O
potentially	O
fatal	O
side	O
effects	O
,	O
better	O
prevented	O
by	O
clinical	O
than	O
by	O
laboratory	O
monitoring	O
.	O

Participation	O
of	O
a	O
bulbospinal	O
serotonergic	O
pathway	O
in	O
the	O
rat	O
brain	O
in	O
clonidine-induced	O
hypotension	B_Disease
and	O
bradycardia	B_Disease
.	O

The	O
effects	O
of	O
microinjection	O
of	O
clonidine	B_Chemical
(	O
1	O
-	O
10	O
micrograms	O
in	O
1	O
microliter	O
)	O
into	O
a	O
region	O
adjacent	O
to	O
the	O
ventrolateral	O
surface	O
of	O
the	O
medulla	O
oblongata	O
on	O
cardiovascular	O
function	O
were	O
assessed	O
in	O
urethane-anesthetized	O
rats	O
.	O

Intramedullary	O
administration	O
of	O
clonidine	B_Chemical
,	O
but	O
not	O
saline	O
vehicle	O
,	O
caused	O
a	O
dose-dependent	O
decrease	O
in	O
both	O
the	O
mean	O
arterial	O
pressure	O
and	O
the	O
heart	O
rate	O
.	O

The	O
clonidine-induced	O
hypotension	B_Disease
was	O
antagonized	O
by	O
prior	O
spinal	O
transection	O
,	O
but	O
not	O
bilateral	O
vagotomy	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
clonidine-induced	O
bradycardia	B_Disease
was	O
antagonized	O
by	O
prior	O
bilateral	O
vagotomy	O
,	O
but	O
not	O
spinal	O
transection	O
.	O

Furthermore	O
,	O
selective	O
destruction	O
of	O
the	O
spinal	O
5-HT	B_Chemical
nerves	O
,	O
produced	O
by	O
bilateral	O
spinal	O
injection	O
of	O
5,7-dihydroxytryptamine	B_Chemical
,	O
reduced	O
the	O
magnitude	O
of	O
the	O
vasodepressor	O
or	O
the	O
bradycardiac	B_Disease
responses	O
to	O
clonidine	B_Chemical
microinjected	O
into	O
the	O
area	O
near	O
the	O
ventrolateral	O
surface	O
of	O
the	O
medulla	O
oblongata	O
in	O
rats	O
.	O

The	O
data	O
indicate	O
that	O
a	O
bulbospinal	O
serotonergic	O
pathway	O
is	O
involved	O
in	O
development	O
of	O
clonidine-induced	O
hypotension	B_Disease
and	O
bradycardia	B_Disease
.	O

The	O
induced	O
hypotension	B_Disease
is	O
brought	O
about	O
by	O
a	O
decrease	O
in	O
sympathetic	O
efferent	O
activity	O
,	O
whereas	O
the	O
induced	O
bradycardia	B_Disease
was	O
due	O
to	O
an	O
increase	O
in	O
vagal	O
efferent	O
activity	O
.	O

Hypertension	B_Disease
in	O
neuroblastoma	B_Disease
induced	O
by	O
imipramine	B_Chemical
.	O

Hypertension	B_Disease
is	O
a	O
well-known	O
finding	O
in	O
some	O
patients	O
with	O
neuroblastoma	B_Disease
.	O

However	O
,	O
it	O
has	O
not	O
previously	O
been	O
described	O
in	O
association	O
with	O
the	O
use	O
of	O
Imipramine	B_Chemical
.	O

We	O
report	O
the	O
occurrence	O
of	O
severe	O
hypertension	B_Disease
(	O
blood	O
pressure	O
190/160	O
)	O
in	O
a	O
4-year-old	O
girl	O
with	O
neuroblastoma	B_Disease
who	O
was	O
given	O
Imipramine	B_Chemical
to	O
control	O
a	O
behavior	B_Disease
disorder	I_Disease
.	O

It	O
was	O
determined	O
later	O
that	O
this	O
patient	O
's	O
tumor	B_Disease
was	O
recurring	O
at	O
the	O
time	O
of	O
her	O
hypertensive	B_Disease
episode	O
.	O

Since	O
she	O
had	O
no	O
blood	O
pressure	O
elevation	O
at	O
initial	O
diagnosis	O
and	O
none	O
following	O
discontinuation	O
of	O
the	O
Imipramine	B_Chemical
(	O
when	O
she	O
was	O
in	O
florid	O
relapse	O
)	O
,	O
we	O
believe	O
that	O
this	O
drug	O
rather	O
than	O
her	O
underlying	O
disease	O
alone	O
caused	O
her	O
hypertension	B_Disease
.	O

The	O
mechanism	O
for	O
this	O
reaction	O
is	O
believed	O
to	O
be	O
increased	O
levels	O
of	O
vasoactive	O
catecholamines	B_Chemical
due	O
to	O
interference	O
of	O
their	O
physiologic	O
inactivation	O
by	O
Imipramine	B_Chemical
.	O

From	O
this	O
experience	O
,	O
we	O
urge	O
extreme	O
caution	O
in	O
the	O
use	O
of	O
tricyclic	O
antidepressants	O
in	O
children	O
with	O
active	O
neuroblastoma	B_Disease
.	O

Rechallenge	O
of	O
patients	O
who	O
developed	O
oral	B_Disease
candidiasis	I_Disease
or	O
hoarseness	B_Disease
with	O
beclomethasone	B_Chemical
dipropionate	I_Chemical
.	O

Of	O
158	O
asthmatic	B_Disease
patients	O
who	O
were	O
placed	O
on	O
inhaled	O
beclomethasone	B_Chemical
,	O
15	O
(	O
9.5	O
%	O
)	O
developed	O
either	O
hoarseness	B_Disease
(	O
8)	O
,	O
oral	O
thrush	B_Disease
(	O
6	O
)	O
,	O
or	O
both	O
(	O
1	O
)	O
.	O

When	O
their	O
adverse	O
reactions	O
subsided	O
,	O
seven	O
of	O
these	O
15	O
patients	O
were	O
rechallenged	O
with	O
inhaled	O
beclomethasone	B_Chemical
.	O

These	O
included	O
five	O
cases	O
who	O
developed	O
hoarseness	B_Disease
and	O
three	O
who	O
developed	O
Candidiasis	B_Disease
.	O

One	O
patient	O
had	O
both	O
.	O

Oral	O
thrush	B_Disease
did	O
not	O
recur	O
,	O
but	O
60	O
%	O
(	O
3/5	O
)	O
of	O
patients	O
with	O
hoarseness	B_Disease
had	O
recurrence	O
.	O

We	O
conclude	O
that	O
patients	O
may	O
be	O
restarted	O
on	O
inhaled	O
beclomethasone	B_Chemical
when	O
clinically	O
indicated	O
;	O
however	O
,	O
because	O
of	O
the	O
high	O
recurrence	O
rate	O
,	O
patients	O
who	O
develop	O
hoarseness	B_Disease
should	O
not	O
be	O
re-challenged	O
.	O

Concomitant	O
use	O
of	O
oral	O
prednisone	B_Chemical
and	O
topical	O
beclomethasone	B_Chemical
may	O
increase	O
the	O
risk	O
of	O
developing	O
hoarseness	B_Disease
or	O
candidiasis	B_Disease
.	O

Cyclophosphamide	B_Chemical
cardiotoxicity	B_Disease
:	O
an	O
analysis	O
of	O
dosing	O
as	O
a	O
risk	O
factor	O
.	O

Patients	O
who	O
undergo	O
bone	O
marrow	O
transplantation	O
are	O
generally	O
immunosuppressed	O
with	O
a	O
dose	O
of	O
cyclophosphamide	B_Chemical
(	O
CYA	B_Chemical
)	O
which	O
is	O
usually	O
calculated	O
based	O
on	O
the	O
patient	O
's	O
weight	O
.	O

At	O
these	O
high	O
doses	O
of	O
CYA	B_Chemical
,	O
serious	O
cardiotoxicity	B_Disease
may	O
occur	O
,	O
but	O
definitive	O
risk	O
factors	O
for	O
the	O
development	O
of	O
such	O
cardiotoxicity	B_Disease
have	O
not	O
been	O
described	O
.	O

Since	O
chemotherapeutic	O
agent	O
toxicity	B_Disease
generally	O
correlates	O
with	O
dose	O
per	O
body	O
surface	O
area	O
,	O
we	O
retrospectively	O
calculated	O
the	O
dose	O
of	O
CYA	B_Chemical
in	O
patients	O
transplanted	O
at	O
our	O
institution	O
to	O
determine	O
whether	O
the	O
incidence	O
of	O
CYA	B_Chemical
cardiotoxicity	B_Disease
correlated	O
with	O
the	O
dose	O
per	O
body	O
surface	O
area	O
.	O

Eighty	O
patients	O
who	O
were	O
to	O
receive	O
CYA	B_Chemical
50	O
mg/kg/d	O
for	O
four	O
days	O
as	O
preparation	O
for	O
marrow	O
grafting	O
underwent	O
a	O
total	O
of	O
84	O
transplants	O
for	O
aplastic	B_Disease
anemia	I_Disease
,	O
Wiskott-Aldrich	B_Disease
syndrome	I_Disease
,	O
or	O
severe	B_Disease
combined	I_Disease
immunodeficiency	I_Disease
syndrome	I_Disease
.	O

Fourteen	O
of	O
84	O
(	O
17	O
%	O
)	O
patients	O
had	O
symptoms	O
and	O
signs	O
consistent	O
with	O
CYA	B_Chemical
cardiotoxicity	B_Disease
within	O
ten	O
days	O
of	O
receiving	O
1	O
to	O
4	O
doses	O
of	O
CYA	B_Chemical
.	O

Six	O
of	O
the	O
14	O
patients	O
died	O
with	O
congestive	B_Disease
heart	I_Disease
failure	I_Disease
.	O

The	O
dose	O
of	O
CYA	B_Chemical
per	O
body	O
surface	O
area	O
was	O
calculated	O
for	O
all	O
patients	O
and	O
the	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
based	O
on	O
daily	O
CYA	B_Chemical
dose	O
:	O
Group	O
1	O
,	O
CYA	B_Chemical
less	O
than	O
or	O
equal	O
to	O
1.55	O
g/m2/d	O
;	O
Group	O
2	O
,	O
CYA	B_Chemical
greater	O
than	O
1.55	O
g/m2/d	O
.	O

Cardiotoxicity	B_Disease
that	O
was	O
thought	O
to	O
be	O
related	O
to	O
CYA	B_Chemical
occurred	O
in	O
1/32	O
(	O
3	O
%	O
)	O
of	O
patients	O
in	O
Group	O
1	O
and	O
in	O
13/52	O
(	O
25	O
%	O
)	O
patients	O
in	O
Group	O
2	O
(	O
P	O
less	O
than	O
0.025	O
)	O
.	O

Congestive	B_Disease
heart	I_Disease
failure	I_Disease
caused	O
or	O
contributed	O
to	O
death	O
in	O
0/32	O
patients	O
in	O
Group	O
1	O
v	O
6/52	O
(	O
12	O
%	O
)	O
of	O
patients	O
in	O
Group	O
2	O
(	O
P	O
less	O
than	O
0.25	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
rate	O
of	O
engraftment	O
of	O
evaluable	O
patients	O
in	O
the	O
two	O
groups	O
(	O
P	O
greater	O
than	O
0.5	O
)	O
.	O

We	O
conclude	O
that	O
the	O
CYA	B_Chemical
cardiotoxicity	B_Disease
correlates	O
with	O
CYA	B_Chemical
dosage	O
as	O
calculated	O
by	O
body	O
surface	O
area	O
,	O
and	O
that	O
patients	O
with	O
aplastic	B_Disease
anemia	I_Disease
and	O
immunodeficiencies	B_Disease
can	O
be	O
effectively	O
prepared	O
for	O
bone	O
marrow	O
grafting	O
at	O
a	O
CYA	B_Chemical
dose	O
of	O
1.55	O
g/m2/d	O
for	O
four	O
days	O
with	O
a	O
lower	O
incidence	O
of	O
cardiotoxicity	B_Disease
than	O
patients	O
whose	O
CYA	B_Chemical
dosage	O
is	O
calculated	O
based	O
on	O
weight	O
.	O

This	O
study	O
reaffirms	O
the	O
principle	O
that	O
drug	O
toxicity	B_Disease
correlates	O
with	O
dose	O
per	O
body	O
surface	O
area	O
.	O

Studies	O
of	O
risk	O
factors	O
for	O
aminoglycoside	B_Chemical
nephrotoxicity	B_Disease
.	O

The	O
epidemiology	O
of	O
aminoglycoside-induced	O
nephrotoxicity	B_Disease
is	O
not	O
fully	O
understood	O
.	O

Experimental	O
studies	O
in	O
healthy	O
human	O
volunteers	O
indicate	O
aminoglycosides	B_Chemical
cause	O
proximal	O
tubular	O
damage	O
in	O
most	O
patients	O
,	O
but	O
rarely	O
,	O
if	O
ever	O
,	O
cause	O
glomerular	B_Disease
or	I_Disease
tubular	I_Disease
dysfunction	I_Disease
.	O

Clinical	O
trials	O
of	O
aminoglycosides	B_Chemical
in	O
seriously	O
ill	O
patients	O
indicate	O
that	O
the	O
relative	O
risk	O
for	O
developing	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
during	O
therapy	O
ranges	O
from	O
8	O
to	O
10	O
and	O
that	O
the	O
attributable	O
risk	O
is	O
70	O
%	O
to	O
80	O
%	O
.	O

Further	O
analysis	O
of	O
these	O
data	O
suggests	O
that	O
the	O
duration	O
of	O
therapy	O
,	O
plasma	O
aminoglycoside	B_Chemical
levels	O
,	O
liver	B_Disease
disease	I_Disease
,	O
advanced	O
age	O
,	O
high	O
initial	O
estimated	O
creatinine	B_Chemical
clearance	O
and	O
,	O
possibly	O
,	O
female	O
gender	O
all	O
increase	O
the	O
risk	O
for	O
nephrotoxicity	B_Disease
.	O

Other	O
causes	O
of	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
,	O
such	O
as	O
shock	B_Disease
,	O
appear	O
to	O
have	O
an	O
additive	O
effect	O
.	O

Predictive	O
models	O
have	O
been	O
developed	O
from	O
these	O
analyses	O
that	O
should	O
be	O
useful	O
for	O
identifying	O
patients	O
at	O
high	O
risk	O
.	O

These	O
models	O
may	O
also	O
be	O
useful	O
in	O
developing	O
insights	O
into	O
the	O
pathophysiology	O
of	O
aminoglycoside-induced	O
nephrotoxicity	B_Disease
.	O

Central	O
action	O
of	O
narcotic	O
analgesics	O
.	O

Part	O
IV	O
.	O

Noradrenergic	O
influences	O
on	O
the	O
activity	O
of	O
analgesics	O
in	O
rats	O
.	O

The	O
effect	O
of	O
clonidine	B_Chemical
,	O
naphazoline	B_Chemical
and	O
xylometazoline	B_Chemical
on	O
analgesia	O
induced	O
by	O
morphine	B_Chemical
,	O
codeine	B_Chemical
,	O
fentanyl	B_Chemical
and	O
pentazocine	B_Chemical
,	O
and	O
on	O
cataleptic	B_Disease
effect	O
of	O
morphine	B_Chemical
,	O
codine	B_Chemical
and	O
fentanyl	B_Chemical
was	O
studied	O
in	O
rats	O
.	O

The	O
biochemical	O
assays	O
on	O
the	O
influence	O
of	O
four	O
analgesics	O
on	O
the	O
brain	O
concentration	O
and	O
turnover	O
of	O
noradrenaline	B_Chemical
(	O
NA	B_Chemical
)	O
were	O
also	O
performed	O
.	O

It	O
was	O
found	O
that	O
three	O
drugs	O
stimulating	O
central	O
NA	B_Chemical
receptors	O
failed	O
to	O
affect	O
the	O
analgesic	O
ED50	O
of	O
all	O
antinociceptive	O
agents	O
and	O
they	O
enhanced	O
catalepsy	B_Disease
induced	O
by	O
morphine	B_Chemical
and	O
fentanyl	B_Chemical
.	O

Codeine	B_Chemical
catalepsy	B_Disease
was	O
increased	O
by	O
clonidine	B_Chemical
and	O
decreased	O
by	O
naphazoline	B_Chemical
and	O
xylometazoline	B_Chemical
.	O

The	O
brain	O
concentration	O
of	O
NA	B_Chemical
was	O
not	O
changed	O
by	O
morphine	B_Chemical
and	O
fentanyl	B_Chemical
,	O
but	O
one	O
of	O
the	O
doses	O
of	O
codeine	B_Chemical
(	O
45	O
mg/kg	O
)	O
slightly	O
enhanced	O
it	O
.	O

Pentazocine	B_Chemical
dose-dependently	O
decreased	O
the	O
brain	O
level	O
of	O
NA	B_Chemical
.	O

The	O
rate	O
of	O
NA	B_Chemical
turnover	O
was	O
not	O
altered	O
by	O
analgesics	O
except	O
for	O
the	O
higher	O
dose	O
of	O
fentanyl	B_Chemical
(	O
0.2	O
mg/kg	O
)	O
following	O
which	O
the	O
disappearance	O
of	O
NA	B_Chemical
from	O
the	O
brain	O
was	O
diminished	O
.	O

The	O
results	O
are	O
discussed	O
in	O
the	O
light	O
of	O
various	O
and	O
non-uniform	O
data	O
from	O
the	O
literature	O
.	O

It	O
is	O
suggested	O
that	O
in	O
rats	O
the	O
brain	O
NA	B_Chemical
plays	O
a	O
less	O
important	O
function	O
than	O
the	O
other	O
monoamines	B_Chemical
in	O
the	O
behavioural	O
activity	O
of	O
potent	O
analgesics	O
.	O

Flurothyl	B_Chemical
seizure	B_Disease
thresholds	O
in	O
mice	O
treated	O
neonatally	O
with	O
a	O
single	O
injection	O
of	O
monosodium	B_Chemical
glutamate	I_Chemical
(	O
MSG	B_Chemical
):	O
evaluation	O
of	O
experimental	O
parameters	O
in	O
flurothyl	B_Chemical
seizure	B_Disease
testing	O
.	O

Monosodium	B_Chemical
glutamate	I_Chemical
(	O
MSG	B_Chemical
)	O
administration	O
to	O
neonatal	O
rodents	O
produces	O
convulsions	B_Disease
and	O
results	O
in	O
numerous	O
biochemical	O
and	O
behavioral	O
deficits	O
.	O

These	O
studies	O
were	O
undertaken	O
to	O
determine	O
if	O
neonatal	O
administration	O
of	O
MSG	B_Chemical
produced	O
permanent	O
alterations	O
in	O
seizure	B_Disease
susceptibility	O
,	O
since	O
previous	O
investigations	O
were	O
inconclusive	O
.	O

A	O
flurothyl	B_Chemical
ether	B_Chemical
seizure	B_Disease
screening	O
technique	O
was	O
used	O
to	O
evaluate	O
seizure	B_Disease
susceptibility	O
in	O
adult	O
mice	O
that	O
received	O
neonatal	O
injections	O
of	O
MSG	B_Chemical
(	O
4	O
mg/g	O
and	O
1	O
mg/g	O
)	O
.	O

MSG	B_Chemical
treatment	O
resulted	O
in	O
significant	O
reductions	O
in	O
whole	O
brain	O
weight	O
but	O
did	O
not	O
alter	O
seizure	B_Disease
threshold	O
.	O

A	O
naloxone	B_Chemical
(	O
5	O
mg/kg	O
)	O
challenge	O
was	O
also	O
ineffective	O
in	O
altering	O
the	O
seizure	B_Disease
thresholds	O
of	O
either	O
control	O
of	O
MSG-treated	O
mice	O
.	O

Flurothyl	B_Chemical
ether	B_Chemical
produced	O
hypothermia	B_Disease
which	O
was	O
correlated	O
with	O
the	O
duration	O
of	O
flurothyl	B_Chemical
exposure	O
;	O
however	O
,	O
the	O
relationship	O
of	O
hypothermia	B_Disease
to	O
seizure	B_Disease
induction	O
was	O
unclear	O
.	O

Flurothyl	B_Chemical
seizure	B_Disease
testing	O
proved	O
to	O
be	O
a	O
rapid	O
and	O
reliable	O
technique	O
with	O
which	O
to	O
evaluate	O
seizure	B_Disease
susceptibility	O
.	O

Susceptibility	O
to	O
seizures	B_Disease
produced	O
by	O
pilocarpine	B_Chemical
in	O
rats	O
after	O
microinjection	O
of	O
isoniazid	B_Chemical
or	O
gamma-vinyl-GABA	B_Chemical
into	O
the	O
substantia	O
nigra	O
.	O

Pilocarpine	B_Chemical
,	O
given	O
intraperitoneally	O
to	O
rats	O
,	O
reproduces	O
the	O
neuropathological	O
sequelae	O
of	O
temporal	B_Disease
lobe	I_Disease
epilepsy	I_Disease
and	O
provides	O
a	O
relevant	O
animal	O
model	O
for	O
studying	O
mechanisms	O
of	O
buildup	O
of	O
convulsive	B_Disease
activity	O
and	O
pathways	O
operative	O
in	O
the	O
generalization	O
and	O
propagation	O
of	O
seizures	B_Disease
within	O
the	O
forebrain	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
manipulating	O
the	O
activity	O
of	O
the	O
gamma-aminobutyric	B_Chemical
acid	I_Chemical
(GABA)-mediated	O
synaptic	O
inhibition	O
within	O
the	O
substantia	O
nigra	O
on	O
seizures	B_Disease
produced	O
by	O
pilocarpine	B_Chemical
in	O
rats	O
,	O
were	O
investigated	O
.	O

In	O
animals	O
pretreated	O
with	O
microinjections	O
of	O
isoniazid	B_Chemical
,	O
150	O
micrograms	O
,	O
an	O
inhibitor	O
of	O
activity	O
of	O
the	O
GABA-synthesizing	O
enzyme	O
,	O
L-glutamic	B_Chemical
acid	I_Chemical
decarboxylase	O
,	O
into	O
the	O
substantia	O
nigra	O
pars	O
reticulata	O
(	O
SNR	O
)	O
,	O
bilaterally	O
,	O
non-convulsant	O
doses	O
of	O
pilocarpine	B_Chemical
,	O
100	O
and	O
200	O
mg/kg	O
,	O
resulted	O
in	O
severe	O
motor	O
limbic	O
seizures	B_Disease
and	O
status	B_Disease
epilepticus	I_Disease
.	O

Electroencephalographic	O
and	O
behavioral	O
monitoring	O
revealed	O
a	O
profound	O
reduction	O
of	O
the	O
threshold	O
for	O
pilocarpine-induced	O
convulsions	B_Disease
.	O

Morphological	O
analysis	O
of	O
frontal	O
forebrain	O
sections	O
with	O
light	O
microscopy	O
revealed	O
seizure-related	O
damage	O
to	O
the	O
hippocampal	O
formation	O
,	O
thalamus	O
,	O
amygdala	O
,	O
olfactory	O
cortex	O
,	O
substantia	O
nigra	O
and	O
neocortex	O
,	O
which	O
is	O
typically	O
observed	O
with	O
pilocarpine	B_Chemical
in	O
doses	O
exceeding	O
350	O
mg/kg	O
.	O

Bilateral	O
intrastriatal	O
injections	O
of	O
isoniazid	B_Chemical
did	O
not	O
augment	O
seizures	B_Disease
produced	O
by	O
pilocarpine	B_Chemical
,	O
200	O
mg/kg	O
.	O

Application	O
of	O
an	O
irreversible	O
inhibitor	O
of	O
GABA	B_Chemical
transaminase	O
,	O
gamma-vinyl-GABA	B_Chemical
(	O
D	B_Chemical
,	I_Chemical
L-4-amino-hex-5-enoic	I_Chemical
acid	I_Chemical
)	O
,	O
5	O
micrograms	O
,	O
into	O
the	O
SNR	O
,	O
bilaterally	O
,	O
suppressed	O
the	O
appearance	O
of	O
electrographic	O
and	O
behavioral	O
seizures	B_Disease
produced	O
by	O
pilocarpine	B_Chemical
,	O
380	O
mg/kg	O
.	O

This	O
treatment	O
was	O
also	O
sufficient	O
to	O
protect	O
animals	O
from	O
the	O
occurrence	O
of	O
brain	B_Disease
damage	I_Disease
.	O

Microinjections	O
of	O
gamma-vinyl-GABA	B_Chemical
,	O
5	O
micrograms	O
,	O
into	O
the	O
dorsal	O
striatum	O
,	O
bilaterally	O
,	O
failed	O
to	O
prevent	O
the	O
development	O
of	O
convulsions	B_Disease
produced	O
by	O
pilocarpine	B_Chemical
,	O
380	O
mg/kg	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
threshold	O
for	O
pilocarpine-induced	O
seizures	B_Disease
in	O
rats	O
is	O
subjected	O
to	O
the	O
regulation	O
of	O
the	O
GABA-mediated	O
synaptic	O
inhibition	O
within	O
the	O
substantia	O
nigra	O
.	O

Human	O
and	O
canine	O
ventricular	O
vasoactive	O
intestinal	O
polypeptide	O
:	O
decrease	O
with	O
heart	O
failure	O
.	O

Vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
is	O
a	O
systemic	O
and	O
coronary	O
vasodilator	O
that	O
may	O
have	O
positive	O
inotropic	O
properties	O
.	O

Myocardial	O
levels	O
of	O
VIP	O
were	O
assayed	O
before	O
and	O
after	O
the	O
development	O
of	O
heart	B_Disease
failure	I_Disease
in	O
two	O
canine	O
models	O
.	O

In	O
the	O
first	O
,	O
cobalt	B_Chemical
cardiomyopathy	B_Disease
was	O
induced	O
in	O
eight	O
dogs	O
;	O
VIP	O
(	O
by	O
radioimmunoassay	O
)	O
decreased	O
from	O
35	O
+	O
/-	O
11	O
pg/mg	O
protein	O
(	O
mean	O
+	O
/-	O
SD	O
)	O
to	O
5	O
+	O
/-	O
4	O
pg/mg	O
protein	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

In	O
six	O
dogs	O
with	O
doxorubicin-induced	O
heart	B_Disease
failure	I_Disease
,	O
VIP	O
decreased	O
from	O
31	O
+	O
/-	O
7	O
to	O
11	O
+	O
/-	O
4	O
pg/mg	O
protein	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

In	O
addition	O
,	O
VIP	O
content	O
of	O
left	O
ventricular	O
muscle	O
of	O
resected	O
failing	O
hearts	O
in	O
10	O
patients	O
receiving	O
a	O
heart	O
transplant	O
was	O
compared	O
with	O
the	O
papillary	O
muscles	O
in	O
14	O
patients	O
(	O
five	O
with	O
rheumatic	B_Disease
disease	I_Disease
,	O
nine	O
with	O
myxomatous	B_Disease
degeneration	I_Disease
)	O
receiving	O
mitral	O
valve	O
prostheses	O
.	O

The	O
lowest	O
myocardial	O
VIP	O
concentration	O
was	O
found	O
in	O
the	O
hearts	O
of	O
patients	O
with	O
coronary	B_Disease
disease	I_Disease
(	O
one	O
patient	O
receiving	O
a	O
transplant	O
and	O
three	O
receiving	O
mitral	O
prostheses	O
)	O
(	O
6.3	O
+	O
/-	O
1.9	O
pg/mg	O
protein	O
)	O
.	O

The	O
other	O
patients	O
undergoing	O
transplantation	O
had	O
an	O
average	O
ejection	O
fraction	O
of	O
17	O
%	O
+	O
/-	O
6	O
%	O
and	O
a	O
VIP	O
level	O
of	O
8.8	O
+	O
/-	O
3.9	O
pg/mg	O
protein	O
.	O

The	O
hearts	O
without	O
coronary	B_Disease
artery	I_Disease
disease	I_Disease
(	O
average	O
ejection	O
fraction	O
of	O
this	O
group	O
62	O
%	O
+	O
/-	O
10	O
%	O
)	O
had	O
a	O
VIP	O
concentration	O
of	O
14.1	O
+	O
/-	O
7.9	O
pg/mg	O
protein	O
,	O
and	O
this	O
was	O
greater	O
than	O
in	O
hearts	O
of	O
the	O
patients	O
with	O
coronary	B_Disease
disease	I_Disease
and	O
the	O
hearts	O
of	O
patients	O
receiving	O
a	O
transplant	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

Myocardial	O
catecholamines	B_Chemical
were	O
also	O
determined	O
in	O
14	O
subjects	O
;	O
a	O
weak	O
correlation	O
(	O
r	O
=	O
0.57	O
,	O
P	O
less	O
than	O
0.05	O
)	O
between	O
the	O
tissue	O
concentrations	O
of	O
VIP	O
and	O
norepinephrine	B_Chemical
was	O
noted.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Non-invasive	O
detection	O
of	O
coronary	B_Disease
artery	I_Disease
disease	I_Disease
by	O
body	O
surface	O
electrocardiographic	O
mapping	O
after	O
dipyridamole	B_Chemical
infusion	O
.	O

Electrocardiographic	O
changes	O
after	O
dipyridamole	B_Chemical
infusion	O
(	O
0.568	O
mg/kg/4	O
min	O
)	O
were	O
studied	O
in	O
41	O
patients	O
with	O
coronary	B_Disease
artery	I_Disease
disease	I_Disease
and	O
compared	O
with	O
those	O
after	O
submaximal	O
treadmill	O
exercise	O
by	O
use	O
of	O
the	O
body	O
surface	O
mapping	O
technique	O
.	O

Patients	O
were	O
divided	O
into	O
three	O
groups	O
;	O
19	O
patients	O
without	O
myocardial	B_Disease
infarction	I_Disease
(	O
non-MI	O
group	O
)	O
,	O
14	O
with	O
anterior	B_Disease
infarction	I_Disease
(	O
ANT-MI	B_Disease
)	O
and	O
eight	O
with	O
inferior	B_Disease
infarction	I_Disease
(	O
INF-MI	B_Disease
)	O
.	O

Eighty-seven	O
unipolar	O
electrocardiograms	O
(	O
ECGs	O
)	O
distributed	O
over	O
the	O
entire	O
thoracic	O
surface	O
were	O
simultaneously	O
recorded	O
.	O

After	O
dipyridamole	B_Chemical
,	O
ischemic	B_Disease
ST-segment	O
depression	B_Disease
(	O
0.05	O
mV	O
or	O
more	O
)	O
was	O
observed	O
in	O
84	O
%	O
of	O
the	O
non-MI	O
group	O
,	O
29	O
%	O
of	O
the	O
ANT-MI	B_Disease
group	O
,	O
63	O
%	O
of	O
the	O
INF-MI	B_Disease
group	O
and	O
61	O
%	O
of	O
the	O
total	O
population	O
.	O

Exercise-induced	O
ST	O
depression	B_Disease
was	O
observed	O
in	O
84	O
%	O
of	O
the	O
non-MI	O
group	O
,	O
43	O
%	O
of	O
the	O
ANT-MI	B_Disease
group	O
,	O
38	O
%	O
of	O
the	O
INF-MI	B_Disease
group	O
and	O
61	O
%	O
of	O
the	O
total	O
.	O

For	O
individual	O
patients	O
,	O
there	O
were	O
no	O
obvious	O
differences	O
between	O
the	O
body	O
surface	O
distribution	O
of	O
ST	O
depression	B_Disease
in	O
both	O
tests	O
.	O

The	O
increase	O
in	O
pressure	O
rate	O
product	O
after	O
dipyridamole	B_Chemical
was	O
significantly	O
less	O
than	O
that	O
during	O
the	O
treadmill	O
exercise	O
.	O

The	O
data	O
suggest	O
that	O
the	O
dipyridamole-induced	O
myocardial	B_Disease
ischemia	I_Disease
is	O
caused	O
by	O
the	O
inhomogenous	O
distribution	O
of	O
myocardial	O
blood	O
flow	O
.	O

We	O
conclude	O
that	O
the	O
dipyridamole	B_Chemical
ECG	O
test	O
is	O
as	O
useful	O
as	O
the	O
exercise	O
ECG	O
test	O
for	O
the	O
assessment	O
of	O
coronary	B_Disease
artery	I_Disease
disease	I_Disease
.	O

Bradycardia	B_Disease
after	O
high-dose	O
intravenous	O
methylprednisolone	B_Chemical
therapy	O
.	O

In	O
5	O
consecutive	O
patients	O
with	O
rheumatoid	B_Disease
arthritis	I_Disease
who	O
received	O
intravenous	O
high-dose	O
methylprednisolone	B_Chemical
(	O
MP	B_Chemical
)	O
therapy	O
(	O
1	O
g	O
daily	O
for	O
2	O
or	O
3	O
consecutive	O
days	O
)	O
,	O
a	O
decline	O
in	O
pulse	O
rate	O
was	O
observed	O
,	O
most	O
pronounced	O
on	O
day	O
4	O
.	O

In	O
one	O
of	O
the	O
5	O
patients	O
the	O
bradycardia	B_Disease
was	O
associated	O
with	O
complaints	O
of	O
substernal	O
pressure	O
.	O

Reversal	O
to	O
normal	O
heart	O
rate	O
was	O
found	O
on	O
day	O
7	O
.	O

Electrocardiographic	O
registrations	O
showed	O
sinus	B_Disease
bradycardia	I_Disease
in	O
all	O
cases	O
.	O

No	O
significant	O
changes	O
in	O
plasma	O
concentrations	O
of	O
electrolytes	O
were	O
found	O
.	O

Careful	O
observation	O
of	O
patients	O
receiving	O
high-dose	O
MP	B_Chemical
is	O
recommended	O
.	O

High-dose	O
MP	B_Chemical
may	O
be	O
contraindicated	O
in	O
patients	O
with	O
known	O
heart	B_Disease
disease	I_Disease
.	O

Two	O
cases	O
of	O
downbeat	B_Disease
nystagmus	I_Disease
and	O
oscillopsia	B_Disease
associated	O
with	O
carbamazepine	B_Chemical
.	O

Downbeat	B_Disease
nystagmus	I_Disease
is	O
often	O
associated	O
with	O
structural	O
lesions	O
at	O
the	O
craniocervical	O
junction	O
,	O
but	O
has	O
occasionally	O
been	O
reported	O
as	O
a	O
manifestation	O
of	O
metabolic	O
imbalance	O
or	O
drug	O
intoxication	O
.	O

We	O
recorded	O
the	O
eye	O
movements	O
of	O
two	O
patients	O
with	O
reversible	O
downbeat	B_Disease
nystagmus	I_Disease
related	O
to	O
carbamazepine	B_Chemical
therapy	O
.	O

The	O
nystagmus	B_Disease
of	O
both	O
patients	O
resolved	O
after	O
reduction	O
of	O
the	O
serum	O
carbamazepine	B_Chemical
levels	O
.	O

Neuroradiologic	O
investigations	O
including	O
magnetic	O
resonance	O
imaging	O
scans	O
in	O
both	O
patients	O
showed	O
no	O
evidence	O
of	O
intracranial	O
abnormality	O
.	O

In	O
patients	O
with	O
downbeat	B_Disease
nystagmus	I_Disease
who	O
are	O
taking	O
anticonvulsant	O
medications	O
,	O
consideration	O
should	O
be	O
given	O
to	O
reduction	O
in	O
dose	O
before	O
further	O
investigation	O
is	O
undertaken	O
.	O

Improvement	O
by	O
denopamine	B_Chemical
(	O
TA-064	B_Chemical
)	O
of	O
pentobarbital-induced	O
cardiac	B_Disease
failure	I_Disease
in	O
the	O
dog	O
heart-lung	O
preparation	O
.	O

The	O
efficacy	O
of	O
denopamine	B_Chemical
,	O
an	O
orally	O
active	O
beta	O
1-adrenoceptor	O
agonist	O
,	O
in	O
improving	O
cardiac	B_Disease
failure	I_Disease
was	O
assessed	O
in	O
dog	O
heart-lung	O
preparations	O
.	O

Cardiac	O
functions	O
depressed	O
by	O
pentobarbital	B_Chemical
(	O
118	O
+	O
/-	O
28	O
mg	O
;	O
mean	O
value	O
+	O
/-	O
SD	O
)	O
such	O
that	O
cardiac	O
output	O
and	O
maximum	O
rate	O
of	O
rise	O
of	O
left	O
ventricular	O
pressure	O
(	O
LV	O
dP/dt	O
max	O
)	O
had	O
been	O
reduced	O
by	O
about	O
35	O
%	O
and	O
26	O
%	O
of	O
the	O
respective	O
controls	O
were	O
improved	O
by	O
denopamine	B_Chemical
(	O
10	O
-	O
300	O
micrograms	O
)	O
in	O
a	O
dose-dependent	O
manner	O
.	O

With	O
100	O
micrograms	O
denopamine	B_Chemical
,	O
almost	O
complete	O
restoration	O
of	O
cardiac	O
performance	O
was	O
attained	O
,	O
associated	O
with	O
a	O
slight	O
increase	O
in	O
heart	O
rate	O
.	O

No	O
arrhythmias	B_Disease
were	O
induced	O
by	O
these	O
doses	O
of	O
denopamine	B_Chemical
.	O

The	O
results	O
warrant	O
clinical	O
trials	O
of	O
denopamine	B_Chemical
in	O
the	O
treatment	O
of	O
cardiac	B_Disease
failure	I_Disease
.	O

Clonazepam	B_Chemical
monotherapy	O
for	O
epilepsy	B_Disease
in	O
childhood	O
.	O

Sixty	O
patients	O
(	O
age-range	O
one	O
month	O
to	O
14	O
years	O
)	O
with	O
other	O
types	O
of	O
epilepsy	B_Disease
than	O
infantile	B_Disease
spasms	I_Disease
were	O
treated	O
with	O
clonazepam	B_Chemical
.	O

Disappearance	O
of	O
seizures	B_Disease
and	O
normalization	O
of	O
abnormal	O
EEG	O
with	O
disappearance	O
of	O
seizures	B_Disease
were	O
recognized	O
in	O
77	O
%	O
and	O
50	O
%	O
,	O
respectively	O
.	O

Seizures	B_Disease
disappeared	O
in	O
71	O
%	O
of	O
the	O
patients	O
with	O
generalized	O
seizures	B_Disease
and	O
89	O
%	O
of	O
partial	O
seizures	B_Disease
.	O

Improvement	O
of	O
abnormal	O
EEG	O
was	O
noticed	O
in	O
76	O
%	O
of	O
diffuse	O
paroxysms	O
and	O
in	O
67	O
%	O
of	O
focal	O
paroxysms	O
.	O

In	O
excellent	O
cases	O
,	O
mean	O
effective	O
dosages	O
were	O
0.086	O
+	O
/-	O
0.021	O
mg/kg/day	O
in	O
infants	O
and	O
0.057	O
+	O
/-	O
0.022	O
mg/kg/day	O
in	O
schoolchildren	O
,	O
this	O
difference	O
was	O
statistically	O
significant	O
(	O
p	O
less	O
than	O
0.005	O
)	O
.	O

The	O
incidence	O
of	O
side	O
effects	O
such	O
as	O
drowsiness	B_Disease
and	O
ataxia	B_Disease
was	O
only	O
5	O
%	O
.	O

Postmarketing	O
study	O
of	O
timolol-hydrochlorothiazide	O
antihypertensive	O
therapy	O
.	O

A	O
postmarketing	O
surveillance	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
a	O
fixed-ratio	O
combination	O
containing	O
10	O
mg	O
of	O
timolol	B_Chemical
maleate	I_Chemical
and	O
25	O
mg	O
of	O
hydrochlorothiazide	B_Chemical
,	O
administered	O
twice	O
daily	O
for	O
one	O
month	O
to	O
hypertensive	B_Disease
patients	O
.	O

Data	O
on	O
9,037	O
patients	O
were	O
collected	O
by	O
1,455	O
participating	O
physicians	O
.	O

Mean	O
systolic	O
blood	O
pressure	O
decreased	O
25	O
mmHg	O
and	O
mean	O
diastolic	O
blood	O
pressure	O
declined	O
15	O
mmHg	O
after	O
one	O
month	O
of	O
timolol-hydrochlorothiazide	O
therapy	O
(	O
P	O
less	O
than	O
0.01	O
,	O
both	O
comparisons	O
)	O
.	O

Age	O
,	O
race	O
,	O
and	O
sex	O
appeared	O
to	O
have	O
no	O
influence	O
on	O
the	O
decrease	O
in	O
blood	O
pressure	O
.	O

The	O
antihypertensive	O
effect	O
of	O
the	O
drug	O
was	O
greater	O
in	O
patients	O
with	O
more	O
severe	O
hypertension	B_Disease
.	O

Overall	O
,	O
1,453	O
patients	O
experienced	O
a	O
total	O
of	O
2,658	O
adverse	O
events	O
,	O
the	O
most	O
common	O
being	O
fatigue	B_Disease
,	O
dizziness	B_Disease
,	O
and	O
weakness	B_Disease
.	O

Treatment	O
in	O
590	O
patients	O
was	O
discontinued	O
because	O
of	O
adverse	O
events	O
.	O

Salicylate	B_Chemical
nephropathy	B_Disease
in	O
the	O
Gunn	O
rat	O
:	O
potential	O
role	O
of	O
prostaglandins	B_Chemical
.	O

We	O
examined	O
the	O
potential	O
role	O
of	O
prostaglandins	B_Chemical
in	O
the	O
development	O
of	O
analgesic	O
nephropathy	B_Disease
in	O
the	O
Gunn	O
strain	O
of	O
rat	O
.	O

The	O
homozygous	O
Gunn	O
rats	O
have	O
unconjugated	O
hyperbilirubinemia	B_Disease
due	O
to	O
the	O
absence	O
of	O
glucuronyl	B_Chemical
transferase	O
,	O
leading	O
to	O
marked	O
bilirubin	B_Chemical
deposition	O
in	O
renal	O
medulla	O
and	O
papilla	O
.	O

These	O
rats	O
are	O
also	O
highly	O
susceptible	O
to	O
develop	O
papillary	B_Disease
necrosis	I_Disease
with	O
analgesic	O
administration	O
.	O

We	O
used	O
homozygous	O
(	O
jj	O
)	O
and	O
phenotypically	O
normal	O
heterozygous	O
(	O
jJ	O
)	O
animals	O
.	O

Four	O
groups	O
of	O
rats	O
(	O
n	O
=	O
7	O
)	O
were	O
studied	O
:	O
jj	O
and	O
jJ	O
rats	O
treated	O
either	O
with	O
aspirin	B_Chemical
300	O
mg/kg	O
every	O
other	O
day	O
or	O
sham-treated	O
.	O

After	O
one	O
week	O
,	O
slices	O
of	O
cortex	O
,	O
outer	O
and	O
inner	O
medulla	O
from	O
one	O
kidney	O
were	O
incubated	O
in	O
buffer	O
and	O
prostaglandin	B_Chemical
synthesis	O
was	O
determined	O
by	O
radioimmunoassay	O
.	O

The	O
other	O
kidney	O
was	O
examined	O
histologically	O
.	O

A	O
marked	O
corticomedullary	O
gradient	O
of	O
prostaglandin	B_Chemical
synthesis	O
was	O
observed	O
in	O
all	O
groups	O
.	O

PGE2	B_Chemical
synthesis	O
was	O
significantly	O
higher	O
in	O
outer	O
medulla	O
,	O
but	O
not	O
cortex	O
or	O
inner	O
medulla	O
,	O
of	O
jj	O
(	O
38	O
+	O
/-	O
6	O
ng/mg	O
prot	O
)	O
than	O
jJ	O
rats	O
(	O
15	O
+	O
/-	O
3	O
)	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

Aspirin	B_Chemical
treatment	O
reduced	O
PGE2	B_Chemical
synthesis	O
in	O
all	O
regions	O
,	O
but	O
outer	O
medullary	O
PGE2	B_Chemical
remained	O
higher	O
in	O
jj	O
(	O
18	O
+	O
/-	O
3	O
)	O
than	O
jJ	O
rats	O
(	O
9	O
+	O
/-	O
2	O
)	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

PGF2	B_Chemical
alpha	I_Chemical
was	O
also	O
significantly	O
higher	O
in	O
the	O
outer	O
medulla	O
of	O
jj	O
rats	O
with	O
and	O
without	O
aspirin	B_Chemical
administration	O
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

The	O
changes	O
in	O
renal	O
prostaglandin	B_Chemical
synthesis	O
were	O
accompanied	O
by	O
evidence	O
of	O
renal	B_Disease
damage	I_Disease
in	O
aspirin-treated	O
jj	O
but	O
not	O
jJ	O
rats	O
as	O
evidenced	O
by	O
:	O
increased	O
incidence	O
and	O
severity	O
of	O
hematuria	B_Disease
(	O
p	O
less	O
than	O
0.01	O
)	O
;	O
increased	O
serum	O
creatinine	B_Chemical
(	O
p	O
less	O
than	O
0.05	O
)	O
;	O
and	O
increase	O
in	O
outer	O
medullary	O
histopathologic	O
lesions	O
(	O
p	O
less	O
than	O
0.005	O
compared	O
to	O
either	O
sham-treated	O
jj	O
or	O
aspirin-treated	O
jJ	O
)	O
.	O

These	O
results	O
suggest	O
that	O
enhanced	O
prostaglandin	B_Chemical
synthesis	O
contributes	O
to	O
maintenance	O
of	O
renal	O
function	O
and	O
morphological	O
integrity	O
,	O
and	O
that	O
inhibition	O
of	O
prostaglandin	B_Chemical
synthesis	O
may	O
lead	O
to	O
pathological	B_Disease
renal	I_Disease
medullary	I_Disease
lesions	I_Disease
and	O
deterioration	B_Disease
of	I_Disease
renal	I_Disease
function	I_Disease
.	O

Prophylactic	O
lidocaine	B_Chemical
in	O
the	O
early	O
phase	O
of	O
suspected	O
myocardial	B_Disease
infarction	I_Disease
.	O

Four	O
hundred	O
two	O
patients	O
with	O
suspected	O
myocardial	B_Disease
infarction	I_Disease
seen	O
within	O
6	O
hours	O
of	O
the	O
onset	O
of	O
symptoms	O
entered	O
a	O
double-blind	O
randomized	O
trial	O
of	O
lidocaine	B_Chemical
vs	O
placebo	O
.	O

During	O
the	O
1	O
hour	O
after	O
administration	O
of	O
the	O
drug	O
the	O
incidence	O
of	O
ventricular	B_Disease
fibrillation	I_Disease
or	O
sustained	O
ventricular	B_Disease
tachycardia	I_Disease
among	O
the	O
204	O
patients	O
with	O
acute	O
myocardial	B_Disease
infarction	I_Disease
was	O
low	O
,	O
1.5	O
%	O
.	O

Lidocaine	B_Chemical
,	O
given	O
in	O
a	O
300	O
mg	O
dose	O
intramuscularly	O
followed	O
by	O
100	O
mg	O
intravenously	O
,	O
did	O
not	O
prevent	O
sustained	O
ventricular	B_Disease
tachycardia	I_Disease
,	O
although	O
there	O
was	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
patients	O
with	O
warning	O
arrhythmias	B_Disease
between	O
15	O
and	O
45	O
minutes	O
after	O
the	O
administration	O
of	O
lidocaine	B_Chemical
(	O
p	O
less	O
than	O
0.05	O
)	O
.	O

The	O
average	O
plasma	O
lidocaine	B_Chemical
level	O
10	O
minutes	O
after	O
administration	O
for	O
patients	O
without	O
a	O
myocardial	B_Disease
infarction	I_Disease
was	O
significantly	O
higher	O
than	O
that	O
for	O
patients	O
with	O
an	O
acute	O
infarction	B_Disease
.	O

The	O
mean	O
plasma	O
lidocaine	B_Chemical
level	O
of	O
patients	O
on	O
beta-blocking	O
agents	O
was	O
no	O
different	O
from	O
that	O
in	O
patients	O
not	O
on	O
beta	O
blocking	O
agents	O
.	O

During	O
the	O
1-hour	O
study	O
period	O
,	O
the	O
incidence	O
of	O
central	O
nervous	O
system	O
side	O
effects	O
was	O
significantly	O
greater	O
in	O
the	O
lidocaine	B_Chemical
group	O
,	O
hypotension	B_Disease
occurred	O
in	O
11	O
patients	O
,	O
nine	O
of	O
whom	O
had	O
received	O
lidocaine	B_Chemical
,	O
and	O
four	O
patients	O
died	O
from	O
asystole	B_Disease
,	O
three	O
of	O
whom	O
had	O
had	O
lidocaine	B_Chemical
.	O

We	O
can	O
not	O
advocate	O
the	O
administration	O
of	O
lidocaine	B_Chemical
prophylactically	O
in	O
the	O
early	O
hours	O
of	O
suspected	O
myocardial	B_Disease
infarction	I_Disease
.	O

Evidence	O
for	O
a	O
cholinergic	O
role	O
in	O
haloperidol-induced	O
catalepsy	B_Disease
.	O

Experiments	O
in	O
mice	O
tested	O
previous	O
evidence	O
that	O
activation	O
of	O
cholinergic	O
systems	O
promotes	O
catalepsy	B_Disease
and	O
that	O
cholinergic	O
mechanisms	O
need	O
to	O
be	O
intact	O
for	O
full	O
expression	O
of	O
neuroleptic-induced	O
catalepsy	B_Disease
.	O

Large	O
doses	O
of	O
the	O
cholinomimetic	O
,	O
pilocarpine	B_Chemical
,	O
could	O
induce	O
catalepsy	B_Disease
when	O
peripheral	O
cholinergic	O
receptors	O
were	O
blocked	O
.	O

Low	O
doses	O
of	O
pilocarpine	B_Chemical
caused	O
a	O
pronounced	O
enhancement	O
of	O
the	O
catalepsy	B_Disease
that	O
was	O
induced	O
by	O
the	O
dopaminergic	O
blocker	O
,	O
haloperidol	B_Chemical
.	O

A	O
muscarinic	O
receptor	O
blocker	O
,	O
atropine	B_Chemical
,	O
disrupted	O
haloperidol-induced	O
catalepsy	B_Disease
.	O

Intracranial	O
injection	O
of	O
an	O
acetylcholine-synthesis	O
inhibitor	O
,	O
hemicholinium	B_Chemical
,	O
prevented	O
the	O
catalepsy	B_Disease
that	O
is	O
usually	O
induced	O
by	O
haloperidol	B_Chemical
.	O

These	O
findings	O
suggest	O
the	O
hypothesis	O
that	O
the	O
catalepsy	B_Disease
that	O
is	O
produced	O
by	O
neuroleptics	B_Chemical
such	O
as	O
haloperidol	B_Chemical
is	O
actually	O
mediated	O
by	O
intrinsic	O
central	O
cholinergic	O
systems	O
.	O

Alternatively	O
,	O
activation	O
of	O
central	O
cholinergic	O
systems	O
could	O
promote	O
catalepsy	B_Disease
by	O
suppression	O
of	O
dopaminergic	O
systems	O
.	O

Cardiovascular	B_Disease
dysfunction	I_Disease
and	O
hypersensitivity	B_Disease
to	O
sodium	B_Chemical
pentobarbital	I_Chemical
induced	O
by	O
chronic	O
barium	B_Chemical
chloride	I_Chemical
ingestion	O
.	O

Barium-supplemented	O
Long-Evans	O
hooded	O
rats	O
were	O
characterized	O
by	O
a	O
persistent	O
hypertension	B_Disease
that	O
was	O
evident	O
after	O
1	O
month	O
of	O
barium	B_Chemical
(	O
100	O
micrograms/ml	O
mineral	O
fortified	O
water	O
)	O
treatment	O
.	O

Analysis	O
of	O
in	O
vivo	O
myocardial	O
excitability	O
,	O
contractility	O
,	O
and	O
metabolic	O
characteristics	O
at	O
16	O
months	O
revealed	O
other	O
significant	O
barium-induced	O
disturbances	B_Disease
within	I_Disease
the	I_Disease
cardiovascular	I_Disease
system	I_Disease
.	O

The	O
most	O
distinctive	O
aspect	O
of	O
the	O
barium	B_Chemical
effect	O
was	O
a	O
demonstrated	O
hypersensitivity	B_Disease
of	O
the	O
cardiovascular	O
system	O
to	O
sodium	B_Chemical
pentobarbital	I_Chemical
.	O

Under	O
barbiturate	B_Chemical
anesthesia	O
,	O
virtually	O
all	O
of	O
the	O
myocardial	O
contractile	O
indices	O
were	O
depressed	O
significantly	O
in	O
barium-exposed	O
rats	O
relative	O
to	O
the	O
corresponding	O
control-fed	O
rats	O
.	O

The	O
lack	O
of	O
a	O
similar	O
response	O
to	O
ketamine	B_Chemical
and	O
xylazine	B_Chemical
anesthesia	O
revealed	O
that	O
the	O
cardiovascular	O
actions	O
of	O
sodium	B_Chemical
pentobarbital	I_Chemical
in	O
barium-treated	O
rats	O
were	O
linked	O
specifically	O
to	O
this	O
anesthetic	O
,	O
and	O
were	O
not	O
representative	O
of	O
a	O
generalized	O
anesthetic	O
response	O
.	O

Other	O
myocardial	O
pathophysiologic	O
and	O
metabolic	O
changes	O
induced	O
by	O
barium	B_Chemical
were	O
manifest	O
,	O
irrespective	O
of	O
the	O
anesthetic	O
employed	O
.	O

The	O
contractile	O
element	O
shortening	O
velocity	O
of	O
the	O
cardiac	O
muscle	O
fibers	O
was	O
significantly	O
slower	O
in	O
both	O
groups	O
of	O
barium-treated	O
rats	O
relative	O
to	O
the	O
control	O
groups	O
,	O
irrespective	O
of	O
the	O
anesthetic	O
regimen	O
.	O

Similarly	O
,	O
significant	O
disturbances	O
in	O
myocardial	O
energy	O
metabolism	O
were	O
detected	O
in	O
the	O
barium-exposed	O
rats	O
which	O
were	O
consistent	O
with	O
the	O
reduced	O
contractile	O
element	O
shortening	O
velocity	O
.	O

In	O
addition	O
,	O
the	O
excitability	O
of	O
the	O
cardiac	O
conduction	O
system	O
was	O
depressed	O
preferentially	O
in	O
the	O
atrioventricular	O
nodal	O
region	O
of	O
hearts	O
from	O
barium-exposed	O
rats	O
.	O

Overall	O
,	O
the	O
altered	O
cardiac	O
contractility	O
and	O
excitability	O
characteristics	O
,	O
the	O
myocardial	O
metabolic	B_Disease
disturbances	I_Disease
,	O
and	O
the	O
hypersensitivity	B_Disease
of	O
the	O
cardiovascular	O
system	O
to	O
sodium	B_Chemical
pentobarbital	I_Chemical
suggest	O
the	O
existence	O
of	O
a	O
heretofore	O
undescribed	O
cardiomyopathic	B_Disease
disorder	I_Disease
induced	O
by	O
chronic	O
barium	B_Chemical
exposure	O
.	O

These	O
experimental	O
findings	O
represent	O
the	O
first	O
indication	O
that	O
life-long	O
barium	B_Chemical
ingestion	O
may	O
have	O
significant	O
adverse	O
effects	O
on	O
the	O
mammalian	O
cardiovascular	O
system	O
.	O

Propranolol	B_Chemical
antagonism	O
of	O
phenylpropanolamine-induced	O
hypertension	B_Disease
.	O

Phenylpropanolamine	B_Chemical
(	O
PPA	B_Chemical
)	O
overdose	B_Disease
can	O
cause	O
severe	O
hypertension	B_Disease
,	O
intracerebral	B_Disease
hemorrhage	I_Disease
,	O
and	O
death	O
.	O

We	O
studied	O
the	O
efficacy	O
and	O
safety	O
of	O
propranolol	B_Chemical
in	O
the	O
treatment	O
of	O
PPA-induced	O
hypertension	B_Disease
.	O

Subjects	O
received	O
propranolol	B_Chemical
either	O
by	O
mouth	O
for	O
48	O
hours	O
before	O
PPA	B_Chemical
or	O
as	O
a	O
rapid	O
intravenous	O
infusion	O
after	O
PPA	B_Chemical
.	O

PPA	B_Chemical
,	O
75	O
mg	O
alone	O
,	O
increased	O
blood	O
pressure	O
(	O
31	O
+	O
/-	O
14	O
mm	O
Hg	O
systolic	O
,	O
20	O
+	O
/-	O
5	O
mm	O
Hg	O
diastolic	O
)	O
,	O
and	O
propranolol	B_Chemical
pretreatment	O
antagonized	O
this	O
increase	O
(	O
12	O
+	O
/-	O
10	O
mm	O
Hg	O
systolic	O
,	O
10	O
+	O
/-	O
7	O
mm	O
Hg	O
diastolic	O
)	O
.	O

Intravenous	O
propranolol	B_Chemical
after	O
PPA	B_Chemical
also	O
decreased	O
blood	O
pressure	O
.	O

Left	O
ventricular	O
function	O
(	O
assessed	O
by	O
echocardiography	O
)	O
showed	O
that	O
PPA	B_Chemical
increased	O
the	O
stroke	B_Disease
volume	O
30	O
%	O
(	O
from	O
62.5	O
+	O
/-	O
20.9	O
to	O
80.8	O
+	O
/-	O
22.4	O
ml	O
)	O
,	O
the	O
ejection	O
fraction	O
9	O
%	O
(	O
from	O
64	O
%	O
+	O
/-	O
10	O
%	O
to	O
70	O
%	O
+	O
/-	O
7	O
%	O
)	O
,	O
and	O
cardiac	O
output	O
14	O
%	O
(	O
from	O
3.6	O
+	O
/-	O
0.6	O
to	O
4.1	O
+	O
/-	O
1.0	O
L/min	O
)	O
.	O

Intravenous	O
propranolol	B_Chemical
reversed	O
these	O
effects	O
.	O

Systemic	O
vascular	O
resistance	O
was	O
increased	O
by	O
PPA	B_Chemical
28	O
%	O
(	O
from	O
1710	O
+	O
/-	O
200	O
to	O
2190	O
+	O
/-	O
700	O
dyne	O
X	O
sec/cm5	O
)	O
and	O
was	O
further	O
increased	O
by	O
propranolol	B_Chemical
22	O
%	O
(	O
to	O
2660	O
+	O
/-	O
1200	O
dyne	O
X	O
sec/cm5	O
)	O
.	O

We	O
conclude	O
that	O
PPA	B_Chemical
increases	O
blood	O
pressure	O
by	O
increasing	O
systemic	O
vascular	O
resistance	O
and	O
cardiac	O
output	O
,	O
and	O
that	O
propranolol	B_Chemical
antagonizes	O
this	O
increase	O
by	O
reversing	O
the	O
effect	O
of	O
PPA	B_Chemical
on	O
cardiac	O
output	O
.	O

That	O
propranolol	B_Chemical
antagonizes	O
the	O
pressor	O
effect	O
of	O
PPA	B_Chemical
is	O
in	O
contrast	O
to	O
the	O
interaction	O
in	O
which	O
propranolol	B_Chemical
enhances	O
the	O
pressor	O
effect	O
of	O
norepinephrine	B_Chemical
.	O

This	O
is	O
probably	O
because	O
PPA	B_Chemical
has	O
less	O
beta	O
2	O
activity	O
than	O
does	O
norepinephrine	B_Chemical
.	O

Mesangial	O
function	O
and	O
glomerular	B_Disease
sclerosis	I_Disease
in	O
rats	O
with	O
aminonucleoside	B_Chemical
nephrosis	B_Disease
.	O

The	O
possible	O
relationship	O
between	O
mesangial	B_Disease
dysfunction	I_Disease
and	O
development	O
of	O
glomerular	B_Disease
sclerosis	I_Disease
was	O
studied	O
in	O
the	O
puromycin	B_Chemical
aminonucleoside	I_Chemical
(	O
PAN	B_Chemical
)	O
model	O
.	O

Five	O
male	O
Wistar	O
rats	O
received	O
repeated	O
subcutaneous	O
PAN	B_Chemical
injections	O
;	O
five	O
controls	O
received	O
saline	O
only	O
.	O

After	O
4	O
weeks	O
the	O
PAN	B_Chemical
rats	O
were	O
severely	O
proteinuric	B_Disease
(	O
190	O
+	O
/-	O
80	O
mg/24	O
hr	O
)	O
,	O
and	O
all	O
rats	O
were	O
given	O
colloidal	O
carbon	B_Chemical
(	O
CC	O
)	O
intravenously	O
.	O

At	O
5	O
months	O
glomerular	B_Disease
sclerosis	I_Disease
was	O
found	O
in	O
7.6	O
+	O
/-	O
3.4	O
%	O
of	O
the	O
glomeruli	O
of	O
PAN	B_Chemical
rats	O
;	O
glomeruli	O
of	O
the	O
controls	O
were	O
normal	O
.	O

Glomeruli	O
of	O
PAN	B_Chemical
rats	O
contained	O
significantly	O
more	O
CC	O
than	O
glomeruli	O
of	O
controls	O
.	O

Glomeruli	O
with	O
sclerosis	B_Disease
contained	O
significantly	O
more	O
CC	O
than	O
non-sclerotic	O
glomeruli	O
in	O
the	O
same	O
kidneys	O
.	O

CC	O
was	O
preferentially	O
localized	O
within	O
the	O
sclerotic	O
areas	O
of	O
the	O
affected	O
glomeruli	O
.	O

Since	O
mesangial	O
CC	O
clearance	O
from	O
the	O
mesangium	O
did	O
not	O
change	O
during	O
chronic	O
PAN	B_Chemical
treatment	O
,	O
we	O
conclude	O
that	O
this	O
preferential	O
CC	O
localization	O
within	O
the	O
lesions	O
is	O
caused	O
by	O
an	O
increased	O
CC	O
uptake	O
shortly	O
after	O
injection	O
in	O
apparent	O
vulnerable	O
areas	O
where	O
sclerosis	B_Disease
will	O
develop	O
subsequently	O
.	O

Cluster	O
analysis	O
showed	O
a	O
random	O
distribution	O
of	O
lesions	O
in	O
the	O
PAN	B_Chemical
glomeruli	O
in	O
concordance	O
with	O
the	O
random	O
localization	O
of	O
mesangial	O
areas	O
with	O
dysfunction	O
in	O
this	O
model	O
.	O

Similar	O
to	O
the	O
remnant	O
kidney	O
model	O
in	O
PAN	B_Chemical
nephrosis	B_Disease
the	O
development	O
of	O
glomerular	B_Disease
sclerosis	I_Disease
may	O
be	O
related	O
to	O
"	O
mesangial	O
overloading	O
.	O
"	O

Relationship	O
between	O
nicotine-induced	O
seizures	B_Disease
and	O
hippocampal	O
nicotinic	O
receptors	O
.	O

A	O
controversy	O
has	O
existed	O
for	O
several	O
years	O
concerning	O
the	O
physiological	O
relevance	O
of	O
the	O
nicotinic	O
receptor	O
measured	O
by	O
alpha-bungarotoxin	O
binding	O
.	O

Using	O
mice	O
derived	O
from	O
a	O
classical	O
F2	O
and	O
backcross	O
genetic	O
design	O
,	O
a	O
relationship	O
between	O
nicotine-induced	O
seizures	B_Disease
and	O
alpha-bungarotoxin	O
nicotinic	O
receptor	O
concentration	O
was	O
found	O
.	O

Mice	O
sensitive	O
to	O
the	O
convulsant	O
effects	O
of	O
nicotine	B_Chemical
had	O
greater	O
alpha-bungarotoxin	O
binding	O
in	O
the	O
hippocampus	O
than	O
seizure	B_Disease
insensitive	O
mice	O
.	O

The	O
binding	O
sites	O
from	O
seizure	B_Disease
sensitive	O
and	O
resistant	O
mice	O
were	O
equally	O
affected	O
by	O
treatment	O
with	O
dithiothreitol	B_Chemical
,	O
trypsin	O
or	O
heat	O
.	O

Thus	O
it	O
appears	O
that	O
the	O
difference	O
between	O
seizure	B_Disease
sensitive	O
and	O
insensitive	O
animals	O
may	O
be	O
due	O
to	O
a	O
difference	O
in	O
hippocampal	O
nicotinic	O
receptor	O
concentration	O
as	O
measured	O
with	O
alpha-bungarotoxin	O
binding	O
.	O

The	O
role	O
of	O
p-aminophenol	B_Chemical
in	O
acetaminophen-induced	O
nephrotoxicity	B_Disease
:	O
effect	O
of	O
bis(p-nitrophenyl	B_Chemical
)	I_Chemical
phosphate	I_Chemical
on	O
acetaminophen	B_Chemical
and	O
p-aminophenol	B_Chemical
nephrotoxicity	B_Disease
and	O
metabolism	O
in	O
Fischer	O
344	O
rats	O
.	O

Acetaminophen	B_Chemical
(	O
APAP	B_Chemical
)	O
produces	O
proximal	O
tubular	B_Disease
necrosis	I_Disease
in	O
Fischer	O
344	O
(	O
F344	O
)	O
rats	O
.	O

Recently	O
,	O
p-aminophenol	B_Chemical
(	O
PAP	B_Chemical
)	O
,	O
a	O
known	O
potent	O
nephrotoxicant	O
,	O
was	O
identified	O
as	O
a	O
metabolite	O
of	O
APAP	B_Chemical
in	O
F344	O
rats	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
PAP	B_Chemical
formation	O
is	O
a	O
requisite	O
step	O
in	O
APAP-induced	O
nephrotoxicity	B_Disease
.	O

Therefore	O
,	O
the	O
effect	O
of	O
bis(p-nitrophenyl	B_Chemical
)	I_Chemical
phosphate	I_Chemical
(	O
BNPP	B_Chemical
)	O
,	O
an	O
acylamidase	O
inhibitor	O
,	O
on	O
APAP	B_Chemical
and	O
PAP	B_Chemical
nephrotoxicity	B_Disease
and	O
metabolism	O
was	O
determined	O
.	O

BNPP	B_Chemical
(	O
1	O
to	O
8	O
mM	O
)	O
reduced	O
APAP	B_Chemical
deacetylation	O
and	O
covalent	O
binding	O
in	O
F344	O
renal	O
cortical	O
homogenates	O
in	O
a	O
concentration-dependent	O
manner	O
.	O

Pretreatment	O
of	O
animals	O
with	O
BNPP	B_Chemical
prior	O
to	O
APAP	B_Chemical
or	O
PAP	B_Chemical
administration	O
resulted	O
in	O
marked	O
reduction	O
of	O
APAP	B_Chemical
(	O
900	O
mg/kg	O
)	O
nephrotoxicity	B_Disease
but	O
not	O
PAP	B_Chemical
nephrotoxicity	B_Disease
.	O

This	O
result	O
was	O
not	O
due	O
to	O
altered	O
disposition	O
of	O
either	O
APAP	B_Chemical
or	O
acetylated	O
metabolites	O
in	O
plasma	O
or	O
renal	O
cortical	O
and	O
hepatic	O
tissue	O
.	O

Rather	O
,	O
BNPP	B_Chemical
pretreatment	O
reduced	O
the	O
fraction	O
of	O
APAP	B_Chemical
excreted	O
as	O
PAP	B_Chemical
by	O
64	O
and	O
75	O
%	O
after	O
APAP	B_Chemical
doses	O
of	O
750	O
and	O
900	O
mg/kg	O
.	O

BNPP	B_Chemical
did	O
not	O
alter	O
the	O
excretion	O
of	O
APAP	B_Chemical
or	O
any	O
of	O
its	O
non-deacetylated	O
metabolites	O
nor	O
did	O
BNPP	B_Chemical
alter	O
excretion	O
of	O
PAP	B_Chemical
or	O
its	O
metabolites	O
after	O
PAP	B_Chemical
doses	O
of	O
150	O
and	O
300	O
mg/kg	O
.	O

Therefore	O
,	O
the	O
BNPP-induced	O
reduction	O
in	O
APAP-induced	O
nephrotoxicity	B_Disease
appears	O
to	O
be	O
due	O
to	O
inhibition	O
of	O
APAP	B_Chemical
deacetylation	O
.	O

It	O
is	O
concluded	O
that	O
PAP	B_Chemical
formation	O
,	O
in	O
vivo	O
,	O
accounts	O
,	O
at	O
least	O
in	O
part	O
,	O
for	O
APAP-induced	O
renal	B_Disease
tubular	I_Disease
necrosis	I_Disease
.	O

Morphine-induced	O
seizures	B_Disease
in	O
newborn	O
infants	O
.	O

Two	O
neonates	O
suffered	O
from	O
generalized	O
seizures	B_Disease
during	O
the	O
course	O
of	O
intravenous	O
morphine	B_Chemical
sulfate	I_Chemical
for	O
post-operative	O
analgesia	O
.	O

They	O
received	O
morphine	B_Chemical
in	O
doses	O
of	O
32	O
micrograms/kg/hr	O
and	O
40	O
micrograms/kg/hr	O
larger	O
than	O
a	O
group	O
of	O
10	O
neonates	O
who	O
received	O
6	O
-	O
24	O
micrograms/kg/hr	O
and	O
had	O
no	O
seizures	B_Disease
.	O

Plasma	O
concentrations	O
of	O
morphine	B_Chemical
in	O
these	O
neonates	O
was	O
excessive	O
(	O
60	O
and	O
90	O
mg/ml	O
)	O
.	O

Other	O
known	O
reasons	O
for	O
seizures	B_Disease
were	O
ruled	O
out	O
and	O
the	O
convulsions	B_Disease
stopped	O
a	O
few	O
hours	O
after	O
cessation	O
of	O
morphine	B_Chemical
and	O
did	O
not	O
reoccur	O
in	O
the	O
subsequent	O
8	O
months	O
.	O

It	O
is	O
suggested	O
that	O
post-operative	O
intravenous	O
morphine	B_Chemical
should	O
not	O
exceed	O
20	O
micrograms/kg/ml	O
in	O
neonates	O
.	O

Indomethacin	B_Chemical
induced	O
hypotension	B_Disease
in	O
sodium	B_Chemical
and	O
volume	O
depleted	O
rats	O
.	O

After	O
a	O
single	O
oral	O
dose	O
of	O
4	O
mg/kg	O
indomethacin	B_Chemical
(	O
IDM	B_Chemical
)	O
to	O
sodium	B_Chemical
and	O
volume	O
depleted	O
rats	O
plasma	O
renin	O
activity	O
(	O
PRA	O
)	O
and	O
systolic	O
blood	O
pressure	O
fell	O
significantly	O
within	O
four	O
hours	O
.	O

In	O
sodium	B_Chemical
repleted	O
animals	O
indomethacin	B_Chemical
did	O
not	O
change	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
although	O
plasma	O
renin	O
activity	O
was	O
decreased	O
.	O

Thus	O
,	O
indomethacin	B_Chemical
by	O
inhibition	O
of	O
prostaglandin	B_Chemical
synthesis	O
may	O
diminish	O
the	O
blood	O
pressure	O
maintaining	O
effect	O
of	O
the	O
stimulated	O
renin-angiotensin	O
system	O
in	O
sodium	B_Chemical
and	O
volume	O
depletion	O
.	O

On	O
the	O
antiarrhythmic	O
activity	O
of	O
one	O
N-substituted	O
piperazine	B_Chemical
derivative	O
of	O
trans-2-amino-3-hydroxy-1	B_Chemical
,	I_Chemical
2	I_Chemical
,	I_Chemical
3	I_Chemical
,	I_Chemical
4-tetrahydroanaphthalene	I_Chemical
.	O

The	O
antiarrhythmic	O
activity	O
of	O
the	O
compound	O
N-(trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-N-(3-oxo-3-phenyl-2-methylpropyl)-piperazine	B_Chemical
hydrochloride	I_Chemical
,	O
referred	O
to	O
as	O
P11	B_Chemical
,	O
is	O
studied	O
on	O
anaesthesized	O
cats	O
and	O
Wistar	O
albino	O
rats	O
,	O
as	O
well	O
as	O
on	O
non-anaesthesized	O
rabbits	O
.	O

Four	O
types	O
of	O
experimental	O
arrhythmia	B_Disease
are	O
used	O
--	O
with	O
BaCl2	B_Chemical
,	O
with	O
chloroform-adrenaline	O
,	O
with	O
strophantine	B_Chemical
G	I_Chemical
and	O
with	O
aconitine	B_Chemical
.	O

The	O
compound	O
P11	B_Chemical
is	O
introduced	O
in	O
doses	O
of	O
0.25	O
and	O
0.50	O
mg/kg	O
intravenously	O
and	O
10	O
mg/kg	O
orally	O
.	O

The	O
compound	O
manifests	O
antiarrhythmic	O
activity	O
in	O
all	O
models	O
of	O
experimental	O
arrhythmia	B_Disease
used	O
,	O
causing	O
greatest	O
inhibition	O
on	O
the	O
arrhythmia	B_Disease
induced	O
by	O
chloroform-adrenaline	O
(	O
in	O
90	O
per	O
cent	O
)	O
and	O
with	O
BaCl2	B_Chemical
(	O
in	O
84	O
per	O
cent	O
)	O
.	O

The	O
results	O
obtained	O
are	O
associated	O
with	O
the	O
beta-adrenoblocking	O
and	O
with	O
the	O
membrane-stabilizing	O
action	O
of	O
the	O
compound	O
.	O

Recurrent	O
subarachnoid	B_Disease
hemorrhage	I_Disease
associated	O
with	O
aminocaproic	B_Chemical
acid	I_Chemical
therapy	O
and	O
acute	B_Disease
renal	I_Disease
artery	I_Disease
thrombosis	I_Disease
.	O

Case	O
report	O
.	O

Epsilon	B_Chemical
aminocaproic	I_Chemical
acid	I_Chemical
(	O
EACA	B_Chemical
)	O
has	O
been	O
used	O
to	O
prevent	O
rebleeding	O
in	O
patients	O
with	O
subarachnoid	B_Disease
hemorrhage	I_Disease
(	O
SAH	B_Disease
)	O
.	O

Although	O
this	O
agent	O
does	O
decrease	O
the	O
frequency	O
of	O
rebleeding	O
,	O
several	O
reports	O
have	O
described	O
thrombotic	B_Disease
complications	O
of	O
EACA	B_Chemical
therapy	O
.	O

These	O
complications	O
have	O
included	O
clinical	O
deterioration	O
and	O
intracranial	B_Disease
vascular	I_Disease
thrombosis	I_Disease
in	O
patients	O
with	O
SAH	B_Disease
,	O
arteriolar	O
and	O
capillary	O
fibrin	O
thrombi	B_Disease
in	O
patients	O
with	O
fibrinolytic	O
syndromes	O
treated	O
with	O
EACA	B_Chemical
,	O
or	O
other	O
thromboembolic	B_Disease
phenomena	I_Disease
.	O

Since	O
intravascular	O
fibrin	O
thrombi	B_Disease
are	O
often	O
observed	O
in	O
patients	O
with	O
fibrinolytic	O
disorders	O
,	O
EACA	B_Chemical
should	O
not	O
be	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
fibrin	O
thrombi	B_Disease
in	O
patients	O
with	O
disseminated	B_Disease
intravascular	I_Disease
coagulation	I_Disease
or	O
other	O
"	O
consumption	B_Disease
coagulopathies	I_Disease
.	O
"	O
This	O
report	O
describes	O
subtotal	O
infarction	B_Disease
of	O
the	O
kidney	O
due	O
to	O
thrombosis	B_Disease
of	I_Disease
a	I_Disease
normal	I_Disease
renal	I_Disease
artery	I_Disease
.	O

This	O
occlusion	O
occurred	O
after	O
EACA	B_Chemical
therapy	O
in	O
a	O
patient	O
with	O
SAH	B_Disease
and	O
histopathological	O
documentation	O
of	O
recurrent	O
SAH	B_Disease
.	O

The	O
corresponding	O
clinical	O
event	O
was	O
characterized	O
by	O
marked	O
hypertension	B_Disease
and	O
abrupt	O
neurological	O
deterioration	O
.	O

Effect	O
of	O
vincristine	B_Chemical
sulfate	I_Chemical
on	O
Pseudomonas	B_Disease
infections	I_Disease
in	O
monkeys	O
.	O

In	O
rhesus	O
monkeys	O
,	O
intravenous	O
challenge	O
with	O
0.6	O
x	O
10(10	O
)	O
to	O
2.2	O
x	O
10(10)Pseudomonas	O
aeruginosa	O
organisms	O
caused	O
acute	O
illness	O
of	O
4	O
to	O
5	O
days	O
'	O
duration	O
with	O
spontaneous	O
recovery	O
in	O
13	O
of	O
15	O
monkeys	O
;	O
blood	O
cultures	O
became	O
negative	O
3	O
to	O
17	O
days	O
after	O
challenge	O
.	O

Leukocytosis	B_Disease
was	O
observed	O
in	O
all	O
monkeys	O
.	O

Intravenous	O
or	O
intratracheal	O
inoculation	O
of	O
2.0	O
to	O
2.5	O
mg	O
of	O
vincristine	B_Chemical
sulfate	I_Chemical
was	O
followed	O
by	O
leukopenia	B_Disease
in	O
4	O
to	O
5	O
days	O
.	O

Intravenous	O
inoculation	O
of	O
4.2	O
x	O
10(10	O
)	O
to	O
7.8	O
x	O
10(10	O
)	O
pyocin	O
type	O
6	O
Pseudomonas	O
organisms	O
in	O
monkeys	O
given	O
vincristine	B_Chemical
sulfate	I_Chemical
4	O
days	O
previously	O
resulted	O
in	O
fatal	O
infection	B_Disease
in	O
11	O
of	O
14	O
monkeys	O
,	O
whereas	O
none	O
of	O
four	O
receiving	O
Pseudomonas	O
alone	O
died	O
.	O

These	O
studies	O
suggest	O
that	O
an	O
antimetabolite-induced	O
leukopenia	B_Disease
predisposes	O
to	O
severe	O
Pseudomonas	O
sepsis	B_Disease
and	O
that	O
such	O
monkeys	O
may	O
serve	O
as	O
a	O
biological	O
model	O
for	O
study	O
of	O
comparative	O
efficacy	O
of	O
antimicrobial	O
agents	O
.	O

Modification	O
by	O
propranolol	B_Chemical
of	O
cardiovascular	O
effects	O
of	O
induced	O
hypoglycaemia	B_Disease
.	O

The	O
cardiovascular	O
effects	O
of	O
hypoglycaemia	B_Disease
,	O
with	O
and	O
without	O
beta-blockade	O
,	O
were	O
compared	O
in	O
fourteen	O
healthy	O
men	O
.	O

Eight	O
received	O
insulin	O
alone	O
,	O
and	O
eight	O
,	O
including	O
two	O
of	O
the	O
original	O
insulin-only	O
group	O
,	O
were	O
given	O
propranolol	B_Chemical
and	O
insulin	O
.	O

In	O
the	O
insulin-group	O
the	O
period	O
of	O
hypoglycaemia	B_Disease
was	O
associated	O
with	O
an	O
increase	O
in	O
heart-rate	O
and	O
a	O
fall	O
in	O
diastolic	O
blood-pressure	O
.	O

In	O
the	O
propranolol-insulin	O
group	O
there	O
was	O
a	O
significant	O
fall	O
in	O
heart-rate	O
in	O
most	O
subjects	O
and	O
an	O
increase	O
in	O
diastolic	O
pressure	O
.	O

Typical	O
S-T/T	O
changes	O
occurred	O
in	O
the	O
insulin-group	O
but	O
in	O
none	O
of	O
the	O
propranolol-insulin	O
group	O
.	O

Hypertension	B_Disease
in	O
diabetics	B_Disease
prone	O
to	O
hypoglycaemia	B_Disease
attacks	O
should	O
not	O
be	O
treated	O
with	O
beta-blockers	O
because	O
these	O
drugs	O
may	O
cause	O
a	O
sharp	O
rise	O
in	O
blood-pressure	O
in	O
such	O
patients	O
.	O

Long-term	O
propranolol	O
therapy	O
in	O
pregnancy	O
:	O
maternal	O
and	O
fetal	O
outcome	O
.	O

Propranolol	B_Chemical
,	O
a	O
beta-adrenergic	O
blocking	O
agent	O
,	O
has	O
found	O
an	O
important	O
position	O
in	O
the	O
practice	O
of	O
medicine	O
.	O

Its	O
use	O
in	O
pregnancy	O
,	O
however	O
,	O
is	O
an	O
open	O
question	O
as	O
a	O
number	O
of	O
detrimental	O
side	O
effects	O
have	O
been	O
reported	O
in	O
the	O
fetus	O
and	O
neonate	O
.	O

Ten	O
patients	O
and	O
12	O
pregnancies	O
are	O
reported	O
where	O
chronic	O
propranolol	B_Chemical
has	O
been	O
administered	O
.	O

Five	O
patients	O
with	O
serial	O
pregnancies	O
with	O
and	O
without	O
propranolol	B_Chemical
therapy	O
are	O
also	O
examined	O
.	O

Maternal	O
,	O
fetal	O
,	O
and	O
neonatal	O
complications	O
are	O
examined	O
.	O

An	O
attempt	O
is	O
made	O
to	O
differentiate	O
drug-related	O
complications	O
from	O
maternal	O
disease	O
--	O
related	O
complications	O
.	O

We	O
conclude	O
that	O
previously	O
reported	O
hypoglycemia	B_Disease
,	O
hyperbilirubinemia	B_Disease
,	O
polycythemia	B_Disease
,	O
neonatal	B_Disease
apnea	I_Disease
,	O
and	O
bradycardia	B_Disease
are	O
not	O
invariable	O
and	O
can	O
not	O
be	O
statistically	O
correlated	O
with	O
chronic	O
propranolol	B_Chemical
therapy	O
.	O

Growth	B_Disease
retardation	I_Disease
,	O
however	O
,	O
appears	O
to	O
be	O
significant	O
in	O
both	O
of	O
our	O
series	O
.	O

Central	O
excitatory	O
actions	O
of	O
flurazepam	O
.	O

Toxic	O
actions	O
of	O
flurazepam	B_Chemical
(	O
FZP	B_Chemical
)	O
were	O
studied	O
in	O
cats	O
,	O
mice	O
and	O
rats	O
.	O

High	O
doses	O
caused	O
an	O
apparent	O
central	O
excitation	O
,	O
most	O
clearly	O
seen	O
as	O
clonic	O
convulsions	B_Disease
,	O
superimposed	O
on	O
general	O
depression	B_Disease
.	O

Following	O
a	O
lethal	O
dose	O
,	O
death	O
was	O
always	O
associated	O
with	O
convulsions	B_Disease
.	O

Comparing	O
the	O
relative	O
sensitivity	O
to	O
central	O
depression	B_Disease
and	O
excitation	O
revealed	O
that	O
rats	O
were	O
least	O
likely	O
to	O
have	O
convulsions	B_Disease
at	O
doses	O
that	O
did	O
not	O
first	O
cause	O
loss	B_Disease
of	I_Disease
consciousness	I_Disease
,	O
while	O
cats	O
most	O
clearly	O
showed	O
marked	O
central	O
excitatory	O
actions	O
.	O

Signs	O
of	O
FZP	B_Chemical
toxocity	B_Disease
in	O
cats	O
included	O
excessive	O
salivation	B_Disease
,	O
extreme	O
apprehensive	O
behavior	O
,	O
retching	O
,	O
muscle	B_Disease
tremors	I_Disease
and	O
convulsions	B_Disease
.	O

An	O
interaction	O
between	O
FZP	B_Chemical
and	O
pentylenetetrazol	B_Chemical
(	O
PTZ	B_Chemical
)	O
was	O
shown	O
by	O
pretreating	O
mice	O
with	O
FZP	B_Chemical
before	O
PTZ	B_Chemical
challenge	O
.	O

As	O
a	O
function	O
of	O
dose	O
,	O
FZP	B_Chemical
first	O
protected	O
against	O
convulsions	B_Disease
and	O
death	O
.	O

At	O
higher	O
doses	O
,	O
however	O
,	O
convulsions	B_Disease
again	O
emerged	O
.	O

These	O
doses	O
of	O
FZP	B_Chemical
were	O
lower	O
than	O
those	O
that	O
would	O
alone	O
cause	O
convulsions	B_Disease
.	O

These	O
results	O
may	O
be	O
relevant	O
to	O
the	O
use	O
of	O
FZP	B_Chemical
in	O
clinical	O
situations	O
in	O
which	O
there	O
is	O
increased	O
neural	O
excitability	O
,	O
such	O
as	O
epilepsy	B_Disease
or	O
sedative-hypnotic	O
drug	O
withdrawal	O
.	O

Use	O
of	O
propranolol	B_Chemical
in	O
the	O
treatment	O
of	O
idiopathic	B_Disease
orthostatic	I_Disease
hypotension	I_Disease
.	O

Five	O
patients	O
with	O
idiopathic	B_Disease
orthostatic	I_Disease
hypotension	I_Disease
who	O
had	O
physiologic	O
and	O
biochemical	O
evidence	O
of	O
severe	O
autonomic	O
dysfunction	O
were	O
included	O
in	O
the	O
study	O
.	O

They	O
all	O
exhibited	O
markedly	O
reduced	O
plasma	O
catecholamines	B_Chemical
and	O
plasma	O
renin	O
activity	O
in	O
both	O
recumbent	O
and	O
upright	O
positions	O
and	O
had	O
marked	O
hypersensitivity	B_Disease
to	O
the	O
pressor	O
effects	O
of	O
infused	O
norepinephrine	B_Chemical
.	O

Treatment	O
with	O
propanolol	B_Chemical
administered	O
intravenously	O
(	O
1	O
-	O
5	O
mg	O
)	O
produced	O
increases	O
in	O
supine	O
and	O
upright	O
blood	O
pressure	O
in	O
4	O
of	O
the	O
5	O
individuals	O
with	O
rises	O
ranging	O
from	O
11/6	O
to	O
22/11	O
mmHg	O
.	O

Chronic	O
oral	O
administration	O
of	O
propranolol	B_Chemical
(	O
40	O
-	O
160	O
mg/day	O
)	O
also	O
elevated	O
the	O
blood	O
pressures	O
of	O
these	O
individuals	O
with	O
increases	O
in	O
the	O
order	O
of	O
20	O
-	O
35/15	O
-	O
25	O
mmg	O
being	O
observed	O
.	O

In	O
1	O
patient	O
,	O
marked	O
hypertension	B_Disease
was	O
induced	O
by	O
propranolol	B_Chemical
and	O
the	O
drug	O
had	O
to	O
be	O
withdrawn	O
.	O

It	O
otherwise	O
was	O
well	O
tolerated	O
and	O
no	O
important	O
side	O
effects	O
were	O
observed	O
.	O

Treatment	O
has	O
been	O
continued	O
in	O
3	O
individuals	O
for	O
6	O
-	O
13	O
months	O
with	O
persistence	O
of	O
the	O
pressor	O
effect	O
,	O
although	O
there	O
appears	O
to	O
have	O
been	O
some	O
decrease	O
in	O
the	O
degree	O
of	O
response	O
with	O
time	O
.	O

Hemodynamic	O
measurements	O
in	O
1	O
of	O
the	O
patients	O
demonstrated	O
an	O
increase	O
in	O
total	O
peripheral	O
resistance	O
and	O
essentially	O
no	O
change	O
in	O
cardiac	O
output	O
following	O
propranolol	B_Chemical
therapy	O
.	O

The	O
studies	O
suggest	O
that	O
propranolol	B_Chemical
is	O
a	O
useful	O
drug	O
in	O
selected	O
patients	O
with	O
severe	O
idiopathic	B_Disease
orthostatic	I_Disease
hypotension	I_Disease
.	O

Total	O
intravenous	O
anesthesia	O
with	O
etomidate	O
.	O

III	O
.	O
Some	O
observations	O
in	O
adults	O
.	O

An	O
investigation	O
was	O
undertaken	O
to	O
determine	O
the	O
dosage	O
of	O
etomidate	B_Chemical
required	O
to	O
maintain	O
sleep	O
in	O
adults	O
undergoing	O
surgery	O
under	O
regional	O
local	O
anesthesia	O
.	O

Premedication	O
of	O
diazepam	B_Chemical
10	O
mg	O
and	O
atropine	B_Chemical
0.5	O
mg	O
was	O
given	O
,	O
and	O
sleep	O
was	O
induced	O
and	O
maintained	O
by	O
intermittent	O
intravenous	O
injections	O
of	O
etomidate	B_Chemical
0.1/mg/kg	O
,	O
given	O
whenever	O
the	O
patient	O
would	O
open	O
his	O
eyes	O
on	O
request	O
.	O

A	O
mean	O
overall	O
dose	O
of	O
etomidate	B_Chemical
17.4	O
microgram/kg/min	O
.	O
was	O
required	O
to	O
maintain	O
sleep	O
,	O
but	O
great	O
individual	O
variation	O
occurred	O
,	O
with	O
older	O
patients	O
requiring	O
less	O
drug	O
.	O

The	O
investigation	O
was	O
discontinued	O
after	O
18	O
patients	O
because	O
of	O
the	O
frequency	O
and	O
intensity	O
of	O
side-effects	O
,	O
particularly	O
pain	B_Disease
and	O
myoclonia	B_Disease
,	O
which	O
caused	O
the	O
technique	O
to	O
be	O
abandoned	O
in	O
two	O
cases	O
.	O

It	O
is	O
considered	O
unlikely	O
that	O
etomidate	B_Chemical
will	O
prove	O
to	O
be	O
the	O
hypnotic	O
of	O
choice	O
for	O
a	O
totally	O
intravenous	O
anesthetic	O
technique	O
in	O
adults	O
because	O
of	O
the	O
high	O
incidence	O
of	O
myoclonia	B_Disease
after	O
prolonged	O
administration	O
.	O

In	O
several	O
patients	O
uncontrollable	O
muscle	O
movements	O
persisted	O
for	O
many	O
minutes	O
after	O
complete	O
recovery	O
of	O
consciousness	O
.	O

Evidence	O
for	O
cardiac	O
beta	O
2-adrenoceptors	O
in	O
man	O
.	O

We	O
compared	O
the	O
effects	O
of	O
single	O
doses	O
of	O
50	O
mg	O
atenolol	B_Chemical
(	O
cardioselective	O
)	O
,	O
40	O
mg	O
propranolol	B_Chemical
(	O
nonselective	O
)	O
,	O
and	O
placebo	O
on	O
both	O
exercise-	O
and	O
isoproterenol-induced	O
tachycardia	B_Disease
in	O
two	O
experiments	O
involving	O
nine	O
normal	O
subjects	O
.	O

Maximal	O
exercise	O
heart	O
rate	O
was	O
reduced	O
from	O
187	O
+	O
/-	O
4(SEM	O
)	O
after	O
placebo	O
to	O
146	O
+	O
/-	O
7	O
bpm	O
after	O
atenolol	B_Chemical
and	O
138	O
+	O
/-	O
6	O
bpm	O
after	O
propranolol	B_Chemical
,	O
but	O
there	O
were	O
no	O
differences	O
between	O
the	O
drugs	O
.	O

The	O
effects	O
on	O
isoproterenol	B_Chemical
tachycardia	B_Disease
were	O
determined	O
before	O
and	O
after	O
atropine	B_Chemical
(	O
0.04	O
mg/kg	O
IV	O
)	O
.	O

Isoproterenol	B_Chemical
sensitivity	O
was	O
determined	O
as	O
the	O
intravenous	O
dose	O
that	O
increased	O
heart	O
rate	O
by	O
25	O
bpm	O
(	O
CD25	O
)	O
and	O
this	O
was	O
increased	O
from	O
1.8	O
+	O
/-	O
0.3	O
micrograms	O
after	O
placebo	O
to	O
38.9	O
+	O
/-	O
8.3	O
micrograms	O
after	O
propranolol	B_Chemical
and	O
8.3	O
+	O
/-	O
1.7	O
micrograms	O
after	O
atenolol	B_Chemical
.	O

The	O
difference	O
in	O
the	O
effects	O
of	O
the	O
two	O
was	O
significant	O
.	O

After	O
atropine	B_Chemical
the	O
CD25	O
was	O
unchanged	O
after	O
placebo	O
(	O
2.3	O
+	O
/-	O
0.3	O
micrograms	O
)	O
and	O
atenolol	B_Chemical
(	O
7.7	O
+	O
/-	O
1.3	O
micrograms	O
)	O
;	O
it	O
was	O
reduced	O
after	O
propranolol	B_Chemical
(	O
24.8	O
+	O
/-	O
5.0	O
micrograms	O
)	O
,	O
but	O
remained	O
different	O
from	O
atenolol	B_Chemical
.	O

This	O
change	O
with	O
propranolol	B_Chemical
sensitivity	O
was	O
calculated	O
as	O
the	O
apparent	O
Ka	O
,	O
this	O
was	O
unchanged	O
by	O
atropine	B_Chemical
(	O
11.7	O
+	O
/-	O
2.1	O
and	O
10.1	O
+	O
/-	O
2.5	O
ml/ng	O
)	O
.	O

These	O
data	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
exercise-induced	O
tachycardia	B_Disease
results	O
largely	O
from	O
beta	O
1-receptor	O
activation	O
that	O
is	O
blocked	O
by	O
both	O
cardioselective	O
and	O
nonselective	O
drugs	O
,	O
whereas	O
isoproterenol	B_Chemical
activates	O
both	O
beta	O
1-	O
and	O
beta	O
2-receptors	O
so	O
that	O
after	O
cardioselective	O
blockade	O
there	O
remains	O
a	O
beta	O
2-component	O
that	O
can	O
be	O
blocked	O
with	O
a	O
nonselective	O
drug	O
.	O

While	O
there	O
appear	O
to	O
be	O
beta	O
2-receptors	O
in	O
the	O
human	O
heart	O
,	O
their	O
physiologic	O
or	O
pathologic	O
roles	O
remain	O
to	O
be	O
defined	O
.	O

Hormones	O
and	O
risk	O
of	O
breast	O
cancer	O
.	O

This	O
paper	O
reports	O
the	O
results	O
of	O
a	O
study	O
of	O
50	O
menopausal	O
women	O
receiving	O
hormonal	O
replacement	O
therapy	O
.	O

The	O
majority	O
(	O
29	O
)	O
had	O
surgical	O
menopause	O
;	O
their	O
mean	O
age	O
was	O
45.7	O
years	O
.	O

It	O
was	O
hypothesized	O
that	O
progestins	B_Chemical
could	O
equilibrate	O
the	O
effects	O
of	O
the	O
estrogenic	O
stimulation	O
on	O
the	O
mammary	O
and	O
endometrial	O
target	O
tissues	O
of	O
women	O
on	O
hormonal	O
replacement	O
therapy	O
.	O

The	O
treatment	O
schedule	O
consisted	O
of	O
conjugated	B_Chemical
estrogens	I_Chemical
(	O
Premarin	B_Chemical
)	O
1.25	O
mg/day	O
for	O
21	O
days	O
and	O
Medroxyprogesterone	B_Chemical
acetate	I_Chemical
10	O
mg/day	O
for	O
10	O
days	O
in	O
each	O
month	O
.	O

The	O
mean	O
treatment	O
period	O
was	O
18	O
months	O
.	O

During	O
the	O
follow-up	O
period	O
,	O
attention	O
was	O
paid	O
to	O
breast	O
modifications	O
as	O
evidenced	O
by	O
symptomatology	O
,	O
physical	O
examination	O
,	O
and	O
plate	O
thermography	O
.	O

Mastodynia	B_Disease
was	O
reported	O
by	O
21	O
patients	O
,	O
and	O
physical	O
examination	O
revealed	O
a	O
light	O
increase	O
in	O
breast	O
firmness	O
in	O
12	O
women	O
and	O
a	O
moderate	O
increase	O
in	O
breast	O
nodularity	O
in	O
2	O
women	O
.	O

Themography	O
confirmed	O
the	O
existence	O
of	O
an	O
excessive	O
breast	O
stimulation	O
in	O
1	O
women	O
who	O
complained	O
of	O
moderate	O
mastodynia	B_Disease
and	O
in	O
5	O
of	O
the	O
7	O
women	O
who	O
complained	O
of	O
severe	O
mastodynia	B_Disease
.	O

Normalization	O
was	O
obtained	O
by	O
halving	O
the	O
estrogen	B_Chemical
dose	O
.	O

These	O
results	O
suggest	O
that	O
hormonal	O
replacement	O
therapy	O
can	O
be	O
safely	O
prescribed	O
if	O
the	O
following	O
criteria	O
are	O
satisfied	O
:	O
1	O
)	O
preliminary	O
evaluation	O
of	O
patients	O
from	O
a	O
clinical	O
,	O
metabolic	O
,	O
cytologic	O
,	O
and	O
mammographic	O
perspective	O
;	O
2	O
)	O
cyclic	O
treatment	O
schedule	O
,	O
with	O
a	O
progestative	O
phase	O
of	O
10	O
days	O
;	O
and	O
3	O
)	O
periodic	O
complete	O
follow-up	O
,	O
with	O
accurate	O
thermographic	O
evaluation	O
of	O
the	O
breast	O
target	O
tissues	O
.	O

Early	O
infections	B_Disease
in	O
kidney	O
,	O
heart	O
,	O
and	O
liver	O
transplant	O
recipients	O
on	O
cyclosporine	B_Chemical
.	O

Eighty-one	O
renal	O
,	O
seventeen	O
heart	O
,	O
and	O
twenty-four	O
liver	O
transplant	O
patients	O
were	O
followed	O
for	O
infection	B_Disease
.	O

Seventeen	O
renal	O
patients	O
received	O
azathioprine	B_Chemical
(	O
Aza	B_Chemical
)	O
and	O
prednisone	B_Chemical
as	O
part	O
of	O
a	O
randomized	O
trial	O
of	O
immunosuppression	O
with	O
21	O
cyclosporine-and-prednisone-treated	O
renal	O
transplant	O
patients	O
.	O

All	O
others	O
received	O
cyclosporine	B_Chemical
and	O
prednisone	B_Chemical
.	O

The	O
randomized	O
Aza	B_Chemical
patients	O
had	O
more	O
overall	O
infections	B_Disease
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
more	O
nonviral	O
infections	B_Disease
(	O
P	O
less	O
than	O
0.02	O
)	O
than	O
the	O
randomized	O
cyclosporine	B_Chemical
patients	O
.	O

Heart	O
and	O
liver	O
patients	O
had	O
more	O
infections	B_Disease
than	O
cyclosporine	B_Chemical
renal	O
patients	O
but	O
fewer	O
infections	B_Disease
than	O
the	O
Aza	B_Chemical
renal	O
patients	O
.	O

There	O
were	O
no	O
infectious	O
deaths	O
in	O
renal	O
transplant	O
patients	O
on	O
cyclosporine	B_Chemical
or	O
Aza	B_Chemical
,	O
but	O
infection	B_Disease
played	O
a	O
major	O
role	O
in	O
3	O
out	O
of	O
6	O
cardiac	O
transplant	O
deaths	O
and	O
in	O
8	O
out	O
of	O
9	O
liver	O
transplant	O
deaths	O
.	O

Renal	O
patients	O
on	O
cyclosporine	B_Chemical
had	O
the	O
fewest	O
bacteremias	B_Disease
.	O

Analysis	O
of	O
site	O
of	O
infection	B_Disease
showed	O
a	O
preponderance	O
of	O
abdominal	B_Disease
infections	I_Disease
in	O
liver	O
patients	O
,	O
intrathoracic	O
infections	B_Disease
in	O
heart	O
patients	O
,	O
and	O
urinary	B_Disease
tract	I_Disease
infections	I_Disease
in	O
renal	O
patients	O
.	O

Pulmonary	O
infections	B_Disease
were	O
less	O
common	O
in	O
cyclosporine-treated	O
renal	O
patients	O
than	O
in	O
Aza-treated	O
patients	O
(	O
P	O
less	O
than	O
0.05	O
)	O
.	O

Aza	B_Chemical
patients	O
had	O
significantly	O
more	O
staphylococcal	B_Disease
infections	I_Disease
than	O
all	O
other	O
transplant	O
groups	O
(	O
P	O
less	O
than	O
0.005	O
)	O
,	O
and	O
systemic	O
fungal	B_Disease
infections	I_Disease
occurred	O
only	O
in	O
the	O
liver	O
transplant	O
group	O
.	O

Cytomegalovirus	O
(	O
CMV	O
)	O
shedding	O
or	O
serological	O
rises	O
in	O
antibody	O
titer	O
,	O
or	O
both	O
occurred	O
in	O
78	O
%	O
of	O
cyclosporine	B_Chemical
patients	O
and	O
76	O
%	O
of	O
Aza	B_Chemical
patients	O
.	O

Of	O
the	O
cyclosporine	B_Chemical
patients	O
,	O
15	O
%	O
had	O
symptoms	O
related	O
to	O
CMV	B_Disease
infection	I_Disease
.	O

Serological	O
evidence	O
for	O
Epstein	B_Disease
Barr	I_Disease
Virus	I_Disease
infection	I_Disease
was	O
found	O
in	O
20	O
%	O
of	O
65	O
cyclosporine	B_Chemical
patients	O
studied	O
.	O

Three	O
had	O
associated	O
symptoms	O
,	O
and	O
one	O
developed	O
a	O
lymphoma	B_Disease
.	O

Structure-activity	O
and	O
dose-effect	O
relationships	O
of	O
the	O
antagonism	O
of	O
picrotoxin-induced	O
seizures	B_Disease
by	O
cholecystokinin	B_Chemical
,	O
fragments	O
and	O
analogues	O
of	O
cholecystokinin	B_Chemical
in	O
mice	O
.	O

Intraperitoneal	O
administration	O
of	O
cholecystokinin	B_Chemical
octapeptide	I_Chemical
sulphate	O
ester	O
(	O
CCK-8-SE	O
)	O
and	O
nonsulphated	O
cholecystokinin	B_Chemical
octapeptide	I_Chemical
(	O
CCK-8-NS	O
)	O
enhanced	O
the	O
latency	O
of	O
seizures	B_Disease
induced	O
by	O
picrotoxin	B_Chemical
in	O
mice	O
.	O

Experiments	O
with	O
N-	O
and	O
C-terminal	O
fragments	O
revealed	O
that	O
the	O
C-terminal	O
tetrapeptide	O
(	O
CCK-5	O
-	O
8)	O
was	O
the	O
active	O
centre	O
of	O
the	O
CCK	O
octapeptide	O
molecule	O
.	O

The	O
analogues	O
CCK-8-SE	O
and	O
CCK-8-NS	O
(	O
dose	O
range	O
0.2	O
-	O
6.4	O
mumol/kg	O
)	O
and	O
caerulein	B_Chemical
dose	O
range	O
0.1	O
-	O
0.8	O
mumol/kg	O
)	O
showed	O
bell-shaped	O
dose-effect	O
curves	O
,	O
with	O
the	O
greatest	O
maximum	O
inhibition	O
for	O
CCK-8-NS	O
.	O

The	O
peptide	O
CCK-5	O
-	O
8	O
had	O
weak	O
anticonvulsant	O
activity	O
in	O
comparison	O
to	O
the	O
octapeptides	O
,	O
3.2	O
mumol/kg	O
and	O
larger	O
doses	O
of	O
the	O
reference	O
drug	O
,	O
diazepam	B_Chemical
,	O
totally	O
prevented	O
picrotoxin-induced	O
seizures	B_Disease
and	O
mortality	O
.	O

The	O
maximum	O
effect	O
of	O
the	O
peptides	O
tested	O
was	O
less	O
than	O
that	O
of	O
diazepam	B_Chemical
.	O

Experiments	O
with	O
analogues	O
and	O
derivatives	O
of	O
CCK-5	O
-	O
8	O
demonstrated	O
that	O
the	O
effectiveness	O
of	O
the	O
beta-alanyl	O
derivatives	O
of	O
CCK-5	O
-	O
8	O
were	O
enhanced	O
and	O
that	O
they	O
were	O
equipotent	O
with	O
CCK-8-SE	O
.	O

Of	O
the	O
CCK-2	O
-	O
8	O
analogues	O
,	O
Ser(SO3H)7-Ac-CCK-2	O
-	O
8-SE	O
and	O
Thr(SO3H)7-Ac-CCK-2	O
-	O
8-SE	O
and	O
Hyp(SO3H)-Ac-CCK-2	O
-	O
8-SE	O
were	O
slightly	O
more	O
active	O
than	O
CCK-8-SE	O
.	O

Vasopressin	B_Chemical
as	O
a	O
possible	O
contributor	O
to	O
hypertension	B_Disease
.	O

The	O
role	O
of	O
vasopressin	B_Chemical
as	O
a	O
pressor	O
agent	O
to	O
the	O
hypertensive	B_Disease
process	O
was	O
examined	O
.	O

Vasopressin	B_Chemical
plays	O
a	O
major	O
role	O
in	O
the	O
pathogenesis	O
of	O
DOCA-salt	O
hypertension	B_Disease
,	O
since	O
the	O
elevation	O
of	O
blood	O
pressure	O
was	O
not	O
substantial	O
in	O
the	O
rats	O
with	O
lithium-treated	O
diabetes	B_Disease
insipidus	I_Disease
after	O
DOCA-salt	O
treatment	O
.	O

Administration	O
of	O
DDAVP	B_Chemical
which	O
has	O
antidiuretic	O
action	O
but	O
minimal	O
vasopressor	O
effect	O
failed	O
to	O
increase	O
blood	O
pressure	O
to	O
the	O
levels	O
observed	O
after	O
administration	O
of	O
AVP	O
.	O

Furthermore	O
,	O
the	O
pressor	O
action	O
of	O
vasopressin	B_Chemical
appears	O
to	O
be	O
important	O
in	O
the	O
development	O
of	O
this	O
model	O
of	O
hypertension	B_Disease
,	O
since	O
the	O
enhanced	O
pressor	O
responsiveness	O
to	O
the	O
hormone	O
was	O
observed	O
in	O
the	O
initial	O
stage	O
of	O
hypertension	B_Disease
.	O

Increased	O
secretion	O
of	O
vasopressin	B_Chemical
from	O
neurohypophysis	O
also	O
promotes	O
the	O
function	O
of	O
the	O
hormone	O
as	O
a	O
pathogenetic	O
factor	O
in	O
hypertension	B_Disease
.	O

An	O
unproportional	O
release	O
of	O
vasopressin	B_Chemical
compared	O
to	O
plasma	O
osmolality	O

may	O
be	O
induced	O
by	O
the	O
absence	O
of	O
an	O
adjusting	O
control	O
of	O
angiotensin	B_Chemical
II	O
forming	O
and	O
receptor	O
binding	O
capacity	O
for	O
sodium	B_Chemical
balance	O
in	O
the	O
brain	O
.	O

However	O
,	O
the	O
role	O
of	O
vasopressin	B_Chemical
remains	O
to	O
be	O
determined	O
in	O
human	O
essential	O
hypertension	B_Disease
.	O

Toxic	B_Disease
hepatitis	I_Disease
induced	O
by	O
disulfiram	B_Chemical
in	O
a	O
non-alcoholic	O
.	O

A	O
reversible	O
toxic	B_Disease
liver	I_Disease
damage	I_Disease
was	O
observed	O
in	O
a	O
non-alcoholic	O
woman	O
treated	O
with	O
disulfiram	B_Chemical
.	O

The	O
causative	O
relationship	O
was	O
proven	O
by	O
challenge	O
.	O

Atrial	B_Disease
thrombosis	I_Disease
involving	O
the	O
heart	O
of	O
F-344	O
rats	O
ingesting	O
quinacrine	B_Chemical
hydrochloride	I_Chemical
.	O

Quinacrine	B_Chemical
hydrochloride	I_Chemical
is	O
toxic	O
for	O
the	O
heart	O
of	O
F-344	O
rats	O
.	O

Rats	O
treated	O
with	O
500	O
ppm	O
quinacrine	B_Chemical
hydrochloride	I_Chemical
in	O
the	O
diet	O
all	O
developed	O
a	O
high	O
incidence	O
of	O
left	O
atrial	B_Disease
thrombosis	I_Disease
.	O

The	O
lesion	O
was	O
associated	O
with	O
cardiac	B_Disease
hypertrophy	I_Disease
and	O
dilatation	O
and	O
focal	O
myocardial	B_Disease
degeneration	I_Disease
.	O

Rats	O
died	O
from	O
cardiac	B_Disease
hypertrophy	I_Disease
with	O
severe	O
acute	O
and	O
chronic	O
congestion	O
of	O
the	O
lungs	O
,	O
liver	O
,	O
and	O
other	O
organs	O
.	O

Seventy	O
percent	O
of	O
rats	O
given	O
250	O
ppm	O
quinacrine	B_Chemical
hydrochloride	I_Chemical
and	O
1,000	O
ppm	O
sodium	B_Chemical
nitrite	I_Chemical
simultaneously	O
in	O
the	O
diet	O
had	O
thrombosis	B_Disease
of	O
the	O
atria	O
of	O
the	O
heart	O
,	O
while	O
untreated	O
control	O
rats	O
in	O
this	O
laboratory	O
did	O
not	O
have	O
atrial	B_Disease
thrombosis	I_Disease
.	O

Sodium	B_Chemical
nitrite	I_Chemical
in	O
combination	O
with	O
quinacrine	B_Chemical
hydrochloride	I_Chemical
appeared	O
to	O
have	O
no	O
additional	O
effect	O
.	O

Alternating	B_Disease
sinus	I_Disease
rhythm	I_Disease
and	O
intermittent	O
sinoatrial	B_Disease
block	I_Disease
induced	O
by	O
propranolol	B_Chemical
.	O

Alternating	B_Disease
sinus	I_Disease
rhythm	I_Disease
and	O
intermittent	O
sinoatrial	B_Disease
(	I_Disease
S-A	I_Disease
)	I_Disease
block	I_Disease
was	O
observed	O
in	O
a	O
57-year-old	O
woman	O
,	O
under	O
treatment	O
for	O
angina	B_Disease
with	O
80	O
mg	O
propranolol	B_Chemical
daily	O
.	O

The	O
electrocardiogram	O
showed	O
alternation	O
of	O
long	O
and	O
short	O
P-P	O
intervals	O
and	O
occasional	O
pauses	O
.	O

These	O
pauses	O
were	O
always	O
preceded	O
by	O
the	O
short	O
P-P	O
intervals	O
and	O
were	O
usually	O
followed	O
by	O
one	O
or	O
two	O
P-P	O
intervals	O
of	O
0.92	O
-	O
0.95	O
s	O
representing	O
the	O
basic	O
sinus	O
cycle	O
.	O

Following	O
these	O
basic	O
sinus	O
cycles	O
,	O
alternating	B_Disease
rhythm	I_Disease
started	O
with	O
the	O
longer	O
P-P	O
interval	O
.	O

The	O
long	O
P-P	O
intervals	O
ranged	O
between	O
1.04	O
-	O
1.12	O
s	O
and	O
the	O
short	O
P-P	O
intervals	O
between	O
0.80	O
-	O
0.84	O
s	O
,	O
respectively	O
.	O

The	O
duration	O
of	O
the	O
pauses	O
were	O
equal	O
or	O
almost	O
equal	O
to	O
one	O
short	O
plus	O
one	O
long	O
P-P	O
interval	O
or	O
to	O
twice	O
the	O
basic	O
sinus	O
cycle	O
.	O

In	O
one	O
recording	O
a	O
short	O
period	O
of	O
regular	O
sinus	O
rhythm	O
with	O
intermittent	O
2/1	O
S-A	B_Disease
block	I_Disease
was	O
observed	O
.	O

This	O
short	O
period	O
of	O
sinus	O
rhythm	O
was	O
interrupted	O
by	O
sudden	O
prolongation	O
of	O
the	O
P-P	O
interval	O
starting	O
the	O
alternative	O
rhythm	O
.	O

There	O
were	O
small	O
changes	O
in	O
the	O
shape	O
of	O
the	O
P	O
waves	O
and	O
P-R	O
intervals	O
.	O

S-A	O
conduction	O
through	O
two	O
pathways	O
,	O
the	O
first	O
with	O
2/1	O
block	O
the	O
second	O
having	O
0.12	O
-	O
0.14	O
s	O
longer	O
conduction	O
time	O
and	O
with	O
occasional	O
2/1	O
block	O
was	O
proposed	O
for	O
the	O
explanation	O
of	O
the	O
alternating	O
P-P	O
interval	O
and	O
other	O
electrocardiographic	O
features	O
seen	O
.	O

Atropine	B_Chemical
1	O
mg	O
given	O
intravenously	O
resulted	O
in	O
shortening	O
of	O
all	O
P-P	O
intervals	O
without	O
changing	O
the	O
rhythm	O
.	O

The	O
abnormal	O
rhythm	O
disappeared	O
with	O
the	O
withdrawal	O
of	O
propranolol	B_Chemical
and	O
when	O
the	O
drug	O
was	O
restarted	O
a	O
2/1	O
S-A	B_Disease
block	I_Disease
was	O
seen	O
.	O

This	O
was	O
accepted	O
as	O
evidence	O
for	O
propranolol	B_Chemical
being	O
the	O
cause	O
of	O
this	O
conduction	B_Disease
disorder	I_Disease
.	O

Antitumor	O
effect	O
,	O
cardiotoxicity	B_Disease
,	O
and	O
nephrotoxicity	B_Disease
of	O
doxorubicin	B_Chemical
in	O
the	O
IgM	O
solid	O
immunocytoma-bearing	O
LOU/M/WSL	O
rat	O
.	O

Antitumor	O
activity	O
,	O
cardiotoxicity	B_Disease
,	O
and	O
nephrotoxicity	B_Disease
induced	O
by	O
doxorubicin	B_Chemical
were	O
studied	O
in	O
LOU/M/WSL	O
inbred	O
rats	O
each	O
bearing	O
a	O
transplantable	O
solid	O
IgM	O
immunocytoma	B_Disease
.	O

Animals	O
with	O
a	O
tumor	B_Disease
(	O
diameter	O
,	O
15.8	O
+	O
/-	O
3.3	O
mm	O
)	O
were	O
treated	O
with	O
iv	O
injections	O
of	O
doxorubicin	B_Chemical
on	O
5	O
consecutive	O
days	O
,	O
followed	O
by	O
1	O
weekly	O
injection	O
for	O
7	O
weeks	O
(	O
dose	O
range	O
,	O
0.015	O
-	O
4.0	O
mg/kg	O
body	O
wt	O
)	O
.	O

Tumor	B_Disease
regression	O
was	O
observed	O
with	O
0.5	O
mg	O
doxorubicin/kg	O
.	O

Complete	O
disappearance	O
of	O
the	O
tumor	B_Disease
was	O
induced	O
with	O
1.0	O
mg	O
doxorubicin/kg	O
.	O

Histologic	O
evidence	O
of	O
cardiotoxicity	B_Disease
scored	O
as	O
grade	O
III	O
was	O
only	O
observed	O
at	O
a	O
dose	O
of	O
1.0	O
mg	O
doxorubicin/kg	O
.	O

Light	O
microscopic	O
evidence	O
of	O
renal	B_Disease
damage	I_Disease
was	O
seen	O
above	O
a	O
dose	O
of	O
0.5	O
mg	O
doxorubicin/kg	O
,	O
which	O
resulted	O
in	O
albuminuria	B_Disease
and	O
very	O
low	O
serum	O
albumin	O
levels	O
.	O

In	O
the	O
group	O
that	O
received	O
1.0	O
mg	O
doxorubicin/kg	O
,	O
the	O
serum	O
albumin	O
level	O
decreased	O
from	O
33.6	O
+	O
/-	O
4.1	O
to	O
1.5	O
+	O
/-	O
0.5	O
g/liter	O
.	O
Ascites	B_Disease
and	O
hydrothorax	B_Disease
were	O
observed	O
simultaneously	O
.	O

The	O
same	O
experiments	O
were	O
performed	O
with	O
non-tumor-bearing	O
rats	O
,	O
in	O
which	O
no	O
major	O
differences	O
were	O
observed	O
.	O

In	O
conclusion	O
,	O
antitumor	O
activity	O
,	O
cardiotoxicity	B_Disease
,	O
and	O
nephrotoxicity	B_Disease
were	O
studied	O
simultaneously	O
in	O
the	O
same	O
LOU/M/WSL	O
rat	O
.	O

Albuminuria	B_Disease
due	O
to	O
renal	B_Disease
damage	I_Disease
led	O
to	O
extremely	O
low	O
serum	O
albumin	O
levels	O
,	O
so	O
ascites	B_Disease
and	O
hydrothorax	B_Disease
were	O
not	O
necessarily	O
a	O
consequence	O
of	O
the	O
observed	O
cardiomyopathy	B_Disease
.	O

Intraoperative	O
bradycardia	B_Disease
and	O
hypotension	B_Disease
associated	O
with	O
timolol	B_Chemical
and	O
pilocarpine	B_Chemical
eye	O
drops	O
.	O

A	O
69-yr-old	O
man	O
,	O
who	O
was	O
concurrently	O
being	O
treated	O
with	O
pilocarpine	B_Chemical
nitrate	I_Chemical
and	O
timolol	B_Chemical
maleate	I_Chemical
eye	O
drops	O
,	O
developed	O
a	O
bradycardia	B_Disease
and	O
became	O
hypotensive	B_Disease
during	O
halothane	B_Chemical
anaesthesia	O
.	O

Both	O
timolol	B_Chemical
and	O
pilocarpine	B_Chemical
were	O
subsequently	O
identified	O
in	O
a	O
24-h	O
collection	O
of	O
urine	O
.	O

Timolol	B_Chemical
(	O
but	O
not	O
pilocarpine	B_Chemical
)	O
was	O
detected	O
in	O
a	O
sample	O
of	O
plasma	O
removed	O
during	O
surgery	O
;	O
the	O
plasma	O
concentration	O
of	O
timolol	B_Chemical
(	O
2.6	O
ng	O
ml-1	O
)	O
was	O
consistent	O
with	O
partial	O
beta-adrenoceptor	O
blockade	O
.	O

It	O
is	O
postulated	O
that	O
this	O
action	O
may	O
have	O
been	O
enhanced	O
during	O
halothane	B_Chemical
anaesthesia	O
with	O
resultant	O
bradycardia	B_Disease
and	O
hypotension	B_Disease
.	O

Pilocarpine	B_Chemical
may	O
have	O
had	O
a	O
contributory	O
effect	O
.	O

Succinylcholine	B_Chemical
apnoea	B_Disease
:	O
attempted	O
reversal	O
with	O
anticholinesterases	O
.	O

Anticholinesterases	O
were	O
administered	O
in	O
an	O
attempt	O
to	O
antagonize	O
prolonged	O
neuromuscular	B_Disease
blockade	I_Disease
following	O
the	O
administration	O
of	O
succinylcholine	B_Chemical
in	O
a	O
patient	O
later	O
found	O
to	O
be	O
homozygous	O
for	O
atypical	O
plasma	O
cholinesterase	O
.	O

Edrophonium	B_Chemical
10	O
mg	O
,	O
given	O
74	O
min	O
after	O
succinylcholine	B_Chemical
,	O
when	O
train-of-four	O
stimulation	O
was	O
characteristic	O
of	O
phase	O
II	O
block	O
,	O
produced	O
partial	O
antagonism	O
which	O
was	O
not	O
sustained	O
.	O

Repeated	O
doses	O
of	O
edrophonium	B_Chemical
to	O
70	O
mg	O
and	O
neostigmine	B_Chemical
to	O
2.5	O
mg	O
did	O
not	O
antagonize	O
or	O
augment	O
the	O
block	O
.	O

Spontaneous	O
respiration	O
recommenced	O
200	O
min	O
after	O
succinylcholine	B_Chemical
administration	O
.	O

It	O
is	O
concluded	O
that	O
anticholinesterases	O
are	O
only	O
partially	O
effective	O
in	O
restoring	O
neuromuscular	O
function	O
in	O
succinylcholine	B_Chemical
apnoea	B_Disease
despite	O
muscle	O
twitch	O
activity	O
typical	O
of	O
phase	O
II	O
block	O
.	O

Effect	O
of	O
doxorubicin	B_Chemical
on	O
[omega-I-131]heptadecanoic	B_Chemical
acid	I_Chemical
myocardial	O
scintigraphy	O
and	O
echocardiography	O
in	O
dogs	O
.	O

The	O
effects	O
of	O
serial	O
treatment	O
with	O
doxorubicin	B_Chemical
on	O
dynamic	O
myocardial	O
scintigraphy	O
with	O
[omega-I-131]heptadecanoic	B_Chemical
acid	I_Chemical
(	O
I-131	B_Chemical
HA	I_Chemical
)	O
,	O
and	O
on	O
global	O
left-ventricular	O
function	O
determined	O
echocardiographically	O
,	O
were	O
studied	O
in	O
a	O
group	O
of	O
nine	O
mongrel	O
dogs	O
.	O

Total	O
extractable	O
myocardial	O
lipid	O
was	O
compared	O
postmortem	O
between	O
a	O
group	O
of	O
control	O
dogs	O
and	O
doxorubicin-treated	O
dogs	O
.	O

A	O
significant	O
and	O
then	O
progressive	O
fall	O
in	O
global	O
LV	O
function	O
was	O
observed	O
at	O
a	O
cumulative	O
doxorubicin	B_Chemical
dose	O
of	O
4	O
mg/kg	O
.	O

A	O
significant	O
increase	O
in	O
the	O
myocardial	O
t1/2	O
of	O
the	O
I-131	B_Chemical
HA	I_Chemical
was	O
observed	O
only	O
at	O
a	O
higher	O
cumulative	O
dose	O
,	O
10	O
mg/kg	O
.	O

No	O
significant	O
alteration	O
in	O
total	O
extractable	O
myocardial	O
lipids	O
was	O
observed	O
between	O
control	O
dogs	O
and	O
those	O
treated	O
with	O
doxorubicin	B_Chemical
.	O

Our	O
findings	O
suggest	O
that	O
the	O
changes	O
leading	O
to	O
an	O
alteration	O
of	O
myocardial	O
dynamic	O
imaging	O
with	O
I-131	B_Chemical
HA	I_Chemical
are	O
not	O
the	O
initiating	O
factor	O
in	O
doxorubicin	B_Chemical
cardiotoxicity	B_Disease
.	O

Hemodynamics	O
and	O
myocardial	O
metabolism	O
under	O
deliberate	O
hypotension	O
.	O

An	O
experimental	O
study	O
in	O
dogs	O
.	O

Coronary	O
blood	O
flow	O
,	O
cardiac	O
work	O
and	O
metabolism	O
were	O
studied	O
in	O
dogs	O
under	O
sodium	B_Chemical
nitroprusside	I_Chemical
(	O
SNP	B_Chemical
)	O
and	O
trimetaphan	B_Chemical
(	O
TMP	B_Chemical
)	O
deliberate	O
hypotension	B_Disease
(	O
20	O
%	O
and	O
40	O
%	O
mean	O
pressure	O
decrease	O
from	O
baseline	O
)	O
.	O

Regarding	O
the	O
effects	O
of	O
drug-induced	O
hypotension	B_Disease
on	O
coronary	O
blood	O
flow	O
,	O
aortic	O
and	O
coronary	O
sinus	O
metabolic	O
data	O
(	O
pH	O
,	O
pO2	O
,	O
pCO2	O
)	O
we	O
could	O
confirm	O
that	O
nitroprusside	B_Chemical
hypotension	B_Disease
could	O
be	O
safely	O
used	O
to	O
30	O
%	O
mean	O
blood	O
pressure	O
decrease	O
from	O
control	O
,	O
trimetaphan	B_Chemical
hypotension	B_Disease
to	O
20	O
%	O
mean	O
blood	O
pressure	O
decrease	O
.	O

Cardiac	O
work	O
was	O
significantly	O
reduced	O
during	O
SNP	B_Chemical
hypotension	B_Disease
.	O

Myocardial	O
O2	B_Chemical
consumption	O
and	O
O2	B_Chemical
availability	O
were	O
directly	O
dependent	O
on	O
the	O
coronary	O
perfusion	O
.	O

Careful	O
invasive	O
monitoring	O
of	O
the	O
blood	O
pressure	O
,	O
blood	O
gases	O
and	O
of	O
the	O
ECG	O
ST-T	O
segment	O
is	O
mandatory	O
.	O

Evidence	O
for	O
a	O
selective	O
brain	O
noradrenergic	O
involvement	O
in	O
the	O
locomotor	O
stimulant	O
effects	O
of	O
amphetamine	O
in	O
the	O
rat	O
.	O

Male	O
rats	O
received	O
the	O
noradrenaline	B_Chemical
neurotoxin	O
DSP4	B_Chemical
(	O
50	O
mg/kg	O
)	O
7	O
days	O
prior	O
to	O
injection	O
of	O
D-amphetamine	B_Chemical
(	O
10	O
or	O
40	O
mumol/kg	O
i.p	O
.	O
)	O
.	O

The	O
hyperactivity	B_Disease
induced	O
by	O
D-amphetamine	B_Chemical
(	O
10	O
mumol/kg	O
)	O
was	O
significantly	O
reduced	O
by	O
DSP4	B_Chemical
pretreatment	O
.	O

However	O
,	O
the	O
increased	O
rearings	O
and	O
the	O
amphetamine-induced	O
stereotypies	B_Disease
were	O
not	O
blocked	O
by	O
pretreatment	O
with	O
DSP4	B_Chemical
.	O

The	O
reduction	O
of	O
amphetamine	B_Chemical
hyperactivity	B_Disease
induced	O
by	O
DSP4	B_Chemical
was	O
blocked	O
by	O
pretreatment	O
with	O
the	O
noradrenaline-uptake	O
blocking	O
agent	O
,	O
desipramine	B_Chemical
,	O
which	O
prevents	O
the	O
neurotoxic	B_Disease
action	O
of	O
DSP4	B_Chemical
.	O

The	O
present	O
results	O
suggest	O
a	O
selective	O
involvement	O
of	O
central	O
noradrenergic	O
neurones	O
in	O
the	O
locomotor	O
stimulant	O
effect	O
of	O
amphetamine	B_Chemical
in	O
the	O
rat	O
.	O

Accelerated	B_Disease
junctional	I_Disease
rhythms	I_Disease
during	O
oral	O
verapamil	B_Chemical
therapy	O
.	O

This	O
study	O
examined	O
the	O
frequency	O
of	O
atrioventricular	O
(	O
AV	O
)	O
dissociation	O
and	O
accelerated	B_Disease
junctional	I_Disease
rhythms	I_Disease
in	O
59	O
patients	O
receiving	O
oral	O
verapamil	B_Chemical
.	O

Accelerated	B_Disease
junctional	I_Disease
rhythms	I_Disease
and	O
AV	O
dissociation	O
were	O
frequent	O
in	O
patients	O
with	O
supraventricular	B_Disease
tachyarrhythmias	I_Disease
,	O
particularly	O
AV	O
nodal	O
reentry	O
.	O

Verapamil	B_Chemical
administration	O
to	O
these	O
patients	O
led	O
to	O
an	O
asymptomatic	O
increase	O
in	O
activity	O
of	O
these	O
junctional	O
pacemakers	O
.	O

In	O
patients	O
with	O
various	O
chest	B_Disease
pain	I_Disease
syndromes	O
,	O
verapamil	B_Chemical
neither	O
increased	O
the	O
frequency	O
of	O
junctional	O
rhythms	O
nor	O
suppressed	O
their	O
role	O
as	O
escape	O
rhythms	O
under	O
physiologically	O
appropriate	O
circumstances	O
.	O

Interstrain	O
variation	O
in	O
acute	O
toxic	O
response	O
to	O
caffeine	O
among	O
inbred	O
mice	O
.	O

Acute	O
toxic	O
dosage-dependent	O
behavioral	O
effects	O
of	O
caffeine	B_Chemical
were	O
compared	O
in	O
adult	O
males	O
from	O
seven	O
inbred	O
mouse	O
strains	O
(	O
A/J	O
,	O
BALB/cJ	O
,	O
CBA/J	O
,	O
C3H/HeJ	O
,	O
C57BL/6J	O
,	O
DBA/2J	O
,	O
SWR/J	O
)	O
.	O

C57BL/6J	O
,	O
chosen	O
as	O
a	O
"	O
prototypic	O
"	O
mouse	O
strain	O
,	O
was	O
used	O
to	O
determine	O
behavioral	O
responses	O
to	O
a	O
broad	O
range	O
(	O
5	O
-	O
500	O
mg/kg	O
)	O
of	O
caffeine	B_Chemical
doses	O
.	O

Five	O
phenotypic	O
characteristics	O
--	O
locomotor	O
activity	O
,	O
righting	O
ability	O
,	O
clonic	B_Disease
seizure	I_Disease
induction	O
,	O
stress-induced	O
lethality	O
,	O
death	O
without	O
external	O
stress	O
--	O
were	O
scored	O
at	O
various	O
caffeine	B_Chemical
doses	O
in	O
drug-naive	O
animals	O
under	O
empirically	O
optimized	O
,	O
rigidly	O
constant	O
experimental	O
conditions	O
.	O

Mice	O
(	O
n	O
=	O
12	O
for	O
each	O
point	O
)	O
received	O
single	O
IP	O
injections	O
of	O
a	O
fixed	O
volume/g	O
body	O
weight	O
of	O
physiological	O
saline	O
carrier	O
with	O
or	O
without	O
caffeine	B_Chemical
in	O
doses	O
ranging	O
from	O
125	O
-	O
500	O
mg/kg	O
.	O

Loss	O
of	O
righting	O
ability	O
was	O
scored	O
at	O
1	O
,	O
3	O
,	O
5	O
min	O
post	O
dosing	O
and	O
at	O
5	O
min	O
intervals	O
thereafter	O
for	O
20	O
min	O
.	O

In	O
the	O
same	O
animals	O
the	O
occurrence	O
of	O
clonic	B_Disease
seizures	I_Disease
was	O
scored	O
as	O
to	O
time	O
of	O
onset	O
and	O
severity	O
for	O
20	O
min	O
after	O
drug	O
administration	O
.	O

When	O
these	O
proceeded	O
to	O
tonic	B_Disease
seizures	I_Disease
,	O
death	O
occurred	O
in	O
less	O
than	O
20	O
min	O
.	O

Animals	O
surviving	O
for	O
20	O
min	O
were	O
immediately	O
stressed	O
by	O
a	O
swim	O
test	O
in	O
25	O
degrees	O
C	O
water	O
,	O
and	O
death-producing	O
tonic	B_Disease
seizures	I_Disease
were	O
scored	O
for	O
2	O
min	O
.	O

In	O
other	O
animals	O
locomotor	O
activity	O
was	O
measured	O
15	O
or	O
60	O
min	O
after	O
caffeine	B_Chemical
administration	O
.	O

By	O
any	O
single	O
behavioral	O
criterion	O
or	O
a	O
combination	O
of	O
these	O
criteria	O
,	O
marked	O
differences	O
in	O
response	O
to	O
toxic	O
caffeine	B_Chemical
doses	O
were	O
observed	O
between	O
strains	O
.	O

These	O
results	O
indicate	O
that	O
behavioral	O
toxicity	B_Disease
testing	O
of	O
alkylxanthines	B_Chemical
in	O
a	O
single	O
mouse	O
strain	O
may	O
be	O
misleading	O
and	O
suggest	O
that	O
toxic	O
responses	O
of	O
the	O
central	O
nervous	O
system	O
to	O
this	O
class	O
of	O
compounds	O
are	O
genetically	O
influenced	O
in	O
mammals	O
.	O

Treatment	O
of	O
ovarian	B_Disease
cancer	I_Disease
with	O
a	O
combination	O
of	O
cis-platinum	B_Chemical
,	O
adriamycin	B_Chemical
,	O
cyclophosphamide	B_Chemical
and	O
hexamethylmelamine	B_Chemical
.	O

During	O
the	O
last	O
2	O
1/2	O
years	O
,	O
38	O
patients	O
with	O
ovarian	B_Disease
cancer	I_Disease
were	O
treated	O
with	O
a	O
combination	O
of	O
cisplatinum	B_Chemical
(	O
CPDD	B_Chemical
)	O
,	O
50	O
mg/m2	O
,	O
adriamycin	B_Chemical
,	O
30	O
mg/m2	O
,	O
cyclophosphamide	B_Chemical
,	O
300	O
mg/m2	O
,	O
on	O
day	O
1	O
;	O
and	O
hexamethylmelamine	B_Chemical
(	O
HMM	B_Chemical
)	O
,	O
6	O
mg/kg	O
daily	O
,	O
for	O
14	O
days	O
.	O

Each	O
course	O
was	O
repeated	O
monthly	O
.	O

2	O
patients	O
had	O
stage	O
II	O
,	O
14	O
stage	O
III	O
and	O
22	O
stage	O
IV	O
disease	O
.	O

14	O
of	O
the	O
38	O
patients	O
were	O
previously	O
treated	O
with	O
chemotherapy	O
,	O
1	O
with	O
radiation	O
,	O
6	O
with	O
both	O
chemotherapy	O
and	O
radiation	O
,	O
and	O
17	O
did	O
not	O
have	O
any	O
treatment	O
before	O
CPDD	B_Chemical
combination	O
.	O

31	O
of	O
the	O
38	O
cases	O
(	O
81.5	O
%	O
)	O
demonstrated	O
objective	O
responses	O
lasting	O
for	O
2	O
months	O
or	O
more	O
.	O

These	O
responses	O
were	O
partial	O
in	O
19	O
and	O
complete	O
in	O
12	O
cases	O
.	O

Hematologic	B_Disease
toxicity	I_Disease
was	O
moderate	O
and	O
with	O
reversible	O
anemia	B_Disease
developing	O
in	O
71	O
%	O
of	O
patients	O
.	O

Gastrointestinal	O
side	O
effects	O
from	O
CPDD	B_Chemical
were	O
universal	O
.	O

HMM	B_Chemical
gastrointestinal	B_Disease
toxicity	I_Disease
necessitated	O
discontinuation	O
of	O
the	O
drug	O
in	O
5	O
patients	O
.	O

Severe	O
nephrotoxicity	B_Disease
was	O
observed	O
in	O
2	O
patients	O
but	O
was	O
reversible	O
.	O

There	O
were	O
no	O
drug-related	O
deaths	O
.	O

Nontraumatic	O
dissecting	O
aneurysm	O
of	O
the	O
basilar	O
artery	O
.	O

A	O
case	O
of	O
nontraumatic	O
dissecting	B_Disease
aneurysm	I_Disease
of	O
the	O
basilar	O
artery	O
in	O
association	O
with	O
hypertension	B_Disease
,	O
smoke	O
,	O
and	O
oral	B_Chemical
contraceptives	I_Chemical
is	O
reported	O
in	O
a	O
young	O
female	O
patient	O
with	O
a	O
locked-in	B_Disease
syndrome	I_Disease
.	O

A	O
method	O
for	O
the	O
measurement	O
of	O
tremor	O
,	O
and	O
a	O
comparison	O
of	O
the	O
effects	O
of	O
tocolytic	O
beta-mimetics	O
.	O

A	O
method	O
permitting	O
measurement	O
of	O
finger	O
tremor	B_Disease
as	O
a	O
displacement-time	O
curve	O
is	O
described	O
,	O
using	O
a	O
test	O
system	O
with	O
simple	O
amplitude	O
calibration	O
.	O

The	O
coordinates	O
of	O
the	O
inversion	O
points	O
of	O
the	O
displacement-time	O
curves	O
were	O
transferred	O
through	O
graphical	O
input	O
equipment	O
to	O
punched	O
tape	O
.	O

By	O
means	O
of	O
a	O
computer	O
program	O
,	O
periods	O
and	O
amplitudes	O
of	O
tremor	B_Disease
oscillations	O
were	O
calculated	O
and	O
classified	O
.	O

The	O
event	O
frequency	O
for	O
each	O
class	O
of	O
periods	O
and	O
amplitudes	O
was	O
determined	O
.	O

The	O
actions	O
of	O
fenoterol-hydrobromide	B_Chemical
,	O
ritodrin-HCl	B_Chemical
and	O
placebo	O
given	O
to	O
10	O
healthy	O
subjects	O
by	O
intravenous	O
infusion	O
in	O
a	O
double-blind	O
crossover	O
study	O
were	O
tested	O
by	O
this	O
method	O
.	O

At	O
therapeutic	O
doses	O
both	O
substances	O
raised	O
the	O
mean	O
tremor	B_Disease
amplitude	O
to	O
about	O
three	O
times	O
the	O
control	O
level	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
mean	O
period	O
within	O
each	O
class	O
of	O
amplitudes	O
shortened	O
by	O
10	O
-	O
-20	O
ms	O
,	O
whereas	O
the	O
mean	O
periods	O
calculated	O
from	O
all	O
oscillations	O
together	O
did	O
not	O
change	O
significantly	O
.	O

After	O
the	O
end	O
of	O
fenoterol-hydrobromide	B_Chemical
infusion	O
,	O
tremor	B_Disease
amplitudes	O
decreased	O
significantly	O
faster	O
than	O
those	O
following	O
ritodrin-HCl	B_Chemical
infusion	O
.	O

Propylthiouracil-induced	O
hepatic	B_Disease
damage	I_Disease
.	O

Two	O
cases	O
of	O
propylthiouracil-induced	O
liver	B_Disease
damage	I_Disease
have	O
been	O
observed	O
.	O

The	O
first	O
case	O
is	O
of	O
an	O
acute	O
type	O
of	O
damage	O
,	O
proven	O
by	O
rechallenge	O
;	O
the	O
second	O
presents	O
a	O
clinical	O
and	O
histologic	O
picture	O
resembling	O
chronic	B_Disease
active	I_Disease
hepatitis	I_Disease
,	O
with	O
spontaneous	O
remission	O
.	O

Studies	O
on	O
the	O
bradycardia	B_Disease
induced	O
by	O
bepridil	B_Chemical
.	O

Bepridil	B_Chemical
,	O
a	O
novel	O
active	O
compound	O
for	O
prophylactic	O
treatment	O
of	O
anginal	B_Disease
attacks	I_Disease
,	O
induced	O
persistent	O
bradycardia	B_Disease
and	O
a	O
non-specific	O
anti-tachycardial	O
effect	O
,	O
the	O
mechanisms	O
of	O
which	O
were	O
investigated	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
vitro	O
perfusion	O
of	O
bepridil	B_Chemical
in	O
the	O
life-support	O
medium	O
for	O
isolated	O
sino-atrial	O
tissue	O
from	O
rabbit	O
heart	O
,	O
caused	O
a	O
reduction	O
in	O
action	O
potential	O
(	O
AP	O
)	O
spike	O
frequency	O
(	O
recorded	O
by	O
KCl	B_Chemical
microelectrodes	O
)	O
starting	O
at	O
doses	O
of	O
5	O
X	O
10(-6	O
)	O
M.	O
This	O
effect	O
was	O
dose-dependent	O
up	O
to	O
concentrations	O
of	O
5	O
X	O
10(-5	O
)	O
M	O
,	O
whereupon	O
blockade	O
of	O
sinus	O
activity	O
set	O
in	O
.	O

Bepridil	B_Chemical
at	O
a	O
dose	O
of	O
5	O
X	O
10(-6	O
)	O
M	O
,	O
induced	O
a	O
concomitant	O
reduction	O
in	O
AP	O
amplitude	O
(	O
falling	O
from	O
71	O
+	O
/-	O
8	O
mV	O
to	O
47	O
+	O
/-	O
6	O
mV	O
)	O
,	O
maximum	O
systolic	O
depolarization	O
velocity	O
(	O
phase	O
0	O
)	O
which	O
fell	O
from	O
1.85	O
+	O
/-	O
0.35	O
V/s	O
to	O
0.84	O
+	O
/-	O
0.28	O
V/s	O
,	O
together	O
with	O
maximum	O
diastolic	O
depolarization	O
velocity	O
(	O
phase	O
4	O
)	O
which	O
fell	O
from	O
38	O
+	O
/-	O
3	O
mV/s	O
to	O
24	O
+	O
/-	O
5	O
mV/s	O
.	O

In	O
vivo	O
injection	O
of	O
bepridil	B_Chemical
at	O
a	O
dose	O
of	O
5	O
mg/kg	O
(	O
i.v	O
.	O
)	O
into	O
6	O
anaesthetized	O
dogs	O
which	O
had	O
undergone	O
ablation	O
of	O
all	O
the	O
extrinsic	O
cardiac	O
afferent	O
nerve	O
supply	O
,	O
together	O
with	O
a	O
bilateral	O
medullo-adrenalectomy	O
,	O
caused	O
a	O
marked	O
reduction	O
in	O
heart	O
rate	O
which	O
fell	O
from	O
98.7	O
+	O
/-	O
4.2	O
beats/min	O
to	O
76	O
+	O
/-	O
5.3	O
beats/min	O
sustained	O
for	O
more	O
than	O
45	O
min	O
.	O

It	O
is	O
concluded	O
that	O
bepridil	B_Chemical
reduces	O
heart	O
rate	O
by	O
acting	O
directly	O
on	O
the	O
sinus	O
node	O
.	O

This	O
effect	O
,	O
which	O
results	O
in	O
a	O
flattening	O
of	O
the	O
phase	O
0	O
and	O
phase	O
4	O
slope	O
,	O
together	O
with	O
a	O
longer	O
AP	O
duration	O
,	O
may	O
be	O
due	O
to	O
an	O
increase	O
in	O
the	O
time	O
constants	O
of	O
slow	O
inward	O
ionic	O
currents	O
(	O
already	O
demonstrated	O
elsewhere	O
)	O
,	O
but	O
also	O
to	O
an	O
increased	O
time	O
constant	O
for	O
deactivation	O
of	O
the	O
outward	O
potassium	B_Chemical
current	O
(	O
Ip	O
)	O
.	O

Hepatitis	B_Disease
and	O
renal	B_Disease
tubular	I_Disease
acidosis	I_Disease
after	O
anesthesia	O
with	O
methoxyflurane	B_Chemical
.	O

A	O
69-year-old	O
man	O
operated	O
for	O
acute	B_Disease
cholecystitis	I_Disease
under	O
methoxyflurane	B_Chemical
anesthesia	O
developed	O
postoperatively	O
a	O
hepatic	B_Disease
insufficiency	I_Disease
syndrome	I_Disease
and	O
renal	B_Disease
tubular	I_Disease
acidosis	I_Disease
.	O

Massive	O
bleeding	B_Disease
appeared	O
during	O
surgery	O
which	O
lasted	O
for	O
six	O
hours	O
.	O

Postoperative	O
evolution	O
under	O
supportive	O
therapy	O
was	O
favourable	O
.	O

Complete	O
recovery	O
was	O
confirmed	O
by	O
repeated	O
controls	O
performed	O
over	O
a	O
period	O
of	O
one	O
year	O
after	O
surgery	O
.	O

Pituitary	O
response	O
to	O
luteinizing	O
hormone-releasing	O
hormone	O
during	O
haloperidol-induced	O
hyperprolactinemia	B_Disease
.	O

The	O
effects	O
of	O
a	O
6-hour	O
infusion	O
with	O
haloperidol	B_Chemical
on	O
serum	O
prolactin	O
and	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
levels	O
was	O
studied	O
in	O
a	O
group	O
of	O
male	O
subjects	O
.	O

Five	O
hours	O
after	O
starting	O
the	O
infusions	O
,	O
a	O
study	O
of	O
the	O
pituitary	O
responses	O
to	O
LH-releasing	O
hormone	O
(	O
LH-RH	O
)	O
was	O
carried	O
out	O
.	O

Control	O
patients	O
received	O
infusions	O
of	O
0.9	O
%	O
NaCl	B_Chemical
solution	O
.	O

During	O
the	O
course	O
of	O
haloperidol	B_Chemical
infusions	O
,	O
significant	O
hyperprolactinemia	B_Disease
was	O
found	O
,	O
together	O
with	O
an	O
abolished	O
pituitary	O
response	O
to	O
LH-RH	O
,	O
as	O
compared	O
with	O
responses	O
of	O
control	O
subjects	O
.	O

Antirifampicin	O
antibodies	O
in	O
acute	O
rifampicin-associated	O
renal	O
failure.5	O
patients	O
with	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
(	O
3	O
with	O
thrombopenia	B_Disease
and	O
hemolysis	B_Disease
)	O
induced	O
by	O
the	O
reintroduction	O
of	O
rifampicin	B_Chemical
are	O
described	O
.	O

No	O
correlation	O
was	O
found	O
between	O
the	O
severity	O
of	O
clinical	O
manifestations	O
and	O
the	O
total	O
dose	O
taken	O
by	O
the	O
patients	O
.	O

In	O
all	O
but	O
1	O
patient	O
,	O
antirifampicin	O
antibodies	O
were	O
detected	O
.	O

Antibodies	O
suggested	O
to	O
be	O
of	O
the	O
IgM	O
class	O
were	O
detected	O
in	O
all	O
3	O
patients	O
with	O
hematological	B_Disease
disorders	I_Disease
.	O

The	O
pattern	O
of	O
non-specific	O
acute	B_Disease
tubular	I_Disease
necrosis	I_Disease
found	O
in	O
the	O
2	O
biopsied	O
patients	O
,	O
indistinguishable	O
from	O
that	O
of	O
ischemic	O
origin	O
,	O
raised	O
the	O
possibility	O
of	O
a	O
vascular-mediated	O
damage	O
.	O

In	O
3	O
patients	O
,	O
the	O
possibility	O
of	O
a	O
triggering	O
immunoallergic	O
mechanism	O
is	O
discussed	O
.	O

Cardiovascular	O
effects	O
of	O
hypotension	B_Disease
induced	O
by	O
adenosine	B_Chemical
triphosphate	I_Chemical
and	O
sodium	B_Chemical
nitroprusside	I_Chemical
on	O
dogs	O
with	O
denervated	O
hearts	O
.	O

Adenosine	B_Chemical
triphosphate	I_Chemical
(	O
ATP	B_Chemical
)	O
and	O
sodium	B_Chemical
nitroprusside	I_Chemical
(	O
SNP	B_Chemical
)	O
are	O
administered	O
to	O
patients	O
to	O
induce	O
and	O
control	O
hypotension	B_Disease
during	O
anesthesia	O
.	O

SNP	B_Chemical
is	O
authorized	O
for	O
clinical	O
use	O
in	O
USA	O
and	O
UK	O
,	O
and	O
ATP	B_Chemical
is	O
clinically	O
used	O
in	O
other	O
countries	O
such	O
as	O
Japan	O
.	O

We	O
investigated	O
how	O
these	O
two	O
drugs	O
act	O
on	O
the	O
cardiovascular	O
systems	O
of	O
20	O
dogs	O
whose	O
hearts	O
had	O
been	O
denervated	O
by	O
a	O
procedure	O
we	O
had	O
devised	O
.	O

ATP	B_Chemical
(	O
10	O
dogs	O
)	O
or	O
SNP	B_Chemical
(	O
10	O
dogs	O
)	O
was	O
administered	O
to	O
reduce	O
mean	O
arterial	O
pressure	O
by	O
30	O
%	O
to	O
70	O
%	O
of	O
control	O
.	O

Before	O
,	O
during	O
and	O
after	O
induced	O
hypotension	B_Disease
,	O
we	O
measured	O
major	O
cardiovascular	O
parameters	O
.	O

Hypotension	B_Disease
induced	O
by	O
ATP	B_Chemical
was	O
accompanied	O
by	O
significant	O
decreases	O
in	O
mean	O
pulmonary	O
arterial	O
pressure	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
central	O
venous	O
pressure	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
left	O
ventricular	O
end-diastolic	O
pressure	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
total	O
peripheral	O
resistance	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
rate	O
pressure	O
product	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
total	O
body	O
oxygen	B_Chemical
consumption	O
(	O
p	O
less	O
than	O
0.05	O
)	O
,	O
and	O
heart	O
rate	O
(	O
p	O
less	O
than	O
0.001	O
)	O
;	O
all	O
these	O
variables	O
returned	O
normal	O
within	O
30	O
min	O
after	O
ATP	B_Chemical
was	O
stopped	O
.	O

Cardiac	O
output	O
did	O
not	O
change	O
.	O

During	O
hypotension	B_Disease
produced	O
by	O
SNP	B_Chemical
similar	O
decreases	O
were	O
observed	O
in	O
mean	O
pulmonary	O
arterial	O
pressure	O
(	O
p	O
less	O
than	O
0.01	O
)	O
,	O
central	O
venous	O
pressure	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
left	O
ventricular	O
end-diastolic	O
pressure	O
(	O
p	O
less	O
than	O
0.01	O
)	O
,	O
total	O
peripheral	O
resistance	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
rate	O
pressure	O
product	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
and	O
oxygen	B_Chemical
content	O
difference	O
between	O
arterial	O
and	O
mixed	O
venous	O
blood	O
(	O
p	O
less	O
than	O
0.05	O
)	O
,	O
while	O
heart	O
rate	O
(	O
p	O
less	O
than	O
0.001	O
)	O
and	O
cardiac	O
output	O
(	O
p	O
less	O
than	O
0.05	O
)	O
were	O
increased	O
.	O

Recoveries	O
of	O
heart	O
rate	O
and	O
left	O
ventricular	O
end-diastolic	O
pressure	O
were	O
not	O
shown	O
within	O
60	O
min	O
after	O
SNP	B_Chemical
had	O
been	O
stopped	O
.	O

Both	O
ATP	B_Chemical
and	O
SNP	B_Chemical
should	O
act	O
on	O
the	O
pacemaker	O
tissue	O
of	O
the	O
heart	O
.	O

Comparative	O
study	O
:	O
Endografine	B_Chemical
(	O
diatrizoate	B_Chemical
)	O
,	O
Vasurix	B_Chemical
polyvidone	I_Chemical
(	O
acetrizoate	B_Chemical
)	O
,	O
Dimer-X	B_Chemical
(	O
iocarmate	B_Chemical
)	O
and	O
Hexabrix	B_Chemical
(	O
ioxaglate	B_Chemical
)	O
in	O
hysterosalpingography	O
.	O

Side	O
effects	O
of	O
hysterosalpingography	O
with	O
Dimer-X	B_Chemical
,	O
Hexabrix	B_Chemical
,	O
Vasurix	B_Chemical
polyvidone	I_Chemical
and	O
Endografine	B_Chemical
in	O
142	O
consecutive	O
patients	O
,	O
receiving	O
one	O
of	O
the	O
four	O
tested	O
media	O
were	O
evaluated	O
from	O
replies	O
to	O
postal	O
questionnaires	O
.	O

The	O
Dimer-X	B_Chemical
group	O
had	O
a	O
higher	O
incidence	O
of	O
nausea	B_Disease
and	O
dizziness	B_Disease
.	O

The	O
Endografine	B_Chemical
group	O
had	O
a	O
higher	O
incidence	O
of	O
abdominal	B_Disease
pain	I_Disease
.	O

These	O
differences	O
occur	O
especially	O
in	O
the	O
age	O
groups	O
under	O
30	O
years	O
.	O

Hexabrix	B_Chemical
and	O
Vasurix	B_Chemical
polyvidone	I_Chemical
are	O
considered	O
the	O
best	O
contrast	B_Chemical
media	I_Chemical
for	O
hysterosalpingography	O
and	O
perhaps	O
because	O
of	O
its	O
low	O
toxicity	B_Disease
Hexabrix	B_Chemical
should	O
be	O
preferred	O
.	O

Post-suxamethonium	O
pains	B_Disease
in	O
Nigerian	O
surgical	O
patients	O
.	O

Contrary	O
to	O
an	O
earlier	O
report	O
by	O
Coxon	O
,	O
scoline	B_Chemical
pain	B_Disease
occurs	O
in	O
African	O
negroes	O
.	O

Its	O
incidence	O
was	O
determined	O
in	O
a	O
prospective	O
study	O
involving	O
a	O
total	O
of	O
100	O
Nigerian	O
patients	O
(	O
50	O
out-patients	O
and	O
50	O
in-patients	O
)	O
.	O

About	O
62	O
%	O
of	O
the	O
out-patients	O
developed	O
scoline	B_Chemical
pain	B_Disease
as	O
compared	O
with	O
about	O
26	O
%	O
among	O
the	O
in-patients	O
.	O

The	O
abolition	O
of	O
muscle	O
fasciculations	B_Disease
(	O
by	O
0.075mg/kg	O
dose	O
of	O
Fazadinium	B_Chemical
)	O
did	O
not	O
influence	O
the	O
occurrence	O
of	O
scoline	B_Chemical
pain	B_Disease
.	O

Neither	O
the	O
type	O
of	O
induction	O
agent	O
(	O
Althesin	B_Chemical
or	O
Thiopentone	B_Chemical
)	O
nor	O
the	O
salt	O
preparation	O
of	O
suxamethonium	B_Chemical
used	O
(	O
chloride	B_Chemical
or	O
bromide	B_Chemical
)	O
,	O
affected	O
the	O
incidence	O
of	O
scoline	B_Chemical
pain	B_Disease
.	O

Invasive	O
carcinoma	B_Disease
of	I_Disease
the	I_Disease
renal	I_Disease
pelvis	I_Disease
following	O
cyclophosphamide	B_Chemical
therapy	O
for	O
nonmalignant	O
disease	O
.	O

A	O
47-year-old	O
woman	O
with	O
right	O
hydroureteronephrosis	B_Disease
due	O
to	O
ureterovesical	O
junction	O
obstruction	O
had	O
gross	O
hematuria	B_Disease
after	O
being	O
treated	O
for	O
five	O
years	O
wtih	O
cyclophosphamide	B_Chemical
for	O
cerebral	B_Disease
vasculitis	I_Disease
.	O

A	O
right	O
nephroureterectomy	O
was	O
required	O
for	O
control	O
of	O
bleeding	B_Disease
.	O

The	O
pathology	O
specimen	O
contained	O
clinically	O
occult	O
invasive	O
carcinoma	B_Disease
of	I_Disease
the	I_Disease
renal	I_Disease
pelvis	I_Disease
.	O

Although	O
the	O
ability	O
of	O
cyclophosphamide	B_Chemical
to	O
cause	O
hemorrhagic	B_Disease
cystitis	B_Disease
and	O
urine	O
cytologic	O
abnormalities	O
indistinguishable	O
from	O
high	O
grade	O
carcinoma	B_Disease
is	O
well	O
known	O
,	O
it	O
is	O
less	O
widely	O
appreciated	O
that	O
it	O
is	O
also	O
associated	O
with	O
carcinoma	B_Disease
of	I_Disease
the	I_Disease
urinary	I_Disease
tract	I_Disease
.	O

Twenty	O
carcinomas	B_Disease
of	I_Disease
the	I_Disease
urinary	I_Disease
bladder	I_Disease
and	O
one	O
carcinoma	B_Disease
of	I_Disease
the	I_Disease
prostate	I_Disease
have	O
been	O
reported	O
in	O
association	O
with	O
its	O
use	O
.	O

The	O
present	O
case	O
is	O
the	O
first	O
carcinoma	B_Disease
of	I_Disease
the	I_Disease
renal	I_Disease
pelvis	I_Disease
reported	O
in	O
association	O
with	O
cyclophosphamide	B_Chemical
treatment	O
.	O

It	O
is	O
the	O
third	O
urinary	B_Disease
tract	I_Disease
cancer	I_Disease
reported	O
in	O
association	O
with	O
cyclophosphamide	B_Chemical
treatment	O
for	O
nonmalignant	O
disease	O
.	O

The	O
association	O
of	O
the	O
tumor	B_Disease
with	O
preexisting	O
hydroureteronephrosis	B_Disease
suggests	O
that	O
stasis	O
prolonged	O
and	O
intensified	O
exposure	O
of	O
upper	O
urinary	O
tract	O
epithelium	O
to	O
cyclophosphamide	B_Chemical
.	O

Patients	O
who	O
are	O
candidates	O
for	O
long-term	O
cyclophosphamide	B_Chemical
treatment	O
should	O
be	O
routinely	O
evaluated	O
for	O
obstructive	B_Disease
uropathy	I_Disease
.	O

Medial	O
changes	O
in	O
arterial	O
spasm	B_Disease
induced	O
by	O
L-norepinephrine	B_Chemical
.	O

In	O
normal	O
rats	O
,	O
the	O
media	O
of	O
small	O
arteries	O
(	O
0.4	O
-	O
-0.2	O
mm	O
in	O
diameter	O
)	O
previously	O
was	O
shown	O
to	O
contain	O
intracellular	O
vacuoles	O
,	O
identified	O
ultrastructurally	O
as	O
herniations	O
of	O
one	O
smooth	O
muscle	O
cell	O
into	O
another	O
.	O

The	O
hypothesis	O
that	O
intense	O
vasoconstriction	O
would	O
increase	O
the	O
number	O
of	O
such	O
vacuoles	O
has	O
been	O
tested	O
.	O

In	O
the	O
media	O
of	O
the	O
saphenous	O
artery	O
and	O
its	O
distal	O
branch	O
,	O
vasoconstriction	O
induced	O
by	O
L-norepinephrine	B_Chemical
produced	O
many	O
cell-to-cell	O
hernias	B_Disease
within	O
15	O
minutes	O
.	O

At	O
1	O
day	O
their	O
number	O
was	O
reduced	O
to	O
about	O
1/10	O
of	O
the	O
original	O
number	O
.	O

By	O
7	O
days	O
the	O
vessel	O
was	O
almost	O
restored	O
to	O
normal	O
.	O

Triple	O
stimulation	O
over	O
1	O
day	O
induced	O
more	O
severe	O
changes	O
in	O
the	O
media	O
.	O

These	O
findings	O
suggest	O
that	O
smooth	O
muscle	O
cells	O
are	O
susceptible	O
to	O
damage	O
in	O
the	O
course	O
of	O
their	O
specific	O
function	O
.	O

The	O
experimental	O
data	O
are	O
discussed	O
in	O
relation	O
to	O
medial	O
changes	O
observed	O
in	O
other	O
instances	O
of	O
arterial	O
spasm	B_Disease
.	O

Endothelial	O
changes	O
that	O
developed	O
in	O
the	O
same	O
experimental	O
model	O
were	O
described	O
in	O
a	O
previous	O
paper	O
.	O

Bilateral	O
retinal	B_Disease
artery	I_Disease
and	I_Disease
choriocapillaris	I_Disease
occlusion	I_Disease
following	O
the	O
injection	O
of	O
long-acting	O
corticosteroid	B_Chemical
suspensions	O
in	O
combination	O
with	O
other	O
drugs	O
:	O
I.	O
Clinical	O
studies	O
.	O

Two	O
well-documented	O
cases	O
of	O
bilateral	O
retinal	B_Disease
artery	I_Disease
and	I_Disease
choriocapillaris	I_Disease
occlusions	I_Disease
with	O
blindness	B_Disease
following	O
head	O
and	O
neck	O
soft-tissue	O
injection	O
with	O
methylprednisolone	B_Chemical
acetate	I_Chemical
in	O
combination	O
with	O
lidocaine	B_Chemical
,	O
epinephrine	B_Chemical
,	O
or	O
penicillin	B_Chemical
are	O
reported	O
.	O

One	O
case	O
had	O
only	O
a	O
unilateral	O
injection	O
.	O

The	O
acute	O
observations	O
included	O
hazy	O
sensorium	O
,	O
superior	O
gaze	O
palsy	B_Disease
,	O
pupillary	B_Disease
abnormalities	I_Disease
,	O
and	O
conjunctival	O
hemorrhages	B_Disease
with	O
edema	B_Disease
.	O

Follow-up	O
changes	O
showed	O
marked	O
visual	B_Disease
loss	I_Disease
,	O
constricted	O
visual	O
fields	O
,	O
optic	O
nerve	O
pallor	O
,	O
vascular	O
attenuation	O
,	O
and	O
chorioretinal	B_Disease
atrophy	I_Disease
.	O

The	O
literature	O
is	O
reviewed	O
,	O
and	O
possible	O
causes	O
are	O
discussed	O
.	O

Abnormalities	O
of	O
the	O
pupil	O
and	O
visual-evoked	O
potential	O
in	O
quinine	B_Chemical
amblyopia	B_Disease
.	O

Total	O
blindness	B_Disease
with	O
a	O
transient	O
tonic	B_Disease
pupillary	I_Disease
response	O
,	O
denervation	O
supersensitivity	O
,	O
and	O
abnormal	O
visual-evoked	O
potentials	O
developed	O
in	O
a	O
54-year-old	O
man	O
after	O
the	O
use	O
of	O
quinine	B_Chemical
sulfate	I_Chemical
for	O
leg	B_Disease
cramps	I_Disease
.	O

He	O
later	O
recovered	O
normal	O
visual	O
acuity	O
.	O

A	O
transient	O
tonic	B_Disease
pupillary	I_Disease
response	O
,	O
denervation	O
supersensitivity	O
,	O
and	O
abnormal	O
visual-evoked	O
potentials	O
in	O
quinine	B_Chemical
toxicity	B_Disease
,	O
to	O
our	O
knowledge	O
,	O
have	O
not	O
been	O
previously	O
reported	O
.	O

Suxamethonium-induced	O
jaw	B_Disease
stiffness	I_Disease
and	O
myalgia	B_Disease
associated	O
with	O
atypical	O
cholinesterase	O
:	O
case	O
report	O
.	O

An	O
11-year-old	O
boy	O
was	O
given	O
halothane	B_Chemical
,	O
nitrous	B_Chemical
oxide	I_Chemical
and	O
oxygen	B_Chemical
,	O
pancuronium	B_Chemical
0.4	O
mg	O
and	O
suxamethonium	B_Chemical
100	O
mg	O
for	O
induction	O
of	O
anaesthesia	O
.	O

In	O
response	O
to	O
this	O
a	O
marked	O
jaw	B_Disease
stiffness	I_Disease
occurred	O
which	O
lasted	O
for	O
two	O
minutes	O
and	O
the	O
anaesthesia	O
were	O
terminated	O
.	O

Four	O
hours	O
of	O
apnoea	B_Disease
ensued	O
and	O
he	O
suffered	O
generalized	O
severe	O
myalgia	B_Disease
lasting	O
for	O
one	O
week	O
.	O

He	O
was	O
found	O
to	O
have	O
atypical	O
plasma	O
cholinesterase	O
with	O
a	O
dibucaine	B_Chemical
number	O
of	O
12	O
,	O
indicating	O
homozygocity	O
.	O

This	O
was	O
verified	O
by	O
study	O
of	O
the	O
family	O
.	O

The	O
case	O
shows	O
that	O
prolonged	B_Disease
jaw	I_Disease
rigidity	I_Disease
and	O
myalgia	B_Disease
may	O
occur	O
after	O
suxamethonium	B_Chemical
in	O
patients	O
with	O
atypical	O
cholinesterase	O
despite	O
pretreatment	O
with	O
pancuronium	B_Chemical
.	O

Indomethacin-induced	O
hyperkalemia	B_Disease
in	O
three	O
patients	O
with	O
gouty	B_Disease
arthritis	I_Disease
.	O

We	O
describe	O
three	O
patients	O
in	O
whom	O
severe	O
,	O
life-threatening	O
hyperkalemia	B_Disease
and	O
renal	B_Disease
insufficiency	I_Disease
developed	O
after	O
treatment	O
of	O
acute	O
gouty	B_Disease
arthritis	I_Disease
with	O
indomethacin	B_Chemical
.	O

This	O
complication	O
may	O
result	O
from	O
an	O
inhibition	O
of	O
prostaglandin	B_Chemical
synthesis	O
and	O
consequent	O
hyporeninemic	B_Disease
hypoaidosteronism	I_Disease
.	O

Careful	O
attention	O
to	O
renal	O
function	O
and	O
potassium	B_Chemical
balance	O
in	O
patients	O
receiving	O
indomethacin	B_Chemical
or	O
other	O
nonsteroidal	O
anti-inflammatory	O
agents	O
,	O
particularly	O
in	O
those	O
patients	O
with	O
diabetes	B_Disease
mellitus	I_Disease
or	O
preexisting	O
renal	B_Disease
disease	I_Disease
,	O
will	O
help	O
prevent	O
this	O
potentially	O
serious	O
complication	O
.	O

Etomidate	O
:	O
a	O
foreshortened	O
clinical	O
trial	O
.	O

A	O
clinical	O
evaluation	O
of	O
etomidate	B_Chemical
for	O
outpatient	O
cystoscopy	O
was	O
embarked	O
upon	O
.	O

Unpremedicated	O
patients	O
were	O
given	O
fentanyl	B_Chemical
1	O
microgram/kg	O
followed	O
by	O
etomidate	B_Chemical
0.3	O
mg/kg	O
.	O

Anaesthesia	O
was	O
maintained	O
with	O
intermittent	O
etomidate	B_Chemical
in	O
2	O
-	O
4	O
mg	O
doses	O
.	O

Patients	O
were	O
interviewed	O
personally	O
later	O
the	O
same	O
day	O
,	O
and	O
by	O
questionnaire	O
three	O
to	O
four	O
weeks	O
later	O
.	O

The	O
trial	O
was	O
discontinued	O
after	O
20	O
cases	O
because	O
of	O
an	O
unacceptable	O
incidence	O
of	O
side	O
effects	O
.	O

Venous	O
pain	B_Disease
occurred	O
in	O
68	O
%	O
of	O
patients	O
and	O
50	O
%	O
had	O
redness	O
,	O
pain	B_Disease
or	O
swelling	B_Disease
related	O
to	O
the	O
injection	O
site	O
,	O
in	O
some	O
cases	O
lasting	O
up	O
to	O
three	O
weeks	O
after	O
anaesthesia	O
.	O

Skeletal	O
movements	O
occurred	O
in	O
50	O
%	O
of	O
patients	O
;	O
30	O
%	O
experienced	O
respiratory	B_Disease
upset	I_Disease
,	O
one	O
sufficiently	O
severe	O
to	O
necessitate	O
abandoning	O
the	O
technique	O
.	O

Nausea	B_Disease
and	O
vomiting	B_Disease
occurred	O
in	O
40	O
%	O
and	O
25	O
%	O
had	O
disturbing	O
emergence	O
psychoses	B_Disease
.	O

Levodopa-induced	O
dyskinesias	B_Disease
are	O
improved	O
by	O
fluoxetine	B_Chemical
.	O

We	O
evaluated	O
the	O
severity	O
of	O
motor	B_Disease
disability	I_Disease
and	O
dyskinesias	B_Disease
in	O
seven	O
levodopa-responsive	O
patients	O
with	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
after	O
an	O
acute	O
challenge	O
with	O
the	O
mixed	O
dopamine	B_Chemical
agonist	O
,	O
apomorphine	B_Chemical
,	O
before	O
and	O
after	O
the	O
administration	O
of	O
fluoxetine	B_Chemical
(	O
20	O
mg	O
twice	O
per	O
day	O
)	O
for	O
11	O
+	O
/-	O
1	O
days	O
.	O

After	O
fluoxetine	B_Chemical
treatment	O
,	O
there	O
was	O
a	O
significant	O
47	O
%	O
improvement	O
(	O
p	O
<	O
0.05	O
)	O
of	O
apomorphine-induced	O
dyskinesias	B_Disease
without	O
modification	O
of	O
parkinsonian	B_Disease
motor	B_Disease
disability	I_Disease
.	O

The	O
dyskinesias	B_Disease
were	O
reduced	O
predominantly	O
in	O
the	O
lower	O
limbs	O
during	O
the	O
onset	O
and	O
disappearance	O
of	O
dystonic	B_Disease
dyskinesias	B_Disease
(	O
onset-	O
and	O
end-of-dose	O
dyskinesias	B_Disease
)	O
and	O
in	O
the	O
upper	O
limbs	O
during	O
choreic	B_Disease
mid-dose	B_Disease
dyskinesias	I_Disease
.	O

The	O
results	O
suggest	O
that	O
increased	O
brain	O
serotoninergic	O
transmission	O
with	O
fluoxetine	B_Chemical
may	O
reduce	O
levodopa-	O
or	O
dopamine	B_Chemical
agonist-induced	O
dyskinesias	B_Disease
without	O
aggravating	O
parkinsonian	B_Disease
motor	B_Disease
disability	I_Disease
.	O

A	O
large	O
population-based	O
follow-up	O
study	O
of	O
trimethoprim-sulfamethoxazole	B_Chemical
,	O
trimethoprim	B_Chemical
,	O
and	O
cephalexin	B_Chemical
for	O
uncommon	O
serious	O
drug	B_Disease
toxicity	I_Disease
.	O

We	O
conducted	O
a	O
population-based	O
45-day	O
follow-up	O
study	O
of	O
232,390	O
people	O
who	O
were	O
prescribed	O
trimethoprim-sulfamethoxazole	B_Chemical
(	O
TMP-SMZ	B_Chemical
)	O
,	O
266,951	O
prescribed	O
trimethoprim	B_Chemical
alone	O
,	O
and	O
196,397	O
prescribed	O
cephalexin	B_Chemical
,	O
to	O
estimate	O
the	O
risk	O
of	O
serious	O
liver	B_Disease
,	I_Disease
blood	I_Disease
,	I_Disease
skin	I_Disease
,	I_Disease
and	I_Disease
renal	B_Disease
disorders	I_Disease
resulting	O
in	O
referral	O
or	O
hospitalization	O
associated	O
with	O
these	O
drugs	O
.	O

The	O
results	O
were	O
based	O
on	O
information	O
recorded	O
on	O
office	O
computers	O
by	O
selected	O
general	O
practitioners	O
in	O
the	O
United	O
Kingdom	O
,	O
together	O
with	O
a	O
review	O
of	O
clinical	O
records	O
.	O

The	O
risk	O
of	O
clinically	O
important	O
idiopathic	O
liver	B_Disease
disease	I_Disease
was	O
similar	O
for	O
persons	O
prescribed	O
TMP-SMZ	B_Chemical
(	O
5.2/100,000	O
)	O
and	O
those	O
prescribed	O
trimethoprim	B_Chemical
alone	O
(	O
3.8/100,000	O
)	O
.	O

The	O
risk	O
for	O
those	O
prescribed	O
cephalexin	B_Chemical
was	O
somewhat	O
lower	O
(	O
2.0/100,000	O
)	O
.	O

Only	O
five	O
patients	O
experienced	O
blood	O
disorders	O
,	O
one	O
of	O
whom	O
was	O
exposed	O
to	O
TMP-SMZ	B_Chemical
;	O
of	O
seven	O
with	O
erythema	B_Disease
multiforme	I_Disease
and	O
Stevens-Johnson	B_Disease
syndrome	I_Disease
,	O
four	O
were	O
exposed	O
to	O
TMP-SMZ	B_Chemical
.	O

The	O
one	O
case	O
of	O
toxic	B_Disease
epidermal	I_Disease
necrolysis	I_Disease
occurred	O
in	O
a	O
patient	O
who	O
took	O
cephalexin	B_Chemical
.	O

Finally	O
,	O
only	O
five	O
cases	O
of	O
acute	O
parenchymal	O
renal	B_Disease
disease	I_Disease
occurred	O
,	O
none	O
likely	O
to	O
be	O
caused	O
by	O
a	O
study	O
drug	O
.	O

We	O
conclude	O
that	O
the	O
risk	O
of	O
the	O
serious	O
diseases	O
studied	O
is	O
small	O
for	O
the	O
three	O
agents	O
,	O
and	O
compares	O
reasonably	O
with	O
the	O
risk	O
for	O
many	O
other	O
antibiotics	O
.	O

Clinical	O
safety	O
of	O
lidocaine	B_Chemical
in	O
patients	O
with	O
cocaine-associated	O
myocardial	B_Disease
infarction	I_Disease
.	O

STUDY	O
OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
safety	O
of	O
lidocaine	B_Chemical
in	O
the	O
setting	O
of	O
cocaine-induced	O
myocardial	B_Disease
infarction	I_Disease
(	O
MI	B_Disease
)	O
.	O

DESIGN	O
:	O
A	O
retrospective	O
,	O
multicenter	O
study	O
.	O

SETTING	O
:	O
Twenty-nine	O
university	O
,	O
university-affiliated	O
,	O
or	O
community	O
hospitals	O
during	O
a	O
6-year	O
period	O
(	O
total	O
of	O
117	O
cumulative	O
hospital-years	O
)	O
.	O

PARTICIPANTS	O
:	O
Patients	O
with	O
cocaine-associated	O
MI	B_Disease
who	O
received	O
lidocaine	B_Chemical
in	O
the	O
emergency	O
department	O
.	O

RESULTS	O
:	O
Of	O
29	O
patients	O
who	O
received	O
lidocaine	B_Chemical
in	O
the	O
setting	O
of	O
cocaine-associated	O
MI	B_Disease
,	O
no	O
patient	O
died	O
;	O
exhibited	O
bradydysrhythmias	B_Disease
,	O
ventricular	B_Disease
tachycardia	I_Disease
,	O
or	O
ventricular	B_Disease
fibrillation	I_Disease
;	O
or	O
experienced	O
seizures	B_Disease
after	O
administration	O
of	O
lidocaine	B_Chemical
(	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
%	O
to	O
11	O
%	O
)	O
.	O

CONCLUSION	O
:	O
Despite	O
theoretical	O
concerns	O
that	O
lidocaine	B_Chemical
may	O
enhance	O
cocaine	B_Chemical
toxicity	B_Disease
,	O
the	O
use	O
of	O
lidocaine	B_Chemical
in	O
patients	O
with	O
cocaine-associated	O
MI	B_Disease
was	O
not	O
associated	O
with	O
significant	O
cardiovascular	B_Disease
or	I_Disease
central	B_Disease
nervous	I_Disease
system	I_Disease
toxicity	I_Disease
.	O

Experimental	O
progressive	O
muscular	O
dystrophy	O
and	O
its	O
treatment	O
with	O
high	O
doses	O
anabolizing	O
agents	O
.	O

We	O
are	O
still	O
a	O
long	O
way	O
from	O
discovering	O
an	O
unequivocal	O
pathogenetic	O
interpretation	O
of	O
progressive	O
muscular	B_Disease
dystrophy	I_Disease
in	O
man	O
.	O

Noteworthy	O
efforts	O
have	O
been	O
made	O
in	O
the	O
experimental	O
field	O
;	O
a	O
recessive	O
autosomic	O
form	O
found	O
in	O
the	O
mouse	O
seems	O
to	O
bear	O
the	O
closest	O
resemblance	O
to	O
the	O
human	O
form	O
from	O
the	O
genetic	O
point	O
of	O
view	O
.	O

Myopathy	B_Disease
due	O
to	O
lack	O
of	O
vitamin	B_Chemical
E	I_Chemical
and	O
myopathy	B_Disease
induced	O
by	O
certain	O
viruses	O
have	O
much	O
in	O
common	O
anatomically	O
and	O
pathologically	O
with	O
the	O
human	O
form	O
.	O

The	O
authors	O
induced	O
myodystrophy	B_Disease
in	O
the	O
rat	O
by	O
giving	O
it	O
a	O
diet	O
lacking	O
in	O
vitamin	O
E.	O
The	O
pharmacological	O
characteristics	O
of	O
vitamin	B_Chemical
E	I_Chemical
and	O
the	O
degenerative	O
changes	O
brought	O
about	O
by	O
its	O
deficiency	O
,	O
especially	O
in	O
the	O
muscles	O
,	O
are	O
illustrated	O
.	O

It	O
is	O
thus	O
confirmed	O
that	O
the	O
histological	O
characteristics	O
of	O
myopathic	B_Disease
rat	O
muscle	O
induced	O
experimentally	O
are	O
extraordinarily	O
similar	O
to	O
those	O
of	O
human	O
myopathy	B_Disease
as	O
confirmed	O
during	O
biopsies	O
performed	O
at	O
the	O
Orthopaedic	O
Traumatological	O
Centre	O
,	O
Florence	O
.	O

The	O
encouraging	O
results	O
obtained	O
in	O
various	O
authoratative	O
departments	O
in	O
myopathic	B_Disease
patients	O
by	O
using	O
anabolizing	O
steroids	B_Chemical
have	O
encouraged	O
the	O
authors	O
to	O
investigate	O
the	O
beneficial	O
effects	O
of	O
one	O
anabolizing	O
agent	O
(	O
Dianabol	B_Chemical
,	O
CIBA	B_Chemical
)	O
at	O
high	O
doses	O
in	O
rats	O
rendered	O
myopathic	B_Disease
by	O
a	O
diet	O
deficient	O
in	O
vitamin	O
E.	O
In	O
this	O
way	O
they	O
obtained	O
appreciable	O
changes	O
in	O
body	O
weight	O
(	O
increased	O
from	O
50	O
to	O
70	O
g	O
after	O
forty	O
days	O
at	O
a	O
dose	O
of	O
5	O
mg	O
per	O
day	O
of	O
anabolizing	O
agent	O
)	O
,	O
but	O
most	O
of	O
all	O
they	O
found	O
histological	O
changes	O
due	O
to	O
"	O
regenerative	O
"	O
changes	O
in	O
the	O
muscle	O
tissue	O
,	O
which	O
however	O
maintained	O
its	O
myopathic	B_Disease
characteristics	O
in	O
the	O
control	O
animals	O
that	O
were	O
not	O
treated	O
with	O
the	O
anabolizing	O
agent	O
.	O

The	O
authors	O
conclude	O
by	O
affirming	O
the	O
undoubted	O
efficacy	O
of	O
the	O
anabolizing	O
steroids	B_Chemical
in	O
experimental	O
myopathic	B_Disease
disease	I_Disease
,	O
but	O
they	O
have	O
reservations	O
as	O
to	O
the	O
transfer	O
of	O
the	O
results	O
into	O
the	O
human	O
field	O
,	O
where	O
high	O
dosage	O
can	O
not	O
be	O
carried	O
out	O
continuously	O
because	O
of	O
the	O
effects	O
of	O
the	O
drug	O
on	O
virility	O
;	O
because	O
the	O
tissue	O
injury	O
too	O
often	O
occurs	O
at	O
an	O
irreversible	O
stage	O
vis-a-vis	O
the	O
"	O
regeneration	O
"	O
of	O
the	O
muscle	O
tissue	O
;	O
and	O
finally	O
because	O
the	O
dystrophic	O
injurious	O
agent	O
is	O
certainly	O
not	O
the	O
lack	O
of	O
vitamin	B_Chemical
E	I_Chemical
but	O
something	O
as	O
yet	O
unknown	O
.	O

Paclitaxel	B_Chemical
3-hour	O
infusion	O
given	O
alone	O
and	O
combined	O
with	O
carboplatin	B_Chemical
:	O
preliminary	O
results	O
of	O
dose-escalation	O
trials	O
.	O

Paclitaxel	B_Chemical
(	O
Taxol	B_Chemical
;	O
Bristol-Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
by	O
3-hour	O
infusion	O
was	O
combined	O
with	O
carboplatin	B_Chemical
in	O
a	O
phase	O
I/II	O
study	O
directed	O
to	O
patients	O
with	O
non-small	B_Disease
cell	I_Disease
lung	I_Disease
cancer	I_Disease
.	O

Carboplatin	B_Chemical
was	O
given	O
at	O
a	O
fixed	O
target	O
area	O
under	O
the	O
concentration-time	O
curve	O
of	O
6.0	O
by	O
the	O
Calvert	O
formula	O
,	O
whereas	O
paclitaxel	B_Chemical
was	O
escalated	O
in	O
patient	O
cohorts	O
from	O
150	O
mg/m2	O
(	O
dose	O
level	O
I	O
)	O
to	O
175	O
,	O
200	O
,	O
225	O
,	O
and	O
250	O
mg/m2	O
.	O

The	O
225	O
mg/m2	O
level	O
was	O
expanded	O
for	O
the	O
phase	O
II	O
study	O
since	O
the	O
highest	O
level	O
achieved	O
(	O
250	O
mg/m2	O
)	O
required	O
modification	O
because	O
of	O
nonhematologic	O
toxicities	B_Disease
(	O
arthralgia	B_Disease
and	O
sensory	B_Disease
neuropathy	I_Disease
)	O
.	O

Therapeutic	O
effects	O
were	O
noted	O
at	O
all	O
dose	O
levels	O
,	O
with	O
objective	O
responses	O
in	O
17	O
(	O
two	O
complete	O
and	O
15	O
partial	O
regressions	O
)	O
of	O
41	O
previously	O
untreated	O
patients	O
.	O

Toxicities	B_Disease
were	O
compared	O
with	O
a	O
cohort	O
of	O
patients	O
in	O
a	O
phase	O
I	O
trial	O
of	O
paclitaxel	B_Chemical
alone	O
at	O
identical	O
dose	O
levels	O
.	O

Carboplatin	B_Chemical
did	O
not	O
appear	O
to	O
add	O
to	O
the	O
hematologic	B_Disease
toxicities	I_Disease
observed	O
,	O
and	O
the	O
paclitaxel/carboplatin	O
combination	O
could	O
be	O
dosed	O
every	O
3	O
weeks	O
.	O

The	O
dose-dependent	O
effect	O
of	O
misoprostol	B_Chemical
on	O
indomethacin-induced	O
renal	B_Disease
dysfunction	I_Disease
in	O
well	O
compensated	O
cirrhosis	B_Disease
.	O

Misoprostol	B_Chemical
(	O
200	O
micrograms	O
)	O
has	O
been	O
shown	O
to	O
acutely	O
counteract	O
the	O
indomethacin-induced	O
renal	B_Disease
dysfunction	I_Disease
in	O
well	O
compensated	O
cirrhotic	B_Disease
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
the	O
prophylactic	O
value	O
of	O
misoprostol	B_Chemical
was	O
dose-dependent	O
.	O

Parameters	O
of	O
renal	O
hemodynamics	O
and	O
tubular	O
sodium	B_Chemical
and	O
water	O
handling	O
were	O
assessed	O
by	O
clearance	O
techniques	O
in	O
26	O
well	O
compensated	O
cirrhotic	B_Disease
patients	O
before	O
and	O
after	O
an	O
oral	O
combination	O
of	O
50	O
mg	O
of	O
indomethacin	B_Chemical
and	O
various	O
doses	O
of	O
misoprostol	B_Chemical
.	O

The	O
200-micrograms	O
dose	O
was	O
able	O
to	O
totally	O
abolish	O
the	O
deleterious	O
renal	O
effects	O
of	O
indomethacin	B_Chemical
,	O
whereas	O
the	O
800-micrograms	O
dose	O
resulted	O
in	O
significant	O
worsening	O
of	O
renal	O
hemodynamics	O
and	O
sodium	B_Chemical
retention	O
.	O

These	O
changes	O
were	O
maximal	O
in	O
the	O
hour	O
immediately	O
after	O
medications	O
and	O
slowly	O
returned	O
toward	O
base-line	O
levels	O
thereafter	O
.	O

These	O
results	O
suggest	O
that	O
the	O
renal	O
protective	O
effects	O
of	O
misoprostol	B_Chemical
is	O
dose-dependent	O
.	O

However	O
,	O
until	O
this	O
apparent	O
ability	O
of	O
200	O
micrograms	O
of	O
misoprostol	B_Chemical
to	O
prevent	O
the	O
adverse	O
effects	O
of	O
indomethacin	B_Chemical
on	O
renal	O
function	O
is	O
confirmed	O
with	O
chronic	O
frequent	O
dosing	O
,	O
it	O
would	O
be	O
prudent	O
to	O
avoid	O
nonsteroidal	O
anti-inflammatory	O
therapy	O
in	O
patients	O
with	O
cirrhosis	B_Disease
.	O

Increased	O
frequency	O
and	O
severity	O
of	O
angio-oedema	B_Disease
related	O
to	O
long-term	O
therapy	O
with	O
angiotensin-converting	B_Chemical
enzyme	I_Chemical
inhibitor	I_Chemical
in	O
two	O
patients	O
.	O

Adverse	O
reactions	O
to	O
drugs	O
are	O
well	O
recognized	O
as	O
a	O
cause	O
of	O
acute	O
or	O
chronic	O
urticaria	B_Disease
,	O
and	O
angio-oedema	B_Disease
.	O

Angiotensin-converting	B_Chemical
enzyme	I_Chemical
(	I_Chemical
ACE	I_Chemical
)	I_Chemical
inhibitors	I_Chemical
,	O
used	O
to	O
treat	O
hypertension	B_Disease
and	O
congestive	B_Disease
heart	I_Disease
failure	I_Disease
,	O
were	O
introduced	O
in	O
Europe	O
in	O
the	O
middle	O
of	O
the	O
eighties	O
,	O
and	O
the	O
use	O
of	O
these	O
drugs	O
has	O
increased	O
progressively	O
.	O

Soon	O
after	O
the	O
introduction	O
of	O
ACE	B_Chemical
inhibitors	I_Chemical
,	O
acute	O
bouts	O
of	O
angio-oedema	B_Disease
were	O
reported	O
in	O
association	O
with	O
the	O
use	O
of	O
these	O
drugs	O
.	O

We	O
wish	O
to	O
draw	O
attention	O
to	O
the	O
possibility	O
of	O
adverse	O
reactions	O
to	O
ACE	B_Chemical
inhibitors	I_Chemical
after	O
long-term	O
use	O
and	O
in	O
patients	O
with	O
pre-existing	O
angio-oedema	B_Disease
.	O

Myoclonus	B_Disease
associated	O
with	O
lorazepam	B_Chemical
therapy	O
in	O
very-low-birth-weight	O
infants	O
.	O

Lorazepam	B_Chemical
is	O
being	O
used	O
with	O
increasing	O
frequency	O
as	O
a	O
sedative	O
in	O
the	O
newborn	O
and	O
the	O
young	O
infant	O
.	O

Concern	O
has	O
been	O
raised	O
with	O
regard	O
to	O
the	O
safety	O
of	O
lorazepam	B_Chemical
in	O
this	O
age	O
group	O
,	O
especially	O
in	O
very-low-birth-weight	O
(	O
VLBW	O
;	O
<	O
1,500	O
g	O
)	O
infants	O
.	O

Three	O
young	O
infants	O
,	O
all	O
of	O
birth	O
weight	O
<	O
1,500	O
g	O
,	O
experienced	O
myoclonus	B_Disease
following	O
the	O
intravenous	O
administration	O
of	O
lorazepam	B_Chemical
.	O

The	O
potential	O
neurotoxic	B_Disease
effects	O
of	O
the	O
drug	O
(	O
and	O
its	O
vehicle	O
)	O
in	O
this	O
population	O
are	O
discussed	O
.	O

Injectable	O
lorazepam	B_Chemical
should	O
be	O
used	O
with	O
caution	O
in	O
VLBW	O
infants	O
.	O

Transvenous	O
right	O
ventricular	O
pacing	O
during	O
cardiopulmonary	O
resuscitation	O
of	O
pediatric	O
patients	O
with	O
acute	O
cardiomyopathy	O
.	O

We	O
describe	O
the	O
cardiopulmonary	O
resuscitation	O
efforts	O
on	O
five	O
patients	O
who	O
presented	O
in	O
acute	O
circulatory	B_Disease
failure	I_Disease
from	O
myocardial	B_Disease
dysfunction	I_Disease
.	O

Three	O
patients	O
had	O
acute	O
viral	O
myocarditis	B_Disease
,	O
one	O
had	O
a	O
carbamazepine-induced	O
acute	O
eosinophilic	B_Disease
myocarditis	B_Disease
,	O
and	O
one	O
had	O
cardiac	O
hemosiderosis	O
resulting	O
in	O
acute	O
cardiogenic	B_Disease
shock	I_Disease
.	O

All	O
patients	O
were	O
continuously	O
monitored	O
with	O
central	O
venous	O
and	O
arterial	O
catheters	O
in	O
addition	O
to	O
routine	O
noninvasive	O
monitoring	O
.	O

An	O
introducer	O
sheath	O
,	O
a	O
pacemaker	O
,	O
and	O
sterile	O
pacing	O
wires	O
were	O
made	O
readily	O
available	O
for	O
the	O
patients	O
,	O
should	O
the	O
need	O
arise	O
to	O
terminate	O
resistant	O
cardiac	O
dysrhythmias	B_Disease
.	O

All	O
patients	O
developed	O
cardiocirculatory	O
arrest	O
associated	O
with	O
extreme	O
hypotension	B_Disease
and	O
dysrhythmias	B_Disease
within	O
the	O
first	O
48	O
hours	O
of	O
their	O
admission	O
to	O
the	O
pediatric	O
intensive	O
care	O
unit	O
(	O
PICU	O
)	O
.	O

Right	O
ventricular	O
pacemaker	O
wires	O
were	O
inserted	O
in	O
all	O
of	O
them	O
during	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	O
)	O
.	O

In	O
four	O
patients	O
,	O
cardiac	O
pacing	O
was	O
used	O
,	O
resulting	O
in	O
a	O
temporary	O
captured	O
rhythm	O
and	O
restoration	O
of	O
their	O
cardiac	O
output	O
.	O

These	O
patients	O
had	O
a	O
second	O
event	O
of	O
cardiac	B_Disease
arrest	I_Disease
,	O
resulting	O
in	O
death	O
,	O
within	O
10	O
to	O
60	O
minutes	O
.	O

In	O
one	O
patient	O
,	O
cardiac	O
pacing	O
was	O
not	O
used	O
,	O
because	O
he	O
converted	O
to	O
normal	O
sinus	O
rhythm	O
by	O
electrical	O
defibrillation	O
within	O
three	O
minutes	O
of	O
initiating	O
CPR	O
.	O

We	O
conclude	O
that	O
cardiac	O
pacing	O
during	O
resuscitative	O
efforts	O
in	O
pediatric	O
patients	O
suffering	O
from	O
acute	O
myocardial	B_Disease
dysfunction	I_Disease
may	O
not	O
have	O
long-term	O
value	O
in	O
and	O
of	O
itself	O
;	O
however	O
,	O
if	O
temporary	O
hemodynamic	O
stability	O
is	O
achieved	O
by	O
this	O
procedure	O
,	O
it	O
may	O
provide	O
additional	O
time	O
needed	O
to	O
institute	O
other	O
therapeutic	O
modalities	O
.	O

Efficacy	O
and	O
safety	O
of	O
granisetron	B_Chemical
,	O
a	O
selective	O
5-hydroxytryptamine-3	O
receptor	O
antagonist	O
,	O
in	O
the	O
prevention	O
of	O
nausea	B_Disease
and	O
vomiting	B_Disease
induced	O
by	O
high-dose	O
cisplatin	B_Chemical
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
antiemetic	O
effects	O
and	O
safety	O
profile	O
of	O
four	O
different	O
doses	O
of	O
granisetron	B_Chemical
(	O
Kytril	B_Chemical
;	O
SmithKline	O
Beecham	O
Pharmaceuticals	O
,	O
Philadelphia	O
,	O
PA	O
)	O
when	O
administered	O
as	O
a	O
single	O
intravenous	O
(	O
IV	O
)	O
dose	O
for	O
prophylaxis	O
of	O
cisplatin-induced	O
nausea	B_Disease
and	O
vomiting	B_Disease
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
One	O
hundred	O
eighty-four	O
chemotherapy-naive	O
patients	O
receiving	O
high-dose	O
cisplatin	B_Chemical
(	O
81	O
to	O
120	O
mg/m2	O
)	O
were	O
randomized	O
to	O
receive	O
one	O
of	O
four	O
granisetron	B_Chemical
doses	O
(	O
5	O
,	O
10	O
,	O
20	O
,	O
or	O
40	O
micrograms/kg	O
)	O
administered	O
before	O
chemotherapy	O
.	O

Patients	O
were	O
observed	O
on	O
an	O
inpatient	O
basis	O
for	O
18	O
to	O
24	O
hours	O
,	O
and	O
vital	O
signs	O
,	O
nausea	B_Disease
,	O
vomiting	B_Disease
,	O
retching	O
,	O
and	O
appetite	O
were	O
assessed	O
.	O

Safety	O
analyses	O
included	O
incidence	O
of	O
adverse	O
experiences	O
and	O
laboratory	O
parameter	O
changes	O
.	O

RESULTS	O
:	O
After	O
granisetron	B_Chemical
doses	O
of	O
5	O
,	O
10	O
,	O
20	O
,	O
and	O
40	O
micrograms/kg	O
,	O
a	O
major	O
response	O
(	O
<	O
or	O
=	O
two	O
vomiting	B_Disease
or	O
retching	O
episodes	O
,	O
and	O
no	O
antiemetic	O
rescue	O
)	O
was	O
recorded	O
in	O
23	O
%	O
,	O
57	O
%	O
,	O
58	O
%	O
,	O
and	O
60	O
%	O
of	O
patients	O
,	O
respectively	O
,	O
and	O
a	O
complete	O
response	O
(	O
no	O
vomiting	B_Disease
or	O
retching	O
,	O
and	O
no	O
antiemetic	O
rescue	O
)	O
in	O
18	O
%	O
,	O
41	O
%	O
,	O
40	O
%	O
,	O
and	O
47	O
%	O
of	O
patients	O
,	O
respectively	O
.	O

There	O
was	O
a	O
statistically	O
longer	O
time	O
to	O
first	O
episode	O
of	O
nausea	B_Disease
(	O
P	O
=	O
.0015	O
)	O
and	O
vomiting	B_Disease
(	O
P	O
=	O
.0001	O
)	O
,	O
and	O
fewer	O
patients	O
were	O
administered	O
additional	O
antiemetic	O
medication	O
in	O
the	O
10-micrograms/kg	O
dosing	O
groups	O
than	O
in	O
the	O
5-micrograms/kg	O
dosing	O
group	O
.	O

As	O
granisetron	B_Chemical
dose	O
increased	O
,	O
appetite	O
return	O
increased	O
(	O
P	O
=	O
.040	O
)	O
.	O

Headache	B_Disease
was	O
the	O
most	O
frequently	O
reported	O
adverse	O
event	O
(	O
20	O
%	O
)	O
.	O

CONCLUSION	O
:	O
A	O
single	O
10-	O
,	O
20-	O
,	O
or	O
40-micrograms/kg	O
dose	O
of	O
granisetron	B_Chemical
was	O
effective	O
in	O
controlling	O
vomiting	B_Disease
in	O
57	O
%	O
to	O
60	O
%	O
of	O
patients	O
who	O
received	O
cisplatin	B_Chemical
at	O
doses	O
greater	O
than	O
81	O
mg/m2	O
and	O
totally	O
prevented	O
vomiting	B_Disease
in	O
40	O
%	O
to	O
47	O
%	O
of	O
patients	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
efficacy	O
between	O
the	O
10-micrograms/kg	O
dose	O
and	O
the	O
20-	O
and	O
40-micrograms/kg	O
doses	O
.	O

Granisetron	B_Chemical
was	O
well	O
tolerated	O
at	O
all	O
doses	O
.	O

Adverse	O
interaction	O
between	O
clonidine	B_Chemical
and	O
verapamil	B_Chemical
.	O

OBJECTIVE	O
:	O
To	O
report	O
two	O
cases	O
of	O
a	O
possible	O
adverse	O
interaction	O
between	O
clonidine	B_Chemical
and	O
verapamil	B_Chemical
resulting	O
in	O
atrioventricular	B_Disease
(	I_Disease
AV	I_Disease
)	I_Disease
block	I_Disease
in	O
both	O
patients	O
and	O
severe	O
hypotension	B_Disease
in	O
one	O
patient	O
.	O

CASE	O
SUMMARIES	O
:	O
A	O
54-year-old	O
woman	O
with	O
hyperaldosteronism	B_Disease
was	O
treated	O
with	O
verapamil	B_Chemical
480	O
mg/d	O
and	O
spironolactone	B_Chemical
100	O
mg/d	O
.	O

After	O
the	O
addition	O
of	O
a	O
minimal	O
dose	O
of	O
clonidine	B_Chemical
(	O
0.15	O
mg	O
bid	O
)	O
,	O
she	O
developed	O
complete	O
AV	B_Disease
block	I_Disease
and	O
severe	O
hypotension	B_Disease
,	O
which	O
resolved	O
upon	O
cessation	O
of	O
all	O
medications	O
.	O

A	O
65-year-old	O
woman	O
was	O
treated	O
with	O
extended-release	O
verapamil	B_Chemical
240	O
mg/d	O
.	O

After	O
the	O
addition	O
of	O
clonidine	B_Chemical
0.15	O
mg	O
bid	O
she	O
developed	O
complete	O
AV	B_Disease
block	I_Disease
,	O
which	O
resolved	O
after	O
all	O
therapy	O
was	O
stopped	O
.	O

DISCUSSION	O
:	O
An	O
adverse	O
interaction	O
between	O
clonidine	B_Chemical
and	O
verapamil	B_Chemical
has	O
not	O
been	O
reported	O
previously	O
.	O

We	O
describe	O
two	O
such	O
cases	O
and	O
discuss	O
the	O
various	O
mechanisms	O
that	O
might	O
cause	O
such	O
an	O
interaction	O
.	O

Clinicians	O
should	O
be	O
acquainted	O
with	O
this	O
possibly	O
fatal	O
interaction	O
between	O
two	O
commonly	O
used	O
antihypertensive	O
drugs	O
.	O

CONCLUSIONS	O
:	O
Caution	O
is	O
recommended	O
in	O
combining	O
clonidine	B_Chemical
and	O
verapamil	B_Chemical
therapy	O
,	O
even	O
in	O
patients	O
who	O
do	O
not	O
have	O
sinus	O
or	O
AV	O
node	O
dysfunction	O
.	O

The	O
two	O
drugs	O
may	O
act	O
synergistically	O
on	O
both	O
the	O
AV	O
node	O
and	O
the	O
peripheral	O
circulation	O
.	O

Pharmacological	O
studies	O
on	O
a	O
new	O
dihydrothienopyridine	B_Chemical
calcium	I_Chemical
antagonist	O
,	O
S-312-d	B_Chemical
.	O

5th	O
communication	O
:	O
anticonvulsant	O
effects	O
in	O
mice	O
.	O

S-312	B_Chemical
,	O
S-312-d	B_Chemical
,	O
but	O
not	O
S-312-l	B_Chemical
,	O
L-type	O
calcium	B_Chemical
channel	O
antagonists	O
,	O
showed	O
anticonvulsant	O
effects	O
on	O
the	O
audiogenic	B_Disease
tonic	I_Disease
convulsions	I_Disease
in	O
DBA/2	O
mice	O
;	O
and	O
their	O
ED50	O
values	O
were	O
18.4	O
(	O
12.8	O
-	O
27.1	O
)	O
mg/kg	O
,	O
p.o	O
.	O
and	O
15.0	O
(	O
10.2	O
-	O
23.7	O
)	O
mg/kg	O
,	O
p.o	O
.	O
,	O
respectively	O
,	O
while	O
that	O
of	O
flunarizine	B_Chemical
was	O
34.0	O
(	O
26.0	O
-	O
44.8	O
)	O
mg/kg	O
,	O
p.o	O
.	O

Although	O
moderate	O
anticonvulsant	O
effects	O
of	O
S-312-d	B_Chemical
in	O
higher	O
doses	O
were	O
observed	O
against	O
the	O
clonic	O
convulsions	B_Disease
induced	O
by	O
pentylenetetrazole	B_Chemical
(	O
85	O
mg/kg	O
,	O
s.c	O
.	O
)	O
or	O
bemegride	B_Chemical
(	O
40	O
mg/kg	O
,	O
s.c	O
.	O
)	O
,	O
no	O
effects	O
were	O
observed	O
in	O
convulsions	B_Disease
induced	O
by	O
N-methyl-D-aspartate	B_Chemical
,	O
picrotoxin	B_Chemical
,	O
or	O
electroshock	O
in	O
Slc	O
:	O
ddY	O
mice	O
.	O

S-312-d	B_Chemical
may	O
be	O
useful	O
in	O
the	O
therapy	O
of	O
certain	O
types	O
of	O
human	O
epilepsy	B_Disease
.	O

Transmural	O
myocardial	B_Disease
infarction	I_Disease
with	O
sumatriptan	B_Chemical
.	O

For	O
sumatriptan	B_Chemical
,	O
tightness	O
in	O
the	O
chest	O
caused	O
by	O
an	O
unknown	O
mechanism	O
has	O
been	O
reported	O
in	O
3	O
-	O
5	O
%	O
of	O
users	O
.	O

We	O
describe	O
a	O
47-year-old	O
woman	O
with	O
an	O
acute	O
myocardial	B_Disease
infarction	I_Disease
after	O
administration	O
of	O
sumatriptan	B_Chemical
6	O
mg	O
subcutaneously	O
for	O
cluster	B_Disease
headache	I_Disease
.	O

The	O
patient	O
had	O
no	O
history	O
of	O
underlying	O
ischaemic	B_Disease
heart	I_Disease
disease	I_Disease
or	O
Prinzmetal	B_Disease
's	I_Disease
angina	I_Disease
.	O

She	O
recovered	O
without	O
complications	O
.	O

Flumazenil	B_Chemical
induces	O
seizures	B_Disease
and	O
death	O
in	O
mixed	O
cocaine-diazepam	O
intoxications	O
.	O

STUDY	O
HYPOTHESIS	O
:	O
Administration	O
of	O
the	O
benzodiazepine	B_Chemical
antagonist	O
flumazenil	B_Chemical
may	O
unmask	O
seizures	B_Disease
in	O
mixed	O
cocaine-benzodiazepine	O
intoxication	O
.	O

DESIGN	O
:	O
Male	O
Sprague-Dawley	O
rats	O
received	O
100	O
mg/kg	O
cocaine	B_Chemical
IP	O
alone	O
,	O
5	O
mg/kg	O
diazepam	B_Chemical
alone	O
,	O
or	O
a	O
combination	O
of	O
diazepam	B_Chemical
and	O
cocaine	B_Chemical
.	O

Three	O
minutes	O
later	O
,	O
groups	O
were	O
challenged	O
with	O
vehicle	O
or	O
flumazenil	B_Chemical
5	O
or	O
10	O
mg/kg	O
IP	O
.	O

Animal	O
behavior	O
,	O
seizures	B_Disease
(	O
time	O
to	O
and	O
incidence	O
)	O
,	O
death	O
(	O
time	O
to	O
and	O
incidence	O
)	O
,	O
and	O
cortical	O
EEG	O
tracings	O
were	O
recorded	O
.	O

INTERVENTIONS	O
:	O
Administration	O
of	O
flumazenil	B_Chemical
to	O
animals	O
after	O
they	O
had	O
received	O
a	O
combination	O
dose	O
of	O
cocaine	B_Chemical
and	O
diazepam	B_Chemical
.	O

RESULTS	O
:	O
In	O
group	O
1	O
,	O
animals	O
received	O
cocaine	B_Chemical
followed	O
by	O
vehicle	O
.	O

This	O
resulted	O
in	O
100	O
%	O
developing	O
seizures	B_Disease
and	O
death	O
.	O

Group	O
2	O
received	O
diazepam	B_Chemical
alone	O
followed	O
by	O
vehicle	O
.	O

Animals	O
became	O
somnolent	O
and	O
none	O
died	O
.	O

Group	O
3	O
received	O
diazepam	B_Chemical
followed	O
by	O
5	O
mg/kg	O
flumazenil	B_Chemical
.	O

Animals	O
became	O
somnolent	O
after	O
diazepam	B_Chemical
and	O
then	O
active	O
after	O
flumazenil	B_Chemical
administration	O
.	O

In	O
group	O
4	O
,	O
a	O
combination	O
of	O
cocaine	B_Chemical
and	O
diazepam	B_Chemical
was	O
administered	O
simultaneously	O
.	O

This	O
resulted	O
in	O
no	O
overt	O
or	O
EEG-detectable	O
seizures	B_Disease
and	O
a	O
50	O
%	O
incidence	O
of	O
death	O
.	O

Group	O
5	O
received	O
a	O
similar	O
combination	O
of	O
cocaine	B_Chemical
and	O
diazepam	B_Chemical
,	O
followed	O
later	O
by	O
5	O
mg/kg	O
flumazenil	B_Chemical
.	O

This	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
seizures	B_Disease
,	O
90	O
%	O
(	O
P	O
<	O
.01	O
)	O
,	O
and	O
death	O
,	O
100	O
%	O
(	O
P	O
<	O
or	O
=	O
.01	O
)	O
,	O
compared	O
with	O
group	O
4	O
.	O

Group	O
6	O
received	O
cocaine	B_Chemical
and	O
diazepam	B_Chemical
followed	O
by	O
10	O
mg/kg	O
flumazenil	B_Chemical
.	O

This	O
also	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
seizures	B_Disease
,	O
90	O
%	O
(	O
P	O
<	O
or	O
=	O
.01	O
)	O
,	O
and	O
death	O
,	O
90	O
%	O
(	O
P	O
<	O
or	O
=	O
.05	O
)	O
,	O
compared	O
with	O
group	O
4	O
.	O

CONCLUSION	O
:	O
Flumazenil	B_Chemical
can	O
unmask	O
seizures	B_Disease
and	O
increase	O
the	O
incidence	O
of	O
death	O
in	O
a	O
model	O
of	O
combined	O
cocaine-diazepam	O
intoxications	O
.	O

Mechanisms	O
for	O
protective	O
effects	O
of	O
free	O
radical	O
scavengers	O
on	O
gentamicin-mediated	O
nephropathy	B_Disease
in	O
rats	O
.	O

Studies	O
were	O
performed	O
to	O
examine	O
the	O
mechanisms	O
for	O
the	O
protective	O
effects	O
of	O
free	O
radical	O
scavengers	O
on	O
gentamicin	B_Chemical
(GM)-mediated	O
nephropathy	B_Disease
.	O

Administration	O
of	O
GM	B_Chemical
at	O
40	O
mg/kg	O
sc	O
for	O
13	O
days	O
to	O
rats	O
induced	O
a	O
significant	O
reduction	O
in	O
renal	O
blood	O
flow	O
(	O
RBF	O
)	O
and	O
inulin	O
clearance	O
(	O
CIn	O
)	O
as	O
well	O
as	O
marked	O
tubular	B_Disease
damage	I_Disease
.	O

A	O
significant	O
reduction	O
in	O
urinary	O
guanosine	B_Chemical
3',5'-cyclic	I_Chemical
monophosphate	I_Chemical
(	O
cGMP	B_Chemical
)	O
excretion	O
and	O
a	O
significant	O
increase	O
in	O
renal	O
cortical	O
renin	O
and	O
endothelin-1	O
contents	O
were	O
also	O
observed	O
in	O
GM-mediated	O
nephropathy	B_Disease
.	O

Superoxide	B_Chemical
dismutase	O
(	O
SOD	O
)	O
or	O
dimethylthiourea	B_Chemical
(	O
DMTU	B_Chemical
)	O
significantly	O
lessened	O
the	O
GM-induced	O
decrement	O
in	O
CIn	O
.	O

The	O
SOD-induced	O
increase	O
in	O
glomerular	O
filtration	O
rate	O
was	O
associated	O
with	O
a	O
marked	O
improvement	O
in	O
RBF	O
,	O
an	O
increase	O
in	O
urinary	O
cGMP	B_Chemical
excretion	O
,	O
and	O
a	O
decrease	O
in	O
renal	O
renin	O
and	O
endothelin-1	O
content	O
.	O

SOD	O
did	O
not	O
attenuate	O
the	O
tubular	B_Disease
damage	I_Disease
.	O

In	O
contrast	O
,	O
DMTU	B_Chemical
significantly	O
reduced	O
the	O
tubular	B_Disease
damage	I_Disease
and	O
lipid	O
peroxidation	O
,	O
but	O
it	O
did	O
not	O
affect	O
renal	O
hemodynamics	O
and	O
vasoactive	O
substances	O
.	O

Neither	O
SOD	O
nor	O
DMTU	B_Chemical
affected	O
the	O
renal	O
cortical	O
GM	B_Chemical
content	O
in	O
GM-treated	O
rats	O
.	O

These	O
results	O
suggest	O
that	O
1	O
)	O
both	O
SOD	O
and	O
DMTU	B_Chemical
have	O
protective	O
effects	O
on	O
GM-mediated	O
nephropathy	B_Disease
,	O
2	O
)	O
the	O
mechanisms	O
for	O
the	O
protective	O
effects	O
differ	O
for	O
SOD	O
and	O
DMTU	B_Chemical
,	O
and	O
3	O
)	O
superoxide	B_Chemical
anions	O
play	O
a	O
critical	O
role	O
in	O
GM-induced	O
renal	O
vasoconstriction	O
.	O

Cephalothin-induced	O
immune	O
hemolytic	B_Disease
anemia	I_Disease
.	O

A	O
patient	O
with	O
renal	B_Disease
disease	I_Disease
developed	O
Coombs-positive	O
hemolytic	B_Disease
anemia	I_Disease
while	O
receiving	O
cephalothin	B_Chemical
therapy	O
.	O

An	O
anti-cephalothin	O
IgG	O
antibody	O
was	O
detected	O
in	O
the	O
patient	O
's	O
serum	O
and	O
in	O
the	O
eluates	O
from	O
her	O
erythrocytes	O
.	O

In	O
addition	O
,	O
nonimmunologic	O
binding	O
of	O
normal	O
and	O
patient	O
's	O
serum	O
proteins	O
to	O
her	O
own	O
and	O
cephalothin-coated	O
normal	O
red	O
cells	O
was	O
demonstrated	O
.	O

Skin	O
tests	O
and	O
in	O
vitro	O
lymphocyte	O
stimulation	O
revealed	O
that	O
the	O
patient	O
was	O
sensitized	O
to	O
cephalothin	B_Chemical
and	O
also	O
to	O
ampicillin	B_Chemical
.	O

Careful	O
investigation	O
of	O
drug-induced	O
hemolytic	B_Disease
anemias	I_Disease
reveals	O
the	O
complexity	O
of	O
the	O
immune	O
mechanisms	O
involved	O
.	O

Assessment	O
of	O
cardiomyocyte	O
DNA	O
synthesis	O
during	O
hypertrophy	O
in	O
adult	O
mice	O
.	O

The	O
ability	O
of	O
cardiomyocytes	O
to	O
synthesize	O
DNA	O
in	O
response	O
to	O
experimentally	O
induced	O
cardiac	B_Disease
hypertrophy	I_Disease
was	O
assessed	O
in	O
adult	O
mice	O
.	O

Isoproterenol	B_Chemical
delivered	O
by	O
osmotic	O
minipump	O
implantation	O
in	O
adult	O
C3Heb/FeJ	O
mice	O
resulted	O
in	O
a	O
46	O
%	O
increase	O
in	O
heart	O
weight	O
and	O
a	O
19.3	O
%	O
increase	O
in	O
cardiomyocyte	O
area	O
.	O

No	O
DNA	O
synthesis	O
,	O
as	O
assessed	O
by	O
autoradiographic	O
analysis	O
of	O
isolated	O
cardiomyocytes	O
,	O
was	O
observed	O
in	O
control	O
or	O
hypertrophic	B_Disease
hearts	I_Disease
.	O

A	O
survey	O
of	O
15	O
independent	O
inbred	O
strains	O
of	O
mice	O
revealed	O
that	O
ventricular	O
cardiomyocyte	O
nuclear	O
number	O
ranged	O
from	O
3	O
to	O
13	O
%	O
mononucleate	O
,	O
suggesting	O
that	O
cardiomyocyte	O
terminal	O
differentiation	O
is	O
influenced	O
directly	O
or	O
indirectly	O
by	O
genetic	O
background	O
.	O

To	O
determine	O
whether	O
the	O
capacity	O
for	O
reactive	O
DNA	O
synthesis	O
was	O
also	O
subject	O
to	O
genetic	O
regulation	O
,	O
cardiac	B_Disease
hypertrophy	I_Disease
was	O
induced	O
in	O
the	O
strains	O
of	O
mice	O
comprising	O
the	O
extremes	O
of	O
the	O
nuclear	O
number	O
survey	O
.	O

These	O
data	O
indicate	O
that	O
adult	O
mouse	O
atrial	O
and	O
ventricular	O
cardiomyocytes	O
do	O
not	O
synthesize	O
DNA	O
in	O
response	O
to	O
isoproterenol-induced	O
cardiac	B_Disease
hypertrophy	I_Disease
.	O

Central	O
cardiovascular	O
effects	O
of	O
AVP	B_Chemical
and	O
ANP	O
in	O
normotensive	O
and	O
spontaneously	O
hypertensive	B_Disease
rats	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
influence	O
of	O
central	O
arginine	B_Chemical
vasopressin	I_Chemical
(	O
AVP	B_Chemical
)	O
and	O
of	O
atrial	O
natriuretic	O
peptide	O
(	O
ANP	O
)	O
on	O
control	O
of	O
arterial	O
blood	O
pressure	O
(	O
MAP	O
)	O
and	O
heart	O
rate	O
(	O
HR	O
)	O
in	O
normotensive	O
(	O
WKY	O
)	O
and	O
spontaneously	O
hypertensive	B_Disease
(	O
SHR	O
)	O
rats	O
.	O

Three	O
series	O
of	O
experiments	O
were	O
performed	O
on	O
30	O
WKY	O
and	O
30	O
SHR	O
,	O
chronically	O
instrumented	O
with	O
guide	O
tubes	O
in	O
the	O
lateral	O
ventricle	O
(	O
LV	O
)	O
and	O
arterial	O
and	O
venous	O
catheters	O
.	O

MAP	O
and	O
HR	O
were	O
monitored	O
before	O
and	O
after	O
i.v	O
.	O

injections	O
of	O
either	O
vehicle	O
or	O
1	O
,	O
10	O
and	O
50	O
ng	O
of	O
AVP	B_Chemical
and	O
25	O
,	O
125	O
and	O
500	O
ng	O
of	O
ANP	O
.	O

Sensitivity	O
of	O
cardiac	O
component	O
of	O
baroreflex	O
(	O
CCB	O
)	O
,	O
expressed	O
as	O
a	O
slope	O
of	O
the	O
regression	O
line	O
was	O
determined	O
from	O
relationships	O
between	O
systolic	O
arterial	O
pressure	O
(	O
SAP	O
)	O
and	O
HR	O
period	O
(	O
HRp	O
)	O
during	O
phenylephrine	B_Chemical
(Phe)-induced	O
hypertension	B_Disease
and	O
sodium	B_Chemical
nitroprusside	I_Chemical
(SN)-induced	O
hypotension	B_Disease
.	O

CCB	O
was	O
measured	O
before	O
and	O
after	O
administration	O
of	O
either	O
vehicle	O
,	O
AVP	B_Chemical
,	O
ANP	O
,	O
or	O
both	O
peptides	O
together	O
.	O

Increases	O
of	O
MAP	O
occurred	O
after	O
LV	O
administration	O
of	O
1	O
,	O
10	O
and	O
50	O
ng	O
of	O
AVP	B_Chemical
in	O
WKY	O
and	O
of	O
10	O
and	O
50	O
ng	O
in	O
SHR	O
.	O

ANP	O
did	O
not	O
cause	O
significant	O
changes	O
in	O
MAP	O
in	O
both	O
strains	O
as	O
compared	O
to	O
vehicle	O
,	O
but	O
it	O
abolished	O
AVP-induced	O
MAP	O
increase	O
in	O
WKY	O
and	O
SHR	O
.	O

CCB	O
was	O
reduced	O
in	O
WKY	O
and	O
SHR	O
after	O
LV	O
administration	O
of	O
AVP	B_Chemical
during	O
SN-induced	O
hypotension	B_Disease
.	O

In	O
SHR	O
but	O
not	O
in	O
WKY	O
administration	O
of	O
ANP	O
,	O
AVP	B_Chemical
and	O
ANP	O
+	O
AVP	B_Chemical
decreased	O
CCB	O
during	O
Phe-induced	O
MAP	O
elevation	O
.	O

The	O
results	O
indicate	O
that	O
centrally	O
applied	O
AVP	B_Chemical
and	O
ANP	O
exert	O
differential	O
effects	O
on	O
blood	O
pressure	O
and	O
baroreflex	O
control	O
of	O
heart	O
rate	O
in	O
WKY	O
and	O
SHR	O
and	O
suggest	O
interaction	O
of	O
these	O
two	O
peptides	O
in	O
blood	O
pressure	O
regulation	O
at	O
the	O
level	O
of	O
central	O
nervous	O
system	O
.	O

Cutaneous	O
exposure	O
to	O
warfarin-like	O
anticoagulant	O
causing	O
an	O
intracerebral	B_Disease
hemorrhage	I_Disease
:	O
a	O
case	O
report	O
.	O

A	O
case	O
of	O
intercerebral	O
hematoma	B_Disease
due	O
to	O
warfarin-induced	O
coagulopathy	B_Disease
is	O
presented	O
.	O

The	O
39-year-old	O
woman	O
had	O
spread	O
a	O
warfarin-type	O
rat	O
poison	O
around	O
her	O
house	O
weekly	O
using	O
her	O
bare	O
hands	O
,	O
with	O
no	O
washing	O
post	O
application	O
.	O

Percutaneous	O
absorption	O
of	O
warfarin	B_Chemical
causing	O
coagulopathy	B_Disease
,	O
reported	O
three	O
times	O
in	O
the	O
past	O
,	O
is	O
a	O
significant	O
risk	O
if	O
protective	O
measures	O
,	O
such	O
as	O
gloves	O
,	O
are	O
not	O
used	O
.	O

An	O
adverse	O
drug	O
interaction	O
with	O
piroxicam	B_Chemical
,	O
which	O
she	O
took	O
occasionally	O
,	O
may	O
have	O
exacerbated	O
the	O
coagulopathy	B_Disease
.	O

Pediatric	O
heart	O
transplantation	O
without	O
chronic	O
maintenance	O
steroids	O
.	O

From	O
1986	O
to	O
February	O
1993	O
,	O
40	O
children	O
aged	O
2	O
months	O
to	O
18	O
years	O
(	O
average	O
age	O
10.4	O
+	O
/-	O
5.8	O
years	O
)	O
underwent	O
heart	O
transplantation	O
.	O

Indications	O
for	O
transplantation	O
were	O
idiopathic	B_Disease
cardiomyopathy	I_Disease
(	O
52	O
%	O
)	O
,	O
congenital	B_Disease
heart	I_Disease
disease	I_Disease
(	O
35	O
%	O
)	O
with	O
and	O
without	O
prior	O
repair	O
(	O
71	O
%	O
and	O
29	O
%	O
,	O
respectively	O
)	O
,	O
hypertrophic	B_Disease
cardiomyopathy	I_Disease
(	O
5	O
%	O
)	O
,	O
valvular	B_Disease
heart	I_Disease
disease	I_Disease
(	O
3	O
%	O
)	O
,	O
and	O
doxorubicin	B_Chemical
cardiomyopathy	B_Disease
(	O
5	O
%	O
)	O
.	O

Patients	O
were	O
managed	O
with	O
cyclosporine	B_Chemical
and	O
azathioprine	B_Chemical
.	O

No	O
prophylaxis	O
with	O
antilymphocyte	O
globulin	O
was	O
used	O
.	O

Steroids	B_Chemical
were	O
given	O
to	O
39	O
%	O
of	O
patients	O
for	O
refractory	O
rejection	O
,	O
but	O
weaning	O
was	O
always	O
attempted	O
and	O
generally	O
successful	O
(	O
64	O
%	O
)	O
.	O

Five	O
patients	O
(	O
14	O
%	O
)	O
received	O
maintenance	O
steroids	B_Chemical
.	O

Four	O
patients	O
died	O
in	O
the	O
perioperative	O
period	O
and	O
one	O
died	O
4	O
months	O
later	O
.	O

There	O
have	O
been	O
no	O
deaths	O
related	O
to	O
rejection	O
or	O
infection	B_Disease
.	O

Average	O
follow-up	O
was	O
36	O
+	O
/-	O
19	O
months	O
(	O
range	O
1	O
to	O
65	O
months	O
)	O
.	O

Cumulative	O
survival	O
is	O
88	O
%	O
at	O
5	O
years	O
.	O

In	O
patients	O
less	O
than	O
7	O
years	O
of	O
age	O
,	O
rejection	O
was	O
monitored	O
noninvasively	O
.	O

In	O
the	O
first	O
postoperative	O
month	O
,	O
89	O
%	O
of	O
patients	O
were	O
treated	O
for	O
rejection	O
.	O

Freedom	O
from	O
serious	O
infections	B_Disease
was	O
83	O
%	O
at	O
1	O
month	O
and	O
65	O
%	O
at	O
1	O
year	O
.	O

Cytomegalovirus	B_Disease
infections	I_Disease
were	O
treated	O
successfully	O
with	O
ganciclovir	B_Chemical
in	O
11	O
patients	O
.	O

No	O
impairment	O
of	O
growth	O
was	O
observed	O
in	O
children	O
who	O
underwent	O
transplantation	O
compared	O
with	O
a	O
control	O
population	O
.	O

Twenty-one	O
patients	O
(	O
60	O
%	O
)	O
have	O
undergone	O
annual	O
catheterizations	O
and	O
no	O
sign	O
of	O
graft	O
atherosclerosis	B_Disease
has	O
been	O
observed	O
.	O

Seizures	B_Disease
occurred	O
in	O
five	O
patients	O
(	O
14	O
%	O
)	O
and	O
hypertension	B_Disease
was	O
treated	O
in	O
10	O
patients	O
(	O
28	O
%	O
)	O
.	O

No	O
patient	O
was	O
disabled	O
and	O
no	O
lymphoproliferative	B_Disease
disorder	I_Disease
was	O
observed.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Delirium	B_Disease
during	O
fluoxetine	B_Chemical
treatment	O
.	O

A	O
case	O
report	O
.	O

The	O
correlation	O
between	O
high	O
serum	O
tricyclic	O
antidepressant	O
concentrations	O
and	O
central	O
nervous	O
system	O
side	O
effects	O
has	O
been	O
well	O
established	O
.	O

Only	O
a	O
few	O
reports	O
exist	O
,	O
however	O
,	O
on	O
the	O
relationship	O
between	O
the	O
serum	O
concentrations	O
of	O
selective	O
serotonin	B_Chemical
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
and	O
their	O
toxic	O
effects	O
.	O

In	O
some	O
cases	O
,	O
a	O
high	O
serum	O
concentration	O
of	O
citalopram	B_Chemical
(	O
>	O
600	O
nmol/L	O
)	O
in	O
elderly	O
patients	O
has	O
been	O
associated	O
with	O
increased	O
somnolence	B_Disease
and	O
movement	B_Disease
difficulties	I_Disease
.	O

Widespread	O
cognitive	B_Disease
disorders	I_Disease
,	O
such	O
as	O
delirium	B_Disease
,	O
have	O
not	O
been	O
previously	O
linked	O
with	O
high	O
blood	O
levels	O
of	O
SSRIs	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
patient	O
with	O
acute	O
hyperkinetic	B_Disease
delirium	B_Disease
connected	O
with	O
a	O
high	O
serum	O
total	O
fluoxetine	B_Chemical
(	O
fluoxetine	B_Chemical
plus	O
desmethylfluoxetine	B_Chemical
)	O
concentration	O
.	O

Pulmonary	B_Disease
edema	I_Disease
and	O
shock	B_Disease
after	O
high-dose	O
aracytine-C	B_Chemical
for	O
lymphoma	B_Disease
;	O
possible	O
role	O
of	O
TNF-alpha	O
and	O
PAF.Four	O
out	O
of	O
23	O
consecutive	O
patients	O
treated	O
with	O
high-dose	O
Ara-C	B_Chemical
for	O
lymphomas	B_Disease
in	O
our	O
institution	O
developed	O
a	O
strikingly	O
similar	O
syndrome	O
during	O
the	O
perfusion	O
.	O

It	O
was	O
characterized	O
by	O
the	O
onset	O
of	O
fever	B_Disease
,	O
diarrhea	B_Disease
,	O
shock	B_Disease
,	O
pulmonary	B_Disease
edema	I_Disease
,	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
,	O
metabolic	B_Disease
acidosis	I_Disease
,	O
weight	B_Disease
gain	I_Disease
and	O
leukocytosis	B_Disease
.	O

Thorough	O
bacteriological	O
screening	O
failed	O
to	O
provide	O
evidence	O
of	O
infection	B_Disease
.	O

Sequential	O
biological	O
assays	O
of	O
IL-1	O
,	O
IL-2	O
,	O
TNF	O
and	O
PAF	O
were	O
performed	O
during	O
Ara-C	B_Chemical
infusion	O
to	O
ten	O
patients	O
,	O
including	O
the	O
four	O
who	O
developed	O
the	O
syndrome	O
.	O

TNF	O
and	O
PAF	O
activity	O
was	O
found	O
in	O
the	O
serum	O
of	O
respectively	O
two	O
and	O
four	O
of	O
the	O
cases	O
,	O
but	O
not	O
in	O
the	O
six	O
controls	O
.	O

As	O
TNF	O
and	O
PAF	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
development	O
of	O
septic	O
shock	B_Disease
and	O
adult	B_Disease
respiratory	I_Disease
distress	I_Disease
syndrome	I_Disease
,	O
we	O
hypothesize	O
that	O
high-dose	O
Ara-C	B_Chemical
may	O
be	O
associated	O
with	O
cytokine	O
release	O
.	O

Protective	O
effect	O
of	O
clentiazem	B_Chemical
against	O
epinephrine-induced	O
cardiac	B_Disease
injury	I_Disease
in	O
rats	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
clentiazem	B_Chemical
,	O
a	O
1,5-benzothiazepine	B_Chemical
calcium	B_Chemical
antagonist	O
,	O
on	O
epinephrine-induced	O
cardiomyopathy	B_Disease
in	O
rats	O
.	O

With	O
2-week	O
chronic	O
epinephrine	B_Chemical
infusion	O
,	O
16	O
of	O
30	O
rats	O
died	O
within	O
4	O
days	O
,	O
and	O
severe	O
ischemic	B_Disease
lesions	I_Disease
and	O
fibrosis	B_Disease
of	O
the	O
left	O
ventricles	O
were	O
observed	O
.	O

In	O
epinephrine-treated	O
rats	O
,	O
left	O
atrial	O
and	O
left	O
ventricular	O
papillary	O
muscle	O
contractile	O
responses	O
to	O
isoproterenol	B_Chemical
were	O
reduced	O
,	O
but	O
responses	O
to	O
calcium	B_Chemical
were	O
normal	O
or	O
enhanced	O
compared	O
to	O
controls	O
.	O

Left	O
ventricular	O
alpha	O
and	O
beta	O
adrenoceptor	O
densities	O
were	O
also	O
reduced	O
compared	O
to	O
controls	O
.	O

Treatment	O
with	O
clentiazem	B_Chemical
prevented	O
epinephrine-induced	O
death	O
(	O
P	O
<	O
.05	O
)	O
,	O
and	O
attenuated	O
the	O
ventricular	O
ischemic	B_Disease
lesions	I_Disease
and	O
fibrosis	B_Disease
,	O
in	O
a	O
dose-dependent	O
manner	O
.	O

Left	O
atrial	O
and	O
left	O
ventricular	O
papillary	O
muscle	O
contractile	O
responses	O
to	O
isoproterenol	B_Chemical
were	O
reduced	O
compared	O
to	O
controls	O
in	O
groups	O
treated	O
with	O
clentiazem	B_Chemical
alone	O
,	O
but	O
combined	O
with	O
epinephrine	B_Chemical
,	O
clentiazem	B_Chemical
restored	O
left	O
atrial	O
responses	O
and	O
enhanced	O
left	O
ventricular	O
papillary	O
responses	O
to	O
isoproterenol	B_Chemical
.	O

On	O
the	O
other	O
hand	O
clentiazem	B_Chemical
did	O
not	O
prevent	O
epinephrine-induced	O
down-regulation	O
of	O
alpha	O
and	O
beta	O
adrenoceptors	O
.	O

Interestingly	O
,	O
clentiazem	B_Chemical
,	O
infused	O
alone	O
,	O
resulted	O
in	O
decreased	O
adrenergic	O
receptor	O
densities	O
in	O
the	O
left	O
ventricle	O
.	O

Clentiazem	B_Chemical
also	O
did	O
not	O
prevent	O
the	O
enhanced	O
responses	O
to	O
calcium	B_Chemical
seen	O
in	O
the	O
epinephrine-treated	O
animals	O
,	O
although	O
the	O
high	O
dose	O
of	O
clentiazem	B_Chemical
partially	O
attenuated	O
the	O
maximal	O
response	O
to	O
calcium	B_Chemical
compared	O
to	O
epinephrine-treated	O
animals	O
.	O

In	O
conclusion	O
,	O
clentiazem	B_Chemical
attenuated	O
epinephrine-induced	O
cardiac	B_Disease
injury	I_Disease
,	O
possibly	O
through	O
its	O
effect	O
on	O
the	O
adrenergic	O
pathway	O
.	O

Kaliuretic	O
effect	O
of	O
L-dopa	B_Chemical
treatment	O
in	O
parkinsonian	B_Disease
patients	O
.	O

Hypokalemia	B_Disease
,	O
sometimes	O
severe	O
,	O
was	O
observed	O
in	O
some	O
L-dopa-treated	O
parkinsonian	B_Disease
patients	O
.	O

The	O
influence	O
of	O
L-dopa	B_Chemical
on	O
the	O
renal	O
excretion	O
of	O
potassium	B_Chemical
was	O
studied	O
in	O
3	O
patients	O
with	O
hypokalemia	B_Disease
and	O
in	O
5	O
normokalemic	O
patients	O
by	O
determination	O
of	O
renal	O
plasma	O
flow	O
,	O
glomerular	O
filtration	O
rate	O
,	O
plasma	O
concentration	O
of	O
potassium	B_Chemical
and	O
sodium	B_Chemical
as	O
well	O
as	O
urinary	O
excretion	O
of	O
potassium	B_Chemical
,	O
sodium	B_Chemical
and	O
aldosterone	B_Chemical
.	O

L-Dopa	B_Chemical
intake	O
was	O
found	O
to	O
cause	O
an	O
increased	O
excretion	O
of	O
potassium	B_Chemical
,	O
and	O
sometimes	O
also	O
of	O
sodium	B_Chemical
,	O
in	O
the	O
hypokalemic	O
but	O
not	O
in	O
the	O
normokalemic	O
patients	O
.	O

This	O
effect	O
on	O
the	O
renal	O
function	O
could	O
be	O
prohibited	O
by	O
the	O
administration	O
of	O
a	O
peripheral	O
dopa	O
decarbodylase	O
inhibitor	O
.	O

It	O
is	O
not	O
known	O
why	O
this	O
effect	O
occurred	O
in	O
some	O
individuals	O
but	O
not	O
in	O
others	O
,	O
but	O
our	O
results	O
indicate	O
a	O
correlation	O
between	O
aldosterone	B_Chemical
production	O
and	O
this	O
renal	O
effect	O
of	O
L-dopa	B_Chemical
.	O

Cocaine	B_Chemical
induced	O
myocardial	B_Disease
ischemia	I_Disease
.	O

We	O
report	O
a	O
case	O
of	O
myocardial	B_Disease
ischemia	I_Disease
induced	O
by	O
cocaine	B_Chemical
.	O

The	O
ischemia	B_Disease
probably	O
induced	O
by	O
coronary	B_Disease
artery	I_Disease
spasm	I_Disease
was	O
reversed	O
by	O
nitroglycerin	B_Chemical
and	O
calcium	B_Chemical
blocking	O
agents	O
.	O

Doxorubicin-induced	O
cardiotoxicity	B_Disease
monitored	O
by	O
ECG	O
in	O
freely	O
moving	O
mice	O
.	O

A	O
new	O
model	O
to	O
test	O
potential	O
protectors	O
.	O

In	O
laboratory	O
animals	O
,	O
histology	O
is	O
most	O
commonly	O
used	O
to	O
study	O
doxorubicin-induced	O
cardiotoxicity	B_Disease
.	O

However	O
,	O
for	O
monitoring	O
during	O
treatment	O
,	O
large	O
numbers	O
of	O
animals	O
are	O
needed	O
.	O

Recently	O
we	O
developed	O
a	O
new	O
method	O
to	O
measure	O
ECG	O
values	O
in	O
freely	O
moving	O
mice	O
by	O
telemetry	O
.	O

With	O
this	O
model	O
we	O
investigated	O
the	O
effect	O
of	O
chronic	O
doxorubicin	B_Chemical
administration	O
on	O
the	O
ECG	O
of	O
freely	O
moving	O
BALB/c	O
mice	O
and	O
the	O
efficacy	O
of	O
ICRF-187	B_Chemical
as	O
a	O
protective	O
agent	O
.	O

The	O
ST	O
interval	O
significantly	O
widened	O
from	O
15.0	O
+	O
/-	O
1.5	O
to	O
56.8	O
+	O
/-	O
11.8	O
ms	O
in	O
week	O
10	O
(	O
7	O
weekly	O
doses	O
of	O
4	O
mg/kg	O
doxorubicin	B_Chemical
given	O
i.v	O
.	O
plus	O
3	O
weeks	O
of	O
observation	O
)	O
.	O

The	O
ECG	O
of	O
the	O
control	O
animals	O
did	O
not	O
change	O
during	O
the	O
entire	O
study	O
.	O

After	O
sacrifice	O
the	O
hearts	O
of	O
doxorubicin-treated	O
animals	O
were	O
enlarged	O
and	O
the	O
atria	O
were	O
hypertrophic	B_Disease
.	O

As	O
this	O
schedule	O
exerted	O
more	O
toxicity	B_Disease
than	O
needed	O
to	O
investigate	O
protective	O
agents	O
,	O
the	O
protection	O
of	O
ICRF-187	B_Chemical
was	O
determined	O
using	O
a	O
dose	O
schedule	O
with	O
lower	O
general	O
toxicity	B_Disease
(	O
6	O
weekly	O
doses	O
of	O
4	O
mg/kg	O
doxorubicin	B_Chemical
given	O
i.v	O
.	O
plus	O
2	O
weeks	O
of	O
observation	O
)	O
.	O

On	O
this	O
schedule	O
,	O
the	O
animals	O
'	O
hearts	O
appeared	O
normal	O
after	O
sacrifice	O
and	O
ICRF-187	B_Chemical
(	O
50	O
mg/kg	O
given	O
i.p	O
.	O

1	O
h	O
before	O
doxorubicin	B_Chemical
)	O
provided	O
almost	O
full	O
protection	O
.	O

These	O
data	O
were	O
confirmed	O
by	O
histology	O
.	O

The	O
results	O
indicate	O
that	O
this	O
new	O
model	O
is	O
very	O
sensitive	O
and	O
enables	O
monitoring	O
of	O
the	O
development	O
of	O
cardiotoxicity	B_Disease
with	O
time	O
.	O

These	O
findings	O
result	O
in	O
a	O
model	O
that	O
allows	O
the	O
testing	O
of	O
protectors	O
against	O
doxorubicin-induced	O
cardiotoxicity	B_Disease
as	O
demonstrated	O
by	O
the	O
protection	O
provided	O
by	O
ICRF-187	B_Chemical
.	O

Epinephrine	B_Chemical
dysrhythmogenicity	O
is	O
not	O
enhanced	O
by	O
subtoxic	O
bupivacaine	B_Chemical
in	O
dogs	O
.	O

Since	O
bupivacaine	B_Chemical
and	O
epinephrine	B_Chemical
may	O
both	O
precipitate	O
dysrhythmias	B_Disease
,	O
circulating	O
bupivacaine	B_Chemical
during	O
regional	O
anesthesia	O
could	O
potentiate	O
dysrhythmogenic	O
effects	O
of	O
epinephrine	B_Chemical
.	O

We	O
therefore	O
examined	O
whether	O
bupivacaine	B_Chemical
alters	O
the	O
dysrhythmogenicity	O
of	O
subsequent	O
administration	O
of	O
epinephrine	B_Chemical
in	O
conscious	O
,	O
healthy	O
dogs	O
and	O
in	O
anesthetized	O
dogs	O
with	O
myocardial	B_Disease
infarction	I_Disease
.	O

Forty-one	O
conscious	O
dogs	O
received	O
10	O
micrograms.kg-1.min-1	O
epinephrine	B_Chemical
.	O

Seventeen	O
animals	O
responded	O
with	O
ventricular	B_Disease
tachycardia	I_Disease
(	O
VT	B_Disease
)	O
within	O
3	O
min	O
.	O

After	O
3	O
h	O
,	O
these	O
responders	O
randomly	O
received	O
1	O
or	O
2	O
mg/kg	O
bupivacaine	B_Chemical
or	O
saline	O
over	O
5	O
min	O
,	O
followed	O
by	O
10	O
micrograms.kg-1.min-1	O
epinephrine	B_Chemical
.	O

In	O
the	O
bupivacaine	B_Chemical
groups	O
,	O
epinephrine	B_Chemical
caused	O
fewer	O
prodysrhythmic	O
effects	O
than	O
without	O
bupivacaine	B_Chemical
.	O

VT	B_Disease
appeared	O
in	O
fewer	O
dogs	O
and	O
at	O
a	O
later	O
time	O
,	O
and	O
there	O
were	O
more	O
sinoatrial	O
beats	O
and	O
less	O
ectopies	O
.	O

Epinephrine	B_Chemical
shortened	O
QT	O
less	O
after	O
bupivacaine	B_Chemical
than	O
in	O
control	O
animals	O
.	O

One	O
day	O
after	O
experimental	O
myocardial	B_Disease
infarction	I_Disease
,	O
six	O
additional	O
halothane-anesthetized	O
dogs	O
received	O
4	O
micrograms.kg-1.min-1	O
epinephrine	B_Chemical
until	O
VT	B_Disease
appeared	O
.	O

After	O
45	O
min	O
,	O
1	O
mg/kg	O
bupivacaine	B_Chemical
was	O
injected	O
over	O
5	O
min	O
,	O
again	O
followed	O
by	O
4	O
micrograms.kg-1.min-1	O
epinephrine	B_Chemical
.	O

In	O
these	O
dogs	O
,	O
the	O
prodysrhythmic	O
response	O
to	O
epinephrine	B_Chemical
was	O
also	O
mitigated	O
by	O
preceding	O
bupivacaine	B_Chemical
.	O

Bupivacaine	B_Chemical
antagonizes	O
epinephrine	B_Chemical
dysrhythmogenicity	O
in	O
conscious	O
dogs	O
susceptible	O
to	O
VT	B_Disease
and	O
in	O
anesthetized	O
dogs	O
with	O
spontaneous	O
postinfarct	O
dysrhythmias	B_Disease
.	O

There	O
is	O
no	O
evidence	O
that	O
systemic	O
subtoxic	O
bupivacaine	B_Chemical
administration	O
enhances	O
the	O
dysrhythmogenicity	O
of	O
subsequent	O
epinephrine	B_Chemical
.	O

Milk-alkali	B_Disease
syndrome	I_Disease
induced	O
by	O
1,25(OH)2D	B_Chemical
in	O
a	O
patient	O
with	O
hypoparathyroidism	B_Disease
.	O

Milk-alkali	B_Disease
syndrome	I_Disease
was	O
first	O
described	O
70	O
years	O
ago	O
in	O
the	O
context	O
of	O
the	O
treatment	O
of	O
peptic	B_Disease
ulcer	I_Disease
disease	I_Disease
with	O
large	O
amounts	O
of	O
calcium	B_Chemical
and	O
alkali	B_Chemical
.	O

Although	O
with	O
current	O
ulcer	B_Disease
therapy	O
(	O
H-2	O
blockers	O
,	O
omeprazole	B_Chemical
,	O
and	O
sucralfate	B_Chemical
)	O
,	O
the	O
frequency	O
of	O
milk-alkali	B_Disease
syndrome	I_Disease
has	O
decreased	O
significantly	O
,	O
the	O
classic	O
triad	O
of	O
hypercalcemia	B_Disease
,	O
alkalosis	B_Disease
,	O
and	O
renal	B_Disease
impairment	I_Disease
remains	O
the	O
hallmark	O
of	O
the	O
syndrome	O
.	O

Milk-alkali	B_Disease
syndrome	I_Disease
can	O
present	O
serious	O
and	O
occasionally	O
life-threatening	O
illness	O
unless	O
diagnosed	O
and	O
treated	O
appropriately	O
.	O

This	O
article	O
presents	O
a	O
patient	O
with	O
hypoparathyroidism	B_Disease
who	O
was	O
treated	O
with	O
calcium	B_Chemical
carbonate	I_Chemical
and	O
calcitriol	B_Chemical
resulting	O
in	O
two	O
admissions	O
to	O
the	O
hospital	O
for	O
milk-alkali	B_Disease
syndrome	I_Disease
.	O

The	O
patient	O
was	O
successfully	O
treated	O
with	O
intravenous	O
pamidronate	B_Chemical
on	O
his	O
first	O
admission	O
and	O
with	O
hydrocortisone	B_Chemical
on	O
the	O
second	O
.	O

This	O
illustrates	O
intravenous	O
pamidronate	B_Chemical
as	O
a	O
valuable	O
therapeutic	O
tool	O
when	O
milk-alkali	B_Disease
syndrome	I_Disease
presents	O
as	O
hypercalcemic	B_Disease
emergency	I_Disease
.	O

Famotidine-associated	O
delirium	B_Disease
.	O

A	O
series	O
of	O
six	O
cases	O
.	O

Famotidine	B_Chemical
is	O
a	O
histamine	O
H2-receptor	O
antagonist	O
used	O
in	O
inpatient	O
settings	O
for	O
prevention	O
of	O
stress	O
ulcers	B_Disease
and	O
is	O
showing	O
increasing	O
popularity	O
because	O
of	O
its	O
low	O
cost	O
.	O

Although	O
all	O
of	O
the	O
currently	O
available	O
H2-receptor	O
antagonists	O
have	O
shown	O
the	O
propensity	O
to	O
cause	O
delirium	B_Disease
,	O
only	O
two	O
previously	O
reported	O
cases	O
have	O
been	O
associated	O
with	O
famotidine	B_Chemical
.	O

The	O
authors	O
report	O
on	O
six	O
cases	O
of	O
famotidine-associated	O
delirium	B_Disease
in	O
hospitalized	O
patients	O
who	O
cleared	O
completely	O
upon	O
removal	O
of	O
famotidine	B_Chemical
.	O

The	O
pharmacokinetics	O
of	O
famotidine	B_Chemical
are	O
reviewed	O
,	O
with	O
no	O
change	O
in	O
its	O
metabolism	O
in	O
the	O
elderly	O
population	O
seen	O
.	O

The	O
implications	O
of	O
using	O
famotidine	B_Chemical
in	O
elderly	O
persons	O
are	O
discussed	O
.	O

Encephalopathy	B_Disease
during	O
amitriptyline	B_Chemical
therapy	O
:	O
are	O
neuroleptic	B_Disease
malignant	I_Disease
syndrome	I_Disease
and	O
serotonin	B_Disease
syndrome	I_Disease
spectrum	O
disorders?This	O
report	O
describes	O
a	O
case	O
of	O
encephalopathy	B_Disease
developed	O
in	O
the	O
course	O
of	O
amitriptyline	B_Chemical
therapy	O
,	O
during	O
a	O
remission	O
of	O
unipolar	B_Disease
depression	I_Disease
.	O

This	O
patient	O
could	O
have	O
been	O
diagnosed	O
as	O
having	O
either	O
neuroleptic	B_Disease
malignant	I_Disease
syndrome	I_Disease
(	O
NMS	B_Disease
)	O
or	O
serotonin	B_Disease
syndrome	I_Disease
(	O
SS	B_Disease
)	O
.	O

The	O
major	O
determinant	O
of	O
the	O
symptoms	O
may	O
have	O
been	O
dopamine/serotonin	O
imbalance	O
in	O
the	O
central	O
nervous	O
system	O
.	O

The	O
NMS-like	O
encephalopathy	B_Disease
that	O
develops	O
in	O
association	O
with	O
the	O
use	O
of	O
antidepressants	O
indicates	O
that	O
NMS	B_Disease
and	O
SS	B_Disease
are	O
spectrum	O
disorders	O
induced	O
by	O
drugs	O
with	O
both	O
antidopaminergic	O
and	O
serotonergic	O
effects	O
.	O

Genetic	O
separation	O
of	O
tumor	B_Disease
growth	O
and	O
hemorrhagic	B_Disease
phenotypes	O
in	O
an	O
estrogen-induced	O
tumor	B_Disease
.	O

Chronic	O
administration	O
of	O
estrogen	B_Chemical
to	O
the	O
Fischer	O
344	O
(	O
F344	O
)	O
rat	O
induces	O
growth	O
of	O
large	O
,	O
hemorrhagic	B_Disease
pituitary	B_Disease
tumors	I_Disease
.	O

Ten	O
weeks	O
of	O
diethylstilbestrol	B_Chemical
(	O
DES	B_Chemical
)	O
treatment	O
caused	O
female	O
F344	O
rat	O
pituitaries	O
to	O
grow	O
to	O
an	O
average	O
of	O
109.2	O
+	O
/-	O
6.3	O
mg	O
(	O
mean	O
+	O
/-	O
SE	O
)	O
versus	O
11.3	O
+	O
/-	O
1.4	O
mg	O
for	O
untreated	O
rats	O
,	O
and	O
to	O
become	O
highly	O
hemorrhagic	B_Disease
.	O

The	O
same	O
DES	B_Chemical
treatment	O
produced	O
no	O
significant	O
growth	O
(	O
8.9	O
+	O
/-	O
0.5	O
mg	O
for	O
treated	O
females	O
versus	O
8.7	O
+	O
/-	O
1.1	O
for	O
untreated	O
females	O
)	O
or	O
morphological	O
changes	O
in	O
Brown	O
Norway	O
(	O
BN	O
)	O
rat	O
pituitaries	O
.	O

An	O
F1	O
hybrid	O
of	O
F344	O
and	O
BN	O
exhibited	O
significant	O
pituitary	O
growth	O
after	O
10	O
weeks	O
of	O
DES	B_Chemical
treatment	O
with	O
an	O
average	O
mass	O
of	O
26.3	O
+	O
/-	O
0.7	O
mg	O
compared	O
with	O
8.6	O
+	O
/-	O
0.9	O
mg	O
for	O
untreated	O
rats	O
.	O

Surprisingly	O
,	O
the	O
F1	O
hybrid	O
tumors	B_Disease
were	O
not	O
hemorrhagic	B_Disease
and	O
had	O
hemoglobin	O
content	O
and	O
outward	O
appearance	O
identical	O
to	O
that	O
of	O
BN	O
.	O

Expression	O
of	O
both	O
growth	O
and	O
morphological	O
changes	O
is	O
due	O
to	O
multiple	O
genes	O
.	O

However	O
,	O
while	O
DES-induced	O
pituitary	O
growth	O
exhibited	O
quantitative	O
,	O
additive	O
inheritance	O
,	O
the	O
hemorrhagic	B_Disease
phenotype	O
exhibited	O
recessive	O
,	O
epistatic	O
inheritance	O
.	O

Only	O
5	O
of	O
the	O
160	O
F2	O
pituitaries	O
exhibited	O
the	O
hemorrhagic	B_Disease
phenotype	O
;	O
36	O
of	O
the	O
160	O
F2	O
pituitaries	O
were	O
in	O
the	O
F344	O
range	O
of	O
mass	O
,	O
but	O
31	O
of	O
these	O
were	O
not	O
hemorrhagic	B_Disease
,	O
indicating	O
that	O
the	O
hemorrhagic	B_Disease
phenotype	O
is	O
not	O
merely	O
a	O
consequence	O
of	O
extensive	O
growth	O
.	O

The	O
hemorrhagic	B_Disease
F2	O
pituitaries	O
were	O
all	O
among	O
the	O
most	O
massive	O
,	O
indicating	O
that	O
some	O
of	O
the	O
genes	O
regulate	O
both	O
phenotypes	O
.	O

Increased	O
expression	O
of	O
neuronal	O
nitric	B_Chemical
oxide	I_Chemical
synthase	O
in	O
bladder	O
afferent	O
pathways	O
following	O
chronic	O
bladder	B_Disease
irritation	I_Disease
.	O

Immunocytochemical	O
techniques	O
were	O
used	O
to	O
examine	O
alterations	O
in	O
the	O
expression	O
of	O
neuronal	O
nitric	B_Chemical
oxide	I_Chemical
synthase	O
(	O
NOS	O
)	O
in	O
bladder	O
pathways	O
following	O
acute	O
and	O
chronic	O
irritation	B_Disease
of	I_Disease
the	I_Disease
urinary	I_Disease
tract	I_Disease
of	O
the	O
rat	O
.	O

Chemical	O
cystitis	B_Disease
was	O
induced	O
by	O
cyclophosphamide	B_Chemical
(	O
CYP	B_Chemical
)	O
which	O
is	O
metabolized	O
to	O
acrolein	B_Chemical
,	O
an	O
irritant	O
eliminated	O
in	O
the	O
urine	O
.	O

Injection	O
of	O
CYP	B_Chemical
(	O
n	O
=	O
10	O
,	O
75	O
mg/kg	O
,	O
i.p	O
.	O
)	O
2	O
hours	O
prior	O
to	O
perfusion	O
(	O
acute	O
treatment	O
)	O
of	O
the	O
animals	O
increased	O
Fos-immunoreactivity	O
(	O
IR	O
)	O
in	O
neurons	O
in	O
the	O
dorsal	O
commissure	O
,	O
dorsal	O
horn	O
,	O
and	O
autonomic	O
regions	O
of	O
spinal	O
segments	O
(	O
L1-L2	O
and	O
L6-S1	O
)	O
which	O
receive	O
afferent	O
inputs	O
from	O
the	O
bladder	O
,	O
urethra	O
,	O
and	O
ureter	O
.	O

Fos-IR	O
in	O
the	O
spinal	O
cord	O
was	O
not	O
changed	O
in	O
rats	O
receiving	O
chronic	O
CYP	B_Chemical
treatment	O
(	O
n	O
=	O
15	O
,	O
75	O
mg/kg	O
,	O
i.p	O
.	O
,	O
every	O
3rd	O
day	O
for	O
2	O
weeks	O
)	O
.	O

In	O
control	O
animals	O
and	O
in	O
animals	O
treated	O
acutely	O
with	O
CYP	B_Chemical
,	O
only	O
small	O
numbers	O
of	O
NOS-IR	O
cells	O
(	O
0.5	O
-	O
0.7	O
cell	O
profiles/sections	O
)	O
were	O
detected	O
in	O
the	O
L6-S1	O
dorsal	O
root	O
ganglia	O
(	O
DRG	O
)	O
.	O

Chronic	O
CYP	B_Chemical
administration	O
significantly	O
(	O
P	O
<	O
or	O
=	O
.002	O
)	O
increased	O
bladder	O
weight	O
by	O
60	O
%	O
and	O
increased	O
(	O
7-	O
to	O
11-fold	O
)	O
the	O
numbers	O
of	O
NOS-immunoreactive	O
(	O
IR	O
)	O
afferent	O
neurons	O
in	O
the	O
L6-S1	O
DRG	O
.	O

A	O
small	O
increase	O
(	O
1.5-fold	O
)	O
also	O
occurred	O
in	O
the	O
L1	O
DRG	O
,	O
but	O
no	O
change	O
was	O
detected	O
in	O
the	O
L2	O
and	O
L5	O
DRG	O
.	O

Bladder	O
afferent	O
cells	O
in	O
the	O
L6-S1	O
DRG	O
labeled	O
by	O
Fluorogold	O
(	O
40	O
microliters	O
)	O
injected	O
into	O
the	O
bladder	O
wall	O
did	O
not	O
exhibit	O
NOS-IR	O
in	O
control	O
animals	O
;	O
however	O
,	O
following	O
chronic	O
CYP	B_Chemical
administration	O
,	O
a	O
significant	O
percentage	O
of	O
bladder	O
afferent	O
neurons	O
were	O
NOS-IR	O
:	O
L6	O
(	O
19.8	O
+	O
/-	O
4.6	O
%	O
)	O
and	O
S1	O
(	O
25.3	O
+	O
/-	O
2.9	O
%	O
)	O
.	O

These	O
results	O
indicate	O
that	O
neuronal	O
gene	O
expression	O
in	O
visceral	O
sensory	O
pathways	O
can	O
be	O
upregulated	O
by	O
chemical	O
irritation	O
of	O
afferent	O
receptors	O
in	O
the	O
urinary	O
tract	O
and/or	O
that	O
pathological	O
changes	O
in	O
the	O
urinary	O
tract	O
can	O
initiate	O
chemical	O
signals	O
that	O
alter	O
the	O
chemical	O
properties	O
of	O
visceral	O
afferent	O
neurons	O
.	O

Effects	O
of	O
a	O
new	O
calcium	B_Chemical
antagonist	O
,	O
CD-832	B_Chemical
,	O
on	O
isoproterenol-induced	O
myocardial	B_Disease
ischemia	I_Disease
in	O
dogs	O
with	O
partial	O
coronary	B_Disease
stenosis	I_Disease
.	O

Effects	O
of	O
CD-832	B_Chemical
on	O
isoproterenol	B_Chemical
(ISO)-induced	O
myocardial	B_Disease
ischemia	I_Disease
were	O
studied	O
in	O
dogs	O
with	O
partial	O
coronary	B_Disease
stenosis	I_Disease
of	O
the	O
left	O
circumflex	O
coronary	O
artery	O
and	O
findings	O
were	O
compared	O
with	O
those	O
for	O
nifedipine	B_Chemical
or	O
diltiazem	B_Chemical
.	O

In	O
the	O
presence	O
of	O
coronary	B_Disease
artery	I_Disease
stenosis	I_Disease
,	O
3-min	O
periods	O
of	O
intracoronary	O
ISO	B_Chemical
infusion	O
(	O
10	O
ng/kg/min	O
)	O
increased	O
heart	O
rate	O
and	O
maximal	O
rate	O
of	O
left	O
ventricular	O
pressure	O
rise	O
,	O
which	O
resulted	O
in	O
a	O
decrease	O
in	O
percentage	O
segmental	O
shortening	O
and	O
ST-segment	O
elevation	O
of	O
the	O
epicardial	O
electrocardiogram	O
.	O

After	O
the	O
control	O
ISO	B_Chemical
infusion	O
with	O
stenosis	B_Disease
was	O
performed	O
,	O
equihypotensive	O
doses	O
of	O
CD-832	B_Chemical
(	O
3	O
and	O
10	O
micrograms/kg/min	O
,	O
n	O
=	O
7	O
)	O
,	O
nifedipine	B_Chemical
(	O
1	O
and	O
3	O
micrograms/kg/min	O
,	O
n	O
=	O
9	O
)	O
or	O
diltiazem	B_Chemical
(	O
10	O
and	O
30	O
micrograms/kg/min	O
,	O
n	O
=	O
7	O
)	O
were	O
infused	O
5	O
min	O
before	O
and	O
during	O
the	O
second	O
and	O
third	O
ISO	B_Chemical
infusion	O
.	O

Both	O
CD-832	B_Chemical
and	O
diltiazem	B_Chemical
,	O
but	O
not	O
nifedipine	B_Chemical
,	O
significantly	O
reduced	O
the	O
increase	O
in	O
heart	O
rate	O
induced	O
by	O
ISO	B_Chemical
infusion	O
.	O

In	O
contrast	O
to	O
nifedipine	B_Chemical
,	O
CD-832	B_Chemical
(	O
10	O
micrograms/kg/min	O
)	O
prevented	O
the	O
decrease	O
in	O
percentage	O
segmental	O
shortening	O
from	O
32	O
+	O
/-	O
12	O
%	O
to	O
115	O
+	O
/-	O
26	O
%	O
of	O
the	O
control	O
value	O
(	O
P	O
<	O
.01	O
)	O
and	O
ST-segment	O
elevation	O
from	O
5.6	O
+	O
/-	O
1.0	O
mV	O
to	O
1.6	O
+	O
/-	O
1.3	O
mV	O
(	O
P	O
<	O
.01	O
)	O
at	O
3	O
min	O
after	O
ISO	B_Chemical
infusion	O
with	O
stenosis	B_Disease
.	O

Diltiazem	B_Chemical
(	O
30	O
micrograms/kg/min	O
)	O
also	O
prevented	O
the	O
decrease	O
in	O
percentage	O
segmental	O
shortening	O
from	O
34	O
+	O
/-	O
14	O
%	O
to	O
63	O
+	O
/-	O
18	O
%	O
of	O
the	O
control	O
value	O
(	O
P	O
<	O
.05	O
)	O
and	O
ST-segment	O
elevation	O
from	O
4.7	O
+	O
/-	O
0.7	O
mV	O
to	O
2.1	O
+	O
/-	O
0.7	O
mV	O
(	O
P	O
<	O
.01	O
)	O
at	O
3	O
min	O
after	O
ISO	B_Chemical
infusion	O
with	O
stenosis	B_Disease
.	O

These	O
data	O
show	O
that	O
CD-832	B_Chemical
improves	O
myocardial	B_Disease
ischemia	I_Disease
during	O
ISO	B_Chemical
infusion	O
with	O
stenosis	B_Disease
and	O
suggest	O
that	O
the	O
negative	O
chronotropic	O
property	O
of	O
CD-832	B_Chemical
plays	O
a	O
major	O
role	O
in	O
the	O
beneficial	O
effects	O
of	O
CD-832	B_Chemical
.	O

The	O
effect	O
of	O
recombinant	O
human	O
insulin-like	O
growth	O
factor-I	O
on	O
chronic	O
puromycin	B_Chemical
aminonucleoside	I_Chemical
nephropathy	B_Disease
in	O
rats	O
.	O

We	O
recently	O
demonstrated	O
that	O
recombinant	O
hGH	O
exacerbates	O
renal	O
functional	O
and	O
structural	O
injury	O
in	O
chronic	O
puromycin	B_Chemical
aminonucleoside	I_Chemical
(	O
PAN	B_Chemical
)	O
nephropathy	B_Disease
,	O
an	O
experimental	O
model	O
of	O
glomerular	B_Disease
disease	I_Disease
.	O

Therefore	O
,	O
we	O
examined	O
whether	O
recombinant	O
human	O
(	O
rh	O
)	O
IGF-I	O
is	O
a	O
safer	O
alternative	O
for	O
the	O
treatment	O
of	O
growth	B_Disease
failure	I_Disease
in	O
rats	O
with	O
chronic	O
PAN	B_Chemical
nephropathy	B_Disease
.	O

The	O
glomerulopathy	B_Disease
was	O
induced	O
by	O
seven	O
serial	O
injections	O
of	O
PAN	B_Chemical
over	O
12	O
wk	O
.	O

Experimental	O
animals	O
(	O
n	O
=	O
6	O
)	O
received	O
rhIGF-I	O
,	O
400	O
micrograms/d	O
,	O
whereas	O
control	O
rats	O
(	O
n	O
=	O
6	O
)	O
received	O
the	O
vehicle	O
.	O

rhIGF-I	O
improved	O
weight	O
gain	O
by	O
14	O
%	O
(	O
p	O
<	O
0.05	O
)	O
,	O
without	O
altering	O
hematocrit	O
or	O
blood	O
pressure	O
in	O
rats	O
with	O
renal	B_Disease
disease	I_Disease
.	O

Urinary	O
protein	O
excretion	O
was	O
unaltered	O
by	O
rhIGF-I	O
treatment	O
in	O
rats	O
with	O
chronic	O
PAN	B_Chemical
nephropathy	B_Disease
.	O

After	O
12	O
wk	O
,	O
the	O
inulin	O
clearance	O
was	O
higher	O
in	O
rhIGF-I-treated	O
rats	O
,	O
0.48	O
+	O
/-	O
0.08	O
versus	O
0.24	O
+	O
/-	O
0.06	O
mL/min/100	O
g	O
of	O
body	O
weight	O
in	O
untreated	O
PAN	B_Chemical
nephropathy	B_Disease
animals	O
,	O
p	O
<	O
0.05	O
.	O

The	O
improvement	O
in	O
GFR	O
was	O
not	O
associated	O
with	O
enhanced	O
glomerular	B_Disease
hypertrophy	I_Disease
or	O
increased	O
segmental	O
glomerulosclerosis	B_Disease
,	O
tubulointerstitial	B_Disease
injury	I_Disease
,	O
or	O
renal	O
cortical	O
malondialdehyde	B_Chemical
content	O
.	O

In	O
rats	O
with	O
PAN	B_Chemical
nephropathy	B_Disease
,	O
administration	O
of	O
rhIGF-I	O
increased	O
IGF-I	O
and	O
GH	O
receptor	O
gene	O
expression	O
,	O
without	O
altering	O
the	O
steady	O
state	O
level	O
of	O
IGF-I	O
receptor	O
mRNA	O
.	O

In	O
normal	O
rats	O
with	O
intact	O
kidneys	O
,	O
rhIGF-I	O
administration	O
(	O
n	O
=	O
4	O
)	O
did	O
not	O
alter	O
weight	O
gain	O
,	O
blood	O
pressure	O
,	O
proteinuria	B_Disease
,	O
GFR	O
,	O
glomerular	O
planar	O
area	O
,	O
renal	O
cortical	O
malondialdehyde	B_Chemical
content	O
,	O
or	O
glomerular	O
or	O
tubulointerstitial	B_Disease
damage	I_Disease
,	O
compared	O
with	O
untreated	O
animals	O
(	O
n	O
=	O
4	O
)	O
.	O

rhIGF-I	O
treatment	O
reduced	O
the	O
steady	O
state	O
renal	O
IGF-I	O
mRNA	O
level	O
but	O
did	O
not	O
modify	O
gene	O
expression	O
of	O
the	O
IGF-I	O
or	O
GH	O
receptors	O
.	O

We	O
conclude	O
that	O
:	O
1	O
)	O
administration	O
of	O
rhIGF-I	O
improves	O
growth	O
and	O
GFR	O
in	O
rats	O
with	O
chronic	O
PAN	B_Chemical
nephropathy	B_Disease
and	O
2	O
)	O
unlike	O
rhGH	O
,	O
long-term	O
use	O
of	O
rhIGF-I	O
does	O
not	O
worsen	O
renal	O
functional	O
and	O
structural	O
injury	O
in	O
this	O
disease	O
model	O
.	O

Nefiracetam	B_Chemical
(	O
DM-9384	B_Chemical
)	O
reverses	O
apomorphine-induced	O
amnesia	B_Disease
of	O
a	O
passive	O
avoidance	O
response	O
:	O
delayed	O
emergence	O
of	O
the	O
memory	O
retention	O
effects	O
.	O

Nefiracetam	B_Chemical
is	O
a	O
novel	O
pyrrolidone	B_Chemical
derivative	O
which	O
attenuates	O
scopolamine-induced	O
learning	B_Disease
and	I_Disease
post-training	I_Disease
consolidation	I_Disease
deficits	I_Disease
.	O

Given	O
that	O
apomorphine	B_Chemical
inhibits	O
passive	O
avoidance	O
retention	O
when	O
given	O
during	O
training	O
or	O
in	O
a	O
defined	O
10	O
-	O
12h	O
post-training	O
period	O
,	O
we	O
evaluated	O
the	O
ability	O
of	O
nefiracetam	B_Chemical
to	O
attenuate	O
amnesia	B_Disease
induced	O
by	O
dopaminergic	O
agonism	O
.	O

A	O
step-down	O
passive	O
avoidance	O
paradigm	O
was	O
employed	O
and	O
nefiracetam	B_Chemical
(	O
3	O
mg/kg	O
)	O
and	O
apomorphine	B_Chemical
(	O
0.5	O
mg/kg	O
)	O
were	O
given	O
alone	O
or	O
in	O
combination	O
during	O
training	O
and	O
at	O
the	O
10	O
-	O
12h	O
post-training	O
period	O
of	O
consolidation	O
.	O

Co-administration	O
of	O
nefiracetam	B_Chemical
and	O
apomorphine	B_Chemical
during	O
training	O
or	O
10h	O
thereafter	O
produced	O
no	O
significant	O
anti-amnesic	O
effect	O
.	O

However	O
,	O
administration	O
of	O
nefiracetam	B_Chemical
during	O
training	O
completely	O
reversed	O
the	O
amnesia	B_Disease
induced	O
by	O
apomorphine	B_Chemical
at	O
the	O
10h	O
post-training	O
time	O
and	O
the	O
converse	O
was	O
also	O
true	O
.	O

These	O
effects	O
were	O
not	O
mediated	O
by	O
a	O
dopaminergic	O
mechanism	O
as	O
nefiracetam	B_Chemical
,	O
at	O
millimolar	O
concentrations	O
,	O
failed	O
to	O
displace	O
either	O
[3H]SCH	O
23390	O
or	O
[3H]spiperone	O
binding	O
from	O
D1	O
or	O
D2	O
dopamine	B_Chemical
receptor	O
subtypes	O
,	O
respectively	O
.	O

It	O
is	O
suggested	O
that	O
nefiracetam	B_Chemical
augments	O
molecular	O
processes	O
in	O
the	O
early	O
stages	O
of	O
events	O
which	O
ultimately	O
lead	O
to	O
consolidation	O
of	O
memory	O
.	O

Phenytoin	B_Chemical
encephalopathy	B_Disease
as	O
probable	O
idiosyncratic	O
reaction	O
:	O
case	O
report	O
.	O

A	O
case	O
of	O
phenytoin	B_Chemical
(	O
DPH	B_Chemical
)	O
encephalopathy	B_Disease
with	O
increasing	O
seizures	B_Disease
and	O
EEG	O
and	O
mental	O
changes	O
is	O
described	O
.	O

Despite	O
adequate	O
oral	O
dosage	O
of	O
DPH	B_Chemical
(	O
5	O
mg/kg/daily	O
)	O
the	O
plasma	O
level	O
was	O
very	O
low	O
(	O
2.8	O
microgramg/ml	O
)	O
.	O

The	O
encephalopathy	B_Disease
was	O
probably	O
an	O
idiosyncratic	O
and	O
not	O
toxic	O
or	O
allergic	O
reaction	O
.	O

In	O
fact	O
the	O
concentration	O
of	O
free	O
DPH	B_Chemical
was	O
normal	O
,	O
the	O
patient	O
presented	O
a	O
retarded	O
morbilliform	O
rash	B_Disease
during	O
DPH	B_Chemical
treatment	O
,	O
the	O
protidogram	O
was	O
normal	O
,	O
and	O
an	O
intradermic	O
DPH	B_Chemical
injection	O
had	O
no	O
local	O
effect	O
.	O

The	O
authors	O
conclude	O
that	O
in	O
a	O
patient	O
starting	O
DPH	B_Chemical
treatment	O
an	O
unexpected	O
increase	O
in	O
seizures	B_Disease
,	O
with	O
EEG	O
and	O
mental	O
changes	O
occurring	O
simultaneously	O
,	O
should	O
alert	O
the	O
physician	O
to	O
the	O
possible	O
need	O
for	O
eliminating	O
DPH	B_Chemical
from	O
the	O
therapeutic	O
regimen	O
,	O
even	O
if	O
plasma	O
concentrations	O
are	O
low	O
.	O

Prevention	O
and	O
treatment	O
of	O
endometrial	B_Disease
disease	I_Disease
in	O
climacteric	O
women	O
receiving	O
oestrogen	B_Chemical
therapy	O
.	O

The	O
treatment	O
regimens	O
are	O
described	O
in	O
74	O
patients	O
with	O
endometrial	B_Disease
disease	I_Disease
among	O
850	O
climacteric	O
women	O
receiving	O
oestrogen	B_Chemical
therapy	O
.	O

Cystic	O
hyperplasia	B_Disease
was	O
associated	O
with	O
unopposed	O
oestrogen	B_Chemical
therapy	O
without	O
progestagen	B_Chemical
.	O

Two	O
courses	O
of	O
21	O
days	O
of	O
5	O
mg	O
norethisterone	B_Chemical
daily	O
caused	O
reversion	O
to	O
normal	O
in	O
all	O
57	O
cases	O
of	O
cystic	O
hyperplasia	B_Disease
and	O
6	O
of	O
the	O
8	O
cases	O
of	O
atypical	O
hyperplasia	B_Disease
.	O

4	O
cases	O
of	O
endometrial	B_Disease
carcinoma	I_Disease
referred	O
from	O
elsewhere	O
demonstrated	O
the	O
problems	O
of	O
inappropriate	O
and	O
unsupervised	O
unopposed	O
oestrogen	B_Chemical
therapy	O
and	O
the	O
difficulty	O
in	O
distinguishing	O
severe	O
hyperplasia	B_Disease
from	O
malignancy	B_Disease
.	O

Cyclical	O
low-dose	O
oestrogen	B_Chemical
therapy	O
with	O
7	O
-	O
-13	O
days	O
of	O
progestagen	B_Chemical
does	O
not	O
seem	O
to	O
increase	O
the	O
risk	O
of	O
endometrial	B_Disease
hyperplasia	I_Disease
or	O
carcinoma	B_Disease
.	O

Effects	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol-induced	O
myocardial	B_Disease
infarction	I_Disease
.	O

The	O
effect	O
of	O
exercise	O
on	O
the	O
severity	O
of	O
isoproterenol-induced	O
myocardial	B_Disease
infarction	I_Disease
was	O
studied	O
in	O
male	O
rats	O
.	O

Ninety-three	O
rats	O
were	O
randomly	O
divided	O
into	O
three	O
groups	O
.	O

The	O
exercise-isoproterenol	O
(	O
E-1	O
)	O
and	O
exercise	O
control	O
(	O
EC	O
)	O
groups	O
exercised	O
daily	O
for	O
thirty	O
days	O
on	O
a	O
treadmill	O
at	O
1	O
mph	O
,	O
2	O
%	O
grade	O
while	O
animals	O
of	O
the	O
sedentary-isoproterenol	O
(	O
S-I	O
)	O
group	O
remained	O
sedentary	O
.	O

Eight	O
animals	O
were	O
assigned	O
to	O
the	O
sedentary	O
control	O
(	O
SC	O
)	O
group	O
which	O
remained	O
sedentary	O
throughout	O
the	O
experimental	O
period	O
.	O

Forty-eight	O
hours	O
after	O
the	O
final	O
exercise	O
period	O
,	O
S-I	O
and	O
E-I	O
animals	O
received	O
a	O
single	O
subcutaneous	O
injection	O
of	O
isoproterenol	B_Chemical
(	O
250	O
mg/kg	O
body	O
weight	O
)	O
.	O

Animals	O
of	O
the	O
S-I	O
group	O
exhibited	O
significantly	O
(	O
Pp	O
less	O
than	O
0.05	O
)	O
greater	O
mortality	O
from	O
the	O
effects	O
of	O
isoproterenol	B_Chemical
than	O
animals	O
of	O
the	O
E-I	O
group	O
.	O

Serum	O
CPK	O
activity	O
for	O
E-I	O
animals	O
was	O
significantly	O
(	O
p	O
less	O
than	O
0.05	O
)	O
greater	O
than	O
for	O
animals	O
in	O
the	O
S-I	O
and	O
EC	O
groups	O
twenty	O
hours	O
following	O
isoproterenol	B_Chemical
injection	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
two	O
isoproterenol	B_Chemical
treated	O
groups	O
for	O
severity	O
of	O
the	O
induced	O
lesions	O
,	O
changes	O
in	O
heart	O
weight	O
,	O
or	O
heart	O
weight	O
to	O
body	O
weight	O
ratios	O
.	O

The	O
results	O
indicated	O
that	O
exercise	O
reduced	O
the	O
mortality	O
associated	O
with	O
the	O
effects	O
of	O
large	O
dosages	O
of	O
isoproterenol	B_Chemical
but	O
had	O
little	O
on	O
the	O
severity	O
of	O
the	O
infarction	B_Disease
.	O

Human	O
corticotropin-releasing	O
hormone	O
and	O
thyrotropin-releasing	O
hormone	O
modulate	O
the	O
hypercapnic	B_Disease
ventilatory	O
response	O
in	O
humans	O
.	O

Human	O
corticotropin-releasing	O
hormone	O
(	O
hCRH	O
)	O
and	O
thyrotropin-releasing	O
hormone	O
(	O
TRH	O
)	O
are	O
known	O
to	O
stimulate	O
ventilation	O
after	O
i.v	O
.	O

administration	O
in	O
humans	O
.	O

In	O
a	O
placebo-controlled	O
,	O
single-blind	O
study	O
we	O
aimed	O
to	O
clarify	O
if	O
both	O
peptides	O
act	O
by	O
altering	O
central	O
chemosensitivity	O
.	O

Two	O
subsequent	O
CO2-rebreathing	O
tests	O
were	O
performed	O
in	O
healthy	O
young	O
volunteers	O
.	O

During	O
the	O
first	O
test	O
0.9	O
%	O
NaCl	B_Chemical
was	O
given	O
i.v	O
.	O
;	O
during	O
the	O
second	O
test	O
200	O
micrograms	O
of	O
hCRH	O
(	O
n	O
=	O
12	O
)	O
or	O
400	O
micrograms	O
of	O
TRH	O
(	O
n	O
=	O
6	O
)	O
was	O
administered	O
i.v	O
.	O

Nine	O
subjects	O
received	O
0.9	O
%	O
NaCl	B_Chemical
i.v	O
.	O
during	O
both	O
rebreathing	O
manoeuvres	O
.	O

The	O
CO2-response	O
curves	O
for	O
the	O
two	O
tests	O
were	O
compared	O
within	O
the	O
same	O
subject	O
.	O

In	O
the	O
hCRH	O
group	O
a	O
marked	O
parallel	O
shift	O
of	O
the	O
CO2-response	O
curve	O
to	O
the	O
left	O
was	O
observed	O
after	O
hCRH	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
same	O
effect	O
occurred	O
following	O
TRH	O
but	O
was	O
less	O
striking	O
(	O
P	O
=	O
0.05	O
)	O
.	O

hCRH	O
and	O
TRH	O
caused	O
a	O
reduction	O
in	O
the	O
CO2	B_Chemical
threshold	O
.	O

The	O
CO2-response	O
curves	O
in	O
the	O
control	O
group	O
were	O
nearly	O
identical	O
.	O

The	O
results	O
indicate	O
an	O
additive	O
effect	O
of	O
both	O
releasing	O
hormones	O
on	O
the	O
hypercapnic	B_Disease
ventilatory	O
response	O
in	O
humans	O
,	O
presumably	O
independent	O
of	O
central	O
chemosensitivity	O
.	O

Lamivudine	B_Chemical
is	O
effective	O
in	O
suppressing	O
hepatitis	B_Disease
B	I_Disease
virus	O
DNA	O
in	O
Chinese	O
hepatitis	B_Chemical
B	I_Chemical
surface	I_Chemical
antigen	I_Chemical
carriers	O
:	O
a	O
placebo-controlled	O
trial	O
.	O

Lamivudine	B_Chemical
is	O
a	O
novel	O
2',3'-dideoxy	B_Chemical
cytosine	I_Chemical
analogue	O
that	O
has	O
potent	O
inhibitory	O
effects	O
on	O
hepatitis	B_Disease
B	I_Disease
virus	O
replication	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
performed	O
a	O
single-blind	O
,	O
placebo-controlled	O
study	O
to	O
assess	O
its	O
effectiveness	O
and	O
safety	O
in	O
Chinese	O
hepatitis	B_Chemical
B	I_Chemical
surface	I_Chemical
antigen	I_Chemical
(	O
HBsAg	B_Chemical
)	O
carriers	O
.	O

Forty-two	O
Chinese	O
HBsAg	B_Chemical
carriers	O
were	O
randomized	O
to	O
receive	O
placebo	O
(	O
6	O
patients	O
)	O
or	O
lamivudine	B_Chemical
orally	O
in	O
dosages	O
of	O
25	O
mg	O
,	O
100	O
mg	O
,	O
or	O
300	O
mg	O
daily	O
(	O
12	O
patients	O
for	O
each	O
dosage	O
)	O
.	O

The	O
drug	O
was	O
given	O
for	O
4	O
weeks	O
.	O

The	O
patients	O
were	O
closely	O
monitored	O
clinically	O
,	O
biochemically	O
,	O
and	O
serologically	O
up	O
to	O
4	O
weeks	O
after	O
drug	O
treatment	O
.	O

All	O
36	O
patients	O
receiving	O
lamivudine	B_Chemical
had	O
a	O
decrease	O
in	O
hepatitis	B_Disease
B	I_Disease
virus	O
(	O
HBV	O
)	O
DNA	O
values	O
of	O
>	O
90	O
%	O
(	O
P	O
<	O
.001	O
compared	O
with	O
placebo	O
)	O
.	O

Although	O
25	O
mg	O
of	O
lamivudine	B_Chemical
was	O
slightly	O
less	O
effective	O
than	O
100	O
mg	O
(	O
P	O
=	O
.011	O
)	O
and	O
300	O
mg	O
(	O
P	O
=	O
.005	O
)	O
,	O
it	O
still	O
induced	O
94	O
%	O
suppression	O
of	O
HBV	O
DNA	O
after	O
the	O
fourth	O
week	O
of	O
therapy	O
.	O

HBV	O
DNA	O
values	O
returned	O
to	O
pretreatment	O
levels	O
within	O
4	O
weeks	O
of	O
cessation	O
of	O
therapy	O
.	O

There	O
was	O
no	O
change	O
in	O
the	O
hepatitis	B_Disease
B	I_Disease
e	O
antigen	O
status	O
or	O
in	O
aminotransferase	O
levels	O
.	O

No	O
serious	O
adverse	O
events	O
were	O
observed	O
.	O

In	O
conclusion	O
,	O
a	O
4-week	O
course	O
of	O
lamivudine	B_Chemical
was	O
safe	O
and	O
effective	O
in	O
suppression	O
of	O
HBV	O
DNA	O
in	O
Chinese	O
HBsAg	B_Chemical
carriers	O
.	O

The	O
suppression	O
was	O
>	O
90	O
%	O
but	O
reversible	O
.	O

Studies	O
with	O
long-term	O
lamivudine	B_Chemical
administration	O
should	O
be	O
performed	O
to	O
determine	O
if	O
prolonged	O
suppression	O
of	O
HBV	O
DNA	O
can	O
be	O
achieved	O
.	O

Population-based	O
study	O
of	O
risk	O
of	O
venous	B_Disease
thromboembolism	I_Disease
associated	O
with	O
various	O
oral	B_Chemical
contraceptives	I_Chemical
.	O

BACKGROUND	O
:	O
Four	O
studies	O
published	O
since	O
December	O
,	O
1995	O
,	O
reported	O
that	O
the	O
incidence	O
of	O
venous	B_Disease
thromboembolism	I_Disease
(	O
VTE	B_Disease
)	O
was	O
higher	O
in	O
women	O
who	O
used	O
oral	B_Chemical
contraceptives	I_Chemical
(	O
OCs	B_Chemical
)	O
containing	O
the	O
third-generation	O
progestagens	B_Chemical
gestodene	B_Chemical
or	O
desogestrel	B_Chemical
than	O
in	O
users	O
of	O
OCs	B_Chemical
containing	O
second-generation	O
progestagens	B_Chemical
.	O

However	O
,	O
confounding	O
and	O
bias	O
in	O
the	O
design	O
of	O
these	O
studies	O
may	O
have	O
affected	O
the	O
findings	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
re-examine	O
the	O
association	O
between	O
risk	O
of	O
VTE	B_Disease
and	O
OC	B_Chemical
use	O
with	O
a	O
different	O
study	O
design	O
and	O
analysis	O
to	O
avoid	O
some	O
of	O
the	O
bias	O
and	O
confounding	O
of	O
the	O
earlier	O
studies	O
.	O

METHODS	O
:	O
We	O
used	O
computer	O
records	O
of	O
patients	O
from	O
143	O
general	O
practices	O
in	O
the	O
UK	O
.	O

The	O
study	O
was	O
based	O
on	O
the	O
medical	O
records	O
of	O
about	O
540,000	O
women	O
born	O
between	O
1941	O
and	O
1981	O
.	O

All	O
women	O
who	O
had	O
a	O
recorded	O
diagnosis	O
of	O
deep-vein	B_Disease
thrombosis	I_Disease
,	O
venous	B_Disease
thrombosis	I_Disease
not	O
otherwise	O
specified	O
,	O
or	O
pulmonary	O
embolus	O
during	O
the	O
study	O
period	O
,	O
and	O
who	O
had	O
been	O
treated	O
with	O
an	O
anticoagulant	O
were	O
identified	O
as	O
potential	O
cases	O
of	O
VTE	B_Disease
.	O

We	O
did	O
a	O
cohort	O
analysis	O
to	O
estimate	O
and	O
compare	O
incidence	O
of	O
VTE	B_Disease
in	O
users	O
of	O
the	O
main	O
OC	B_Chemical
preparations	O
,	O
and	O
a	O
nested	O
case-control	O
study	O
to	O
calculate	O
the	O
odds	O
ratios	O
of	O
VTE	B_Disease
associated	O
with	O
use	O
of	O
different	O
types	O
of	O
OC	B_Chemical
,	O
after	O
adjustment	O
for	O
potential	O
confounding	O
factors	O
.	O

In	O
the	O
case-control	O
study	O
,	O
we	O
matched	O
cases	O
to	O
controls	O
by	O
exact	O
year	O
of	O
birth	O
,	O
practice	O
,	O
and	O
current	O
use	O
of	O
OCs	B_Chemical
.	O

We	O
used	O
a	O
multiple	O
logistic	O
regression	O
model	O
that	O
included	O
body-mass	O
index	O
,	O
number	O
of	O
cycles	O
,	O
change	O
in	O
type	O
of	O
OC	B_Chemical
prescribed	O
within	O
3	O
months	O
of	O
the	O
event	O
,	O
previous	O
pregnancy	O
,	O
and	O
concurrent	O
disease	O
.	O

FINDINGS	O
:	O
85	O
women	O
met	O
the	O
inclusion	O
criteria	O
for	O
VTE	B_Disease
,	O
two	O
of	O
whom	O
were	O
users	O
of	O
progestagen-only	O
OCs	B_Chemical
.	O

Of	O
the	O
83	O
cases	O
of	O
VTE	B_Disease
associated	O
with	O
use	O
of	O
combined	O
OCs	B_Chemical
,	O
43	O
were	O
recorded	O
as	O
deep-vein	B_Disease
thrombosis	I_Disease
,	O
35	O
as	O
pulmonary	O
thrombosis	B_Disease
,	O
and	O
five	O
as	O
venous	B_Disease
thrombosis	I_Disease
not	O
otherwise	O
specified	O
.	O

The	O
crude	O
rate	O
of	O
VTE	B_Disease
per	O
10,000	O
woman-years	O
was	O
4.10	O
in	O
current	O
users	O
of	O
any	O
OC	B_Chemical
,	O
3.10	O
in	O
users	O
of	O
second-generation	O
OCs	B_Chemical
,	O
and	O
4.96	O
in	O
users	O
of	O
third-generation	O
preparations	O
.	O

After	O
adjustment	O
for	O
age	O
,	O
the	O
rate	O
ratio	O
of	O
VTE	B_Disease
in	O
users	O
of	O
third-generation	O
relative	O
to	O
second-generation	O
OCs	B_Chemical
was	O
1.68	O
(	O
95	O
%	O
CI	O
1.04	O
-	O
2.75	O
)	O
.	O

Logistic	O
regression	O
showed	O
no	O
significant	O
difference	O
in	O
the	O
risk	O
of	O
VTE	B_Disease
between	O
users	O
of	O
third-generation	O
and	O
second-generation	O
OCs	B_Chemical
.	O

Among	O
users	O
of	O
third-generation	O
progestagens	B_Chemical
,	O
the	O
risk	O
of	O
VTE	B_Disease
was	O
higher	O
in	O
users	O
of	O
desogestrel	B_Chemical
with	O
20	O
g	O
ethinyloestradiol	B_Chemical
than	O
in	O
users	O
of	O
gestodene	B_Chemical
or	O
desogestrel	B_Chemical
with	O
30	O
g	O
ethinyloestradiol	B_Chemical
.	O

With	O
all	O
second-generation	O
OCs	B_Chemical
as	O
the	O
reference	O
,	O
the	O
odds	O
ratios	O
for	O
VTE	B_Disease
were	O
3.49	O
(	O
1.21	O
-	O
10.12	O
)	O
for	O
desogestrel	B_Chemical
plus	O
20	O
g	O
ethinyloestradiol	B_Chemical
and	O
1.18	O
(	O
0.66	O
-	O
2.17	O
)	O
for	O
the	O
other	O
third-generation	O
progestagens	B_Chemical
.	O

INTERPRETATION	O
:	O
The	O
previously	O
reported	O
increase	O
in	O
odds	O
ratio	O
associated	O
with	O
third-generation	O
OCs	B_Chemical
when	O
compared	O
with	O
second-generation	O
products	O
is	O
likely	O
to	O
have	O
been	O
the	O
result	O
of	O
residual	O
confounding	O
by	O
age	O
.	O

The	O
increased	O
odds	O
ratio	O
associated	O
with	O
products	O
containing	O
20	O
micrograms	O
ethinyloestradiol	B_Chemical
and	O
desogestrel	B_Chemical
compared	O
with	O
the	O
30	O
micrograms	O
product	O
is	O
biologically	O
implausible	O
,	O
and	O
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
preferential	O
prescribing	O
and	O
,	O
thus	O
,	O
confounding	O
.	O

MK-801	B_Chemical
augments	O
pilocarpine-induced	O
electrographic	O
seizure	B_Disease
but	O
protects	O
against	O
brain	B_Disease
damage	I_Disease
in	O
rats.1	O
.	O

The	O
authors	O
examined	O
the	O
anticonvulsant	O
effects	O
of	O
MK-801	B_Chemical
on	O
the	O
pilocarpine-induced	O
seizure	B_Disease
model	O
.	O

Intraperitoneal	O
injection	O
of	O
pilocarpine	B_Chemical
(	O
400	O
mg/kg	O
)	O
induced	O
tonic	B_Disease
and	I_Disease
clonic	I_Disease
seizure	I_Disease
.	O

Scopolamine	B_Chemical
(	O
10	O
mg/kg	O
)	O
and	O
pentobarbital	B_Chemical
(	O
5	O
mg/kg	O
)	O
prevented	O
development	O
of	O
pilocarpine-induced	O
behavioral	O
seizure	B_Disease
but	O
MK-801	B_Chemical
(	O
0.5	O
mg/kg	O
)	O
did	O
not	O
.	O

2	O
.	O
An	O
electrical	O
seizure	B_Disease
measured	O
with	O
hippocampal	O
EEG	O
appeared	O
in	O
the	O
pilocarpine-treated	O
group	O
.	O

Scopolamine	B_Chemical
and	O
pentobarbital	B_Chemical
blocked	O
the	O
pilocarpine-induced	O
electrographic	O
seizure	B_Disease
,	O
MK-801	B_Chemical
treatment	O
augmented	O
the	O
electrographic	O
seizure	B_Disease
induced	O
by	O
pilocarpine	B_Chemical
.	O

3	O
.	O
Brain	B_Disease
damage	I_Disease
was	O
assessed	O
by	O
examining	O
the	O
hippocampus	O
microscopically	O
.	O

Pilocarpine	B_Chemical
produced	O
neuronal	B_Disease
death	I_Disease
in	O
the	O
hippocampus	O
,	O
which	O
showed	O
pyknotic	O
changes	O
.	O

Pentobarbital	B_Chemical
,	O
scopolamine	B_Chemical
and	O
MK-801	B_Chemical
protected	O
the	O
brain	B_Disease
damage	I_Disease
by	O
pilocarpine	B_Chemical
,	O
though	O
in	O
the	O
MK-801-treated	O
group	O
,	O
the	O
pyramidal	O
cells	O
of	O
hippocampus	O
appeared	O
darker	O
than	O
normal	O
.	O

In	O
all	O
treatments	O
,	O
granule	O
cells	O
of	O
the	O
dentate	O
gyrus	O
were	O
not	O
affected	O
.	O

4	O
.	O

These	O
results	O
indicate	O
that	O
status	B_Disease
epilepticus	I_Disease
induced	O
by	O
pilocarpine	B_Chemical
is	O
initiated	O
by	O
cholinergic	O
overstimulation	O
and	O
propagated	O
by	O
glutamatergic	O
transmission	O
,	O
the	O
elevation	O
of	O
which	O
may	O
cause	O
brain	B_Disease
damage	I_Disease
through	O
an	O
excitatory	O
NMDA	B_Chemical
receptor-mediated	O
mechanism	O
.	O

Paclitaxel	B_Chemical
,	O
5-fluorouracil	B_Chemical
,	O
and	O
folinic	B_Chemical
acid	I_Chemical
in	O
metastatic	O
breast	B_Disease
cancer	I_Disease
:	O
BRE-26	O
,	O
a	O
phase	O
II	O
trial.5-Fluorouracil	O
plus	O
folinic	B_Chemical
acid	I_Chemical
and	O
paclitaxel	B_Chemical
(	O
Taxol	B_Chemical
;	O
Bristol-Myers	O
Squibb	O
Company	O
,	O
Princeton	O
,	O
NJ	O
)	O
are	O
effective	O
salvage	O
therapies	O
for	O
metastatic	O
breast	B_Disease
cancer	I_Disease
patients	O
.	O

Paclitaxel	B_Chemical
and	O
5-fluorouracil	B_Chemical
have	O
additive	O
cytotoxicity	B_Disease
in	O
MCF-7	O
cell	O
lines	O
.	O

We	O
performed	O
a	O
phase	O
II	O
trial	O
of	O
paclitaxel	B_Chemical
175	O
mg/m2	O
over	O
3	O
hours	O
on	O
day	O
I	O
followed	O
by	O
folinic	B_Chemical
acid	I_Chemical
300	O
mg	O
over	O
1	O
hour	O
before	O
5-fluorouracil	B_Chemical
350	O
mg/m2	O
on	O
days	O
1	O
to	O
3	O
every	O
28	O
days	O
(	O
TFL	O
)	O
in	O
women	O
with	O
metastatic	O
breast	B_Disease
cancer	I_Disease
.	O

Analysis	O
is	O
reported	O
on	O
37	O
patients	O
with	O
a	O
minimum	O
of	O
6	O
months	O
follow-up	O
who	O
received	O
a	O
total	O
of	O
192	O
cycles	O
of	O
TFL	O
:	O
nine	O
cycles	O
(	O
5	O
%	O
)	O
were	O
associated	O
with	O
grade	O
3/4	O
neutropenia	B_Disease
requiring	O
hospitalization	O
;	O
seven	O
(	O
4	O
%	O
)	O
cycles	O
in	O
two	O
patients	O
required	O
granulocyte	B_Chemical
colony-stimulating	I_Chemical
factor	I_Chemical
due	O
to	O
neutropenia	B_Disease
;	O
no	O
patient	O
required	O
platelet	O
transfusions	O
.	O

Grade	O
3/4	O
nonhematologic	O
toxicities	B_Disease
were	O
uncommon	O
.	O

Among	O
the	O
34	O
patients	O
evaluable	O
for	O
response	O
,	O
there	O
were	O
three	O
complete	O
responses	O
(	O
9	O
%	O
)	O
and	O
18	O
partial	O
responses	O
(	O
53	O
%	O
)	O
for	O
an	O
overall	O
response	O
rate	O
of	O
62	O
%	O
.	O

Of	O
the	O
19	O
evaluable	O
patients	O
with	O
prior	O
doxorubicin	B_Chemical
exposure	O
,	O
11	O
(	O
58	O
%	O
)	O
responded	O
compared	O
with	O
nine	O
of	O
15	O
(	O
60	O
%	O
)	O
without	O
prior	O
doxorubicin	B_Chemical
.	O

Plasma	O
paclitaxel	B_Chemical
concentrations	O
were	O
measured	O
at	O
the	O
completion	O
of	O
paclitaxel	B_Chemical
infusion	O
and	O
at	O
24	O
hours	O
in	O
19	O
patients	O
.	O

TFL	O
is	O
an	O
active	O
,	O
well-tolerated	O
regimen	O
in	O
metastatic	O
breast	B_Disease
cancer	I_Disease
.	O

Efficacy	O
and	O
proarrhythmia	B_Disease
with	O
the	O
use	O
of	O
d	B_Chemical
,	I_Chemical
l-sotalol	I_Chemical
for	O
sustained	O
ventricular	B_Disease
tachyarrhythmias	I_Disease
.	O

This	O
study	O
prospectively	O
evaluated	O
the	O
clinical	O
efficacy	O
,	O
the	O
incidence	O
of	O
torsades	B_Disease
de	I_Disease
pointes	I_Disease
,	O
and	O
the	O
presumable	O
risk	O
factors	O
for	O
torsades	B_Disease
de	I_Disease
pointes	I_Disease
in	O
patients	O
treated	O
with	O
d	B_Chemical
,	I_Chemical
l-sotalol	I_Chemical
for	O
sustained	O
ventricular	B_Disease
tachyarrhythmias	I_Disease
.	O

Eighty-one	O
consecutive	O
patients	O
(	O
54	O
with	O
coronary	B_Disease
artery	I_Disease
disease	I_Disease
,	O
and	O
20	O
with	O
dilated	B_Disease
cardiomyopathy	I_Disease
)	O
with	O
inducible	O
sustained	O
ventricular	B_Disease
tachycardia	I_Disease
or	O
ventricular	B_Disease
fibrillation	I_Disease
received	O
oral	O
d	B_Chemical
,	I_Chemical
l-sotalol	I_Chemical
to	O
prevent	O
induction	O
of	O
the	O
ventricular	B_Disease
tachyarrhythmia	I_Disease
.	O

During	O
oral	O
loading	O
with	O
d	B_Chemical
,	I_Chemical
l-sotalol	I_Chemical
,	O
continuous	O
electrocardiographic	O
(	O
ECG	O
)	O
monitoring	O
was	O
performed	O
.	O

Those	O
patients	O
in	O
whom	O
d	B_Chemical
,	I_Chemical
l-sotalol	I_Chemical
prevented	O
induction	O
of	O
ventricular	B_Disease
tachycardia	I_Disease
or	O
ventricular	B_Disease
fibrillation	I_Disease
were	O
discharged	O
with	O
the	O
drug	O
and	O
followed	O
up	O
on	O
an	O
outpatient	O
basis	O
for	O
21	O
+	O
/-	O
18	O
months	O
.	O

Induction	O
of	O
the	O
ventricular	B_Disease
tachyarrhythmia	I_Disease
was	O
prevented	O
by	O
oral	O
d	B_Chemical
,	I_Chemical
l-sotalol	I_Chemical
in	O
35	O
(	O
43	O
%	O
)	O
patients	O
;	O
the	O
ventricular	B_Disease
tachyarrhythmia	I_Disease
remained	O
inducible	O
in	O
40	O
(	O
49	O
%	O
)	O
patients	O
;	O
and	O
two	O
(	O
2.5	O
%	O
)	O
patients	O
did	O
not	O
tolerate	O
even	O
40	O
mg	O
of	O
d	B_Chemical
,	I_Chemical
l-sotalol	I_Chemical
once	O
daily	O
.	O

Four	O
(	O
5	O
%	O
)	O
patients	O
had	O
from	O
torsades	B_Disease
de	I_Disease
pointes	I_Disease
during	O
the	O
initial	O
oral	O
treatment	O
with	O
d	B_Chemical
,	I_Chemical
l-sotalol	I_Chemical
.	O

Neither	O
ECG	O
[	O
sinus-cycle	O
length	O
(	O
SCL	O
)	O
,	O
QT	O
or	O
QTc	O
interval	O
,	O
or	O
U	O
wave	O
]	O
nor	O
clinical	O
parameters	O
identified	O
patients	O
at	O
risk	O
for	O
torsades	B_Disease
de	I_Disease
pointes	I_Disease
.	O

However	O
,	O
the	O
oral	O
dose	O
of	O
d	B_Chemical
,	I_Chemical
l-sotalol	I_Chemical
was	O
significantly	O
lower	O
in	O
patients	O
with	O
torsades	B_Disease
de	I_Disease
pointes	I_Disease
(	O
200	O
+	O
/-	O
46	O
vs.	O
328	O
+	O
/-	O
53	O
mg/day	O
;	O
p	O
=	O
0.0017	O
)	O
.	O

Risk	O
factors	O
associated	O
with	O
the	O
development	O
of	O
torsades	B_Disease
de	I_Disease
pointes	I_Disease
were	O
the	O
appearance	O
of	O
an	O
U	O
wave	O
(	O
p	O
=	O
0.049	O
)	O
,	O
female	O
gender	O
(	O
p	O
=	O
0.015	O
)	O
,	O
and	O
significant	O
dose-corrected	O
changes	O
of	O
SCL	O
,	O
QT	O
interval	O
,	O
and	O
QTc	O
interval	O
(	O
p	O
<	O
0.05	O
)	O
.	O

During	O
follow-up	O
,	O
seven	O
(	O
20	O
%	O
)	O
patients	O
had	O
a	O
nonfatal	O
ventricular	B_Disease
tachycardia	I_Disease
recurrence	O
,	O
and	O
two	O
(	O
6	O
%	O
)	O
patients	O
died	O
suddenly	O
.	O

One	O
female	O
patient	O
with	O
stable	O
cardiac	B_Disease
disease	I_Disease
had	O
recurrent	O
torsades	B_Disease
de	I_Disease
pointes	I_Disease
after	O
2	O
years	O
of	O
successful	O
treatment	O
with	O
d	B_Chemical
,	I_Chemical
l-sotalol	I_Chemical
.	O

Torsades	B_Disease
de	I_Disease
pointes	I_Disease
occurred	O
early	O
during	O
treatment	O
even	O
with	O
low	O
doses	O
of	O
oral	O
d	B_Chemical
,	I_Chemical
l-sotalol	I_Chemical
.	O

Pronounced	O
changes	O
in	O
the	O
surface	O
ECG	O
(	O
cycle	O
length	O
,	O
QT	O
,	O
and	O
QTc	O
)	O
in	O
relation	O
to	O
the	O
dose	O
of	O
oral	O
d	B_Chemical
,	I_Chemical
l-sotalol	I_Chemical
might	O
identify	O
a	O
subgroup	O
of	O
patients	O
with	O
an	O
increased	O
risk	O
for	O
torsades	B_Disease
de	I_Disease
pointes	I_Disease
.	O

Other	O
ECG	O
parameters	O
before	O
the	O
application	O
of	O
d	B_Chemical
,	I_Chemical
l-sotalol	I_Chemical
did	O
not	O
identify	O
patients	O
at	O
increased	O
risk	O
for	O
torsades	B_Disease
de	I_Disease
pointes	I_Disease
.	O

Recurrence	O
rates	O
of	O
ventricular	B_Disease
tachyarrhythmias	I_Disease
are	O
high	O
despite	O
complete	O
suppression	O
of	O
the	O
arrhythmia	B_Disease
during	O
programmed	O
stimulation	O
.	O

Therefore	O
programmed	O
electrical	O
stimulation	O
in	O
the	O
case	O
of	O
d	B_Chemical
,	I_Chemical
l-sotalol	I_Chemical
seems	O
to	O
be	O
of	O
limited	O
prognostic	O
value	O
.	O

Chronic	O
hyperprolactinemia	B_Disease
and	O
changes	O
in	O
dopamine	B_Chemical
neurons	O
.	O

The	O
tuberoinfundibular	O
dopaminergic	O
(	O
TIDA	O
)	O
system	O
is	O
known	O
to	O
inhibit	O
prolactin	O
(	O
PRL	O
)	O
secretion	O
.	O

In	O
young	O
animals	O
this	O
system	O
responds	O
to	O
acute	O
elevations	O
in	O
serum	O
PRL	O
by	O
increasing	O
its	O
activity	O
.	O

However	O
,	O
this	O
responsiveness	O
is	O
lost	O
in	O
aging	O
rats	O
with	O
chronically	O
high	O
serum	O
PRL	O
levels	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
induce	O
hyperprolactinemia	B_Disease
in	O
rats	O
for	O
extended	O
periods	O
of	O
time	O
and	O
examine	O
its	O
effects	O
on	O
dopaminergic	O
systems	O
in	O
the	O
brain	O
.	O

Hyperprolactinemia	B_Disease
was	O
induced	O
by	O
treatment	O
with	O
haloperidol	B_Chemical
,	O
a	O
dopamine	B_Chemical
receptor	O
antagonist	O
,	O
and	O
Palkovits	O
'	O
microdissection	O
technique	O
in	O
combination	O
with	O
high-performance	O
liquid	O
chromatography	O
was	O
used	O
to	O
measure	O
neurotransmitter	O
concentrations	O
in	O
several	O
areas	O
of	O
the	O
brain	O
.	O

After	O
6	O
months	O
of	O
hyperprolactinemia	B_Disease
,	O
dopamine	B_Chemical
(	O
DA	B_Chemical
)	O
concentrations	O
in	O
the	O
median	O
eminence	O
(	O
ME	O
)	O
increased	O
by	O
84	O
%	O
over	O
the	O
control	O
group	O
.	O

Nine	O
months	O
of	O
hyperprolactinemia	B_Disease
produced	O
a	O
50	O
%	O
increase	O
in	O
DA	B_Chemical
concentrations	O
in	O
the	O
ME	O
over	O
the	O
control	O
group	O
.	O

However	O
,	O
DA	B_Chemical
response	O
was	O
lost	O
if	O
a	O
9-month	O
long	O
haloperidol-induced	O
hyperprolactinemia	B_Disease
was	O
followed	O
by	O
a	O
1	O
1/2	O
month-long	O
extremely	O
high	O
increase	O
in	O
serum	O
PRL	O
levels	O
produced	O
by	O
implantation	O
of	O
MMQ	O
cells	O
under	O
the	O
kidney	O
capsule	O
.	O

There	O
was	O
no	O
change	O
in	O
the	O
levels	O
of	O
DA	B_Chemical
,	O
norepinephrine	B_Chemical
(	O
NE	B_Chemical
)	O
,	O
serotonin	B_Chemical
(	O
5-HT	B_Chemical
)	O
,	O
or	O
their	O
metabolites	O
in	O
the	O
arcuate	O
nucleus	O
(	O
AN	O
)	O
,	O
medial	O
preoptic	O
area	O
(	O
MPA	O
)	O
,	O
caudate	O
putamen	O
(	O
CP	O
)	O
,	O
substantia	O
nigra	O
(	O
SN	O
)	O
,	O
and	O
zona	O
incerta	O
(	O
ZI	O
)	O
,	O
except	O
for	O
a	O
decrease	O
in	O
5-hydroxyindoleacetic	B_Chemical
acid	I_Chemical
(	O
5-HIAA	B_Chemical
)	O
in	O
the	O
AN	O
after	O
6-months	O
of	O
hyperprolactinemia	B_Disease
and	O
an	O
increase	O
in	O
DA	B_Chemical
concentrations	O
in	O
the	O
AN	O
after	O
9-months	O
of	O
hyperprolactinemia	B_Disease
.	O

These	O
results	O
demonstrate	O
that	O
hyperprolactinemia	B_Disease
specifically	O
affects	O
TIDA	O
neurons	O
and	O
these	O
effects	O
vary	O
,	O
depending	O
on	O
the	O
duration	O
and	O
intensity	O
of	O
hyperprolactinemia	B_Disease
.	O

The	O
age-related	O
decrease	O
in	O
hypothalamic	O
dopamine	B_Chemical
function	O
may	O
be	O
associated	O
with	O
increases	O
in	O
PRL	O
secretion	O
.	O

Treatment-related	O
disseminated	O
necrotizing	O
leukoencephalopathy	O
with	O
characteristic	O
contrast	O
enhancement	O
of	O
the	O
white	O
matter	O
.	O

This	O
report	O
describes	O
unique	O
contrast	O
enhancement	O
of	O
the	O
white	O
matter	O
on	O
T1-weighted	O
magnetic	O
resonance	O
images	O
of	O
two	O
patients	O
with	O
disseminated	O
necrotizing	O
leukoencephalopathy	B_Disease
,	O
which	O
developed	O
from	O
acute	B_Disease
lymphoblastic	I_Disease
leukemia	I_Disease
treated	O
with	O
high-dose	O
methotrexate	B_Chemical
.	O

In	O
both	O
patients	O
,	O
the	O
enhancement	O
was	O
more	O
pronounced	O
near	O
the	O
base	O
of	O
the	O
brain	O
than	O
at	O
the	O
vertex	O
.	O

Necropsy	O
of	O
the	O
first	O
case	O
revealed	O
loss	B_Disease
of	I_Disease
myelination	I_Disease
and	O
necrosis	B_Disease
of	O
the	O
white	O
matter	O
.	O

Possible	O
mechanisms	O
causing	O
such	O
a	O
leukoencephalopathy	B_Disease
are	O
discussed	O
.	O

Thrombotic	B_Disease
complications	O
in	O
acute	B_Disease
promyelocytic	I_Disease
leukemia	I_Disease
during	O
all-trans-retinoic	B_Chemical
acid	I_Chemical
therapy	O
.	O

A	O
case	O
of	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
,	O
due	O
to	O
occlusion	B_Disease
of	I_Disease
renal	I_Disease
vessels	I_Disease
in	O
a	O
patient	O
with	O
acute	B_Disease
promyelocytic	I_Disease
leukemia	I_Disease
(	O
APL	B_Disease
)	O
treated	O
with	O
all-trans-retinoic	B_Chemical
acid	I_Chemical
(	O
ATRA	B_Chemical
)	O
and	O
tranexamic	B_Chemical
acid	I_Chemical
has	O
been	O
described	O
recently	O
.	O

We	O
report	O
a	O
case	O
of	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
in	O
an	O
APL	B_Disease
patient	O
treated	O
with	O
ATRA	B_Chemical
alone	O
.	O

This	O
case	O
further	O
supports	O
the	O
concern	O
about	O
thromboembolic	B_Disease
complications	O
associated	O
with	O
ATRA	B_Chemical
therapy	O
in	O
APL	B_Disease
patients	O
.	O

The	O
patients	O
,	O
a	O
43-year-old	O
man	O
,	O
presented	O
all	O
the	O
signs	O
and	O
symptoms	O
of	O
APL	B_Disease
and	O
was	O
included	O
in	O
a	O
treatment	O
protocol	O
with	O
ATRA	B_Chemical
.	O

After	O
10	O
days	O
of	O
treatment	O
,	O
he	O
developed	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
that	O
was	O
completely	O
reversible	O
after	O
complete	O
remission	O
of	O
APL	B_Disease
was	O
achieved	O
and	O
therapy	O
discontinued	O
.	O

We	O
conclude	O
that	O
ATRA	B_Chemical
is	O
a	O
valid	O
therapeutic	O
choice	O
for	O
patients	O
with	O
APL	B_Disease
,	O
although	O
the	O
procoagulant	O
tendency	O
is	O
not	O
completely	O
corrected	O
.	O

Thrombotic	B_Disease
events	O
,	O
however	O
,	O
could	O
be	O
avoided	O
by	O
using	O
low-dose	O
heparin	B_Chemical
.	O

Pupillary	O
changes	O
associated	O
with	O
the	O
development	O
of	O
stimulant-induced	O
mania	O
:	O
a	O
case	O
report	O
.	O

A	O
30-year-old	O
cocaine-dependent	O
man	O
who	O
was	O
a	O
subject	O
in	O
a	O
study	O
evaluating	O
the	O
anticraving	O
efficacy	O
of	O
the	O
stimulant	O
medication	O
diethylpropion	B_Chemical
(	O
DEP	B_Chemical
)	O
became	O
manic	B_Disease
during	O
his	O
second	O
week	O
on	O
the	O
study	O
drug	O
.	O

Pupillometric	O
changes	O
while	O
on	O
DEP	B_Chemical
,	O
especially	O
changes	O
in	O
the	O
total	O
power	O
of	O
pupillary	B_Disease
oscillation	I_Disease
,	O
were	O
dramatically	O
different	O
than	O
those	O
observed	O
in	O
the	O
eight	O
other	O
study	O
subjects	O
who	O
did	O
not	O
become	O
manic	B_Disease
.	O

The	O
large	O
changes	O
in	O
total	O
power	O
of	O
pupillary	B_Disease
oscillation	I_Disease
occurred	O
a	O
few	O
days	O
before	O
the	O
patient	O
became	O
fully	O
manic	B_Disease
.	O

Such	O
medication-associated	O
changes	O
in	O
the	O
total	O
power	O
of	O
pupillary	B_Disease
oscillation	I_Disease
might	O
be	O
of	O
utility	O
in	O
identifying	O
persons	O
at	O
risk	O
for	O
manic-like	O
adverse	O
effects	O
during	O
the	O
medical	O
use	O
of	O
psychomotor	O
stimulants	O
or	O
sympathomimetic	O
agents	O
.	O

Fetal	O
risks	O
due	O
to	O
warfarin	O
therapy	O
during	O
pregnancy	O
.	O

Two	O
mothers	O
with	O
heart	O
valve	O
prosthesis	O
were	O
treated	O
with	O
warfarin	B_Chemical
during	O
pregnancy	O
.	O

In	O
the	O
first	O
case	O
a	O
caesarean	O
section	O
was	O
done	O
one	O
week	O
after	O
replacement	O
of	O
warfarin	B_Chemical
with	O
heparin	B_Chemical
.	O

The	O
baby	O
died	O
of	O
cerebral	B_Disease
and	I_Disease
pulmonary	B_Disease
hemorrhage	B_Disease
.	O

The	O
second	O
mother	O
had	O
a	O
male	O
infant	O
by	O
caesarean	O
section	O
.	O

The	O
baby	O
showed	O
warfarin-induced	O
embryopathy	B_Disease
with	O
nasal	B_Disease
hypoplasia	I_Disease
and	O
stippled	B_Disease
epiphyses	I_Disease
(	O
chondrodysplasia	B_Disease
punctata	I_Disease
)	O
.	O

Nasal	B_Disease
hypoplasia	I_Disease
with	O
or	O
without	O
stippled	B_Disease
epiphyses	I_Disease
has	O
now	O
been	O
reported	O
in	O
11	O
infants	O
born	O
to	O
mothers	O
treated	O
with	O
warfarin	B_Chemical
during	O
the	O
first	O
trimester	O
,	O
and	O
a	O
causal	O
association	O
is	O
probable	O
.	O

In	O
view	O
of	O
the	O
risks	O
to	O
both	O
mother	O
and	O
fetus	O
in	O
women	O
with	O
prosthetic	O
cardiac	O
valves	O
it	O
is	O
recommended	O
that	O
therapeutic	O
abortion	O
be	O
advised	O
as	O
the	O
first	O
alternative	O
.	O

The	O
negative	O
mucosal	O
potential	O
:	O
separating	O
central	O
and	O
peripheral	O
effects	O
of	O
NSAIDs	O
in	O
man	O
.	O

OBJECTIVE	O
:	O
We	O
wanted	O
to	O
test	O
whether	O
assessment	O
of	O
both	O
a	O
central	O
pain-related	O
signal	O
(	O
chemo-somatosensory	O
evoked	O
potential	O
,	O
CSSEP	O
)	O
and	O
a	O
concomitantly	O
recorded	O
peripheral	O
signal	O
(	O
negative	O
mucosal	O
potential	O
,	O
NMP	O
)	O
allows	O
for	O
separation	O
of	O
central	O
and	O
peripheral	O
effects	O
of	O
NSAIDs	O
.	O

For	O
this	O
purpose	O
,	O
experimental	O
conditions	O
were	O
created	O
in	O
which	O
NSAIDs	O
had	O
previously	O
been	O
observed	O
to	O
produce	O
effects	O
on	O
phasic	O
and	O
tonic	O
pain	B_Disease
by	O
either	O
central	O
or	O
peripheral	O
mechanisms	O
.	O

METHODS	O
:	O
According	O
to	O
a	O
double-blind	O
,	O
randomised	O
,	O
controlled	O
,	O
threefold	O
cross-over	O
design	O
,	O
18	O
healthy	O
subjects	O
(	O
11	O
males	O
,	O
7	O
females	O
;	O
mean	O
age	O
26	O
years	O
)	O
received	O
either	O
placebo	O
,	O
400	O
mg	O
ibuprofen	B_Chemical
,	O
or	O
800	O
mg	O
ibuprofen	B_Chemical
.	O

Phasic	O
pain	B_Disease
was	O
applied	O
by	O
means	O
of	O
short	O
pulses	O
of	O
CO2	B_Chemical
to	O
the	O
nasal	O
mucosa	O
(	O
stimulus	O
duration	O
500	O
ms	O
,	O
interval	O
approximately	O
60	O
s	O
)	O
,	O
and	O
tonic	O
pain	B_Disease
was	O
induced	O
in	O
the	O
nasal	O
cavity	O
by	O
means	O
of	O
dry	O
air	O
of	O
controlled	O
temperature	O
,	O
humidity	O
and	O
flow	O
rate	O
(	O
22	O
degrees	O
C	O
,	O
0	O
%	O
relative	O
humidity	O
,	O
145	O
ml.s-1	O
)	O
.	O

Both	O
CSSEPs	O
as	O
central	O
and	O
NMPs	O
as	O
peripheral	O
correlates	O
of	O
pain	B_Disease
were	O
obtained	O
in	O
response	O
to	O
the	O
CO2	B_Chemical
stimuli	O
.	O

Additionally	O
,	O
the	O
subjects	O
rated	O
the	O
intensity	O
of	O
both	O
phasic	O
and	O
tonic	O
pain	B_Disease
by	O
means	O
of	O
visual	O
analogue	O
scales	O
.	O

RESULTS	O
:	O
As	O
described	O
earlier	O
,	O
administration	O
of	O
ibuprofen	B_Chemical
was	O
followed	O
by	O
a	O
decrease	O
in	O
tonic	O
pain	B_Disease
but-relative	O
to	O
placebo-an	O
increase	O
in	O
correlates	O
of	O
phasic	O
pain	B_Disease
,	O
indicating	O
a	O
specific	O
effect	O
of	O
ibuprofen	B_Chemical
on	O
the	O
interaction	O
between	O
the	O
pain	B_Disease
stimuli	O
under	O
these	O
special	O
experimental	O
conditions	O
.	O

Based	O
on	O
the	O
similar	O
behaviour	O
of	O
CSSEP	O
and	O
NMP	O
,	O
it	O
was	O
concluded	O
that	O
the	O
pharmacological	O
process	O
underlying	O
this	O
phenomenon	O
was	O
localised	O
in	O
the	O
periphery	O
.	O

By	O
means	O
of	O
the	O
simultaneous	O
recording	O
of	O
interrelated	O
peripheral	O
and	O
central	O
electrophysiologic	O
correlates	O
of	O
nociception	O
,	O
it	O
was	O
possible	O
to	O
separate	O
central	O
and	O
peripheral	O
effects	O
of	O
an	O
NSAID	O
.	O

The	O
major	O
advantage	O
of	O
this	O
pain	B_Disease
model	O
is	O
the	O
possibility	O
of	O
obtaining	O
peripheral	O
pain-related	O
activity	O
directly	O
using	O
a	O
non-invasive	O
technique	O
in	O
humans	O
.	O

Effect	O
of	O
D-Glucarates	B_Chemical
on	O
basic	O
antibiotic-induced	O
renal	B_Disease
damage	I_Disease
in	O
rats	O
.	O

Dehydrated	B_Disease
rats	O
regularly	O
develop	O
acute	B_Disease
renal	I_Disease
failure	I_Disease
following	O
single	O
injection	O
of	O
aminoglycoside	B_Chemical
antibiotics	O
combined	O
with	O
dextran	O
or	O
of	O
antibiotics	O
only	O
.	O

Oral	O
administration	O
of	O
2,5-di-O-acetyl-D-glucaro-1,4	B_Chemical
-	I_Chemical
6,3-dilactone	I_Chemical
protected	O
rats	O
against	O
renal	B_Disease
failure	I_Disease
induced	O
by	O
kanamycin-dextran	O
.	O

The	O
protective	O
effect	O
was	O
prevalent	O
among	O
D-glucarates	B_Chemical
,	O
and	O
also	O
to	O
other	O
saccharic	B_Chemical
acid	I_Chemical
,	O
hexauronic	B_Chemical
acids	I_Chemical
and	O
hexaaldonic	B_Chemical
acids	I_Chemical
,	O
although	O
to	O
a	O
lesser	O
degree	O
,	O
but	O
not	O
to	O
a	O
hexaaldose	O
,	O
sugar	B_Chemical
alcohols	I_Chemical
,	O
substances	O
inthe	O
TCA	B_Chemical
cycle	O
and	O
other	O
acidic	O
compounds	O
.	O

D-Glucarates	B_Chemical
were	O
effective	O
against	O
renal	B_Disease
damage	I_Disease
induced	O
by	O
peptide	O
antibiotics	O
as	O
well	O
as	O
various	O
aminoglycoside	B_Chemical
antibitocis	O
.	O

Dose-responses	O
were	O
observed	O
in	O
the	O
protective	O
effect	O
of	O
D-Glucarates	B_Chemical
.	O

With	O
a	O
D-glucarate	B_Chemical
of	O
a	O
fixed	O
size	O
of	O
dose	O
,	O
approximately	O
the	O
same	O
degree	O
of	O
protection	O
was	O
obtained	O
against	O
renal	B_Disease
damages	I_Disease
induced	O
by	O
different	O
basic	O
antibiotics	O
despite	O
large	O
disparities	O
in	O
administration	O
doses	O
of	O
different	O
antibiotics	O
.	O

D-Glucarates	B_Chemical
had	O
the	O
ability	O
to	O
prevent	O
renal	B_Disease
damage	I_Disease
but	O
not	O
to	O
cure	O
it	O
.	O

Rats	O
excreted	O
acidic	O
urine	O
when	O
they	O
were	O
spared	O
from	O
renal	B_Disease
lesions	I_Disease
by	O
monosaccharides	B_Chemical
.	O

The	O
reduction	O
effect	O
of	O
D-glucarates	B_Chemical
against	O
nephrotoxicity	B_Disease
of	O
basic	O
antibiotics	O
was	O
discussed	O
.	O

Acute	O
severe	O
depression	B_Disease
following	O
peri-operative	O
ondansetron	B_Chemical
.	O

A	O
41-year-old	O
woman	O
with	O
a	O
strong	O
history	O
of	O
postoperative	B_Disease
nausea	I_Disease
and	I_Disease
vomiting	I_Disease
presented	O
for	O
abdominal	O
hysterectomy	O
3	O
months	O
after	O
a	O
previous	O
anaesthetic	O
where	O
ondansetron	B_Chemical
prophylaxis	O
had	O
been	O
used	O
.	O

She	O
had	O
developed	O
a	O
severe	O
acute	O
major	B_Disease
depression	I_Disease
disorder	I_Disease
almost	O
immediately	O
thereafter	O
,	O
possibly	O
related	O
to	O
the	O
use	O
of	O
a	O
serotonin	B_Chemical
antagonist	O
.	O

Nine	O
years	O
before	O
she	O
had	O
experienced	O
a	O
self-limited	O
puerperal	O
depressive	B_Disease
episode	I_Disease
.	O

Anaesthesia	O
with	O
a	O
propofol	B_Chemical
infusion	O
and	O
avoidance	O
of	O
serotonin	B_Chemical
antagonists	O
provided	O
a	O
nausea-free	O
postoperative	O
course	O
without	O
exacerbation	O
of	O
the	O
depression	B_Disease
disorder	I_Disease
.	O

Hypertensive	B_Disease
response	O
during	O
dobutamine	B_Chemical
stress	O
echocardiography	O
.	O

Among	O
3,129	O
dobutamine	B_Chemical
stress	O
echocardiographic	O
studies	O
,	O
a	O
hypertensive	B_Disease
response	O
,	O
defined	O
as	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
>	O
or	O
=	O
220	O
mm	O
Hg	O
and/or	O
diastolic	O
BP	O
>	O
or	O
=	O
110	O
mm	O
Hg	O
,	O
occurred	O
in	O
30	O
patients	O
(	O
1	O
%	O
)	O
.	O

Patients	O
with	O
this	O
response	O
more	O
often	O
had	O
a	O
history	O
of	O
hypertension	B_Disease
and	O
had	O
higher	O
resting	O
systolic	O
and	O
diastolic	O
BP	O
before	O
dobutamine	B_Chemical
infusion	O
.	O

Continuously	O
nebulized	O
albuterol	B_Chemical
in	O
severe	O
exacerbations	O
of	O
asthma	B_Disease
in	O
adults	O
:	O
a	O
case-controlled	O
study	O
.	O

A	O
retrospective	O
,	O
case-controlled	O
analysis	O
comparing	O
patients	O
admitted	O
to	O
a	O
medical	O
intensive	O
care	O
unit	O
with	O
severe	O
exacerbations	O
of	O
asthma	B_Disease
who	O
received	O
continuously	O
nebulized	O
albuterol	B_Chemical
(	O
CNA	O
)	O
versus	O
intermittent	O
albuterol	B_Chemical
(	O
INA	O
)	O
treatments	O
is	O
reported	O
.	O

Forty	O
matched	O
pairs	O
of	O
patients	O
with	O
asthma	B_Disease
are	O
compared	O
.	O

CNA	O
was	O
administered	O
for	O
a	O
mean	O
of	O
11	O
+	O
/-	O
10	O
hr	O
.	O

The	O
incidence	O
of	O
cardiac	B_Disease
dysrhythmias	I_Disease
was	O
similar	O
between	O
groups	O
.	O

Symptomatic	O
hypokalemia	B_Disease
did	O
not	O
occur	O
.	O

CNA	O
patients	O
had	O
higher	O
heart	O
rates	O
during	O
treatment	O
,	O
which	O
may	O
reflect	O
severity	O
of	O
illness	O
.	O

The	O
incidence	O
of	O
intubation	O
was	O
similar	O
.	O

We	O
conclude	O
that	O
CNA	O
and	O
INA	O
demonstrated	O
similar	O
profiles	O
with	O
regard	O
to	O
safety	O
,	O
morbidity	O
,	O
and	O
mortality	O
.	O

Paraplegia	B_Disease
following	O
intrathecal	O
methotrexate	B_Chemical
:	O
report	O
of	O
a	O
case	O
and	O
review	O
of	O
the	O
literature	O
.	O

A	O
patient	O
who	O
developed	O
paraplegia	B_Disease
following	O
the	O
intrathecal	O
instillation	O
of	O
methotrexate	B_Chemical
is	O
discribed	O
.	O

The	O
ten	O
previously	O
reported	O
cases	O
of	O
this	O
unusual	O
complication	O
are	O
reviewed	O
.	O

The	O
following	O
factors	O
appear	O
to	O
predispose	O
to	O
the	O
development	O
of	O
this	O
complication	O
:	O
abnormal	O
cerebrospinal	O
dynamics	O
related	O
to	O
the	O
presence	O
of	O
central	B_Disease
nervous	I_Disease
system	I_Disease
leukemia	I_Disease
,	O
and	O
epidural	O
cerebrospinal	O
leakage	O
;	O
elevated	O
cerebrospinal	O
fluid	O
methothexate	B_Chemical
concentration	O
related	O
to	O
abnormal	O
cerebrospinal	O
fluid	O
dynamics	O
and	O
to	O
inappropriately	O
high	O
methotrexate	B_Chemical
doses	O
based	O
on	O
body	O
surface	O
area	O
calculations	O
in	O
older	O
children	O
and	O
adults	O
;	O
the	O
presence	O
of	O
neurotoxic	B_Disease
preservatives	O
in	O
commercially	O
available	O
methotrexate	B_Chemical
preparations	O
and	O
diluents	O
;	O
and	O
the	O
use	O
of	O
methotrexate	B_Chemical
diluents	O
of	O
unphysiologic	O
pH	O
,	O
ionic	O
content	O
and	O
osmolarity	O
.	O

The	O
role	O
of	O
methotrexate	B_Chemical
contaminants	O
,	O
local	O
folate	B_Disease
deficiency	I_Disease
,	O
and	O
cranial	O
irradiation	O
in	O
the	O
pathogenesis	O
of	O
intrathecal	O
methotrexate	B_Chemical
toxicity	B_Disease
is	O
unclear	O
.	O

The	O
incidence	O
of	O
neurotoxicity	B_Disease
may	O
be	O
reduced	O
by	O
employing	O
lower	O
doses	O
of	O
methotrexate	B_Chemical
in	O
the	O
presence	O
of	O
central	B_Disease
nervous	I_Disease
system	I_Disease
leukemia	I_Disease
,	O
in	O
older	O
children	O
and	O
adults	O
,	O
and	O
in	O
the	O
presence	O
of	O
epidural	O
leakage	O
.	O

Only	O
preservative-free	O
methotrexate	B_Chemical
in	O
Elliott	O
's	O
B	O
Solution	O
at	O
a	O
concentration	O
of	O
not	O
more	O
than	O
1	O
mg/ml	O
should	O
be	O
used	O
for	O
intrathecal	O
administration	O
.	O

Periodic	O
monitoring	O
of	O
cerebruspinal	O
fluid	O
methotrexate	B_Chemical
levels	O
may	O
be	O
predictive	O
of	O
the	O
development	O
of	O
serious	O
neurotoxicity	B_Disease
.	O

Hyperosmolar	B_Disease
nonketotic	I_Disease
coma	I_Disease
precipitated	O
by	O
lithium-induced	O
nephrogenic	B_Disease
diabetes	I_Disease
insipidus	I_Disease
.	O

A	O
45-year-old	O
man	O
,	O
with	O
a	O
10-year	O
history	O
of	O
manic	B_Disease
depression	I_Disease
treated	O
with	O
lithium	B_Chemical
,	O
was	O
admitted	O
with	O
hyperosmolar	B_Disease
,	I_Disease
nonketotic	I_Disease
coma	I_Disease
.	O

He	O
gave	O
a	O
five-year	O
history	O
of	O
polyuria	B_Disease
and	O
polydipsia	B_Disease
,	O
during	O
which	O
time	O
urinalysis	O
had	O
been	O
negative	O
for	O
glucose	B_Chemical
.	O

After	O
recovery	O
from	O
hyperglycaemia	B_Disease
,	O
he	O
remained	O
polyuric	B_Disease
despite	O
normal	O
blood	O
glucose	B_Chemical
concentrations	O
;	O
water	O
deprivation	O
testing	O
indicated	O
nephrogenic	B_Disease
diabetes	I_Disease
insipidus	I_Disease
,	O
likely	O
to	O
be	O
lithium-induced	O
.	O

We	O
hypothesize	O
that	O
when	O
this	O
man	O
developed	O
type	B_Disease
2	I_Disease
diabetes	I_Disease
,	O
chronic	O
polyuria	B_Disease
due	O
to	O
nephrogenic	B_Disease
diabetes	I_Disease
insipidus	I_Disease
was	O
sufficient	O
to	O
precipitate	O
hyperosmolar	O
dehydration	B_Disease
.	O

Effects	O
of	O
the	O
intracoronary	O
infusion	O
of	O
cocaine	O
on	O
left	O
ventricular	O
systolic	O
and	O
diastolic	O
function	O
in	O
humans	O
.	O

BACKGROUND	O
:	O
In	O
dogs	O
,	O
a	O
large	O
amount	O
of	O
intravenous	O
cocaine	B_Chemical
causes	O
a	O
profound	O
deterioration	B_Disease
of	I_Disease
left	I_Disease
ventricular	I_Disease
(	I_Disease
LV	I_Disease
)	I_Disease
systolic	I_Disease
function	I_Disease
and	O
an	O
increase	O
in	O
LV	O
end-diastolic	O
pressure	O
.	O

This	O
study	O
was	O
done	O
to	O
assess	O
the	O
influence	O
of	O
a	O
high	O
intracoronary	O
cocaine	B_Chemical
concentration	O
on	O
LV	O
systolic	O
and	O
diastolic	O
function	O
in	O
humans	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
In	O
20	O
patients	O
(	O
14	O
men	O
and	O
6	O
women	O
aged	O
39	O
to	O
72	O
years	O
)	O
referred	O
for	O
cardiac	O
catheterization	O
for	O
the	O
evaluation	O
of	O
chest	B_Disease
pain	I_Disease
,	O
we	O
measured	O
heart	O
rate	O
,	O
systemic	O
arterial	O
pressure	O
,	O
LV	O
pressure	O
and	O
its	O
first	O
derivative	O
(	O
dP/dt	O
)	O
,	O
and	O
LV	O
volumes	O
and	O
ejection	O
fraction	O
before	O
and	O
during	O
the	O
final	O
2	O
to	O
3	O
minutes	O
of	O
a	O
15-minute	O
intracoronary	O
infusion	O
of	O
saline	O
(	O
n=10	O
,	O
control	O
subjects	O
)	O
or	O
cocaine	B_Chemical
hydrochloride	I_Chemical
1	O
mg/min	O
(	O
n=10	O
)	O
.	O

No	O
variable	O
changed	O
with	O
saline	O
.	O

With	O
cocaine	B_Chemical
,	O
the	O
drug	O
concentration	O
in	O
blood	O
obtained	O
from	O
the	O
coronary	O
sinus	O
was	O
3.0+/-0.4	O
(	O
mean+/-SD	O
)	O
mg/L	O
,	O
similar	O
in	O
magnitude	O
to	O
the	O
blood	O
cocaine	B_Chemical
concentration	O
reported	O
in	O
abusers	O
dying	O
of	O
cocaine	B_Chemical
intoxication	O
.	O

Cocaine	B_Chemical
induced	O
no	O
significant	O
change	O
in	O
heart	O
rate	O
,	O
LV	O
dP/dt	O
(	O
positive	O
or	O
negative	O
)	O
,	O
or	O
LV	O
end-diastolic	O
volume	O
,	O
but	O
it	O
caused	O
an	O
increase	O
in	O
systolic	O
and	O
mean	O
arterial	O
pressures	O
,	O
LV	O
end-diastolic	O
pressure	O
,	O
and	O
LV	O
end-systolic	O
volume	O
,	O
as	O
well	O
as	O
a	O
decrease	O
in	O
LV	O
ejection	O
fraction	O
.	O

CONCLUSIONS	O
:	O
In	O
humans	O
,	O
the	O
intracoronary	O
infusion	O
of	O
cocaine	B_Chemical
sufficient	O
in	O
amount	O
to	O
achieve	O
a	O
high	O
drug	O
concentration	O
in	O
coronary	O
sinus	O
blood	O
causes	O
a	O
deterioration	B_Disease
of	I_Disease
LV	I_Disease
systolic	I_Disease
and	I_Disease
diastolic	I_Disease
performance	I_Disease
.	O

Ascending	O
dose	O
tolerance	O
study	O
of	O
intramuscular	O
carbetocin	O
administered	O
after	O
normal	O
vaginal	O
birth	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
carbetocin	B_Chemical
(	O
a	O
long-acting	O
synthetic	O
analogue	O
of	O
oxytocin	B_Chemical
)	O
,	O
when	O
administered	O
immediately	O
after	O
vaginal	O
delivery	O
at	O
term	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Carbetocin	B_Chemical
was	O
given	O
as	O
an	O
intramuscular	O
injection	O
immediately	O
after	O
the	O
birth	O
of	O
the	O
infant	O
in	O
45	O
healthy	O
women	O
with	O
normal	O
singleton	O
pregnancies	O
who	O
delivered	O
vaginally	O
at	O
term	O
.	O

Dosage	O
groups	O
of	O
15	O
,	O
30	O
,	O
50	O
,	O
75	O
,	O
100	O
,	O
125	O
,	O
150	O
,	O
175	O
or	O
200	O
microg	O
carbetocin	B_Chemical
were	O
assigned	O
to	O
blocks	O
of	O
three	O
women	O
according	O
to	O
the	O
continual	O
reassessment	O
method	O
(	O
CRM	O
)	O
.	O

RESULTS	O
:	O
All	O
dosage	O
groups	O
consisted	O
of	O
three	O
women	O
,	O
except	O
those	O
with	O
100	O
microg	O
(	O
n=6	O
)	O
and	O
200	O
microg	O
(	O
n=18	O
)	O
.	O

Recorded	O
were	O
dose-limiting	O
adverse	O
events	O
:	O
hyper-	B_Disease
or	I_Disease
hypotension	I_Disease
(	O
three	O
)	O
,	O
severe	O
abdominal	B_Disease
pain	I_Disease
(	O
0	O
)	O
,	O
vomiting	B_Disease
(	O
0	O
)	O
and	O
retained	B_Disease
placenta	I_Disease
(	O
four	O
)	O
.	O

Serious	O
adverse	O
events	O
occurred	O
in	O
seven	O
women	O
:	O
six	O
cases	O
with	O
blood	B_Disease
loss	I_Disease
>	O
or	O
=	O
1000	O
ml	O
,	O
four	O
cases	O
of	O
manual	O
placenta	O
removal	O
,	O
five	O
cases	O
of	O
additional	O
oxytocics	O
administration	O
and	O
five	O
cases	O
of	O
blood	O
transfusion	O
.	O

Maximum	O
blood	B_Disease
loss	I_Disease
was	O
greatest	O
at	O
the	O
upper	O
and	O
lower	O
dose	O
levels	O
,	O
and	O
lowest	O
in	O
the	O
70	O
-	O
125	O
microg	O
dose	O
range	O
.	O

Four	O
out	O
of	O
six	O
cases	O
with	O
blood	B_Disease
loss	I_Disease
>	O
or	O
=	O
1000	O
ml	O
occurred	O
in	O
the	O
200	O
microg	O
group	O
.	O

The	O
majority	O
of	O
additional	O
administration	O
of	O
oxytocics	O
(	O
4/5	O
)	O
and	O
blood	O
transfusion	O
(	O
3/5	O
)	O
occurred	O
in	O
the	O
dose	O
groups	O
of	O
200	O
microg	O
.	O

All	O
retained	O
placentae	O
were	O
found	O
in	O
the	O
group	O
of	O
200	O
microg	O
.	O

CONCLUSION	O
:	O
The	O
MTD	O
was	O
calculated	O
to	O
be	O
at	O
200	O
microg	O
carbetocin	B_Chemical
.	O

Heparin-induced	O
thrombocytopenia	B_Disease
,	O
paradoxical	O
thromboembolism	B_Disease
,	O
and	O
other	O
side	O
effects	O
of	O
heparin	B_Chemical
therapy	O
.	O

Although	O
several	O
new	O
anticoagulant	O
drugs	O
are	O
in	O
development	O
,	O
heparin	B_Chemical
remains	O
the	O
drug	O
of	O
choice	O
for	O
most	O
anticoagulation	O
needs	O
.	O

The	O
clinical	O
effects	O
of	O
heparin	B_Chemical
are	O
meritorious	O
,	O
but	O
side	O
effects	O
do	O
exist	O
.	O

Important	O
untoward	O
effects	O
of	O
heparin	B_Chemical
therapy	O
including	O
heparin-induced	O
thrombocytopenia	B_Disease
,	O
heparin-associated	O
osteoporosis	B_Disease
,	O
eosinophilia	B_Disease
,	O
skin	B_Disease
reactions	I_Disease
,	O
allergic	B_Disease
reactions	I_Disease
other	O
than	O
thrombocytopenia	B_Disease
and	O
alopecia	B_Disease
will	O
be	O
discussed	O
in	O
this	O
article	O
.	O

Nonopaque	O
crystal	O
deposition	O
causing	O
ureteric	B_Disease
obstruction	I_Disease
in	O
patients	O
with	O
HIV	O
undergoing	O
indinavir	B_Chemical
therapy	O
.	O

OBJECTIVE	O
:	O
We	O
describe	O
the	O
unique	O
CT	O
features	O
of	O
ureteric	B_Disease
calculi	I_Disease
in	O
six	O
HIV-infected	B_Disease
patients	O
receiving	O
indinavir	B_Chemical
,	O
the	O
most	O
commonly	O
used	O
HIV	O
protease	O
inhibitor	O
,	O
which	O
is	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
urolithiasis	B_Disease
.	O

CONCLUSION	O
:	O
Ureteric	B_Disease
obstruction	I_Disease
caused	O
by	O
precipitated	O
indinavir	B_Chemical
crystals	O
may	O
be	O
difficult	O
to	O
diagnose	O
with	O
unenhanced	O
CT	O
.	O

The	O
calculi	O
are	O
not	O
opaque	O
,	O
and	O
secondary	O
signs	O
of	O
obstruction	O
may	O
be	O
absent	O
or	O
minimal	O
and	O
should	O
be	O
sought	O
carefully	O
.	O

Images	O
may	O
need	O
to	O
be	O
obtained	O
using	O
i.v	O
.	O

contrast	O
material	O
to	O
enable	O
diagnosis	O
of	O
ureteric	B_Disease
stones	I_Disease
or	I_Disease
obstruction	I_Disease
in	O
patients	O
with	O
HIV	B_Disease
infection	I_Disease
who	O
receive	O
indinavir	B_Chemical
therapy	O
.	O

Ischemic	B_Disease
colitis	I_Disease
and	O
sumatriptan	B_Chemical
use	O
.	O

Sumatriptan	B_Chemical
succinate	I_Chemical
,	O
a	O
serotonin-1	O
(	O
5-hydroxytryptamine-1	O
)	O
receptor	O
agonist	O
,	O
is	O
an	O
antimigraine	O
drug	O
that	O
is	O
reported	O
to	O
act	O
by	O
selectively	O
constricting	O
intracranial	O
arteries	O
.	O

Recently	O
,	O
vasopressor	O
responses	O
that	O
are	O
distinct	O
from	O
the	O
cranial	O
circulation	O
have	O
been	O
demonstrated	O
to	O
occur	O
in	O
the	O
systemic	O
,	O
pulmonary	O
,	O
and	O
coronary	O
circulations	O
.	O

Cases	O
have	O
been	O
published	O
of	O
coronary	B_Disease
vasospasm	I_Disease
,	O
myocardial	B_Disease
ischemia	I_Disease
,	O
and	O
myocardial	B_Disease
infarction	I_Disease
occurring	O
after	O
sumatriptan	B_Chemical
use	O
.	O

We	O
report	O
on	O
the	O
development	O
of	O
8	O
serious	O
cases	O
of	O
ischemic	B_Disease
colitis	I_Disease
in	O
patients	O
with	O
migraine	B_Disease
treated	O
with	O
sumatriptan	B_Chemical
.	O

Pallidotomy	O
with	O
the	O
gamma	O
knife	O
:	O
a	O
positive	O
experience.51	O
patients	O
with	O
medically	O
refractory	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
underwent	O
stereotactic	O
posteromedial	O
pallidotomy	O
between	O
August	O
1993	O
and	O
February	O
1997	O
for	O
treatment	O
of	O
bradykinesia	B_Disease
,	O
rigidity	B_Disease
,	O
and	O
L-DOPA-induced	O
dyskinesias	B_Disease
.	O

In	O
29	O
patients	O
,	O
the	O
pallidotomies	O
were	O
performed	O
with	O
the	O
Leksell	O
Gamma	O
Knife	O
and	O
in	O
22	O
they	O
were	O
performed	O
with	O
the	O
standard	O
radiofrequency	O
(	O
RF	O
)	O
method	O
.	O

Clinical	O
assessment	O
as	O
well	O
as	O
blinded	O
ratings	O
of	O
Unified	O
Parkinson	B_Disease
's	I_Disease
Disease	I_Disease
Rating	O
Scale	O
(	O
UPDRS	O
)	O
scores	O
were	O
carried	O
out	O
pre-	O
and	O
postoperatively	O
.	O

Mean	O
follow-up	O
time	O
is	O
20.6	O
months	O
(	O
range	O
6	O
-	O
48	O
)	O
and	O
all	O
except	O
4	O
patients	O
have	O
been	O
followed	O
more	O
than	O
one	O
year	O
.	O

85	O
percent	O
of	O
patients	O
with	O
dyskinesias	B_Disease
were	O
relieved	O
of	O
symptoms	O
,	O
regardless	O
of	O
whether	O
the	O
pallidotomies	O
were	O
performed	O
with	O
the	O
Gamma	O
Knife	O
or	O
radiofrequency	O
methods	O
.	O

About	O
2/3	O
of	O
the	O
patients	O
in	O
both	O
Gamma	O
Knife	O
and	O
radiofrequency	O
groups	O
showed	O
improvements	O
in	O
bradykinesia	B_Disease
and	O
rigidity	B_Disease
,	O
although	O
when	O
considered	O
as	O
a	O
group	O
neither	O
the	O
Gamma	O
Knife	O
nor	O
the	O
radiofrequency	O
group	O
showed	O
statistically	O
significant	O
improvements	O
in	O
UPDRS	O
scores	O
.	O

One	O
patient	O
in	O
the	O
Gamma	O
Knife	O
group	O
(	O
3.4	O
%	O
)	O
developed	O
a	O
homonymous	B_Disease
hemianopsia	I_Disease
9	O
months	O
following	O
treatment	O
and	O
5	O
patients	O
(	O
27.7	O
%	O
)	O
in	O
the	O
radiofrequency	O
group	O
became	O
transiently	O
confused	O
postoperatively	O
.	O

No	O
other	O
complications	O
were	O
seen	O
.	O

Gamma	O
Knife	O
pallidotomy	O
is	O
as	O
effective	O
as	O
radiofrequency	O
pallidotomy	O
in	O
controlling	O
certain	O
of	O
the	O
symptoms	O
of	O
Parkinson	B_Disease
's	I_Disease
disease	I_Disease
.	O

It	O
may	O
be	O
the	O
only	O
practical	O
technique	O
available	O
in	O
certain	O
patients	O
,	O
such	O
as	O
those	O
who	O
take	O
anticoagulants	O
,	O
have	O
bleeding	B_Disease
diatheses	O
or	O
serious	O
systemic	O
medical	O
illnesses	O
.	O

It	O
is	O
a	O
viable	O
option	O
for	O
other	O
patients	O
as	O
well	O
.	O

Centrally	O
mediated	O
cardiovascular	O
effects	O
of	O
intracisternal	O
application	O
of	O
carbachol	O
in	O
anesthetized	O
rats	O
.	O

The	O
pressor	O
response	O
to	O
the	O
intracisternal	O
(	O
i.c	O
.	O
)	O
injection	O
of	O
carbachol	B_Chemical
(	O
1	O
mug	O
)	O
in	O
anesthetized	O
rats	O
was	O
analyzed	O
.	O

This	O
response	O
was	O
significantly	O
reduced	O
by	O
the	O
intravenous	O
(	O
i.v	O
.	O
)	O
injection	O
of	O
guanethidine	B_Chemical
(	O
5	O
mg	O
)	O
,	O
hexamethonium	B_Chemical
(	O
10	O
mg	O
)	O
or	O
phentolamine	B_Chemical
(	O
5	O
mg	O
)	O
,	O
and	O
conversely	O
,	O
potentiated	O
by	O
i.v	O
.	O

desmethylimipramine	B_Chemical
(	O
0.3	O
mg	O
)	O
,	O
while	O
propranolol	B_Chemical
(	O
0.5	O
mg	O
)	O
i.v	O
.	O
selectively	O
inhibited	O
the	O
enlargement	B_Disease
of	I_Disease
pulse	I_Disease
pressure	I_Disease
and	O
the	O
tachycardia	B_Disease
following	O
i.c	O
.	O

carbachol	B_Chemical
(	O
1	O
mug	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
pressor	O
response	O
to	O
i.c	O
.	O
carbachol	B_Chemical
(	O
1	O
mug	O
)	O
was	O
almost	O
completely	O
blocked	O
by	O
i.c	O
.	O

atropine	B_Chemical
(	O
3	O
mug	O
)	O
or	O
hexamethonium	B_Chemical
(	O
500	O
mug	O
)	O
,	O
and	O
significantly	O
reduced	O
by	O
i.c	O
.	O

chlorpromazine	B_Chemical
(	O
50	O
mug	O
)	O
but	O
significantly	O
potentiated	O
by	O
i.c	O
.	O

desmethylimipramine	B_Chemical
(	O
30	O
mug	O
)	O
.	O

The	O
pressor	O
response	O
to	O
i.c	O
.	O

carbachol	B_Chemical
(	O
1	O
mug	O
)	O
remained	O
unchanged	O
after	O
sectioning	O
of	O
the	O
bilateral	O
cervical	O
vagal	O
nerves	O
but	O
disappeared	O
after	O
sectioning	O
of	O
the	O
spinal	O
cord	O
(	O
C7-C8	O
)	O
.	O

From	O
the	O
above	O
result	O
it	O
is	O
suggested	O
that	O
the	O
pressor	O
response	O
to	O
i.c	O
.	O
carbachol	B_Chemical
ortral	O
and	O
peripheral	O
adrenergic	O
mechanisms	O
,	O
and	O
that	O
the	O
sympathetic	O
trunk	O
is	O
the	O
main	O
pathway	O
.	O

Neuroleptic	B_Disease
malignant	I_Disease
syndrome	I_Disease
and	O
methylphenidate	B_Chemical
.	O

A	O
1-year-old	O
female	O
presented	O
with	O
neuroleptic	B_Disease
malignant	I_Disease
syndrome	I_Disease
probably	O
caused	O
by	O
methylphenidate	B_Chemical
.	O

She	O
had	O
defects	O
in	O
the	O
supratentorial	O
brain	O
including	O
the	O
basal	O
ganglia	O
and	O
the	O
striatum	O
(	O
multicystic	B_Disease
encephalomalacia	I_Disease
)	O
due	O
to	O
severe	O
perinatal	O
hypoxic-ischemic	B_Disease
encephalopathy	I_Disease
,	O
which	O
was	O
considered	O
to	O
be	O
a	O
possible	O
predisposing	O
factor	O
causing	O
neuroleptic	B_Disease
malignant	I_Disease
syndrome	I_Disease
.	O

A	O
dopaminergic	O
blockade	O
mechanism	O
generally	O
is	O
accepted	O
as	O
the	O
pathogenesis	O
of	O
this	O
syndrome	O
.	O

However	O
,	O
methylphenidate	B_Chemical
is	O
a	O
dopamine	B_Chemical
agonist	O
via	O
the	O
inhibition	O
of	O
uptake	O
of	O
dopamine	B_Chemical
,	O
and	O
therefore	O
dopaminergic	O
systems	O
in	O
the	O
brainstem	O
(	O
mainly	O
the	O
midbrain	O
)	O
and	O
the	O
spinal	O
cord	O
were	O
unlikely	O
to	O
participate	O
in	O
the	O
onset	O
of	O
this	O
syndrome	O
.	O

A	O
relative	O
gamma-aminobutyric	O
acid-ergic	O
deficiency	O
might	O
occur	O
because	O
diazepam	B_Chemical
,	O
a	O
gamma-aminobutyric	O
acid-mimetic	O
agent	O
,	O
was	O
strikingly	O
effective	O
.	O

This	O
is	O
the	O
first	O
reported	O
patient	O
with	O
neuroleptic	B_Disease
malignant	I_Disease
syndrome	I_Disease
probably	O
caused	O
by	O
methylphenidate	B_Chemical
.	O

Differential	O
effects	O
of	O
17alpha-ethinylestradiol	B_Chemical
on	O
the	O
neutral	O
and	O
acidic	O
pathways	O
of	O
bile	B_Chemical
salt	I_Chemical
synthesis	O
in	O
the	O
rat	O
.	O

Effects	O
of	O
17alpha-ethinylestradiol	B_Chemical
(	O
EE	B_Chemical
)	O
on	O
the	O
neutral	O
and	O
acidic	O
biosynthetic	O
pathways	O
of	O
bile	B_Chemical
salt	I_Chemical
(	O
BS	B_Chemical
)	O
synthesis	O
were	O
evaluated	O
in	O
rats	O
with	O
an	O
intact	O
enterohepatic	O
circulation	O
and	O
in	O
rats	O
with	O
long-term	O
bile	O
diversion	O
to	O
induce	O
BS	B_Chemical
synthesis	O
.	O

For	O
this	O
purpose	O
,	O
bile	B_Chemical
salt	I_Chemical
pool	O
composition	O
,	O
synthesis	O
of	O
individual	O
BS	B_Chemical
in	O
vivo	O
,	O
hepatic	O
activities	O
,	O
and	O
expression	O
levels	O
of	O
cholesterol	B_Chemical
7alpha-hydroxylase	O
(	O
CYP7A	O
)	O
,	O
and	O
sterol	B_Chemical
27-hydroxylase	O
(	O
CYP27	O
)	O
,	O
as	O
well	O
as	O
of	O
other	O
enzymes	O
involved	O
in	O
BS	B_Chemical
synthesis	O
,	O
were	O
analyzed	O
in	O
rats	O
treated	O
with	O
EE	B_Chemical
(	O
5	O
mg/kg	O
,	O
3	O
days	O
)	O
or	O
its	O
vehicle	O
.	O

BS	B_Chemical
pool	O
size	O
was	O
decreased	O
by	O
27	O
%	O
but	O
total	O
BS	B_Chemical
synthesis	O
was	O
not	O
affected	O
by	O
EE	B_Chemical
in	O
intact	O
rats	O
.	O

Synthesis	O
of	O
cholate	B_Chemical
was	O
reduced	O
by	O
68	O
%	O
in	O
EE-treated	O
rats	O
,	O
while	O
that	O
of	O
chenodeoxycholate	B_Chemical
was	O
increased	O
by	O
60	O
%	O
.	O

The	O
recently	O
identified	O
Delta22-isomer	O
of	O
beta-muricholate	O
contributed	O
for	O
5.4	O
%	O
and	O
18.3	O
%	O
(	O
P	O
<	O
0.01	O
)	O
to	O
the	O
pool	O
in	O
control	O
and	O
EE-treated	O
rats	O
,	O
respectively	O
,	O
but	O
could	O
not	O
be	O
detected	O
in	O
bile	O
after	O
exhaustion	O
of	O
the	O
pool	O
.	O

A	O
clear	O
reduction	O
of	O
BS	B_Chemical
synthesis	O
was	O
found	O
in	O
bile-diverted	O
rats	O
treated	O
with	O
EE	B_Chemical
,	O
yet	O
biliary	O
BS	B_Chemical
composition	O
was	O
only	O
minimally	O
affected	O
.	O

Activity	O
of	O
CYP7A	O
was	O
decreased	O
by	O
EE	B_Chemical
in	O
both	O
intact	O
and	O
bile-diverted	O
rats	O
,	O
whereas	O
the	O
activity	O
of	O
the	O
CYP27	O
was	O
not	O
affected	O
.	O

Hepatic	O
mRNA	O
levels	O
of	O
CYP7A	O
were	O
significantly	O
reduced	O
by	O
EE	B_Chemical
in	O
bile-diverted	O
rats	O
only	O
;	O
CYP27	O
mRNA	O
levels	O
were	O
not	O
affected	O
by	O
EE	B_Chemical
.	O

In	O
addition	O
,	O
mRNA	O
levels	O
of	O
sterol	B_Chemical
12alpha-hydroxylase	O
and	O
lithocholate	O
6beta-hydroxylase	O
were	O
increased	O
by	O
bile	O
diversion	O
and	O
suppressed	O
by	O
EE	B_Chemical
.	O

This	O
study	O
shows	O
that	O
17alpha-ethinylestradiol	B_Chemical
(EE)-induced	O
intrahepatic	B_Disease
cholestasis	I_Disease
in	O
rats	O
is	O
associated	O
with	O
selective	O
inhibition	O
of	O
the	O
neutral	O
pathway	O
of	O
bile	B_Chemical
salt	I_Chemical
(	O
BS	B_Chemical
)	O
synthesis	O
.	O

Simultaneous	O
impairment	O
of	O
other	O
enzymes	O
in	O
the	O
BS	B_Chemical
biosynthetic	O
pathways	O
may	O
contribute	O
to	O
overall	O
effects	O
of	O
EE	B_Chemical
on	O
BS	B_Chemical
synthesis	O
.	O

Glibenclamide-sensitive	O
hypotension	B_Disease
produced	O
by	O
helodermin	B_Chemical
assessed	O
in	O
the	O
rat	O
.	O

The	O
effects	O
of	O
helodermin	B_Chemical
,	O
a	O
basic	O
35-amino	O
acid	O
peptide	O
isolated	O
from	O
the	O
venom	O
of	O
a	O
lizard	O
salivary	O
gland	O
,	O
on	O
arterial	O
blood	O
pressure	O
and	O
heart	O
rate	O
were	O
examined	O
in	O
the	O
rat	O
,	O
focusing	O
on	O
the	O
possibility	O
that	O
activation	O
of	O
ATP	B_Chemical
sensitive	O
K+	O
(	O
K(ATP	O
)	O
)	O
channels	O
is	O
involved	O
in	O
the	O
responses	O
.	O

The	O
results	O
were	O
also	O
compared	O
with	O
those	O
of	O
vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
.	O

Helodermin	B_Chemical
produced	O
hypotension	B_Disease
in	O
a	O
dose-dependent	O
manner	O
with	O
approximately	O
similar	O
potency	O
and	O
duration	O
to	O
VIP	O
.	O

Hypotension	B_Disease
induced	O
by	O
both	O
peptides	O
was	O
significantly	O
attenuated	O
by	O
glibenclamide	B_Chemical
,	O
which	O
abolished	O
a	O
levcromakalim-produced	O
decrease	O
in	O
arterial	O
blood	O
pressure	O
.	O

Oxyhemoglobin	O
did	O
not	O
affect	O
helodermin-induced	O
hypotension	B_Disease
,	O
whereas	O
it	O
shortened	O
the	O
duration	O
of	O
acetylcholine	B_Chemical
(ACh)-produced	O
hypotension	B_Disease
.	O

These	O
findings	O
suggest	O
that	O
helodermin-produced	O
hypotension	B_Disease
is	O
partly	O
attributable	O
to	O
the	O
activation	O
of	O
glibenclamide-sensitive	O
K+	O
channels	O
(	O
K(ATP	O
)	O
channels	O
)	O
,	O
which	O
presumably	O
exist	O
on	O
arterial	O
smooth	O
muscle	O
cells	O
.	O

EDRF	O
(	O
endothelium-derived	O
relaxing	O
factor)/nitric	O
oxide	O
does	O
not	O
seem	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
peptide-produced	O
hypotension	B_Disease
.	O

Long-term	O
efficacy	O
and	O
adverse	O
event	O
of	O
nifedipine	B_Chemical
sustained-release	O
tablets	O
for	O
cyclosporin	O
A-induced	O
hypertension	B_Disease
in	O
patients	O
with	O
psoriasis	B_Disease
.	O

Thirteen	O
psoriatic	B_Disease
patients	O
with	O
hypertension	B_Disease
during	O
the	O
course	O
of	O
cyclosporin	B_Chemical
A	I_Chemical
therapy	O
were	O
treated	O
for	O
25	O
months	O
with	O
a	O
calcium	B_Chemical
channel	O
blocker	O
,	O
sustained-release	O
nifedipine	B_Chemical
,	O
to	O
study	O
the	O
clinical	O
antihypertensive	O
effects	O
and	O
adverse	O
events	O
during	O
treatment	O
with	O
both	O
drugs	O
.	O

Seven	O
of	O
the	O
13	O
patients	O
had	O
exhibited	O
a	O
subclinical	O
hypertensive	B_Disease
state	O
before	O
cyclosporin	B_Chemical
A	I_Chemical
therapy	O
.	O

Both	O
systolic	O
and	O
diastolic	O
blood	O
pressures	O
of	O
these	O
13	O
patients	O
were	O
decreased	O
significantly	O
after	O
4	O
weeks	O
of	O
nifedipine	B_Chemical
therapy	O
,	O
and	O
blood	O
pressure	O
was	O
maintained	O
within	O
the	O
normal	O
range	O
thereafter	O
for	O
25	O
months	O
.	O

The	O
adverse	O
events	O
during	O
combined	O
therapy	O
with	O
cyclosporin	B_Chemical
A	I_Chemical
and	O
nifedipine	B_Chemical
included	O
an	O
increase	O
in	O
blood	B_Chemical
urea	I_Chemical
nitrogen	I_Chemical
levels	O
in	O
9	O
of	O
the	O
13	O
patients	O
and	O
development	O
of	O
gingival	B_Disease
hyperplasia	I_Disease
in	O
2	O
of	O
the	O
13	O
patients	O
.	O

Our	O
findings	O
indicate	O
that	O
sustained-release	O
nifedipine	B_Chemical
is	O
useful	O
for	O
hypertensive	B_Disease
psoriatic	B_Disease
patients	O
under	O
long-term	O
treatment	O
with	O
cyclosporin	B_Chemical
A	I_Chemical
,	O
but	O
that	O
these	O
patients	O
should	O
be	O
monitored	O
for	O
gingival	B_Disease
hyperplasia	I_Disease
.	O

